0000920148-24-00009910-Q LABCORP HOLDINGS INC. 20240802202408021437181437183718143718 0 0000920148-24-000099 10-Q 64 20240630 20240802 20240802 LABCORP HOLDINGS INC. 0000920148 8071 992588107 1231 10-Q 34 001-11353 241170263 358 S MAIN ST BURLINGTON NC 27215 3362291127 358 S MAIN ST BURLINGTON NC 27215 LABORATORY CORP OF AMERICA HOLDINGS 19950504 NATIONAL HEALTH LABORATORIES HOLDINGS INC 19940314 10-Q 1 lh-20240630.htm 10-Q lh-2024063034.132.7000092014812/312024Q2falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Rate00009201482024-01-012024-06-3000009201482024-08-0100009201482024-06-3000009201482023-12-3100009201482024-04-012024-06-3000009201482023-04-012023-06-3000009201482023-01-012023-06-300000920148us-gaap:CommonStockMember2022-12-310000920148us-gaap:AdditionalPaidInCapitalMember2022-12-310000920148us-gaap:RetainedEarningsMember2022-12-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100009201482022-12-310000920148us-gaap:CommonStockMember2023-01-012023-03-310000920148us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000920148us-gaap:RetainedEarningsMember2023-01-012023-03-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100009201482023-01-012023-03-310000920148us-gaap:CommonStockMember2023-06-300000920148us-gaap:AdditionalPaidInCapitalMember2023-06-300000920148us-gaap:RetainedEarningsMember2023-06-300000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000009201482023-06-300000920148us-gaap:CommonStockMember2023-04-012023-06-300000920148us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000920148us-gaap:RetainedEarningsMember2023-04-012023-06-300000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000920148us-gaap:CommonStockMember2023-03-310000920148us-gaap:AdditionalPaidInCapitalMember2023-03-310000920148us-gaap:RetainedEarningsMember2023-03-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100009201482023-03-310000920148us-gaap:CommonStockMember2023-12-310000920148us-gaap:AdditionalPaidInCapitalMember2023-12-310000920148us-gaap:RetainedEarningsMember2023-12-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000920148us-gaap:CommonStockMember2024-01-012024-03-310000920148us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000920148us-gaap:RetainedEarningsMember2024-01-012024-03-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100009201482024-01-012024-03-310000920148us-gaap:CommonStockMember2024-03-310000920148us-gaap:AdditionalPaidInCapitalMember2024-03-310000920148us-gaap:RetainedEarningsMember2024-03-310000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100009201482024-03-310000920148us-gaap:CommonStockMember2024-04-012024-06-300000920148us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000920148us-gaap:RetainedEarningsMember2024-04-012024-06-300000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000920148us-gaap:CommonStockMember2024-06-300000920148us-gaap:AdditionalPaidInCapitalMember2024-06-300000920148us-gaap:RetainedEarningsMember2024-06-300000920148us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000920148us-gaap:SegmentContinuingOperationsMember2024-01-012024-06-300000920148us-gaap:SegmentContinuingOperationsMember2023-01-012023-06-300000920148us-gaap:SegmentDiscontinuedOperationsMember2024-01-012024-06-300000920148us-gaap:SegmentDiscontinuedOperationsMember2023-01-012023-06-300000920148us-gaap:SegmentContinuingOperationsMember2024-06-300000920148us-gaap:SegmentContinuingOperationsMember2023-06-300000920148lh:DiagnosticsMember2024-04-012024-06-300000920148lh:DrugDevelopmentMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148lh:DrugDevelopmentMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-01-012024-06-3000009201482023-09-300000920148lh:FortreaRevolverDue2028Member2023-09-300000920148lh:FortreaTermLoanAMaturing2028Member2023-09-300000920148lh:FortreaTermLoanBMaturing2028Member2023-09-300000920148srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2024-04-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-04-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2023-04-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-04-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMembersrt:EuropeMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMembersrt:EuropeMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMemberlh:OthercountriesMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2023-04-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMemberlh:MedicareandMedicaidMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMemberlh:OthercountriesMember2024-04-012024-06-300000920148lh:MedicareandMedicaidMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMemberlh:MedicareandMedicaidMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMemberlh:OthercountriesMember2023-04-012023-06-300000920148lh:MedicareandMedicaidMember2023-04-012023-06-300000920148srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2024-04-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-04-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2023-04-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-04-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-04-012024-06-300000920148lh:LabCorpDiagnosticsMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-04-012023-06-300000920148lh:LabCorpDiagnosticsMember2023-04-012023-06-300000920148lh:DrugDevelopmentMembersrt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-04-012024-06-300000920148lh:DrugDevelopmentMembersrt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-04-012024-06-300000920148lh:DrugDevelopmentMemberlh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-04-012024-06-300000920148lh:DrugDevelopmentMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-04-012024-06-300000920148srt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember2023-04-012023-06-300000920148srt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember2023-04-012023-06-300000920148lh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember2023-04-012023-06-300000920148lh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember2023-04-012023-06-300000920148srt:NorthAmericaMember2024-04-012024-06-300000920148srt:EuropeMember2024-04-012024-06-300000920148lh:OthercountriesMember2024-04-012024-06-300000920148srt:NorthAmericaMember2023-04-012023-06-300000920148srt:EuropeMember2023-04-012023-06-300000920148lh:OthercountriesMember2023-04-012023-06-300000920148srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2024-01-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-01-012024-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2023-01-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-01-012023-06-300000920148lh:ClientMemberlh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMembersrt:EuropeMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMemberlh:OthercountriesMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2024-01-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMembersrt:EuropeMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMemberlh:OthercountriesMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMemberus-gaap:SelfPayMember2023-01-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMemberlh:MedicareandMedicaidMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMemberlh:OthercountriesMember2024-01-012024-06-300000920148lh:MedicareandMedicaidMember2024-01-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMemberlh:MedicareandMedicaidMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMemberlh:MedicareandMedicaidMemberlh:OthercountriesMember2023-01-012023-06-300000920148lh:MedicareandMedicaidMember2023-01-012023-06-300000920148srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2024-01-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-01-012024-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMembersrt:EuropeMember2023-01-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-01-012023-06-300000920148lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMemberlh:OthercountriesMember2024-01-012024-06-300000920148srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMembersrt:EuropeMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMemberlh:OthercountriesMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMember2023-01-012023-06-300000920148lh:DrugDevelopmentMembersrt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-01-012024-06-300000920148lh:DrugDevelopmentMembersrt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-01-012024-06-300000920148lh:DrugDevelopmentMemberlh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2024-01-012024-06-300000920148lh:DrugDevelopmentMembersrt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2023-01-012023-06-300000920148lh:DrugDevelopmentMembersrt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2023-01-012023-06-300000920148lh:DrugDevelopmentMemberlh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2023-01-012023-06-300000920148lh:DrugDevelopmentMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMember2023-01-012023-06-300000920148srt:NorthAmericaMember2024-01-012024-06-300000920148srt:EuropeMember2024-01-012024-06-300000920148lh:OthercountriesMember2024-01-012024-06-300000920148srt:NorthAmericaMember2023-01-012023-06-300000920148srt:EuropeMember2023-01-012023-06-300000920148lh:OthercountriesMember2023-01-012023-06-300000920148country:US2024-04-012024-06-300000920148country:US2023-04-012023-06-300000920148country:US2024-01-012024-06-300000920148country:US2023-01-012023-06-300000920148lh:DiagnosticsMember2024-06-300000920148lh:DiagnosticsMember2023-12-310000920148lh:DrugDevelopmentMember2024-06-300000920148lh:DrugDevelopmentMember2023-12-310000920148us-gaap:AccountsReceivableMember2024-01-012024-06-300000920148lh:UnbilledContractsReceivableMember2024-01-012024-06-300000920148us-gaap:NotesReceivableMember2024-01-012024-06-300000920148lh:BaystateMedicalCenterMember2024-06-300000920148lh:ProvidenceMedicalFoundationMember2024-06-300000920148lh:WestpacLabsInc.Member2024-06-300000920148lh:InvitaeCorporationMember2024-06-300000920148lh:OtheracquireesMember2024-01-012024-06-300000920148us-gaap:CustomerListsMembersrt:MaximumMember2024-01-012024-06-300000920148lh:BaystateMedicalCenterMember2024-04-012024-06-300000920148lh:WestpacLabsInc.Member2024-04-012024-06-300000920148lh:InvitaeCorporationMember2024-04-012024-06-300000920148lh:BaystateMedicalCenterMember2024-01-012024-06-300000920148lh:ProvidenceMedicalFoundationMember2024-01-012024-06-300000920148lh:WestpacLabsInc.Member2024-01-012024-06-300000920148lh:InvitaeCorporationMember2024-01-012024-06-300000920148us-gaap:GoodwillMember2024-01-012024-06-300000920148us-gaap:OtherNoncurrentAssetsMember2024-01-012024-06-300000920148lh:OperatingLeaseLiabilityMember2024-04-012024-06-300000920148us-gaap:OtherNoncurrentLiabilitiesMember2024-04-012024-06-300000920148lh:OtherAcquisitionsMember2024-06-300000920148lh:BioReferenceHealthMember2024-01-012024-06-300000920148lh:OtheracquireesMember2023-01-012023-06-300000920148us-gaap:CustomerListsMembersrt:MinimumMember2024-01-012024-06-300000920148us-gaap:CustomerListsMembersrt:MaximumMember2023-01-012023-06-300000920148us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-01-012023-06-300000920148us-gaap:GoodwillMember2023-01-012023-06-300000920148us-gaap:AccruedLiabilitiesMember2023-01-012023-06-300000920148us-gaap:OtherNoncurrentLiabilitiesMember2023-01-012023-06-300000920148lh:LabCorpDiagnosticsMember2023-12-310000920148lh:CovanceDrugDevelopmentMember2023-12-310000920148lh:CovanceDrugDevelopmentMember2024-01-012024-06-300000920148lh:LabCorpDiagnosticsMember2024-06-300000920148lh:CovanceDrugDevelopmentMember2024-06-300000920148us-gaap:CustomerRelationshipsMember2024-06-300000920148us-gaap:CustomerRelationshipsMember2023-12-310000920148lh:PatentsLicensesAndTechnologyMember2024-06-300000920148lh:PatentsLicensesAndTechnologyMember2023-12-310000920148us-gaap:NoncompeteAgreementsMember2024-06-300000920148us-gaap:NoncompeteAgreementsMember2023-12-310000920148us-gaap:LicensingAgreementsMember2024-06-300000920148us-

gaap:LicensingAgreementsMember2023-12-310000920148lh:InProcessRAAndMediaMember2024-06-300000920148lh:InProcessRAAndMediaMember2023-12-310000920148us-gaap:OtherCurrentLiabilitiesMember2024-06-300000920148us-gaap:OtherCurrentLiabilitiesMember2023-12-310000920148us-gaap:InterestRateSwapMember2024-06-300000920148us-gaap:InterestRateSwapMember2023-12-310000920148us-gaap:RevolvingCreditFacilityMember2024-06-300000920148us-gaap:CommonStockMember2023-12-310000920148us-gaap:CommonStockMember2024-01-012024-06-300000920148us-gaap:CommonStockMember2024-06-300000920148us-gaap:SubsequentEventMember2024-07-240000920148us-gaap:SubsequentEventMember2024-07-252024-07-250000920148us-gaap:SubsequentEventMember2024-07-250000920148lh:InitialDamagesMember2024-04-012024-06-300000920148lh:EnhancedDamagesMember2024-04-012024-06-300000920148us-gaap:FairValueInputsLevel1Member2024-06-300000920148us-gaap:FairValueInputsLevel2Member2024-06-300000920148us-gaap:FairValueInputsLevel3Member2024-06-300000920148us-gaap:FairValueInputsLevel1Member2023-12-310000920148us-gaap:FairValueInputsLevel2Member2023-12-310000920148us-gaap:FairValueInputsLevel3Member2023-12-310000920148lh:Seniornotesdue2027Member2024-06-300000920148lh:A2018SwapAgreementsMemberlh:SeniorNotesDue2022Member2024-06-300000920148lh:SeniorNotesDue2024Memberlh:A2022SwapAgreementsMember2024-06-300000920148lh:DiagnosticsMemberus-gaap:OperatingSegmentsMember2024-04-012024-06-300000920148lh:DiagnosticsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000920148lh:DiagnosticsMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-300000920148lh:DiagnosticsMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000920148lh:DrugDevelopmentMemberus-gaap:OperatingSegmentsMember2024-04-012024-06-300000920148lh:DrugDevelopmentMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000920148lh:DrugDevelopmentMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-300000920148lh:DrugDevelopmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000920148us-gaap:IntersegmentEliminationMember2024-04-012024-06-300000920148us-gaap:IntersegmentEliminationMember2023-04-012023-06-300000920148us-gaap:IntersegmentEliminationMember2024-01-012024-06-300000920148us-gaap:IntersegmentEliminationMember2023-01-012023-06-300000920148us-gaap:OperatingSegmentsMember2024-04-012024-06-300000920148us-gaap:OperatingSegmentsMember2023-04-012023-06-300000920148us-gaap:OperatingSegmentsMember2024-01-012024-06-300000920148us-gaap:OperatingSegmentsMember2023-01-012023-06-300000920148us-gaap:CorporateMember2024-04-012024-06-300000920148us-gaap:CorporateMember2023-04-012023-06-300000920148us-gaap:CorporateMember2024-01-012024-06-300000920148us-gaap:CorporateMember2023-01-012023-06-300000920148lh:KerriAndersonMember2024-04-012024-06-300000920148lh:KerriAndersonMember2024-06-30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C.Â Â 20549FORM 10-Q â˜´ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2024ORâ˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ toÂ Â _____Commission File NumberÂ Â Â 1-11353 LABCORP HOLDINGS INC.(Exact name of registrant as specified in its charter)Delaware99-2588107(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)358 South Main StreetÂ Burlington,North Carolina27215(Address of principal executive offices)(Zip Code)(Registrant's telephone number, including area code) 336-229-1127Securities registered pursuant to Section 12(b) of the Exchange Act.Title of Each ClassÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Trading SymbolÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Name of exchange on which registeredCommon Stock, $0.10 par valueÂ Â Â Â Â Â Â Â LHÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes â˜´ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜´ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerâ˜´Accelerated filerâ˜Non-accelerated filer â˜Smaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â Yes â˜ No â˜´.ClassShares OutstandingDateCommon Stock $0.10 par value83,963,277August 1, 2024INDEXINDEXPART I. FINANCIAL INFORMATIONItem 1.Financial Statements (unaudited)Â Â Â Condensed Consolidated Balance Sheets2Â June 30, 2024 and December 31, 2023Â Â Â Condensed Consolidated Statements of Operations3Â Three and Six Months Ended June 30, 2024 and 2023Â Â Condensed Consolidated Statements of Comprehensive Earnings4Three and Six Months Ended June 30, 2024 and 2023Â Condensed Consolidated Statements of Changes in Shareholdersâ€™ Equity5Â Three and Six Months Ended June 30, 2024 and 2023Â Â Â Condensed Consolidated Statements of Cash Flows6Â Six Months Ended June 30, 2024 and 2023Â Â Â Notes to Unaudited Condensed Consolidated Financial Statements7Â Â Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations22Â Â Item 3.Quantitative and Qualitative Disclosures about Market Risk32Â Â Item 4.Controls and Procedures33PART II. OTHER INFORMATIONItem 1.Legal Proceedings34Â Â Item 1A.Risk Factors34Â Â Item 2.Unregistered Sales of Equity Securities and Use of Proceeds35Item 5.Other Information35Â Â Item 6.Exhibits351INDEXPART IÂ â€“Â FINANCIAL INFORMATIONItem 1. Financial Statements (unaudited)LABCORP HOLDINGS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in millions)(unaudited)June 30, 2024December 31, 2023ASSETSÂ Â Current assets:Â Â Cash and cash equivalents$265.1Â $536.8Â Accounts receivable, net2,088.9Â 1,913.3Â Unbilled services157.5Â 185.4Â Supplies inventory441.8Â 474.6Â Prepaid expenses and other618.0Â 655.3Â Total current assets3,571.3Â 3,765.4Â Property, plant and equipment, net2,932.5Â 2,911.8Â Goodwill, net6,220.2Â 6,142.5Â Intangible assets, net3,332.0Â 3,342.0Â Joint venture partnerships and equity method investments17.5Â 26.9Â Other assets, net638.8Â 536.5Â Total assets$16,712.3Â $16,725.1Â LIABILITIES AND SHAREHOLDERSâ€™ EQUITYÂ Â Current liabilities:Â Â Accounts payable$760.6Â $827.5Â Accrued expenses and other707.5Â 804.0Â Unearned revenue388.3Â 421.7Â Short-term operating lease liabilities182.1Â 165.8Â Short-term finance lease liabilities6.7Â 6.4Â Short-term borrowings and current portion of long-term debt2,019.5Â 999.8Â Total current liabilities4,064.7Â 3,225.2Â Long-term debt, less current portion3,047.3Â 4,054.7Â Operating lease liabilities642.6Â 648.9Â Financing lease liabilities76.9Â 78.6Â Deferred income taxes and other tax liabilities376.1Â 417.9Â Other liabilities483.9Â 409.3Â Total liabilities8,691.5Â 8,834.6Â Commitments and contingent liabilitiesNoncontrolling interest15.0Â 15.5Â Shareholdersâ€™ equity:Â Â Common stock, $0.10 par value, 83.8 and 83.9 shares outstanding at June 30, 2024, and December 31, 2023, respectively7.7Â 7.7Â Additional paid-in capital12.5Â 38.4Â Retained earnings8,177.6Â 7,888.2Â Accumulated other comprehensive loss(192.0)(59.3)Total shareholdersâ€™ equity8,005.8Â 7,875.0Â Total liabilities and shareholdersâ€™ equity$16,712.3Â $16,725.1Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.2INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in millions, except per share data)(unaudited)Three Months Ended June 30,Six Months Ended June 30,Â 2024202320242023Revenues$3,220.9Â $3,033.7Â $6,397.5Â $6,071.5Â Cost of revenues2,294.5Â 2,191.5Â 4,573.8Â 4,379.2Â Gross profit926.4Â 842.2Â 1,823.7Â 1,692.3Â Selling, general and administrative expenses557.8Â 505.8Â 1,066.2Â 963.0Â Amortization of intangibles and other assets62.2Â 51.5Â 122.3Â 104.9Â Goodwill and other asset impairmentsâ€”Â 2.8Â 2.5Â 5.0Â Restructuring and other charges11.6Â 15.8Â 16.6Â 23.3Â Operating income294.8Â 266.3Â 616.1Â 596.1Â Other income (expense):Interest expense(47.6)(49.8)(94.5)(100.5)Investment income1.3Â 4.5Â 4.2Â 6.7Â Equity method income (expense), net(0.3)0.9Â (0.2)(1.2)Other, net19.5Â (16.9)39.5Â (23.8)Earnings from continuing operations before income taxes267.7Â 205.0Â 565.1Â 477.3Â Provision for income taxes62.1Â 49.8Â 131.2Â 113.7Â Earnings from continuing operations205.6Â 155.2Â 433.9Â 363.6Â Earnings from discontinued operations, net of taxâ€”Â 33.9Â â€”Â 38.8Â Net earnings205.6Â 189.1Â 433.9Â 402.4Â Less: Net earnings attributable to the noncontrolling interest(0.3)(0.2)(0.6)(0.6)Net earnings attributable to Labcorp Holdings Inc.$205.3Â $188.9Â $433.3Â $401.8Â Basic earnings per share:Basic earnings per share continuing operations$2.44Â $1.75Â $5.15Â $4.10Â Basic earnings per share discontinued operations$â€”Â $0.38Â $â€”Â $0.43Â Basic earnings per share$2.44Â $2.13Â $5.15Â $4.53Â Diluted earnings per share:Diluted earnings per share continuing operations$2.43Â $1.74Â $5.13Â $4.08Â Diluted earnings per share discontinued operations$â€”Â $0.38Â $â€”Â $0.43Â Diluted earnings per share$2.43Â $2.12Â $5.13Â $4.51Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.3INDEX LABCORP HOLDINGS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS(in millions)(unaudited)Three Months Ended June 30,Six Months Ended June 30,Â 2024202320242023Net earnings$205.6Â $189.1Â $433.9Â $402.4Â Foreign currency translation adjustments(7.2)51.7Â (131.5)99.8Â Net benefit plan adjustments0.7Â 1.1Â (1.7)2.3Â Other comprehensive earnings (loss) before tax(6.5)52.8Â (133.2)102.1Â (Provision) benefit for income tax related to items of comprehensive earnings(0.1)(0.3)0.5Â (0.6)Other comprehensive earnings (loss), net of tax(6.6)52.5Â (132.7)101.5Â Comprehensive earnings199.0Â 241.6Â 301.2Â 503.9Â Less: Net earnings attributable to the noncontrolling interest(0.3)(0.2)(0.6)(0.6)Comprehensive earnings attributable to Labcorp Holdings Inc.$198.7Â $241.4Â $300.6Â $503.3Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.4INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CHANGES INSHAREHOLDERSâ€™ EQUITY(in millions)(unaudited)CommonStockAdditionalPaid-inCapitalRetained EarningsAccumulatedOtherComprehensiveEarnings (Loss)TotalShareholdersâ€™EquityBALANCE AT DECEMBER 31, 2022$8.1Â $â€”Â $10,581.7Â (493.2)10,096.6Â Net earnings attributable to Labcorp Holdings Inc.â€”Â â€”Â 212.9Â â€”Â 212.9Â Other comprehensive earnings (loss), net of taxâ€”Â â€”Â â€”Â 49.0Â 49.0Â Dividends declaredâ€”Â â€”Â (64.7)â€”Â (64.7)Issuance of common stock under employee stock plansâ€”Â 27.6Â â€”Â â€”Â 27.6Â Net share settlement tax payments from issuance of stock to employeesâ€”Â (20.5)â€”Â â€”Â (20.5)Stock compensationâ€”Â 40.6Â â€”Â â€”Â 40.6Â BALANCE AT MARCH 31, 2023$8.1Â $47.7Â $10,729.9Â (444.2)10,341.5Â Net earnings attributable to Labcorp Holdings Inc.â€”Â â€”Â 188.9Â â€”Â 188.9Â Other comprehensive earnings (loss), net of taxâ€”Â â€”Â â€”Â 52.5Â 52.5Â Fortrea Holdings Inc. spin-offâ€”Â â€”Â (2,018.1)238.0Â (1,780.1)Dividends declaredâ€”Â â€”Â (64.5)â€”Â (64.5)Issuance of common stock under employee stock plansâ€”Â 26.8Â â€”Â â€”Â 26.8Â Net share settlement tax payments from issuance of stock to employeesâ€”Â (18.2)â€”Â â€”Â (18.2)Stock compensationâ€”Â 38.1Â â€”Â â€”Â 38.1Â BALANCE AT JUNE 30, 2023$8.1Â $94.4Â $8,836.2Â (153.7)8,785.0Â BALANCE AT DECEMBER 31, 2023$7.7Â $38.4Â $7,888.2Â (59.3)7,875.0Â Net earnings attributable to Labcorp Holdings Inc.â€”Â â€”Â 228.0Â â€”Â 228.0Â Other comprehensive earnings (loss), net of taxâ€”Â â€”Â â€”Â (126.1)(126.1)Dividends declaredâ€”Â â€”Â (60.9)â€”Â (60.9)Issuance of common stock under employee stock plansâ€”Â 26.7Â â€”Â â€”Â 26.7Â Net share settlement tax payments from issuance of stock to employeesâ€”Â (14.7)â€”Â â€”Â (14.7)Stock compensationâ€”Â 31.6Â â€”Â â€”Â 31.6Â BALANCE AT MARCH 31, 2024$7.7Â $82.0Â $8,055.3Â (185.4)7,959.6Â Net earnings attributable to Labcorp Holdings Inc.â€”Â â€”Â 205.3Â â€”Â 205.3Â Other comprehensive earnings (loss), net of taxâ€”Â â€”Â â€”Â (6.6)(6.6)Dividends declaredâ€”Â â€”Â (60.2)â€”Â (60.2)Net share settlement tax payments from issuance of stock to employeesâ€”Â (23.1)â€”Â â€”Â (23.1)Stock compensationâ€”Â 30.8Â â€”Â â€”Â 30.8Â Purchase of common stockâ€”Â (77.2)(22.8)â€”Â (100.0)BALANCE AT JUNE 30, 2024$7.7Â $12.5Â $8,177.6Â (192.0)8,005.8Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.5INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in millions)(unaudited)Six Months Ended June 30,Â 20242023CASH FLOWS FROM OPERATING ACTIVITIES:Â Â Net earnings$433.9Â $402.4Â Earnings from discontinued operations, net of taxâ€”Â (38.8)Adjustments to reconcile net earnings to net cash provided by operating activities:Â Â Depreciation and amortization311.4Â 285.0Â Stock compensation62.4Â 67.3Â Operating lease right-of-use asset expense88.6Â 85.1Â Goodwill and other asset impairments2.5Â 5.0Â Deferred income taxes(39.1)16.2Â Other36.6Â 3.1Â Change in assets and liabilities (net of effects of acquisitions and divestitures):Â Â Increase in accounts receivable(192.2)(107.6)Decrease in unbilled services26.8Â 74.1Â Decrease (increase) in supplies inventory27.7Â (16.1)Decrease (increase) in prepaid expenses and other21.6Â (30.2)Decrease in accounts payable(51.7)(160.3)(Decrease) increase in unearned revenue(30.8)34.8Â Decrease in accrued expenses and other(166.4)(272.8)Net cash provided by continuing operating activities531.3Â 347.2Â Net cash provided by discontinued operating activitiesâ€”Â 125.4Â Net cash provided by operating activities531.3Â 472.6Â CASH FLOWS FROM INVESTING ACTIVITIES:Â Â Capital expenditures(262.0)(181.5)Proceeds from sale of assets0.2Â 0.2Â Proceeds from sale of business13.5Â â€”Â Investments in equity affiliates(36.7)(10.4)Acquisition of businesses, net of cash acquired(293.1)(136.9)Net cash used for continuing investing activities(578.1)(328.6)Net cash used for discontinued investing activitiesâ€”Â (24.7)Net cash used for investing activities(578.1)(353.3)CASH FLOWS FROM FINANCING ACTIVITIES:Â Â Proceeds from revolving credit facilities951.9Â 1,420.9Â Payments on revolving credit facilities(932.1)(1,420.9)Net share settlement tax payments from issuance of stock to employees(37.8)(38.7)Net proceeds from issuance of stock to employees26.7Â 54.4Â Dividends paid(122.5)(129.0)Purchase of common stock(100.0)â€”Â Other(7.9)(11.4)Net cash used for continuing financing activities(221.7)(124.7)Net cash provided by discontinued financing activitiesâ€”Â 1,609.1Â Net cash (used for) provided by financing activities(221.7)1,484.4Â Effect of exchange rate changes on cash and cash equivalents(3.2)6.3Â Net (decrease) increase in cash and cash equivalents(271.7)1,610.0Â Cash and cash equivalents at beginning of period536.8Â 430.0Â Less: Cash and cash equivalents of discontinued operations at end of periodâ€”Â $109.4Â Cash and cash equivalents at end of period$265.1Â $1,930.6Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.6INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)1.Â Â Â Â BASIS OF FINANCIAL STATEMENT PRESENTATIONLabcorpÂ® Holdings Inc. (LabcorpÂ® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. On April 25, 2024, the Company announced plans to implement a new public holding company structure, with Labcorp Holdings Inc. as the new holding company. On May 17, 2024, the Company completed the holding company reorganization (Reorganization) and Labcorp Holdings Inc. became the successor issuer to Laboratory Corporation of America Holdings (LCAH). The new holding company has no independent assets or operations and its sole ownership interest is in LCAH.The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the six months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company.The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Companyâ€™s fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Companyâ€™s Annual Report.The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency.Â Assets and liabilities are translated at exchange rates as of the balance sheet date.Â Revenues and expenses are translated at average monthly exchange rates prevailing during the period.Â Resulting translation adjustments are included in â€œAccumulated other

comprehensive income (loss).â€2.Â Â Â Â DISCONTINUED OPERATIONSOn June 30, 2023 (the Distribution Date), Labcorp completed the previously announced separation (the Separation) from the Company of Fortrea Holdings Inc. (Fortrea), formerly the Company's Clinical Development and Commercialization Services (CDCS) business, into a separate, publicly-traded company. All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the Condensed Consolidated Statements of Operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes.The spin-off of Fortrea from Labcorp was achieved through the Companyâ€™s pro-rata distribution of 100% of the outstanding shares of Fortrea common stock to holders of record of Labcorp common stock. Each holder of record of Labcorp common stock received one share of Fortrea common stock for every share of Labcorp common stock held at 5:00 p.m., Burlington, North Carolina, time on June 20, 2023, the record date for the distribution.In June 2023, Fortrea, prior to the Separation and while a subsidiary of the Company, issued $570.0 of 7.500% senior secured notes due 2030 (the Fortrea Notes). The proceeds from the Fortrea Notes were used to fund cash payments of 7INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)approximately $1,600.0 to the Company in connection with the Separation. The Company does not guarantee the Fortrea Notes following the Separation. Also in June 2023, Fortrea entered into three floating secured overnight financing rate (SOFR) credit facilities totaling $1,520.0. These are comprised of a $450.0 Revolver maturing June 30, 2028; a $500.0 Term Loan A maturing June 30, 2028; and a $570.0 Term Loan B maturing June 30, 2030. In connection with the spin-off, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Companyâ€™s relationship with Fortrea after the spin-off, including a separation and distribution agreement, a tax matters agreement, an employee matters agreement, and a transition services agreement. These agreements contain the key provisions relating to the spin-off, including provisions relating to the principal intercompany transactions required to effect the spin-off, the conditions to the spin-off and provisions governing the relationship between Fortrea and the Company after the spin-off. The costs to provide these services are included in operating income but the service fees are included in other income.Financial Information of Discontinued OperationsEarnings from discontinued operations, net of tax in the Consolidated Statements of Operations reflect the after-tax results of Fortrea's business and Separation-related fees, and do not include any allocation of general corporate overhead expense or interest expense of the Company.The following table summarizes the significant line items included in Earnings from Discontinued Operations, Net of Tax in the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023:Three Months Ended June 30, 2023Six Months Ended June 30, 2023Revenues$766.5Â $1,506.6Â Cost of revenues629.1Â 1,244.5Â Gross profit137.4Â 262.1Â Selling, general and administrative expenses85.4Â 184.1Â Amortization of intangibles and other assets16.0Â 31.9Â Restructuring and other charges4.1Â 3.0Â Operating income31.9Â 43.1Â Other income (expense):Other, net8.3Â 2.5Â Earnings before income taxes40.2Â 45.6Â Provision for income taxes6.3Â 6.8Â Net earnings attributable to Labcorp Holdings Inc.$33.9Â $38.8Â 3.Â Â Â Â REVENUESThe Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows:For the Three Months Ended June 30, 2024For the Three Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %24Â %â€”Â %â€”Â %24Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %77Â %â€”Â %â€”Â %77Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %10Â %9Â %4Â %23Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %8INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)For the Six Months Ended June 30, 2024For the Six Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %25Â %â€”Â %â€”Â %25Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %78Â %â€”Â %â€”Â %78Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %9Â %9Â %4Â %22Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively.Accounts Receivable, Unbilled Services and Unearned RevenueThe following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers as of June 30, 2024 and December 31, 2023:June 30, 2024December 31, 2023Dx accounts receivable$1,331.4Â $1,135.2Â BLS accounts receivable791.6Â 810.8Â Less BLS allowance for doubtful accounts(34.1)(32.7)Accounts receivable$2,088.9Â $1,913.3Â Gross unbilled services$159.3Â $192.9Â Less reserve for unbilled services(1.8)(7.5)Unbilled services$157.5Â $185.4Â Unearned revenue$388.3Â $421.7Â Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $26.8 and $20.2 for the three months ended June 30, 2024 and 2023, respectively, and $77.8 and $72.8 for the six months ended June 30, 2024 and 2023, respectively.Credit Loss RollforwardThe Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows:Accounts ReceivableUnbilled ServicesNote and Other ReceivablesTotalBalance as of December 31, 2023$32.7Â $7.5Â $0.7Â $40.9Â Plus, credit loss expense3.4Â â€”Â â€”Â 3.4Â Less, write offs2.0Â 5.7Â â€”Â 7.7Â Balance as of June 30, 2024$34.1Â $1.8Â $0.7Â $36.6Â The credit loss expense in the first six months primarily related to the collection risk from several biotech receivable balances.9INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)4.Â Â Â Â BUSINESS ACQUISITIONS AND DISPOSITIONSDuring the six months ended June 30, 2024, the Company acquired several businesses and related assets for cash of approximately $293.1. These acquisitions consisted of the clinical and outreach businesses of Baystate Medical Center ($116.6), Providence Medical Foundation ($54.9), and Westpac Labs, Inc. ($97.7) and an escrow payment of $23.9 for selected assets of the Invitae Corporation that is anticipated to close on August 5, 2024. The preliminary purchase considerations for these acquisitions were allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $159.4 in identifiable intangible assets. A residual amount of tax deductible goodwill of approximately $141.7 was recorded as of June 30, 2024. The amortization period for non-compete agreements and customer list assets acquired from these businesses are 5 and 15 years, respectively. The valuation of acquired assets and assumed liabilities, include the following:Baystate Medical CenterProvidence Medical FoundationWestpac Labs, Inc.Invitae CorporationAmounts Acquired During the Six Months Ended June 30, 2024Measurement Period Adjustments for Prior Year Acquisitions During the Six Months Ended June 30, 2024Cash and cash equivalents$â€”Â $â€”Â $â€”Â $â€”Â $â€”Â $â€”Â Inventoriesâ€”Â â€”Â 1.8Â â€”Â 1.8Â â€”Â 1.8Â â€”Â Property, plant and equipment7.2Â 0.9Â â€”Â â€”Â 8.1Â (3.9)Goodwill70.7Â 25.9Â 45.1Â â€”Â 141.7Â (7.4)Intangible assets79.6Â 29.0Â 50.8Â â€”Â 159.4Â 7.4Â Other assetsâ€”Â â€”Â â€”Â 23.9Â 23.9Â â€”Â Total assets acquired$157.5Â $55.8Â $97.7Â $23.9Â $334.9Â $(3.9)Lease liabilities7.2Â 0.9Â â€”Â â€”Â 8.1Â (3.9)Other liabilities3.7Â â€”Â â€”Â 3.7Â â€”Â Total liabilities acquired10.9Â 0.9Â â€”Â â€”Â 11.8Â (3.9)Net assets acquired$146.6Â $54.9Â $97.7Â $23.9Â $323.1Â $â€”Â Less escrow payment made in 202330.0Â â€”Â â€”Â â€”Â 30.0Â â€”Â Cash paid for acquisitions$116.6Â $54.9Â $97.7Â $23.9Â $293.1Â $â€”Â On March 28, 2024, the Company announced that it entered into an agreement to acquire selected assets of BioReference Health, a wholly owned subsidiary of OPKO Health for $237.5. The transaction is anticipated to close in the third quarter of 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction Labcorp will acquire laboratory testing businesses focused on clinical diagnostics and reproductive and women's health across the United States, outside of New York and New Jersey.On April 24, 2024, the Company announced that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. On May 6, 2024, the United States Bankruptcy Court approved the previously announced bid by Labcorp to acquire the assets of Invitae. The purchase price for the transaction is $239.0. The transaction is anticipated to close on August 5, 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction, the Company would acquire assets being auctioned through a voluntary bankruptcy protection process.During the six months ended June 30, 2023, the Company acquired two businesses and the related assets for cash of approximately $136.9. These acquisitions consisted of Jefferson Health and Valley Medical Laboratories in British Columbia which expanded the Company's presence in the northeastern U.S. and Canada. The preliminary purchase considerations for these acquisitions were allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $84.1 in identifiable intangible assets. A residual amount of non-tax deductible goodwill of approximately $50.8 was recorded as of June 30, 2023. The amortization period for non-compete agreements and customer list assets acquired from these businesses are 7 and 15 years, respectively. 10INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)During the six months ended June 30, 2023, the Company recorded several measurement period adjustments for 2022 acquisitions, relating to final valuations and deferred tax true-ups. The adjustments include the following:Measurement Period Adjustments During Six Months Ended June 30, 2023Cash and cash equivalents$0.2Â Prepaid expenses and other0.6Â Property, plant and equipment(1.5)Goodwill(29.4)Intangible assets19.5Â Total assets acquired$(10.6)Accrued expenses and other(8.3)Deferred income taxes(2.3)Total liabilities acquired(10.6)Net assets acquired$â€”Â Pro Forma InformationHad the Company's total 2024 and 2023 acquisitions been completed as of January 1, the Company's pro forma results would have been as follows:Three Months Ended June 30,Three Months Ended June 30,Six Months Ended June 30,Six Months Ended June 30,2024202320242023Revenues$3,220.9Â $3,100.5Â 6,412.0Â $6,206.5Â Net earnings from continuing operations attributable to Labcorp Holdings Inc.$205.3Â $193.4Â 432.8Â $409.5Â DispositionsDuring the six months ended June 30, 2024, the Company sold the assets of its Beacon Laboratory Benefit Solutions, Inc. for $13.5 and recorded a gain of $4.9.5.Â Â Â Â EARNINGS PER SHAREBasic earnings per share is computed by dividing net earnings attributable to the Company by the weighted average number of shares of the Company's common stock outstanding. Diluted earnings per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Companyâ€™s outstanding stock options, restricted stock awards, restricted stock units, and performance share awards.11INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)The following represents a reconciliation of basic earnings per share to diluted earnings per share for the three and six months ended June 30:Â Three Months Ended June 30,Six Months Ended June 30,Â 2024202320242023EarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountBasic earnings per share:Â Â Â Â Â Â Â Â Â Â Â Â Net earnings$205.3Â 84.1Â $2.44Â $155.0Â 88.7Â $1.75Â $433.3Â 84.1Â $5.15Â $363.0Â 88.6Â $4.10Â Dilutive effect of employeeÂ stock options and awardsâ€”Â 0.2Â Â â€”Â 0.3Â Â â€”Â 0.4Â Â â€”Â 0.4Â Â Net earnings including impact of dilutive adjustments$205.3Â 84.3Â $2.43Â $155.0Â 89.0Â $1.74Â $433.3Â 84.5Â $5.13Â $363.0Â 89.0Â $4.08Â Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:Three Months Ended June 30,Six Months Ended June 30,Â 20242023202420232Employee stock options and awards0.4Â 0.5Â 0.3Â 0.4Â 6.Â Â Â Â GOODWILL AND INTANGIBLE ASSETSThe changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows:DxBLSTotalBalance as of December 31, 2023$4,813.9Â $1,328.6Â $6,142.5Â Goodwill acquired during the period141.7Â â€”Â 141.7Â Foreign currency impact and other adjustments to goodwill(10.7)(53.3)(64.0)Balance as of June 30, 2024$4,944.9Â $1,275.3Â $6,220.2Â The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value.Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.12INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)The components of identifiable intangible assets were as follows:Â June 30, 2024December 31, 2023Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNetCustomer relationships$3,947.8Â $(1,444.1)$2,503.7Â $3,868.6Â $(1,367.2)$2,501.4Â Patents, licenses, and technology520.3Â (283.1)237.2Â 526.6Â (273.3)253.3Â Non-compete agreements152.4Â (72.5)79.9Â 130.3Â (60.4)69.9Â Canadian licenses495.1Â â€”Â 495.1Â 498.8Â â€”Â 498.8Â Other34.1Â (18.0)16.1Â 34.1Â (15.5)18.6Â Â 5,149.7Â (1,817.7)3,332.0Â 5,058.4Â (1,716.4)3,342.0Â Amortization of intangible assets for the three and six months ended June 30, 2024, and 2023, was $62.2 and $51.5 and $122.3 and $104.9, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $125.0 for the remainder of fiscal 2024, $237.2 in fiscal 2025, $228.2 in fiscal 2026, $216.9 in fiscal 2027, $209.1 in fiscal 2028, and $1,735.8 thereafter.7.Â Â Â Â DEBT Short-term borrowings and the current portion of long-term debt at June 30, 2024, and DecemberÂ 31, 2023, consisted of the following:June 30, 2024December 31, 2023Revolving line of credit$20.0Â $â€”Â 2.30% senior notes due 2024400.0Â 400.0Â 3.25% senior notes due 2024600.0Â 600.0Â 3.60% senior notes due 20251,000.0Â â€”Â Debt issuance costs(1.0)(1.3)Current portion of note payable0.5Â 1.1Â Total short-term borrowings and current portion of long-term debt$2,019.5Â $999.8Â Long-term debt at June 30, 2024, and DecemberÂ 31, 2023, consisted of the following:June 30, 2024December 31, 20233.60% senior notes due 2025â€”Â 1,000.0Â 1.55% senior notes due 2026500.0Â 500.0Â 3.60% senior notes due 2027600.0Â 600.0Â 2.95% senior notes due 2029650.0Â 650.0Â 2.70% senior notes due 2031420.3Â 430.4Â 4.70% senior notes due 2045900.0Â 900.0Â Debt issuance costs(23.4)(26.3)Note payable0.4Â 0.6Â Total long-term debt$3,047.3Â $4,054.7Â Credit FacilitiesThe Company maintains a senior revolving credit facility, which was amended and restated on January 13, 2023. It consists of a five-year facility in the principal amount of up to $1,000.0, with the option of increasing the facility by up to an additional $500.0, subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The revolving credit facility also provides for a subfacility of up to $100.0 for swing line borrowings and a subfacility of up to $150.0 for issuances of letters of credit. The Company is required to pay a facility fee on the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.10% to 0.225%, depending on the Company's debt ratings. The revolving credit facility is permitted to be used for general corporate purposes, including working capital, capital expenditures, funding of share repurchases and certain other payments, acquisitions, and other investments. The revolving credit facility also provides for the issuance of letters of credit without a reduction of the availability of borrowings under the facility. There was $20.0 outstanding on the Company's current revolving credit facility and $90.7 in outstanding letters of credit on the Company's subfacility as of June 30, 2024. As of June 30, 2024, the effective interest rate on the revolving credit facility was 6.44%. The credit facility expires on April 30, 2026. 13INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)Under the revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers, and the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants in the revolving credit facility at June 30, 2024, and expects that it will remain in compliance with its existing debt covenants for the next twelve months. 8.Â Â Â Â PREFERRED STOCK AND COMMON SHAREHOLDERSâ€™ EQUITYThe Company is authorized to issue up to

265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were no preferred shares outstanding as of June 30, 2024, and DecemberÂ 31, 2023. The changes in common shares issued during the six months ended June 30, 2024 are summarized below:Issued and OutstandingCommon shares at December 31, 202383.9Â Shares issued under employee stock plans0.4Â Shares repurchased(0.5)Common shares at June 30, 202483.8Â Share Repurchase ProgramWhen the Company repurchases shares of Common Stock, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a reduction in retained earnings. During the six months ended June 30, 2024, the Company purchased 0.5 shares of its common stock at an average price of $202.66 for a total cost of $100.0. As of June 30, 2024, the Company had outstanding authorization from the board of directors to purchase up to $430.4 of the Company's common stock. On July 24, 2024, the Board adopted a new share repurchase plan authorizing up to $1,000.0 of the Company's shares in addition to the remaining amount outstanding under the previous plan. In aggregate, the share repurchase authorization is $1,430.4.DividendsFor the six months ended June 30, 2024, the Company paid $122.5 in common stock dividends. On July 25, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the third quarter, or approximately $61.2 in the aggregate. The dividend will be payable on September 13, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on August 29, 2024. The declaration and payment of any future dividends will be at the discretion of the Company's board of directors.Accumulated Other Comprehensive Earnings (Loss)The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows:Foreign Currency Translation AdjustmentsNet Benefit Plan AdjustmentsAccumulated Other Comprehensive Earnings (Loss)Balance as of December 31, 2023(47.6)(11.7)$(59.3)Current year adjustments(131.5)(1.5)(133.0)Amounts reclassified from accumulated other comprehensive incomeâ€”Â (0.2)(0.2)Tax effect of adjustmentsâ€”Â 0.5Â 0.5Â Balance as of June 30, 2024(179.1)(12.9)$(192.0)9.Â Â Â Â COMMITMENTS AND CONTINGENCIESThe Company (and/or its subsidiaries and affiliates) is involved from time to time in various claims and legal actions, including arbitrations, class actions, and other litigation (including those described in more detail below), arising in the ordinary course of business. Some of these actions involve claims that are substantial in amount. These matters include, but are not limited to, intellectual property disputes, commercial and contract disputes, professional liability claims, employee-related matters, transaction-related disputes, securities and corporate law matters, and inquiries, including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and managed care organizations (MCOs) reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention 14INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)through billing audits or third parties. The Company receives civil investigative demands or other inquiries from various governmental bodies in the ordinary course of its business. Such inquiries can relate to the Company or other parties, including physicians and other health care providers. The Company works cooperatively to respond to appropriate requests for information.The Company also is named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from U.S. federal or state healthcare programs. The suits may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the qui tam plaintiff. Such claims are an inevitable part of doing business in the healthcare field today.The Company believes that it is in compliance in all material respects with all statutes, regulations, and other requirements applicable to its commercial laboratory operations and biopharma laboratory services. These industries are, however, subject to extensive regulation, and the courts have not interpreted many of the applicable statutes and regulations. Therefore, the applicable statutes and regulations could be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that would adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant civil and criminal penalties, fines, the loss of various licenses, certificates and authorizations, additional liabilities from third-party claims, and/or exclusion from participation in government programs.Many of the current claims and legal actions against the Company are in preliminary stages, and many of these cases seek an indeterminate amount of damages. The Company records an aggregate legal reserve, which is determined using calculations based on historical loss rates and assessment of trends experienced in settlements and defense costs. In accordance with FASB Accounting Standards Codification Topic 450 â€œContingencies,â€ the Company establishes reserves for judicial, regulatory, and arbitration matters outside the aggregate legal reserve if and when those matters present loss contingencies that are both probable and reasonably estimable. When loss contingencies are not both probable and reasonably estimable, the Company does not establish separate reserves.The Company is unable to estimate a range of reasonably probable loss for the proceedings described in more detail below in which damages either have not been specified or, in the Company's judgment, are unsupported and/or exaggerated and (i) the proceedings are in early stages, (ii) there is uncertainty as to the outcome of pending appeals or motions, (iii) there are significant factual issues to be resolved, and/or (iv) there are novel legal issues to be presented. For these proceedings, however, the Company does not believe, based on currently available information, that the adverse outcomes are probable and reasonably estimable, and it does not believe they will have a material adverse effect on the Company's financial statements. The Company has received various subpoenas and other civil investigative demands related to Medicaid billing. In October 2013, the Company received a Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On October 5, 2018, the Company received a second Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On January 26, 2021, the Company was notified that a qui tam Petition was pending under seal in the District Court, 250th Judicial District, Travis County, Texas, and that the State of Texas had intervened. On April 14, 2021, the Petition was unsealed. The Petition alleges that the Company submitted claims for reimbursement to Texas Medicaid that were higher than permitted under Texas Medicaidâ€™s alleged â€œbest priceâ€ regulations, and that the Company offered remuneration to Texas health care providers in the form of discounted pricing for certain laboratory testing services in exchange for the providersâ€™ referral of Texas Medicaid business to the Company. The Petition seeks actual and double damages and civil penalties, as well as recovery of costs, attorney's fees, and legal expenses. On August 1, 2022, the District Court entered an order granting the Company's Motion for Partial Summary Judgment with respect to the claim that the Company submitted claims for reimbursement to Texas Medicaid that were higher than permitted under Texas Medicaid's alleged â€œbest priceâ€ regulations. Plaintiffs filed a Notice of Non-Suit and Motion for Entry of Final Judgment and, on November 11, 2022, the court entered a Judgment. Plaintiffs filed a Notice of Appeal with respect to the court's order granting the Company's Motion for Partial Summary Judgment, referenced above. The Company will vigorously defend the lawsuit.On August 31, 2015, the Company was served with a putative class action lawsuit, Patty Davis v. Laboratory Corporation of America, et al., filed in the Circuit Court of the Thirteenth Judicial Circuit for Hillsborough County, Florida. The complaint alleges that the Company violated the Florida Consumer Collection Practices Act by billing patients who were collecting benefits under the Workers' Compensation Statutes. The lawsuit seeks injunctive relief and actual and statutory damages, as well as recovery of attorney's fees and legal expenses. In April 2017, the Circuit Court granted the Companyâ€™s Motion for Judgment on the Pleadings. The Plaintiff appealed the Circuit Courtâ€™s ruling to the Florida Second District Court of Appeal. On 15INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)October 16, 2019, the Florida Second District Court of Appeal reversed the Circuit Courtâ€™s dismissal, but certified a controlling issue of Florida law to the Florida Supreme Court. On February 17, 2020, the Florida Supreme Court accepted jurisdiction of the lawsuit. The court held oral arguments on December 9, 2020. On May 26, 2022, the Florida Supreme Court issued an opinion approving the result of the Florida Second District Court of Appeal in favor of the Plaintiff. The Company will vigorously defend the lawsuit.On December 29, 2021, the Company was served with a putative class action lawsuit, Nathaniel J. Nolan, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Middle District of North Carolina. The complaint alleges that the Company's patient acknowledgement of estimated financial responsibility form is misleading. The lawsuit seeks a declaratory judgment under the consumer protection laws of Nevada and Florida that the form is materially misleading and deceptive, an injunction barring the use of the form, damages on behalf of an alleged class, and attorney's fees and expenses. On February 28, 2022, the Company filed a Motion to Dismiss all claims. On February 13, 2023, the court entered an order granting the Company's Motion to Dismiss. On March 13, 2023, Plaintiffs filed a Notice of Appeal. On April 10, 2024, the U.S. Court of Appeals for the Fourth Circuit issued an order affirming in part, reversing in part, and remanding the case to the District Court for further proceedings. The Company will vigorously defend the lawsuit.On April 1, 2019, Covance Research Products was served with a Grand Jury Subpoena issued by the Department of Justice (DOJ) in Miami, Florida requiring the production of documents related to the importation into the United States of live non-human primate shipments originating from or transiting through China, Cambodia, and/or Vietnam from April 1, 2014 through March 28, 2019. The Company is cooperating with the DOJ.On May 14, 2019, Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (AMCA), an external collection agency, notified the Company about a security incident AMCA experienced that may have involved certain personal information about some of the Companyâ€™s patients (the AMCA Incident). The Company referred patient balances to AMCA only when direct collection efforts were unsuccessful. The Companyâ€™s systems were not impacted by the AMCA Incident. Upon learning of the AMCA Incident, the Company promptly stopped sending new collection requests to AMCA and stopped AMCA from continuing to work on any pending collection requests from the Company. AMCA informed the Company that it appeared that an unauthorized user had access to AMCAâ€™s system between August 1, 2018, and March 30, 2019, and that AMCA could not rule out the possibility that personal information on AMCAâ€™s system was at risk during that time period. Information on AMCAâ€™s affected system from the Company may have included name, address, and balance information for the patient and person responsible for payment, along with the patientâ€™s phone number, date of birth, referring physician, and date of service. The Company was later informed by AMCA that health insurance information may have been included for some individuals, and because some insurance carriers utilize the Social Security Number as a subscriber identification number, the Social Security Number for some individuals may also have been affected. No ordered tests, laboratory test results, or diagnostic information from the Company were in the AMCA affected system. The Company notified individuals for whom it had a valid mailing address. For the individuals whose Social Security Number was affected, the notice included an offer to enroll in credit monitoring and identity protection services that was provided free of charge for 24 months.Twenty-three putative class action lawsuits were filed against the Company related to the AMCA Incident in various U.S. District Courts. Numerous similar lawsuits have been filed against other health care providers who used AMCA. These lawsuits were consolidated into a multidistrict litigation in the District of New Jersey. On November 15, 2019, the Plaintiffs filed a Consolidated Class Action Complaint in the U.S. District Court of New Jersey. The consolidated Complaint generally alleged that the Company did not adequately protect its patientsâ€™ data and failed to timely notify those patients of the AMCA Incident. The Complaint asserted various causes of action, including but not limited to negligence, breach of implied contract, unjust enrichment, and the violation of state data protection statutes. The Complaint sought damages on behalf of a class of all affected Company customers. On January 22, 2020, the Company filed Motions to Dismiss all claims. On December 16, 2021, the court granted in part and denied in part the Company's Motion to Dismiss. On March 31, 2022, the Plaintiffs filed an Amended Complaint alleging claims for negligence, negligence per se, breach of confidence, invasion of privacy, and various state statutory claims, including a claim under the California Confidentiality of Medical Information Act. The Company filed a Motion to Dismiss certain claims of the Amended Complaint. On May 5, 2023, the court granted in part and denied in part the Company's Motion to Dismiss. The Company will vigorously defend the remaining claims in the multi-district litigation.The Company was served with a shareholder derivative lawsuit, Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al., filed in the Court of Chancery of the State of Delaware on April 23, 2020.Â The complaint asserts derivative claims on the Companyâ€™s behalf against the Companyâ€™s board of directors and certain executive officers. The complaint generally alleges that the defendants failed to ensure that the Company utilized proper cybersecurity safeguards and failed to implement a sufficient response to data security incidents, including the AMCA Incident.Â The complaint asserts derivative claims for breach of fiduciary duty and seeks relief including 16INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)damages, certain disclosures, and certain changes to the Companyâ€™s internal governance practices. On June 2, 2020, the Company filed a Motion to Stay the lawsuit due to its overlap with the multi-district litigation referenced above. On July 2, 2020, the Company filed a Motion to Dismiss. On July 14, 2020, the court entered an order staying the lawsuit pending the resolution of the multi-district litigation. The Company will vigorously defend the lawsuit.Certain governmental entities have requested information from the Company related to the AMCA Incident. The Company received a request for information from the Office for Civil Rights (OCR) of the Department of Health and Human Services.Â On April 28, 2020, OCR notified the Company of the closure of its inquiry. The Company has also received requests from a multi-state group of state Attorneys General and is cooperating with these requests for information.On January 31, 2020, the Company was served with a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Central District of California. The lawsuit alleges that visually impaired patients are unable to use the Company's touchscreen kiosks at Company patient service centers in violation of the Americans with Disabilities Act and similar California statutes. The lawsuit seeks statutory damages, injunctive relief, and attorney's fees and costs. On March 20, 2020, the Company filed a Motion to Dismiss Plaintiffs' Complaint and to Strike Class Allegations. In August 2020, the Plaintiffs filed an Amended Complaint. On April 26, 2021, the Plaintiffs and the Company each filed Motions for Summary Judgment and the Plaintiffs filed a Motion for Class Certification. On May 23, 2022, the court entered an order granting Plaintiffsâ€™ Motion for Class Certification. On June 6, 2022, the Company filed a Petition for Permission to Appeal the Order Granting Class Certification with the U.S. Court of Appeals for the Ninth Circuit. On September 22, 2022, the Ninth Circuit granted the Company's Petition for Permission to Appeal the Order Granting Class Certification. On February 8, 2024, the Ninth Circuit affirmed the trial courtâ€™s decision to certify both a California damages class and a nationwide injunctive class. On March 25, 2024, the Company filed a Petition for Rehearing En Banc with the Ninth Circuit. On April 18, 2024, the Ninth Circuit denied the Petition for Rehearing En Banc. The Company will vigorously defend the lawsuit.On October 16, 2020, Ravgen Inc. filed a patent infringement lawsuit, Ravgen Inc. v. Laboratory Corporation of America Holdings, in the U.S. District Courtâ€¯for the Western District ofâ€¯Texas, alleging infringement of two Ravgen-owned U.S. patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, and recovery of attorneyâ€™s fees and costs. On September 28, 2022, a jury rendered a verdict in favor of the Plaintiff on the remaining patent at issue, finding that the Company willfully infringed Ravgen's patent, and awarded damages of $272.0. Plaintiff filed post-trial motions seeking enhanced damages of up to $817.0 based on the finding of willfulness, as well as attorney's fees and costs. On May 12, 2023, the court issued an order granting Plaintiff's motion in part and awarding enhanced damages of $100.0. The Company strongly disagrees with the verdict, based on a number of legal factors, and will vigorously defend the lawsuit through the appeal process. On June 4, 2021, the Company also instituted proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office challenging the validity of the Ravgen patent at issue in the trial. In November 2022, the Patent Trial and Appeal Board issued a decision upholding the validity of the Ravgen patent, and the Company has filed an appeal of this decision.On May 14, 2020, the Company was served with a putative class action lawsuit, Jose Bermejo v. Laboratory Corporation of America (Bermejo I) filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain non-exempt California-based employees were not properly compensated for driving time or properly paid wages upon termination of employment. The Plaintiff asserts these actions violate various California Labor Code provisions and Section 17200 of the Business and Professional Code. The lawsuit seeks monetary damages, civil penalties, and recovery of attorneyâ€™s fees and costs. On June 15, 2020, the lawsuit was removed to the U.S. District Court for the Central District of California. On June 16, 2020, the Company was served with a Private Attorney General Act lawsuit by the same plaintiff in Jose Bermejo v. Laboratory Corporation of America (Bermejo II), filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain Company practices violated California Labor Code penalty provisions related to unpaid and minimum wages, unpaid overtime, unpaid meal and rest break premiums, untimely payment of wages following separation of employment, failure to maintain accurate pay records, and non-reimbursement of business expenses. The second lawsuit seeks to recover civil penalties and recovery of attorney's fees and costs. On October 28, 2020, the court issued an order staying proceedings in Bermejo II pending resolution of Bermejo I. The second lawsuit seeks to recover civil penalties and recovery of attorney's fees and costs. On February 24, 2022, the parties entered into a Memorandum of Understanding of the terms of a settlement of the Bermejo I and Bermejo II lawsuits. The court granted preliminary approval of the partiesâ€™ settlement agreement of the Bermejo I lawsuit on March 17, 2023, and of the Bermejo II lawsuit on November 29, 2023. The settlement funds for the Bermejo I and Bermejo II settlements have been transferred to a claims administrator for processing. Once the claims administration is completed, the parties will seek final settlement approval from the

court.17INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)On June 14, 2021, a single plaintiff filed a Private Attorney General Act lawsuit, Becker v. Laboratory Corporation of America, in the Superior Court of California, County of Orange, alleging various violations of the California Labor Code, including that the Plaintiff was not properly compensated for work and overtime hours, not properly paid meal and rest break premiums, not reimbursed for certain business-related expenses, and received inaccurate wage statements. The lawsuit seeks monetary damages, civil penalties, and recovery of attorneyâ€™s fees and costs. A settlement of the Bermejo I and Bermejo II lawsuits, if approved by the court, will resolve the Becker lawsuit.On November 23, 2021, the Company was served with a single plaintiff Private Attorney General Act lawsuit, Poole v. Laboratory Corporation of America, filed in the Superior Court of California, County of Kern, alleging various violations of the California Labor Code, including that Plaintiff was not properly paid wages owed, not properly paid meal and rest break premiums, not reimbursed for certain business related expenses, and other allegations including the untimely payment of wages and receipt of inaccurate wage statements. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney's fees and costs. The case was removed to the U.S. District Court for the Eastern District of California. A settlement of the Bermejo I and Bermejo II lawsuits, if approved by the court, will resolve the portion of the Poole lawsuit relating to service representatives and senior service representatives.On October 5, 2020, the Company was served with a putative class action lawsuit, Williams v. LabCorp Employer Services, Inc. et al., filed in the Superior Court of California, County of Los Angeles, alleging that certain non-exempt California-based employees were not properly compensated for work and overtime hours, not properly paid meal and rest break premiums, not reimbursed for certain business-related expenses, not properly paid for driving or wait times, and received inaccurate wage statements. The Plaintiff also asserts claims for unfair competition under Section 17200 of the Business and Professional Code. On November 4, 2020, the lawsuit was removed to the U.S. District Court for the Central District of California. The lawsuit seeks monetary damages, liquidated damages, civil penalties, and recovery of attorney's fees and costs. On June 24, 2021, the District Court remanded the case to the Superior Court of California, County of Los Angeles on the grounds that potential damages did not meet the Class Action Fairness Act (CAFA), 28 U.S.C. Â§ 1332(d), jurisdictional threshold. The parties entered into a settlement agreement which received court preliminary approval on December 13, 2023. Settlement proceeds were transferred to the settlement fund administrator in January 2024 and have been distributed by the settlement fund administrator. A case review is scheduled by the court for September 13, 2024, at which time the court is expected to sua sponte dismiss the lawsuit given its resolution by settlement. On June 7, 2023, the Company was served with a putative class action lawsuit, Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds, et al. v. Laboratory Corporation of America, Laboratory Corporation of America Holdings, and Meta Platforms, Inc., filed in the U.S. District Court for the Northern District of California, alleging that the Companyâ€™s website includes a tracking code created by Meta, known as the Meta Pixel, that sent information related to Plaintiffs and their online activities to Meta. Plaintiffs assert claims against the Company under California and Pennsylvania law and seek to represent classes of all persons in California, or in Pennsylvania, who allegedly entered search terms into the Companyâ€™s website and who used Facebook during a time that Plaintiffs allege the Meta Pixel was active on the Companyâ€™s website. Plaintiffs seek an injunction, damages, attorneysâ€™ fees, and costs. On August 23, 2023, the Company filed a Motion to Dismiss. On September 5, 2023, the lawsuit was transferred to the U.S. District Court for the Middle District of North Carolina. On September 9, 2023, Plaintiffs filed an Amended Complaint. Among other things, the Amended Complaint contains allegations that in addition to the Meta Pixel, the Company's website uses Google Analytics and other online tracking technologies. The Company will vigorously defend the lawsuit.On August 14, 2020, the Company was served with a Subpoena Duces Tecum issued by the State of Colorado Office of the Attorney General requiring the production of documents related to urine drug testing in all states. The Company is cooperating with this request.On February 7, 2022, the Company was served with a Subpoena Duces Tecum issued by the DOJ in Camden, New Jersey requiring the production of documents related to non-invasive prenatal screening tests. The Company responded to the DOJ.On June 27, 2022, the Company was served with a Subpoena Duces Tecum issued by the DOJ in Boston, Massachusetts requiring the production of documents related to urine drug testing. The Company is cooperating with the DOJ.In April 2023, the Company received Civil Investigative Demands issued by the DOJ in Washington, D.C. requiring the production of information related to the Medicare billing rule regarding reimbursement for laboratory testing performed for hospital patients. The Company is cooperating with the DOJ.On February 13, 2024, a putative class action lawsuit, Michael Wiggins and Teri Stevens v. Laboratory Corporation of America Holdings, was filed in the U.S. District Court for the Eastern District of Pennsylvania, alleging that the Companyâ€™s 18INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)website includes a computer code created by Google that sent information to Google related to Plaintiffs and their online activities. Plaintiffs assert statutory and common law claims against the Company and seek to represent a class of all persons whose health information was allegedly shared with Google from the Companyâ€™s website before March 8, 2023. Plaintiffs seek an injunction, damages, attorneysâ€™ fees, and costs. On April 12, 2024, the Company filed a Motion to Compel Arbitration and Stay Proceedings. The Company will vigorously defend the lawsuit.There are various other pending legal proceedings involving the Company including, but not limited to, additional employment-related lawsuits, professional liability lawsuits, and commercial lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, the likelihood of loss is remote and any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Companyâ€™s financial condition, results of operations, or cash flows, either individually or in the aggregate.Under the Company's present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers' compensation. The self-insured retentions are on a per-occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company's estimates of the aggregated liability of claims incurred.10. Â Â Â Â FAIR VALUE MEASUREMENTSThe Companyâ€™s population of financial assets and liabilities subject to fair value measurements as of June 30, 2024, and DecemberÂ 31, 2023, was as follows:Fair Value Measurements as ofJune 30, 2024Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationJune 30, 2024Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.0Â $â€”Â $15.0Â $â€”Â Cross currency swapsOther liabilities103.6Â â€”Â 103.6Â â€”Â Interest rate swapsOther liabilities79.7Â â€”Â 79.7Â â€”Â Cash surrender value of life insurance policiesOther assets, net96.4Â â€”Â 96.4Â â€”Â Deferred compensation assetOther assets, net31.0Â â€”Â 31.0Â â€”Â Deferred compensation liabilityOther liabilities125.3Â â€”Â 125.3Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities20.0Â â€”Â Â â€”Â 20.0Â Fair Value Measurements as ofDecember 31, 2023Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationDecember 31, 2023Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.5Â $â€”Â $15.5Â $â€”Â Cross currency swapsAccrued expenses and other; Other liabilities109.0Â â€”Â 109.0Â â€”Â Interest rate swapsOther liabilities, net69.6Â â€”Â 69.6Â â€”Â Cash surrender value of life insurance policiesOther assets, net95.4Â â€”Â 95.4Â â€”Â Deferred compensation assetOther assets, net21.1Â â€”Â 21.1Â â€”Â Deferred compensation liabilityOther liabilities107.4Â â€”Â 107.4Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities66.1Â â€”Â â€”Â 66.1Â The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Companyâ€™s condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value.The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of multiple measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in 19INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments, which are typically invested in a similar manner to the participant's allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.Contingent accrued earn-out business acquisition consideration liabilities are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3.The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the senior notes, based on market pricing, was approximately $4,812.3 and $4,850.4 as of June 30, 2024, and DecemberÂ 31, 2023, respectively. The Company's note and debt instruments are classified as Level 2 instruments, as the fair market values of these instruments are determined using other observable inputs.Cross-Currency SwapDuring the fourth quarter of 2018, the Company entered into U.S. Dollar (USD) to Swiss Franc cross-currency swap agreements with an aggregate notional value of $600.0. During the second quarter of 2022, the Company terminated $300.0 of those cross-currency swap agreements and entered into new USD to Swiss Franc cross-currency swap agreements with an aggregate notional value of $300.0 that mature in 2024. During the first quarter of 2024, the Company terminated its 2024 and 2025 USD to Swiss Franc cross currency swaps and entered into two new swaps, each with a notional value of $300.0 and maturity dates of 2031 and 2034, respectively. These cross currency swaps are included in Accrued expenses and other and other long-term liabilities as appropriate with an aggregate fair value of $103.6 and $109.0 as of June 30, 2024 and DecemberÂ 31, 2023, respectively. Changes in the fair value of the cross-currency swaps are charged or credited through accumulated other comprehensive income in the Consolidated Balance Sheet until the hedged item is recognized in earnings. The cumulative amount of the fair value hedging adjustments are recognized as currency translation within the Condensed Consolidated Statement of Comprehensive Earnings.11. Â Â Â Â SUPPLEMENTAL CASH FLOW INFORMATIONSix Months Ended June 30,Â 20242023Cash paid during period for:Â Â Interest$106.6Â $109.5Â Income taxes, net of refunds153.0Â 133.3Â Disclosure of non-cash financing and investing activities:Â Â Change in accrued property, plant, and equipment(19.2)16.5Â 12. Â Â Â Â BUSINESS SEGMENT INFORMATIONThe following table is a summary of segment information for the three and six months ended June 30, 2024, and 2023. The â€œmanagement approachâ€ has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Companyâ€™s chief executive officer has been identified as the CODM.Segment asset information is not presented because it is not used by the CODM at the segment level. The Corporate costs not allocated to segments include the costs of centralized functions, other charges such as acquisition expenses, spin-off costs, remaining unallocated costs of the CDCS business, and COVID-19 related costs unrelated to the segment. Centralized functions include corporate governance, executive management and related human resources, finance, legal, risk management, and information technology functions.20INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data)Three Months Ended June 30,Six Months Ended June 30,2024202320242023Revenues:Dx$2,524.9Â $2,340.8Â $5,004.6Â $4,723.6Â BLS707.0Â 699.0Â 1,417.9Â 1,360.3Â Intercompany eliminations and other(11.0)(6.1)(25.0)(12.4)Total revenues$3,220.9Â $3,033.7Â $6,397.5Â $6,071.5Â Operating Earnings:Dx segment operating income$441.5Â $409.7Â $859.4Â $851.2Â BLS segment operating income107.4Â 104.6Â 207.3Â 178.2Â Segment operating income548.9Â 514.3Â 1,066.7Â 1,029.4Â General corporate and unallocated expenses(180.3)(177.9)(309.2)(300.1)Amortization of intangibles and other assets(62.2)(51.5)(122.3)(104.9)Goodwill and other asset impairmentsâ€”Â (2.8)(2.5)(5.0)Restructuring and other charges(11.6)(15.8)(16.6)(23.3)Total operating income$294.8Â $266.3Â $616.1Â $596.1Â 21INDEXITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSFORWARD-LOOKING STATEMENTS The Company has made in this report, and from time to time may otherwise make in its public filings, press releases, and discussions by Company management, forward-looking statements concerning the Companyâ€™s operations, performance, and financial condition, as well as its strategic objectives.Â Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as â€œbelievesâ€, â€œexpectsâ€, â€œmayâ€, â€œwillâ€, â€œshouldâ€, â€œseeksâ€, â€œapproximatelyâ€, â€œintendsâ€, â€œplansâ€, â€œestimatesâ€, or â€œanticipatesâ€ or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the â€œSummary of Material Risksâ€ and â€œRisk Factorsâ€ section of the Annual Report on Form 10-K, and in the Companyâ€™s other public filings, press releases, and discussions with Company management, including:1.changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the U.S. healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S. Protecting Access to Medicare Act of 2014 (PAMA);2.significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Companyâ€™s reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business;3.significant fines, penalties, costs, unanticipated compliance expenditures, and/or damage to the Companyâ€™s reputation arising from the failure to comply with applicable privacy and security laws and regulations, including the U.S. Health Insurance Portability and Accountability Act of 1996, the U.S. Health Information Technology for Economic and Clinical Health Act, the European Union's General Data Protection Regulation and similar laws and regulations in jurisdictions in which the Company conducts business;4.loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories, the development and commercialization of laboratory-developed tests (LDTs), and the delivery of clinical laboratory test results, including, but not limited to, the U.S. Clinical Laboratory Improvement Act of 1967, the U.S. Clinical Laboratory Improvement Amendments of 1988, the European Union In Vitro Diagnostics Regulation, and similar laws and regulations in jurisdictions in which the Company conducts business;5.penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements, the U.S. Needlestick Safety and Prevention Act, and similar laws and regulations in jurisdictions in which the Company conducts business;6.fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company's reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with current good manufacturing practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business;7.sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the Animal Welfare Act or applicable national, state and local laws and regulations in jurisdictions in which the Company conducts business;8.changes in testing guidelines or recommendations by government agencies, medical specialty societies, and other authoritative bodies affecting the development, validation, approval, clearance, commercialization, or utilization of laboratory tests;9.changes in applicable government regulations or policies affecting the approval, availability of, and the selling and marketing of diagnostic tests, including LDTs, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicine and Healthcare products Regulatory Agency in the United Kingdom, the National Medical Products Administration in China, the Pharmaceutical and Medical Devices Agency in Japan, the 22INDEXEuropean Medicines Agency in the European Union, and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business;10.changes in government regulations or reimbursement pertaining to the pharmaceutical, biotechnology and medical device and diagnostic industries, changes in reimbursement of pharmaceutical products, or reduced spending on research and development by pharmaceutical, biotechnology and medical device and diagnostic customers;11.liabilities that result from the failure to comply with corporate governance requirements;12.increased competition, including price competition, potential reduction in rates in response to price transparency initiatives and consumerism, competitive bidding and/or changes or reductions to fee schedules, and competition from companies that do

not comply with existing applicable laws or regulations or otherwise disregard compliance standards in the industry;13.changes in payer mix or payment structure or process, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of clearinghouses on the claims reimbursement process, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing or testing methodologies;14.failure to retain or attract business from managed care organizations (MCOs) as a result of changes in business models, including risk based or network approaches, out-sourced laboratory network management or utilization management companies, or other changes in strategy or business models by MCOs;15.failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted, or services requested by existing customers, and delays in payments from customers;16.consolidation and convergence of customers, competitors, and suppliers, potentially causing material shifts in insourcing, utilization, pricing, reimbursement and supply chain access;17.failure to invest in or effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market, business, and customer trends and needs;18.customers choosing to insource services that are or could be purchased from the Company;19.failure to identify, successfully close and effectively integrate and/or manage acquisitions of new businesses or failure to maintain key customers and/or employees as a result of uncertainty surrounding the integration of acquisitions;20.inability to achieve the expected benefits and synergies of newly-acquired businesses, including due to items not discovered in the due diligence process, and the impact on the Companyâ€™s cash position, levels of indebtedness and stock price;21.termination, loss, delay, reduction in scope or increased costs of contracts, including large contracts and multiple contracts;22.liability arising from errors or omissions in the performance of testing and other services or other contractual arrangements;23.changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Companyâ€™s performance standards and requirements;24.damage or disruption to the Companyâ€™s facilities;25.damage to the Companyâ€™s reputation, loss of business, or other harm from acts of animal rights activists or potential harm and/or liability arising from animal research activities;26.adverse results in litigation matters;27.inability to attract, retain, and develop experienced and qualified personnel or the loss of significant personnel as a result of illness, increased competition for talent, wage growth, or other market factors beyond the Companyâ€™s control;28.failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests;29.substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;23INDEX30.failure to obtain, maintain, and enforce intellectual property rights for protection of the Companyâ€™s products and services and defend against challenges to those rights;31.scope, validity, and enforceability of patents and other proprietary rights held by third parties that may impact the Companyâ€™s ability to develop, perform, or market the Company's products or services or operate its business;32.business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in material cost or other operating costs, or other impacts on the business due to natural disasters, including adverse weather, fires and earthquakes; geopolitical crises, including terrorism and war; public health crises and disease epidemics and pandemics, including, but not limited to the continued impact of COVID-19; and other events beyond the Companyâ€™s control;33.discontinuation or recalls of existing testing products;34.a failure in the Companyâ€™s information technology systems, including with respect to testing turnaround time and billing processes, the failure of the Company or its third-party suppliers and vendors to maintain the security of business information or systems or to protect against cybersecurity incidents such as denial of service attacks, malware, ransomware, and computer viruses, delays or failures in the development and implementation of the Companyâ€™s automation platforms, or adverse effects from the use of or regulation of artificial intelligence and machine learning tools, any of which could result in a negative effect on the Companyâ€™s performance of services, a loss of business or increased costs, delays in cash collections, damages to the Companyâ€™s reputation, significant litigation exposure, an inability to meet required financial reporting deadlines, or the failure to meet future regulatory or customer information technology, data security and connectivity requirements;35.business interruption, increased costs, and other adverse effects on the Companyâ€™s operations due to the unionization of employees, union strikes, work stoppages, general labor unrest or failure to comply with labor or employment laws;36.failure to maintain the Companyâ€™s days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third-party utilization management organizations, and increasing levels of patient payment responsibility;37.impact on the Companyâ€™s revenues, cash collections, and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company's credit ratings by Standard & Poorâ€™s and/or Moodyâ€™s;38.failure to maintain the expected capital structure for the Company, including failure to maintain the Company's investment grade rating, or leverage ratio covenants under its revolving credit facility;39.changes in reimbursement by foreign governments and foreign currency fluctuations;40.inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts, and ongoing reductions in reimbursements and revenues;41.expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions;42.failure to achieve expected efficiencies, benefits, and savings in connection with the Companyâ€™s business process improvement initiatives;43.changes in tax laws and regulations or changes in their interpretation;44.changing global economic conditions and government and regulatory changes; 45.risks associated with the impacts and expected benefits and costs of the completed spin-off of Fortrea, including but not limited to factors that could adversely affect the Companyâ€™s ability to realize the expected benefits of the spin-off, the failure of the spin-off to qualify as a tax-free transaction for U.S. federal income tax purposes, and potential exposure to unexpected claims, liabilities, or costs under the Companyâ€™s agreements with Fortrea and/or otherwise in connection with the spin-off; and46.risks and uncertainties as to the expected benefits of the Reorganization, including, but not limited to the effect of the Reorganization on the Company's business generally, and unexpected issues that may arise as a result of the Reorganization.24INDEXExcept as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Given these uncertainties, one should not put undue reliance on any forward-looking statements.Separation of Fortrea Holdings Inc.On June 30, 2023, Labcorp completed the previously announced separation of Fortrea from the Company.All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the Condensed Consolidated Statements of operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes.As a result of the separation of Fortrea, the Company recast segment results to exclude the historical results of the CDCS business for all periods presented. The remaining operations of the previously reported Drug Development segment have been renamed the Biopharma Laboratory Services segment.GENERAL (dollars in millions, except per share data)Revenues for the six months ended June 30, 2024, were $6,397.5, an increase of 5.4% from $6,071.5 during the six months ended June 30, 2023. The increase was due to organic revenue of 3.0%, acquisitions, net of divestitures, of 2.1%, and favorable foreign currency translation of 0.2%. The 3.0% increase in organic revenue was driven by a 4.3% increase in the company's organic Base Business, partially offset by a 1.3% decrease in COVID-19 PCR testing (COVID-19 Testing). Compared to the Base Business last year, Base Business revenue grew 6.8%. Base Business includes Labcorp's operations except for COVID-19 Testing. The Company defines organic growth as the increase in revenue excluding the year-over-year impact of acquisitions, divestitures, and currency. Acquisition and divestiture impact is considered for a twelve month period following the close of each transaction.RESULTS OF OPERATIONS (dollars in millions)Three months ended June 30, 2024, compared with three months ended June 30, 2023 Revenues Three Months Ended June 30,20242023ChangeDx$2,524.9Â $2,340.8Â 7.9Â %BLS707.0Â 699.0Â 1.1Â %Intercompany eliminations and other(11.0) (6.1)80.3Â %Total$3,220.9Â $3,033.7Â 6.2Â %Total revenues for the three months ended June 30, 2024, were $3,220.9, an increase of 6.2% over $3,033.7 in the second quarter of 2023. The increase was due to organic revenue of 3.8%, acquisitions, net of divestitures, of 2.5%, partially offset by unfavorable foreign currency translation of 0.1%. The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset by a 0.7% decrease in COVID-19 Testing. Compared to Base Business last year, Base Business revenue grew 6.9%. Base Business includes Labcorp's operations except for COVID-19 Testing.Dx revenues for the three months ended June 30, 2024, were $2,524.9, an increase of 7.9% over $2,340.8 in the second quarter of 2023. The increase was due to organic revenue of 4.7% and acquisitions, net of divestitures, of 3.2%, partially offset by unfavorable foreign currency translation of 0.1%. The 4.7% increase in organic growth was due to a 5.6% increase in the Base Business, partially offset by a 0.9% decrease in COVID-19 Testing. Total Base Business growth compared to the Base Business in the prior year was 8.9%. Dx organic volume increased by 2.9% for the three months ended June 30, 2024, while total volume (measured by requisitions) increased by 5.7% as acquisition volume, net of divestitures, contributed 2.8%. Organic volume was up due to a 3.4% increase in the Base Business, partially offset by a 0.5% decrease in COVID-19 Testing. Price/mix increased by 2.1% due to organic Base Business growth of 2.2% and acquisitions of 0.4%, partially offset by a decrease in COVID-19 Testing of 0.4%. Base Business volume increased 6.3% compared to the Base Business last year. Price/mix was up 2.5% in the Base Business compared to the Base Business last year.BLS revenues for the three months ended June 30, 2024, were $707.0, an increase of 1.1% over $699.0 in the second quarter of 2023. The increase was due to organic growth of 1.2%, partially offset by unfavorable foreign currency translation of 0.1%.25INDEXCost of RevenuesThree Months Ended June 30,Â Â 20242023ChangeCost of revenues$2,294.5Â $2,191.5Â 4.7Â %Cost of revenues as a % of revenues71.2Â %72.2Â %Â Cost of revenues increased 4.7% during the three months ended June 30, 2024, as compared with the corresponding period in 2023. Cost of revenues as a percentage of revenues during the three months ended June 30, 2024, decreased to 71.2% as compared to 72.2% in the corresponding period in 2023. This decrease in cost of revenues as a percent of revenues was primarily due to demand, LaunchPad savings, and CDCS costs in 2023 that do not qualify as discontinued operations, partially offset by higher personnel costs.Selling, General and Administrative ExpensesÂ Three Months Ended June 30,Â Â 20242023ChangeSelling, general and administrative expenses$557.8Â $505.8Â 10.3Â %Selling, general and administrative expenses as a % of revenues17.3Â %16.7Â %Â Selling, general and administrative expenses as a percentage of revenues was 17.3% and 16.7% during the three months ended June 30, 2024, and 2023, respectively. The increase is primarily due to higher personnel costs partially offset by LaunchPad savings and demand.Amortization of Intangibles and Other AssetsÂ Three Months Ended June 30,Â Â 20242023ChangeAmortization of intangibles and other assets$62.2Â $51.5Â 20.8Â %The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to June 30, 2023.Goodwill and Other Asset ImpairmentsThree Months Ended June 30,20242023ChangeGoodwill and other asset impairments$â€”Â $2.8Â (100.0)%The Company recorded no impairment charges during the three months ended June 30, 2024. The Company recorded impairment charges of $2.8 in intangible assets during the three months ended June 30, 2023.Restructuring and Other ChargesÂ Three Months Ended June 30,Â Â 20242023ChangeRestructuring and other charges$11.6Â $15.8Â (26.3)%During the three months ended June 30, 2024, the Company recorded net restructuring and other charges of $11.6. The charges were comprised of $9.2 related to severance and other personnel cost and $2.7 in facility-related costs. The charges were adjusted by the reversal of a previously established liability of $0.3 in unused facility-related costs.During the three months ended June 30, 2023, the Company recorded net restructuring and other charges of $15.8. The charges were comprised of $5.2 related to severance and other personnel costs and $8.9 in facility closures, lease terminations, and general integration activities. The charges were adjusted by the reversal of a previously established liability of $0.6 in unused severance liabilities and the increase of a previously established liability of $2.3 in facility-related costs.Interest ExpenseThree Months Ended June 30,Â Â 20242023ChangeInterest expense(47.6)(49.8)(4.4)%The decrease in interest expense for the three months ended June 30, 2024, as compared with the corresponding period in 2023, is primarily due to the repayment of the November 2023 $300.0 senior notes.26INDEXEquity Method IncomeÂ Three Months Ended June 30,Â Â 20242023ChangeEquity method income (expense), net(0.3)0.9Â (133.0)%Â Equity method income (expense) represents the Company's ownership share in joint venture partnerships along with equity investments in other companies in the health care industry. The decrease in income for the three months ended June 30, 2024, as compared with the corresponding period in 2023, was partially due to the sale of the Company's interest in one joint venture and the acquisition of the remaining interest in another joint venture during 2023. Other, netÂ Three Months Ended June 30,Â Â 20242023ChangeOther, net$19.5Â $(16.9)215.0Â %Â The change in Other, net for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023, is primarily due to $22.9 of transition services fees charged to Fortrea related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income. In addition, the Company recorded investment losses of $1.5 for the three months ended June 30, 2024 compared to investment losses of $4.1 for the corresponding period of 2023. Foreign currency transaction losses of $1.9 were recognized for the three months ended June 30, 2024, as compared to losses of $11.2 for the corresponding period of 2023. Income Tax ExpenseThree Months Ended June 30,Â Â 20242023ChangeIncome tax expense$62.1Â $49.8Â 24.7Â %Income tax expense as a % of earnings before income taxes23.2Â %24.3Â %Â The current year and prior year effective tax rate differs from the U.S. federal statutory rate of 21.0% primarily due to state income taxes and the disallowance of certain executive compensation, which were partially offset by research and development tax credits and favorable foreign rate differentials. Operating Income by SegmentAs a result of the spin-off of Fortrea, the Company recast the segment results to exclude the historical results of the CDCS business for all periods presented. The remaining operations of the previously reported Drug Development segment have been renamed the Biopharma Laboratory Services segment.Â Three Months Ended June 30,Â Â 20242023ChangeDx segment operating income$441.5Â $409.7Â 7.8Â %Dx segment operating margin17.5Â %17.5Â %â€”Â %BLS segment operating income107.4Â 104.6Â 2.7Â %BLS segment operating margin15.2Â %15.0Â %0.2Â %Segment operating income548.9Â 514.3Â 6.7Â %General corporate and unallocated expenses(180.3)(177.9)1.3Â %Amortization of intangibles and other assets(62.2)(51.5)20.8Â %Goodwill and other asset impairmentsâ€”Â (2.8)(100.0)%Restructuring and other charges(11.6)(15.8)(26.3)%Total operating income$294.8Â $266.3Â 10.7Â %Dx operating income was $441.5 for the three months ended June 30, 2024, an increase of $31.8 over operating income of $409.7 in the corresponding period of 2023. The increase in adjusted operating income was driven by organic demand, acquisitions, and LaunchPad savings, partially offset by higher personnel costs.BLS operating income was $107.4 for the three months ended June 30, 2024, an increase of $2.8 over operating income of $104.6 in the corresponding period of 2023. The increase was due to organic growth and LaunchPad savings, partially offset by higher personnel costs. General corporate and unallocated expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. General corporate and unallocated 27INDEXexpenses were $180.3 for the three months ended June 30, 2024, an increase of $2.4 over corporate expenses of $177.9 in the corresponding period of 2023, primarily due to costs related to the spin-off of Fortrea and personnel costs.The Company remains on track to deliver approximately $100.0 to $125.0 of Launchpad savings in fiscal 2024.Six Months Ended June 30, 2024, compared with six months ended June 30, 2023 Revenues Six Months Ended June 30,20242023ChangeDx$5,004.6Â $4,723.6Â 5.9Â %BLS$1,417.9Â $1,360.3Â 4.2Â %Intercompany eliminations and other(25.0)(12.4)101.6Â %Total$6,397.5Â $6,071.5Â 5.4Â %The increase in revenues for the six months ended June 30, 2024, as compared with the corresponding period in 2023 was 5.4%. The increase was due to organic revenue of 3.0%, acquisitions, net of divestitures, of 2.1%, and favorable foreign currency translation of 0.2%. The 3.0% increase in organic revenue was driven by a 4.3% increase in the company's organic Base Business, partially offset by a 1.3% decrease in COVID-19 Testing. Compared to the Base Business last year, Base Business revenue grew 6.8%.Dx revenues for the six months ended June 30, 2024, were $5,004.6, an increase of 5.9% over $4,723.6 during the six months ended June 30, 2023. The increase was due to organic revenue of 3.3% and acquisitions, net of divestitures, of 2.7%. The 3.3% increase in organic growth was due to a 4.9% increase in the Base Business, partially offset by a 1.7% decrease in COVID-19 Testing. Total Base Business growth compared to the Base Business in the prior year was 7.8%. Dx total volume (measured by requisitions) for the six months ended June 30, 2024, increased by 4.6% as acquisition volume, net of divestitures, contributed 2.5%, while organic volume increased by 2.1%. Organic volume was up due to a 3.0% increase in the Base Business, partially offset by a 1.0% decrease in COVID-19 Testing. Price/mix increased by 1.4% due to organic Base Business growth of 1.9% and acquisitions, net of divestitures of 0.2%, partially offset by a decrease in COVID-19 Testing of 0.7%. Base Business volume increased 5.6% compared to the Base Business last year. Price/mix was up 2.2% in the Base Business compared to the Base Business last year.BLS revenues for the six months ended June 30, 2024, were $1,417.9, an increase of 4.2% over $1,360.3 during the six months ended June 30, 2023. The increase was due to organic growth of 3.1% and favorable foreign currency translation of 1.1%.Cost of RevenuesSix Months Ended June 30,Â Â 20242023ChangeCost of revenues$4,573.8Â $4,379.2Â 4.4Â %Cost of revenues as a % of revenues71.5Â %72.1Â %Â Cost of revenues increased 4.4%

during the six months ended June 30, 2024, as compared with the corresponding period in 2023. Cost of revenues as a percentage of revenues during the six months ended June 30, 2024, decreased to 71.5% as compared to 72.1% in the corresponding period in 2023. This decrease in cost of revenues as a percent of revenues was primarily due to LaunchPad saving, demand, and CDCS costs in 2023 that do not qualify as discontinued operations, largely offset by higher personnel costs and lower COVID-19 Testing.Selling, General and Administrative ExpensesÂ Six Months Ended June 30,Â Â 20242023ChangeSelling, general and administrative expenses$1,066.2Â $963.0Â 10.7Â %Selling, general and administrative expenses as a % of revenues16.7Â %15.9Â %Â Selling, general and administrative expenses as a percentage of revenues were 16.7% and 15.9% during the six months ended June 30, 2024, and 2023, respectively. The increase is primarily due to higher personnel costs and a reduction in COVID-19 Testing revenues, partially offset by LaunchPad savings and demand. 28INDEXAmortization of Intangibles and Other AssetsÂ Six Months Ended June 30,Â Â 20242023ChangeAmortization of intangibles and other assets$122.3Â $104.9Â 16.6Â %The increase in amortization of intangibles and other assets primarily reflects additional amortization for assets acquired subsequent to June 30, 2023.Goodwill and Other Asset ImpairmentsSix Months Ended June 30,20242023ChangeGoodwill and other asset impairments$2.5Â $5.0Â (50.9)%The Company recorded impairment charges of $2.5 related to a decommissioned robotic asset during the six months ended June 30, 2024. The Company recorded impairment charges of $5.0 in capitalized software costs and other intangible assets six months ended June 30, 2023.Restructuring and Other ChargesÂ Six Months Ended June 30,Â Â 20242023ChangeRestructuring and other charges$16.6Â $23.3Â (28.6)%During the six months ended June 30, 2024, the Company recorded net restructuring and other charges of $16.6. The charges were comprised of $15.1 related to severance and other personnel costs and $1.8 in facility-related costs. The charges were adjusted by the reversal of a previously established liability of $0.3 in unused facility-related costs.During the six months ended June 30, 2023, the Company recorded net restructuring and other charges of $23.3. The charges were comprised of $9.2 related to severance and other personnel costs and $13.2 in facility closures, lease terminations, and general integration activities. The charges were adjusted by the reversal of a previously established liability of $1.1 in unused severance liabilities and the increase of a previously established liability of $2.0 in facility-related costs.Interest ExpenseSix Months Ended June 30,Â Â 20242023ChangeInterest expense(94.5)(100.5)(6.0)%The decrease in interest expense for the six months ended June 30, 2024, as compared with the corresponding period in 2023, is primarily due to decreased borrowings under the Company's revolving credit facility, repayment of the November 2023 $300.0 senior notes, and partially offset by a higher interest rate on variable rate debt.Equity Method IncomeÂ Six Months Ended June 30,Â Â 20242023ChangeEquity method expense, net(0.2)(1.2)(79.9)%Â Equity method expense represents the Company's ownership share in joint venture partnerships along with equity investments in other companies in the health care industry. Other, netÂ Six Months Ended June 30,Â Â 20242023ChangeOther, net$39.5Â $(23.8)265.7Â %Â The change in Other, net for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, is primarily due to $45.3 of transition services fees charged to Fortrea related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income. In addition, the Company recorded investment losses of $5.7 for the six months ended June 30, 2024 compared to investment losses of $5.6 for the corresponding period of 2023. Foreign currency transaction losses of $5.2 were recognized for the six months ended June 30, 2024, as compared to losses of $18.0 for the corresponding period of 2023. The Company also recorded a $4.9 gain on the sale of the assets of its Beacon Laboratory Benefit Solutions, Inc. business in 2024.29INDEXIncome Tax ExpenseSix Months Ended June 30,Â Â 20242023ChangeIncome tax expense$131.2Â $113.7Â 15.4Â %Income tax expense as a % of earnings before income taxes23.2Â %23.8Â %Â The current year and prior year effective tax rate differs from the U.S. federal statutory rate of 21.0% primarily due to state income taxes and the disallowance of certain executive compensation, which were partially offset by research and development tax credits and favorable foreign rate differentials. Operating Income by SegmentDuring the fourth quarter of 2022, the Company modified the segment performance measure to exclude the amortization of intangibles and other assets, restructuring and other charges, goodwill and other asset impairments, and certain corporate charges for items such as transaction costs, remaining unallocated costs of the CDCS business, COVID-19-related costs, and other special items. These changes align with how the CODM now evaluates segment performance and allocates resources. Prior periods have been conformed for comparability.Â Six Months Ended June 30,Â Â 20242023ChangeDx segment operating income$859.4Â $851.2Â 0.9Â %Dx segment operating margin17.2Â %18.0Â %(0.8)%BLS segment operating income207.3Â 178.2Â 16.3Â %BLS segment operating margin14.6Â %13.1Â %1.5Â %Segment operating income1,066.7Â 1,029.4Â 3.6Â %General corporate and unallocated expenses(309.2)(300.1)3.0Â %Amortization of intangibles and other assets(122.3)(104.9)16.6Â %Goodwill and other asset impairments(2.5)(5.0)(50.9)%Restructuring and other charges(16.6)(23.3)(28.6)%Total operating income$616.1Â $596.1Â 3.3Â %Dx operating income was $859.4 for the six months ended June 30, 2024, an increase of $8.2 over operating income of $851.2 in the corresponding period of 2023, and Dx operating margin decreased 80 basis points year-over-year. The decrease was due to a reduction in COVID-19 Testing and higher personnel costs, partially offset by a recovery in the Base Business.BLS operating income was $207.3 for the six months ended June 30, 2024, an increase of $29.1 over operating income of $178.2 in the corresponding period of 2023. The increase was due to organic growth and LaunchPad savings, partially offset by higher personnel expense. General corporate expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. Corporate expenses were $309.2 for the six months ended June 30, 2024, a increase of $9.1 over corporate expenses of $300.1 in the corresponding period of 2023, primarily due to costs related to the spin-off of Fortrea, and personnel costs.The Company remains on track to deliver approximately $100.0 to $125.0 of Launchpad savings in fiscal 2024.LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions)The Company's cash-generating ability and financial condition typically have provided ready access to capital markets. The Company's principal source of liquidity is operating cash flow, supplemented by proceeds from debt offerings. The Company believes that its balances of cash and cash equivalents and borrowing capacity, along with cash generated from operations, will be sufficient to satisfy its cash requirements, cash dividends, and share repurchases over the next twelve months and beyond. The Company's senior unsecured revolving credit facility is further discussed in Note 7 (Debt) to the Company's condensed consolidated financial statements.30INDEXIn summary, the Company's cash flows from continuing operations were as follows for the six months ended June 30, 2024, and 2023, respectively:Â Six Months Ended June 30,Â 20242023Net cash provided by operating activities from continuing operations$531.3Â $347.2Â Net cash used for investing activities from continuing operations(578.1)(328.6)Net cash used for financing activities from continuing operations(221.7)(124.7)Effect of exchange rate changes on cash and cash equivalents(3.2)6.3Â Net decrease in cash and cash equivalents from continuing operations(271.7)(99.8)Cash and Cash EquivalentsCash and cash equivalents at June 30, 2024, and 2023, totaled $265.1 and $1,930.6, respectively. Cash and cash equivalents consist of highly liquid instruments, such as time deposits, commercial paper, and other money market investments, which have original maturities of three months or less.Cash Flows from Operating ActivitiesÂ During the six months ended June 30, 2024, the Company's continuing operations used $531.3 of cash as compared to providing $347.2 during the same period in 2023. The $184.1 increase in cash provided from operations in 2024 as compared with the corresponding 2023 period is primarily due to higher cash earnings.Cash Flows from Investing Activities Net cash used for investing activities from continuing operations for the six months ended June 30, 2024, was $578.1 as compared to $328.6 for the six months ended June 30, 2023. The change in cash used for investing activities was primarily due to an increase in business acquisitions and higher capital expenditures during the six months ended June 30, 2024. Capital expenditures were $262.0 and $181.5 for the six months ended June 30, 2024, and 2023, respectively. On March 28, 2024, the Company announced that it entered into an agreement to acquire selected assets of BioReference Health, a wholly owned subsidiary of OPKO Health for $237.5. The transactions is anticipated to close in the third quarter of 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction Labcorp will acquire laboratory testing businesses focused on clinical diagnostics and reproductive and women's health across the United States, outside of New York and New Jersey.On April 24, 2024, the Company announced that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. On May 6, 2024, the United States Bankruptcy Court approved the previously announced bid by Labcorp to acquire the assets of Invitae. The purchase price for the transaction is $239.0. The transaction is anticipated to close on August 5, 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction, the Company would acquire assets being auctioned through a voluntary bankruptcy protection process.Cash Flows from Financing Activities Net cash used by financing activities from continuing operations for the six months ended June 30, 2024, was $221.7 as compared to $124.7 for the six months ended June 30, 2023. The change in cash flows from financing activities from continuing operations for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, was primarily due to share repurchases of $100.0 in 2024. At June 30, 2024, the Company had $265.1 of cash and $980.0 of available borrowings under its revolving credit facility, which does not mature until 2026. Under the Company's revolving credit facility and indentures relating to the Company's senior notes, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers , and with respect to the revolving credit facility, the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants under the revolving credit facility and the indentures related to the Company's outstanding senior notes at June 30, 2024. The Company expects that it will remain in compliance with all covenants associated with its existing debt obligations for the next twelve months.The Company continues to evaluate its outstanding debt portfolio to take advantage of market conditions that would allow the Company to maintain a reasonable interest rate and lower financing risk. The Company anticipates that it will refinance the $2,000.0 in debt coming due during the next 12 months.As of June 30, 2024, the Company had outstanding authorization from the board of directors to purchase up to $430.4 of the Company's common stock. On July 24, 2024, the Board adopted a new share repurchase plan authorizing up to $1,000.0 of the Company's shares in addition to the remaining amount outstanding under the previous plan. In aggregate, the share repurchase authorization is $1,430.4.31INDEXFor the six months ended June 30, 2024, the Company paid $122.5 in common stock dividends. On July 25, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the second quarter, or approximately $61.2 in the aggregate. The dividend will be payable on September 13, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on August 29, 2024. The declaration and payment of any future dividends will be at the discretion of the Companyâ€™s board of directors.Guarantor InformationIn connection with the Reorganization, the Company, LCAH and U.S. Bank Trust Company, National Association (the Trustee) entered a seventeenth supplemental indenture (the Seventeenth Supplemental Indenture) to the indenture, dated as of November 19, 2010 between LCAH and the Trustee (the Indenture), in order to (i) provide for the full and unconditional guarantee by the Company of LCAHâ€™s obligations under the Indenture and each series of senior unsecured notes issued and outstanding thereunder (the Labcorp Holdings Guarantee), (ii) permit the Company to satisfy LCAHâ€™s reporting obligations under the Indenture for so long as the Labcorp Holdings Guarantee remains in place and the Companyâ€™s financial statements and other information comply with the requirements of Rule 3-10 of Regulation S-X and the Exchange Act (Regulation S-X) and (iii) make certain other changes to the Indenture consistent with the foregoing. As of June 30, 2024, there was $5,070.3 aggregate principal amount of issued and outstanding senior notes of LCAH that are fully and unconditionally guaranteed by the Company. Accordingly, pursuant to Rule 3-10 of Regulation S-X, separate consolidated financial statements of LCAH have not been presented. As permitted under Rule 13-01(a)(4)(vi) of Regulation S-X, we have excluded the summarized financial information for LCAH because the assets, liabilities and results of operations of LCAH are not materially different than the corresponding amounts in the Companyâ€™s consolidated financial statements and management believes such summarized financial information would be repetitive and would not provide incremental value to investors. Credit RatingsThe Companyâ€™s investment grade debt ratings from Moodyâ€™s and from Standard and Poorâ€™s (S&P) contribute to its ability to access capital markets.ITEM 3. Quantitative and Qualitative Disclosures about Market Risk (dollars in millions)Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates, and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to various market risks, including changes in foreign currency exchange and interest rates, and the Company regularly evaluates its exposure to such changes. The Company addresses its exposure to market risks, principally the market risks associated with changes in foreign currency exchange rates and interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as foreign currency forward contracts, and interest rate and cross currency swap agreements.Foreign Currency Exchange RatesApproximately 13.7% of the Companyâ€™s revenues for the six months ended June 30, 2024, and approximately 13.6% of the Companyâ€™s revenue for the six months ended June 30, 2023, were denominated in currencies other than the U.S. Dollar (USD). The Companyâ€™s financial statements are reported in USD and, accordingly, fluctuations in exchange rates will affect the translation of revenues and expenses denominated in foreign currencies into USD for purposes of reporting the Companyâ€™s consolidated financial results. In the second quarter of 2024 and the year ended DecemberÂ 31, 2023, the most significant currency exchange rate exposures were to the Canadian dollar, Swiss Franc, Euro and British Pound. Excluding the impacts from any outstanding or future hedging transactions, a hypothetical change of 10% in average exchange rates used to translate all foreign currencies to USD would have impacted income before income taxes for the six months ended June 30, 2024, by approximately $13.5. Gross accumulated currency translation adjustments recorded as a separate component of shareholdersâ€™ equity were $(7.2) and $51.7 for the quarter ended June 30, 2024 and 2023, respectively. The Company does not have significant operations in countries in which the economy is considered to be highly inflationary.The Company earns revenue from service contracts over a period of time, ranging from months to years. Accordingly, exchange rate fluctuations during this period may affect the Companyâ€™s profitability with respect to such contracts. The Company is also subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of transactions. The Company limits its foreign currency transaction risk through exchange rate fluctuation provisions stated in some of its contracts with customers, or it may hedge transaction risk with foreign currency forward contracts. At June 30, 2024, the Company had 10 open foreign exchange forward contracts with various amounts maturing monthly through July 2024 with a notional value totaling approximately $361.0. At DecemberÂ 31, 2023, the Company had 9 open foreign exchange forward contracts with various amounts maturing monthly through January 2024 with a notional value totaling approximately $305.8.32INDEXThe Company is party to USD to Swiss Franc cross-currency swap agreements with an aggregate notional amount of $600.0, $300.0 maturing in 2031 and $300.0 maturing in 2034, as a hedge against the impact of foreign exchange movements on its net investment in a Swiss Franc functional currency subsidiary.Interest RatesSome of the Companyâ€™s debt from time to time is subject to interest at variable rates. As a result, fluctuations in interest rates can affect the business. The Company attempts to manage interest rate risk and overall borrowing costs through an appropriate mix of fixed and variable rate debt including by the utilization of derivative financial instruments, primarily interest rate swaps. Borrowings under the Companyâ€™s term loan credit facility, now repaid, and revolving credit facility are subject to variable interest rates, unless fixed through interest rate swaps or other agreements.In May 2021, to hedge against changes in the fair value portion of the Companyâ€™s long-term debt, the Company entered into fixed-to-variable interest rate swap agreements for the 2.70% senior notes due 2031 with an aggregate notional value of $500.0 and variable interest rates based on three-month SOFR plus 1.0706%.ITEM 4. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresAs of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out, under the supervision and with the participation of the Companyâ€™s management, including the Companyâ€™s principal executive officer and principal financial officer, an evaluation of the effectiveness of the design and operation of the Companyâ€™s disclosure controls and procedures (as defined in Rules13a-15 and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon this evaluation, the Companyâ€™s principal executive officer and principal financial officer concluded that the Companyâ€™s disclosure controls and procedures were effective as of June 30, 2024.Changes in Internal Control Over Financial ReportingThere were no changes in the Companyâ€™s internal control over financial reporting (as defined in Rules13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that occurred during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting.33INDEXLABCORP HOLDINGS INC. AND SUBSIDIARIESPART I - OTHER INFORMATIONItem 1. Legal ProceedingsSee Note 9 (Commitments and Contingencies) to the Companyâ€™s condensed consolidated financial statements, above, which is incorporated herein by reference.Item 1A. Risk FactorsThe risk factors set forth below revise and supplement the corresponding risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. With the exception of the following, there have been no material changes in the risk factors that appear in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.U.S. Food and Drug Administration (FDA) regulation of diagnostic products, increased FDA regulation of laboratory-developed tests (LDTs), and regulation by other countries of diagnostic tests and related products could result in increased costs and the imposition of fines or penalties, and could have a material adverse effect upon the Companyâ€™s business.The FDA has regulatory responsibility for instruments, test kits, reagents and other devices used by clinical laboratories. The FDA enforces laws and regulations that govern the development, testing, manufacturing, performance, labeling, advertising, marketing, distribution, and surveillance of diagnostic products, and it regularly inspects and reviews the

manufacturing processes and product performance of diagnostic products. Dxâ€™s point-of-care testing devices are subject to regulation by the FDA.LDTs developed by high complexity clinical laboratories are currently generally offered as services to health care providers under the CLIA regulatory framework administered by CMS, without the requirement for FDA clearance or approval. However, since the 1990s, the FDA has asserted that it has authority to regulate LDTs as medical devices but has exercised enforcement discretion to refrain from systematic regulation of LDTs. In 2014, the FDA issued draft guidance describing how it intended to discontinue its enforcement discretion policy and begin regulating LDTs as medical devices; however, that draft guidance was not finalized, and the FDA instead continued its enforcement discretion policy and indicated that it intended to work with Congress to enact comprehensive legislative reform of diagnostics oversight. In February 2020, the FDA issued a statement with a table of pharmacogenetic associations setting forth certain gene-drug interactions that the agency determined are supported by the scientific literature to help ensure that claims being made for pharmacogenetic tests are grounded in sound science, thereby reducing the risk of enforcement actions with respect to LDTs offering claims consistent with the table. The FDA noted that it could take enforcement actions under the current medical device framework regarding diagnostic claims the agency determines not to be sufficiently supported. In addition, in 2021, the Verifying Accurate, Leading-edge, IVCT Development (VALID) Act was introduced in Congress and provided a framework to regulate in vitro diagnostics and LDTs as in vitro clinical tests. In 2022, the VALID Act was incorporated into the Senate user fee bill but was not included in the year-end Consolidated Appropriations Act of 2022. On March 29, 2023, the VALID Act was reintroduced and remains pending. On April 29, 2024, the FDA released a final rule purporting to clarify its authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act, under which it will phase out its general enforcement discretion approach for LDTs under a four-year period subject to certain continuing enforcement discretion policies. More specifically, among other policies, the final rule provides that the FDA will continue to exercise discretion not to enforce premarket review and most FDA quality system requirements for unmodified LDTs first marketed prior to issuance of the final rule; will continue to exercise discretion not to enforce premarket review requirements for LDTs approved by the State of New York; and will continue to exercise discretion not to enforce premarket review and most FDA quality system requirements for LDTs developed and performed by a laboratory integrated into a health system for unmet needs for patients under the care of the same health system, where no FDA cleared or approved test is available. The final rule was published on May 6, 2024, and in the absence of a successful legal challenge, will become effective on May 6, 2025. On May 29, 2024, the American Clinical Laboratory Association (ACLA) and its member company, HealthTrackRx, filed a lawsuit against the FDA in the United States District Court for the Eastern District of Texas, challenging the FDA's final rule. While the lawsuit may change the final rule or delay or prevent its enforcement, the issuance of the final rule presents an increased risk of FDA enforcement actions for laboratory tests offered by companies without FDA clearance or approval that do not fall within the ongoing enforcement discretion policies. However, the outcome and its ultimate impact on the Companyâ€™s business remain difficult to predict at this time.Current FDA regulation of the Companyâ€™s diagnostic products and the potential for future increased regulation of the Companyâ€™s LDTs could result in increased costs and administrative and legal actions for noncompliance, including warning letters, fines, penalties, product suspensions, product recalls, injunctions, and other civil and criminal sanctions, and could impair the development and commercialization of new tests, which could have a material adverse effect upon the Company.34INDEXRegulation of diagnostics products in jurisdictions outside the U.S. in which the Company operates may impact laboratory testing offered by the Company in both Dx and BLS. For example, the European Union In Vitro Diagnostics Regulation (Regulation (EU) 2017/746 (EU IVDR)) established a new legislative framework for in vitro diagnostic devices that are used in certain circumstances, and includes a rule-based classification and quality and safety standards. The EU IVDR, where applicable to BLS's services, could impact BLS's ability to support trials, result in increased costs and administrative and legal actions, and have an adverse effect.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds (dollars and shares in millions, except per share data)During the three months ended June 30, 2024, the Company repurchased the following shares of its common stock:Total Number of Shares RepurchasedAverage Price Paid Per ShareTotal Number of Shares Repurchased as Part of Publicly Announced ProgramMaximum Dollar Value of Shares that May Yet Be Repurchased Under the ProgramApril 1 - April 30â€”Â â€”Â 530.4Â May 1 - May 310.5Â 202.66Â 0.5Â 430.4Â June 1 - June 30â€”Â â€”Â 430.4Â 0.5Â $202.66Â 0.5Â $430.4Â As of June 30, 2024, the Company had outstanding authorization from the board of directors to purchase up to $430.4 of the Company's common stock. The repurchase authorization has no expiration date. On July 24, 2024, the Board adopted a new share repurchase plan authorizing up to $1,000.0 of the Company's shares in addition to the remaining amount outstanding under the previous plan. In aggregate, the share repurchase authorization is $1,430.4.Item 5. Other InformationInsider Adoption or Termination of Trading Arrangements:During the fiscal quarter ended June 30, 2024, none of the Company's directors or officers informed it of the adoption, modification or termination of a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as those terms are defined in Regulation S-K, Item 408, except as described in the table below:Name and TitleDate AdoptedCharacter of Trading AgreementAggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading AgreementDurationKerri B. AndersonMay 3, 2024Rule 10b5-1 Trading ArrangementUp to(3,000)(1)5/3/2025(2)Director(1) The figure presented represents the shares to be sold on the vesting of equity awards before reduction for shares to be withheld for tax purposes(2) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table.35INDEXItem 6. Exhibits(a)2.1Agreement and Plan of Merger, dated May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Radiance Merger Sub Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on May 17, 2024)3.1Amended and Restated Certificate of Incorporation of Labcorp Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 17, 2024)3.2Amended and Restated By-Laws of Labcorp Holdings Inc. (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 17, 2024)4.1Seventeenth Supplemental Indenture dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, as issuer, Labcorp Holdings Inc., as guarantor, and U.S. Bank National Trust Company Association, as trustee (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 17, 2024)4.2New Holding Company Guarantee, dated May 17, 2024, by Labcorp Holdings Inc. (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on May 17, 2024)10.1Guarantor Joinder Agreement, dated May 17, 2024, by Labcorp Holdings Inc. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 17, 2024)10.2+Assignment and Assumption Agreement, dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Adam H. Schechter. (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on May 17, 2024)10.3+Assignment and Assumption Agreement, dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Radiance Merger Sub Inc. (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on May 17, 2024)10.4+Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed on May 17, 2024)10.5+Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed on May 17, 2024)22.1*Subsidiary Issuers of Guaranteed Securities31.1*Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)31.2*Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)32**Written Statement of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)101.INS*Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase101.LAB*Inline XBRL Taxonomy Extension Label Linkbase101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)*Â filed herewith**furnished herewith+Management contracts or compensatory plans or arrangements36INDEXSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.LABCORP HOLDINGS INC.RegistrantÂ By:/s/ ADAM H. SCHECHTERÂ Â Adam H. SchechterÂ Â Chief Executive OfficerÂ By:/s/ GLENN A. EISENBERGÂ Â Glenn A. EisenbergÂ Â Executive Vice President andÂ Â Chief Financial OfficerAugustÂ 2, 2024 37 EX-22.1 2 ex221q22024.htm EX-22.1 DocumentExhibit 22.1Subsidiary Issuers of Guaranteed SecuritiesGuaranteed SecuritiesThe following securities (collectively referred to in this exhibit as the â€œSenior Notesâ€) issued by Laboratory Corporation of America Holdings (â€œLCAHâ€), a Delaware corporation and wholly-owned subsidiary of Labcorp Holdings Inc. (â€œLHIâ€), a Delaware corporation, were outstanding as of June 30, 2024.Description of Senior Notes2.30% Senior Notes due 2024 (issued under the Thirteenth Supplemental Indenture)3.25% Senior Notes due 2024 (issued under the Eleventh Supplemental Indenture)3.60% Senior Notes due 2025 (issued under the Ninth Supplemental Indenture)1.55% Senior Notes due 2026 (issued under the Fifteenth Supplemental Indenture)3.60% Senior Notes due 2027 (issued under the Twelfth Supplemental Indenture)2.95% Senior Notes due 2029 (issued under the Fourteenth Supplemental Indenture)2.70% Senior Notes due 2031 (issued under the Sixteenth Supplemental Indenture)4.70% Senior Notes due 2045 (issued under the Tenth Supplemental Indenture)ObligorsAs of June 30, 2024, the obligors under the Senior Notes consisted of LHI, as guarantor, and LCAH, as issuer. EX-31.1 3 ex311q22024.htm EX-31.1 DocumentExhibit 31.1CertificationI, Adam H. Schechter, certify that:1. I have reviewed this quarterly report on Form 10-Q of Laboratory Corporation of America Holdings;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date:August 2, 2024By:/s/ ADAM H. SCHECHTERAdam H. SchechterChief Executive Officer(Principal Executive Officer) EX-31.2 4 ex312q22024.htm EX-31.2 DocumentExhibit 31.2CertificationI, Glenn A. Eisenberg, certify that:1. I have reviewed this quarterly report on Form 10-Q of Laboratory Corporation of America Holdings;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date:August 2, 2024By:/s/ GLENN A. EISENBERGGlenn A. EisenbergChief Financial Officer(Principal Financial Officer) EX-32.1 5 ex32q22024.htm EX-32.1 DocumentExhibit 32Written Statement ofChief Executive Officer and Chief Financial OfficerPursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) The undersigned, the Chief Executive Officer and the Chief Financial Officer of Laboratory Corporation of America Holdings (the â€œCompanyâ€), each hereby certifies that, to his knowledge on the date hereof: (a) the Form 10-Q of the Company for the Period Ended June 30, 2024, filed on the date hereof with the Securities and Exchange Commission (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (b) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.By:/s/ ADAM H. SCHECHTERAdam H. SchechterChief Executive OfficerAugust 2, 2024By:/s/ GLENN A. EISENBERGGlenn A. EisenbergChief Financial OfficerAugust 2, 2024A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Laboratory Corporation of America Holdings and will be retained by Laboratory Corporation of America Holdings and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 6 lh-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - BASIS OF FINANCIAL STATEMENT PRESENTATION Restated Financial Statements link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - BASIS OF FINANCIAL STATEMENT PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - NONCONTROLLING INTEREST PUTS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - FAIR VALUE

MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - BUSINESS ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - BUSINESS SEGMENT INFORMATION (Notes) link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment information (Notes) link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - REVENUE (Notes) link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Discontinued Operations and Disposal Groups link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Intangible Assets, Goodwill and Other (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue from Contract with Customer (Policies) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Discontinued Operations and Disposal Groups (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - NONCONTROLLING INTEREST PUTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - DEBT (Long-term debt) (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - DEBT (Senior Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - DEBT (Credit Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - BUSINESS ACQUISITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - REVENUE Disaggregated Revenue Table (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Discontinued Operations and Disposal Groups (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 lh-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 lh-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 lh-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Loss Contingency, Damages Type [Axis] Loss Contingency, Damages Type [Axis] Loss Contingency, Damages Type Fortrea Term Loan A maturing 2028 Fortrea Term Loan A maturing 2028 [Member] Fortrea Term Loan A maturing 2028 Proceeds from revolving credit facilities Proceeds from Long-Term Lines of Credit Increase (Decrease) in Unbilled Contract Receivable Increase (Decrease) in Unbilled Contract Receivable Increase (Decrease) in Unbilled Contract Receivable Covance Drug Development [Member] Covance Drug Development [Member] Covance Drug Development [Member] Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill, Acquired During Period Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Contract with Customer, Asset, after Allowance for Credit Loss, Current Contract with Customer, Asset, after Allowance for Credit Loss, Current Cover [Abstract] Cover [Abstract] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Notes Payable Notes Payable, Current Per Share Amount [Abstract] Per Share Amount [Abstract] Commons Stock Issued During Period Shares Employee Stock Plans Commons Stock Issued During Period Shares Employee Stock Plans Number of common shares issued during the period as a result of an employee stock purchase plan and/or stock option plan. Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Segment Reconciliation of Operating Income to Consolidated [Abstract] Segment Reconciliation of Operating Income to Consolidated [Abstract] Segment Reconciliation of Operating Income to Consolidated [Abstract] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Reconciliation of Basic earnings per Share to Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Disposal Group, Including Discontinued Operation, Operating Income (Loss) Disposal Group, Including Discontinued Operation, Operating Income (Loss) Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income taxes, net of refunds Income Taxes Paid, Net Goodwill and Intangible Assets, Goodwill, Policy Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Dividends, Cash Dividends, Cash Initial Damages Initial Damages [Member] Initial Damages Pay vs Performance Disclosure [Line Items] Line of Credit Facility [Table] Line of Credit Facility [Table] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Interest Interest Paid In Cash The amount of cash paid during the current period for interest owed on money borrowed Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Other comprehensive earnings (loss) before tax Other Comprehensive Income (Loss), before Tax Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Financing Receivable, Allowance for Credit Loss [Table Text Block] Financing Receivable, Allowance for Credit Loss [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Estimated amortization expense, 2014 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Common stock, shares outstanding (in shares) Common shares outstanding, beginning balance (in shares) Common shares outstanding, ending balance (in shares) Common Stock, Shares, Outstanding Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Third party [Member] Third party [Member] Third party [Member] LabCorp Diagnostics [Member] LabCorp Diagnostics [Member] LabCorp Diagnostics [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] UNITED STATES UNITED STATES Other assets, net Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Schedule of Finite-Lived Intangible Assets by Major Class [Table] Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] 1.55% senior notes due 2026 1.55% senior notes due 2026 1.55% senior notes due 2026 Allowance for Credit Loss Allowance for Credit Loss Allowance for Credit Loss Operating Segments Operating Segments [Member] Diagnostics Diagnostics [Member] Diagnostics [Member] Net Cash Provided by (Used in) Operating Activities, Total Net Cash Provided by (Used in) Operating Activities Long term debt issuance costs Long term debt issuance costs Long term debt issuance costs CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Intersegment Eliminations Intersegment Eliminations [Member] Fortrea Term Loan B maturing 2028 Fortrea Term Loan B maturing 2028 [Member] Fortrea Term Loan B maturing 2028 Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Prepaid expenses and other Prepaid Expense, Current Statement, Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Net cash used for discontinued investing activities Cash Provided by (Used in) Investing Activities, Discontinued Operations Insider Trading Policies and Procedures [Line Items] Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Net cash provided by discontinued financing activities Cash Provided by (Used in) Financing Activities, Discontinued Operations Impaired Long-Lived Assets Held and Used by Type [Axis] Impaired Long-Lived Assets Held and Used by Type [Axis] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Disclosure of non-cash financing and investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Gain (Loss) on Disposition of Business Gain (Loss) on Disposition of Business Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets Acquired Purchase of common stock Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Foreign Currency Contract, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Accrued Liabilities, Current Accrued Liabilities, Current Stock options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Credit Facility [Axis] Fortrea Credit Facilities [Axis] Fortrea Credit Facilities Issuance of common stock under employee stock plans Issuance of common stock under employee plans Aggregate change in value for stock issued in period under ESPP combined with the value of stock issued as a result of option exercises. Patents, Licenses And Technology [Member] Patents, Licenses And Technology [Member] Patents are the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Licenses are rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory). Technology-based intangible assets are innovations or scientific advances that have not been patented. Credit Facility Option to Increase Credit Facility Option to Increase Credit Facility Option to Increase Credit Facility [Domain] Credit Facility [Domain] Fair market value of senior notes Senior Notes Fair Value Estimated fair value of the debt instrument (senior notes) at the balance-sheet date Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] Current assets: Current Assets: Assets, Current [Abstract] BioReference Health BioReference Health [Member] BioReference Health Goodwill, net Balance as of January 1 Balance at end of period Goodwill Goodwill Note Receivable, Allowance for Credit Loss Note Receivable, Allowance for Credit Loss Note Receivable, Allowance for Credit Loss Consolidation Items [Axis] Consolidation Items [Axis] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Net share settlement tax payments from issuance of stock to employees Payment, Tax Withholding, Share-Based Payment Arrangement Share Repurchase Program, Authorized, Amount Share Repurchase Program, Authorized, Amount Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Noncontrolling Interest Puts [Abstract] Noncontrolling Interest Puts [Abstract] Noncontrolling Interest Puts [Abstract] Operating lease right-of-use asset expense Depreciation And Amortization Of Leased Assets The amount of depreciation recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Also, may include amortization charged against earnings for the periodic recognition of capitalized leases. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Comprehensive earnings attributable to Laboratory Corporation of America Holdings Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Payments on revolving credit facilities Repayments of Lines of Credit Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Client [Member] Client [Member] Client [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Noncontrolling interest Liabilities Other Other Financing Cash Flows Other Financing Cash Flows Foreign Currency Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Continuing Operations Continuing Operations [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving Credit Facility [Member] Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Net cash provided by continuing operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash Surrender Value, Fair Value Disclosure Cash Surrender Value, Fair Value Disclosure Operating Lease, Liability, Current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common shares issued, beginning balance (in shares) Common shares issued, ending balance (in shares) Common Stock, Shares, Issued Common Stock, Shares, Issued Net restructuring and other special charges Net restructuring and other special charges Amount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program planned and controlled by management, and materially changes either the scope or manner of conduct of a business undertaken. Also, may include reversals and other adjustments to accrued liabilities and special charges, if any, for asset abandonment, uncollectible balances, etc. Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Unbilled Contracts Receivable [Member] Unbilled Contracts Receivable [Member] Unbilled Contracts Receivable [Member] Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of Credit Facility, Maximum Borrowing Capacity Revolving Credit Facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Net Benefit Plan Adjustments, Beginning balance Net Benefit Plan Adjustments, Ending balance Accumulated Other Comprehensive (Income)

Loss, Defined Benefit Plan, after Tax Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Decrease in Capital Expenditures Incurred but not yet Paid Increase in Capital Expenditures Incurred but not yet Paid Increase in Capital Expenditures Incurred but not yet Paid Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common Stock, Shares Authorized Common Stock, Shares Authorized Europe [Member] Europe [Member] Goodwill and other asset impairments Goodwill and Intangible Asset Impairment Goodwill and Intangible Asset Impairment Rollforward of common shares issued Common Shares Issued Rollforward [Abstract] Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Enhanced Damages Enhanced Damages [Member] Enhanced Damages Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Accrued Liabilities [Member] Accrued Liabilities [Member] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Stockholders' Equity Attributable to Parent BALANCE BALANCE Stockholders' Equity Attributable to Parent Equity, Attributable to Parent Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Changes in common shares issued and held in treasury Changes In Common Shares Issued And Held In Treasury [Table Text Block] Schedule is used to show the changes in common shares issued and held in treasury by the entity. Disposal Group, Including Discontinued Operation, Revenue Disposal Group, Including Discontinued Operation, Revenue Business Combinations [Abstract] Business Combinations [Abstract] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Deferred income taxes Deferred Income Tax Expense (Benefit) Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Investment income Investment Income, Net Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Selling, general and administrative expenses Selling, General and Administrative Expense Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively Noncontrolling Interest Mezzanine Equity Represents contractual value of a noncontrolling interest put (includes underlying noncontrolling interest). In February 2010, the Company completed a transaction to sell the partnership units acquired from the previous noncontrolling interest holder to a new Canadian partner. As a result of this transaction, the Company recorded a component of noncontrolling interest in liabilities and a component in mezzanine equity. This item represents the mezzanine equity component. Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current Asset Impairment Charges Asset Impairment Charges Fortrea Credit Facilities [Domain] Fortrea Credit Facilities [Domain] Fortrea Credit Facilities [Domain] 4.00% senior notes due 2023 4.00% senior notes due 2023 4.00% senior notes due 2023 Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Common Shares Outstanding Rollforward [Abstract] Common Shares Outstanding Rollforward [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Dilutive effect of employee stock options and awards, (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Estimated amortization expense, 2013 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Other comprehensive earnings (loss), net of tax Other comprehensive earnings, net of tax Other Comprehensive Income (Loss), Net of Tax Earnings before income taxes Earnings before income taxes Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury Stock Acquired, Average Cost Per Share Shares Acquired, Average Cost Per Share Tax effect of adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Joint venture partnerships and equity method investments Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Cash paid during period for: Cash Paid During Period For [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Deferred Compensation Plan Assets Deferred Compensation Plan Assets Contract with Customer, Asset and Liability [Table Text Block] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Subsequent Event [Table] Subsequent Event [Table] Maximum [Member] Maximum [Member] Amortization of intangibles and other assets Amortization of intangible assets Amortization of Intangible Assets Amortization of Intangible Assets Line of Credit Facility, Commitment Fee Description Line of Credit Facility, Commitment Fee Description Contract with Customer, Liability Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounts Payable, Current Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Net cash used for continuing financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] All Award Types Award Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Canadian licenses [Member] Licensing Agreements [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Potential common shares not included in computation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Stockholders' Equity Note, Spinoff Transaction Stockholders' Equity Note, Spinoff Transaction Restatement [Axis] Revision of Prior Period [Axis] Non-PEO NEO Non-PEO NEO [Member] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Contingent Consideration Classified as Equity, Fair Value Disclosure Contingent Consideration Classified as Equity, Fair Value Disclosure Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Other comprehensive income before reclassifications Other comprehensive income before reclassifications Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Customer Relationships [Member] Customer Relationships [Member] Short-term Debt [Line Items] Short-Term Debt [Line Items] Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Loss Contingency, Damages Type [Domain] Loss Contingency, Damages Type [Domain] Loss Contingency, Damages Type [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Fortrea Revolver due 2028 Fortrea Revolver due 2028 [Member] Fortrea Revolver due 2028 Operating Activities [Axis] Operating Activities [Axis] Westpac Labs, Inc. Westpac Labs, Inc. [Member] Westpac Labs, Inc. Customer [Axis] Customer [Axis] Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased Share Repurchase Program, Remaining Authorized, Number of Shares Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Credit Facility, Maximum Swing Line Borrowings Credit Facility, Maximum Swing Line Borrowings Credit Facility, Maximum Swing Line Borrowings Notes Payable, Noncurrent Notes Payable, Noncurrent Stock compensation Share-Based Payment Arrangement, Noncash Expense Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2.95% senior notes due 2029 2.95% senior notes due 2029 2.95% senior notes due 2029 Proceeds from sale of assets Proceeds from Sale of Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Provision for income taxes Income Tax Expense (Benefit) Derivative, Notional Amount Derivative, Notional Amount Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities Rollforward of common shares held in treasury Common Shares Held In Treasury Rollforward [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Senior notes due 2027 [Member] Senior notes due 2027 [Member] Senior notes due 2027 [Member] Surrender of restricted stock and performance share awards Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Operating Income (Loss) Operating Income (Loss) Operating Income (Loss) Interest Expense Interest Expense, Operating and Nonoperating Business Acquisition [Line Items] Business Acquisition [Line Items] Variable Rate [Domain] Variable Rate [Domain] Swap, Type [Axis] Swap, Type [Axis] Swap, Type Liabilities and Equity Liabilities and Equity Providence Medical Foundation Providence Medical Foundation [Member] Providence Medical Foundation Other Other Operating Activities, Cash Flow Statement Dividends Dividends All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis] Fair Value Hierarchy and NAV [Axis] Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Legal Entity [Axis] Legal Entity [Axis] Dividends paid Payments of Dividends Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Other countries [Member] Other countries [Member] Other countries [Member] Net proceeds from issuance of stock to employees Net proceeds from issuance of stock to employees The cash inflow associated with the amount received from holders exercising their stock options and employees related to shares purchased under the employee stock purchase plan. Basis of Presentation and Significant Accounting Policies [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Accumulated Other Comprehensive Income [Member] AOCI Attributable to Parent [Member] Supplies inventories Inventory, Net Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Net cash used for continuing investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Product and Service [Axis] Product and Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Medicare and Medicaid [Member] Medicare and Medicaid [Member] Medicare and Medicaid [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Other acquirees Other acquirees [Member] Other acquirees [Member] Dividends Payable, Date Declared Dividends Payable, Date Declared Disposal Group, Including Discontinued Operation, Fortrea Distribution Disposal Group, Including Discontinued Operation, Fortrea Distribution Disposal Group, Including Discontinued Operation, Fortrea Distribution LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Current debt excluding finance lease liability Current debt excluding finance lease liability Current debt excluding finance lease liability Minimum [Member] Minimum [Member] Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Tax effect of adjustments Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Line of Credit, Current Line of Credit, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Segments [Axis] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Company's population of financial assets and liabilities subject to fair value measurements Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Investments in equity affiliates Payments to Acquire Equity Method Investments Exercise Price Award Exercise Price Disposal Group, Including Discontinued Operation, General and Administrative Expense Disposal Group, Including Discontinued Operation, General and Administrative Expense Earnings Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Senior notes due 2022 [Member] Senior notes due 2022 [Member] Senior notes due 2022 [Member] Discontinued Operations Discontinued Operations [Member] Subsequent Event [Member] Subsequent Event [Member] Contract with Customer, Asset, before Allowance for Credit Loss Contract with Customer, Asset, before Allowance for Credit Loss Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Income (Loss) from Continuing Operations, Per Basic Share Income (Loss) from Continuing Operations, Per Basic Share Short term debt issuance costs Short term debt issuance costs Short term debt issuance costs Shareholders' equity: Shareholders' Equity: Equity, Attributable to Parent [Abstract] Goodwill [Member] Goodwill [Member] 3.25% senior notes due 2024 3.25% senior notes due 2024 3.25% senior notes due 2024 Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Segments [Domain] Segments [Domain] Segments [Domain] Tax effect of adjustments Other Comprehensive Income (Loss), Tax Swap, Type [Domain] Swap, Type [Domain] Swap, Type [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Estimated amortization expense, 2015 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Notes Receivable [Member] Notes Receivable [Member] Business Combination, Price of Acquisition, Expected Business Combination, Price of Acquisition, Expected Less: Cash and cash equivalents of discontinued operations at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations Reporting Unit [Axis] Reporting Unit [Axis] PEO PEO [Member] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Variable Rate [Axis] Variable Rate [Axis] Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Document Information, Document [Axis] Document Information, Document [Axis] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Accumulated Other Comprehensive Earnings [Roll Forward] Accumulated Other Comprehensive Earnings [Roll Forward] Accumulated Other Comprehensive Earnings [Roll Forward] Equity method income, net Income (Loss) from Equity Method Investments Self-Pay

[Member] Self-Pay [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Lender Name [Axis] Lender Name [Axis] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Proceeds from Sales of Business, Affiliate and Productive Assets Proceeds from Sales of Business, Affiliate and Productive Assets Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Local Phone Number Local Phone Number Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Liability Class [Axis] Liability Class [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Unbilled Services, Allowance for Credit Loss Unbilled Services, Allowance for Credit Loss Unbilled Services, Allowance for Credit Loss Cash Acquired in Excess of Payments to Acquire Business Cash Acquired in Excess of Payments to Acquire Business Change in assets and liabilities (net of effects of acquisitions and divestitures): Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Estimated amortization expense, Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock [Member] Common Stock [Member] Measure: Measure [Axis] Asset Class [Domain] Asset Class [Domain] Noncompete Agreements [Member] Noncompete Agreements [Member] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Deferred income taxes and other tax liabilities Deferred income taxes and other tax liabilities Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax, combined with the noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Loss Contingency, Damages Sought, Value Loss Contingency, Damages Sought, Value Scenario [Axis] Scenario [Axis] Noncontrolling interest puts Fair Value Liabilities Measured On Recurring Basis Noncontrolling Interest Puts This element represents a certain statement of financial position liability caption which represents a class of liabilities, or which may include an individual liability, measured at fair value on a recurring basis. Disposal Group, Including Discontinued Operation, Costs of Goods Sold Disposal Group, Including Discontinued Operation, Costs of Goods Sold Ownership percentage below which investments are generally accounted for on the cost method (in thousandths) Cost Method Investments Maximum Ownership Percentage This element represents the maximum ownership percentage of cost-method investments held by the Company. Generally, such investments do not have readily determinable fair values and are not required to be accounted for by the equity method. The carrying amount of such securities equates to cost, adjusted for other-than-temporary impairment. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Corporate Segment [Member] Corporate Segment [Member] Preferred Stock and Common Shareholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Allowance for Credit Loss, Write Off Allowance for Credit Loss, Write Off Allowance for Credit Loss, Write Off Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Net cash provided by discontinued operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense) Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense) Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense) Title Trading Arrangement, Individual Title Income [Abstract] Income [Abstract] Statement [Table] Statement [Table] Shares [Abstract] Shares [Abstract] Credit Facility, Maximum Letters of Credit Credit Facility, Maximum Letters of Credit Credit Facility, Maximum Letters of Credit Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Discontinued Operation, Tax Effect of Discontinued Operation Discontinued Operation, Tax Effect of Discontinued Operation Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Liabilities, Current [Abstract] Liabilities, Current [Abstract] Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Fair Value Hedges, Net Fair Value Hedges, Net Senior notes due 2024 Senior notes due 2024 [Member] Senior notes due 2024 Revenue Revenue [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total current assets Assets, Current Accounts Receivable, before Allowance for Credit Loss Accounts Receivable, before Allowance for Credit Loss Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Restatement [Domain] Revision of Prior Period [Domain] Purchase of common stock Payments for Repurchase of Common Stock Document Information [Table] Document Information [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term Debt, Excluding Current Maturities Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Adjustments to goodwill Goodwill, Translation and Measurement Period Adjustments Stock Repurchased and Retired During Period, Shares Stock Repurchased and Retired During Period, Shares Class of Stock [Domain] Class of Stock [Domain] Increase (Decrease) in Inventories Increase (Decrease) in Inventories Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash (used for) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Operating lease liability Operating lease liability [Member] Operating lease liability Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax Deferred Revenue, Current Deferred Revenue, Current Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Foreign Currency Translation Adjustments, Beginning balance Foreign Currency Translation Adjustments, Ending balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Gross Profit Gross Profit Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Baystate Medical Center Baystate Medical Center [Member] Baystate Medical Center Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Unbilled Contracts Receivable Unbilled Contracts Receivable Drug Development Drug Development [Member] Covance Drug Development [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Invitae Corporation Invitae Corporation [Member] Invitae Corporation Interest Rate Swap [Member] Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Dividends Payable, Date of Record Dividends Payable, Date of Record Title of 12(b) Security Title of 12(b) Security Retained earnings Common Stock, Value, Issued 2022 Swap Agreements 2022 Swap Agreements [Member] 2022 Swap Agreements Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Disposal Group, Including Discontinued Operation, Restructuring and other charges Disposal Group, Including Discontinued Operation, Restructuring and other charges Disposal Group, Including Discontinued Operation, Restructuring and other charges Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document [Domain] Document [Domain] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Other Current Liabilities Other Current Liabilities [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Reporting Unit [Domain] Reporting Unit [Domain] Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Schedule of Short-term Debt [Table] Short-Term Debt [Table] Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Long-term debt, less current portion Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Estimated amortization expense, 2012 Finite-Lived Intangible Asset, Expected Amortization, Year One Kerrii Anderson [Member] Kerrii Anderson Capital expenditures Payments to Acquire Property, Plant, and Equipment Commitments and contingent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Termination Date Trading Arrangement Termination Date Rollforward of Share Repurchase Program Outstanding Stock Repurchase Authorization [Abstract] 2018 Swap Agreements 2018 Swap Agreements [Member] 2018 Swap Agreements Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Operating Activities [Domain] Operating Activities [Domain] Revenues Revenues Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Net Restructuring Charges Net Restructuring Charges Amount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and changes either scope of business by an entity, or manner business is conducted. May include amount of reversals and other adjustments during the period to amounts of previously accrued liabilities for specified types of restructuring costs. Schedule Of Other Intangible Assets By Major Class [Domain] Schedule Of Other Intangible Assets By Major Class [Domain] Disposal Groups, Including Discontinued Operations, Disclosure Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net earnings attributable to Labcorp Holdings Inc. Net Income (Loss) Attributable to Parent Net earnings attributable to Labcorp Holdings Inc. Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Escrow Deposit Escrow Deposit Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Decrease in accrued expenses and other Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Estimated amortization expense, 2016 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] 3.60% senior notes due 2027 3.60% senior notes due 2027 3.60% senior notes due 2027 Finance Lease, Liability, Current Finance Lease, Liability, Current 3.60% senior notes due 2025 3.60% senior notes due 2025 3.60% senior notes due 2025 Award Timing MNPI Considered Award Timing MNPI Considered [Flag] 2.70% senior notes due 2031 2.70% senior notes due 2031 2.70% senior notes due 2031 Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Asset Class [Axis] Asset Class [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Contract with Customer, Sales Channel [Domain] Contract

with Customer, Sales Channel [Domain] 4.70% senior notes due 2045 4.70% senior notes due 2045 4.70% senior notes due 2045 PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Income (Loss) from Continuing Operations, Per Diluted Share Income (Loss) from Continuing Operations, Per Diluted Share Dividends Payable, Date to be Paid Dividends Payable, Date to be Paid Cost of Revenue Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable [Member] Accounts Receivable [Member] Net Income (Loss) Attributable to Noncontrolling Interest Less: Net earnings attributable to the noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Customer Lists Customer Lists [Member] Customer [Domain] Customer [Domain] Fair Value, Liabilities Measured on Recurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Total liabilities and shareholders' equity Accumulated Other Comprehensive Earnings, Beginning balance Accumulated Other Comprehensive Earnings, Ending balance Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings [Member] Retained Earnings [Member] Biopharmaceutical and medical device companies [Member] Biopharmaceutical and medical device companies [Member] Biopharmaceutical and medical device companies [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Schedule Of Other Intangible Assets By Major Class [Axis] Schedule Of Other Intangible Assets By Major Class [Axis] Percent of Revenue Contributed Percent of Revenue Contributed Percent of Revenue Contributed Net earnings, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] In Process R&A and Media In Process R&A and Media [Member] In Process R&A and Media Document Information [Table] Document Information [Table] Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment North America North America [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Disposal Group, Including Discontinued Operation, Depreciation and Amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Other Acquisitions Other Acquisitions [Member] Other Acquisitions Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Allowance for Credit Loss, Receivable, Other, Current Allowance for Credit Loss, Receivable, Other, Current Entity Filer Category Entity Filer Category Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 lh-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 6 Months Ended Jun. 30, 2024 Aug. 01, 2024 Document Information [Table] Â Â Â Entity Common Stock, Shares Outstanding Â 83,963,277 Entity Central Index Key 0000920148 Â Document Fiscal Year Focus 2024 Â Entity Registrant Name LABCORP HOLDINGS INC. Â Entity Filer Category Large Accelerated Filer Â Document Type 10-Q Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 83,963,277 Document Fiscal Period Focus Q2 Â Amendment Flag false Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 1-11353 Â Entity Registrant Name LABCORP HOLDINGS INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 99-2588107 Â Entity Address, Address Line One 358 South Main Street Â Entity Address, City or Town Burlington, Â Entity Address, State or Province NC Â Entity Address, Postal Zip Code 27215 Â City Area Code 336 Â Local Phone Number 229-1127 Â Title of 12(b) Security Common Stock, $0.10 par value Â Trading Symbol LH Â Security Exchange Name NYSE Â Entity Current Reporting Status Yes Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity Central Index Key 0000920148 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Current assets: Â Â Â Accounts Receivable, after Allowance for Credit Loss, Current $ 2,088,900,000 $ 2,088,900,000 $ 1,913,300,000 Unbilled Contracts Receivable 157,500,000 157,500,000 185,400,000 Supplies inventories 441,800,000 441,800,000 474,600,000 Prepaid expenses and other 618,000,000.0 618,000,000.0 655,300,000 Total current assets 3,571,300,000 3,571,300,000 3,765,400,000 Property, plant and equipment, net 2,932,500,000 2,932,500,000 2,911,800,000 Goodwill, net 6,220,200,000 6,220,200,000 6,142,500,000 Intangible Assets, Net (Excluding Goodwill) 3,332,000,000 3,332,000,000 3,342,000,000 Joint venture partnerships and equity method investments 17,500,000 17,500,000 26,900,000 Other assets, net 638,800,000 638,800,000 536,500,000 Total assets 16,712,300,000 16,712,300,000 16,725,100,000 Liabilities, Current [Abstract] Â Â Â Accounts Payable, Current 760,600,000 760,600,000 827,500,000 Accrued Liabilities, Current 707,500,000 707,500,000 804,000,000.0 Deferred Revenue, Current 388,300,000 388,300,000 421,700,000 Operating Lease, Liability, Current 182,100,000 182,100,000 165,800,000 Finance Lease, Liability, Current 6,700,000 6,700,000 6,400,000 Current debt excluding finance lease liability 2,019,500,000 2,019,500,000 999,800,000 Long-term debt, less current portion 4,064,700,000 4,064,700,000 3,225,200,000 Long-term Debt, Excluding Current Maturities 3,047,300,000 3,047,300,000 4,054,700,000 Commitments and contingent liabilities 483,900,000 483,900,000 409,300,000 Operating Lease, Liability, Noncurrent 642,600,000 642,600,000 648,900,000 Finance Lease, Liability, Noncurrent 76,900,000 76,900,000 78,600,000 Deferred income taxes and other tax liabilities 376,100,000 376,100,000 417,900,000 Noncontrolling interest 8,691,500,000 8,691,500,000 8,834,600,000 Shareholders' equity: Â Â Â Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively 15,000,000.0 15,000,000.0 15,500,000 Additional paid-in capital 12,500,000 12,500,000 38,400,000 Retained earnings 7,700,000 7,700,000 7,700,000 Accumulated other comprehensive income (8,177,600,000) (8,177,600,000) (7,888,200,000) Total liabilities and shareholders' equity (192,000,000.0) (192,000,000.0) (59,300,000) Stockholders' Equity Attributable to Parent 8,005,800,000 8,005,800,000 7,875,000,000 Liabilities and Equity 16,712,300,000 16,712,300,000 16,725,100,000 Net earnings 205,600,000 433,900,000 Â Cash and cash equivalents $ 265,100,000 $ 265,100,000 $ 536,800,000 X - DefinitionCurrent debt excluding finance lease liability + ReferencesNo definition available. + Details Name: lh_CurrentDebtExcludingFinanceLeaseLiability Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax, combined with the noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. + ReferencesNo definition available. + Details Name: lh_DeferredIncomeTaxesAndOtherTaxLiabilities Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents contractual value of a noncontrolling interest put (includes underlying noncontrolling interest). In February 2010, the Company completed a transaction to sell the partnership units acquired from the previous noncontrolling interest holder to a new Canadian partner. As a result of this transaction, the Company recorded a component of noncontrolling interest in liabilities and a component in mezzanine equity. This item represents the mezzanine equity component. + ReferencesNo definition available. + Details Name: lh_NoncontrollingInterestMezzanineEquity Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity method investee and investment in and advance to affiliate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period

Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace

Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUnbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2 + Details Name: us-gaap_UnbilledContractsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals) - USD ($) shares in Millions, $ in Millions Jun. 30, 2024 Dec. 31, 2023 Accounts Receivable, Allowance for Credit Loss $ 34.1 $ 32.7 Shareholders' Equity: Â Â Common stock, shares outstanding (in shares) 83.8 83.9 X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Net restructuring and other special charges $ 11.6 $ 15.8 $ 16.6 $ 23.3 Operating Income (Loss) 294.8 266.3 616.1 596.1 Interest Expense 47.6 49.8 94.5 100.5 Equity method income, net (0.3) 0.9 (0.2) (1.2) Investment income 1.3 4.5 4.2 6.7 Other, net 19.5 (16.9) 39.5 (23.8) Earnings before income taxes 267.7 205.0 565.1 477.3 Provision for income taxes 62.1 49.8 131.2 113.7 Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 205.6 155.2 433.9 363.6 Net earnings 205.6 189.1 433.9 402.4 Net Income (Loss) Attributable to Noncontrolling Interest 0.3 0.2 0.6 0.6 Net earnings attributable to Labcorp Holdings Inc. $ 205.3 $ 188.9 $ 433.3 $ 401.8 Income (Loss) from Continuing Operations, Per Basic Share $ 2.44 $ 1.75 $ 5.15 $ 4.10 Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 0 0.38 0 0.43 Basic earnings per common share (in dollars per share) 2.44 2.13 5.15 4.53 Diluted earnings per common share (in dollars per share) $ 2.43 $ 2.12 $ 5.13 $ 4.51 Revenues $ 3,220.9 $ 3,033.7 $ 6,397.5 $ 6,071.5 Cost of Revenue 2,294.5 2,191.5 4,573.8 4,379.2 Gross Profit 926.4 842.2 1,823.7 1,692.3 Selling, general and administrative expenses 557.8 505.8 1,066.2 963.0 Amortization of intangibles and other assets 62.2 51.5 122.3 104.9 Asset Impairment Charges 0.0 2.8 2.5 5.0 Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 0.0 $ 33.9 $ 0.0 $ 38.8 Income (Loss) from Continuing Operations, Per Diluted Share $ 2.43 $ 1.74 $ 5.13 $ 4.08 Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share $ 0 $ 0.38 $ 0 $ 0.43 Revenues $ 3,220.9 $ 3,033.7 $ 6,397.5 $ 6,071.5 Cost of Revenue 2,294.5 2,191.5 4,573.8 4,379.2 Gross Profit 926.4 842.2 1,823.7 1,692.3 Selling, general and administrative expenses 557.8 505.8 1,066.2 963.0 Amortization of intangibles and other assets 62.2 51.5 122.3 104.9 Asset Impairment Charges 0.0 2.8 2.5 5.0 Net restructuring and other special charges 11.6 15.8 16.6 23.3 Operating Income (Loss) 294.8 266.3 616.1 596.1 Earnings before income taxes 267.7 205.0 565.1 477.3 Provision for income taxes 62.1 49.8 131.2 113.7 Net earnings 205.6 189.1 433.9 402.4 Less: Net earnings attributable to the noncontrolling interest (0.3) (0.2) (0.6) (0.6) Net earnings attributable to Labcorp Holdings Inc. $ 205.3 $ 188.9 $ 433.3 $ 401.8 Basic earnings per common share (in dollars per share) $ 2.44 $ 2.13 $ 5.15 $ 4.53 Diluted earnings per common share (in dollars per share) $ 2.43 $ 2.12 $ 5.13 $ 4.51 X - DefinitionIncome (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest + ReferencesNo definition available. + Details Name: lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program planned and controlled by management, and materially changes either the scope or manner of conduct of a business undertaken. Also, may include reversals and other adjustments to accrued liabilities and special charges, if any, for asset abandonment, uncollectible balances, etc. + ReferencesNo definition available. + Details Name: lh_NetRestructuringAndOtherSpecialCharges Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name

Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16:

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Unaudited) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Provision for income taxes $ 62.1 $ 49.8 $ 131.2 $ 113.7 Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 205.6 155.2 433.9 363.6 Foreign currency translation adjustments (7.2) 51.7 (131.5) 99.8 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 0.7 1.1 (1.7) 2.3 Other comprehensive earnings (loss) before tax (6.5) 52.8 (133.2) 102.1 Tax effect of adjustments (0.1) (0.3) 0.5 (0.6) Other comprehensive earnings (loss), net of tax (6.6) 52.5 (132.7) 101.5 Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 0.0 33.9 0.0 38.8 Net earnings 205.6 189.1 433.9 402.4 Net Income (Loss) Attributable to Noncontrolling Interest 0.3 0.2 0.6 0.6 Net Income (Loss) Attributable to Parent 205.3 188.9 433.3 401.8 Net earnings 205.6 189.1 433.9 402.4 Comprehensive earnings 199.0 241.6 301.2 503.9 Less: Net earnings attributable to the noncontrolling interest (0.3) (0.2) (0.6) (0.6) Comprehensive earnings attributable to Laboratory Corporation of America Holdings $ 198.7 $ 241.4 $ 300.6 $ 503.3 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4:

http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -

Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Millions Total Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income [Member] BALANCE at Dec. 31, 2022 $ 10,096.6 $ 8.1 $ 0.0 $ 10,581.7 $ (493.2) Net earnings attributable to Labcorp Holdings Inc. 212.9 0.0 0.0 212.9 0.0 Other comprehensive earnings, net of tax 49.0 0.0 0.0 0.0 49.0 Dividends 64.7 0.0 0.0 64.7 0.0 Issuance of common stock under employee stock plans (27.6) 0.0 (27.6) 0.0 0.0 Surrender of restricted stock and performance share awards (20.5) 0.0 (20.5) 0.0 0.0 Stock compensation 40.6 0.0 40.6 0.0 0.0 BALANCE at Mar. 31, 2023 8,785.0 8.1 94.4 8,836.2 (153.7) BALANCE at Dec. 31, 2022 10,096.6 8.1 0.0 10,581.7 (493.2) Net earnings attributable to Labcorp Holdings Inc. 401.8 Â Â Â Â Other comprehensive earnings, net of tax 101.5 Â Â Â Â BALANCE at Jun. 30, 2023 10,341.5 8.1 47.7 10,729.9 (444.2) BALANCE at Mar. 31, 2023 8,785.0 8.1 94.4 8,836.2 (153.7) Net earnings attributable to Labcorp Holdings Inc. 188.9 0.0 0.0 188.9 0.0 Other comprehensive earnings, net of tax 52.5 0.0 0.0 0.0 52.5 Dividends Â 0.0 0.0 64.5 0.0 Issuance of common stock under employee stock plans (26.8) 0.0 (26.8) 0.0 0.0 Surrender of restricted stock and performance share awards (18.2) 0.0 (18.2) 0.0 0.0 Stock compensation 38.1 0.0 38.1 0.0 0.0 BALANCE at Jun. 30, 2023 10,341.5 8.1 47.7 10,729.9 (444.2) Stockholders' Equity Note, Spinoff Transaction (1,780.1) 0.0 0.0 (2,018.1) 238.0 Dividends, Cash (64.5) Â Â Â Â Retained Earnings (Accumulated Deficit) 7,888.2 Â Â Â Â BALANCE at Dec. 31, 2023 7,875.0 7.7 38.4 7,888.2 (59.3) Net earnings attributable to Labcorp Holdings Inc. 228.0 0.0 0.0 228.0 0.0 Other comprehensive earnings, net of tax (126.1) 0.0 0.0 0.0 (126.1) Dividends 60.9 0.0 0.0 60.9 0.0 Issuance of common stock under employee stock plans (26.7) 0.0 (26.7) 0.0 0.0 Surrender of restricted stock and performance share awards (14.7) 0.0 (14.7) 0.0 0.0 Stock compensation 31.6 0.0 31.6 0.0 0.0 BALANCE at Mar. 31, 2024 7,959.6 7.7 82.0 8,055.3 (185.4) BALANCE at Dec. 31, 2023 7,875.0 7.7 38.4 7,888.2 (59.3) Net earnings attributable to Labcorp Holdings Inc. 433.3 Â Â Â Â Other comprehensive earnings, net of tax (132.7) Â Â Â Â BALANCE at Jun. 30, 2024 8,005.8 7.7 12.5 8,177.6 (192.0) BALANCE at Mar. 31, 2024 7,959.6 7.7 82.0 8,055.3 (185.4) Net earnings attributable to Labcorp Holdings Inc. 205.3 0.0 0.0 205.3 0.0 Other comprehensive earnings, net of tax (6.6) 0.0 0.0 0.0 (6.6) Dividends 60.2 0.0 0.0 60.2 0.0 Surrender of restricted stock and performance share awards (23.1) 0.0 (23.1) 0.0 0.0 Stock compensation 30.8 0.0 30.8 0.0 0.0 BALANCE at Jun. 30, 2024 8,005.8 7.7 12.5 8,177.6 (192.0) Purchase of common stock (100.0) $ 0.0 $ 77.2 $ 22.8 $ 0.0 Retained Earnings (Accumulated Deficit) $ 8,177.6 Â Â Â Â X - DefinitionAggregate change in value for stock issued in period under ESPP combined with the value of stock issued as a result of option exercises. + ReferencesNo definition available. + Details Name: lh_Issuanceofcommonstockunderemployeeplans Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of stock related to Restricted Stock Awards forfeited during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 60 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481423/505-60-25-2 + Details Name: us-gaap_StockholdersEquityNoteSpinoffTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net earnings $ 433.9 $ 402.4 Earnings from discontinued

operations, net of tax 0.0 (38.8) Adjustments to reconcile net earnings to net cash provided by operating activities: Â Â Depreciation and amortization 311.4 285.0 Stock compensation 62.4 67.3 Operating lease right-of-use asset expense 88.6 85.1 Goodwill and other asset impairments 2.5 5.0 Deferred income taxes (39.1) 16.2 Other 36.6 3.1 Change in assets and liabilities (net of effects of acquisitions and divestitures): Â Â Increase (Decrease) in Accounts Receivable (192.2) (107.6) Increase (Decrease) in Unbilled Contract Receivable 26.8 74.1 Increase (Decrease) in Inventories 27.7 (16.1) Increase (Decrease) in Prepaid Expense and Other Assets (21.6) 30.2 Increase (Decrease) in Accounts Payable (51.7) (160.3) Increase (Decrease) in Deferred Revenue (30.8) 34.8 Decrease in accrued expenses and other (166.4) (272.8) Net Cash Provided by (Used in) Operating Activities, Total 531.3 472.6 CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Capital expenditures (262.0) (181.5) Proceeds from sale of assets 0.2 0.2 Proceeds from Sales of Business, Affiliate and Productive Assets 13.5 0.0 Investments in equity affiliates (36.7) (10.4) Acquisition of businesses, net of cash acquired (293.1) (136.9) Net cash used for investing activities (578.1) (353.3) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from revolving credit facilities 951.9 1,420.9 Payments on revolving credit facilities (932.1) (1,420.9) Net share settlement tax payments from issuance of stock to employees 37.8 38.7 Net proceeds from issuance of stock to employees 26.7 54.4 Dividends paid 122.5 129.0 Purchase of common stock (100.0) 0.0 Other 7.9 11.4 Net cash (used for) provided by financing activities (221.7) 1,484.4 Effect of exchange rate changes on cash and cash equivalents (3.2) 6.3 Net (decrease) increase in cash and cash equivalents (271.7) 1,610.0 Cash and cash equivalents at beginning of period 536.8 430.0 Cash and cash equivalents at end of period 265.1 1,930.6 Discontinued Operations Â Â Change in assets and liabilities (net of effects of acquisitions and divestitures): Â Â Net cash provided by discontinued operating activities 0.0 125.4 CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Net cash used for discontinued investing activities 0.0 (24.7) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Net cash provided by discontinued financing activities 0.0 1,609.1 Continuing Operations Â Â Change in assets and liabilities (net of effects of acquisitions and divestitures): Â Â Net cash provided by continuing operating activities 531.3 347.2 CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Net cash used for continuing investing activities (578.1) (328.6) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Net cash used for continuing financing activities (221.7) (124.7) Less: Cash and cash equivalents of discontinued operations at end of period $ 0.0 $ 109.4 X - DefinitionThe amount of depreciation recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Also, may include amortization charged against earnings for the periodic recognition of capitalized leases. + ReferencesNo definition available. + Details Name: lh_DepreciationAndAmortizationOfLeasedAssets Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) in Unbilled Contract Receivable + ReferencesNo definition available. + Details Name: lh_IncreaseDecreaseinUnbilledContractReceivable Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock options and employees related to shares purchased under the employee stock purchase plan. + ReferencesNo definition available. + Details Name: lh_NetProceedsFromIssuanceOfStockToEmployees Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther Financing Cash Flows + ReferencesNo definition available. + Details Name: lh_OtherFinancingCashFlows Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BASIS OF FINANCIAL STATEMENT PRESENTATION 3 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] BASIS OF FINANCIAL STATEMENT PRESENTATIONLabcorpÂ® Holdings Inc. (LabcorpÂ® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. On April 25, 2024, the Company announced plans to implement a new public holding company structure, with Labcorp Holdings Inc. as the new holding company. On May 17, 2024, the Company completed the holding company reorganization (Reorganization) and Labcorp Holdings Inc. became the successor issuer to Laboratory Corporation of America Holdings (LCAH). The new holding company has no independent assets or operations and its sole ownership interest is in LCAH.The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the six months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company.The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Companyâ€™s fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Companyâ€™s Annual Report.The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency.Â Assets and liabilities are translated at exchange rates as of the balance sheet date.Â Revenues and expenses are translated at average monthly exchange rates prevailing during the period.Â Resulting translation adjustments are included in â€œAccumulated other comprehensive income (loss).â€ Basis of Presentation and Significant Accounting Policies [Text Block] BASIS OF FINANCIAL STATEMENT PRESENTATIONLabcorpÂ® Holdings Inc. (LabcorpÂ® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. On April 25, 2024, the Company announced plans to implement a new public holding company structure, with Labcorp Holdings Inc. as the new holding company. On May 17, 2024, the Company completed the holding company reorganization (Reorganization) and Labcorp Holdings Inc. became the successor issuer to Laboratory Corporation of America Holdings (LCAH). The new holding company has no independent assets or operations and its sole ownership interest is in LCAH.The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the six months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company.The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Companyâ€™s fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Companyâ€™s Annual Report.The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency.Â Assets and liabilities are translated at exchange rates as of the balance sheet date.Â Revenues and expenses are translated at average monthly exchange rates prevailing during the period.Â Resulting translation adjustments are included in â€œAccumulated other comprehensive income (loss).â€ X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Earnings Per Share EARNINGS PER SHAREBasic earnings per share is computed by dividing net earnings attributable to the Company by the weighted average number of shares of the Company's common stock outstanding. Diluted earnings per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Companyâ€™s outstanding stock options, restricted stock awards, restricted stock units, and performance share awards.The following represents a reconciliation of basic earnings per share to diluted earnings per share for the three and six months ended June 30:Â Three Months Ended June 30,Six Months Ended June 30,Â 2024202320242023EarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountBasic earnings per share:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net earnings$205.3Â 84.1Â $2.44Â $155.0Â 88.7Â $1.75Â $433.3Â 84.1Â $5.15Â $363.0Â 88.6Â $4.10Â Dilutive effect of employeeÂ stock options and awardsâ€”Â 0.2Â Â â€”Â 0.3Â Â â€”Â 0.4Â Â â€”Â 0.4Â Â Net earnings including impact of dilutive adjustments$205.3Â 84.3Â $2.43Â $155.0Â 89.0Â $1.74Â $433.3Â 84.5Â $5.13Â $363.0Â 89.0Â $4.08Â Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:Three Months Ended June 30,Six Months Ended June 30,Â 2024202320242023Employee stock options and awards0.4Â 0.5Â 0.3Â 0.4Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Stockholders' Equity Note [Abstract] Â Â Changes in common shares issued and held in treasury The changes in common shares issued during the six months ended June 30, 2024 are summarized below:Issued and OutstandingCommon shares at December 31, 202383.9Â Shares issued under employee stock plans0.4Â Shares repurchased(0.5)Common shares at June 30, 202483.8Â Â Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows:Foreign Currency Translation AdjustmentsNet Benefit Plan AdjustmentsAccumulated Other Comprehensive Earnings (Loss)Balance as of December 31, 2023(47.6)(11.7)$(59.3)Current year adjustments(131.5)(1.5)(133.0)Amounts reclassified from accumulated other comprehensive incomeâ€”Â (0.2)(0.2)Tax effect of adjustmentsâ€”Â 0.5Â 0.5Â Balance as of June 30, 2024(179.1)(12.9)$(192.0) Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Preferred Stock and Common Shareholders' Equity Â PREFERRED STOCK AND COMMON SHAREHOLDERSâ€™ EQUITYThe Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were no preferred shares outstanding as of June 30, 2024, and DecemberÂ 31, 2023. The changes in common shares issued during the six months ended June 30, 2024 are summarized below:Issued and OutstandingCommon shares at December 31, 202383.9Â Shares issued under employee stock plans0.4Â Shares repurchased(0.5)Common shares at June 30, 202483.8Â Share Repurchase ProgramWhen the Company repurchases shares of Common Stock, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a reduction in retained earnings. During the six months ended June 30, 2024, the Company purchased 0.5 shares of its common stock at an average price of $202.66 for a total cost of $100.0. As of June 30, 2024, the Company had outstanding authorization from the board of directors to purchase up to $430.4 of the Company's common stock. On July 24, 2024, the Board adopted a new share repurchase plan authorizing up to $1,000.0 of the Company's shares in addition to the remaining amount outstanding under the previous plan. In aggregate, the share repurchase authorization is $1,430.4.DividendsFor the six months ended June 30, 2024, the Company paid $122.5 in common stock dividends. On July 25, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the third quarter, or approximately $61.2 in the aggregate. The dividend will be payable on September 13, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on August 29, 2024. The declaration and payment of any future dividends will be at the discretion of the Company's board of directors.Accumulated Other Comprehensive Earnings (Loss)The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows:Foreign Currency Translation AdjustmentsNet Benefit Plan AdjustmentsAccumulated Other Comprehensive Earnings (Loss)Balance as of December 31, 2023(47.6)(11.7)$(59.3)Current year adjustments(131.5)(1.5)(133.0)Amounts reclassified from accumulated other comprehensive incomeâ€”Â (0.2)(0.2)Tax effect of adjustmentsâ€”Â 0.5Â 0.5Â Balance as of June 30, 2024(179.1)(12.9)$(192.0) X - DefinitionSchedule is used to show the changes in common shares issued and held in treasury by the entity. + ReferencesNo definition available. + Details Name:

lh_ChangesInCommonSharesIssuedAndHeldInTreasuryTableTextBlock Namespace Prefix: lh_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES 3 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies COMMITMENTS AND CONTINGENCIES X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS 3 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements FAIR VALUE MEASUREMENTSThe Companyâ€™s population of financial assets and liabilities subject to fair value measurements as of June 30, 2024, and DecemberÂ 31, 2023, was as follows:Fair Value Measurements as ofJune 30, 2024Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationJune 30, 2024Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.0Â $â€”Â $15.0Â $â€”Â Cross currency swapsOther liabilities103.6Â â€”Â 103.6Â â€”Â Interest rate swapsOther liabilities79.7Â â€”Â 79.7Â â€”Â Cash surrender value of life insurance policiesOther assets, net96.4Â â€”Â 96.4Â â€”Â Deferred compensation assetOther assets, net31.0Â â€”Â 31.0Â â€”Â Deferred compensation liabilityOther liabilities125.3Â â€”Â 125.3Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities20.0Â â€”Â â€”Â 20.0Â Fair Value Measurements as ofDecember 31, 2023Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationDecember 31, 2023Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.5Â $â€”Â $15.5Â $â€”Â Cross currency swapsAccrued expenses and other; Other liabilities109.0Â â€”Â 109.0Â â€”Â Interest rate swapsOther liabilities, net69.6Â â€”Â 69.6Â â€”Â Cash surrender value of life insurance policiesOther assets, net95.4Â â€”Â 95.4Â â€”Â Deferred compensation assetOther assets, net21.1Â â€”Â 21.1Â â€”Â Deferred compensation liabilityOther liabilities107.4Â â€”Â 107.4Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities66.1Â â€”Â â€”Â 66.1Â The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Companyâ€™s condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value.The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of multiple measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments, which are typically invested in a similar manner to the participant's allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.Contingent accrued earn-out business acquisition consideration liabilities are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3.The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the senior notes, based on market pricing, was approximately $4,812.3 and $4,850.4 as of June 30, 2024, and DecemberÂ 31, 2023, respectively. The Company's note and debt instruments are classified as Level 2 instruments, as the fair market values of these instruments are determined using other observable inputs. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL CASH FLOW INFORMATION 3 Months Ended Jun. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â Supplemental Cash Flow Information SUPPLEMENTAL CASH FLOW INFORMATIONSix Months Ended June 30,Â 20242023Cash paid during period for:Â Â Interest$106.6Â $109.5Â Income taxes, net of refunds153.0Â 133.3Â Disclosure of non-cash financing and investing activities:Â Â Change in accrued property, plant, and equipment(19.2)16.5Â X - DefinitionThe entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/230/tableOfContent + Details Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS ACQUISITIONS 6 Months Ended Jun. 30, 2024 Business Combinations [Abstract] Â Business Combination Disclosure [Text Block] BUSINESS ACQUISITIONS AND DISPOSITIONSDuring the six months ended June 30, 2024, the Company acquired several businesses and related assets for cash of approximately $293.1. These acquisitions consisted of the clinical and outreach businesses of Baystate Medical Center

($116.6), Providence Medical Foundation ($54.9), and Westpac Labs, Inc. ($97.7) and an escrow payment of $23.9 for selected assets of the Invitae Corporation that is anticipated to close on August 5, 2024. The preliminary purchase considerations for these acquisitions were allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $159.4 in identifiable intangible assets. A residual amount of tax deductible goodwill of approximately $141.7 was recorded as of June 30, 2024. The amortization period for non-compete agreements and customer list assets acquired from these businesses are 5 and 15 years, respectively. The valuation of acquired assets and assumed liabilities, include the following: X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS SEGMENT INFORMATION Business Segment information (Notes) 3 Months Ended Jun. 30, 2024 Segment Reporting Information [Line Items] Â Segment Reporting Disclosure [Text Block] BUSINESS SEGMENT INFORMATIONThe following table is a summary of segment information for the three and six months ended June 30, 2024, and 2023. The â€œmanagement approachâ€ has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Companyâ€™s chief executive officer has been identified as the CODM.Segment asset information is not presented because it is not used by the CODM at the segment level. The Corporate costs not allocated to segments include the costs of centralized functions, other charges such as acquisition expenses, spin-off costs, remaining unallocated costs of the CDCS business, and COVID-19 related costs unrelated to the segment. Centralized functions include corporate governance, executive management and related human resources, finance, legal, risk management, and information technology functions.Three Months Ended June 30,Six Months Ended June 30,20242023202420232023Revenues:Dx$2,524.9Â $2,340.8Â $5,004.6Â $4,723.6Â BLS707.0Â 699.0Â 1,417.9Â 1,360.3Â Intercompany eliminations and other(11.0)(6.1)(25.0)(12.4)Total revenues$3,220.9Â $3,033.7Â $6,397.5Â $6,071.5Â Operating Earnings:Dx segment operating income$441.5Â $409.7Â $859.4Â $851.2Â BLS segment operating income107.4Â 104.6Â 207.3Â 178.2Â Segment operating income548.9Â 514.3Â 1,066.7Â 1,029.4Â General corporate and unallocated expenses(180.3)(177.9)(309.2)(300.1)Amortization of intangibles and other assets(62.2)(51.5)(122.3)(104.9)Goodwill and other asset impairmentsâ€”Â (2.8)(2.5)(5.0)Restructuring and other charges(11.6)(15.8)(16.6)(23.3)Total operating income$294.8Â $266.3Â $616.1Â $596.1Â X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations and Disposal Groups 3 Months Ended Jun. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â Disposal Groups, Including Discontinued Operations, Disclosure 2.Â Â Â Â DISCONTINUED OPERATIONSOn June 30, 2023 (the Distribution Date), Labcorp completed the previously announced separation (the Separation) from the Company of Fortrea Holdings Inc. (Fortrea), formerly the Company's Clinical Development and Commercialization Services (CDCS) business, into a separate, publicly-traded company. All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the Condensed Consolidated Statements of Operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes.The spin-off of Fortrea from Labcorp was achieved through the Companyâ€™s pro-rata distribution of 100% of the outstanding shares of Fortrea common stock to holders of record of Labcorp common stock. Each holder of record of Labcorp common stock received one share of Fortrea common stock for every share of Labcorp common stock held at 5:00 p.m., Burlington, North Carolina, time on June 20, 2023, the record date for the distribution.In June 2023, Fortrea, prior to the Separation and while a subsidiary of the Company, issued $570.0 of 7.500% senior secured notes due 2030 (the Fortrea Notes). The proceeds from the Fortrea Notes were used to fund cash payments of approximately $1,600.0 to the Company in connection with the Separation. The Company does not guarantee the Fortrea Notes following the Separation. Also in June 2023, Fortrea entered into three floating secured overnight financing rate (SOFR) credit facilities totaling $1,520.0. These are comprised of a $450.0 Revolver maturing June 30, 2028; a $500.0 Term Loan A maturing June 30, 2028; and a $570.0 Term Loan B maturing June 30, 2030. In connection with the spin-off, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Companyâ€™s relationship with Fortrea after the spin-off, including a separation and distribution agreement, a tax matters agreement, an employee matters agreement, and a transition services agreement. These agreements contain the key provisions relating to the spin-off, including provisions relating to the principal intercompany transactions required to effect the spin-off, the conditions to the spin-off and provisions governing the relationship between Fortrea and the Company after the spin-off. The costs to provide these services are included in operating income but the service fees are included in other income.Financial Information of Discontinued OperationsEarnings from discontinued operations, net of tax in the Consolidated Statements of Operations reflect the after-tax results of Fortrea's business and Separation-related fees, and do not include any allocation of general corporate overhead expense or interest expense of the Company.The following table summarizes the significant line items included in Earnings from Discontinued Operations, Net of Tax in the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023:Three Months Ended June 30, 2023Six Months Ended June 30, 2023Revenues$766.5Â $1,506.6Â Cost of revenues629.1Â 1,244.5Â Gross profit137.4Â 262.1Â Selling, general and administrative expenses85.4Â 184.1Â Amortization of intangibles and other assets16.0Â 31.9Â Restructuring and other charges4.1Â 3.0Â Operating income31.9Â 43.1Â Other income (expense):Other, net8.3Â 2.5Â Earnings before income taxes40.2Â 45.6Â Provision for income taxes6.3Â 6.8Â Net earnings attributable to Labcorp Holdings Inc.$33.9Â $38.8Â X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Net Income (Loss) Attributable to Parent $ 205.3 $ 228.0 $ 188.9 $ 212.9 $ 433.3 $ 401.8 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21:

http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement Insider Adoption or Termination of Trading Arrangements:During the fiscal quarter ended June 30, 2024, none of the Company's directors or officers informed it of the adoption, modification or termination of a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as those terms are defined in Regulation S-K, Item 408, except as described in the table below:Name and TitleDate AdoptedCharacter of Trading AgreementAggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading AgreementDurationKerrii B. AndersonMay 3, 2024Rule 10b5-1 Trading ArrangementUp to(3,000)(1)5/3/2025(2)Director(1) The figure presented represents the shares to be sold on the vesting of equity awards before reduction for shares to be withheld for tax purposes(2) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table. Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date May 3, 2024 Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Kerrii Anderson [Member] Â Trading Arrangements, by Individual Â Name Kerrii B. Anderson Title Director Aggregate Available 3,000 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=lh_KerriiAndersonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets, Goodwill and Other (Policies) 3 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Intangible Assets, Goodwill, Policy 6.Â Â Â Â GOODWILL AND INTANGIBLE ASSETSThe changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows:DxBLSTotalBalance as of December 31, 2023$4,813.9Â $1,328.6Â $6,142.5Â Goodwill acquired during the period141.7Â â€”Â 141.7Â Foreign currency impact and other adjustments to goodwill(10.7)(53.3)(64.0)Balance as of June 30, 2024$4,944.9Â $1,275.3Â $6,220.2Â The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value.Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.The components of identifiable intangible assets were as follows:Â June 30, 2024December 31, 2023Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNetCustomer relationships$3,947.8Â $(1,444.1)$2,503.7Â $3,868.6Â $(1,367.2)$2,501.4Â Patents, licenses, and technology520.3Â (283.1)237.2Â 526.6Â (273.3)253.3Â Non-compete agreements152.4Â (72.5)79.9Â 130.3Â (60.4)69.9Â Canadian licenses495.1Â â€”Â 495.1Â 498.8Â â€”Â 498.8Â Other34.1Â (18.0)16.1Â 34.1Â (15.5)18.6Â Â 5,149.7Â (1,817.7)3,332.0Â 5,058.4Â (1,716.4)3,342.0Â Amortization of intangible assets for the three and six months ended June 30, 2024, and 2023, was $62.2 and $51.5 and $122.3 and $104.9, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $125.0 for the remainder of fiscal 2024, $237.2 in fiscal 2025, $228.2 in fiscal 2026, $216.9 in fiscal 2027, $209.1 in fiscal 2028, and $1,735.8 thereafter. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue from Contract with Customer (Policies) 3 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue REVENUESThe Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows:For the Three Months Ended June 30, 2024For the Three Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %24Â %â€”Â %â€”Â %24Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %77Â %â€”Â %â€”Â %77Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %10Â %9Â %4Â %23Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %For the Six Months Ended June 30, 2024For the Six Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %25Â %â€”Â %â€”Â %25Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %78Â %â€”Â %â€”Â %78Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %9Â %9Â %4Â %22Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively.Accounts Receivable, Unbilled Services and Unearned RevenueThe following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers as of June 30, 2024 and December 31, 2023:June 30, 2024December 31, 2023Dx accounts receivable$1,331.4Â $1,135.2Â BLS accounts receivable791.6Â 810.8Â Less BLS allowance for doubtful accounts(34.1)(32.7)Accounts receivable$2,088.9Â $1,913.3Â Gross unbilled services$159.3Â $192.9Â Less reserve for unbilled services(1.8)(7.5)Unbilled services$157.5Â $185.4Â Unearned revenue$388.3Â $421.7Â Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $26.8 and $20.2 for the three months ended June 30, 2024 and 2023, respectively, and $77.8 and $72.8 for the six months ended June 30, 2024 and 2023, respectively.Credit Loss RollforwardThe Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows:Accounts ReceivableUnbilled ServicesNote and Other ReceivablesTotalBalance as of December 31, 2023$32.7Â $7.5Â $0.7Â $40.9Â Plus, credit loss expense3.4Â â€”Â â€”Â 3.4Â Less, write offs2.0Â 5.7Â â€”Â 7.7Â Balance as of June 30, 2024$34.1Â $1.8Â $0.7Â $36.6Â The credit loss expense in the first six months primarily related to the collection risk from several biotech receivable balances. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Tables) 3 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Reconciliation of Basic earnings per Share to Diluted Earnings per Share The following represents a reconciliation of basic earnings per share to diluted earnings per share for the three and six months ended June 30:Â Three Months Ended June 30,Six Months Ended June 30,Â 20242023202420232023EarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountEarningsShares Per Share AmountBasic earnings per share:Â Â Â Â Â Â Â Â Â Â Â Â Net earnings$205.3Â 84.1Â $2.44Â $155.0Â 88.7Â $1.75Â $433.3Â 84.1Â $5.15Â $363.0Â 88.6Â $4.10Â Dilutive effect of employeeÂ stock options and awardsâ€”Â 0.2Â Â â€”Â 0.3Â Â â€”Â 0.4Â Â â€”Â 0.4Â Â Net earnings including impact of dilutive adjustments$205.3Â 84.3Â $2.43Â $155.0Â 89.0Â $1.74Â $433.3Â 84.5Â $5.13Â $363.0Â 89.0Â $4.08Â Potential common shares not included in computation of diluted earnings per share The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:Three Months Ended June 30,Six Months Ended June 30,Â 20242023202420232023Employee stock options and awards0.4Â 0.5Â 0.3Â 0.4Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS (Tables) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Changes in Carrying Amount of Goodwill Â The changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows:DxBLSTotalBalance as of December 31, 2023$4,813.9Â $1,328.6Â $6,142.5Â Goodwill acquired during the period141.7Â â€”Â 141.7Â Foreign currency impact and other adjustments to goodwill(10.7)(53.3)(64.0)Balance as of June 30, 2024$4,944.9Â $1,275.3Â $6,220.2Â Schedule of Intangible Assets and Goodwill [Table Text Block] he components of identifiable intangible assets were as follows:Â June 30, 2024December 31, 2023Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNetCustomer relationships$3,947.8Â $(1,444.1)$2,503.7Â $3,868.6Â $(1,367.2)$2,501.4Â Patents, licenses, and technology520.3Â (283.1)237.2Â 526.6Â (273.3)253.3Â Non-compete agreements152.4Â (72.5)79.9Â 130.3Â (60.4)69.9Â Canadian licenses495.1Â â€”Â 495.1Â 498.8Â â€”Â 498.8Â Other34.1Â (18.0)16.1Â 34.1Â (15.5)18.6Â Â 5,149.7Â (1,817.7)3,332.0Â $5,058.4Â (1,716.4)3,342.0Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS (Tables) 3 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Company's population of financial assets and liabilities subject to fair value measurements The Companyâ€™s population of financial assets and liabilities subject to fair value measurements as of June 30, 2024, and DecemberÂ 31, 2023, was as follows:Fair Value Measurements as ofJune 30, 2024Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationJune 30, 2024Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.0Â $â€”Â $15.0Â $â€”Â Cross currency swapsOther liabilities103.6Â â€”Â 103.6Â â€”Â Interest rate swapsOther liabilities79.7Â â€”Â 79.7Â â€”Â Cash surrender value of life insurance policiesOther assets, net96.4Â â€”Â 96.4Â â€”Â Deferred compensation assetOther assets, net31.0Â â€”Â 31.0Â â€”Â Deferred compensation liabilityOther liabilities125.3Â â€”Â 125.3Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities20.0Â â€”Â â€”Â 20.0Â Fair Value Measurements as ofDecember 31, 2023Balance SheetFair Value as ofUsing Fair Value HierarchyÂ ClassificationDecember 31, 2023Level 1Level 2Level 3Noncontrolling interest putNoncontrolling interest$15.5Â $â€”Â $15.5Â $â€”Â Cross currency swapsAccrued expenses and other; Other liabilities109.0Â â€”Â 109.0Â â€”Â Interest rate swapsOther liabilities, net69.6Â â€”Â 69.6Â â€”Â Cash surrender value of life insurance policiesOther assets, net95.4Â â€”Â 95.4Â â€”Â Deferred compensation assetOther assets, net21.1Â â€”Â 21.1Â â€”Â Deferred compensation liabilityOther liabilities107.4Â â€”Â 107.4Â â€”Â Contingent considerationAccrued expenses and other; Other liabilities66.1Â â€”Â â€”Â 66.1Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL CASH FLOW INFORMATION (Tables) 3 Months Ended Jun. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â Supplemental Cash Flow Information Six Months Ended June 30,Â 20242023Cash paid during period for:Â Â Interest$106.6Â $109.5Â Income taxes, net of refunds153.0Â 133.3Â Disclosure of non-cash financing and investing activities:Â Â Change in accrued property, plant, and equipment(19.2)16.5Â X - DefinitionTabular disclosure of supplemental cash flow information for the periods presented. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE (Tables) 3 Months Ended Jun. 30, 2024 Disaggregation of Revenue [Line Items] Â Financing Receivable, Allowance for Credit Loss [Table Text Block] The rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows:Accounts ReceivableUnbilled ServicesNote and Other ReceivablesTotalBalance as of December 31, 2023$32.7Â $7.5Â $0.7Â $40.9Â Plus, credit loss expense3.4Â â€”Â â€”Â 3.4Â Less, write offs2.0Â 5.7Â â€”Â 7.7Â Balance as of June 30, 2024$34.1Â $1.8Â $0.7Â $36.6Â Contract with Customer, Asset and Liability [Table Text Block] June 30, 2024December 31, 2023Dx accounts receivable$1,331.4Â $1,135.2Â BLS accounts receivable791.6Â 810.8Â Less BLS allowance for doubtful accounts(34.1)(32.7)Accounts receivable$2,088.9Â $1,913.3Â Gross unbilled services$159.3Â $192.9Â Less reserve for unbilled services(1.8)(7.5)Unbilled services$157.5Â $185.4Â Unearned revenue$388.3Â $421.7Â Disaggregation of Revenue [Table Text Block] The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows:For the Three Months Ended June 30, 2024For the Three Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %24Â %â€”Â %â€”Â %24Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %77Â %â€”Â %â€”Â %77Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %10Â %9Â %4Â %23Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %For the Six Months Ended June 30, 2024For the Six Months Ended June 30, 2023North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotalPayer/CustomerDxÂ Â Â Clients24Â %â€”Â %â€”Â %24Â %25Â %â€”Â %â€”Â %25Â %Â Â Â Patients10Â %â€”Â %â€”Â %10Â %10Â %â€”Â %â€”Â %10Â %Â Â Â Medica and Medicaid8Â %â€”Â %â€”Â %8Â %8Â %â€”Â %â€”Â %8Â %Â Â Â Third party36Â %â€”Â %â€”Â %36Â %35Â %â€”Â %â€”Â %35Â %Total Dx revenues by payer78Â %â€”Â %â€”Â %78Â %78Â %â€”Â %â€”Â %78Â %BLSPharmaceutical, biotechnology, and medical device companies9Â %9Â %4Â %22Â %9Â %9Â %4Â %22Â %Total revenues87Â %9Â %4Â %100Â %87Â %9Â %4Â %100Â %Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively. X - DefinitionTabular disclosure of allowance for credit loss on financing receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Â Â Â Asset Impairment Charges $ 0.0 Â $ 2.8 Â $ 2.5 $ 5.0 Â Â Revenues 3,220.9 Â $ 3,033.7 Â 6,397.5 $ 6,071.5 Â Â Contract with Customer, Liability $ 388.3 Â Â Â $ 388.3 Â $ 421.7 Â Percent of Revenue Contributed 100.00% Â 100.00% Â 100.00% 100.00% Â Â Ownership percentage below which investments are generally accounted for on the cost method (in thousandths) Â Â Â Â 20.00% Â Â Â Provision for income taxes $ 62.1 Â $ 49.8 Â $ 131.2 $ 113.7 Â Â Net Income (Loss) Attributable to Parent 205.3 $ 228.0 188.9 $ 212.9 433.3 401.8 Â Â Stockholders' Equity Attributable to Parent 8,005.8 $ 7,959.6 10,341.5 $ 8,785.0 8,005.8 10,341.5 7,875.0 $ 10,096.6 Deferred Revenue, Revenue Recognized 26.8 Â $ 20.2 Â 77.8 $ 72.8 Â Â Cash and cash equivalents $ 265.1 Â Â Â $ 265.1 Â $ 536.8 Â LabCorp Diagnostics [Member] Â Â Â Â Â Â Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Â Â Â Percent of Revenue Contributed 78.00% Â 77.00% Â 78.00% 78.00% Â Â X - DefinitionThis element represents the maximum ownership percentage of cost-method investments held by the Company. Generally, such investments do not have readily determinable fair values and are not required to be accounted for by the equity method. The carrying amount of such securities equates to cost, adjusted for other-than-temporary impairment. + ReferencesNo definition available. + Details Name: lh_CostMethodInvestmentsMaximumOwnershipPercentage Namespace Prefix: lh_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionPercent of Revenue Contributed + ReferencesNo definition available. + Details Name: lh_PercentofRevenueContributed Namespace Prefix: lh_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near

their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously reported as deferred or unearned revenue. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueRevenueRecognized1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic

235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Shares [Abstract] Â Â Â Â Net earnings, basic (in shares) 84.1 88.7 84.1 88.6 Dilutive effect of employee stock options and awards, (in shares) 0.2 0.3 0.4 0.4 Income (Loss) from Continuing Operations, Per Diluted Share $ 2.43 $ 1.74 $ 5.13 $ 4.08 Per Share Amount [Abstract] Â Â Â Â Net Income (Loss) Available to Common Stockholders, Diluted $ 205.3 $ 155.0 $ 433.3 $ 363.0 Weighted Average Number of Shares Outstanding, Diluted 84.3 89.0 84.5 89.0 Income (Loss) from Continuing Operations, Per Basic Share $ 2.44 $ 1.75 $ 5.15 $ 4.10 Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent $ 205.3 Â Â Â X - ReferencesNo definition available. + Details Name: lh_PerShareAmountAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: lh_SharesAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) - shares shares in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Stock options (in shares) 0.4 0.5 0.3 0.4 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Goodwill [Line Items] Â Â Â Â Â Amortization of intangibles and other assets $ 62.2 $ 51.5 $ 122.3 $ 104.9 Â Intangible Assets, Gross (Excluding Goodwill) 5,149.7 Â 5,149.7 Â $ 5,058.4 Balance as of January 1 Â Â 6,142.5 Â Â Adjustments to goodwill Â Â (64.0) Â Â Balance at end of period 6,220.2 Â 6,220.2 Â Â Finite-Lived Intangible Assets, Accumulated Amortization 1,817.7 Â 1,817.7 Â 1,716.4 Intangible Assets, Net (Excluding Goodwill) $ 3,332.0 Â 3,332.0 Â 3,342.0 Goodwill, Acquired During Period Â Â 141.7 Â Â Goodwill [Roll Forward] Â Â Â Â Â Goodwill and Intangible Assets, Goodwill, Policy 6.Â Â Â Â GOODWILL AND INTANGIBLE ASSETSThe changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows:DxBLSTotalBalance as of December 31, 2023$4,813.9Â $1,328.6Â $6,142.5Â Goodwill acquired during the period141.7Â â€”Â 141.7Â Foreign currency impact and other adjustments to goodwill(10.7)(53.3)(64.0)Balance as of June 30, 2024$4,944.9Â $1,275.3Â $6,220.2Â The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value.Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.The components of identifiable intangible assets were as follows:Â June 30, 2024December 31, 2023Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNetCustomer relationships$3,947.8Â $(1,444.1)$2,503.7Â $3,868.6Â $(1,367.2)$2,501.4Â Patents, licenses, and technology520.3Â (283.1)237.2Â 526.6Â (273.3)253.3Â Non-compete agreements152.4Â (72.5)79.9Â 130.3Â (60.4)69.9Â Canadian licenses495.1Â â€”Â 495.1Â 498.8Â â€”Â 498.8Â Other34.1Â (18.0)16.1Â 34.1Â (15.5)18.6Â Â 5,149.7Â (1,817.7)3,332.0Â 5,058.4Â (1,716.4)3,342.0Â Amortization of intangible assets for the three and six months ended June 30, 2024, and 2023, was $62.2 and $51.5 and $122.3 and $104.9, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $125.0 for the remainder of fiscal 2024, $237.2 in fiscal 2025, $228.2 in fiscal 2026, $216.9 in fiscal 2027, $209.1 in fiscal 2028, and $1,735.8 thereafter. Â Â Â Â LabCorp Diagnostics [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Balance as of January 1 Â Â 4,813.9 Â Â Adjustments to goodwill Â Â (10.7) Â Â Balance at end of period $ 4,944.9 Â 4,944.9 Â Â Goodwill, Acquired During Period Â Â 141.7 Â Â Covance Drug Development [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Balance as of January 1 Â Â 1,328.6 Â Â Adjustments to goodwill Â Â (53.3) Â Â Balance at end of period 1,275.3 Â 1,275.3 Â Â Goodwill, Acquired During Period Â Â 0.0 Â Â Customer Relationships [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Intangible Assets, Gross (Excluding Goodwill) 3,947.8 Â 3,947.8 Â 3,868.6 Finite-Lived Intangible Assets, Accumulated Amortization 1,444.1 Â 1,444.1 Â 1,367.2 Intangible Assets, Net (Excluding Goodwill) 2,503.7 Â 2,503.7 Â 2,501.4 Patents, Licenses And Technology [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Intangible Assets, Gross (Excluding Goodwill) 520.3 Â 520.3 Â 526.6 Finite-Lived Intangible Assets, Accumulated Amortization 283.1 Â 283.1 Â 273.3 Intangible Assets, Net (Excluding Goodwill) 237.2 Â 237.2 Â 253.3 Noncompete Agreements [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Intangible Assets, Gross (Excluding Goodwill) 152.4 Â 152.4 Â 130.3 Finite-Lived Intangible Assets, Accumulated Amortization 72.5 Â 72.5 Â 60.4 Intangible Assets, Net (Excluding Goodwill) 79.9 Â 79.9 Â 69.9 Canadian licenses [Member] Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Intangible Assets, Gross (Excluding Goodwill) 495.1 Â 495.1 Â 498.8 Finite-Lived Intangible Assets, Accumulated Amortization 0.0 Â 0.0 Â 0.0 Intangible Assets, Net (Excluding Goodwill) $ 495.1 Â $ 495.1 Â $ 498.8 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillAcquiredDuringPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_CovanceDrugDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=lh_PatentsLicensesAndTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) $ 5,149.7 $ 5,058.4 Finite-Lived Intangible Assets, Accumulated Amortization (1,817.7) (1,716.4) Intangible Assets, Net (Excluding Goodwill) 3,332.0 3,342.0 Customer Relationships [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) 3,947.8 3,868.6 Finite-Lived Intangible Assets, Accumulated Amortization (1,444.1) (1,367.2) Intangible Assets, Net (Excluding Goodwill) 2,503.7 2,501.4 Patents, Licenses And Technology [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) 520.3 526.6 Finite-Lived Intangible Assets, Accumulated Amortization (283.1) (273.3) Intangible Assets, Net (Excluding Goodwill) 237.2 253.3 Noncompete Agreements [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) 152.4 130.3 Finite-Lived Intangible Assets, Accumulated Amortization (72.5) (60.4) Intangible Assets, Net (Excluding Goodwill) 79.9 69.9 Canadian licenses [Member] Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) 495.1 498.8 Finite-Lived Intangible Assets, Accumulated Amortization 0.0 0.0 Intangible Assets, Net (Excluding Goodwill) 495.1 498.8 In Process R&A and Media Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible Assets, Gross (Excluding Goodwill) 34.1 34.1 Finite-Lived Intangible Assets, Accumulated Amortization (18.0) (15.5) Intangible Assets, Net (Excluding Goodwill) $ 16.1 $ 18.6 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=lh_PatentsLicensesAndTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis=lh_InProcessRAAndMediaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Intangible Assets, Gross (Excluding Goodwill) $ 5,149.7 Â $ 5,149.7 Â $ 5,058.4 Goodwill 6,220.2 Â 6,220.2 Â 6,142.5 Amortization of intangibles and other assets 62.2 $ 51.5 122.3 $ 104.9 Â Adjustments to goodwill Â Â (64.0) Â Â Estimated amortization expense, 2013 237.2 Â 237.2 Â Â Estimated amortization expense, 2014 228.2 Â 228.2 Â Â Estimated amortization expense, 2015 216.9 Â 216.9 Â Â Estimated amortization expense, 2016 209.1 Â 209.1 Â Â Estimated amortization expense, Thereafter 1,735.8 Â 1,735.8 Â Â Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Â Â 3.4 Â Â Amortization of intangible assets 62.2 $ 51.5 122.3 $ 104.9 Â LabCorp Diagnostics [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Goodwill 4,944.9 Â 4,944.9 Â 4,813.9 Adjustments to goodwill Â Â (10.7) Â Â Covance Drug Development [Member] Â Â Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Goodwill $ 1,275.3 Â 1,275.3 Â $ 1,328.6 Adjustments to goodwill Â Â $ (53.3) Â Â X - DefinitionCurrent Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings + ReferencesNo definition available. + Details Name: lh_CurrentExpectedCreditLossesOpeningBalanceSheetImpactonRetainedEarnings Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting

Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_CovanceDrugDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Short-term Debt [Line Items] Â Â Current debt excluding finance lease liability $ 2,019.5 $ 999.8 Notes Payable 0.5 1.1 3.60% senior notes due 2025 0.0 1,000.0 4.00% senior notes due 2023 400.0 400.0 Short term debt issuance costs (1.0) (1.3) Line of Credit, Current 20.0 0.0 Other Current Liabilities Â Â Short-term Debt [Line Items] Â Â 3.60% senior notes due 2025 1,000.0 0.0 3.25% senior notes due 2024 $ 600.0 $ 600.0 X - Definition3.25% senior notes due 2024 + ReferencesNo definition available. + Details Name: lh_A325SeniorNotesDue2024 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition3.60% senior notes due 2025 + ReferencesNo definition available. + Details Name: lh_A360SeniorNotesDue2025 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition4.00% senior notes due 2023 + ReferencesNo definition available. + Details Name: lh_A400SeniorNotesDue2023 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCurrent debt excluding finance lease liability + ReferencesNo definition available. + Details Name: lh_CurrentDebtExcludingFinanceLeaseLiability Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionShort term debt issuance costs + ReferencesNo definition available. + Details Name: lh_Shorttermdebtissuancecosts Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_OtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT (Long-term debt) (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â 4.00% senior notes due 2023 $ 400.0 $ 400.0 3.60% senior notes due 2025 0.0 1,000.0 1.55% senior notes due 2026 500.0 500.0 3.60% senior notes due 2027 600.0 600.0 2.95% senior notes due 2029 650.0 650.0 4.70% senior notes due 2045 900.0 900.0 Long term debt issuance costs 23.4 26.3 Notes Payable, Noncurrent 0.4 0.6 Long-term Debt, Excluding Current Maturities 3,047.3 $ 4,054.7 Senior notes due 2027 [Member] Â Â Debt Instrument [Line Items] Â Â Long-term Debt, Excluding Current Maturities $ 600.0 Â X - Definition1.55% senior notes due 2026 + ReferencesNo definition available. + Details Name: lh_A155SeniorNotesDue2026 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition2.95% senior notes due 2029 + ReferencesNo definition available. + Details Name: lh_A2.95seniornotesdue2029 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition3.60% senior notes due 2025 + ReferencesNo definition available. + Details Name: lh_A360SeniorNotesDue2025 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition3.60% senior notes due 2027 + ReferencesNo definition available. + Details Name: lh_A360SeniorNotesDue2027 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition4.00% senior notes due 2023 + ReferencesNo definition available. + Details Name: lh_A400SeniorNotesDue2023 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition4.70% senior notes due 2045 + ReferencesNo definition available. + Details Name: lh_A470SeniorNotesDue2045 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLong term debt issuance costs + ReferencesNo definition available. + Details Name: lh_Longtermdebtissuancecosts Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=lh_Seniornotesdue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT (Senior Notes) (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Long-term Debt, Excluding Current Maturities $ 3,047.3 $ 4,054.7 Line of Credit Facility, Maximum Borrowing Capacity 1,000.0 Â Credit Facility Option to Increase 500.0 Â Credit Facility, Maximum Swing Line Borrowings 100.0 Â Long term debt issuance costs 23.4 26.3 Notes Payable 0.5 1.1 Foreign Currency Contract, Asset, Fair Value Disclosure Â 109.0 2.95% senior notes due 2029 650.0 650.0 Interest Rate Swap [Member] Â Â Debt Instrument [Line Items] Â Â 2.70% senior notes due 2031 420.3 $ 430.4 Senior notes due 2027 [Member] Â Â Debt Instrument [Line Items] Â Â Long-term Debt, Excluding Current Maturities $ 600.0 Â X - Definition2.95% senior notes due 2029 + ReferencesNo definition available. + Details Name: lh_A2.95seniornotesdue2029 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition2.70% senior notes due 2031 + ReferencesNo definition available. + Details Name: lh_A270SeniorNotesDue2031 Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit Facility, Maximum Swing Line Borrowings + ReferencesNo definition available. + Details Name: lh_CreditFacilityMaximumSwingLineBorrowings Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit Facility Option to Increase + ReferencesNo definition available. + Details Name: lh_CreditFacilityOptiontoIncrease Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLong term debt issuance costs + ReferencesNo definition available. + Details Name: lh_Longtermdebtissuancecosts Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef

-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=lh_Seniornotesdue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT (Credit Facilities) (Details) - USD ($) 3 Months Ended Jun. 30, 2024 Dec. 31, 2023 Line of Credit Facility [Line Items] Â Â Revolving Credit Facility, maximum borrowing capacity $ 1,000,000,000 Â Line of Credit Facility, Commitment Fee Description 0.10% to 0.225% Â Notes Payable $ 500,000 $ 1,100,000 Credit Facility Option to Increase $ 500,000,000.0 Â Credit Facility, Maximum Swing Line Borrowings 100,000,000.0 Â Letters of Credit Outstanding, Amount 90,700,000 Â Revolving Credit Facility [Member] Â Â Line of Credit Facility [Line Items] Â Â Credit Facility, Maximum Letters of Credit $ 150,000,000.0 Â Line of Credit Facility, Interest Rate at Period End 6.44% Â X - DefinitionCredit Facility, Maximum Letters of Credit + ReferencesNo definition available. + Details Name: lh_CreditFacilityMaximumLettersofCredit Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit Facility, Maximum Swing Line Borrowings + ReferencesNo definition available. + Details Name: lh_CreditFacilityMaximumSwingLineBorrowings Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCredit Facility Option to Increase + ReferencesNo definition available. + Details Name: lh_CreditFacilityOptiontoIncrease Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the fees for amounts available, but unused under the credit facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeeDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe effective interest rate at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details) - USD ($) 3 Months Ended 6 Months Ended Jul. 25, 2024 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Jul. 24, 2024 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased Â 430,400,000 Â Â Â 430,400,000 Â Â Common Shares Outstanding Rollforward [Abstract] Â Â Â Â Â Â Â Â Â Â Common shares outstanding, beginning balance (in shares) Â Â 83,900,000 Â Â 83,900,000 Â Â Common shares outstanding, ending balance (in shares) Â 83,800,000 Â Â Â 83,800,000 Â Â Rollforward of common shares held in treasury Â Â Â Â Â Â Â Â Â Â Common Stock, Shares Authorized Â 265,000,000.0 Â Â Â 265,000,000.0 Â Â Common Stock, Par or Stated Value Per Share Â $ 0.10 Â Â Â $ 0.10 Â Â Preferred Stock, Shares Authorized Â 30,000,000.0 Â Â Â 30,000,000.0 Â Â Preferred Stock, Par or Stated Value Per Share Â $ 0.10 Â Â Â $ 0.10 Â Â Preferred Stock, Shares Outstanding Â 0 Â Â Â 0 Â Â Tax effect of adjustments Â Â Â Â Â Â Â $ 0 Â Â Dividends Â $ 60,200,000 $ 60,900,000 Â $ 64,700,000 Â Â Â Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Â Â Â Â Â Â (200,000) Â Â Foreign currency translation adjustments Â (7,200,000) Â $ 51,700,000 Â $ (131,500,000) $ 99,800,000 Â Stock Repurchased and Retired During Period, Shares Â Â Â Â Â (500,000) Â Â Purchase of common stock Â Â Â Â Â $ (100,000,000.0) $ 0 Â Treasury Stock Acquired, Average Cost Per Share Â Â Â Â Â $ 202.66 Â Â Dividends Â $ 60,200,000 $ 60,900,000 Â $ 64,700,000 Â Â Â Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased Â Â Â Â Â Â Â Â Â Â 1,430,400,000 Rollforward of common shares held in treasury Â Â Â Â Â Â Â Â Â Â Dividends Payable, Date of Record Aug. 29, 2024 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Date Declared Jul. 25, 2024 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Amount Per Share $ 0.72 Â Â Â Â Â Â Â Â Â Â Dividends $ 61,200,000 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Date to be Paid Sep. 13, 2024 Â Â Â Â Â Â Â Â Â Â Share Repurchase Program, Authorized, Amount Â Â Â Â Â Â Â Â Â Â $ 1,000,000,000 Dividends Payable, Date Declared Jul. 25, 2024 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Date to be Paid Sep. 13, 2024 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Date of Record Aug. 29, 2024 Â Â Â Â Â Â Â Â Â Â Dividends Payable, Amount Per Share $ 0.72 Â Â Â Â Â Â Â Â Â Â Dividends $ 61,200,000 Â Â Â Â Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Rollforward of common shares issued Â Â Â Â Â Â Â Â Â Â Common shares issued, beginning balance (in shares) Â Â 83,900,000 Â Â Â 83,900,000 Â Â Commons Stock Issued During Period Shares Employee Stock Plans Â Â Â Â Â 400,000 Â Â Common shares issued, ending balance (in shares) Â 83,800,000 Â Â Â 83,800,000 Â Â Common Stock, Shares, Issued Â 83,800,000 Â Â Â 83,800,000 Â Â Common Shares Outstanding Rollforward [Abstract] Â Â Â Â Â Â Â Â Â Â Commons Stock Issued During Period Shares Employee Stock Plans Â Â Â Â Â 400,000 Â Â Commons Stock Issued During Period Shares Employee Stock Plans Â Â Â Â Â 400,000 Â Â Rollforward of common shares held in treasury Â Â Â Â Â Â Â Â Â Â Stock Repurchased and Retired During Period, Shares Â Â Â Â Â (500,000) Â Â X - ReferencesNo definition available. + Details Name: lh_CommonSharesHeldInTreasuryRollforwardAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: lh_CommonSharesIssuedRollforwardAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: lh_CommonSharesOutstandingRollforwardAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of common shares issued during the period as a result of an employee stock purchase plan and/or stock option plan. + ReferencesNo definition available. + Details Name: lh_CommonsStockIssuedDuringPeriodSharesEmployeeStockPlans Namespace Prefix: lh_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDate the declared dividend will be paid, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendPayableDateToBePaidDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe per share amount of a dividend declared, but not paid, as of the financial reporting date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendsPayableAmountPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDate the dividend to be paid was declared, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendsPayableDateDeclaredDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDate the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_DividendsPayableDateOfRecordDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4 + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal cost of shares repurchased divided by the total number of shares repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48

R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows:Foreign Currency Translation AdjustmentsNet Benefit Plan AdjustmentsAccumulated Other Comprehensive Earnings (Loss)Balance as of December 31, 2023(47.6)(11.7)$(59.3)Current year adjustments(131.5)(1.5)(133.0)Amounts reclassified from accumulated other comprehensive incomeâ€”Â (0.2)(0.2)Tax effect of adjustmentsâ€”Â 0.5Â 0.5Â Balance as of June 30, 2024(179.1)(12.9)$(192.0) Â Â Â Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax Â Â $ (1,500,000) Â Other Comprehensive Income (Loss), before Reclassifications, before Tax Â Â (133,000,000.0) Â Accumulated Other Comprehensive Earnings [Roll Forward] Â Â Â Â Foreign Currency Translation Adjustments, Beginning balance Â Â (47,600,000) Â Other comprehensive income before reclassifications Â Â (131,500,000) Â Tax effect of adjustments Â Â 0 Â Foreign Currency Translation Adjustments, Ending balance $ (179,100,000) Â (179,100,000) Â Net Benefit Plan Adjustments, Beginning balance Â Â (11,700,000) Â Tax effect of adjustments Â Â 500,000 Â Net Benefit Plan Adjustments, Ending balance (12,900,000) Â (12,900,000) Â Accumulated Other Comprehensive Earnings, Beginning balance Â Â (59,300,000) Â Other comprehensive income before reclassifications Â Â (131,500,000) Â Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Â Â 0 Â Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Â Â (200,000) Â Tax effect of adjustments (100,000) $ (300,000) 500,000 $ (600,000) Accumulated Other Comprehensive Earnings, Ending balance $ (192,000,000.0) Â $ (192,000,000.0) Â X - DefinitionAccumulated Other Comprehensive Earnings [Roll Forward] + ReferencesNo definition available. + Details Name: lh_AccumulatedOtherComprehensiveEarningsRollForward Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (j) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAccumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 16 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A + Details Name: us-

gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES (Details) $ in Millions 3 Months Ended Jun. 30, 2024 USD ($) Loss Contingencies [Line Items] Â Loss Contingency, Damages Sought, Value $ 817.0 Enhanced Damages Â Loss Contingencies [Line Items] Â Loss Contingency, Damages Awarded, Value 100.0 Initial Damages Â Loss Contingencies [Line Items] Â Loss Contingency, Damages Awarded, Value $ 272.0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of damages awarded to the plaintiff in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesAwardedValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value (monetary amount) of the award the plaintiff seeks in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesSoughtValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: lh_LossContingencyDamagesTypeAxis=lh_EnhancedDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_LossContingencyDamagesTypeAxis=lh_InitialDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Noncontrolling interest puts $ 15.0 $ 15.5 Foreign Currency Contracts, Liability, Fair Value Disclosure 103.6 Â Fair market value of senior notes 4,812.3 4,850.4 Cash Surrender Value, Fair Value Disclosure 96.4 95.4 Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability 125.3 107.4 Contingent Consideration Classified as Equity, Fair Value Disclosure 20.0 66.1 Foreign Currency Contract, Asset, Fair Value Disclosure Â 109.0 Fair Value Hedges, Net 79.7 69.6 Tax effect of adjustments 0.0 Â Long-term Debt, Excluding Current Maturities 3,047.3 4,054.7 Senior notes due 2027 [Member] Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Long-term Debt, Excluding Current Maturities 600.0 Â Senior notes due 2022 [Member] | 2018 Swap Agreements Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Derivative, Notional Amount 300.0 Â Senior notes due 2024 | 2022 Swap Agreements Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Derivative, Notional Amount 300.0 Â Level 1 [Member] Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Noncontrolling interest puts 0.0 0.0 Cash Surrender Value, Fair Value Disclosure 0.0 0.0 Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability 0.0 0.0 Contingent Consideration Classified as Equity, Fair Value Disclosure 0.0 0.0 Foreign Currency Contract, Asset, Fair Value Disclosure 0.0 0.0 Fair Value Hedges, Net 0.0 0.0 Deferred Compensation Plan Assets 0.0 0.0 Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Noncontrolling interest puts 15.0 15.5 Foreign Currency Contracts, Liability, Fair Value Disclosure 103.6 Â Cash Surrender Value, Fair Value Disclosure 96.4 95.4 Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability 125.3 107.4 Contingent Consideration Classified as Equity, Fair Value Disclosure 0.0 0.0 Foreign Currency Contract, Asset, Fair Value Disclosure Â 109.0 Fair Value Hedges, Net 79.7 69.6 Deferred Compensation Plan Assets 31.0 21.1 Level 3 [Member] Â Â Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items] Â Â Noncontrolling interest puts 0.0 0.0 Cash Surrender Value, Fair Value Disclosure 0.0 0.0 Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability 0.0 0.0 Contingent Consideration Classified as Equity, Fair Value Disclosure 20.0 66.1 Foreign Currency Contract, Asset, Fair Value Disclosure 0.0 0.0 Fair Value Hedges, Net 0.0 0.0 Deferred Compensation Plan Assets $ 0.0 $ 0.0 X - DefinitionFair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability + ReferencesNo definition available. + Details Name: lh_FairValueLiabilitiesMeasuredOnRecurringBasisDeferredCompensationLiability Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis element represents a certain statement of financial position liability caption which represents a class of liabilities, or which may include an individual liability, measured at fair value on a recurring basis. + ReferencesNo definition available. + Details Name: lh_FairValueLiabilitiesMeasuredOnRecurringBasisNoncontrollingInterestPuts Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEstimated fair value of the debt instrument (senior notes) at the balance-sheet date + ReferencesNo definition available. + Details Name: lh_SeniorNotesFairValue Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashSurrenderValueFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of contingent consideration in a business combination that is classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of assets held under deferred compensation agreements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredCompensationPlanAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet fair value of all derivative instruments designated as fair value hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5 + Details Name: us-gaap_FairValueHedgesAtFairValueNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debit issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a

foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=lh_Seniornotesdue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=lh_SeniorNotesDue2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_SwapTypeAxis=lh_A2018SwapAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=lh_SeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: lh_SwapTypeAxis=lh_A2022SwapAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash paid during period for: Â Â Interest $ 106.6 $ 109.5 Income taxes, net of refunds 153.0 133.3 Disclosure of non-cash financing and investing activities: Â Â Decrease in Capital Expenditures Incurred but not yet Paid $ (19.2) $ 16.5 X - ReferencesNo definition available. + Details Name: lh_CashPaidDuringPeriodForAbstract Namespace Prefix: lh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncrease in Capital Expenditures Incurred but not yet Paid + ReferencesNo definition available. + Details Name: lh_IncreaseInCapitalExpendituresIncurredButNotYetPaid Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of cash paid during the current period for interest owed on money borrowed + ReferencesNo definition available. + Details Name: lh_InterestPaidInCash Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS ACQUISITIONS (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Business Combinations [Abstract] Â Â Â Â Payments to Acquire Businesses, Net of Cash Acquired Â Â $ 293.1 $ 136.9 Business Acquisition [Line Items] Â Â Â Â Goodwill, Acquired During Period Â Â 141.7 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets $ 23.9 Â 23.9 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (334.9) Â (334.9) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities (11.8) Â (11.8) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net 323.1 Â 323.1 Â Business Acquisition, Pro Forma Revenue 3,100.5 $ 3,220.9 6,412.0 6,206.5 Business Acquisition, Pro Forma Net Income (Loss) 193.4 $ 205.3 432.8 409.5 Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 8.1 Â 8.1 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 1.8 Â 1.8 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill (159.4) Â (159.4) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 0.0 Â 0.0 Â Payments to Acquire Businesses, Net of Cash Acquired Â Â 293.1 136.9 Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other 3.7 Â 3.7 Â Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 293.1 Â 293.1 Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Â Â 0.0 Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Â Â (3.9) Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â 0.0 Â Escrow Deposit 30.0 Â 30.0 Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Â Â 7.4 Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets Â Â (3.9) Â Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation 8.1 Â 8.1 Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities Â Â (3.9) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Â Â 0.0 Â Estimated amortization expense, 2012 125.0 Â 125.0 Â Gain (Loss) on Disposition of Business Â Â (4.9) Â Prepaid Expenses and Other Current Assets [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â Â 0.6 Other Noncurrent Liabilities [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â Â (2.3) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities 0.0 Â Â Â Operating lease liability Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities (3.9) Â Â Â Accrued Liabilities [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â Â (8.3) Goodwill [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Â Â Â (29.4) Goodwill [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â (7.4) Â Other Noncurrent Assets [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â 0.0 Â Other acquirees Â Â Â Â Business Combinations [Abstract] Â Â Â Â Finite-lived Intangible Assets Acquired Â Â 159.4 84.1 Business Acquisition [Line Items] Â Â Â Â Finite-lived Intangible Assets Acquired Â Â 159.4 84.1 Goodwill, Acquired During Period Â Â 141.7 50.8 Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Â Â Â (1.5) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period Â Â Â 0.0 Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Â Â Â 19.5 Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets Â Â Â (10.6) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities Â Â Â (10.6) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Â Â Â $ 0.2 Providence Medical Foundation Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Goodwill, Acquired During Period Â Â 25.9 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (55.8) Â (55.8) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities (0.9) Â (0.9) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities (0.9) Â (0.9) Â Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 0.9 Â 0.9 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 29.0 Â 29.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 54.9 Â 54.9 Â Escrow Deposit 0.0 Â 0.0 Â Westpac Labs, Inc. Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Goodwill, Acquired During Period Â Â 45.1 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (97.7) Â (97.7) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities 0.0 Â 0.0 Â Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 1.8 Â 1.8 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 50.8 Â 50.8 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 97.7 Â 97.7 Â Escrow Deposit 0.0 Â 0.0 Â Cash Acquired in Excess of Payments to Acquire Business 0.0 Â Â Â Â Baystate Medical Center Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Goodwill, Acquired During Period Â Â 70.7 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (157.5) Â (157.5) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities (7.2) Â (7.2) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities (10.9) Â (10.9) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net 146.6 Â 146.6 Â Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 7.2 Â 7.2 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 79.6 Â 79.6 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other 3.7 Â 3.7 Â Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 116.6 Â 116.6 Â Escrow Deposit 30.0 Â 30.0 Â Cash Acquired in Excess of Payments to Acquire Business 0.0 Â Â Â Other Acquisitions Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Escrow Deposit 0.0 Â 0.0 Â Invitae Corporation Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Goodwill, Acquired During Period Â Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 23.9 Â 23.9 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (23.9) Â (23.9) Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities 0.0 Â 0.0 Â Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other 0.0 Â 0.0 Â Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 23.9 Â 23.9 Â Escrow Deposit 0.0 Â 0.0 Â Cash Acquired in Excess of Payments to Acquire Business $ 0.0 Â Â Â Business Combination, Price of Acquisition, Expected Â Â 239.0 Â BioReference Health Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Business Combination, Price of Acquisition, Expected Â Â $ 237.5 Â Customer Lists | Maximum [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Â Â 15 years 15 years Customer Lists | Minimum [Member] Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Â Â 7 years Â X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 15 -Paragraph 3 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479455/805-10-15-3 + Details Name: us-gaap_BusinessCombinationPriceOfAcquisitionExpected Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents the amount of any measurement period

adjustment (as defined) realized during the reporting period to financial liabilities assumed in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A + Details Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease obligation assumed in business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of inventory recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business. + ReferencesNo definition available. + Details Name: us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 + Details Name: us-gaap_EscrowDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details Name: us-gaap_FinitelivedIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillAcquiredDuringPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=lh_OperatingLeaseLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_GoodwillMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_OtheracquireesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_ProvidenceMedicalFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_WestpacLabsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_BaystateMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_OtherAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_InvitaeCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=lh_BioReferenceHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS SEGMENT INFORMATION Business Segment Information (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Segment Reporting Information [Line Items] Â Â Â Â Percent of Revenue Contributed 100.00% 100.00% 100.00% 100.00% Revenues $ 3,220.9 $ 3,033.7 $ 6,397.5 $ 6,071.5 Operating Income (Loss) 294.8 266.3 616.1 596.1 Amortization of Intangible Assets (62.2) (51.5) (122.3) (104.9)

Net Restructuring Charges (11.6) (15.8) (16.6) (23.3) Goodwill and Intangible Asset Impairment 0.0 (2.8) (2.5) (5.0) Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Operating Income (Loss) 548.9 514.3 1,066.7 1,029.4 Intersegment Eliminations Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Revenues 11.0 6.1 25.0 12.4 Corporate Segment [Member] Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Operating Income (Loss) $ (180.3) $ (177.9) $ (309.2) $ (300.1) LabCorp Diagnostics [Member] Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Percent of Revenue Contributed 78.00% 77.00% 78.00% 78.00% Diagnostics Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Percent of Revenue Contributed 78.00% Â Â Â Diagnostics | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Revenues $ 2,524.9 $ 2,340.8 $ 5,004.6 $ 4,723.6 Operating Income (Loss) $ 441.5 409.7 859.4 851.2 Drug Development Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Percent of Revenue Contributed 22.00% Â Â Â Drug Development | Operating Segments Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Revenues $ 707.0 699.0 1,417.9 1,360.3 Operating Income (Loss) $ 107.4 $ 104.6 $ 207.3 $ 178.2 X - DefinitionAmount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and changes either scope of business by an entity, or manner business is conducted. May include amount of reversals and other adjustments during the period to amounts of previously accrued liabilities for specified types of restructuring costs. + ReferencesNo definition available. + Details Name: lh_NetRestructuringCharges Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercent of Revenue Contributed + ReferencesNo definition available. + Details Name: lh_PercentofRevenueContributed Namespace Prefix: lh_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_DrugDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue from Contract with Customer [Abstract] Â Â Â Â Deferred Revenue, Revenue Recognized $ 26.8 $ 20.2 $ 77.8 $ 72.8 X - DefinitionAmount of revenue recognized that was previously reported as deferred or unearned revenue. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueRevenueRecognized1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE Disaggregated Revenue Table (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Â Accounts Receivable, Allowance for Credit Loss $ 34.1 Â $ 34.1 Â $ 32.7 Unbilled Services, Allowance for Credit Loss 1.8 Â 1.8 Â 7.5 Note Receivable, Allowance for Credit Loss 0.7 Â 0.7 Â 0.7 Allowance for Credit Loss 36.6 Â 36.6 Â 40.9 Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Â Â 3.4 Â Â Allowance for Credit Loss, Write Off Â Â 7.7 Â Â Deferred Revenue, Revenue Recognized 26.8 $ 20.2 77.8 $ 72.8 Â Contract with Customer, Asset, before Allowance for Credit Loss 159.3 Â 159.3 Â 192.9 Contract with Customer, Liability 388.3 Â 388.3 Â 421.7 Unbilled Contracts Receivable $ 157.5 Â $ 157.5 Â 185.4 Percent of Revenue Contributed 100.00% 100.00% 100.00% 100.00% Â Revenues $ 3,220.9 $ 3,033.7 $ 6,397.5 $ 6,071.5 Â Accounts Receivable, after Allowance for Credit Loss, Current 2,088.9 Â 2,088.9 Â 1,913.3 Allowance for Credit Loss, Receivable, Other, Current (1.8) Â (1.8) Â (7.5) Contract with Customer, Asset, after Allowance for Credit Loss, Current $ 157.5 Â $ 157.5 Â 185.4 Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 9.00% 9.00% 9.00% 9.00% Â North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 87.00% 87.00% 87.00% 87.00% Â Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 4.00% 4.00% 4.00% 4.00% Â UNITED STATES Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 83.80% 83.60% 83.70% 83.90% Â Revenues $ 2,698.8 $ 2,537.0 $ 5,353.4 $ 5,094.4 Â Medicare and Medicaid [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 8.00% 8.00% 8.00% 8.00% Â LabCorp Diagnostics [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 78.00% 77.00% 78.00% 78.00% Â LabCorp Diagnostics [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 78.00% 77.00% 78.00% 78.00% Â LabCorp Diagnostics [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Client [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 24.00% 24.00% 24.00% 25.00% Â LabCorp Diagnostics [Member] | Client [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Client [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 24.00% 24.00% 24.00% 25.00% Â LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Self-Pay [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 10.00% 10.00% 10.00% 10.00% Â LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Self-Pay [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 10.00% 10.00% 10.00% 10.00% Â LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 8.00% 8.00% 8.00% 8.00% Â LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Third party [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 36.00% 35.00% 36.00% 35.00% Â LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â LabCorp Diagnostics [Member] | Third party [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 36.00% 35.00% 36.00% 35.00% Â LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00% Â Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed Â 23.00% Â Â Â Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed Â 9.00% Â Â Â Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed Â 10.00% Â Â Â Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line

Items] Â Â Â Â Â Percent of Revenue Contributed Â 4.00% Â Â Â Diagnostics Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 78.00% Â Â Â Â Accounts Receivable, before Allowance for Credit Loss $ 1,331.4 Â $ 1,331.4 Â 1,135.2 Drug Development Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 22.00% Â Â Â Â Accounts Receivable, before Allowance for Credit Loss $ 791.6 Â $ 791.6 Â $ 810.8 Drug Development | Biopharmaceutical and medical device companies [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 22.00% Â 22.00% 22.00% Â Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 9.00% Â 9.00% 9.00% Â Drug Development | Biopharmaceutical and medical device companies [Member] | North America Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 9.00% Â 9.00% 9.00% Â Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Percent of Revenue Contributed 4.00% Â 4.00% 4.00% Â Notes Receivable [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Â Â $ 0.0 Â Â Allowance for Credit Loss, Write Off Â Â 0.0 Â Â Unbilled Contracts Receivable [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Â Â 0.0 Â Â Allowance for Credit Loss, Write Off Â Â 5.7 Â Â Accounts Receivable [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings Â Â 3.4 Â Â Allowance for Credit Loss, Write Off Â Â $ 2.0 Â Â X - DefinitionAllowance for Credit Loss + ReferencesNo definition available. + Details Name: lh_AllowanceforCreditLoss Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAllowance for Credit Loss, Write Off + ReferencesNo definition available. + Details Name: lh_AllowanceforCreditLossWriteOff Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCurrent Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings + ReferencesNo definition available. + Details Name: lh_CurrentExpectedCreditLossesOpeningBalanceSheetImpactonRetainedEarnings Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNote Receivable, Allowance for Credit Loss + ReferencesNo definition available. + Details Name: lh_NoteReceivableAllowanceforCreditLoss Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercent of Revenue Contributed + ReferencesNo definition available. + Details Name: lh_PercentofRevenueContributed Namespace Prefix: lh_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionUnbilled Services, Allowance for Credit Loss + ReferencesNo definition available. + Details Name: lh_UnbilledServicesAllowanceforCreditLoss Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsReceivableGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on receivable, classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 + Details Name: us-gaap_ContractWithCustomerAssetGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously reported as deferred or unearned revenue. + ReferencesNo definition available. + Details Name: us-gaap_DeferredRevenueRevenueRecognized1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2 + Details Name: us-gaap_UnbilledContractsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: instant X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_NorthAmericaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=lh_OthercountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=lh_MedicareandMedicaidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=lh_ClientMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SelfPayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=lh_ThirdpartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_CovanceDrugDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=lh_BiopharmaceuticalandmedicaldevicecompaniesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=lh_DrugDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_NotesReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=lh_UnbilledContractsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) - USD ($) 3 Months Ended Jul. 25, 2024 Jun. 30, 2024 Mar. 31, 2024 Mar. 31, 2023 Subsequent Event [Line Items] Â Â Â Â Dividends Â $ 60,200,000 $ 60,900,000 $ 64,700,000 Subsequent Event [Member] Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Dividends $ 61,200,000 Â Â Â X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Sep. 30, 2023 Discontinued Operations and Disposal Groups [Abstract] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Revenue Â $ 766.5 $ 1,506.6 Â Â Disposal Group, Including Discontinued Operation, Costs of Goods Sold Â 629.1 1,244.5 Â Â Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Â 137.4 262.1 Â Â Disposal Group, Including Discontinued Operation, General and Administrative Expense Â 85.4 184.1 Â Â Disposal Group, Including Discontinued Operation, Depreciation and Amortization Â 16.0 31.9 Â Â Disposal Group, Including Discontinued Operation, Restructuring and other charges Â 4.1 3.0 Â Â Disposal Group, Including Discontinued Operation, Operating Income (Loss) Â 31.9 43.1 Â Â Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Â 40.2 45.6 Â Â Discontinued Operation, Tax Effect of Discontinued Operation Â 6.3 6.8 Â Â Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 0.0 33.9 0.0 $ 38.8 Â Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Â Â Â Â $ 570.0 Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate Â Â Â Â 7.50% Disposal Group, Including Discontinued Operation, Fortrea Distribution $ 1,600.0 Â 1,600.0 Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â $ 1,520.0 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 1,520.0 Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense) Â $ 8.3 2.5 Â Â Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Â Â $ 38.8 Â Â Fortrea Revolver due 2028 Â Â Â Â Â Discontinued Operations and Disposal Groups [Abstract] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 450.0 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 450.0 Fortrea Term Loan A maturing 2028 Â Â Â Â Â Discontinued Operations and Disposal Groups [Abstract] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 500.0 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 500.0 Fortrea Term Loan B maturing 2028 Â Â Â Â Â Discontinued Operations and Disposal Groups [Abstract] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â 570.0 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities Â Â Â Â $ 570.0 X - DefinitionDisposal Group, Including Discontinued Operation, Fortrea Credit Facilities + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationFortreaCreditFacilities Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Fortrea Distribution + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationFortreaDistribution Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Fortrea Senior Notes + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotes Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotesInterestRate Namespace Prefix: lh_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Restructuring and other charges + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationRestructuringAndOtherCharges Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal Group, Including Discontinued Operations, Other Nonoperating income (expense) + ReferencesNo definition available. + Details Name: lh_DisposalGroupIncludingDiscontinuedOperationsOtherNonoperatingIncomeExpense Namespace Prefix: lh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -

SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable activities with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: lh_FortreaCreditFacilitiesAxis=lh_FortreaRevolverDue2028Member Namespace Prefix: lh_ Data Type: na Balance Type: Period Type: X - Details Name: lh_FortreaCreditFacilitiesAxis=lh_FortreaTermLoanAMaturing2028Member Namespace Prefix: lh_ Data Type: na Balance Type: Period Type: X - Details Name: lh_FortreaCreditFacilitiesAxis=lh_FortreaTermLoanBMaturing2028Member Namespace Prefix: lh_ Data Type: na Balance Type: Period Type: EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (*9T ED'04UB@0 +$ 0 9&]C4'}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a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£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jB/,^=9)>;;1"FQ>G+K/N\M#)E8P !S@_IY"-1>]:SKK27,V2 MXMTLB?'HWWQ>K<;HVZ+HT7V#/);-^PTMD*%)%Y.+&C^%'3 ?Q^2O>-'}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{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{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n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

MTS85/3)H=*)0IA*YRT 8^J)PH:)=^%D5$MLR54=8TK P>$KA#;E$>A12HB @ M%;BQ(TKY38D,@'T#'T,XA&6[(5::IXH6!.%]!HP?EY8*&S%^G1)T6Z(§O]IF@%T9V?(T')9P
MH$7YKNH9P@Z&9>\W9H2+HJ^SB(CMHS1"=A,.3Z)$!A9'?)XP8&B?Y$H3DKE$4<;=@:! M0!<6\]K#HOC?%K=NDH)M'5.!I#REJ!:7H/9[7TA^28%!MD MQH"8V)19/.RJJ -Q67OR!M'%PD-
6F;H>N2(7Z%FJ[5FPTF,RQ\:CU]P":D4CRYFU:?X\+")K578@&W"O ,DZ,?_&0P* M'522])CB=&W-K&O-C0O#IC^!\5;50)^JK:QS#8H!?,5O7:5MDRREM!@=B1;U
MU1@A\Z^8F1(OJRCK,&E24*\&S*7V&UE)AX#AC:5N\]2/NAD*,<>XA3M#=+* M!0NT*/25ZA7R]5 MZC:[//((6"CT1/7P:P)H42VB$E@KN,(-WI6A\L=M[B"(T2!48I+:9J7/%NN?M MV!$ \?
=:>Q*W$@N%*H0-*^X]%0\],()'?@$(EHU5I-L)F M;5F"SUE3;B@44KXV*A%YM:A-4S&;:)R28[B+\@[XNI!VP5%:HJ)S8YA>7:0J MESO6GM(*1R*1*
<__NV6JL0R#Z43[K[^\'1^]>0_GP5HR.8[R]5A,K*VQ<,>% M6(#'4C$T>CE7\3!UKO4)7"N<=0N4R'431!UC!,*5QLX 'IC8B(8@/L5[9GA MM4;Y&2M3U"N4@D;O[RNWA??
G_;J_JMA4F7I7U6@:72F_H@7%U4MJ=CD2A%$Q(T M-&R=1Q*G1*K4GU KG/0Y,CR5[.#.4^Y@N14I:M@^3G"0'/!MDEE*=A4$W&I]XBL=ST*4V MR,%MA;F_TFC7#'-
S/I&XH+8BA<\332W@9D&91O4Z5Q15"&W"MM$-)6Y"36++ M*]CYI(PFSMPK[W=YG[?R4-V1\X",8#3M)$@VX')'1D#; MY]978TJ%DNV[)>N\2=*G3>IIE?N)+$_H?V! 0!PUC1MY044/:FWG.:$IE:36
MDW?R!R=:_JFAWR+L5^O3P[PI@9U7<$N:I8H9LT\,JR$IM9J^D$Y0 ML@7[A[Z*UGZW'I^(KW]LR#*[F$H^_S5#I5D]%8(D>Y" !+7RS?@'DV@]"W?L M$EYMF/*4_&0&Z3J*RO1X]'Z29759)Q
\T#PY08/$(0,.T-/#X8")CIZ[XWC= MWG&\?O[&0 ;-9MNZS/AOW%3\![G[FXK]3<7^IF)_4[& J=C?5.QO*08W%?N; MBOU-Q?ZF8G]3L;^IV-J4[&]N*H:=;V@PUR_X2R$JLXC<]#E-N]I^C#1)
MW^!LMJ/.Z)WSZ.B@]1%?Q%SDS%Z,K^6?!%P*T > _G M#IVJ>2 !'[2=:9.\&4$L#!!0 (*9T EEA])G5G 0 $H, 8 >&PO M=V]R:W-H965T&ULO5?;;N,V$/T50EML7Q:2;,F)F]@&G&S:
MW04V,.)>'HH^T-+88B.1*DG%<;^^,ZOLRUW;6Q1%'V(-R;F<(6<.F351C2R%DL3T6EQ2\PTN8H4YEJJHKKW1V4:CL-!L%^XDEL"DL3T6Q2\PTN8H4YEJJ
RGP7QP2OE/X6<#6]&1&F:R4>J;!QWP:Q 0(2L@L>>#X M>8%[$MRA##^:'T&74@R[,M[[^[W#&7%3=PK\I?1&Z+:3 .6 YKWI3V26T_M0)O/B(QEJC3NEVV];A('+&N,555KC @J(?V7O[;
[T#,8GS,8M@9#A]L'B/!I>JL$9R0="A+JW%5H)V=/:0']M'B*<#-=R#NAM>=/BID2%+XG=L M&_3" Z2+LG$^4O.)3X]A?"BC],(OSQJ=L>-R!CL(J88 MT;CM$89EJJH;"SE;
[5@N7D2.*DPB373JW%HM5HWEJQ*85OB5MBN6/G9,T,:.99+BAVR]Z)T@/XM M7B&SLG'3%%%@P,Q2_)S\(CA8\T_2& /M,WC@)3598/@E$5'@I?E M[A#!*[]C'-&XQ'>LX @90&(.IJ%
U@5&U*7P@6B8(4D&/P^(6>79#(C-&'(1(!?= M(!2Z3/=?NT=6Z+5Z15B,/I)>E+7X4N_^P=6FE>JD?;_4#C7^3?LL=\RWR#B M49BP<1H.:!"F*7X&HU$B_$XO*9!=W"3YHD!
[U1.*"YY"KQ>E>D$ YBW\)4 M?[!>@^\^J.I2[7!KC\K)'88O!>:*;WC+XG#8DY.>G!()CZ>; _BL-WTLU\:DF MAU2_PQ^7:MI/=>1330ZI>KTTC,>7V*HK9M^Q^_YL<6%%VP)9(%--F3.598TF MLC"
@K""N 9I 2TUJDAWB1FJ<\BWUQ4MC1GKW.D,#?V]G?&?XE*/[$&,<;<4CN@ -V_#[._ %!+ P4" "F=)9 M$PG#[^0& #'%@ &0 'AL+W=O4"O*LG;9-KSF(GE*7MP/>[[8P)V3HYJ_S-"5%Z,;W2F>K-
DF"S>NY M]O7=(7J=2X7YA6:_T61(6Q M*JN$T8-,R/(_NZ]P>(Y 4 D$SQ4(*X'0!5IZYL(Z8Y:=\&DU!4VK41M=.&R< M-
$8C)&7QQFI*U#.GEP/!^\'P^'@#&YNK_I_0N_R#/I7%Q=7EW#SH3<#88WKR!P5^?SF__.6I;-$JB[:@R<%H:"'Y@((0+)6UB8"!C'J^0[Z^7[ZZ1 M;V.P=<3!/.+38*W"/PKI0>AO0^
'.ZO(\?GO?)2"^0-^-5=&W1*4Q MUP91_EX(.X-+93E\Z8V,UA7FK=6:V5:O_0Y"SBQRTL;L/U'6^=0[5 MZ?KO5H7\BY0M ;!3 ["S3OM)/V%RP@T("9'*,BQMDS!-#XPI> Q,QI#P-*8%
M%AN5*?1L%2!KK:R.X3;A$#UA/BZTD!.PN-2(>\A*,G(B(R 7>,T%0*FJ&8K_M\.6(.N0AG"^BN"JLL7A!^OI+MIB%,Q[Q;,0UA!VG+X3]T#N FR5G"C2K@6=Y MJF8%QK@,2FSZWN[68VO+GJ.E?
5C%BY_]$E>[-:\ MV%W+BR&/4F:,&(N(N8Z/,PC4&'I15&1%RBQ&=X5IT10=VD]HM-QQ.)>81ZR> M6S9*.=SR>PNG*>*TLHK6N^#X@6,. :<4SB) _4)K+J,9W&K,1C
M8>$:N;#T\BFT!K7#'YW#IPPU1,X3#/OP6]3!7T5M=Y1A?'6F5/@$S*#+]^M1]T@G=$ M\6"K^KUE]\#'8]PCN&PUJ)BOQGIP?\N!+N>"8ML[\#IEE(%W4%X50I??
+1Q2'<\LSL[(>NK]RJOPB94NP[-6P[*TMW6O< M#7+D8PQNP+K^6W5!UR4?3-Q56*PU\%(LGO#V>;LPQ^&]=]5>#*@J4;*9G.& M %;81)6SQZIR8D"1TW70W?7\>?
='ML\''2&S#3F6ZQU+%A5B)9A69!'X?<>-TT'.B M@<+,6]>N2D(0KW#D1>X1JF)Q+&C&L=1I?RODVXCEPN)](5-29HK15^KPN#@5 M&;XIMP?:F1A5?1UMK]&$1OE]PG Z\-
A#8.B\ZQA6#26'"P>3FDB7;R0>P_NX M*,^>@@ZP%D7PU75B>W#V7#9M+R&^R">-I07F MUH%BJE%H<[M^,:C]=8* *C MQ'4;J-+K=G'C@%,7,:'P(F7< -
SH^%B8'O16%4[3B83%RY5657H)K9O*#ES% M=$RJ8H'H6*4-):%.?=D+-G9"(FR5\LK"F^5@/+B2Z$\Z_)DX<^I,\!BE1,;
M&$@^+2%I,HR*HO:0O*WL=K9]"O>QY04=YY2@];1&/\C\$@AE13K>:GXG5&&< M:0]G*K#)1/,)C6WRB_'&_?=9Y?=99?U9I=Q'MQO?"C.N)^X3*C5G#+#\;%@_K;_2]MS'R?9B>?F)
M]X+IB<#M2S\A@S4 MWZY/_@=02P,$% @ IG0"6?5, @@B @ V 0 !D !X;"]W;W)K&ULC53!CILP$/T5RY5ZJ@*!9%NE@)20M$VE9*--VAZJ M'AR8@+78IX99MG?VQ":2MFT%_#8\]Z!S:..6B$?
50F@T3.KN(IQJ74]\SR5 ME<"(&HD:N#DY"32#2ZHAQV$JF& M,2)_+: 2;8S'^+SQ0(M2VPTOB6I2P![TEWHG3>0-+#EEP!45'$DXQ7@^GBTF M-M\E?
*70JHLULDZ.0CS:8)W'V+>"H(),6P9B7D^00E59(B/C9\^)AY(6>+D^ MLW]PWHV7(U&0BNH;S749XW<8Y7 B3:4?1/L)>C]3RY>)2KDG:KO<:8!1UB@M M6 \V"ACEW9L\]]_A A#Z+P"'"A
XW5TAIW))-$DB*5HD;;9ALPMGU:&-.,KM M3]EK:4ZIP>DDO=]LUH?:-GO8H_EVB=+[[6&]_;C:INO5/O*T*6$3O:RG6W1T MP0MT(=H(KDN%5CR'_&^\9Z0-^H*SOD5PD_!SPTID4MY 3RCH-
"2]JP2JI& OL^/2DO3-#^N?86NR.1Z$3M(M,U63#&)L)D6!? *1;&PO=V]R:W-H965T4@\[YV1JY)*-"NJ$I2>.7E;&%]!C:]GXT*]?3@ZB+,O;=7%Z;RN=+TW@I7%86TVVO*S>9R,!DT$Q_4
M.O,\,;JZ*.6:'LA_+-];C$:ME505I)TR6EA:70X6D]?I[P^+/BD:.,ZWP5[MLC3F,P_>I9>#,0.BG!+/%B0^'NF&\IP- <:7VN:@/9(W=K\WUM\&W^+4CJZ M,?
F_5>JSR\'+@4AI):O%%#>2B^O+JS9",NK88V_!%?#;H!3FH/RX"U^ M5=CGK]XNWGT0GQ8_?[P3]W>+AX\?[N[O?QEMXD+D89R7C)+:T'4T-#UB:"; N MC?:9$W[-CGDIE
MQ2>95R1NE4MRXRI+3OQGL73>0AS_/>1S-'EZV"0GS&M7RH0N!\@(1_:1!E<_ M?#M=P/F**7>_O#=R^GD M_(T3I2FK7(:$,2NQ4EKJ1,E<2.?(.R%U*G(EERI77H$]5RU_1WX);\2*X3X&
MN$4'+G:R)423VFB>!#NWE%"Q)"MFDS].Q$;&=:O3(YBX5Z+(Q0OLC(_J77W>F?%%EIDVPK;G)XIU8JB7[WS?Y,CY2+2?TYK3]GXA>C M$PC> BH;5HM3).!%6?FCOWT0)O/A&!^!
[NF;_8D;:.YQ#WEM+.MD*MY&E$[_Z M#"QU:9^,9\.S=E-_]*XYS4I/1RVMUMZ@QOI,L25$:341!0$YFI%< 6_M!)I+FDS$+47;41\G0H/[5V?#T]9<;W!+*X+A5"20'2I[#$L/6!G-@$WS=;>
MX+"=QK_M(<:F\^%LQUAO=(-8(4Y0%NRAW<#M:'"1)+;"*?3$AU"4OV';;PX< M,1UW$#:?8?)Y&>_EP;>3\K[I;R[G^1_E//\S.?\U5B?C5QU:^Z/_2^I12V>O
M.BG2&WP#O<^[>I_;;U/)\)3CC=P=_0^_B\@Z,_^D9Z/SOK(&RIYHI 4OVHOK3+<6@!-X:8H?"9],+0DTB*I-8XMF"KHZU>I MT?$$?:F8"Z6Q?K^QX?B4G4J#SPAF&@Y=UJD6;E!N&*_!U:YJ!"
<[0/:7013I;0>>BQ9^%@K=\M?K"J^@?'5](!F2K@K_GE[_[' MH5CLK&C_#U?OD#D"9E%KT(.3R-$V(.@L9@0&E!LK"F-#NA2X!JLR[S5_P5!< MRX%EJ"D]Q5C3$ZC2@;5":CP I"Y4+RUIA
>5W]>QI\GX;S5BM.&D20&T<"9 M_'V-6Y7/FJCW'5+Z7+2&22F$ISIG7$@8BB:DI6^I%L!W8%ZJT]6A91>4O2 MA$H;%%J#:;8-Q4TFD6&NP94<*3+\V[%"PWSQ T/ MPV_S;91N0T
O"GY;HD,P\W$!CF -":<*E4O+\=! R>SO<5K+ EK:][)S!:RQ M0&C"+'.UKBL?#@D! R^HL_I@")C+?9R1^T2=81$ 6],TEY3(RA'OA.-*HS"X MGF] J)DQIGC%:C9+?CJ0R[QU N5',M[$V%
F9Z:\&Q^Q7Y][U9OAENG:JAEG=C%R#0W YYKX@T>'862 M=[! =.UO4#-1VN%>NG= '21-$SF3.A>^L*)B@M*BF=2KE"L:V72N((O-:!]X?X(K^:'VU'+BU-K M':Y^,%)K,C1.9E0;W]6@ZN93*
(G;*'FAA;[@#HTJ[L%?]"RLK].R5[UPC(). M0!YW@I;H3AD"'_53ZZ[!0ZO?GYZ\G$SQB,%^\6 ^QOWKKSP)[]S)M[U; DHP MXPG[4EIRJ)VW5?U T2];;0BGW54G/.\/^>UJQQWM6>U<;&)Y"-?"OJ98
O'5R>$.[Z:F?;%WV+^'YKMSR>);R7=@UL2*85MHZ'Y_.! ML/'-6QQX4X:W74OCO2Q"UXPD%,0+\O^@+UZP >TKS^O_@=02P,$% @ MIG0"65]%*&UL MA51M;]HP$/XKIVR:-HF1-V M
R1@164J+2KM^F':!Y,(!K99*G3?28S)NZZKHP0SIILR1T$G*ZDR9LA4 M:U?G"EE<)F6I&WA>Q\T8%\Z@5_KF:M"3A4FYP+D"76094V\C3.6F[_C.WG'/ MUXFQ#G?0R]D:%V@>\
[DBRZU18IZAT%P*4+CJ.T._.VK9^#+@%\>-/MB#[60I MY;,UIG'?\2PA3#$R%H'1\HIC3%,+1#1>=IA.7=(F'N[WZ).R=^IER32.9?K$ M8Y/TG0L'8ERQ(C7W+JYA)7TTRV),IQP5?DT_!XNM5'T8/X<:
[[";AW'MD/4U3F+L. 0E&A4K^@, M/GWP.][W,\Q;-?/6.?13S*>B&D]ZY\<8G\4\SOC [P(6?/ONHH&N">MKLI^P MHI@S'D-<*"[6D*/B,@:BVR76!JF@@8 @>YUFIUPOFVTZB&2&8-@6=0,$29-<
M604H1*S!;X=-#_PP;(;P@^LHE;I0:".$%%\C6W#%!1.1+<=$#%R\4I'2LA+ M#4?=A7'"Q!KID+R1*HA^KDCJE'EX0)XR81IE,KX4/+?_&S[[E\W@"_@=(GCL M)MV#(4ZC6_M1U0E;Q4
MAI%Y.=)+:4@@RFU"BHS*!M#Y2DJS-VR!6N,'?P%02P,$% @ IG0"6=%V M +(L! R@@ !D !X;"]W;W)K&ULA59MQLW M#/XKQ"T86L"]\VO29+8!.VDQ#TN:UGLN)V3 M?;'U0CXD'U+D#3?:/-
D"T<&VE,J.DL*YZBK++"^P9#;5%2JZ66I3,D=;L\IL M99#E0:F46;?=/L]*)E0R'H:S>S,>ZMI)H?#>@*W+DIG=%*?>C)).LC_X+%:% M\P?9>%BQ%<[1/5;WAG;9 247)2HKM *#RU$RZ5Q-
^UX^"/PM<&./UN C66C] MY#>S?)2TO4,HD3N/P.AOC=1 MNV*4O$\@QR6KI?NL-[]C$_XW$M;?B%393M#Q+@+M76Z;)3)@U*H^,^V#0]' M"N_;+RAT&X5N\#L:"E[>,,?&OZ,W8+PTH?
E%"#5HDW-"^:3,G:%;07IN/'V< MS^X^S._NGN_IMU7 ?^H50J]=@NZ[6[_%;S>(P.N]%&=MZ<1:N-;E0BCF2\+" MU\G".D.5\<^ID"-B_S2B?RU7MF(<1PD!XMFCV +T$5E5&;P6]-
I0[..M>]M). "@\%\1MAK8B9X_0CK$'%LFN2G;64?0<(MYD+UG\Y= # F[-.YSP]?]N">Z/7(D?%GV4^ MZEKED?\W9X-^>DEBWL87M([2#W^RA6W!3/&4[B\OTHNWX9HI0,MJUBNVHR[F MO -
GW5YZ&0*.?>F9A":*F5H+QSR5IM(F6G4%3%)E!4L4/ :Y M8RDHT14Z<,)X)X)RQ+;7I MO*;V[V576N<;(>6):NOT.^D%;)@E&*Y-'K+CY7ZH]4&PX1LG_HT9JM (8L,3 MJK1ZQ^D=
(%496QE$G_I8]K&;$?ST"O?G\&%I=-FDX_BY4"X&0;LS@! TR0Z5& M,588AIG<16<\M]&3D) &<6]!A65=TI$DZH2D%*+=\XTA(4M-*=\0]U>G>E=V M-%\H@%68HOX-$L5QU!Q.#X-Z$N?
3LWB<\K?,K 15F<0EJ;;3"YJ+)D[.N'&Z M"M-JH1VQ%98%?6R@\0)TO]3:[3?>P.'S9?P=4$L#!!0 (*9T EG1.C4# MP 4 ,X, 9 >&PO=V]R:W-H965T&(/MXI_6 *, ,N>JE*:DU%A[?9P/#99
14WOMJ"Q#=KI2MN\59OQF:K M@>?.J2K'41"DXXH+.3H]=L^^ZM-C5=M22/BJF:FKBNOG!91J=S(*1)V#.[$I
M+#T8GQYO^0:68+]MOV]&_ =1O2WJG=W]#RF5"\3)7& _;)=8YNF(Y;5Q]JJ=48$E9#-E3^U M.@P<9L$K#E'K$#G<32*\H);?GJLU8YILL9HM'!4G3>"$Y**LK0:WPKTLZ>+ M;\NKF\OEDBTO/U]?
WMRSJYM/MW?79_=7MS=L4ILT-X8M88.%L$S(I@U(SX,;_M9<%\.!Y;A$'!QEF;PY1QV$1O1GPGUKZ M+ X\%@51\D:\N-^O!5]#_(+8;)2F5H#^W$/3Y8M M2I4][7^9NC]P-
LGOL"V%J5N.T)B.6K$I@PC'<#@*DU,WL:"U?,HJ\M- #C M,F=&/+&JZ1F@GF%8<>@K[CD;7,6^R_G^W2R*@J.*2YPJ+CK?;K7B6>'>A$>L MX(:M "2K#0:SBCE&:&A@[P''&4@#FU XD,S(6?
U%I&3^XX_N^L@/?*D^>]MVG*)M/6&2_$+3)? X)ZWA<.1)9&?!;W5PH#3H>(/A 1GL.:NGCED@@:B<:2Y M,;@JZ3D:.) R Y]]$A(7@I>_Z8I8M>L+A-N"1>SXU!8<25HR<(((PB!Y63ZS
M54,F*P2LJZ @?*#9P?GMQ?4'!Q@>>5DW1IU\ V@.-#GG9%!@"TR1-)75N3H+-8"2*1&?L3H MJY.,E+-_RB.5[5H!_5:0<=2C58;>.75:22@(2R ZQ1:F*5*6,;
M]XYH/N2'&+*RSJ'1V=EBOV3X2O,2NR1GZUJZ+YCQF$(CC>2YWE#[U-B!R(YG M/VLLAV,!3_BYQJ;PF-D*^1%U:8)ZJ"Y]HTGW6KX@Z3,Z3A?G2[9JAWZSK9];)LU",U&3:%-ZCC<--B]BY)4>.+
ME_[PV%JTKB5L>(GDA'D8.#?8A]6UD!52E6KS_(***D4C9O<Y>ADM2QPZ^]_0 MT'S9K"ZP]++&LPANWAB?['(FT2)/W>K. G\&:XF7A D?HJKQ)OBL$K9XLN2 M38.I'[T/L?:T$O"*7J%7IP&?
HR?'=R(63LVH!3X_>>VW_Q-,QR$H1]\8 >I M*^)O-'$W8>0G']B]LC@"=(L,\\8>#D:'*O:"./:GN$J]>#[U)VX53$-8\0>N6M 2IY5] ']U30/;@^8NCOLK[CK@#T5B^:/Z\D(]8NI]N@64H _Z;KO)#
(>G#$KP,QTDL9! MK&IIF^-F_[0_K)\U9]07\^:D?XW !39Q"6MT#?SI9(0;V)V>FQNKMN[$NE(6 MS[]N6> ?#M!D@. 7"H^>[0TEZ/_"G/X/4$L#!!0 (*9T EDV*KBLQ@< M H3 9 >&PO=V]R:W-
H965T8X7:Z=+K $$[[H=,/BBTGFN-(7DDFL+^^SRO9CLU)V.GT"\'6 M>WW>JWR^T>:[70GAV-LZ5_:BMW*N.!L,;+(2:VXC70B%DTR;-7=X-,N!+8S@ MJ6=:YX-
1',\&:RY5[_+Z=+E4XLDP6Z[7W+Q?BUQO+GK#7OWB62Y7 MCEX,+L\+OA1SX;X53P9@T9**M=%6:D5,R*[Z%T-SZXG1.\)_BG%QK;^9^3) M0NOO]"?
7O1B,DCD(G$D@>/G5=R(/"=!,./W2F:O44F,[?]KZ5^][_!EP:VX MT?F_9.I6%[W3'DM%QLOO-KZ+R9TKR$IU;_Y=M NULW&-):9U>5\RP8"U5 M^.5O%0XMAM-X#\.H8AAYNX,B;^4M=_SRW.@-
,T0-:?2/=]5SPSBI*"AS9W J MP>O2IP+^7*F+CN,]&\6CRB;QQX_W8RQO_ M_JZS?U\MK#/(HO_L B+HF>S60Y5U9@N>B(L>2L<*\RIZES_-)S%7S[Q8M)X M,?E,^N4'2 OL7B5YF4JU9'L<[/N#7-
O2B%W>?*IOMS>CB-W>SV\>'U[N'[[= MW;+'I[OGJY?[QXU0,@1-UX,;LT*T$6>",7)2^.)&[XJC/_L$7B38%2_2Z MR(6#S40)):]2ES9_1V"4+E6" RL*'KP)XN;\Q'+C%YSAO(X>]=Z8RAAAVZ
M%OM5YX2,)9 B=EB]AFYJ<,) 1XOQKY;=P'N9 -Q;\8H65J A.9\?(%](GDN M_PAVS(&$3(1EAS>W-_,CMB@MD+- 6RJG&:]M%GU6E(M<)OG[,3(*I>$=AKZ(M7>4Y6P$9;;Q2'4*&2)H-
!K;=H4;CXV%11#['?YH*W1W,#K^1K94'](FE17D MB+(ZERDG*7.'' +1:]K*B-@+F&PAU'.,B8M$V\%.BN%2+.%8&1190;4'&=& M"(*T$P:"34*R7<'T%0(AC/5$WZY@#*!9 @L% =
4P&62V^*B]A8$/=9TV MRCGR4HB4I0YJ(;EJFW SS^=CH8G7RQ0T\=PC+.TG800.XSCOWBDP(019AU, M)O2]Q1WP8>,:/(A4\IT@J-T!B1&P]J7_6OG<$$?L#C96]'].3L=^DD,:)>3M MV&L&00G?
S?N6;J?(E<@1*,>F9W',BF@=]=EU:9#H2Z=5GSU]HK=<(.L+S/ M'*8PM(52 M+JQ,)7:%.B15')'$UE*.'TQ/XBBFTY-H2J%#+9!<*Q)TMI0I[1"UM"3UXS@T MBAJY!SH["IF%?B2.VVN 9JG2T*
[X$N"%-/#-L-<+44$PWSW\8>7C+79]QE..2:9!0!=%TH@+1KS*E M,L@,7PO:,3_VTZ:=&9&'+KV21=<(GCEA/G@DF^V MZN(KG]U*:4.HBRY 9.S(")J8RT^PQ/O<
M,F$9JJBJSDZD%L)MA%#;8*FT.RY_"%[H#HFVSNNM<\1Y!+?8HM@"'#Y76TM$ M-5H1X" V<&#R[N+RZ1@X(O8U= @=Z_"5;":F/M6Z#ONO:Y::MJFTCLWD]9B M\N?K"-T'\SHT'J=C$O'CDH0-
KE[#/+[;]GCL8P$=Y'U(U53[9ENAP'P,T%N3 MQMFE4+[F::1JWPHINBM9R^ M#=3QLNQT*K[AZ01\5VLD4KWA0R^"R]52(F0AH4*9<&L% "I M95(-G2UA@L5L"582/0;QX\?:]-R3,8X?
6P7(#BO;CL["^U YI]&8C>!UDPH+ M@6")U@I-JN)HQ^938/=4MR4?T@[1#))FT:G/%E%+0T/WT\ G*/I-O4QV[U ' M;#R&S?@YA8!=]]E!Z_L$[DQ+_Q6&^GRI7/A4T;QM/O1\;6_+PE>@WP">1
MD[G(P!I')],>,^'+2WAPNO!?.Q;:.;WV_U)]"D,$.,\TEJ;J@10TG[\N_PM0 M2P,$% @ IG0"685YKRS' @ F0D !D !X;"]W;W)K&ULK59M;]HP$/XK5E9-G;215U[&(%(I+^NT3JA5M\\F.<"J8S/; M@?;?
SW9""C1%J.,+L<_W/'?G.WS7VW#Q*)< "CUEE,F^LU1JU75=F2PAP[+! M5\#TR9R+#"N]%0M7K@3@U((RZ@:>UW(S3)@3]ZQL*N(>SQ4E#*8"R3S+L'@> M .6;ON,[6\$=62R5$;AQ;X47<
_J8345>N=6+"G)@$G"&1(P[SM7?G<2&7VK M\)O 1NZLD8EDQOFCV=RD?<)9 M"=8>9(057_Q4WL,.0//4 X(2$!P"MV(0EH#P5$!4 J)3 W:U RQPG%/\ T21ENSF87-KT7KC!!F*O%>"7U*-
$[%4_R,UA)- M0=BJ9@F@(9$)Y3(7@+Z@A_LANKSXA"X08>B64*KK1_9> M[JYU52U152W2, M/?ZEN_,-2W@&Z/(GE_(3NE)*D%FN\(P"4AQ-L0"FZ@JG8&Y;9M.BUW'@-1NZ MAM>
[%5%HM7:U@LZ^SO UD]_I-+[N:XUJ[/G!H=;XM584AH=>36JT/+_QXE=Q MF>Y.)\A +&R3ERCA.5/%/[*25G/$E6V?!. *!WQWY-?*QGCN*,>&%OAA:]*.T M($PB"G-MRFNT=<<3Q2!0;!1?
V3XTXTIW-;M&PO=V]R:W-H965TM(9HH'G7!1ZTLN,*<^" M0"<9YDP?RA(+6EE(E3-#4[4,=*F0I4XI%T$:R (6+ M26\6G5U$OZO@)/[0=N-8[8["NS*5\LI/K=-
(-+2,4F!@+P>AOA9FFS2.^E!B@M6"7,OU[]AX]#(XB52:/<+ MZUIV<-J#I-)&YHTR,=/T5%X[J$\;"D/?>C3&V90<2;@$56N02ZZ4M9%V@^[R?\LE:4K$ZFMII1Y_!5:7L1Y,A++A.B-
CWBBGB"&AS#Y0Y;#/7AT+2E,"L_*7,2U:_*(A MY8]J4RIMS!K'ZX-YC ,3_J SPF6QJGJ!/%Y[6"]=":P.=F>VS9Y!K11C1<6H7;*I_74@^N;NR(0I];6D8F3V D
MV8.]!RG2?;BK5))1>TOM2%>,H&C]9WS*>^W:5U2*<[@XA!DE7&GZ=,-->8-#4 MZFXH.W802"LM_MZ@'X;A/NQ%^S *!G28Q/"8B_?AJMD9;N71;;)E16%VE578 M."ALQMK%K^X-C4^:7
)9!W:%VECCY#U^K[AY ;9F*M4D1]L,"2>MZA."IJ]A MUMQD&1*473'L&)J)-) M^2!3@E.BR*9,DLIE;(_MN[6$2D5@N[F% ,V$367M&U$MT9UKM)%35WM&O4!J MTV]C-
Z]1W%QP;7[8;H>>OC1J^]+(VT!V\[R;WV:[=G4D/Z!1%7IX';6\CKPP MMS^4\[_DY@==,*%]Y(Y;G+;;VLKNHN%7WZDS#YF3ELS)AS*X.0:Z ^7' M?"]0IRVWTP]GT<_/C_L>ORC^-<-VK;[=^?
ER0OUP0M$M'/5 MB_Z/6T^#^A^SCK>L8_\6H+.PDY9?[>?CR<=F>W&,O)>\]3N0.^GX]3);GF8_$ M]BH8^2]MVS-^MF)2:E&&3D4^SQ;30=TVHZ#U:[U8.?QD*-:NB>2II.G M*DS]CFB_ML^P6?
WXV(K7;[@;II:,2T,/& M#3-Z2J*R K2^D-)L)M9 ^SB=_@-02P,$% @ IG0"6?&@!=EU!P XA M !D !X;"]W;W)K&ULG5AK;^,V%OTKA#MH$T"5 MK8RX+92]'6^>J_'89EM13R6Q<C:%5*)!\-L79;
<[*%H7>7HVC43?PL-UM' M$^.KBXIOQ*-P_ZT>#+[&O919UX7[6NW^+EL^4Y6ZL/XOVS5[I\F(9;5UNFP/ TI5?/+ MGUL[# XL)M\X$+<'8H^[4>11WG+'KRZ,WC%#NR&-
!IZJ/PUP4I%3'IW!JL0Y M=W6G'%<;N2H$6UHKG W81ZWSG2P*QE7./KNM,.SD017HP=M-+9<=9[MN&XTQ-_0D+"?M');RSZH7.3'Y\= VT...\C7\9L"_U.KD"63@,63.'U#7M*; M(/'RDF_(.^+
[PA[L5MJLT+8V@OVV7%EG$$B_OV:&1DOZNA9*KG-;\4QTYY"^)?T?.!Q\&C#OR?UK^-_6, O9Q\^?;W^]^_2) M+>]OV=W]E^7]Q[OK3Q_8\O'QPY='[F4K6+:%9F&95,S1)S=F+]6&\5+7RC&]
M9IL.*0J*WV/E,RN;"!$4(0S^%;U_ [83L#RWV%^@@MAS=OO,KC]!G7:\8->\ MX"KS&R#\5F2B7"%@\@?3]@[E@:+* G/,(J")%Z$,XQF093&X700ZMF?M310 MGM>&\!*P2ABI>G[&2:A
E^9FDX.?T;B2/^GL!9FK8$XODT3#R!.)Z$ ML;?YC89RM<=I*^C?01G!D;#I6BKIQ(\%ZA]-=-%AO0\(NC2$E'""L$M\5 U M+XH]P_IN*Y1X B7\(3:8&G@YDR:K2^L(/TWD,N-.P'Z0]8T(L'6V]6 AK.1[
MIK1C*X$*GVFHX0 6'0<BA8V2?T$^5T.X@&$VH@^D5L-J#\@2*FC.B$H;1_IK MF. '^P*/>,Z$R($<8-80S)YX40/ LG!;76\:*1V2E2@DK& ']P .*)3EQ7= M,]9;75@G<65@:VV]S;V*@6-XL;
<2>PUAY%8KXAW -A4!;CY($*\JHRLC(2L8 M8@&556V1HQ:<=%WD9,(F"]$/-JC5FC]I;\[.7P%P9$6=-P&N/-NF-G9)N'B6 MUEMKR*=C0!N&P=)R"-
DO'(E2D_TRITV'IZ=%=H/D2GAH2(8#M#YQ7E-\SL ; MG8(L]K %W>Y6*J#>%"ZE!GJQ9,T6K5PTJ4 MH^UHI SW)#-MT4FQ999I0\J)(%4-2A=%UE+:&\+XJM 'VR&H?&0,7%3R_) '
M56TJ33J1:.3=]TKSF-^ 79[$N09J.898II2&+<4DKF1#TGKVM$5" Z^$P2P MXRSU@F!T5^I(*$ X(5&0!^NV_H0]',D'CD+T;:0*R)6V7E&5 M9.6)JPZD7[8)?JR/WYH-
MU/GP%6NT#GF]'O8^]T'8MP-MU3U"0RH-L1+KM3B@.=09.-6B:<@;: =/:BN; MB/>)9=$&^T!IK8=#38!D$*153G WS\,%1B=1 MD.*:CDXQCH/I)$&;0.N+6=-R8#V9S<.X6X_"E#U FZ(RA)8,
[QR*PB9 LZW2 MA=[LV12W?,).XD5"DN,$ C W@\23>.Y;B)@Z"7:OU8]D:('$Y1LC1--Y1-,8 M:D[FZ'5.V?P,3424>(&S29B>LAG-W* 6Y!)UIP/!TK-I&/4=3 .5GBU \S!' M7\W;(%IL%M0(Q/-
,&XGIJ0S(O)3=%MG, =,L(CFU/XD09+$X00KD^F"$$;! M'&=3OY+2RI$++*&Y>A$I7[MP6=+W=_JF3I#T4-.@I$6+O9C&,27/OIA%Z03^* MXACF:883-%T!13;=7$C78M\$-!]"HWL-
1NO1*$3+*SW/2_BHO8>$;THOM$]! MO1-E!#WJD;3,.W9\?2*>/!NQ/9L?>D\U>E&N>H/UL_X!?-N_6P_;F M]?^3K[06_><:1]$C3T?,-"_JYL/IRK]B5]HA%?UP*W#M&=J];76KOL@!?U_ M:US]#U!+
P04 " "F=)9YSH$L>8% #+$0 &0 'AL+W=O6>I]>JTUU/IDA54>6+%2E#F0A94XU4N>FHE&L5%R41++Y>>W;%\MPH HR_:IV=C4DCV%XWVM]9W^'+C"IV)?+?>::7YYVD0S(VIU6N\3Z M9U;
[,S#Z4I$K^Y^L'6_[I"T4EH4M3 0%+QT3_I0QZ$ED/A[!,):(+2XG2&+ M\BW5=`PFQ9I(PPUM9F%=M=(QTN3E*F6H'+(Z?$-NV=EQM,DN.)R'G*F3HYZVG8-*]M-9_Z?2'>_1'Y
.4+A6Y+C.6;0=15_((5+.C-))T@9VZ2L:WFPBKIDS2C($XULENKK%TYVTI>RAB1 MCT(BDQ< S%-*KBN)<49^@Z@DMT3 .L,$^-W;U,+;Q_(59]\2XG@?U1 NWT_)9$DQB5-6-;B:=\F,
M"\W292ERL7ATE578,.28S/<\922UI8W914;08?YL;L(FA)N=:(-\ SN)6PR! M;]AW;#6E.$79OZ!B#[+]I_6Z+ZF6\'^]JC7@3O7J_/-OY5N=XT[+RT]7CG M33TWB(_"[G"4>
DY3B(O>75BX6%$$,6>;S>'V-R>]_OG?&O,X]A;,7O[RFNG MG;U!-QI$7M^JCAM[@ZX_ZM>;HY:]PZ?*'FL>N4A349FZO6$IX_=TEK,NN2MG
M/,^A8XKC&%%75ORN%26V&VN!.9H=$<3+Q=$&UFRDN*>9S9\[D9LKY8S7'=Q MP:Q-R9:IJC&E:E,N %5C2[:O'VE]_5#N_M$\ 2HY(T(VB ($WJR :>*&MX%V\\2CPAB0)?-3*>Z:48S1QHF7*
M;,8R4$D3&F.'D(4YY6NX!A[,!I@(X<8MNUWVTO:RL(HA69;)27NF?-!,O.! M:J*)#Z;FB["..:!U?7N*.7YD;KV*51 %)GC\BQ3DUE:.%Y6SE67+UV0U8A5Z3"%9]#K=+ MI6X_Y>WZ*NNU/K QD!?
V9P1%;.+>##@#:GP[&PO=V]R:W-H965TZ"E:XL+16HD M%:?[];ND9$59'2\/PUXDDO>#YY#GDIP=E;XS):*%ATI(,P]*:^M!%)F\Q[J9 M4-4HR;)7NF*6NOH0F5HC*WQ0):
(DCJ^BBG$9+&9^;*T7,]58P26N-9BFJIC^ MLD*ACO-@%)P&-OQ06C<0+68U.^ 6[<_U6E,OZK,4O$)IN)*@

[S2835DR_3CBA=I>-*+&?N.+6*ZLVV@/ M^FNVY%-N?UO?:5RU:RNY*+DT0DG0?''1&$;GX\3=]Q=^%WQKGLC@D,R5NG>+ MJ_RB$;J >,$SZRPP_/O!Q[PHG"$,X_O.9J-VZ12?
RGOKGSQVQ#)GAH]5\57D M=G71Z#8@YPNV*>P7M?V%[_#X #-5&/\+V^IN2AJ0;8Q5Y4X9(RB%K/[9PRX/ M3Q2ZX2L*9*= _JT"W2E0#[2*S,:.,L&?:VVH-UMM.8$GQNOC6B$=*\XM1I/
M!>K9P>7M[>3KU?4U#&\F<'4S&]Y<7HVN/\)P.OTXFT)SQN8%-V?]MD5G3J6= M[0R/*L/D%<,4/BMI5P8^RISG1_3'I_73$_IM!%DC)7ND(W+2X*\;&0 -6T!" M$A^+Y\WJS*A=>*IMT=?
2[Q2^584!3"9PY6T3"X%IAJ&QG!K8"),5BBST1R^ M#>?&:N3[\"=>H?(2\' ?$:,7S2PR W7/WAC\Y=E(8?CJ7@?S+V+"%Q MG9#XE/7!>(4IX :$A#'3^Z'(0)Q+M9$6U +VZ3J6@I-
V_VL*WF!LMN*0':*W M;KE'P&R$R_V#8^OU=XQX@++B.'<;[2+UP6VYEJH'*(X"CKP_EV71.3#;H6M$QNCQ,ZD-9?9(X@2LV$] MB17J:F#YG]BUL,\CB:TZH&Y&8= Y@V9" XI_:1R$9_\
\0R_!]"+XQT TDD" MZ@0@8$3A NJ0F7G'3<%+^(^09++#EV_+$"'J,[2-]\&8<8?+(P*E=T?+<63 M[HY3QU%%E6LE?;XP$)&C)!;"^Q.'J%@5U0M./,_92QI<:F7,BX(:9MFFW!3,
MXL/CEK;B+^:_JCP_5.A7\\+OFI58&WPNBD_8";HH--6C*9Q%, M6DE(D4WNO)M6S,1SFG8"LC^/@ACNT!OFI06%R'!PX"BY9[$\6TE5J.4C)$@& M"DW2I6]WZ@J (&M%U'=^C
M%.7=1N)\1@Y\@D79PW1@"KI1QU4);5%*@A!/PJ3K(HQ:'=2-_4GL3HZUKC?P M[_7NW7XR4^#++OVH99"M2(9JO*AWZVENZ(>8]N%Z-0I^9GHII(&"+U 5VP & MJJOQJEI8M?
83REQ9I)$75SB1,OX,H# !8"P &0 'AL+W=O:RMD8E!R MV8SL85V'[TE(U@F)Y]ULY%F>,-H@)B\@ MIG"II"T,G,L%+K;S0V+74DPV%$^3O8"_U;(':70 293T]^"EK>34XZ4O269< MPQT3-<(9-
YE0IM9HX_ IW%A-+OEKE^8&LK\;TMV<8U.Q#,BRZ1.<5TLZS9)74OF=U2/Q<(:Y9OW[Q+XL.3_X$K M93HDL@.V=CCP.&>883E'#6GLI],#6#&_/E>"/COF&#J'?OD-3#AE@KBW/BO
M8B>S67QKN%QVIS]PU$QGQ2/,!*GC.<\:W=NP'_$>!<3K,5F/*7Q2,J,;HXFJ M ^;2(A760E7;%]_!/&@%]'@RYV M1VEOV"9M1Q>;W32S^"+"X5'OL$W9"F;,%'2NCL$"-R=*!10\1Y)";WR9*R5X MYI
:[,8?!R"I]D2*#7K^%VPK.,$<"7D!&MJ/_B*;@/G<'3AI3;3:I6\%NG(V^ MQUT52P:]*EB6]&,SHK.B9Q%>/3'1;(;P&F6Z9IVP0>W"3;V5P[!9,<62=1A MN!G]Y'X;/[L'KV?
EY]"O;N?!O^T\^):=_UM5X^BH4];MZ+NLWGAI>-2Y(EO! M*_A]T/7[X(?]GL2]^,DXW> '_!X==GAL1Z_D]^&PP[MK9O<]>\9=KJ=$O72 M]W3D#55+VS0^[6S;-DZ;;NEI>=-
S7C*]I(,!@3FE1KW#00"ZZ>.:P*K*]TYS M9:D3\X\%M;ZHW0)ZGRME-X';H&VF) \ 4$L#!!0 (*9T EGQ+JZ_P@(M -4% 9 >&PO=V]R:W-H965T3',1J8J>V4^B_WSF!C$K 2^P[W_?==['O
MNANI7G6J,:&^);D+WG-B8K..Z.HPQ9;HN,Q1TLI[J989,M79UII!%!2A-7- S MVF[*N'#ZW<(W5_VNS$W"!(I"LVE (6KGC-H=(9-&U\$ _.:XT0=[L)4LI7RUQC3J.9X5A F&
MQC(P6MYQA$EBB4C&VX[3J5):X.%^SSXI:J=:EDSC2*8O/#)QS[DFG,(5RQ/S M*#>WN*NG9?E"F>CB"YLRMMET(,RUD>D.3 I2+LJ5;7?_X0!PY9T ^#N 7^@N M$Q4J;YAA_:Z2&U
VFMCLIBBU0),X+NRE+(RB4TXXTU\\S^=WX]GX_FEP!Z/! MXA8F=P\O,+V?/#S.!D_3AWNX>&++!/5EUS64T,+<<$<^+,G]$^0!S*0PL8:Q MB##ZC'=):*76WZL=^F<)?^6B#H%7]_SFV?
X@JKZH. +3E6?9UF"]],8,2V#$ M= P3>J4P+GT:_@R6VBAZ.7^/5H[J989,M79UII!%!2A-7- S MVF[*N'#ZW<(W5_VNS$W"!(I"LVE (6KGC-H=(9-&U\$ _.:XT0=[L)4LI7RUQC3J.9X5A F&
M&2HN(R M9)DD-@,?(6&UZZWB_6ZWJ*#4*8(AFU1UT#0)(KV^>YB#0T6D'= M@T80U .XX3I,I,X5V@@AQ??0)EQP41HTS$1 1?OE*2P;*-SPU%W8!0SL48Z M>^H@U5)4ZV*@ M:
AE+DS9=96WFEF#LE7_AY<#;\;4F@L-":X(ZM5_M!Q0Y1 I#2.SHG&7TM 8 M*+8QS5U4-H#.5U*:O6$35)._P]O2P,$% @ IW0"6?B(9U$X!0 !! M !D !X;"]W;W)K&UL[5?;;N,V$/V5@??2!#!T
MM6PYFQB(G:3=(MD:N6P?%GV@9=HBEA)=DHJ3O^^0DA6YL;1!4: O?;!%<6YG MAH=#\70KY'>54JKA*>.Y.NNE6F].7%14%)JSG,XEJ"++B'R>4BZV9SV_MYNX9>M4FPEW MN?
^R71H]*W"5T:WJC$&D\E"B_ F MY?/RK.<90)331!L/!!^/=$8Y-XX0QI^5SUX=TA@VQSOO5S9WS&5!%)T) CM; MZO2L%_=@25>DX/I6;'^A53Z1\9<(KNP_;$O=X:@'2:&TR"IC1)"QO'R2IZH.
M#8/8:S$(*H/ XBX#69071))/J11;D$8;O9F!3=5:(SB6FT6YTQ*E#.WTY/;R MZ^67ATLXNB<+3M7QJ:O1JY&Y2>5A6GH(6CR$<"-RG2JXS)=TN6_O(IH:4K"# M- TZ'?Y:Y Z$7A\"+QAT^
OK%$/K+VSQ=\$46:\E71/+ [&"6_I(\X+"MVM4 MA<^:9NJ/0XF7?@>`9KML'R-:!/*'LWR].&0JX'V$FZ9)IN!9*P3>[@'!/GS1,N4B^\'RH M,^;AC.Y3=E)"V1"YM8(US9]*4D+A"
(6J6D>Q)\A*=E###L"UI?:]F%+ M%!"C;GRI$SA/$E'D6C5RAH=\P3A'VSO$PQ+T_D5H#)\OX3>,(1NZ"NZ%)ARF MA%M@ZI!7^P+EV0(50]_&#>$]A($SPL?(B?#?L^.!YXQAS@O5;R8#] G[GT+0
MS@ ^OHL#/_A4/\W<-55HL94,,8G52D'@>!"AQYW2",?[@/:*8, ,'!\?OA/7 M8,*A,X0.%D4UBZ).%LVP^![('W85G<+,]A,JD4>X3-K6\)H1K"_3SV]D4&>\ MPPS:S_?UA[<8S$,!#&?NB$\+,TM"AVK%0[
M5J)&-'8,N?QQ@!861E4#"^"UR1$N.<9'%AZ_T'$8E0/XZP"@\Y)3)'#5FU M+Z0)8C,1!X&/M.G@R[#FR["3+QV]DWLZ/9N6LE,9!N2/ ^D=FDH6#QCTFL\
MZ4M&XNN&/%.IW*3B*ZRE*#8O;46GDI8=X$<-QN@8CN$.I9+N]9JKRMF]==8\ MP_ZV0=^H&&)?DKC)SA$P2PA<%A(G:H>5?:E'RK,3=[N;IN:C3'CC!I2(HX/ M=4MICJR@6SK'Q;1.?
*]%S0JZI3?8$A,BR[*7+VP)<8M)7/W:9/V#4%M*1J,VJ1&8[C%/"7[U);30F"KOPX+A ML9.DN>!B_5PR*[-EX/@5:'8L));:#$&,T8?YV;4)=B6L9\(:>0T['C44?,^H M'YC:4?$.:?\&QG:J_:=\;5M4*_B?KP?
XVBG]U_GZ:N(?T?5V\)YRR\<'Y\XI M& '[H#\%$_C,SGFG$]VL6+^MYX4$V.&_&Z3Y66:,ZAX]=MW,QPAZSM_5.!_=(H+VGU M;'W%/2]0=B_JY?
WXAL@URQ5PND)3_S+S%9WCG+%RTV]IZW$!JWHQVF>$VG MTBB@?"60$-6+"5!?_"=_ 5!+ P04 " "G=)9;_V6S6D& #K)P &0 M 'AL+W=OR5<7 MW>XI^\Q#C
7X&D<)O^N$0FQN>CT>A#A&O$LW.)&_K"B+D9"W;-WC&X;1,C.* MHYZN:68O1B3IC&ZS9\]L=$NW(B()?F: ;^,8L6_W.*+[NP[L?'_P0M:A2! T M1K<;M,9S+#YNGIF\ZQU0EB3&"2.-
#,S7(6OQ%\)Z?7(.T*PM* M/ZX0@'(H5 \FN')SB*4B3IQY<"M'/@3 U/K[^CNUGG96<6B.,) MC?XF2Q'>=>P.6.(5VD;BA>X]7'1HD.(%-.+9)]@?;;4."+97H%SR .7'Z/7_T/3^ !JB@4B$;\&
MOX./\RFX>G<-W@&2@$<215*W_+8GI$,I;"\HR.]S[/%OB<'XC :^O?1N-=; ?_<)EU@:.^!KNG]!G\F[>:/B$ES^*;Y]'QV MH\'<.9^]R=S]N;[/?LYYK]U\BH-6Y_WSS?46(1B':6%D>,8;>.,@H-M$\/?@
MB0HLOQXH2CA R1*X)$%)0)(U>,$!)CNTB##X]" !@"]PS/]IF@;T,?C3F7^90?;Q!A,H,18!(BML:-2WF.9&9(:0JU&VFWO=VI+ENY+H&Y+M5E M#F:=T.E=NTSHJ"1TFP@'9<)9?
0PJ+3R5+OF*P$K2&!RD,6B5Q@O>X63;+(7< MTCX9!D/7M>ZPHH=6@DOU,*B%Q] ,HVM5)*&2TZWWTS2&5DT5===,S8+59IY* MUWQ%8"5IF
=IF*W2F,BDB\E=BDQ510@F69**F7Q'$K0@$1''FC1CUN-GVUVC M(IE6XDLEHQ+,40GFGC48,Y647IVRKV[J]/$5499D91UD9;7*ZAFS('T'T14H M%A^0*8TLMJ)Q=W"?XT%XTBE8$50KY:6"^C&?
HY+/_3'?[,=-/)4N^8K 2@*Q M#P*Q6P7R89]@QD.R 9M<+FB-P2*MUX!]2(0;D9WF(LTD6&I.L-@C:4!BJ)O M .7Y/%Z"%66)D"$& 24"Q!C$=(EN"+I,[KE,L67.\KK)KFU>G=I$J\2;*H2 MS%$)YJMV!
6I=O2)BE8R>2C!?$5A)[L.#W(?MZR&C.Y(5%5/-DB20;UD@T-?F MG&Q83T+T;G4U;"6\5'1UQOZPEJ*K9'3KC-" -34UM(*U1-%3Z9BO"*PD$Z@= M2WA:JU">TCU<+H^K!\KY-1B+_+69U28$!<]R-
4Q$8X%.J^6XNC:HY65%L].= MCZY78CUMP((RK:EL"YRB66FG!?5J,[NU#>&F\5:&5 M WY2LX6M 9\+&GP.:;24K\Y?@/-E*W/N2V(.:T-F:S+H=C7HL!8H:S@8=LUJ
MW.MX4#/ZM1V04S0\59%MV8-JX,JS;W8NK5' /8%!W2=D'^;T]L"MC0WS7J46LDO7=0+D MK+VP':6<;D, _+:L>[KIG5JTDY"GUS%>%5A;.L0@-6XM_HPGB859S#M(++.?Y
M#D5I=MNH%J,>.7-02P':*2^6B]+RL5(T][P!F2DE)1I(!T9MTOJJ2,O".I9] M87O=]P$M)I1MP)2@=2)W023@X-,CCA>8-?Y]T0YWZ=9'*=I4*9JC%,U5BC93 MBN8I1?-5H94%?
2Q6P\'_^G\=5%FLG2A%FRI%SLYKYBGUS5>%ELNF=W+P M)\9LG9T:XR!;"_/##H>GAY-IX^P\5N7Y/;QQ8,-S%][,\G-G1_C\&-PC8FLB ME]@(KR25'#-@! X1 !D
!X;"]W;W)K&ULK5A1<^(V$/XK&C?32692;&,;2 K,$'![Z5QR##2]ATX? MA"W $]NBD@RY?W\KV3C&^$ZN=0]@;R;N?M)JV?TD,#Y0]\RTA KTD<+.F+,$"FFQC\ATC.%1.26QV+:MG)CA*C?%0]$@S
M$4EA9-C&L6,1;;9"=ICCX0YOR)*(I]V<0&)6=$8A((":8'A9T^F)(XE M$LSCWP+4*,>4CM7G(_IO*G@(9H4YF=+X:Q2*[<@8&"@D:YS%8D$/GT@1D"?Q M AIS]8T.A:UEH"#C@B:%,\P@B=+\%
[\41%0< $?OT"TNR)NA@4>#QD](":M 4T^*/:5-_ 5I3)1EH+!VPC\Q-B? M+![O'W]?HKF_0,M/DX6/+AJ[[J-@']D:0NF M^AF:^RKU&H]!IW]J-
/MA6%\+Z^D]3LCQ2G^\1G*4M,$^ALAZ#1N;5$*2[&+Z MC1 $RAP\([]3$LD13D.$#YB%0.([]'EGL[8ZW1IA.ANGQI?.QJTQU&QSPDFO MY*37R,E]&M"$H,O/E(.LKQE-T!1T,DHS2"'T94>8VC6 !
[D/'#<'5>XZ-O+! M;BHS[';<6JC3,]!NE['4WG"0T2\4[MHM9O4J3:!)NU">:W!':R(H-R10;OBMIIGD[V< S!JUB=6*8T2>!@Q2U:0MZ!HQ4[\)1-<@(Q!%3>2<:.3Z3H7N9%7-:J)
M]TR+4^/+;\0Y(<*V7@^\5HL"EI]\WY2O8JR:?M6D::JQ @&K)X?&^A2L3HG& MRNW8;Y!2N078+9$B:PNRYD_\;(_5$/-L_Q1/6L5 MS6\+ +5\ALW)E2PC;J+LR1X'<0/)3=-E;WLVIG\F[^_JBO@*
MGU_^S#;1'!FBMP2#3$H#>+^F5!P; M>[DQ MY=#W=9I#075/EB#P92U500T>U<;7I0*..5#! 3 +OV",N'%(W I>[L=?W]A<+MLF-O?#C44DWL 3SM9PK//DM2\8*$)I)012LE
MQ]ZD/TP&5MX)?&.PTP=[8CU92?E@#[?9V NL0< A-9:!XK*%:^#<J9OQI. MKU5I@8?[/?LGYSOZLJ(:KB7_SC*3C[TKCV2PIA4W"[F[@<:?"\N72J[=+]DU MLH%'TDH;631@M*!@HE[I8Q.'
P#R= /"!A ^!0R> 40-('JIAD$#&+Q4PT4# M<*[[M>\N<#-J:#Q24E48VNW'1=VB,%Q.V3I9&X2M#G(F3R>+^]O[SDLR3 M!5G>3!8).9M+ \
(PRDDJBP*SJ7.J0!,A#6$BY54&&6[L:UD9ZA(NUR1CO#*A M E0))C::E*!JZ#DYFX&AC.MS\G[/UBS(<\ M=;GS?]J3?]9^%(RHK:W(\47/U=:^$.98"$N;;O)CLM)&87?XV97LFF[036<[MYE"7-
(6QARU1@]J"%[]]Tl\,/G9%^C7)9J])EKP2V5%.!FU.!J?8XZ61Z0.1 MI?UH-3EC^X_[O"L?-=65H[(#9QL'/:RK[6&8NV0NCF5F73+1L4QR6E?MJW_0 MYPI0&S=@-/:A2IBZ+-O;=H9-
7.M^&PO=V]R:W-H965T5E&FSHUD_';$<3N+)B?.MG<,C7E^F.4S^4C;;QI3F9S"ZW?I2CRQHEC+8T22.6$$Y7;\YNC6O/GHH&\H[?(OJ4MGX3T94'QOX4!^_"-V<3 MH1&-:9)"!_^/-
(EC6.!!'K\58*>U3)%P_;O"MV3G8?.//@I7;+X]RC,-F_. M%FWXF7_S MFK,GPL7=@"9^2+ID:S!PE(B1]3GC<#6"=MG-VU]^<7Y_=W]/;C\XY-V+
[?/[I?/Y'RY\9,U34F4D*7/^3Y*UN1VR_(D(VQ%WC(6/D5Q?$'. M'9KY49Q>D)?DU\..7]Q05Z(5N_A,@RA]/5E!NH*H9=!J=I=H9IYI#6+O&=) MMDF)FX0T[&GOZ-
O/-.TOP4RUKF%O#G/]!D3:S(BYL2T>_19GM[9B@GE(8 JQ=DVLK4. M >? L^AO7ZX;X"*B) ,/CWX$X3\)"0LVU!. #2E6:]/*-#G$ETLBX\W,W-L MOKY\;//8O6EJC*?
J34[W)L,TQY9ZE]MSU\0>7ZEW>=H^?Z-%I[5%IUJ+OJLM M2&ZEV4;D+6=I2L[=YR#.0^&2:T?<9]("?J%8R[X:$P^,JM5BZ.0X3::+*=.; M=D?%9+H8V[5,Q?RSVOPSK?GO_-A/
@I#5@SGG_TDAPB,&'V&U@(-]5688,ZL M0\?,L,W#*>-BRO20P!32YC5I<[T7"O\'L1-$P%E*,D;6Y?3H(TT+-)0T3#"G M)NV2'LYLP\8PQ3H(8$IC"UJQA:G3;..4+%,K,B.\HCUQ7UWB^YH-LU)9Y70
M"AQ*QFDR74R9'A*8PL=5S><5E@\O2J*,OKR'?5](>I:@VR#(MWGL9W"YO>;W M\775L9VQ,.:=I4/I8LKT>F3.C=FQ!8OT:9:F2ZJ3*]7IFT>L7YKAVQHK5_95HSYQ .*(PX!WS><
M)1(6=9AH#BJ:BXKF8:&I##?Y!$.[JVT8%IO,OBU3/8L_LC@*]KW4ZT7,Q0N0K MZ;(O&TJ")F.6B<,J:^;76;,J&B4KQN4]:?1,MD6NBHI<%?2DY3VB=ZQF1)\KE M_F,%8Y<]I=?$>29W]R".97Y,U
V*0P.Z?8 M=I6L(2^(/5H8UO@*?ADCRUR, M9_!K-I(; -+8K7)N8>'R __6MA&N:K\@BF$(W6"0ERSFD2[$FT M!7:S]AZ_/P8GY\9D/+\@YU-K;,&?F3V>7!QT0NF_[,"5;9<=,.?3L24[(.,O M:?,E
^')7J85Q/^-,*%.!#9=%>%,+,.9=DY"<"!4C[C05(2?,?53T0_8Z,7Q MGL#UIPU-Z"-T"?X1O8%3+9:#B$,HE&9"?W$BC *(BL!^@'5D!*1YL"ES(&3K M[TG",O) ":%A#RI'($*L"I=+D@<816"%M=4\.
M@$QT)]_N1 A8)'IHFD5;,$1*\E3:7 IH$>/'^S2">[G0T4]9(OH] MOLA,+% M@0#R=S=CP"K%%;%^C*0Y["'$VA3RR/0\""8A2"/+!!GJS\1R;-6?$U CVJ MF EZEY8TE6-7@-
/G*)76:O>GZH&XH3U8RCZ,R6\^3)1 ^V$$6:E";B'A@/"=M& ?B+QXBSI%0GA/M9 MQ@L+U/>$['G)$UQ'1) MA+42)@W!I5>H!ULSJ.3(:%&T]<-F'NQROF-")LPU<5R/NA[RB+P =GND@AD0
M[KC@5 MXDJV8K*&=;;R!9ITR1L$06C;QTE(T%EFC\(+Y>)3H!E\M(R@"]VI'#CG*2 M"?Q'%N=;VN[5J)P2&Q_,.86ONBI%@-?I8H](8M1U1QV&.-DI!^?UAS+@=A M'0^47E?11HSDE#-A@24):!?
33"R!",5>F26RIIACL?# MB!U E$0+M.0@K4V:+=30,!G&)8 $52KR^/CFZ]?9]_EB 29W,S" >YS">%3WK-\]B"YD!U MAMIS6:,D3+=!"SB]%^<=!V9D..= MW!+#2^A"IZ9$%N=
NTF*E4NQBOM=Z+[_^HP',&M$BO#,-)=5F0B>2\[9RW MWUC;=T]Q;0+0F2"1=/*V ;UT\'8%5M#NY=J?/)N)T68>. MP"IUVIHR!Z:CNR?R5A+FVJKR&3S(V0 _>K8D,),W!-$T5GBB1
MQ1FVHS8L1J@7-D#OLXUDZ&5BR-*-6A.4Q\&F)@A+-@;V\K\79OX3U@OJ"9-) M8C)5^"1>-N0^6SSL[6QM&._=45UA5:M1&%08*\.!79J4;I"J]:B,"FP9Y>2 MX9?GJX5TU3B=UK(PNZG!P,*FP/?
S*5!B0)!KU%J,-,XQ2IJK8@JC GMU*AEZ MI748Y$6BUJ[2J5_I"JTJOW L ML%?+ COU+%VA56M1N!;8LVV!=4,"+53Z$Z7=_I=L-EC[<"RK<"^K9O:"Z+3$'5NT77QKF
MEIZBJOP+]X+>S[UDMRKO0>BG,MI"JA(*SX)Z]2RH;D:D R +:QZ PK.@=L\R M#\%]Q#PBILS#1QSL/DT %D]%MT0T%RG=3AU+5VA5\85C0;TZ%M2I8^D*K5]+
MPK&@GAT+DFRAU'EU9Z992\K[O%T8:&,?#)6J3IJB,J%!U?@1U/.-NE M;Y&>&.&ULM5I=<]HX M%/TK&K:ST\XT8,G&0)8P]C.LD/:3FFW#YU]<+ ;VV+2B)D]]>O_!%C8T6+ M&_4E8.-
[CG2.+.G>:'PD]!O;8NQ]0['/NN2/4[$+QM" M8Y^+2[KML3W%?I %Q5$/&8;=B_TPZ4S&V;T/=#(F!QZ%"?Y 3O$L4__F>&(M'&\ZL/-TXV.XW?'T1F\RWOM;O,+_X#%5>]$B4(8YRPD"2 XLU-
9PJO/832 M@.R)/T-\9)7O(.W*/2'?THM%<-,QTA;A"*]Y"N&+CP<\QU&4(HEV?"] .R5G M&ECJ_H3N99T7G;GW&9Z3Z$L8\-U-9]@! =[XAXA_)??<=&A?HJW)A'+_H)C M\:S1
>L#XR0N@D4+XC#)/ W'0HA*@,"1!Z B)T'6,\$F$6 >2F#5018ES+T MBX#^I0%V$6!GVN=B94H[/O> Q;M/TW>WB]G2!=/5ROVT J\=S/TP8F_ %?B\2>$<=;ROB>Z+W
MI03H28(94@+^<4BZP#3> F0@2]*>^>7AIJP[+V-W7\;NJ<,=O!;A4!9>T](L MAY.9X9G/X'EA$G)\M12S10 6"?>3;7@?83!E#',&OB[%\V#!<3[#7;^VM\TQ&S*,/T
7,WF6TZP1R=8*Y.,$\36,UNJ[3;4]%/ M&@Z_!;>4, 9>NX_KZ!"$R1;<$A(2-J&@875']:<\99]_<*H8E(H.U(H& M?XO=C-B3BF6 $]5!%*%T4E-M50">8DX/U*S)?V=:9%3H)/4U@-<>&I6-#I6,N
MXZ'8NHN%W*^^#?A19#4,IUL&*-MQS(:-$8O,06/P*[G;^G(1I:N3TM,$5G-F M5#HS>JDSLJWD;-24"0T;SBBYVSIS$:6KD]+3!%9S!AJG?,IXJ3=]:=)D-)6"
M]OD4/E>SMW7G,E)7*ZFG"ZUN4"7AA2\UR)8:!)M:&:,N/#=(R=[:H(M(7:VD MGBZTND'H9!!ZD4&?Q-8+^QN.J=0FU-PP#E?S\G= ^< MT-\F1,QZ:P:^WN'X'E-I=4P-U_I=T)KZ:T5SM:)YNM#J-
I]*"=#^F351]"EK M+US'B>9H17.UHGFZT.JNG\H=4%WO4-7FBM#J+&:-K,;\-%=3M#;K,E97*ZLG M8QU"L\):%_A4G8#J\D2+@I(:J?4KI+5T 9NUBRMH-*K16DD]76AUZT[E?BN
M7\S)0[8C=.AA"QS\@".R3XU4KWXZBP1SK6B.5C17*YJG"ZW^O]53/009/W/U M0SI+#W M:(Y6-%[ZJI7A-8VYVC0/]_$S]44K>J;S9-T5HVT866 M6]>K'+Z),=UFQZ086)-#PO.#$^7=\BC6-#N
='9 !J_G4'+?@==N?M#J!)^? M^[KSZ39,&(CP1E")38-(=&A^E"J_X&2?'?VY)YR3./NZPWZ :?J ^'U#"'^Z M2 G* VV3_P!02P,$% @ IW0"69:C 4)F P P@L !D !X;"]W;W)K
M&ULK99OCZ,V$,: RHA>JUWI%@SD[S:)U$U:],J[M=G5[U[ZH^L*!26*=L7.VL]G]JK4-RY&%H%;*&\ PS\-O!MO,["C5%[U#-/!4 M<*'GPJ^0YEY4\"A9!05E(E@,?/W
M[M5B)@^&,X'W"O2A**AZOD,NC_,@#EYN?&3;G7$WHL5L3[?X@.;S_E[9452[MY*Q H9D4H' S#WZ*;Y=QX@0^XD^&1]VX!I?*6LHO;O NGP?$$2"S#@=+:D^/
MN$3.G9/E^%J9!O4{G;!Y_>+^BT_>)K.F&I>2_\5RLYL'DP!RW- #-Q_E\5>L M$AHZOTQR[8]PK&)) -E!&UE48DM0,%&>Z5-5B(8@'IP1))4@^:^"M!*D/M&2 MS*>UHH8N9DH>0;EHZ^8N?
&V\VF;#A/N,#T;9I\SJS&+U\]TGN'K8265N#*H" MUE)9*R:V&JC(+8)2* SL;0 KN]P EV);QN:X-M=P]8FN.=KS"@UE7% .##7Q^ M6,'5FVMX TS
!\:YU>I99"RQ>V^4571W)5URANZW@P@A)6\A(623K(N5U,5*0%]ZQJ]1II5-'?Y^;P/@G<%"_]57.DVZ'9S"_16 M[VF&\\"N0(W]$8/%#]_%(_)C5ZH7,CM)/*T33_O<%\MJ%K@/#OB4\4-N9PAL MF*
B0^!H%Q)P1M>,, _/<58K2?^S]W=;RN$A(/ V'L^BQF60[;#]=AI,ZZH1^ MA-,/>NE_EP8UW--G-T^[X$KYI/%6TB)KQ\1AW,TUK+F&O5QI."+?@T;!I +A M(?,#NLDZ[*(LS89-RE>,[8B8$-
(-.:HA1[V0@Y"<@4R[(R'7*FCM,:;]J+]X?9H7J!@O?5BF;86>>J_^[MO5W([" 3KF'S[*Y*+[NR5W85ROY3;:?*-%B"^Y#Y4N9W=9]J&PO=V]R:W-H965TV@,7NL Q-$33M=E'L9:I/;:(Z39)4G/[[D9^J
M2!'--EMN8E$ZY^7SGE \U/S(^&>Q!Y#HH2RH6#A[*0^7GB?R/918N.P 5#W9 M,EYBJ89YXD#![RID\K""WT_I4I,J)/-ZWNW/)NS2A:$PBU'HBI+S+]>0<&. M"R=POUMX3W9[J6]XV?R =W
\'N/AEJN1UZEL2 E4$$81A^W"^2VX7 :Q3J@C M_B)P%+UKI*VL&?NL!]>;A>-K(B@@EUH']Y[(6$)1:"7%\:45=;HY=6+_ ^IOZ M[[5Y96:-!2Q9\3?9R/W"T3H UM<%?{]. X!K:%Z^6L/5?
=&QBD]1!>24D M*]MD15 2VOSBA[80O01EU)P0M@GACR9$;4)4&VW(:ELK+'$VY^R(N{Y6:OJB MKDV=K=P0JO^-=Y*KIT3ER6SUYNH#.GO+Z.ZU!%ZJ"JSE.3I;@<2D$.PH-?IX MMT)GK\
[1*T0HNB%%H:HOYIY4DVL)+V\GNFHF"D],]&=%713Y%RCTP]B0OK2G MKR!7Z4&=']@W3/66Y\QUVOL-:+SJIMY;HF@K)*[4H)?KT5@6@:PFE^,=DKE&+
MS6KZ7;L4!YS#PE$ODP!^#T[VRT]!ZO]JLOI"8@/C46<\LJEGL>O[/R,!E#". M*),@T*8"0UD;WXU86HOI+>$^BWU_[MWW[=AC!I1Q1QE;*2,W/4&9F"@;L:1' M\)1Q'!"XIR'3#C*Q0@9NDI@A4Q-
D,D)(1J6TQPPHTXXR_8^EG)@HTQ%!.J*T MQPPH)QWEQ$H9NK,3M9R9"=C@N0II3UF0#GM**??>7DFYEK&QF4Y'1,1K6T MQPPH9QWES$JI=W/4[>:(%%AF@/*F9#&G;N1F_88PLB-GX
:@E(W,I,&_F/[M\:VL[^HBWN*O>%W !7K':%YQKG9D8X?Q1PS^B-,8E)[@[+7)X+LU;3JD[AP7 MZ,U#7E0;H@J];'C1#985)Y* N3D&(ZK(CR>] K;T3=QDL)DF:MV=,/#8[P)K M5\GN3!L
^G0#Y1JXL>79!9 ,)UY*;6C_L>L%T8OV\'#:19]M_H74AN8?FVE@ M[Z;_>_'&HPX_;@IVAN=Z]'I'6OT]<8/YCE"!"M@]>=^]!V3-T?TB#9H3[E MKIE49^;ZF">.7^%/M R\O@^OAQYN&?\BU@
2/>19(4;.6LK-A>>)= TY$2[;0*&^+!G/B52/ M?.6)#0>R,$%YY@6^GW@YH84S'IIWMWP\9*7,: &W'(DRSPE_O(2,;4<.=KZ_ MN*.KM=0OO/%P0U8P_EQ<\05D]>H+&@-A:"L0!R6(^8$I\H;$7K
M'FF4.6-?],/U8N3XVA%DD$HM0=3E'B:095I)^?A:BSI-G3JP??]=_*@M!22Y76PB(@]." QH0U@&A :V<&:PID60\Y&R+N"ZMU/2-:1L3K6AH MH;MQ)KGZ2E6<'$_??7Z-
SF904,;1!R9!O$9G4Y*$9NKN#?HXFZ*S5Z_1*T0+ M=$.S3+6]&'I25:T%O+2NYK*]GBBFC_+PD6A?XX/'X@LX9/N\"FD*AR;\' __MW%/ #7704 =&+WQ2;R[1=2$T+]60E.CS>U4
74O(Q;\VN$HMLJOIF78A-B2% MD:.FD@!^#\[XMU]PXO]N0SV1V!YXV("'7>KC]ZQ8O9' TBS^:@Q M'W6;UYW$EFC"84$ENB(IS:A\/%>>'VA>YNB2<25I:(AJ0O7-QE!5$K?,8=_W
M#P@ZG;RPD^*&,^[D/.!#?VW,BB>9&K*I6JL%V+#B(ZSXB*JSWA=2)0U5\ARJ M7:_-3(^9SFTZT#KX$EO''1!V>G@A8:\A[/UP60=3_ZA2WXT/C!V7P2ZV
M^QHTO@:=OM3.K/;=HEZ,TDP;K#^D8DD/AS^ M/RBT[[25(^!.I]>%&M4@)+HC$M1\)1OT^0;R.7#K;MFM]MRV/Y7:/OLN4\"G M317P27.%4ZGMP^^R!=R=+@1NS[<.T1!;V<.C)2$*_*/L
%O2@]!O+7S[;G?I M >[.#V:6J=3K']DGVN9KKI^1-.!=UH#CTX[4$V4#-?S/R"WP+KG W=G%_TUL M:_FDO7 >)1?='I[+Z+5.;?K(?$/XBA8"9;!4\K[;4RW*JU-H]2#9QASDYDRJ
M8Z&Y7:N3.W!=0'U?,C7RZP=]-FS^"QA_ U!+ P04 " "G=)9K@<"$90# M #\#0 &0 'AL+W=O5GDPW058V[:);6#G[V.[FQX83$N+" _@
M6YTZITS9Y<%6R*I]B:CA&RNX&@9+K5=W8:BR)3*BVF*%W,S,A61$FZY3.B1$A$D7]D!'*@W3@QJ8R'8BU<]PC]02U9HS[EZ,XF W\$072VT' MPG2P(@M\1OUY-
96F%]8H.67(%14<),Z'P7U\-XX[UL"M^(OB5NVUP4J9"?'5 M=A[R81!91EA@IBT$,3\'&-16"3#X]*-*A]6L/]]@[]HQ-OQ,R(PK$H_J:Y M7@Z#FP!RG)-

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{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|($BF8F M7$DU(_1GE(QJ/R[$_IP^)ROF9,6=K 3=T;:!5!+(B)9 ?(NFFP!*,_6^JZ![M6*T#J4)%,T<#$K.&75U# M#7.PX0XV@NY@VP]&634_K30D?+9*('2+KWO)>@&%BB-0VD"13.'@O9-)%V= M*!I!%1HHC4%I'$H3*)]9<*70C- GBD:UAWL.YJ N5LS)BCM9";JC;0.IE(_1MJTX3U151'P&4|NYI>T%WN4!I'$H3*)HY*I2<,^KJJ-$(*N) :0Q*XU:0-', MKY52(LX8?=1HI'#4R,&&=-AP!QM:=[!M)4H,G[542/Z T#<%O9T"WQO+2B-M06D<2A,HFCDRE,HS[NHTTABJY$!I#$KC4)I T2 MQE!9!TIC4!]'T@2*9B9E.R3#+]JIE]!TIC4!]'T@2*9B9DR"ZES3;,P88[MV BZ@VT#J/21Y%5GEXY4T$9YE/;J?3M!]\1 :1Q*$RB:.1J4P)-T=6HI@K.#V:@3C;O1!-W9ML%44DCRJA-, M1VJICRA*\#[+H-NC8'2.)0F4#1C8$R4Q#/IZGS3!*KJ0&D,2N-0FD#1S(0K M56>"/M\TJ3MM9-54!QOF8,,=;3=P;8!5"K)A%9)IOECNIS)@!4/=P&K0CC/ M5POK%/V[+%_=I\6B:L5#56O3^?:]TV+[WFD>W,C'K +,\L4J73;55;HUWK<9 M=)L,E;.A-(&BF:-$R3^3K@X\3:#Z#I3&H#0.I0D4S4RXTG%G45JNOL M:/;GD<1V$88*-E".0-',#"K!9D(+-AT6=C=EEVZ?]X" [N.!TCB4)E T<]PH MG6K2U?&L"52*@M(8E,:A-(&BF0E74M0$?3R+!GHGNOZ+IB=VJ8=J2U":0-', M#"IM:4)K2]V6^D8)FFZ=]W" [B>"TCB4)E T<]0H$6W2U;FQ"50<@](8E,;A M-(&B&0D/^TH=V_R,+?4-1-]<[W$-9W:Q7CD6)VX*X^AED=:]>JVX/OHY TM M]\)?T-U16!S'X@0,9XVC2!M'71UWVY-A>85@//CL9:>L,X#GOVA\(WM,@_P6Y^.=:OV.,2W6\8#WO1BU\K*8F6%%HLL]=, M]?&&2EI8'./B.!8G8#@KPO,MPUT)6WLR+.]0:0N+XUB<@.',O(>:NA7"U:VP M5HZ*(KNLTIZ]$PG%<2O.P'!6(C5Y*Z3E+=QS<^=(?WZ-)V'/WD/;T"#__#JY MY5BWHLYM$O9[R9&'9J@)12&]2^Q :(1N"FOP[EUVH3B&Q7$L3L!PUMC0Q*2P MJ[UA>S(L[]#=85@0O06L3VQ^7&+U9G2]L#.Y*L3*55 VZ7HAGG?L5 /9/I)-;[F@G8,VS0J^)3!$MM,GW*2ZF_!VBHKMCM3E RC)X7TW$ M9E5%7E:#I$BUBW TV)C6/ABD&Z#_PC!"ED[W$BOQ@YI\N1E3+X?'M;GTKHZ4.LCNUQ0S*5V,U2*)R52DWWBPRZ.OR.IO/ M-W?N9E94W9<>3VRL<@7%,2R.8W$"AK/RKBE746?*5815K] XAL5Q+$[<&;> M8TVYBFGEZB]Y8M-M\!XA4!S;X\@R#W4I8#@K[9I]%C=LRVK[Q*:Y_JG$BEX[MG+[7>-@;'R03JV6A<%8R-2TKIG=TU>RQHY_4-,_B5@%"XKC6)R X:QL:PI6 MW-D>K1B[1PN*8U@U%C5#8IC>YQ>WN/#\RM0IP*& MLQ*OB6DQO4.L_;,:*Z5!<6R/TX62@UU\4)<"AGM.Y=EZRN)-3 M.9^OG]\>;LJW]M>@D+>;3+^YC$].#0[^+GPS#6O^SL(W?/OW,X6_%^E=_)C M6MQERW4PEI>5]WYO\WV!179W__)+F:^]07827.=EF2^V/|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

MEASUREMENTS Sheet http://www.labcorp.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 9952166 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATION SUPPLEMENTAL CASH FLOW INFORMATION Notes 13 false false R14.htm 9952167 - Disclosure - BUSINESS ACQUISITIONS Sheet http://www.labcorp.com/role/BUSINESSACQUISITIONS BUSINESS ACQUISITIONS Notes 14 false false R15.htm 9952169 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment information (Notes) Notes http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes BUSINESS SEGMENT INFORMATION Business Segment information (Notes) Notes 15 false false R16.htm 9952172 - Disclosure - Discontinued Operations and Disposal Groups Sheet http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroups Discontinued Operations and Disposal Groups Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 9954471 - Disclosure - Intangible Assets, Goodwill and Other (Policies) Sheet http://www.labcorp.com/role/IntangibleAssetsGoodwillandOtherPolicies Intangible Assets, Goodwill and Other (Policies) Policies 19 false false R20.htm 9954472 - Disclosure - Revenue from Contract with Customer (Policies) Sheet http://www.labcorp.com/role/RevenuefromContractwithCustomerPolicies Revenue from Contract with Customer (Policies) Policies 20 false false R21.htm 9954473 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.labcorp.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.labcorp.com/role/EARNINGSPERSHARE 21 false false R22.htm 9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables 22 false false R23.htm 9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.labcorp.com/role/FAIRVALUEMEASUREMENTS 23 false false R24.htm 9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Sheet http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Tables http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATION 24 false false R25.htm 9954478 - Disclosure - REVENUE (Tables) Sheet http://www.labcorp.com/role/REVENUETables REVENUE (Tables) Tables 25 false false R26.htm 9954481 - Disclosure - BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) Sheet http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) Details http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATION 26 false false R27.htm 9954482 - Disclosure - EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) Sheet http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) Details http://www.labcorp.com/role/EARNINGSPERSHARETables 27 false false R28.htm 9954483 - Disclosure - EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) Sheet http://www.labcorp.com/role/EARNINGSPERSHAREPotentialcommonsharesnotincludedincomputationofdilutedearningspershareDetails EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) Details http://www.labcorp.com/role/EARNINGSPERSHARETables 28 false false R29.htm 9954485 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) Sheet http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) Details http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables 29 false false R30.htm 9954486 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) Sheet http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) Details http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables 30 false false R31.htm 9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) Sheet http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails GOODWILL AND INTANGIBLE ASSETS (Details) Details http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables 31 false false R32.htm 9954488 - Disclosure - DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) Sheet http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) Details 32 false false R33.htm 9954489 - Disclosure - DEBT (Long-term debt) (Details) Sheet http://www.labcorp.com/role/DEBTLongtermdebtDetails DEBT (Long-term debt) (Details) Details 33 false false R34.htm 9954490 - Disclosure - DEBT (Senior Notes) (Details) Notes http://www.labcorp.com/role/DEBTSeniorNotesDetails DEBT (Senior Notes) (Details) Details 34 false false R35.htm 9954491 - Disclosure - DEBT (Credit Facilities) (Details) Sheet http://www.labcorp.com/role/DEBTCreditFacilitiesDetails DEBT (Credit Facilities) (Details) Details 35 false false R36.htm 9954492 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details) Sheet http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details) Details http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY 36 false false R37.htm 9954493 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details) Sheet http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details) Details 37 false false R38.htm 9954494 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIES 38 false false R39.htm 9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSTables 39 false false R40.htm 9954496 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details) Sheet http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details) Details 40 false false R41.htm 9954497 - Disclosure - BUSINESS ACQUISITIONS (Details) Sheet http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails BUSINESS ACQUISITIONS (Details) Details http://www.labcorp.com/role/BUSINESSACQUISITIONS 41 false false R42.htm 9954498 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment Information (Details) Sheet http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails BUSINESS SEGMENT INFORMATION Business Segment Information (Details) Details http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes 42 false false R43.htm 9954499 - Disclosure - REVENUE (Details) Sheet http://www.labcorp.com/role/REVENUEDetails REVENUE (Details) Details http://www.labcorp.com/role/REVENUETables 43 false false R44.htm 9954500 - Disclosure - REVENUE Disaggregated Revenue Table (Details) Sheet http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails REVENUE Disaggregated Revenue Table (Details) Details 44 false false R45.htm 9954501 - Disclosure - Subsequent Events (Details) Sheet http://www.labcorp.com/role/SubsequentEventsDetails Subsequent Events (Details) Details 45 false false R46.htm 9954502 - Disclosure - Discontinued Operations and Disposal Groups (Details) Sheet http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails Discontinued Operations and Disposal Groups (Details) Details http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroups 46 false false All Reports Book All Reports lh-20240630.htm lh-20240630.xsd lh-20240630_cal.xml lh-20240630_def.xml lh-20240630_lab.xml lh-20240630_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lh-20240630.htm": { "nsprefix": "lh", "nsuri": "http://www.labcorp.com/20240630", "dts": { "inline": { "local": ["lh-20240630.htm"] }, "schema": { "local": ["lh-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["lh-20240630_cal.xml"] }, "definitionLink": { "local": ["lh-20240630_def.xml"] }, "labelLink": { "local": ["lh-20240630_lab.xml"] }, "presentationLink": { "local": ["lh-20240630_pre.xml"] } }, "keyStandard": 261, "keyCustom": 44, "axisStandard": 21, "axisCustom": 4, "memberStandard": 33, "memberCustom": 31, "hidden": { "total": 7, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 269, "entityCount": 1, "segmentCount": 66, "elementCount": 627, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 821, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 9, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.labcorp.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-2", "name": "dei:EntityCommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:EntityInteractiveDataCurrent", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R2": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R3": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "lh:NetRestructuringAndOtherSpecialCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R5": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R6": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R7": { "role": "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName":

{"9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R8": { "role": "http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATION", "longName": "9952158 - Disclosure - BASIS OF FINANCIAL STATEMENT PRESENTATION", "shortName": "BASIS OF FINANCIAL STATEMENT PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.labcorp.com/role/EARNINGSPERSHARE", "longName": "9952159 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY", "longName": "9952163 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY", "shortName": "PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-5", "name": "lh:ChangesInCommonSharesIssuedAndHeldInTreasuryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "lh:ChangesInCommonSharesIssuedAndHeldInTreasuryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952165 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATION", "longName": "9952166 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.labcorp.com/role/BUSINESSACQUISITIONS", "longName": "9952167 - Disclosure - BUSINESS ACQUISITIONS", "shortName": "BUSINESS ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes", "longName": "9952169 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment information (Notes)", "shortName": "BUSINESS SEGMENT INFORMATION Business Segment information (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroups", "longName": "9952172 - Disclosure - Discontinued Operations and Disposal Groups", "shortName": "Discontinued Operations and Disposal Groups", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-5", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.labcorp.com/role/IntangibleAssetsGoodwillandOtherPolicies", "longName": "9954471 - Disclosure - Intangible Assets, Goodwill and Other (Policies)", "shortName": "Intangible Assets, Goodwill and Other (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://www.labcorp.com/role/RevenuefromContractwithCustomerPolicies", "longName": "9954472 - Disclosure - Revenue from Contract with Customer (Policies)", "shortName": "Revenue from Contract with Customer (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.labcorp.com/role/EARNINGSPERSHARETables", "longName": "9954473 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables", "longName": "9954476 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.labcorp.com/role/REVENUETables", "longName": "9954478 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "longName": "9954481 - Disclosure - BASIS OF FINANCIAL STATEMENT PRESENTATION (Details)", "shortName": "BASIS OF FINANCIAL STATEMENT PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lh:CostMethodInvestmentsMaximumOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R27": { "role": "http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails", "longName": "9954482 - Disclosure - EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details)", "shortName": "EARNINGS PER SHARE (Reconciliation of Basic

Earnings Per Share to Diluted Earnings Per Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.labcorp.com/role/EARNINGSPERSHAREPotentialcommonsharesnotincludedincomputationofdilutedearningspershareDetails", "longName": "9954483 - Disclosure - EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details)", "shortName": "EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "longName": "9954485 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R30": { "role": "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails", "longName": "9954486 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R31": { "role": "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "longName": "9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails", "longName": "9954488 - Disclosure - DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details)", "shortName": "DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "lh:CurrentDebtExcludingFinanceLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "lh:Shorttermdebtissuancecosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R33": { "role": "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "longName": "9954489 - Disclosure - DEBT (Long-term debt) (Details)", "shortName": "DEBT (Long-term debt) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "lh:A400SeniorNotesDue2023", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "lh:A155SeniorNotesDue2026", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R34": { "role": "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "longName": "9954490 - Disclosure - DEBT (Senior Notes) (Details)", "shortName": "DEBT (Senior Notes) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-228", "name": "lh:A270SeniorNotesDue2031", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R35": { "role": "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "longName": "9954491 - Disclosure - DEBT (Credit Facilities) (Details)", "shortName": "DEBT (Credit Facilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LineOfCreditFacilityCommitmentFeeDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R36": { "role": "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails", "longName": "9954492 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details)", "shortName": "PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R37": { "role": "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTableDetails", "longName": "9954493 - Disclosure - PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details)", "shortName": "PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R38": { "role": "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954494 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LossContingencyDamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LossContingencyDamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails", "longName": "9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "lh:FairValueLiabilitiesMeasuredOnRecurringBasisNoncontrollingInterestPuts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "lh:FairValueLiabilitiesMeasuredOnRecurringBasisNoncontrollingInterestPuts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails", "longName": "9954496 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION Description Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "lh:InterestPaidInCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "lh:InterestPaidInCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "longName": "9954497 - Disclosure - BUSINESS ACQUISITIONS (Details)", "shortName": "BUSINESS ACQUISITIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R42": { "role": "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "longName": "9954498 - Disclosure - BUSINESS SEGMENT INFORMATION Business Segment Information (Details)", "shortName": "BUSINESS SEGMENT INFORMATION Business Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-5", "name": "lh:PercentofRevenueContributed", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "lh:NetRestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R43": { "role": "http://www.labcorp.com/role/REVENUEDetails", "longName": "9954499 - Disclosure - REVENUE (Details)", "shortName": "REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredRevenueRevenueRecognized1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "longName": "9954500 - Disclosure - REVENUE Disaggregated Revenue Table (Details)", "shortName": "REVENUE Disaggregated Revenue Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "lh:UnbilledServicesAllowanceforCreditLoss", "unitRef": "usd", "xsiNil": "false",

```
"lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lh-20240630.htm", "unique": true } }, "R45": { "role": "http://www.labcorp.com/role/SubsequentEventsDetails", "longName": "9954501 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Dividends", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails", "longName": "9954502 - Disclosure - Discontinued Operations and Disposal Groups (Details)", "shortName": "Discontinued Operations and Disposal Groups (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "lh-20240630.htm", "first": true, "unique": true } } }, "tag": { "lh_A155SeniorNotesDue2026": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A155SeniorNotesDue2026", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.55% senior notes due 2026", "label": "1.55% senior notes due 2026", "documentation": "1.55% senior notes due 2026" } } }, "auth_ref": [] }, "lh_A2.95seniornotesdue2029": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A2.95seniornotesdue2029", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.95% senior notes due 2029", "label": "2.95% senior notes due 2029", "documentation": "2.95% senior notes due 2029" } } }, "auth_ref": [] }, "lh_A2018SwapAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A2018SwapAgreementsMember", "presentation": [ "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Swap Agreements", "label": "2018 Swap Agreements [Member]", "documentation": "2018 Swap Agreements" } } }, "auth_ref": [] }, "lh_A2022SwapAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A2022SwapAgreementsMember", "presentation": [ "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Swap Agreements", "label": "2022 Swap Agreements [Member]", "documentation": "2022 Swap Agreements" } } }, "auth_ref": [] }, "lh_A270SeniorNotesDue2031": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A270SeniorNotesDue2031", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.70% senior notes due 2031", "label": "2.70% senior notes due 2031", "documentation": "2.70% senior notes due 2031" } } }, "auth_ref": [] }, "lh_A325SeniorNotesDue2024": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A325SeniorNotesDue2024", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.25% senior notes due 2024", "label": "3.25% senior notes due 2024", "documentation": "3.25% senior notes due 2024" } } }, "auth_ref": [] }, "lh_A360SeniorNotesDue2025": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A360SeniorNotesDue2025", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.60% senior notes due 2025", "label": "3.60% senior notes due 2025", "documentation": "3.60% senior notes due 2025" } } }, "auth_ref": [] }, "lh_A360SeniorNotesDue2027": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A360SeniorNotesDue2027", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.60% senior notes due 2027", "label": "3.60% senior notes due 2027", "documentation": "3.60% senior notes due 2027" } } }, "auth_ref": [] }, "lh_A400SeniorNotesDue2023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A400SeniorNotesDue2023", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.00% senior notes due 2023", "label": "4.00% senior notes due 2023", "documentation": "4.00% senior notes due 2023" } } }, "auth_ref": [] }, "lh_A470SeniorNotesDue2045": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "A470SeniorNotesDue2045", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.70% senior notes due 2045", "label": "4.70% senior notes due 2045", "documentation": "4.70% senior notes due 2045" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r331", "r988" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable, Current", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r90", "r828" ] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "presentation": [ "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, before Allowance for Credit Loss", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r219", "r330", "r331", "r1066" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r758" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r987" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities, Current", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities [Member]", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r93" ] }, "lh_AccumulatedOtherComprehensiveEarningsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "AccumulatedOtherComprehensiveEarningsRollForward", "presentation": [ "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Earnings [Roll Forward]", "label": "Accumulated Other Comprehensive Earnings [Roll Forward]", "documentation": "Accumulated Other Comprehensive Earnings [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "presentation": [ "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "periodStartLabel": "Net Benefit Plan Adjustments, Beginning balance", "periodEndLabel": "Net Benefit Plan Adjustments, Ending balance", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r5", "r24", "r109", "r1037" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "periodStartLabel": "Foreign Currency Translation Adjustments, Beginning balance", "periodEndLabel": "Foreign Currency Translation Adjustments, Ending balance", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": [ "r226", "r227", "r228", "r229", "r545" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r237", "r552", "r554", "r555", "r556", "r557", "r559" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities and shareholders' equity", "periodStartLabel": "Accumulated Other Comprehensive Earnings, Beginning balance", "periodEndLabel": "Accumulated Other Comprehensive Earnings, Ending balance", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r110", "r221", "r621", "r661", "r665" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTable"
], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r236", "r237", "r552", "r554", "r555",
"r556", "r557", "r559"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTable"
], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation":
"Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income
(loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r16", "r24", "r513",
"r516", "r569", "r656", "r657", "r963", "r964", "r965", "r973", "r974", "r975", "r977"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful
Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible
assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": ["r366", "r772"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r895"] }, "us-
gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock",
"crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related
transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes
preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r103"] }, "us-
gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember",
"presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the
entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r675", "r973", "r974", "r975", "r977",
"r1045", "r1101"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation
Amount" } } }, "auth_ref": ["r908"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to
Compensation [Axis]" } } }, "auth_ref": ["r908"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to
Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r908"] },
"ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO
Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r908"] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit",
"presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Stock compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional
paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r46", "r47", "r450"] }, "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile
net earnings to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
} } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of
Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r941"] }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r867", "r877",
"r887", "r919"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate
Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r870", "r880", "r890",
"r922"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate
Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r942"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r908"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r915"] }, "ecd_AllIndividualsMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r871", "r881",
"r891", "r915", "r923", "r927", "r935"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading
Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r933"] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": [
"http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "label":
"Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } },
"auth_ref": ["r159", "r990"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals",
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss",
"label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r222", "r332",
"r342", "r343", "r344", "r1066"] }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"
], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for Credit Loss, Receivable, Other, Current", "label": "Allowance for Credit Loss, Receivable, Other, Current",
"documentation": "Amount of allowance for credit loss on receivable, classified as other and current." } } }, "auth_ref": ["r220"] }, "lh_AllowanceforCreditLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "AllowanceforCreditLoss", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Credit Loss", "label": "Allowance for
Credit Loss", "documentation": "Allowance for Credit Loss" } } }, "auth_ref": [] }, "lh_AllowanceforCreditLossWriteOff": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.labcorp.com/20240630", "localname": "AllowanceforCreditLossWriteOff", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Credit Loss, Write Off", "label":
"Allowance for Credit Loss, Write Off", "documentation": "Allowance for Credit Loss, Write Off" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel":
"Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } },
"auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
"parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangibles and other assets",
"verboseLabel": "Amortization of intangible assets", "negatedTerseLabel": "Amortization of Intangible Assets", "label": "Amortization of Intangible Assets", "documentation":
"The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to
the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations
using the indirect method." } } }, "auth_ref": ["r12", "r363", "r370", "r796"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREPotentialcommonsharesnotincludedincomputationofdilutedearningspersharedetails"], "lang": { "en-us":
{ "role": { "terseLabel": "Stock options (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities
(including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that
were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period
presented." } } }, "auth_ref": ["r287"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
"parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment
Charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses
from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r12", "r35"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r148", "r158", "r214", "r251", "r291", "r299", "r318", "r322", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r505", "r510", "r546", "r619", "r711", "r789", "r790", "r828", "r858", "r1028", "r1029", "r1058"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r208", "r225", "r251", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r505", "r510", "r546", "r828", "r1028", "r1029", "r1058"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "verboseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExcrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r930"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r931"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r926"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r926"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r926"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r926"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r926"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r926"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r929"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r928"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r927"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r927"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r378", "r1070", "r1071"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r62", "r64", "r378", "r1070", "r1071"] }, "lh_BaystateMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "BaystateMedicalCenterMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Baystate Medical Center", "label": "Baystate Medical Center [Member]", "documentation": "Baystate Medical Center" } } }, "auth_ref": [] }, "lh_BioReferenceHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "BioReferenceHealthMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "BioReference Health", "label": "BioReference Health [Member]", "documentation": "BioReference Health" } } }, "auth_ref": [] }, "lh_Biopharmaceuticalandmedicaldevicecompanies Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "BiopharmaceuticalandmedicaldevicecompaniesMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Biopharmaceutical and medical device companies [Member]", "label": "Biopharmaceutical and medical device companies [Member]", "documentation": "Biopharmaceutical and medical device companies [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r364", "r365", "r366", "r367", "r368", "r500", "r814", "r815"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r48", "r49", "r364", "r365", "r366", "r367", "r368", "r500", "r814", "r815"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r500"] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r497", "r498"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r497", "r498"] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONS"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination Disclosure [Text Block]", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r143", "r501"] }, "us-gaap_BusinessCombinationPriceOfAcquisitionExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationPriceOfAcquisitionExpected", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Price of Acquisition, Expected", "label": "Business Combination, Price of Acquisition, Expected", "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition." } } }, "auth_ref": ["r951"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialAssets", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial assets acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to financial

liabilities assumed in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": ["r52"] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsRelatedToPreviousPeriod", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period", "documentation": "Amount of increase (decrease) in income that would have been recognized in previous periods if the adjustments to provisional amounts were recognized as of the acquisition date." } } }, "auth_ref": ["r499"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r50", "r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": ["r50", "r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r50", "r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r50", "r51"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r51"] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Acquired in Excess of Payments to Acquire Business", "label": "Cash Acquired in Excess of Payments to Acquire Business", "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r210", "r778"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Less: Cash and cash equivalents of discontinued operations at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal

Group, Including Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r128", "r249"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r128", "r249"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r128"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-cash financing and investing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": ["http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r123"] }, "lh_CashPaidDuringPeriodForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CashPaidDuringPeriodForAbstract", "presentation": ["http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during period for:", "label": "Cash Paid During Period For [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by discontinued financing activities", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r128"] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net cash used for discontinued investing activities", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r85", "r128"] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by discontinued operating activities", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r85", "r128"] }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Surrender Value, Fair Value Disclosure", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, "auth_ref": ["r1046", "r1047", "r1048", "r1049", "r1050", "r1051"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r906"] }, "lh_ChangesInCommonSharesIssuedAndHeldInTreasuryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ChangesInCommonSharesIssuedAndHeldInTreasuryTableTextBlock", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Changes in common shares issued and held in treasury", "label": "Changes In Common Shares Issued And Held In Treasury [Table Text Block]", "documentation": "Schedule is used to show the changes in common shares issued and held in treasury by the entity." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r903"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r901"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r164", "r216", "r217", "r218", "r251", "r273", "r277", "r284", "r286", "r293", "r294", "r337", "r390", "r393", "r394", "r395", "r399", "r400", "r419", "r420", "r423", "r426", "r433", "r546", "r669", "r670", "r671", "r672", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r699", "r720", "r737", "r751", "r752", "r753", "r754", "r755", "r945", "r969", "r978"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r216", "r217", "r218", "r293", "r419", "r420", "r421", "r423", "r426", "r431", "r433", "r669", "r670", "r671", "r672", "r803", "r945", "r969"] }, "lh_ClientMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ClientMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Client [Member]", "label": "Client [Member]", "documentation": "Client [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r907"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r907"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIES"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r137", "r381", "r382", "r759", "r1015", "r1020"] }, "lh_CommonSharesHeldInTreasuryRollforwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CommonSharesHeldInTreasuryRollforwardAbstract", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rollforward of common shares held in treasury", "label": "Common Shares Held In Treasury Rollforward [Abstract]" } } }, "auth_ref": [] }, "lh_CommonSharesIssuedRollforwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CommonSharesIssuedRollforwardAbstract", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rollforward of common shares issued", "label": "Common Shares Issued Rollforward [Abstract]" } } }, "auth_ref": [] }, "lh_CommonSharesOutstandingRollforwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CommonSharesOutstandingRollforwardAbstract", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares Outstanding Rollforward [Abstract]", "label": "Common Shares Outstanding Rollforward [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]",

"label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r846", "r847", "r848", "r850", "r851", "r852", "r855", "r973", "r974", "r977", "r1045", "r1100", "r1101"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r101"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r101", "r699"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Common shares issued, beginning balance (in shares)", "periodEndLabel": "Common shares issued, ending balance (in shares)", "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r101"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Common shares outstanding, beginning balance (in shares)", "periodEndLabel": "Common shares outstanding, ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r17", "r101", "r699", "r717", "r1101", "r1102"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r101", "r620", "r828"] }, "lh_CommonsStockIssuedDuringPeriodSharesEmployeeStockPlans": { "xbrltype": "sharesItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CommonsStockIssuedDuringPeriodSharesEmployeeStockPlans", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commons Stock Issued During Period Shares Employee Stock Plans", "label": "Commons Stock Issued During Period Shares Employee Stock Plans", "documentation": "Number of common shares issued during the period as a result of an employee stock purchase plan and/or stock option plan." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r912"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r911"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r913"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r910"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive earnings attributable to Laboratory Corporation of America Holdings", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r25", "r233", "r235", "r242", "r615", "r632", "r633"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive earnings", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r61", "r145", "r233", "r235", "r241", "r614", "r632"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r156", "r165", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r252", "r291", "r301", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r789", "r790", "r957", "r958", "r1028", "r1029"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r156", "r165", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r252", "r291", "r301", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r789", "r790", "r957", "r958", "r1028", "r1029"] }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Classified as Equity, Fair Value Disclosure", "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure", "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity." } } }, "auth_ref": ["r1046", "r1047", "r1051"] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset and Liability [Table Text Block]", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r1034"] }, "us-gaap_ContractWithCustomerAssetGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetGross", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset, before Allowance for Credit Loss", "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r160", "r345", "r1032", "r1033"] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r435", "r437", "r439"] }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerBasisOfPricingAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Basis of Pricing [Axis]", "label": "Contract with Customer, Basis of Pricing [Axis]", "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer." } } }, "auth_ref": ["r807", "r1035"] }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerBasisOfPricingDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Basis of Pricing [Domain]", "label": "Contract with Customer, Basis of Pricing [Domain]", "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts." } } }, "auth_ref": ["r807", "r1035"] }, "us-gaap_ContractWithCustomerDurationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerDurationAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Duration [Axis]", "label": "Contract with Customer, Duration [Axis]", "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": ["r808", "r1035"] }, "us-gaap_ContractWithCustomerDurationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerDurationDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Duration [Domain]", "label": "Contract with Customer, Duration [Domain]", "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": ["r808", "r1035"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r435", "r436", "r439"] }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel [Axis]", "label": "Contract with Customer, Sales Channel [Axis]", "documentation": "Information by sales channel for delivery of good or service in contract with customer." } } }, "auth_ref": ["r810", "r1035"] }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel [Domain]", "label": "Contract with Customer, Sales Channel [Domain]", "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to

consumer and through intermediary." } } }, "auth_ref": ["r810", "r1035"] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate Segment [Member]", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r981"] }, "lh_CostMethodInvestmentsMaximumOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CostMethodInvestmentsMaximumOwnershipPercentage", "presentation": [
"http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)", "label": "Cost Method Investments Maximum Ownership Percentage", "documentation": "This element represents the maximum ownership percentage of cost-method investments held by the Company. Generally, such investments do not have readily determinable fair values and are not required to be accounted for by the equity method. The carrying amount of such securities equates to cost, adjusted for other-than-temporary impairment." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r116", "r251", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r546", "r789", "r1028"] },
"lh_CovanceDrugDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CovanceDrugDevelopmentMember", "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails",
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails",
"http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Covance Drug Development [Member]", "label": "Covance Drug Development [Member]", "documentation": "Covance Drug Development [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r389", "r1026"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r389", "r1026", "r1027"] }, "lh_CreditFacilityMaximumLettersofCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CreditFacilityMaximumLettersofCredit", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Maximum Letters of Credit", "label": "Credit Facility, Maximum Letters of Credit", "documentation": "Credit Facility, Maximum Letters of Credit" } } }, "auth_ref": [] }, "lh_CreditFacilityMaximumSwingLineBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CreditFacilityMaximumSwingLineBorrowings", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails",
"http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility, Maximum Swing Line Borrowings", "label": "Credit Facility, Maximum Swing Line Borrowings", "documentation": "Credit Facility, Maximum Swing Line Borrowings" } } }, "auth_ref": [] }, "lh_CreditFacilityOptiontoIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CreditFacilityOptiontoIncrease", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility Option to Increase", "label": "Credit Facility Option to Increase", "documentation": "Credit Facility Option to Increase" } } }, "auth_ref": [] },
"lh_CurrentDebtExcludingFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CurrentDebtExcludingFinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current debt excluding finance lease liability", "label": "Current debt excluding finance lease liability", "documentation": "Current debt excluding finance lease liability" } } }, "auth_ref": [] },
"lh_CurrentExpectedCreditLossesOpeningBalanceSheetImpactonRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "CurrentExpectedCreditLossesOpeningBalanceSheetImpactonRetainedEarnings", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings", "label": "Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings", "documentation": "Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings" } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerListsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerListsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Lists", "label": "Customer Lists [Member]", "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information." } } }, "auth_ref": ["r54", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1013", "r1014"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships [Member]", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r55", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1013", "r1014"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails",
"http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r21", "r92", "r93", "r149", "r150", "r252", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r798", "r799", "r800", "r801", "r802", "r827", "r970", "r1016", "r1017", "r1018", "r1056", "r1057"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r252", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r798", "r799", "r800", "r801", "r802", "r827", "r970", "r1056", "r1057"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails",
"http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r21", "r252", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r798", "r799", "r800", "r801", "r802", "r827", "r970", "r1016", "r1017", "r1018", "r1056", "r1057"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r21", "r40", "r43", "r66", "r140", "r141", "r252", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r798", "r799", "r800", "r801", "r802", "r827", "r970", "r1056", "r1057"] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Compensation Plan Assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [
"r960"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r12", "r162", "r972"] }, "lh_DeferredIncomeTaxesAndOtherTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DeferredIncomeTaxesAndOtherTaxLiabilities", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other tax liabilities", "label": "Deferred income taxes and other tax liabilities", "documentation": "Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax, combined with the noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue,

Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r962"] }, "us-gaap_DeferredRevenueRevenueRecognized1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueRevenueRecognized1", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/REVENUEDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Revenue Recognized", "label": "Deferred Revenue, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } }, "auth_ref": [] }, "lh_DepreciationAndAmortizationOfLeasedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DepreciationAndAmortizationOfLeasedAssets", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset expense", "label": "Depreciation And Amortization Of Leased Assets", "documentation": "The amount of depreciation recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Also, may include amortization charged against earnings for the periodic recognition of capitalized leases." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r12", "r291", "r304", "r322", "r789", "r790"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": ["http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": ["r18", "r63", "r65"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1043", "r1044"] }, "lh_DiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DiagnosticsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diagnostics", "label": "Diagnostics [Member]", "documentation": "Diagnostics [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r438", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r438", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table Text Block]", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1035"] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r73", "r74", "r75", "r76", "r77", "r83", "r114", "r1067"] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operation, Tax Effect of Discontinued Operation", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": ["r74", "r75", "r76", "r77", "r83", "r87", "r480", "r486", "r488"] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84", "r207"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84"] }, "lh_DisposalGroupIncludingDiscontinuedOperationFortreaCreditFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationFortreaCreditFacilities", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities", "label": "Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities", "documentation": "Disposal Group, Including Discontinued Operation, Fortrea Credit Facilities" } } }, "auth_ref": [] }, "lh_DisposalGroupIncludingDiscontinuedOperationFortreaDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationFortreaDistribution", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Fortrea Distribution", "label": "Disposal Group, Including Discontinued Operation, Fortrea Distribution", "documentation": "Disposal Group, Including Discontinued Operation, Fortrea Distribution" } } }, "auth_ref": [] }, "lh_DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotes", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes", "label": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes", "documentation": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes" } } }, "auth_ref": [] }, "lh_DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotesInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationFortreaSeniorNotesInterestRate", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate", "label": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate", "documentation": "Disposal Group, Including Discontinued Operation, Fortrea Senior Notes Interest Rate" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84", "r207"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84"] }, "lh_DisposalGroupIncludingDiscontinuedOperationRestructuringAndOtherCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringAndOtherCharges", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Restructuring and other charges", "label": "Disposal Group, Including Discontinued Operation, Restructuring and other charges", "documentation": "Disposal

Group, Including Discontinued Operation, Restructuring and other charges" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Revenue", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r84", "r207"] }, "lh_DisposalGroupIncludingDiscontinuedOperationsOtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationsOtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense)", "label": "Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense)", "documentation": "Disposal Group, Including Discontinued Operations, Other Nonoperating income (expense)" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroups"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r68", "r135"] }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendPayableDateToBePaidDayMonthAndYear", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable, Date to be Paid", "label": "Dividends Payable, Date to be Paid", "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format." } } }, "auth_ref": ["r30"] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails", "http://www.labcorp.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": ["r10", "r142"] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCash", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends, Cash", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": ["r10", "r142"] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableAmountPerShare", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable, Amount Per Share", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": ["r30"] }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable, Date Declared", "label": "Dividends Payable, Date Declared", "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format." } } }, "auth_ref": ["r30"] }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable, Date of Record", "label": "Dividends Payable, Date of Record", "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document [Domain]", "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Information, Document [Axis]", "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r862"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r894"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "lh_DrugDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "DrugDevelopmentMember", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Drug Development", "label": "Drug Development [Member]", "documentation": "Covance Drug Development [Member]" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r905"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r243", "r258", "r259", "r261", "r262", "r263", "r265", "r271", "r273", "r284", "r285", "r286", "r290", "r495", "r503", "r521", "r522", "r616", "r634", "r782"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r243", "r258", "r259", "r261", "r262", "r263", "r265", "r273", "r284", "r285", "r286", "r290", "r495", "r503", "r521", "r522", "r616", "r634", "r782"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHARE"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r270", "r287", "r288", "r289"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1053"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "lh_EnhancedDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "EnhancedDamagesMember", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Enhanced Damages", "label": "Enhanced Damages [Member]", "documentation": "Enhanced Damages" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": {

```
"terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode",
"presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip
Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A
unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r860" ] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
"presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common
Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other
ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as
Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref":
[] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90
days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.labcorp.com/role/NONCONTROLLINGINTERESTPUTSDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure
used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This
item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation":
[ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r860" ] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us":
{ "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may
contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref":
[] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate
whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the
Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r860" ] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or
Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent",
"presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data
Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r944" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The
exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r860" ] }, "dei_EntityShellCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang":
{ "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company
as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r860" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel":
"Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r860" ] },
"dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber",
"presentation": [ "http://www.labcorp.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification
Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } }
}, "auth_ref": [ "r860" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote",
"label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r899" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
"label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r940" ] }, "ecd_EqtyAwrdsAdjsMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r940" ] },
"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate
Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in
Summary Compensation Table [Member]" } } }, "auth_ref": [ "r940" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of
the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r204", "r236", "r237",
"r238", "r253", "r254", "r255", "r257", "r263", "r266", "r268", "r292", "r338", "r341", "r376", "r434", "r484", "r485", "r492", "r493", "r494", "r496", "r502", "r503", "r512",
"r513", "r514", "r515", "r516", "r517", "r520", "r552", "r554", "r555", "r556", "r557", "r559", "r563", "r565", "r569", "r631", "r656", "r657", "r658", "r675", "r737" ] },
"srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain",
"presentation": [ "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]",
"label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r334",
"r335", "r336", "r491", "r947", "r948", "r949", "r1039", "r1040", "r1041", "r1042" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation
Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r909" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r867", "r877", "r887", "r919" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded
Compensation Recovery [Table]" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Escrow Deposit", "label": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the
borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest
money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [
"r147", "r760" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel":
"Europe [Member]", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r953", "r954", "r955", "r956", "r1103", "r1104", "r1105",
"r1106" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r915" ]
}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Financial
Statement Captions [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": [ "r524", "r525", "r538", "r820" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis [Table]",
"label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and
nonrecurring basis." } } }, "auth_ref": [ "r524", "r525", "r538", "r820" ] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]",
"documentation": "Class of asset." } } }, "auth_ref": [ "r529", "r530", "r531", "r532", "r533", "r534", "r539", "r822" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]",
"documentation": "Information by class of asset." } } }, "auth_ref": [ "r529", "r530", "r531", "r532", "r533", "r534", "r539", "r822" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information
```

by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r409", "r441", "r442", "r443", "r444", "r445", "r446", "r523", "r525", "r526", "r527", "r528", "r537", "r538", "r540", "r571", "r572", "r573", "r799", "r800", "r811", "r812", "r813", "r820", "r823"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r529", "r530", "r531", "r532", "r533", "r534", "r539"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTS"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r533", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544", "r611", "r820", "r824"] }, "us-gaap_FairValueHedgesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgesAtFairValueNet", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges, Net", "label": "Fair Value Hedges, Net", "documentation": "Net fair value of all derivative instruments designated as fair value hedging instruments." } } }, "auth_ref": ["r13"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r409", "r441", "r446", "r525", "r538", "r571", "r811", "r812", "r813", "r820"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r409", "r441", "r446", "r525", "r526", "r538", "r572", "r799", "r800", "r811", "r812", "r813", "r820"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r409", "r441", "r442", "r443", "r444", "r445", "r446", "r525", "r526", "r527", "r528", "r538", "r573", "r799", "r800", "r811", "r812", "r813", "r820", "r823"] }, "lh_FairValueLiabilitiesMeasuredOnRecurringBasisDeferredCompensationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDeferredCompensationLiability", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability", "label": "Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability", "documentation": "Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability" } } }, "auth_ref": [] }, "lh_FairValueLiabilitiesMeasuredOnRecurringBasisNoncontrollingInterestPuts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisNoncontrollingInterestPuts", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest puts", "label": "Fair Value Liabilities Measured On Recurring Basis Noncontrolling Interest Puts", "documentation": "This element represents a certain statement of financial position liability caption which represents a class of liabilities, or which may include an individual liability, measured at fair value on a recurring basis." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSTables"], "lang": { "en-us": { "role": { "terseLabel": "Company's population of financial assets and liabilities subject to fair value measurements", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": ["r1046", "r1047"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r529", "r530", "r531", "r532", "r533", "r534", "r539"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r409", "r441", "r442", "r443", "r444", "r445", "r446", "r523", "r525", "r526", "r527", "r528", "r537", "r538", "r540", "r571", "r572", "r573", "r799", "r800", "r811", "r812", "r813", "r820", "r823"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r566"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r566"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r212", "r348", "r369", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1011", "r1107"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, 2012", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r371", "r772", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, 2016", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r371", "r772", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, 2015", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r371", "r772", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, 2014", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r371", "r772", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated amortization expense, 2013", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r371", "r772", "r796"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",

```
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [
"r362", "r364", "r365", "r366", "r368", "r369", "r373", "r374", "r579", "r580", "r772" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label":
"Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r362", "r369", "r373", "r374", "r375", "r579", "r772", "r796" ] },
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name
[Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents,
trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the
operations of a company." } } }, "auth_ref": [ "r362", "r364", "r365", "r366", "r368", "r369", "r373", "r374", "r772" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets Acquired", "label": "Finite-Lived
Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." }
} }, "auth_ref": [ "r364" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.labcorp.com/role/DEBTSeniorNotesDetails",
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Contract, Asset, Fair Value Disclosure",
"label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies,
including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [ "r524", "r525" ] }, "us-
gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
"documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward
(delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [ "r524", "r525" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label":
"Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r871", "r881", "r891", "r923" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone
Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r871", "r881", "r891", "r923" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r871",
"r881", "r891", "r923" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r871", "r881",
"r891", "r923" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } },
"auth_ref": [ "r871", "r881", "r891", "r923" ] }, "lh_FortreaCreditFacilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname":
"FortreaCreditFacilitiesAxis", "presentation": [ "http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Credit Facility [Axis]", "label": "Fortrea Credit Facilities [Axis]", "documentation": "Fortrea Credit Facilities" } } }, "auth_ref": [] }, "lh_FortreaCreditFacilitiesDomain": {
"xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "FortreaCreditFacilitiesDomain", "presentation": [
"http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fortrea Credit Facilities [Domain]", "label":
"Fortrea Credit Facilities [Domain]", "documentation": "Fortrea Credit Facilities [Domain]" } } }, "auth_ref": [] }, "lh_FortreaRevolverDue2028Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "FortreaRevolverDue2028Member", "presentation": [
"http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fortrea Revolver due 2028", "label": "Fortrea
Revolver due 2028 [Member]", "documentation": "Fortrea Revolver due 2028" } } }, "auth_ref": [] }, "lh_FortreaTermLoanAMaturing2028Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "FortreaTermLoanAMaturing2028Member", "presentation": [
"http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fortrea Term Loan A maturing 2028", "label":
"Fortrea Term Loan A maturing 2028 [Member]", "documentation": "Fortrea Term Loan A maturing 2028" } } }, "auth_ref": [] },
"lh_FortreaTermLoanBMaturing2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname":
"FortreaTermLoanBMaturing2028Member", "presentation": [ "http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fortrea Term Loan B maturing 2028", "label": "Fortrea Term Loan B maturing 2028 [Member]", "documentation": "Fortrea Term Loan B maturing 2028" } } },
"auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to
Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting
Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r904" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Gain (Loss) on Disposition of Business", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and
disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic
benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r509", "r968" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag":
"us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "netLabel": "Goodwill, net", "periodStartLabel": "Balance as of
January 1", "periodEndLabel": "Balance at end of period", "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset
representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and
separately recognized." } } }, "auth_ref": [ "r211", "r350", "r612", "r790", "r795", "r821", "r828", "r993", "r1000" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill,
Acquired During Period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from
other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [
"r353", "r795" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other asset
impairments", "negatedTerseLabel": "Goodwill and Intangible Asset Impairment", "label": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss
recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible
assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
"label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/IntangibleAssetsGoodwillandOtherPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy",
"label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may
address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of
the reporting units are determined." } } }, "auth_ref": [ "r349", "r361", "r795" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillLineItems", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line
Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358",
"r359", "r360", "r361", "r795" ] }, "us-gaap_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillMember",
"presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Member]", "label": "Goodwill
[Member]", "documentation": "Asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both,
that is not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillRollForward", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll
Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },
"auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to goodwill", "label": "Goodwill,
Translation and Measurement Period Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation and measurement period adjustments
of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually
```

identified and separately recognized." } } }, "auth_ref": ["r0", "r992"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Gross Profit", "totalLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r111", "r116", "r157", "r251", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r546", "r784", "r789", "r980", "r982", "r983", "r984", "r985", "r1028"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": ["http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r18"] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "documentation": "The name of the impaired assets to be held and used by the entity." } } }, "auth_ref": ["r36"] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "documentation": "Information by type of impaired long-lived asset held and used." } } }, "auth_ref": ["r36"] }, "lh_InProcessRAAndMediaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "InProcessRAAndMediaMember", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "In Process R&A and Media", "label": "In Process R&A and Media [Member]", "documentation": "In Process R&A and Media" } } }, "auth_ref": [] }, "lh_IncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "IncomeAbstract", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income [Abstract]", "label": "Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r58", "r113", "r130", "r258", "r259", "r261", "r262", "r263", "r282", "r286", "r503"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r145", "r157", "r251", "r256", "r263", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r495", "r503", "r522", "r546", "r626", "r784", "r980", "r982", "r983", "r984", "r985", "r1028"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations, Per Basic Share", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r113", "r153", "r243", "r256", "r258", "r259", "r261", "r262", "r263", "r273", "r284", "r285", "r495", "r503", "r522", "r616", "r1068"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r113", "r243", "r256", "r258", "r259", "r261", "r262", "r263", "r273", "r284", "r285", "r286", "r503", "r522", "r616", "r1068"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Earnings from discontinued operations, net of tax", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r73", "r74", "r75", "r76", "r77", "r87", "r207", "r490", "r627"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r73", "r74", "r75", "r76", "r77", "r83", "r87", "r145"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity method income, net", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r12", "r112", "r152", "r291", "r306", "r322", "r333", "r625"] }, "lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Earnings before income taxes", "totalLabel": "Earnings before income taxes", "label": "Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest", "documentation": "Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.labcorp.com/role/DiscontinuedOperationsandDisposalGroupsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r15", "r19", "r22", "r69", "r78", "r79", "r80", "r81", "r82", "r86", "r88", "r89", "r136"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r161", "r163", "r267", "r268", "r291", "r307", "r322", "r480", "r481", "r486", "r635", "r817"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income taxes, net of refunds", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r29", "r248", "r482", "r483"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [

```
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Accounts Payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Accounts Receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accrued expenses and other", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r967" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Deferred Revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r773" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in assets and liabilities (net of effects of acquisitions and divestitures):", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase (Decrease) in Prepaid Expense and Other Assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r11" ] }, "lh_IncreaseDecreaseinUnbilledContractReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "IncreaseDecreaseinUnbilledContractReceivable", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Unbilled Contract Receivable", "label": "Increase (Decrease) in Unbilled Contract Receivable", "documentation": "Increase (Decrease) in Unbilled Contract Receivable" } } }, "auth_ref": [] }, "lh_IncreaseInCapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "IncreaseInCapitalExpendituresIncurredButNotYetPaid", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in Capital Expenditures Incurred but not yet Paid", "label": "Increase in Capital Expenditures Incurred but not yet Paid", "documentation": "Increase in Capital Expenditures Incurred but not yet Paid" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [
"http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of employee stock options and awards, (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r274", "r275", "r276", "r286", "r451" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r362", "r367", "r372", "r796" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r362", "r367", "r372", "r796" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PypDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r871", "r881", "r891", "r915", "r923", "r927", "r935" ] }, "lh_InitialDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "InitialDamagesMember", "presentation": [
"http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Damages", "label": "Initial Damages [Member]", "documentation": "Initial Damages" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r933" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r863", "r939" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r863", "r939" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r863", "r939" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r211" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r362", "r1010", "r1012" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r291", "r299", "r303", "r309", "r322", "r561", "r789", "r790" ] }, "lh_InterestPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "InterestPaidInCash", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONDescriptionInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid In Cash", "documentation": "The amount of cash paid during the current period for interest owed on money borrowed" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [
"http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap [Member]", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r775", "r853", "r854" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r156", "r291", "r301", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r789" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r223", "r779", "r828" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag":
```

"lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Investment income",
"label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend
income on nonoperating securities." } } }, "auth_ref": ["r119", "r120", "r121"] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Joint venture partnerships and equity
method investments", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity
method investee and investment in and advance to affiliate." } } }, "auth_ref": ["r961"] }, "lh_InvitaeCorporationMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.labcorp.com/20240630", "localname": "InvitaeCorporationMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Invitae Corporation", "label": "Invitae Corporation [Member]", "documentation": "Invitae Corporation" } } }, "auth_ref": [] },
"lh_Issuanceofcommonstockunderemployeeplans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname":
"Issuanceofcommonstockunderemployeeplans", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Issuance of common stock under employee stock plans", "label": "Issuance of common stock under employee plans", "documentation": "Aggregate
change in value for stock issued in period under ESPP combined with the value of stock issued as a result of option exercises." } } }, "auth_ref": [] },
"lh_KerriiAndersonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "KerriiAndersonMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Kerrii Anderson [Member]", "documentation": "Kerrii Anderson" } } },
"auth_ref": [] }, "lh_LabCorpDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "LabCorpDiagnosticsMember",
"presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails",
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails",
"http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "LabCorp Diagnostics [Member]", "label": "LabCorp Diagnostics [Member]",
"documentation": "LabCorp Diagnostics [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LegalEntityAxis", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.labcorp.com/role/NONCONTROLLINGINTERESTPUTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit Outstanding, Amount", "label": "Letters of Credit
Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] },
"us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order":
2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Noncontrolling
interest", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." }
} }, "auth_ref": ["r21", "r92", "r93", "r94", "r96", "r97", "r98", "r99", "r251", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r506", "r510",
"r511", "r546", "r698", "r783", "r858", "r1028", "r1058", "r1059"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Liabilities and Equity", "label":
"Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } },
"auth_ref": ["r107", "r151", "r623", "r828", "r971", "r989", "r1052"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND
SHAREHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Long-term debt, less current portion",
"label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or
within one business cycle, if longer." } } }, "auth_ref": ["r94", "r209", "r251", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r506", "r510",
"r511", "r546", "r828", "r1028", "r1058", "r1059"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Liabilities, Current [Abstract]", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails",
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Canadian licenses [Member]", "label": "Licensing
Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or
processes in a specified territory)." } } }, "auth_ref": ["r56", "r479", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1012", "r1013", "r1014", "r1038"] }, "us-
gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]",
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of
entities that participate in the line of credit." } } }, "auth_ref": ["r91", "r95", "r970", "r1026", "r1027"] }, "us-gaap_LineOfCreditFacilityCommitmentFeeDescription": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeDescription", "presentation": [
"http://www.labcorp.com/role/DEBTCreditFacilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Commitment Fee Description", "label": "Line of
Credit Facility, Commitment Fee Description", "documentation": "Description of the fees for amounts available, but unused under the credit facility." } } }, "auth_ref": ["r91",
"r95"] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line
of Credit Facility, Interest Rate at Period End", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the
reporting period." } } }, "auth_ref": ["r91", "r95"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails",
"http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for
example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r91",
"r95", "r970", "r1026"] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityLineItems", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit
Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r389", "r970", "r1026"] }, "us-
gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails",
"http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel":
"Revolving Credit Facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity
under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } }
}, "auth_ref": ["r91", "r95"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityTable", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility
[Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under
which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } },
"auth_ref": ["r91", "r95", "r389", "r970", "r1026"] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LinesOfCreditCurrent", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Line of Credit, Current", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current
portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in
the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a
maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term
obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term
obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a
long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively
determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the
agreement." } } }, "auth_ref": ["r92", "r149"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LocalPhoneNumber", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone
Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Long-term Debt, Excluding Current Maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized
premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r215"] }, "us-
gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit",
"presentation": ["http://www.labcorp.com/role/DEBTLongtermdebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable, Noncurrent", "label": "Notes Payable,
Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if
longer), excluding current portion." } } }, "auth_ref": ["r21"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongtermDebtTypeAxis", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails",
"http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel":

"Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r21", "r1016", "r1017", "r1018"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r21", "r37", "r1016", "r1017", "r1018"] }, "lh_Longtermdebtissuancecosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "Longtermdebtissuancecosts", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long term debt issuance costs", "label": "Long term debt issuance costs", "documentation": "Long term debt issuance costs" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r383", "r384", "r385", "r388", "r478", "r797", "r1022", "r1023"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r383", "r384", "r385", "r388", "r478", "r797", "r1022", "r1023"] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Damages Awarded, Value", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": ["r1021", "r1022", "r1023"] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Damages Sought, Value", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": ["r1021", "r1022", "r1023"] }, "lh_LossContingencyDamagesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "LossContingencyDamagesTypeAxis", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Damages Type [Axis]", "label": "Loss Contingency, Damages Type [Axis]", "documentation": "Loss Contingency, Damages Type" } } }, "auth_ref": [] }, "lh_LossContingencyDamagesTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "LossContingencyDamagesTypeDomain", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Damages Type [Domain]", "label": "Loss Contingency, Damages Type [Domain]", "documentation": "Loss Contingency, Damages Type [Domain]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r329", "r806", "r838", "r843", "r1035", "r1069", "r1072", "r1073", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r166", "r168", "r170", "r171", "r173", "r202", "r203", "r384", "r385", "r386", "r387", "r448", "r478", "r528", "r576", "r654", "r655", "r666", "r690", "r691", "r742", "r744", "r746", "r747", "r749", "r770", "r771", "r794", "r803", "r816", "r823", "r824", "r825", "r826", "r839", "r1030", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r907"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r907"] }, "lh_MedicareandMedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "MedicareandMedicaidMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Medicare and Medicaid [Member]", "label": "Medicare and Medicaid [Member]", "documentation": "Medicare and Medicaid [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r166", "r168", "r170", "r171", "r173", "r202", "r203", "r384", "r385", "r386", "r387", "r448", "r478", "r528", "r576", "r654", "r655", "r666", "r690", "r691", "r742", "r744", "r746", "r747", "r749", "r770", "r771", "r794", "r803", "r816", "r823", "r824", "r825", "r839", "r1030", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065"] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": ["http://www.labcorp.com/role/NONCONTROLLINGINTERESTPUTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": ["http://www.labcorp.com/role/NONCONTROLLINGINTERESTPUTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": ["r57", "r59", "r106", "r115"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r926"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r934"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r329", "r806", "r838", "r843", "r1035", "r1069", "r1072", "r1073", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r908"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used for) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r247"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for continuing financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r966"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r247"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used for continuing investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r966"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from

operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r128", "r129", "r130"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by continuing operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r128", "r129", "r130"] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net earnings attributable to Labcorp Holdings Inc.", "terseLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net earnings attributable to Labcorp Holdings Inc.", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r117", "r130", "r154", "r207", "r231", "r234", "r238", "r251", "r256", "r258", "r259", "r261", "r262", "r263", "r267", "r268", "r282", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r495", "r503", "r522", "r546", "r630", "r719", "r735", "r736", "r856", "r1028"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 }, "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: Net earnings attributable to the noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r60", "r146", "r231", "r234", "r263", "r267", "r268", "r629", "r965"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r244", "r272", "r278", "r279", "r280", "r281", "r283", "r286"] }, "lh_NetProceedsFromIssuanceOfStockToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NetProceedsFromIssuanceOfStockToEmployees", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of stock to employees", "label": "Net proceeds from issuance of stock to employees", "documentation": "The cash inflow associated with the amount received from holders exercising their stock options and employees related to shares purchased under the employee stock purchase plan." } } }, "auth_ref": [] }, "lh_NetRestructuringAndOtherSpecialCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NetRestructuringAndOtherSpecialCharges", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net restructuring and other special charges", "label": "Net restructuring and other special charges", "documentation": "Amount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program planned and controlled by management, and materially changes either the scope or manner of conduct of a business undertaken. Also, may include reversals and other adjustments to accrued liabilities and special charges, if any, for asset abandonment, uncollectible balances, etc." } } }, "auth_ref": [] }, "lh_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NetRestructuringCharges", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net Restructuring Charges", "label": "Net Restructuring Charges", "documentation": "Amount charged against earnings in the period for incurred and estimated costs, excluding asset retirement obligations, associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and changes either scope of business by an entity, or manner business is conducted. May include amount of reversals and other adjustments during the period to amounts of previously accrued liabilities for specified types of restructuring costs." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r907"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r871", "r881", "r891", "r915", "r923"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r898"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r897"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r915"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r934"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r934"] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompeteAgreementsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncompete Agreements [Member]", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": ["r53", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1013", "r1014"] }, "lh_NoncontrollingInterestMezzanineEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NoncontrollingInterestMezzanineEquity", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively", "label": "Noncontrolling Interest Mezzanine Equity", "documentation": "Represents contractual value of a noncontrolling interest put (includes underlying noncontrolling interest). In February 2010, the Company completed a transaction to sell the partnership units acquired from the previous noncontrolling interest holder to a new Canadian partner. As a result of this transaction, the Company recorded a component of noncontrolling interest in liabilities and a component in mezzanine equity. This item represents the mezzanine equity component." } } }, "auth_ref": [] }, "lh_NoncontrollingInterestPutsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NoncontrollingInterestPutsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest Puts [Abstract]", "label": "Noncontrolling Interest Puts [Abstract]", "documentation": "Noncontrolling Interest Puts [Abstract]" } } }, "auth_ref": [] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "North America", "label": "North America [Member]", "documentation": "Continent of North America." } } }, "auth_ref": ["r953", "r954", "r955", "r956", "r1103", "r1104", "r1105", "r1106"] }, "lh_NoteReceivableAllowanceforCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "NoteReceivableAllowanceforCreditLoss", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Note Receivable, Allowance for Credit Loss", "label": "Note Receivable, Allowance for Credit Loss", "documentation": "Note Receivable, Allowance for Credit Loss" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r92", "r93"] }, "us-gaap_NotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable [Member]", "label": "Notes Receivable [Member]", "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating Income (Loss)", "totalLabel": "Operating Income (Loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r157", "r784", "r980", "r982", "r983", "r984", "r985"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {

```
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r566" ] }, "lh_OperatingLeaseLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OperatingLeaseLiabilityMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating lease liability [Member]", "documentation": "Operating lease liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r566" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r323", "r789", "r790" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r67", "r131", "r133", "r144" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [
"http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies [Text Block]", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r131", "r132", "r133", "r144" ] }, "lh_OtherAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OtherAcquisitionsMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Acquisitions", "label": "Other Acquisitions [Member]", "documentation": "Other Acquisitions" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, net", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r213" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income before reclassifications", "verboseLabel": "Other comprehensive income before reclassifications", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r110", "r547", "r548", "r551" ] }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLocationAxis", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Location [Axis]", "label": "Other Comprehensive Income Location [Axis]", "documentation": "Information by location in other comprehensive income." } } }, "auth_ref": [ "r531", "r534", "r539" ] }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLocationDomain", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Location [Domain]", "label": "Other Comprehensive Income Location [Domain]", "documentation": "Location in other comprehensive income." } } }, "auth_ref": [ "r531", "r534", "r539" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r237", "r552", "r555", "r559", "r631", "r963" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive earnings (loss) before tax", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r240", "r552", "r553", "r559", "r613", "r631", "r963", "r964" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r110", "r631" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation." } } }, "auth_ref": [ "r7", "r8", "r110", "r230", "r550" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax effect of adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r6", "r549", "r558" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive earnings (loss), net of tax", "terseLabel": "Other comprehensive earnings, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r20", "r232", "r235", "r240", "r263", "r552", "r553", "r559", "r613", "r631", "r963", "r964" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehe
], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax", "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r5", "r109", "r110" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [
```

"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": ["r4", "r5", "r109", "r110", "r631", "r813", "r1036"] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTables", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax effect of adjustments", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } }, "auth_ref": ["r4", "r5", "r6", "r109", "r145"] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTables", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": ["r7", "r110", "r230", "r447"] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTables"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax effect of adjustments", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": ["r6", "r236", "r240", "r480", "r487", "r489", "r552", "r556", "r559", "r613", "r631"] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": ["http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "lh_OtherFinancingCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OtherFinancingCashFlows", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Financing Cash Flows", "documentation": "Other Financing Cash Flows" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r97"] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets [Member]", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities [Member]", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "lh_IncomeLossfromContinuingOperationsBeforeIncomeTaxesandNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r122"] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r907"] }, "lh_OtheracquireesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OtheracquireesMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other acquirees", "label": "Other acquirees [Member]", "documentation": "Other acquirees [Member]" } } }, "auth_ref": [] }, "lh_OthercountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OthercountriesMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Other countries [Member]", "label": "Other countries [Member]", "documentation": "Other countries [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r869", "r879", "r889", "r921"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r872", "r882", "r892", "r924"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r872", "r882", "r892", "r924"] }, "lh_OutstandingStockRepurchaseAuthorizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "OutstandingStockRepurchaseAuthorizationAbstract", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rollforward of Share Repurchase Program", "label": "Outstanding Stock Repurchase Authorization [Abstract]" } } }, "auth_ref": [] }, "lh_PatentsLicensesAndTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "PatentsLicensesAndTechnologyMember", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Patents, Licenses And Technology [Member]", "label": "Patents, Licenses And Technology [Member]", "documentation": "Patents are the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Licenses are rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory). Technology-based intangible assets are innovations or scientific advances that have not been patented." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r896"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r126"] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": ["r126"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net share settlement tax payments from issuance of stock to employees", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r245"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r26"] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in

equity affiliates", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r26"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r125"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r906"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r906"] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r898"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r915"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r908"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r897"] }, "lh_PerShareAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "PerShareAmountAbstract", "presentation": [
"http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Per Share Amount [Abstract]", "label": "Per Share Amount [Abstract]" } } }, "auth_ref": [] }, "lh_PercentofRevenueContributed": { "xbrltype": "percentItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "PercentofRevenueContributed", "presentation": [
"http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails",
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percent of Revenue Contributed", "label": "Percent of Revenue Contributed", "documentation": "Percent of Revenue Contributed" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r899"] },
"ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r943"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r898"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r100", "r419"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r100", "r699"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r100", "r699", "r717", "r1101", "r1102"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r224", "r346", "r347", "r780"] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets [Member]", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revolving credit facilities", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r27"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of assets", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r124"] }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "crdr": "debit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Sales of Business, Affiliate and Productive Assets", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities." } } }, "auth_ref": ["r952"] },
"srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r175", "r176", "r177", "r178", "r179", "r180", "r200", "r325", "r578", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r776", "r804", "r837", "r839", "r840", "r844", "r845", "r959", "r1024", "r1025", "r1035", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r175", "r176", "r177", "r178", "r179", "r180", "r200", "r325", "r578", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r776", "r804", "r837", "r839", "r840", "r844", "r845", "r959", "r1024", "r1025", "r1035", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net earnings", "totalLabel": "Net earnings", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r207", "r231", "r234", "r246", "r251", "r256", "r263", "r267", "r268", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r495", "r503", "r504", "r507", "r508", "r522", "r546", "r617", "r628", "r674", "r719", "r735", "r736", "r818", "r819", "r857", "r965", "r1028"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r14", "r567", "r618", "r624", "r828"] }, "lh_ProvidenceMedicalFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ProvidenceMedicalFoundationMember", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Providence Medical Foundation", "label": "Providence Medical Foundation [Member]", "documentation": "Providence Medical Foundation" } } }, "auth_ref": [] },
"ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r896"] },

```
"ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text
Block]" } } }, "auth_ref": [ "r896" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails", "http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement
[Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." }
} }, "auth_ref": [ "r166", "r168", "r170", "r171", "r173", "r202", "r203", "r384", "r385", "r386", "r387", "r440", "r448", "r474", "r475", "r476", "r478", "r528", "r574", "r575",
"r576", "r654", "r655", "r666", "r690", "r691", "r742", "r744", "r746", "r747", "r749", "r770", "r771", "r794", "r803", "r816", "r823", "r824", "r825", "r826", "r839", "r848", "r1019", "r1030", "r1049", "r1061", "r1062", "r1063", "r1064", "r1065" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeMember", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails",
"http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to,
minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r166", "r168", "r170", "r171", "r173", "r202", "r203", "r384", "r385", "r386",
"r387", "r440", "r448", "r474", "r475", "r476", "r478", "r528", "r574", "r575", "r576", "r654", "r655", "r666", "r690", "r691", "r742", "r744", "r746", "r747", "r749", "r770",
"r771", "r794", "r803", "r816", "r823", "r824", "r825", "r826", "r839", "r848", "r1019", "r1030", "r1049", "r1061", "r1062", "r1063", "r1064", "r1065" ] }, "us-
gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from
Accumulated Other Comprehensive Income, Current Period, before Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before
Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r237", "r552", "r557", "r559",
"r631", "r963" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [
"r864", "r874", "r884", "r916" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on
revolving credit facilities", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not
limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r127", "r970" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [
"http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit
[Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r360", "r361", "r795" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [ "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for
impairment." } } }, "auth_ref": [ "r360", "r361", "r795" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RestatementAxis", "presentation": [ "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals" ], "lang": { "en-us": { "role": {
"terseLabel": "Restatement [Axis]", "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes,
but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other
revision." } } }, "auth_ref": [ "r201", "r205", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r264", "r265", "r266", "r267", "r268", "r269", "r290", "r339",
"r340", "r493", "r494", "r495", "r496", "r502", "r503", "r519", "r520", "r521", "r522", "r562", "r564", "r568", "r569", "r656", "r657", "r658", "r659", "r660", "r661", "r662",
"r663", "r664", "r665", "r667", "r986" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:",
"label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r865", "r875", "r885", "r917" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r866", "r876", "r886", "r918" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement
does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r873", "r883", "r893", "r925" ] }, "srt_RestatementDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement [Domain]",
"label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for
retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r201",
"r205", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r264", "r265", "r266", "r267", "r268", "r269", "r290", "r339", "r340", "r493", "r494", "r495",
"r496", "r502", "r503", "r519", "r520", "r521", "r522", "r562", "r564", "r568", "r569", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r667",
"r986" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accumulated other comprehensive income", "terseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation":
"Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r104", "r142", "r622", "r660", "r665", "r673", "r700", "r828" ] }, "us-
gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Retained Earnings [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r204", "r253",
"r254", "r255", "r257", "r263", "r266", "r268", "r338", "r341", "r376", "r484", "r485", "r492", "r493", "r494", "r496", "r502", "r503", "r512", "r514", "r515", "r517", "r520",
"r563", "r565", "r656", "r658", "r675", "r1101" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]",
"label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://www.labcorp.com/role/RevenuefromContractwithCustomerPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue [Policy Text Block]",
"documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r721", "r774",
"r781" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": {
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails",
"http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
"http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation":
"Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to,
investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [
"r155", "r156", "r239", "r251", "r291", "r300", "r301", "r316", "r322", "r325", "r327", "r329", "r337", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r399", "r400",
"r546", "r617", "r789", "r1028" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevolvingCreditFacilityMember", "presentation": [ "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan
proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1
Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r934" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-
1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r934" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited",
"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails",
"http://www.labcorp.com/role/DEBTLongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation":
"Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r201",
"r269", "r449", "r946", "r976" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [
"http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and
Financing Receivable [Table]", "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables.
Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r102", "r108", "r331", "r988" ] }, "us-
gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY",
"http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeLossTableTextBlock"
], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "verboseLabel": "Schedule of Accumulated
Other Comprehensive Income (Loss) [Table Text Block]", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation":
"Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r1054", "r1055" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.labcorp.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Potential common shares not included in computation of diluted
earnings per share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure
of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not
included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive
securities." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation":
```

"Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r48", "r49", "r500" } }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.labcorp.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHARETables"], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic earnings per Share to Diluted Earnings per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r979"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.labcorp.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r334", "r335", "r336", "r491", "r947", "r948", "r949", "r1039", "r1040", "r1041", "r1042"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r362", "r369", "r373", "r374", "r375", "r579", "r772", "r796"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r795"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "terseLabel": "Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r795", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r991", "r1003"] }, "lh_ScheduleOfOtherIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ScheduleOfOtherIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Other Intangible Assets By Major Class [Axis]", "label": "Schedule Of Other Intangible Assets By Major Class [Axis]" } } }, "auth_ref": [] }, "lh_ScheduleOfOtherIntangibleAssetsByMajorClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ScheduleOfOtherIntangibleAssetsByMajorClassDomain", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSComponentsofidentifiableintangibleassetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Other Intangible Assets By Major Class [Domain]", "label": "Schedule Of Other Intangible Assets By Major Class [Domain]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r32", "r33", "r34"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r92"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r38", "r39", "r40", "r41", "r42", "r43", "r138", "r140", "r141", "r142", "r216", "r217", "r218", "r293", "r419", "r420", "r421", "r423", "r426", "r431", "r433", "r669", "r670", "r671", "r672", "r803", "r945", "r969"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r859"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r861"] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentContinuingOperationsMember", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Continuing Operations", "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r9", "r70", "r71", "r72"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r155", "r156", "r157", "r158", "r291", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r329", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r375", "r379", "r380", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r786", "r789", "r790", "r795", "r842", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r167", "r169", "r172", "r174", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r327", "r328", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r687", "r688", "r689", "r743", "r745", "r748", "r750", "r757", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r777", "r805", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r841", "r848", "r1035", "r1069", "r1072", "r1073", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Domain]", "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "presentation": ["http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETS"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Disclosure [Text Block]", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r158", "r291", "r295", "r296", "r297", "r298", "r299", "r312", "r314", "r315", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r329", "r785", "r787", "r788", "r789", "r791", "r792", "r793"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SelfPayMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfPayMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Self-Pay [Member]", "label": "Self-Pay [Member]", "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed." } } }, "auth_ref": ["r1035"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {

"http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r118"] }, "lh_SeniorNotesDue2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SeniorNotesDue2022Member", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes due 2022 [Member]", "label": "Senior notes due 2022 [Member]", "documentation": "Senior notes due 2022 [Member]" } } }, "auth_ref": [] }, "lh_SeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SeniorNotesDue2024Member", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes due 2024", "label": "Senior notes due 2024 [Member]", "documentation": "Senior notes due 2024" } } }, "auth_ref": [] }, "lh_SeniorNotesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SeniorNotesFairValue", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair market value of senior notes", "label": "Senior Notes Fair Value", "documentation": "Estimated fair value of the debt instrument (senior notes) at the balance-sheet date" } } }, "auth_ref": [] }, "lh_Seniornotesdue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "Seniornotesdue2027Member", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails", "http://www.labcorp.com/role/DEBTSeniorNotesDetails", "http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes due 2027 [Member]", "label": "Senior notes due 2027 [Member]", "documentation": "Senior notes due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477"] }, "lh_SharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SharesAbstract", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares [Abstract]", "label": "Shares [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r92", "r1016", "r1017", "r1018"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r90", "r1016", "r1017", "r1018"] }, "lh_Shorttermdebtissuancecosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "Shorttermdebtissuancecosts", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/DEBTShorttermborrowingsandcurrentportionoflongtermdebtTableDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Short term debt issuance costs", "label": "Short term debt issuance costs", "documentation": "Short term debt issuance costs" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentInformationDetails", "http://www.labcorp.com/role/BUSINESSSEGMENTINFORMATIONBusinessSegmentinformationNotes", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSChangesinCarryingAmountofGoodwillDetails", "http://www.labcorp.com/role/GOODWILLANDINTANGIBLEASSETSDetails", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r155", "r156", "r157", "r158", "r206", "r291", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r324", "r329", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r375", "r377", "r379", "r380", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r786", "r789", "r790", "r795", "r842", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r164", "r216", "r217", "r218", "r251", "r273", "r277", "r284", "r286", "r293", "r294", "r337", "r390", "r393", "r394", "r395", "r399", "r400", "r419", "r420", "r423", "r426", "r433", "r546", "r669", "r670", "r671", "r672", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r699", "r720", "r737", "r751", "r752", "r753", "r754", "r755", "r945", "r969", "r978"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY", "http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYPREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYAccumulatedOtherComprehensiveIncomeMember"], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r17", "r101", "r105", "r106", "r204", "r236", "r237", "r238", "r253", "r254", "r255", "r257", "r263", "r266", "r268", "r292", "r338", "r341", "r376", "r434", "r484", "r485", "r492", "r493", "r494", "r496", "r502", "r503", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r552", "r554", "r555", "r556", "r557", "r559", "r563", "r565", "r569", "r631", "r656", "r657", "r658", "r675", "r737"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r167", "r169", "r172", "r174", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r327", "r328", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r687", "r688", "r689", "r743", "r745", "r748", "r750", "r757", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r777", "r805", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r841", "r848", "r1035", "r1069", "r1072", "r1073", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r253", "r254", "r255", "r292", "r565", "r578", "r668", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r712", "r713", "r714", "r715", "r716", "r718", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r737", "r849"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities [Axis]", "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.labcorp.com/role/DEBTCreditFacilitiesDetails", "http://www.labcorp.com/role/DEBTLongtermdebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r201", "r269", "r449", "r946", "r950", "r976"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEEARNINGSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r253", "r254", "r255", "r292", "r330", "r565", "r578", "r668", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r712", "r713", "r714", "r715", "r716", "r718", "r721", "r722", "r723", "r724", "r725", "r726", "r727",

"r728", "r729", "r730", "r731", "r732", "r733", "r734", "r737", "r849"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r868", "r878", "r888", "r920"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Surrender of restricted stock and performance share awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period." } } }, "auth_ref": ["r17", "r100", "r101", "r142"] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program, Authorized, Amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1031"] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased", "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock Repurchased and Retired During Period, Shares", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r17", "r100", "r101", "r142"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r17", "r100", "r101", "r142", "r675", "r737", "r754", "r857"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.labcorp.com/role/BASISOFFINANCIALSTATEMENTPRESENTATIONDetails", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Stockholders' Equity Attributable to Parent", "periodStartLabel": "BALANCE", "periodEndLabel": "BALANCE", "terseLabel": "Stockholders' Equity Attributable to Parent", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r101", "r105", "r106", "r134", "r701", "r717", "r738", "r739", "r828", "r858", "r971", "r989", "r1052", "r1101"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity:", "verboseLabel": "Shareholders' Equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock and Common Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r139", "r250", "r418", "r420", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r434", "r518", "r740", "r741", "r756"] }, "us-gaap_StockholdersEquityNoteSpinoffTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteSpinoffTransaction", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note, Spinoff Transaction", "label": "Stockholders' Equity Note, Spinoff Transaction", "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts." } } }, "auth_ref": ["r45"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.labcorp.com/role/SubsequentEventsDetails", "http://www.labcorp.com/role/SubsequentEventsTables"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r560", "r570"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails", "http://www.labcorp.com/role/SubsequentEventsDetails", "http://www.labcorp.com/role/SubsequentEventsTables"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r560", "r570"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.labcorp.com/role/SubsequentEventsDetails", "http://www.labcorp.com/role/SubsequentEventsTables"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r560", "r570"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails", "http://www.labcorp.com/role/SubsequentEventsDetails", "http://www.labcorp.com/role/SubsequentEventsTables"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r560", "r570"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails", "http://www.labcorp.com/role/SubsequentEventsDetails", "http://www.labcorp.com/role/SubsequentEventsTables"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r560", "r570"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information [Abstract]", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "lh_SwapTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SwapTypeAxis", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Swap, Type [Axis]", "label": "Swap, Type [Axis]", "documentation": "Swap, Type" } } }, "auth_ref": [] }, "lh_SwapTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "SwapTypeDomain", "presentation": ["http://www.labcorp.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Swap, Type [Domain]", "label": "Swap, Type [Domain]", "documentation": "Swap, Type [Domain]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r914"] }, "lh_ThirdpartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "ThirdpartyMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails", "http://www.labcorp.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Third party [Member]", "label": "Third party [Member]", "documentation": "Third party [Member]" } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Axis]", "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": ["r809", "r1035"] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Domain]", "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": ["r809", "r1035"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r906"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r913"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r933"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r935"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.labcorp.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r936"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r937"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement

Expiration Date" } } }, "auth_ref": ["r937"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r935"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r935"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r938"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r936"] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://www.labcorp.com/role/PREFERREDSTOCKANDCOMMONSHAREHOLDERSEQUITYDetails"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock Acquired, Average Cost Per Share", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r44"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledContractsReceivable", "crdr": "debit", "calculation": { "http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.labcorp.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unbilled Contracts Receivable", "label": "Unbilled Contracts Receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": ["r577"] }, "lh_UnbilledContractsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "UnbilledContractsReceivableMember", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unbilled Contracts Receivable [Member]", "label": "Unbilled Contracts Receivable [Member]", "documentation": "Unbilled Contracts Receivable [Member]" } } }, "auth_ref": [] }, "lh_UnbilledServicesAllowanceforCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "UnbilledServicesAllowanceforCreditLoss", "crdr": "credit", "presentation": ["http://www.labcorp.com/role/REVENUEDisaggregatedRevenueTableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unbilled Services, Allowance for Credit Loss", "label": "Unbilled Services, Allowance for Credit Loss", "documentation": "Unbilled Services, Allowance for Credit Loss" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r932"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.labcorp.com/role/DEBTLongtermdebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.labcorp.com/role/DEBTLongtermdebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r902"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r272", "r286"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.labcorp.com/role/EARNINGSPERSHAREReconciliationofBasicEarningsPerSharetoDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net earnings, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r271", "r286"] }, "lh_WestpacLabsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.labcorp.com/20240630", "localname": "WestpacLabsInc.Member", "presentation": ["http://www.labcorp.com/role/BUSINESSACQUISITIONSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Westpac Labs, Inc.", "label": "Westpac Labs, Inc. [Member]", "documentation": "Westpac Labs, Inc." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r900"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-

2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "60", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481423/505-60-25-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/230/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher":

"SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r248": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r381": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-

45-25" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r717": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r718": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r721": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r737": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r738": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r739": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r740": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef",

"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r945": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r946": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r947": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479455/805-10-15-3" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r977": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r981": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r985": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r986": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-
10-45-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r989": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r990": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r992": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r996": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r997": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r998": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r999": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1000": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1001": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1004": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1008": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1009": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1010": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1011": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1012": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1013": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1014": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1015": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/405-30/tableOfContent" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" },
"r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1018": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1019": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1020": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1022": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1023": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1024": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1025": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1026": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1027": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1028": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1029": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1030": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1031": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-
10-45-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r1034": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-
10-50-5" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1037": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1038": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
```

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1098": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } ZIP 66 0000920148-24-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 0000920148-24-000009-xbrl.zip M4$L#!!0 (*=T EF9RUG$HP, !<3 / 97@R,C%Q,C(P,C0N;'1M MY5AM,]LV$/Z^7\&IZ-H"EBS)EA/+BH$@Z98,10K4 ?IQH,23190B!9*RX_WZ M4914N[/<;@/VDMD?#$GD'>]Y[N%)QZ30)5LF!6"R_"[YWG71K>-#QI%S,Z MYK$%Y+2F_7 FF)#Q"]_^%LV(F^,2LEW\ZI&6H- #;-$'46+^:]0P5ZX"2?-V MH]*_@HG)A&=QMUV\Q@^C'/KX@R T0;]!*FA*#9VA%WP9\=?0#,/(#.T@_R4@ MJSI5E% L=^A>]1]D0B)'/l588A.5T=,*LEI234'!*9Q_-YKl)]%)95)B36 M5/"XY@1D,\M9/D]$SO*Q)0+QL2VV=;J<^CHM8F 0.;,!M@.2,'FZ$ MK#HF&TU[NO[7 "&W!/!&U5MJLU9"%K91_KCF@B3^R ME<\;R*K&*8,^K0:\D8S;<(LK!7%_L2!450SO8LIMCJS1HL1R;2I;*K0691R9 MA&Y ;D,2ZI;V%60[W-6\>>1-HB;QB38;TZ1?N*N(GJV(8TV.Q^;7WMP_/>Q[MP>>QL?7=^C<(5(7YE3-Q>H,*DX;@.*R>4&""/JA%#)C$*)R_I$=,%RA;D%E MDE;]# _U^[MWQ3.&/KSY0V_BO_P",2(UM._PU!V>M37.;O#'@DI3X+@NT*JN M*@;-^QPSLY6(N:@EO/F_\S7QPNB/_66P>:\V9J=4%T)>HS+_*A=S$LKDDPP->*/!TW M7=-3=$V']OSC7Z%j;+^&_\-MU-<:P_>IR9*0SZ$7O#YN:$8V:Z+#<*C[PX1G M@BNJFM.AIM6ZNQ\UO=&<Z[8B%'-GFK.GB[',K"7G<*75H#\]Q*]&H0)52:E]QI M18],=O:-E>V1_+T)3I5@M3XV^<9A4/??'DR-[8'8;U!+ P04 " "G=)9 MQ6=0ZGL' ! * #P &5X,S$Q<3(R,#(T+FAT;>U:,6 ,.!+^?K^"YV*W M"6 [MF,GK9,&R*8YM,"]|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|$.+W,3=9#@BO=[E_^,C]^#3W?,K+D(0+MX L5'K\28D'0&^;3V!]Y^B+H? $>H3#91N3=U;(%S?]+9 M&Z/]4PKAIYTH+,KM(!MPU,1ZE54ML*U:)KK0?L'U<)=9WBD!1@$A=UWU MKI(?2?RV6=*T1AON$'2NWRE.RBHX$/[O"54HRP6 BA&:\@Y@$? 26$858*7H^ MPGZ&XSYP3 \%S611!R;A7%&6H4'2,T39(6AT4)WWX,1XN;OK";C#!/"9B[U5 M8FK_:=OL+:\DR9N'+.:.W.1+%O2L)6:&,"]V)2QA6?L/(==;A,SG;2^;C7 M=#9A9 -#CZ N+HH[7PCO)ET=\6;*2@#V+K9#ZAC<7.'W>4-$<4CD?DV[A M(!&?^\#^SXWC!Y_;@C/ANX0VUY1 #/2.H)6;,!(>$2!WFK%R`]=I>$>'(M>OA\)MA[)N#G =P'A8?+\(/8ZDFY+ (I7'>[^9SD#5>BV(>$6A0ZJ(",:OEL MX%$(:=KH>(#=P1128:*C.Z+8@::FXX*PY5<(@'$HA Y5T-5EB5/ KQ26T1#Q MSN_L59V_^^R^0C5@T%WM*6]N;FFG_F;+-3[<'AI M-"78*&0[$TAIX[&RQ]GJ ;30B[&N@J!#Y/,L(DFNNHDQGM3CMG C$L*FH7& M2+ 7AYM7E*].NZ?]U_R6TF-!7BT-_R\PN^$%YI%7VV.C;N_DY).CO6[_DV.? MU=&KO#GN?'OY2M<.OHO5XV#T!\NZE!BB$-X8827136;UI';3&]%?R?P M-E,9L_C|DTL(XUOPQ_TRW:S_<4OC_?%-K>NRGB#:8M`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|86'K%S!W:RXV5R=I/,Q[VFLPDC6QBZ!W5QN3I16EM.XD9M MNJ6O-.[C3LH]?PZ?H*(Y[HNC>]$< "21,.DU;]++]W NY2.KKE>^'$=/IM*M MBC=34$ L98&;P^H;WES@I'E-17-(W9)O_XF 1'P> L^O^]QP>Q)S0W@V%$)L M>TT!S$B;"%[S 2/A'@5ZIWQ)MFS?6K:IAN %E9:F\)]K+L8E!I>613,&G M,/T(" .E.:9,_,]MXW(KT&^U@LL! .+5.PY'U^/%,L/],P,\#N *3Y?A 1_& M4D7(95.X5KWYG.0U5Z+8AX1:%#]H\(OJ^65@7@AIVNAX@-W#%#+#1$YR>`D\A#KW')<2AEN<6N;2-] M%"@& B/!ANDM&-M4'IFBAEQ@=+!RTCSAM TK45D59D$8G4]-I")Y"X? S9^ LM=E_/9N#0?=T1WMS'F1>)W9]VS_G-^E^BQ()\M#3>O M&;OA-><.)SW;'3KN]9\]^.- KK]C\X]E&M_>ZH]^'A3U4[^BQ:AZ/NV7!TD-J3 M$-X88B3155*_; U;6X@9#ZH;T=\+O.U4QBS^]0P0PO@]-OGM6MJL_WY+X_WQ M1:WK93U!M,6@'5[WWV-Q/5Y;Z_ZB\]+B4|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f@^$CUQ%W/]0UM0WNNM.;@71O!%E*I9MY(,4'L:\O:4/:B!'75 MI'_!0B(M16G66?YACEM_I^HBI2R8%RE&3CR28/$[(F))*GU5_8.,C_^?QNP, MZB$,2"SZ,:.+NC_*-2Q78T!]/O9<= <8I1-7EN5K;-L6E29D"V@$[28G7NUNB"D5]L%2:Z;/K_FSR-M-U!+ P04 " "G=)9(W.A{+(-L 0"*=A8 #P &QH+3(P,C0P-C,P+FAT M;>RJ;?? B.K(&^OW\"EWFG#/=:P4:VQA#NC=W$4+O9DXZR83TG)GIY2QAB^#9 MQF9LDY?Y],I_1L36'<.TGW[fELE6A/^J"U%;,#OG?BP M9EBWI5U:DI\J$]^277[Y\O+R4K/P2'? <64UWIE_H=.M-I5X)AYJO.T-?1ZY5 M<]PG&"6N?B)Z_7.(7W\6V1YF, M;8 -I8!.K;>JBA0]9^Z[6[^U_07>74S06Y_>BQ(-D[[_>?-4)^0*:Z^GZ;G M^HM/C;$W8I^!%]?6/O>J3QC/- @>&;ZP--CVG(4O:1Z0*1D0? %K\|<%H^O8(M>XL9QVZ,#U8S\OPW MB_Q6,4QO9N&W2]NQ"7R]^7D!QW^-$?T#&*S'^'!]R[6*3W0W#,!]S+^K3+W MC' RK\$++E6I((HYA1;L/BJ6D$VGA(ZDH'BLFM9S@O%VG?'O7;F(W\|MJHZ MDRWO@>@$=-?(@A5Z.J;S:U:0"90>5]M2I:,T:M*W+^MS236WQI'F)L/M!"EWT:V/36 YZZV!K8!GG]' (6/5^]MQN53AW^M$$5 M-%K1]X3/3?$UO;GKPG=|-^D2_D&PV[>-:]AG*B@ ^V\5D(Y+ UZI3N$IDZ]!M5V>A5C]2_$61]I] M+\M9 =7O%6OJ-9Z5#L9O45]S# <,=Y_B5;L %7>_RNZ M\'R#28>%GU8>VZIFQH MLO'D+^NRY)O`3]HQ(M1 %1777L,<-W(Z;!+GO T-M^]\GCF=40 &KTU<,K456:^J N2_!-^V_(KP&SUGI(K+?V)VU2<6$3=R;8'BS M$KT^)=B;NZ03_!:\>>W+^GO1[_09&\^C8O?^8:%NO_PUO${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`Y89H0ONN?+@0.6&2_X=X;O9K3X& "\ MJ_OF.V@Z 32RYW_,<-BL"\G"2/_S@"ETKS2-8'__$"WKF1X:7%)O]!@*NY M!QZ/% [$@M,NMR>6UB9|LQ_--O9R1M2;_P8+MO"G3}?DF5C.C+Y1JO[P'T58 MRR\;/.HY[NRD(I2#W=;D/-^R0D0@E_F*Z6]%2_/]K^I/>W;.=*7&'V")>;X)M MFUB+[[\RG=D$NU.LDSD !%N8EG39UHCO3&;9A 8OO} GAWKF;C7Y/[,]=.',+17CN//?TA+\J).&Y\[H][UU]NN[\3Y\G%LPG= MS@*ZT[=O@?"3+NM/@D^^X?8L,\-]GD\;, \SG=N 0WF0D87L}>>N,ROG40N- MVRB+@"!>KI$E=H..AB?Q:O) (KRUG(&84Z<>;F-VY4%& M8>RUG"#(!0DI <&\[+605=S% M]X6=Q1,J<[+^191?V%D;#?X"MQR#X3PB!5*=V_BI4.(+'G$;7-S-HXQ[C?"> MZ>&IM4DN)8B6W83+5S!ZG$'?R35Y"F-8(S$C';H$#LZ+/6,I8X2Z. M>S;F6X92U'>L:V3T .;S.G3D;B+.,^2>PNA!6BQ9M+Y$Q)R"[V2YS08(M"!4%0MSE$+*U*8MJZG,?QN M]%=>#.$N[LB9_L]++R*F)I$;>RD4@X[]XBHP*#>=ML M>4&1NV!P^:!84&@H10Q(%^0N9<92GGGX$ IW\?BR J0P[EM>2.0N R&0 MR(<5EQ<@N4U$E V0104(=UD"8\? MN4P5E TAA,+F\D,A=9D(@D0[M+B] 5=Y%^86OQ!,N<7("&B/<+6XLK0'*77RBYXBJ:K947+KG- M,P@=LL$K[B+QO-\1. (L.47E9_MR&X1]2/MA8!'86RXO'#(719!X) \&RXO.'%/2@-7 M'(L*#^YB^>?)>1;5K.8S"<25A(Y2Y;+O;,O,T(;@/7 M"$)TGO W(;..03#F;BX3>YBQ4*);" (VPCJ;AZ)OLNYM7K.PP1M_85U20.NOLN+_LJ+(=S%.CG37WGQA;NXW0Z^!/QXN_PU/.96DD>K=8V!N%3^ MK.BI.[3&7?0E?U.D96!Q%US(GQ5YI17<^>HIXCS'/'QCVI "&+L)_>B=_>C- MG1/.!V5]B17%2D3>K>X\[&/%*<3 M=_YS73_"8KX63UX.G&+LZES MYSXGH?F]ZSS3[] CJG^'G<9@A_^2SYIA_0:/O(&MUXI#;6X= MXH^H/;"?31\3>B7% <0L&;VXIXH\(SO((F+[ADK+F0=O<^Lf?3=OTR8WY3(R! M#=:[,L'6Z7H>\;VKMY_XGXI;L/=Z^P^2?2GJS/U_L,CJ&$]-Z^WRSX_+_=DA?TX$RQ_>:+#]M> MU0.RC(.!GOEOP/U^?, MX6R'_=ZOA\'CH#]$W=MKU/|[[T?WJO<^ZMW]_#D8#@=WMSDN04ZTA(_M#G_M;G]_O+N]0>U7NV__R0UZU^^#O^6ZVFAO7<$4NT^_0=^976KP5;SYP/O=PT_T M#:3- =NS;^10>HJ-0*!_(F#4&KB ;4PUF$//RVM%9(1YZWK,'Y'$_ SI2O?I7 M)K/+IW30!BFV"U@VG.ZZ)K;0+]O4'8.@G\-ME*F_HTPCEC+IB?+7.6P[Q+7> M'@B8('X%C1UWBGW06; D4/J7(\>Q1MBR'' DO$;DDRN=___Y36VLTO[ZG8$2C M;'&1;/7HK[^Z#X_JAYM_H(?^_=W#(IK_]3#\U;U]1(W"'3Y$<0520fZ>T"2 M^LGXO OX(?WG>EE\R383[;&N^_H\4VU-MBX- M>*4ZA4=,Z,>]'GZKOA'L5HD=^9E2Z?QE;A.DU"!0-5*VB1]W%3+Y[/&?'3A MZU@'UU0JLQ&JS 9?*O/QH7LI'##%*'0FW^(4Z4Q_ %K]X[^+OHVTB?N:]TB<$*(UVB@O5: ME21%5;C2)=P[3(^*FW\+[T34;U8Z-]VKWMW#/?IQ=W,-KM40#6Y[MM=W.!&\:Y5/_%>L^6S9RQLA=+!=A#WDSHM.(CH%,&YF^A_0)L]5V[(@#4751G M/]S)QR.0SO#=D>.'"%1A;1;>>>0R^N&K87HS"[]=FC:,(?O0UW7E0T,?S\3U M31U;(>$#8.WPZA(NUUKJ0IEL^_"_T:TQ6'1 8K_K+Y>J-54Q4E][UZ34KY MNJK(J3[QX:34#Q_UA2TR6"B0DK+DMXI2B0;/L&&8]M.E/"M9AISJWJ"G,SLZ M"C>DLKZ/5 YL/8R7FI1@(MC1/6=N^^Y;#PS"36O,HR-FKO-,G[.TKK5*YYI8 M^ 6]9*MA[1N[R%NGQ W9=%Y<>,2O@S#HJS-.K&]1K4JGW:;'!EM27?N0P#N-M'*H-JE3DF8]8/A]%Y."2OANZEM'W$T,J AO.H171T3_GKND9HL]L.%^^YBJJ MV3#W"=OFO]GOGI.#@]U(8UU) ,+.<-"+]1G3KU#YOXNP+VUW6+.&3 M;U):74N]2>$__M-_|*=*R4'4$MZ/S]"2Q>3 ;~BXA?BX[FD7&FP*0FW8]P"3{#3EAU/ M?KQS'YV7A15$V\U?S:EC^N0[]L4>N DU9[@#"[*E9$15MK'?N?=@8L(FGMP"_MI9WC;QT7)+>'7:"9C84ANC\7[AT@L_7_F;/ "PA)+%=_ MSCUPEMJR4C+)92@$XILDCQBO%C*D!FD@A[H\CO[''?I\!3K.(9=]$PKC+X7 MK+2$3C[%D-$!GQ?SHUF"'X=.XGB3CN@:26R0X'AON5*4O3-.-3!: 03_<-P_ M LHOA'XC_Y$H ;(,O.0'K?(%,#VOJM-XWN@-Z1."5(`=_0^01,*">U07KF13 M/DF?T01[&Q:H$6Q9<&;],@ 5:[_FIM4M8)&'9%P #QSH5T5&@IDB?=(QZZH MYE5U2]^F:6QDP+N@=NC0F4MTPI20)"- VUL1#G^]YP&;DS4%G>!.'IG2B/+(_MP?][N;_@]5G2*08?#M?P&6';0) D8(DCP]\/?HG+(..9R/A,W02X6/8 7@V M!59'!FH74<&Q-J*4[U!<9_V%@R.D:MZ\|P,N\8^#DXWO- ,1RV>LFF,/*6@$^!8WVM-_/*9 A+<+:@K MXV #I61[0D^N!\^)/HK=K8!D0-C>#C$V;'1!CL9[__E-+EF&96V;(WI:^1L-V M#M@ZOW#HU%K-C[.G+>>@_(-M&!R#Q)EM'_68+32G- 64*F^XF!O&L$9625>^.'<;MU^CTK.OX%P;;C-62L6X MM)L1HTI4DB#IE3]HYP66-/*>,%]=EM,H_7@[^*Q1&-'D=T:27D"1I&B44Z!Q M(T4;XT/(S(?(Q=DU.B;4VH1A<]+F5S$[? *-76X/_&2:.SOQT*A1TY1FV1'1(M6:4C.3$]OP M%'^64+,,)=N%[MN8^,UY@28)&IVE$2U4<]=A|CNM>/S.T>63H'+&PL+2^LPPK$<=NFX&=Y3%Q MJ;RSO>0*6),Z. <66|UNE'G,F@Y&843B0MQ5Q6Z^!8L^G5<-A0*2/_ (!10A[M:&B@-2]=EG+1;BH7LK8X*QE--,_S\;DRK#M_ @L&25%=F,0.[[MJ?]3(@X-;]_[?__V M!6|

*[UWM0A<+C55_+]"QO2(/TAYX+LK{|GL,C&M30I\%M|{8WZ-Z@P2TMQ==]-MC*N"N&/=12@-H=7J[!78FCHG6J"GU,++UDEJ3=\RJ+"DW6K$??2,5C!O:>'8B:.!9M:DDOP4O:M5]3_U]STW\0&5 I_J.)I+-B*A--XUNP7<6AA;11B2;S6I?[#-V(@A)%=;P#\>:6.&!52H3(XIAVZ5=4SAU($3L0Y_JE)5#1\|<1S^Q^P?QT8/I_2$VF%(0!$;3.E7 M5,X-IB$V&-[U2Y"/\UW@"]M<{EU')P;=3\3N40KN*A]>_-E.8ZG@56R""B^# M&KI[_-%_$"5>1(D74>+E[-5A6ZIT;L@3MH)=CK6{$]M<.?BJ"AG@GL=(YRD MDCI)4E=L'+PKF$;E0P-JZ#O6?<<5>T8Y6"KVC/*OJ)OIAC@P+U<T2]=7W;0 MT8;0'M)#);%V "\U=TS=)$"?[Y1Z9NB8B!VF' A0=ERDBG8E,AUG MJQ|5H1\EYXVZ+5SQUI_#>=$\N M3$A?@U\R;;>3QXK"W'[L%<+UYB!UI)03&D5>'X/V=QTKWIW#_?HQ]W-[>=#V M]R&PME=#W=MK-/QU-1Q<#[H/@_Z0^[-"O3N0L]MA_QK!3\.[F\%U]QQ^\N>K> M &+[:/BCWW_D?Q6?3!O!8RUZLV@3C-S-]@/!6>PTR[[V:A 7.^E1+-C;/O5@ M3TMS%]O9]*D-);L35)}4[C#6]M=5)?Y+|]J4FL6QKH(VL]P]&;GA_)W]{PG MPL?-+G; 8H3U/YYHUI-G M/F(U#% T<3Y)<6!.2?C=\C(69(RM3^-V9]"+;LW=UU0<@<Af'QK{IA:TX6C>.N;B\;U.J4C-]6:M-&S/EY'[2-@B9F0?O^/4X-"M!.HJ HWCB$"STE&59JW%B0AD9/<59F_KZC]LQO>0"[XE<&UDD0MD$W^<K>22G MHT6LC!=.;$';L:1%%'Q8$O25^:&I74' 4Y[>*^>I?VO-IU7!8)H, ^+48X--@? M+N]M5]U|'A\ --C(!!)#&6!1!T]-4LDM2H=Z;(M*36%$R2=FQ/QRQZ9ED6ML,1]-G6RX3PDDHND5E2QY6*\AHU{R0HKP.-6!"0&^6U OJK55$X,C"QC=-(I M.S1H*J0H=4!*2ZTU.$'*N9FBP_EL9IFL]{S["". ^R;,T'U5Y" B(5@,,4B7M*fU&0SKTSGIP>DH-.;&8083@&Z2P1%A;D448 MW1(VFF<9X>D%D.2E$'PBZ\P+]=]HG?',5Y,RQ)"P[2]!$9TV<^-/-M S:{G43T1\#VA|MQ3-8TZ18W4R&#/Y2L6S+6F'-@^MI;>A$O"IX((_3 1%A$ MS\!S XNA_ZL:T3)#%$-?A!U#D;I7QP3 M/'Z;#)V!|.VPZ|OS|2.FS%N$?PW-"7^Q#'8F03/G\;=^A"62)I3"2$1!W9WM/##8M$_O$&\Y'GFF8V#6)!S+EZ.Q5\/,8A_X6,,B+$1NETI$R.-DEC%H.H93@ M%$.64&K0FSC<'+,N7UJO@*9X4#U36.$9*Y&RM!<G+N)/6Z3(H:Y7L=COKNK4- R+<'\7-=WB M=\I#KJO,_$Q)6O=-S^D>;%)\C%.DWS E^3Z*N1/-EZ*D"|=4A99BK$3FCE#1<&7(V2Y!81!])>Y39!2OT!R76Y5BX0?!\&X#6/G\Q'L:(50(ZR^]$&5%?[^C4(YAH>T!J6X"%U*M<"07]BW@:.-5Y D>6EY\UMMMP;=YU8=.4VMB"K<@TJJ.-=#PS?6R)G.'>E1H7 M-+T'D@IL7D#0%4F($0()/L.6G6+U"&'>-E5L7$?O-"K9JW#2T;P=3.M*%KS M@?C8I(4;,?U&6BU"A SW5981*?LA);NZ/I_,+>P3XYJ,3=U,>Q6HQ1)UDJ.) MZQ"EQ-,.99H|GAI@GEZT6]W,+O6*XQHELZ&7$ N/*>Q.=.,:2";$|\YD@R_'_ MJ03>I[UWB,'M=Z (+"$,Z:T=41H=MRJMTKFX&S]#=#ZEOAWXT?\&B/+--O4 MEF/239-%Z99KW3.I791I-72W$"(^,-7/I M EG$\JZ,]<*(WUM7 W4?@;C4\%JJ)E..FA.[J+>T+BIRBW,]E-JW4PPU&!{MOIK!GL]7W)EKY7J7<7;N("*^V7G/KI3WZ1U%QIRF8[X"KP@R$:A*/$28;CI^,^1+Y&+T,<#GQA:'((EGU26#Z+:.+Q@)'XD5*X;QNL?!/\LA{$BY&(-KCJ MH#^S*NH@#$V>(+,]OW89+0Z>.;2)FS-4_KE3%<*"S.KRH!:.0?G#(Y]OJ#L4IK\<$"#(.F5#]M-MBV9;RNQ2>3(>%< L/ENP)3]/D!9L#0]VEI)='_?C@>T<#.J>,YV;0;7ZX%PP M? +FGO1 VG+.F7V^7/81P@ETR<2RP M'KRHKFG06DE4;115&TIWPBU+.K,5FMAE41<&7(V2Y!81]])>Y39!2OT!R76Y5BX0?!\&X#6/G\Q'L:(50(ZR^]$&5%?[^C4(YAH>T!J6X"%U*M<"07]BW@:.-5Y D>6EY\UMMMP;=YU8=.4VMB"K<@TJJ.-=#PS?6R)G.'>E1H7 M-+T'D@IL7D#0%4F($0()/L.6G6+U"&'>-E5L7$?O-"K9JW#2T;P=3.M*%KS M@?C8I(4;,?U&6BU"A SW5981*?LA);NZ/I_,+>P3XYJ,3=U,>Q6HQ1)UDJ.) MZQ"EQ-,.99H|GAI@GEZT6]W,+O6*XQHELZ&7$ N/*>Q.=.,:2";$|\YD@R_'_ MJ03>I[UWB,'M=Z (+"$,Z:T=41H=MRJMTKFX&S]#=#ZEOAWXT?\&B/+--O4 MEF/239-%Z99KW3.I791I-72W$"(^,-7/I M EG$\JZ,]<*(WUM7 W4?@;C4\%JJ)E..FA.[J+>T+BIRBW,]E-JW4PPU&![

*MUL4TT_OC,=%9]4_RJD^P_400;-4$!3^S:R-!65#;'"Z@%9>?@:_V8 G6M@_VTUGE[504'$]RKYSD(C>PT)HY?> D="NZH, M @41)Z2T_K5V7%^E3.Y*0<&,X5YS:LBF\WJ;*
I,IF4XH[K96QUR,3-NFT2UPC&8,(#R5[HZ:AF&1 LCM1D8Z0[G-P!JDU;V59LQ=QH/M MP4QRAB&;BU_BNS!XE62^ :M6.@TE@WWDZ(`MW\7[.]+"2E3@.WNAGC>)=]^ MZ<$^MY:<=Q8XI/LA@8]LW0D/#K'-W1'=_SQHB>4QN]76$=7AFA9OBBWA9WC#GR3/?;B=?MO6!UE]1Z,9SYR"*!S7> MU5]@]9{E.YBGVD#+&S@T5M
M1!}3<7:U8*1!'9.9\|\#%_QKF<'<;,^^O$Z)$!>&VB&77:T&&X{/CR= MEO&#R9@ GB<76VB&77: R)\0CP#$,# .;$$#A91#;"WYB)***%PZ*3H_!!SX<7
MV'7FVH(]T8]CM883:L@U385) W98!^-+EY8A,Y_)UQ?3}\"<1W%<^&'*NOOP(M'L$YD0[VCZQP28=9$??T4LOHWERCOGNK?=+84\Z:'Y>;X3=K:F$@-(FD8ZVV5 M:$WXH[84M?
%_,NR1X8C2B!"H &<0$5<@L@2EXZ".6%NYH(F+M6F?]K-GT:E,[B] M[O_]VQ?8\LG*K'CU*]]DT4WU@A[Q)+ GP38;5F,% MC8P_QVF;A91WOHW<+S$ 3:;$%*D20ZI=I]
Q80:6H.UA:_0_93^&FZB56IC M7D]M>)==O632+<;_K>)!.5%=J@46QN;?H?5U.Y_"D_7W@9_W]M6=^X1^U\|. MIL_06&R;\[BP;A+O M$;[ORF)504)+29.J;&%P=?WP-7HX"!Z%9Q3-
/IPL+,=#YPZS6IWWW?A[M/L/ M%YL_-0$MQYN[!$0/@<7F&$PCVT^TG'K, ^&WL^4MB5R5*MO?K;-WTPC$#OA+2DT] ?[CK94; M/(*-< ;0UQI?T8^@^*R'P.*OH4_K;SHN-1)1+[
H/R,35!5ZLIP1&(,6P,") M4CO2M&WGF1EW010,1KMD I8D?<7"(JKK,NX,@OD^FSHLO}\@/[}!L0M0NT 4MMC5
M)X1^@DYD!D]C8;@I_H,@'2;LAA.TQ[15!F<_<)X^]VAJZ>H,5@96/GZCA;,*G MYC88RMBRB 5&L&'B)]L!3NJ!MC;<^1-_)E8SHP5QP;PXE'8G.%BE6K+A9I M$6!#\ "PT^'!].B^MR
@3=[!VLTI_0@!&F#+#R*+TI4L6D!0FNW5G.PHPM_I< MIT+LG8VZ,}-TD*Q>(+DN-]8]C(%^SKZG'TRG8B7C_MTT^O^^%Q#C_`K0Q-8NPWD!'3,"(,(4,,C-/_LKJ6<*4;A
M5=A(''')>;)#!B3EC+B>(I4\5!Q@VI,NV>XX78E?A7*D^KK#=)4!S(8ER"C< M^.GR_1<'=. 3VT.OT/6*1EEP#0)\^G3|&C#_RG0";;?*T6&D1#|=W0P_7[''X M"_@R;^B:.]3KI4;]H>_
H_'"CR$%O-7*PL!W0TGBHH>NY2R%&/^>#]T70%*@[\6BF M!#[SE[E-D%*/Q.GZ-2#%S9"9#:XYFM,GXQGHPU<3ID%@Z5NC9O9\,@+\K_ITU-MU*RO!LZ4E9I$]\2E#H$S?@
Z@H726W[E(HA5E9?&#"U:M7D8[_8E--.2LI} M4@J[.;HY*;9!S@B]"P@TNZ#]P T>Z'W9&&U\19YYNOI21G18M&A@Q2LIJ4 M-:*O*283QS:.1.X*Y'-
&B@M]JXS, ^UP*X39XB?V63 6+0MA@](C M>)9-Z)Z*0=O2VE<8C;'I+K\K8(PWMX)O7>Z"%T$">$S+F 46Z"F45 3=E0P MXT:$@)L/]G,-]0.7'_99ARKJ%Q-4L1$X6.0((@9[_&1M?
G1Q\,U@VE!-,,%L M]+G+)-,&U}JAZX6-UYPNYDD_83O^8F7 /+J](@RW S/.;5%84KGL/WOH'!')@& M]*&B,$?8,T)O DA/@M2H!=8$?@'\!0CZ& 019ECN0?" M8^\=@D399[
M(&S%OL+7&"*_Yj;.E#-X(F C0$=WI@A/6,J9 ^%^@4)U%44DC M'12,RV3 +/#P83!8)91LKL'8OVQ@*B?NW"+!AUSR-+=*(R\4L2=%$,-SV(CH
MO@45O2D8HDN,N.S?52,D9#>;S(H(LS-AVE= I$EU M*,,@W7,4U+7!0;?0 S.SZ(5G,'2F2*I7_P=]6GLO,&Q= M|%+D(SOPPE8X4X MWL296X]6#?XM.PRFV/_$SP*-KT%4=)0F8HR
:4=KGO[XM;F*\#*R!C)OQ_N-N M!_,X_1XZ"%/\3[";_;C2I M^#FA3PO="5[OA*SADCE\+%<8?1DEOs?M?Q^D/*W-M-6F[8'C\Y,M;&59/S$8 MC//I7>0^AG85;-.Q9A1MP1)WM/Z_0CFD?
MA**).]"KK28&F$]EV'0>[1G"2 M&K0@&FKZ',,I[<&P#,& EZ@X!4=%H"FICWW:*P!W@Z"#6R3#C_GC&C BR:& MZ7ZD+TL\ /=8.AHV+]\%N0KF'6ZI-.H(CV+!+?C=,T$@0?
&M,X09YC0$$#K] M8Q.H9Y!8-IM%Q(#2@.TQE A@%3,C:N[. MZ"(7[!VP-2^5R'MSY_W6DB;#O6>0K0C*.($!#=(1&K.TY"OLG["8=>U*.3PE MF)!WOKF6LAP6E@5[%)3-6Q0[&X>
[Z$WTX>;4=SF*?C%G8-XQ#6&_OOPF4R#.&>~<$" MC:5?'!SH7?P3Q1U[*WPRBZZ\,]E7T4@-_!E6K^OSZ3R8";/_WT7/X2,.B/DG M,(&]SS7V(>GKN_S?NZQ%W"LI$H"-
RDJN)'F";>V8D+?ZZ/(R123(-)B$D1: M3+ZKM/E)>6M^\GHPI-W=@)YN?_6OT=U]_X%/EP+;GN0NMJ.ILM5'3@CY1L0/H M!+$5*R#7#(#>?+Q9!<O5P.QS;TYE[UF]"P",TIQ/$VP-
?)OK]<^"EKMI"H%_ ML_!AUWR?)0M??@V_KNO.'JR';>$K 5FFAJB31*TS(`H8]U\&=`O7O>`G1<3X M@NZ%#OCBX9S!] BR&-9;%;2,L3!.WX)M>P*4<=S ;EAH[14X1;24=0<0U.BJ
MC**[E6B&30)C]}+-V7Y$#O<&T;63XC, &\&4#.&8|%"H"J89VQR*$.%YU1 M. WXFNJ8AH/'ZUG'96Z!GH"@"0JP#MF@7I5A#8V)08W92%.R'K6!F5!FWW]!
MTA7&,OQ&LD##+UB?F.29B0-HY:=)K ,Z=45KYXM:\0R]V&/&)1)1H6E)T3A8$(,2(N3%!?5X'#<*6R^U M+!-F<%W!TL=+<_+MG?%Y$?@U!OK/-.>AFUN*%X"[F>)>5;B"(;%A
30+%G>? M06M5.]HK2W$2E.1-+*S->W#?)BE9"B?6@<V[3GBEJ/.0UYO6;HQ+X3&KY,U_X-3$-Z96G05!3;L&Y7
M3_/$G#0^FV/&VO9CQN+$L#@Q+$X,BO/#*4X,;SOLJ*4Z[!AOGN2D(-C&K5@_KYL;,%^BF_,%%EDW=YJJ6UM24"^S2'!V'Q)&:,# M'@.^G)8A+!XEILALR)LYS XTL" >,
<9OR:J42/2M< M_&EX]_WA,])AD$DC[7H4 O0='[.H6WY68(]-ZOMB3JFY*5%NJK%I"L8,. 3NMN7QW-B*1,=986.KX{)[IN\|=FK<0O@)]%[@Q;"/___L?7USXDB2]U=1^&YC
M9R(PC21>W+$1+9Z4[=QW)[]=2%+A=&.D%B]V.U^^B>$JB0D$"""!! }J M8M=M@UZJLGZ9E9F5+Z%P1A^*F!2'5YR8!*BN)FE3!RL8TG, ?X+ ^QEH8/8XQ M.2Y X\-
Q_UKVD$6^\&;\@!Z L_>)05!38&E&9HBIA8\QM- 3QI!H8C! ZE\# M=/CHWXE_84MD.K.<.89SIGV-G$'/1E@45)0*$%T4B<,%&<.@$1SV7X0!M-P M?3Y3W*6&QCQS-
H^MX0(V$@;TC;I3.GA5N8.TM? M SXG=H21#%!V(G&'A<7.X@CRN1=)YT@.A2N<$8[KXZ2]*XD6$0?A9PO=XIFY: M>NR_T.UIK(473&$&\!"/1WHOXC'P 9()B^LE9$$2-
FL/CAX9;%X2LES3<M<,R8H,;NICAT]6;;[]W/?X(%X>0(`82T5{2.AO,,{S?A+Y_#BI2F3&TL_F;^=1V^^K3Z>:M;,_=:[5\UZG+]Y^L> M)??K&K.Y[5%%%OC,-Q&O:NH14VPK78/-
L$M=,1R+PC4+B$9B:5*SX5QH:5T[_LW IP MY9O\^938WM+!-X>+AN,MS273NNIWVNUZJ_(=]LJ7XH76V!6L>DFLNM(M:7]6 MS>GK;U-??Z.]?TF[D^+DC,KO*7 99J7$TVXSM)
Y\SY.Q6Y 2%OO:?R[XQC> MR+&,-]]7/7,2N[.X55BAAV,DXO!4G$2>A5+.45U%T6UTFSF5;JJ!+6"K#0Z MAT[%!3-@PJ.ARF/3+ZB?
9"%]DDZ&IXJ3XW0!E^,!O:=R%M7W53ADMPP]2 MSOMH!HU \D%WD>U{(C6P;+VR?]GZDT)R"5T[*K>AC(B%H66UZ,R01B@84]/& MR =6%"7,&-VGD>29,V.!VPI;!RR*FEB%>
]8(:4E#W MR#,`:8$[1GZ0*J +=9N%-3ZI$OBHOA9AH,'5@,/^.0DQ,V]?L-_,U+(_$@J-8 M2D1.@ MS:N^^M=[9PC0RG<4KNI5EV!_T;Y3M/0VC3^/=E)]HKEOPN3*OY7F2QA)D!^D
MU!,2_Y,1/DU*81OSL]1AA:5U@%VT7&RV80?=7\.K(#8OZ8#G:2DUI:!#GF38 MQ 5XQXLSM*(5&=(%6>NF/SYO%,>RX.TL699ADAW05E1RWCS*?:
MD+X$L^,IELLH_<(/>'ZJR1!)OYM*6"7U!-AS$?X 03A!N).XJDC+0U;]2NL4 MM@6:I2S.<,IU/'F4U(^.I21UL0TGJ+VK?K>NG3)@%$,[WE!N>K0:&B!66
MNU4E>!9D#Y$?~RFJ;_!*>P7%BDGO=Q9QR7;[=E?4*O\M#/;OKC--O>0+72%V MX8OV,XTE93#@&_75#GN[N81/QH_\%G&)6-[NT^J+&S3XGO[9QB>&K8O(=;L M.2P61]O?
[+T%78;:M\LN ZQU3PNZ/8U3OT_C,_6]WQ96B+!"2M@8=H%C$^&X MVMCX].$H?';"<)4BW%G9N5B8CX2VKN:S&J^T^)WO1/UQ$KVN=M0H>3T\=88- M*-
\03BY_V&6X@ET/MOF%BTN@^GD ;2?QFN,IM957U7W#U(I? 6/ MO=D6X#$0\D#(@X.KT7GDP2"VR[TXK,\Z4.P>6PC/TX0%QI-V!]>MSTY8" 53
M$$X0[B2NHH3[1$?>^B!1.7I"=Z*>I.DML9)=G_J_OJTC<16RVC?E+=F=6U MW9GS- MB8F5R-O56WM#(<\D;BY\=\T&_T.UT=:,#=E(%V4UIW![<>XY-*F;JR=T.R:A7B M7_2)##BL-
2]|SR2-O49MH^:FS8GK?=)A J#LN-(;I:R>MS)^D_5.8/VZ:/=- M+6SRY6TMFL\I+"Z!:,J!'Z5M\|\]IHH=G(l:?WG+37]'6).
MU1]345T+BAR3VMW:WT&,J=@Q]38 ;9\F$8]\\XPNO!5[#;>DPT6,71VV5CO^2U2/:B**8=RBY /SGZ/CJN/Y$&5!G7 ML@-Z\\RS$?8,J'3U0%V%O6Y,!VSA'%F'[<87+4& M5X#N(9
j:I<8W,X;6/3GBMRSM$FT)(%IC<;3XUWN?NY35)0,3CYLE1!Q _^&7-M5]"FLO=OD]{,"\PJZ]#IXG$U?N+6,K$3? &E_S;AOPJ\1DHMM#9@T@ZFK\1= MB:'NQH,FU5@1A&?
BHN'HA.$;MW ?C8DDBRY\U\HBC*-WU5>*:MZT5P3C4@>L$7J0=WE**PK0IL"PE<%DK5LI6(IE B M!(1+A7"S; BW!(0%A$N%<*LH7:%=H*Z0Q55\[@@^CZ/-G)M9\W?W;6=_6CG
M?-FT712,=]JZB.WN;B>/*=B6!,.%!"X+L;L=+F97 M(A1%*\$"PJ5">+0Q"@B7"^&B\AA5I3A50?BXSRQ\^V5BNH8TTUQ_+B*X=V34 MHI(R5?6JK[,%F:DX,RT#I64G9:K%)64*"
L(IT&X1*1,M;D83 >$"T"|>5 ME*FXA:6(KBKA>VB,AFQ?2:$M@<6$K@,E);=R:B*3=8!X7(A7'8FHRHR&06$ MRX5P49F,S4:!NH+P;E<|=@U+^.'N?
MK!1[K[F>A%39M/EQ3&G;GYT5ER=Q4 M%%O+5_U.P8=6F3I2G1Q?'_C8|=(!7G;^9[.X_$^!?H"^@M%?=NHIL[C448%^_M@?Z"T5]4UFFS*92:,PI:OW2V*"]QL!D"MN(@MA!ROV(
+SLIM%EX4JA OT!_ M4>@O.Y^T67@^J4"_0'!1Z"\[%,79+5ZYV;U[\;F" SQ"]',>8GQY&(ENR^+^ MPRZM0$UE[R^RV!)A>C-+F^,>1-8/15PEKMIVE0":N$H 35QU/E<)H(FK]@"T
M7!4C.D>W;C?L:LL\3S9J.@GH&K2]^GX1)_8\/:W>8T66IW20[N69)!W4R= MD"D,TR2[-1@3)=>NY491-,>:O:M^3U0[$=5.2D%I41'AK89 J4!22B5BPIP M,1E7?
=%_7:"T')0653JJI5SU%47]'2"T2X W$656VJI133_N$QP"QF\%:9% M10NWFD*?%2@M"Z5%!> ^V6D*?%2@M"Z5%54UJM4&?544MU L)M,J0&QXFAA=0 M_)1-
9DT\7J%D4M@Z,**1;4Z5_WNWH&5.59RRW*=(K?O%H"43]6"*JCMLP1G MRC%%A2*WN@48%()A!,-4G6&*.O=L]0]P;03#"(;I-L,4962U&^A7+,BKLF"0 M+%0]L:1M<=;-13"3+!
<5S]"6CV!@7'Y*$56D'N@R^48]*L&@KQS9S!-L{MCD8 MVQ05\M%6CVWL'+81;'@MBG*=UN\MKDN=#<_T^^]FH1^-WPV1T%7KX\};43'(1+FR"#+K"OX|+%OPU&&(BY>
M!6/2*C,6:>*BK/D/4]64]KA'>ITQD9M$[FB:WFN13AO^:W755O/_0(8,'^_N M_^>W3UH_N71'!5'NZ&C[^/I.'C;5T:/-Y)HQ]?1L.[MX>#[\'Y4^6D\/KW!ROWT9/#\,[7[\=?@X
M>+P=#AZDT0M\\.W^\;7ZT_O%<"Q+;=H2O,D"E'HUB?S4">P% M_^*RKR5#\[5?TP3'D]@~=[Y&!;!]=|VK^6D<)Q][AL($RY659@%_P0W+26I M7?PS\'QS/(<'4*F_$,ETE]-
O:C./W(2_? !SZDR:4H++]#GY0A3^2SLB'7Z@TFVW@(!\S_]H.7WU;_5SIUN]DO15HRZG?KIN49UZH]O)!3UGI?4 M]'>(,55_3%U%K=R8U&Y3C.FP8^IM?M*68*W-
JJ.\,"#WC51;,@I9SG<<@V)E M.Z3B_*OC2OZ$2"/SI_0-KIYXTCTH:H;T9V 326W4)*6A-+,8)KL>^2A=CX3
M]PQ70LT3DIBUJE(!!U:5I^ZCX_H3:4!M8"TIG#?)//!MASX!Z]X'KS(@@6TZR M/0$_KV^K)*B63C4:A55BCB,DGP"CD'QG)_GV=O}7FZ*K4O$\VA=NG/0S]B7\ M=!MX,
/)L>"JK64GNRJ19,MFRCUL,KEJ#*Z,6L$#J90]N]PTL.VGC$\E1I _, M7@S^[]>H!2_N%[7@Q?WQI2FD%OQIZ=#IXI$%7,5_WEHFF#>B>NC.@:5%E5MJ-MMZ[ZBB@1(D]$E
/3W'"6^7)# L,)S% < M6!9Q5Z@+HO1HQ%4#.IVF[@##PRV!88'A73ENH"]4M>'FANG!1#6@5'O%N(8-+@^ENQXPY](BNT",$ALO%\&ZGB3DP MW!,8%A@N%\-%-27I-
@4%X2+^\R"N+\[\;F$EK'C/UA&B*D>U>F+;HQ2E>F M52;%Z:DX/2T!I;N=GF97C[I*B 0&"X5P\W=3A9S8%@5&!88+A?#1746Z#;% MMB "NJN%[:*2&
/LM@6TA@55]MB]-3<7I:"DS+3M3L M%9>H*3 L,)R*X;(3-7O%)6H*# L,IV*XJ$3-GB+4!1'172UPMXK*;NRI .Z] MLY O$]Q"!F^%:=G9C3V1W2@P7#*&R\YN{GL1H'ADC%
<5'9CKUV@NB"\W%6/ MZ*8/$-[*(@;XD>Y^2BX#DR>]$J49=L I*:P[YVK?]?@PZM, M'.M:C[\/2YZZ0 O.R.T5UQ&$+ 0'_!Z"\[E[177"ZI0+]_?Z'H;Q<4Q=MN M-(1N(:H0+] ?
U'H+SD_NMTH M/+=4H%^@OR#TMPN*:F@WFI4K-[LW-SY5\)J'I[.XPO#R/I%6GC4=G^@3&|[^-J_1NJM36G?5D@SR:NH$"#*%89ID MM[YCHOK4M=PNJ+):N]&ZZO=$U1-
1].04E!867=$6*\4H+0NE!:4MM!N=JWY3 MH%2@M(Q M<) VKW]*XI Z>G$HIT]MN5V01DF[49/Z E" I>%TH)J ^+7EAD*I M0&E9*"'VH?
EU;EH4V*U:,%D]+ "C"7E0+569$]7O4PJPR)X6%6> $54-EDUD3C MY4H;N026+]@U6%M6K_K=3K'5'S:NY);+E.D5NWRW*U:!950VV<)S1!C"JH= MV);.:1@4@F$$PU2<83I%1>
[+K0)L&\$P@F$]SC!%L4L;.RP7W&)9,$P6*I58 MT[8XZ^8RF*E3&#MUCF[@7"Y*56D'NA"^<2H^2.X>V\P1,"/8YF!L4U3$A]P[MMK$CV$;PS8'8IJAS):5Q:)/G0C/_/_G:JT7@7\-\[_\&/\
(A33?WS;1#FJGP M?/X)$D-)HO:?@>>;XSG[R+0-6.@;6:VW@+L*GJ?L;@*)R*CK5@CHP+M^T[393?B>9'$68(UKP_&O^9I1 MOML+>,M7?:?6[G?KJ_4KI%|R;U6)40X?
Q^!=PK81FK*J\V%TDR4F^5DGD M4Y%\+:,537Y40.Y"O51$YFI1]WV$@'PP18I%?^(2(DWA01-/(L LAO1G8!-) M;=0DI:$T*9WA%[4EN<2;?7N;E:.[%X)L\N&&Z7M
BMJWZKIK;4^JIV1,BM(M; MA#9=A%4+?S<,=THB7P?)U^@UBR%?ISCR=2GY5BV[&(8[\V=^!->CW8?N-?AX MG(5!#QJ[_OK=IY/C$?,?-M",]L%]-
MRP*RC(B+&7<>]<@/FVBN#9_R=4B28W7R?*]5WFA? QCO[*<#]"$)*I+2#/7 M>3<-NODRED :Z].X$M.2"TW1]T(@I);']<5$71"2BT>42&/?F5+<(R]ZY(S3L'A';P)64929?
JI>I.D.P/$p/,?4EMEIA|EO^]G_MNV_YJP>>1_R#;3R8&LS#],.H7R|`-60!5[THBP&XS>)!O!N0[N[K5 M2D4)/<(1/%1_F;(*2VIL X_4 RVO_D1P0&2>>3_7N;E:.!0]UKH7|GCI>
M;DU<15]3357E%$Y\;M52?$29?'D99]NB4(Y{JG6>4P1/=QHX\1O[IY:K?Z.!}>6#;1E8D#W30 ML=&3U;I:%1{@FUSXHNCDEAX7%ZDR92_>Q0^UJ?YND3V[?QQA:)>@-U K=_58
M/H,1>]K^X#/U|&[!1];&-*QU=G1\T+5Z><7)Z%#^ZT M0;.##RX'.+ Q>+UU?-!<@C|[Z,F+3P09^B:\V%7{CCLB5ME7014\C8&%MTU@
M_>04^LU85P'KW5;NX#SA53L;K]H;?;)M)7-\%SD>R0(=$'2<3]*G(_LW$%/ MB#*.TJ0FAF9TNSN>1>RU*(?4'P3_"/[96??8R#]8HE*14T)5*1D_*;4
2W7FSX4Y#,@*7Y1].B#2#ISH&_*KY+%O>M'4KP!QE7@MB M);_T5;-H6"'<@-^_$]"$C8|SQO$GYD^]WU+]X(Z,"2B|!1Q|$\X*SD-EAAH MT4ZK&I$[LWU+68"=1M>!T352
ON+/*7Z0+W&_A.EUK_J=3B'$WU)48*?1]6!T M2MKHBLS:SYJR7*4<_5N@I.E++#WBJ_=VQ+*#'A^8:YY)_?TO;^A.'+)5#.IA,04<\+0 MSJ4DEYFF[?DN[#RV7Y?
RI=C'_=ILX1[HZ)_LKZ8-G\-K8Q[N-;GVK09C.!.X MQACX_#.4"# Y3^?2EF EEJ7U5XA&?B]NM+-E\M??E6 3KW1[51L M3!B;UJE.^81>O:EN?O>1JB<4B1 G$DN?
K]*LI8,>.#A/3\K21PY_V'!*MS<'DT(\8?3&;S/L\3 M7X,A&?>;BY>D<@_6NMB_I_&};QORRI;M<6*67EQQ55]) M.:]TTF%. 9^:_$HFG3HW4-J-JWZK,+>2 y$U@)+7M!4
2F8|MRT7IN<*$%41 M1 7*&GI85Q59I154+NMKBFH M743?XWW6[DB.&<&]@GI/QKW!!.RTF^E%N 3?"KX5?%LZW^X8'-1N%1(<)+A6 M<*W@VOQEZ?CR3
M=N8"4%P8A^022\/<9=^A5^]+3&/7|/YBS<] E36+.G5!/FO3^-+)RKRH@Y>1 MZ3S"S%0UI3WND5YG3.0FD3N:IO=:1 /@:]>Z:JOY?UAH=5L6_%(M#?R3X^4. MQ=M-J[E]P:
[E;K1>_=|>W4]+F<*QEV:-`S@%@]HAE+.?">+]-R_}3.(C^3;BUNT5\|XX^^_)2W+^.'AXZBTM9^5G)*K(-M/>R/6K2|2_KK4QC/5&LSZT MN8?,%U\X6"/^[ZRT?
+4UTYP/"YM@@P'("X=E|+S!H077^Y'T\B3]>!S\N!N^W-])MT^P"(\C]MOH MZ6%X-\"/OPX?!X^WP\&#-']!#[!=/IY4?WJ_&%C P&5%*KR)YL*C83N!-UF
M4J\&>XQ.8%^>$9=]+1F:K_V:)C@.)L8/3:-FG6E&JS\W%N.0EQV9?P(/GNUY MM\|TU;2I&+@S/1VV\L!-*;O1[JR6W6AW5LMN?/DQ&C[>CT;2X/;__1B.AB]# M0"5EM+OAZ/F)?
[!3OOSZNG6XK9QZ=+>H6]6Y.$-^-7A-6>M'T?P6F2PNV< 6(-MKQ,OW1+]3AH65V452W3-F'AB3:,NCA)7G%&+^]B MODT)X 0^;/^@$<&[|=] 2W AYE+*MT 4ZK6MOJ2"3?
LE'A^Z6PEXI7+,HW31$ MU)ECDSHJZ/]$1/G=<8P/D&(#VP@KTYG$@VL_P.0,(UHV/%"3K.,?]U)SZ[S M;L+;],5\OZ(UQ/@E[YRWE L[W)P[&-K13,E*^955"?L'\?R9IDL/H-36I*&M
MUW//=4MUK@/.%619+ ^UL^59#D.>;,[?:\YA,@9T7HV)"%[X.5D2T;J 6#!*IV^B6C(K MK6X2HI2^\"]8_$*7%3L,]VK-ME2&/-="70,_XBOO2N60$)IVG#!WSBH>RO M\
<*&^*!|A'JWMQD 7T+LPF//GC2&MJ_9:^,*8]=5H~NHK$G4;E@O*FMF##CP M=_A8/D?0N;$$G6D$*.ZG2"Y*'.TGC-0(X#%X!1N'V/ZJVC8'1%#FLV5!IC,M
M=Y8V<3P):J85#]7UP+!HI6M0"_$+/C HPH1=W_RW%J^JAM"#1UWKH 0+ +S MYA)"=ULJ!W1>T%2R8$MPU5ILFL@,? M5,D:'1#5DS?RPR!CQ?TPHQR01@05:DWYC!.Z<:.Z"?
BT$SK+N)^$UWE)E0DHN MY!-&*\(NSH4LOBZ\HB[V07C7PX(79>KUZ MJRWGKH]_5\QM;5UV>1Z5RF&4*K MWNRUMSWJ4$'_IU5TH]>IYM0:
(R)"":Z3F.9&Z^'<)KMJ,YS;#%,4Y7.,XF#* M*B:&^HD4\ZZ,S)_2-^9=N5_UKIP;)X1#1UTU")DBJHT,% +82HC:I/*DK M_2]H58Q>H353),V.FD=6Z<@"]{4QS1U_(4!_4&-Q;?:HJ;%
<5,1%[OF?3T"% MW$MZ8MLKO2YBGM:A?;]3!XOO:.S6/YLC*Z937*F\O NX8TR48"#!0%5BH.+* M)P@&$@<O2T- 92CL9 7<% @H%.GX'4HS%03S"08*!39Z M"9@[GE]GGE935K2-
M^X61GH/;N@W!;8+;3IW;MD1^I7 ;/3WPX!?-&MJ,6 ^"/(,S#U,)4:"#4I,83 M;8OX9.&?O(U"7,RX,$76"R\/UQ5>O*-LKCN4]_3X9<). ^RI!WFK5D#O!XB5#
M^QVDG...&|HVB3J49079IJIXX9+,|^PQ2I4+H0H E16Q7!R-5 &@:@.HG##P M;0!.!4]AM44$2(H%23GQ\\5)F9:0,E4&T $=61ME3%O(F*I"Y*#>EYUDS(GT M!! F?
P6ONH1P/^#'&0QG7!-@ZK9/(_\PZ&^&'"=]QU?#*"1 NTG,N$3_PH0N4 M)O&Z&)?7]4C)?P&;HQG^N4#3PVIS1773$Z Y66-_ V@RZUR]P@^6!:!.UC%0 M'"* JW?! .J
CH(\FUI/N=IW!RI8+B"3#3*_I.4Y\&#!\%N+H1<\.&"]VFU M7*K1745X#"IXU24$"81%1T2$P(88ZC5MH'8LW *ZW>]PBN?.#%+O863U#>_MQ6Y=]976_L:X6.Q2%GN+!R?
O8K>O^LU685UUQ&(7N!A;/"^;%SN[?5OI0RJ! M@RVGG'E9OKNN'IM8ZRH8IKT5{!A!3%/O.ZN, ^^(N^3==)O/8)Z>,2S6KXP MNV5Z>F?99W'8.EPN)RD.6*MQP+I8F)0>+YU&
_BMMW^/%^%)/4SU2TXD;%_M>"5[P N<'#AF>B-.E*M^J[%_2*/ R:F?CB9PDM5>[#2*2\0s#KM\|#EZM9/ M_H2X+Q/+#HW2-/@TU!4_%^ Y/G@.'%*]
<9]JI=N9QX>),*?;#CHJ"O:Q,T_7 MX5-9.Y.NR:-CZX'KPHWLCCP[?W%+H7W\-2-T;W!)(X=*@ZF UJL>X.IN.*\-M DRG;M:N
=,J:'IK^FH)Q!P?,0>T8K/B16X(O%06+W)O2[>R0YV79MZSY.+R M*L[W0)7.H5-Q6_?%\;$?7[*[W!Z%].1$(;T+]QVY:?)G)*X..?>OW]$4],5V MZJWBBT%N6,;RZZ*!KH !C[@KV,]
ZE7_5:KL+-4B3^^"\|1O,.>?YIKVG@+ M_A\'4W^^..!':SN.Q3*?QSMOZ]=S3ONJK.E.PCV"?*LSZ!"H8?(5'
MV#I>MI:G.@75+2B5F0[EYCQ^38#3ODJ05Y#W=*\2Y!7E3O:4"1Z(YA')6NBT M^\12[J$B5DI;JNQIRQUA;;E>M)^Q+|-4I6)JJ>9:W ,$&EPPR@YX))$=9<44
M5Q4HJPS*#NBX7X>RS$$N2G'56 4"*X/]^\T=@X6%6 H''1N!!FQS/3%^S MJ!^\]HHH]+PUDQ]5X%OJKB854:C>/Z6#?K=!6(/"K6*Q)-6VMAG.9/[M&OL7DJA\2)-
^D1P0^XZN5AC-I$QBPH$>GM)VNB;T)-=O6UN#%. E&G;HX7 M@ZCBLK@%HD[=O"X&4<6E<@M$G;;Yg$3$Z@I-[;J841H'+064;O1ET!*DN@ MBAQTGU
N9;%K,J:R9L=5FKCJB^+D\ASPM8!C>DMV)+%(?=Y0>N M5O5N*JB'/%\X/= -4WO'6%77/5= ;N*P.Z]OF6;11K\|K[IL,+9%7E$/O(M:4),X-821]AG=H3]2'Q1".G2$QDKZZ
=*:)H3.V1&L7UF%'I $+[CEQ%TS4 M5# "%W6N^BV12R^8[!*SKH*S:1.2R"=PJOG"GL@+*OS>+RTL\IXD]^3L? \2<337>=# MFFES!(8TU0PBE;.D-
!0U0\32"9X_[/=:R^SY3VEWAV9.9Z9NB$IL"$U\C8U M+N=XZ>S7JIUKK;)+NEV/K,4R%N#-*&X9FV(9CV=/%[>,NR:4B67$KP5-5XJC(4#JW&3A$.@]<$3U6-IRH3 M\-
"2=PIX$#PE>*I.;%5. .,N'*4 1_7ROJ5ZV6.K6PB-;.^:W'X[UB MO:R??!1A|*AOO=_@Q_AU5/-?3/M<(;H7N6?X*R6O*VX(N9XSCXR;92--[): M;\W\PV-6H;5-
;>F;YNH32>G6,#BB69\"9$ =S"8N:39-N!*)P9\OF2Z4LP M8@+"6S)MWX&O)>W-)82&6.#?3+1+'K&(#H +<\ZN)74E?P?^8[-LB_;3VIDZ> MQH.%R_G^YX5.(XTAF]CCG
!M8:Z((W EO@;`WF%6=N\L3[X!'P M3$_RYS-2@[?H5H"\)&FSF07.@MSGDK<.9((#CX1/0:0 F7#@KA.\3?C=L2<^ M.*^ZX\XDW*^C5;8T8%_V#)]X*RD5TY5@L."4<-LX6X=
<(=,*L':OMD.7*HC M10P8!;S:", =[X1^\,$ E/[N21.V)*KN.IY\A%Y-O*\A%Y<-@(?HS@?P MJL@)_^NX?!$'X!|_$MP;V40^7L @6^&@1O %FI5;N>%$DB M#<,)+"-
:3+Z0KX2^(:#74UBP1VG2NV.!@H.#?UV `"%[!$S9:^%4'ZN_(]6K% MN?XN<)$P2#_/_"E-X8:)!WNQ 33Z,[")I#;H@JM+TH";6I+_X<1E,TI*O,YE M>F(?<2*

CL>OL/1T/7\"VGT"_)B+5;8PRC,+R?1>'&X)?HD&!E;?TQ@/@$,; M,8U/,"U8;:>X52B? !?$SXQO:)[IX21A4G^2,:@@'HR?ZQ5(B/_6+(O,I6]< MKCV$NQH6N8,=^HL+3P*:W (@;-193%!7R(_@<(&EUR$?#0;@VM/^JA.7WFKV9JA<5D%BV!.06(M",Y14<-4EE;,*>_.K9FH'PUIWFRD^ EP3 M,^:.0!V6/Y5/L2X-@">`\@$ 09LBM9 .\)!K7_L)@Z6Z"E[_QIT7> [+*5AI$ M3A(^828(0O-M=>[=]WZKD5(I1OJ`7=\E.ML;5 - ,H@+#@9&F#/84_ 6F$BE M;Z'@0PK@/@]FY4+C9W*$[2]T08*W A5I[#I3#MVX_`-<CP M@X^J3^>W99PK\4CECK,-U1I;*P%:T K!NRB?@'OM$?,\OQA&OXD=$'%{N)#:RQNT5X|V,3\|;?$QIO3 M0_]{ZH[<2-(B_G/B+]+;WLCUJTNTOZZU,0SV1K,^M+F"IOX0L&;\(=W%'C[M\|MS7SG \+FV&# D&BF,]:F_HUHU7P9BTRHQ%FK@HYO[#5#6E/>Z17F=,Y":1 M.Y]F|UJDTX;_6EVUU?R_YE5_^'4W_S^_?=+6P_CPZ.]DHNMA\,7VZ?NS|,?3 MP]WP\?>1-'R\A9W_\4X; ?@R&MX-!]^'JZ/*3^/QZ>5^)+T\23\)>!S_NAB_W M=|+M$RS"XXC]-GIZ&-X-\,.OP\?!X^UP\""~7N"#;_>/+]6?WB^&8UFPJ%- MV)N RD#5<7B3AX MS&O+E3QM<5A %3YXBI(P-FK,6.3&PQCL%8L:"MQ"P44R>$|("75EWPW(=3#S MN%X9>SPS'IC_9@QK{'R@GS_'1KNZ1+ >U#N_=.B@(X)F'KD))?_D<>O9-FU*7 MWO0Y^0;<9)=.%>@+V=>+[:/>8%L(C[!F;^9?U^&K3ZN?M]MP5ROUJT9=_EO1 MYO8%7Y5IBJ[<[_0V35%CT'H#$WTJ3D\|F:),GAXFVKZW38_5.I9\074*3#.G/&;'#,S$'.Z*=RBZ>D@N< M:67,,DEXE\Y$N+I5COO4L8;^@<5N#^=!;,:.SK#(8SKTG ,(%^C MCC[#E3LKWC[=CH>Y>B6D:*8'Z980 ND9832PC?L01&ELKE[UY918P.PM$PK] M;RCTE#/34\(@+.27*>KE>247"NY: >17(MX@[3V+FV,7.[5F_OW=Q'JR'; M#)=CG,Z*D4]7!;FP;VP+`J9 U>BEZ!K';.@L%(ZS[OB\6E4)5B_M,D^9MVGU[U4%4H69\0L2?F4X*H'4#SE\8|CLD9=W=|QL1?E33<2HN_NS!.T43L$@Q7),=EEE^*?TUN5%Z^ M=;_ZRE[R[3"^MFIA6T1K"(TUQ1EA+9#1G7.8BG$GZ,\LN92<,)T]K9AV7+/&\]WUEHNBCF#,Z4K6 ME:'EPT)\)$%4/T>P .L;(M942. X3!5B.(K\@:V:EGB;.V&/TCR>^.EM3?M< M3]%3R?E46_5.4RDFYS/3"^5V7>EUMKTPX^=]MWG(=-5L$U3K[7;[4 M.IEU]HI3%M6]#'#9/MT#ED,X(]JO;_9=(.W/B%[%8/5DIGMYQ2N^DW=B!{N> M=Y=XM5OUYJRDM*;H8+X%,) ';KY3M1RYP_';NB]0UNO%VPV9@U4 MKAQ1*

*MG*EXV<,$!%S2^!+RX'AIP78=;(C4:*4$3Q^G>-*.(N+@5IO@J1/G MJ3TLL*T\A>FF/36E^,?I\]1Y)L0><0SY]U*%_!0A^!U/*>QI&@ M&X]-R]1\,K"-YZAA\MJ:(AW,4E)31!SON1PV 93>-),V>=UO&FL2M'Z'AZ,0 M?K)Q-HO)I RXVP'AG-;0$>&=E3]U690R]@C,ON:]0#;N3N=IQ?XT5' M:H?4JK,-:O7GQ@:%)O*RW'-/T#-Q1{@UZ06N_6(Y^E^+U9"O0@\1,08^_PR? M1&#E9O I[.USU;\??'^DJ;.>[!]+HS\&W^^^7VQ(FEP^^XX]E[26CUUVGOU"Y M.I .,35\T#Y8FL(M>E:9K'!V@"UKW;)YFO2OJIVW&FW)F+RS&XB3;SYBTE M)8WUE)3L8/K*NLGSWEF\G^LB3A_>"\(2* &+3_NI^R >X'UUZ^B M/2R^T807ZK2/JH'/I:W>8SUFMD\@'"B?QV*DTLP*8'".CSU=-N!JKF6R%^&?!HA9NAG 11HV\N6]PU_)&^^7 MSB_DC,-8PU\8>%UZ3AM(2C/VTQ*47WH=2%GTH*S 6 MT8>RRM-X%'TH,_:A7*\!*9&#)%V-6[$61OJ$& 'JU93!FNOFR\1,JZA6O=/)FI.WIO/NEJRZK&-JUM5& MKV)C;M7E;E$YD<6-2:R=6+M&O:6FO^.8:U?4F(I[3G*K,$K)P+_0^>6SQ@J<6/-+/X;,JPCAGO<|$ M :[!NV9;-'5N:5U$$98EF#B6*A>SQ!-4W>8I7"5BMON6VQQY:YQVY9|[WW MV]LL=UZIZI++H13Y7"Z88]ME[W'=D%"@05;!;2*/?;D89RS5%PA>VP/"[J MPHZMTAZ[9=WWW6-[#6'""N%4U\XKE[S'!F2L>BA78H\5;*W2# JL)5W$5MK# M_F5M59BK5=I*MZS[WEN2LW5=E677 BGRN%TPU;;*7LK;6*!9?G]]=>/,3 M.2Z^"RN^PA0{W=+IC/+F1/"I)RHXDIKQK$*K&N#%3)T@3P],4X+W"]?+!ZZK MV6_TOK0#^%{K]M^H*P6U%]P2HO9+Q:D^6B15$E)",%\]_0CI6>76*/>LH1SIV4#KNW?RR@H@2TO'B^4](QRJO3K'N MZW*D8U=(QU.5CJ*/J+A*7%7!JP1CBJO$516\ZG*366/I.3? WYLS;##W9!D$% MXAA.@.VJTM*?3SH*

*>QT@%9D MLB\'UDJ URK2N@T6)IT7:,?!DPC^JM(,CI0/" ?W:OA7MR'3C.#*IGH4)MI. M!= 7JB64GSK<;2@[I0Y72'B+/;^PY.,\>S[&<_=. BSZ\A]RIKV>- *% M[E(Y\)>;]!U-=^G0S.]*^"N${B)TEY- (0^|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}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|(LWFU;[! +'A@O#<-](E%G*W_ ZAR&;|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}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{ E^=P$T;/QA,"NBIJUR7"_GZ..':]/&#Y]VTNBEG*XFQ]^M MY9=PA)AH^O)SO#IRLW^$A3U93VN$=Z MG3&1FT3N:)K>:Y%.&_YK==56_\P/X@_9E4C0OT'U2&N EYC7-Z-W-VN$5WC M1:4K1)U4A:A39VKPZL^[^R\O4I)TZ7.NNLXWF@#LK@$(4PGT=M?Y@,7Q6&ED MV!GTP'5AB-(,L,+.R S8H5MD&O(+)[IXZ8W&O4&L^_X:2%_|^:6ZFVYW1/S]7-?VS*^4P?Q5+&6\3@H M=?/+BVE$?5I-00MMB7ZJ1-C<$? T2PKZ_DW?'>D?C K]#\:>[Q#!7&L9NF_/: MU@.[MCK_9$[TZW0+2_0KG;4.U./EJ,_MF8OY]Y&CYKN>#$#6"-$*

.DVJ@602[XU+K2*E(:[A5=?S)@5Y0U9WL(=U5I MK<"]F09W&:MI%J=Q5T"O%A")063-.68NB"C5@L@E]
!4Z^TU^F%+Z(>9)6([M ??VJ@+0RGM4U<5N"[5&A?0#H4"6*3#S(FBC$=YM5J/:SF4IEW=X]F=Z7J#9
M.H%9>L=H5'-4"A21T0/XI^>O>)R*IZDA02D]T[".,<+'*SXA%,K#!I_GA@>&
M?.S56$XHD]EK$J^&1J!**O"EJ\3QN/(>JO!2T==\A?'URS)6QM@MC6X;,?3L^UI M*_>U#F?
E*OU6CD7*VCE1%E67TT;E:\'HGGDP=1>3Z9[/?3=G)O"+O>-R2B)Q\L+V%WD_1HA\DE@.X,W"/% M1'+UE,
(BN%:*;.?"XA=+U%4[:6!O52O?X20B&,]!&F8&2+L* +DLW5"I M]];HACVA&^XB#9&@C)R4F@9%>R\-
[5B+M'7LO5\HAP<7A]D1TJT"0BY+.U3J MG73M4)6%=K@AO:N[>^=E>U?E=/@CB4DE$9*]H+0#T]?
("HHXO:$2*^!1234 M1NXV'4)#W'V1F^LD8E.D3.]64F<5[,U6&MCEJW{OZ,XAH2 >OJ1.5H H50"(
M""P5@00B;_P(>>,8T)LQ+[C7P(8#:IZ^4D*K/N6F97GA@?T0L M5/Y'D<5>1&EF8, 78,!XLG(:
[[4PC7UOBU8H^15$R+;BPQD1TD:$M$]#RS_C M//824],,I:2RGF1I\B((='%[#!I5CXZMIQ4PWQJSV6MTL
MHH]DIS/=>W%I6 MNXG (;GYC!+3"^;F<],]N3F[E6_66NTFO7."7/SJ9F$&=/!U95T\)3><$?J M=<>:8$A?
-1VK()C$VRVUN^K]JK 1[*TSA3?/)>QZZL/_/4D+C[C#YM!0O,_Z=F!YH{EV25I9&#\:>DYA3/W-
-6S=GH&DNNL\&, ^PPNT<#RG9:QY.PX0E? MZODW[:FRWM,S;8XR)9SQF! 4
M0PR(@,0W$$PPO>G4]!&3'DP%YR\2$NMJJ%B\>N M,Y4X.1^#*8A@?
8E^J3V6EB7.;32FKX3<$4]W3;BF.!I^@2D3AJ7P^+258,5T6')/<;GK%(+N*TWV'WH1?E9W\D6'00 MEX8*K&= -$?
P=Z*+4IO-XUT^+UDO"S&",N,!:^G(X-IHM;9Y'-E+-UO^O) MS37=[R28'&S>;R 45B?<0-.]FD,W5J;#%B"_"?
078XQKUM1-2\5A;DQ!2$>G/5&_\WQE[+XP?V M!DGLX40'H+Y9(5W:]?6MH;DRVL2:12!(*%/?
N,32D("+4D5H6L;NXKIV8W&+ M]@IV5N"OOV6EM,R1%&Y93=(B_G/BAJ.9:6_D^A4TL+^N:5OR&\WZT.8>&EAQ
MRP.,#/[P#IB:*W-?.\/QN+09,M,&0(G[ZX,%8!X%8Q)J\Q8I(F+//0?&=]X M7_6'CW?W__/;)ZV_%L:'1U>ZU?HP^'+
[]/U9^N/IX6[X^/M(&C[>@JAZO)-& M/[Z,AG?#P??A_:CRTWA\>KD?22]/TH_'P8^[XAG<#
M_/CK\"P>#L9#&=AOS4RZK2PE-=@@-,>Z<)ET8F.K4A%B,(=68;$"3Y'\0"XD]AF2=>VFZ/&L5V M4=L"RW MKD,/(?
>@7N.IP(WK3,G\^K/C5:CO*S)C7Q'_VOB M6.@DN0=D^7,\)K\S/=UR/#"G7N#>+Q9.DQ;-.V & .??X9/!OM2FZ$T M=
/8DY^_WW^]__X=1.GHY>GVO^A>2^^\C6C^G\UFZ M_W_AB__NVQ\)A<2'T *P#EVXG[(\6I*$ M^UO6JO1,\N>T\M!7X-
@4#R-Z_R!Z<9I%U,58ME::MMXG<5KUS7)FK,X)P M?84*+JY!4Z)(1N"&)RB>^9/K)!
([H4JLEH2*M1=,@0!43+P2R_E8K>#=6LU;@OK.T&6 M3HG$[G!ZG !KCQ*Z!SOL(J.9Y?0&Y)Y?GW^ ,4DQ7*5@:)O
@F,41&]6[" M-^%_KZ@Y\ VOA,?3S=6)7&:W&VGMZ:M2+9UY1GS^ .LFGYX E)HQ>3+UD$I M@S:8N5F>G+
Y3E&2Y19D><].UEN'"6H)[MW@L,U.SN)ETP263Y13/=04^!4 M)D>$@DA:[(S2L^N\N=HT:ZI(73ZM((U_3$@B3#
(1L;LXO>*R;\2.KFA\+$OA MF&DF/8U;W,;<|%$$#,:]>%X858N'7AC@SA)*V/$7GNQ9EJ-K/#HYEB" 3P%EWWFQZD(
L,;$887BV2S#N [XBFFNS(.QSQ@D!SH+ M.!JP%|\ZGK_IY!;[;C>4>GNUD)/AO%IEC_6R-DZ^HVC3CFWY8'\7QUWL3)/
MX]CFG+(2:F-=$LR&2.P07!/-2![=\O-Y)@IH$@<5!H[FTIZN!A!2]QV>CQ2* MJFW9,QD.L;M;\,GWCTC"P&
[X2MRG\7)8P8OSA<10G48O>5UQT%"ZQD+[8_"M M2T\VD-*:2TC$!2F_4-IHAC-#P:O1!*[EK WJZ8R(BX3>*>$HF1?
<"TGFN?X: MNJ&-DVKY%IL5^&6$::[N4L[0P)TBT20F4O>32?P*+WJTM!> MI"?5%AMBG+!)P)J;\D;6J<;-@^
P)JU5I'LZ3.L9-\BE',)J*8AW)B88V<:9 M)@]_Y5I4KHT>=< RMI.G<43M-*@U 6J*DK:7QP))Z 9NA(^ALG!CH(ZBK@PG
M&@0O870'7'U'=$M#G4.;?T,R@1;ROZ))MG%@ NO*17Q@=>&-J>)T==DD08(M;^LSV=P*_0C+28!Q4FN\#5)
(I_):U[Q)-+.=]1%%;<<78_CX==OTF43>H(FH MU#O843;$D"W"*$:QQ_[AWI7X'F^L2MH4ZOS6:N\Q.&YQ,@4\Z-
IY5U;FGX MP@86A JCZU#LF%\,P7 :^"9-&Q_ M#P+%>?)I_)T.<&*@28]"-Y -$M*+YT\?,6I$& [.)*!Y[-2 @&SC@-,BUT(
MGP@88$_X%#">#F9D+.ETH9&L*JZKN^=Q-L"!K@?3P*+6^A/-LZY/2S]\N!XWJ\[A$A&&HP^ 8O;@G6-O9.^,O'&H0U
(_BR-<&2S4:&8,DM MVW45]F8:*@DS=VR:ZHXHBZU%F.\27PL2K86%:Y$CD)(&]VJ8$V)9SH>W&D.9 M2753**U.
(MBRU:EWNZU"@BUEI=Z5U5R/6O]Y2]D:MIEI4+VZ>M@ T //3V[6
M*9=L>-1919+V,AVW@#H/?]H2JQV@SZ47%QYFL2UK8*#Y037M#*&EYTB>1^)+ M7XA-
QJ8O88Q13I(4>9YRCN3=555 BE](:,L7?EK!U,.M0<3E!@Z?38W5DR^A MNE^-?_&#
[\MZ],9M6B^9X1;1FS'6A')Q/XQ?M9XK9W$0W=2>EG'/NX* S MJ:$JF%$PX\[,> >ZB4T,KJ0\X]? AS:[Y]GQ?))>>?
2)/TB#I38R)1R)R2BFE M4V#,(E4MP>2"R2O%Y)N85KWJMWI%=*XIE6DO*MY5Q,[FCYWEI09I76 M@Y%]
MGCE4N83,RB'I&B&S3K*DZ?'LM:_Q+3ZWS731BGTA8SACN]XIN%YYAAH%EZ; M+IGP^%65]\H"N*2F/I<#/
331DTUU&9185W8E&OPMQ 6ZZ'8 BA6%XCEZJX" MU <#=3I"'^<=KH-E&*:FF1*$=')Q"1Q-
9EAN]]3STW8WPC27",9)VVS&S23GD MPG(R"XQWR^N-3=/BUN^;7V$)!T^WP^\$J/9O8OR8.?8(Q-23^V#^*S ->GE,
MAF6NL=7L7/5I$4'E:Q& M[IUA?K(=\G@7@8PA>UVOQ[W>+!LI(U8[54$JQ?BBH)5X/T<: 3=Q?JBCJB_M+)\FYU,
[6HW"U [A?SH%L)7I?DJ7R2TY/4FT2O 27J7S@.H:!"I50N"%>$"2 MP7@;R[MD/&T5_9,OOG]R+J-DI=K-
44/Y6IC,V^G5Y<*B#X[48OEP<4""X07# M'Y'A"PP7;-'TZI3*R6?!^U6/)Q1R1,B1(\J137(!@RUZREXGVI40#!DJUGU:
MZGN5J_-9Z]PZG_5VZWR66K/1C$)Z;BE]WT_-8FWJ?U9J[VT/<6+1)-WGI;&X]- MRP3&]W[%_+&[V)U@,PJ -TE]A--
@ST\&B"5A> MSV(-?'Z%Q[BFAY?SRAL@%DP;NS_J3N FBTG4I1'(,%Y0 >LLL9&$\PUG1-LE MLFY!KUBZPC>Q**#-
JSS1\@YP\U1C3:79>$D-WL+NLAV?E1ZD)0MKM"VT91'= M#[#6H.O,0.C,L<##+/"Q,3J6PB"NCB^A/2IA65%]QJZ F\8P?
%:M$-.)=QYG MPZU%#0BN:2-E>"L?6DWR%Q$!T9>+QWI$#UR@?-A_/>KR;FD?BV?@5Z:-U>;, M9-]WH,[(;;FQ192-]]-
B[?0-'F/3H, D WL (]H>G- Z-K(X#A?SMHUZ1LQ
M0!!C\1>7_V[2FAF$MTV%1\#%,$AVS9MF_)8GO3+M]LGP"U6V2+8A%UZQ<:J M\.^,;CXZ%AQQ:8=.PEI;4H+;M
FX9EGDC3\'@<+O-,$F?H.=D%,G L0K[%3 M7KP F.E*2"2,XE:TO(Y:7C>3M!
MKT7+:J'R6K2\+KGE=;HV=B09Z$_H3A%M M*!ILF;['RA!C$;.9YN+.DFQCZA*=P)
[@;=I%\1%LJXWV9+:OAEI98G]]=0R3 M>!LT(QQ43#L*]$GLN;J&I8Q1:P@K7H8CC0;!YQ%7"V:3N6>"-F/']8()T2Q_
MPG9OT&:PZ)6[W C;MTZ&2@]]\A:?" M*YB^.]!JK@#"&UU>D(GK@5ZH[K)W\$;IUIQI3H2I1LGBNQXH:P:1QO05]$'4
MG).X 8)=T1?Q\;P^F4"BB?H[('JE^U\V$OX_I6^VT-;@9+X8V):
MK';Y@KNH2P5L$_B24(ACVV&4N._$IF7]7LE$L\8AP:.EL+ [O#D>'JK1A.3S.RK%)CTUB(7L8VOS\P \VGDG>R:*%O1EV
M@@T[UYM4B4=S!=ZF651>T*;W%$KX%<*$&3Q,J5^Q/E&6<,>WAT+& G#B$N"* M\G+?
W#ZSM%=4M!R0H5Q,.5S,O9K.#/:QJ1;_!@CPCO9'R$- 7J VL[I=0-_$
M^8#)N;5XT7I8!AXYOQ@M&RRMCPB2&X8TT=Z9G4D1-W,)L_I0,C.XQ6813I\^ M(T8!WJH9@P]K6>_!]UO8.C?Q8E:
(T*4@%<0#,B&:%H""8!F$=6!(+1FYS]A MFV#&+JLK#(8LKB$.WZ9R"Q;Z@[Y&,X
X'NX#&HO)B[%H77IVJ.D%#P*P<4,> MV?;==='@-J\C.7SL=;KM3ARB52<#7;/.E\M %*YXV" KUV+['!ZA>(Q>6#8/
MWQ'NO$ \6#EJT4@$I[0@0 M%H#EPP.YA'M##3<3U+(*7PN-I*D#BS86/4(FJ^T.P*LZ\3TD)-TQ HBSEV@
MRH.!>F%54=^E=43)3Q!,)J%U@%$U(+YO+39@>.D804HK_7NL&+F.8Z:RE(K, MKX/1%U)=)PHCFJ$Q5LUG-
4M:)/AQBV].*)2,U60\)X2Z7Q.>&KK=$/Y<^)
M50!]#:2+Z4UHOS9*#L:RH4A(R@HZQ87_,'*X84%9V'F397:35);,,;W]@W4P M<6+NNAE>A2CM-3C8XZY>6!?0
YZI<*0"0W-_W9]M>@LS"E^49=H@Y24!X5>_MP&S/259Q-AQX -X<40O6$-4RJO0RHIT%4\?
Y!K@AL,,]EQ$&F0VP#C1EU84C MND7TI(0/:T/#ISHA!JT8M]ECC!\R'N0L+!&3V2CAIOI*8%E1BV!I;HY;"]6N
M10U>@.P;\%LYK@^JWG,9#5@$U4$7@;Y%_/7E8%RL40TUUH(I%], M=J5+&%EP,T&=
<8ZA9UQ/!1;0N2<;]B;F:9_-0">D]N'4X=L,/"IZ%O5GQ[:Y ML<8[:W_CDU9D4+C[LJC$CYR7D8((6G$0"?R-W/
MG25T5WK2?0>+'2H-K$*>;$+%7ZU)M_0%P\0+[N@+%EU>1M1(!$9Y 8[TI*?Q MF'?HP2\'/FPU-
BSW[V"TN73_B$X)#$%$H[6*F/!?-=R9:5L"5MV@BP4M:#1C'GZ&Q$7Y=PRJW M[R8J,Z#?
@)9!9Q4:6%RB+)$1^PE%IKU!IS.8N; 8 P1%.IN@K MYC7Q5MTFP#]3TT?ZQ;P?+C&GK^BJHSK>RA)P6PF%\P1XE1E/-
OI4^:,8E9(W MT>R8SF>/#\4(U;=76"G6OBI4W5:LY95!.R '78+R=1K8W!Q>##/5YQHYHF/ 5?CFL[YDXB=-G$C&F?

*0S4T]GD#N0E5$6)J 'L/GR8,#89(_47C M9>I%/I6D|V=IQ= .H&?6 3^?Y6$HH?) #47*FC$K$5[S06 #89(2K;(Y:WH M2G<-#PTI(^*.04(;A&VJJ+VC#RQK#/;,"@87>R9*O';6;=_/-<6'O!JV(6H7, MPX0^7R#169@8"QYB-9/EUNJV0RTJOFMITBSPV(,] M*$T]P_2>09#,I3NZG;W7I8>%K+SEH1S<"S:@44Y:32* .:M>|BPVCKG&&2(T MJ$Q71X9DTHPK*B\3$RPI0$]L_PXO1-3_ >CU7AUVPA;NXU]A_*:A,9Q3_S"R MX/H-E[D)"0,]OQF^!$-N2FN1TX@=I-]S%$6"YR2O\T5X"="7JDP?$X?)-9W? MA0Y[%F7MQ4YC_N&X?\'.]'78/C"1%-]^F;0G,UJGI>7AD M@6&__,"/M5[$^%V'QY&BCY0:%OS5&%F[O)<%,SQ[9B^@.]=7|NI29PGNPF!N M-&KK;\#C&T*;]/XS<$T/M*5XS[A0F>=*$5X_P6@!!RUB6#ON|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|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|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

<,ZD(SJ&-&T1Q) M^P485=L#.J%_&E[!8=2@@RJ(+JY\+Q\ZBJBO$RSWXW\O,",L1)K*5B{(V0M*
MR^1GQ3Q^Y{T!#Z}2;O%1P7LHET]NVQWS/:.=/"'7.H8T5G8C)R]&R\J'3KNV M:V..\E*I@+14*EZ7[5B:*
*[1PQ6I9)O{MB.SMWGCZSK*NRSF"@?#[N]%7;7:4W MH017G83/!&L]A*3#8VJ\2(3% @%.GV=+'/BN8^_(JW!0&J%*
*((*X8WDJY/-K8 M]"P:*
(8+T7F&4#MG5+)3MQMEEIV4V2F)%TIAY4G)=D6YE8FZ!V(X;+$@%X9XSGHG0NVE.P$!=+ODG)TY.S",L8^\-
))R]B/4F4:Q&'_MP8QRJVG62Z)9:TR5,6MZ":I6/\]VY_O7>"LCWG:4&[PV%VMH+G;,J-I-"NS. MN%CIW&
*(Z>*8$5YV"4P!S7F"L7#2P#IV>;*-R0AZ!*]L.L,,IMMCPL-=&TF3[MO:%S*O:N+R5.R 2IUUF@JJ*FO'<5?*
*OPS7CGU[Z)U=FE5M4'O**&T/+!F*S"M M+ECLSM&M<59&G"V-MWDAG%UHG!TWSI9%Z.SX<.R4ZG#4VE)KJ)-*
>$LMFE9I M"?7R/: Z9J/6W '5*-;_-4&/: :S?6:_RQJ({1>-ZD%/:!JG=WU-MK-H-IF M;Z8= ^H@RIEKWM '>S6J:Z(AF](J/M*
Z3Y0N@^4[@.E^T =%%VOU@=J M,;??:AV.KC./[@6UX<+I7E ;+MQ>>D'M==X'T ZJC.MS^!VA]KJJ^RS7?S#6
*M]\;+M\?H5*D]1K.\1?EWZNK15*>I;M;G996G3T9GYWD[FB1+A4Q-DBN1Y!Y: M)'8L?11JNCMQNGM^$73UH_*
*0>B6>5G[K*7>->O{H;9W3LX62O'&KC5F^@REA MU<[V06DZ):R$\)FK{3U_KY9.Z;*_-+1>1&O9(6]J:=YTS*
#:]>&V.F_2E1+W M (Z7ZR-5NJG/B,RZ1N)^Y>8U6[IT+LXN6YWM&QKJ- 28F6YD+RCEBX=71_Q MR(&TVP9V;*
*(*JYCM'#)?M3JE5^0Z,3-='W(?]N!0==$JW++I]3FG$X W[5L X MK+/+3E,WKCA*T"R5AW?=3P MYE=8-*
*0+NL@C$U\@WG"@T[KR(!8YOA'$70."P8&)$0Q;1@[J<>X:= *+PH_X M7W\Q#X9@< ('/!NN3]Y/'*7]/D0P]E*
*Z[I&.@&5NZ*5=668_Q#+{H6G@T!<- MU@E%B#Z\.Z+AVC+A.&:N.P%\P[4C&$U/7%8QGH:./338>!SX/P#Z$:QR'\NX*
MT]=F L+%/7T.>/_]?I\'L$Q %@RVAH_&KC_A\"[<)'\\]JH,(N<8$MW_,D':< M,6;^PK4LO?R\#P0)B]HK]
*(2!TNL9KV^NO[XQC:OT*5[T4A#&*W<@9NQQ0EO03,7 H8;*Q 0ZUQW\(,,. M\, C*,*
JL@%\2I>;QJ^!/S(B6&6\#/^OT/OZ_9!'-!+;!XC!._%G8$!/T5!! M.3\AQWL$,-)(F&T#H\)8L SB .:!#<0"2SPGAP3&
[L#3L_<@)R9RZG/]^$J M)#LY&'6;:5P/&?!G'(*1!RXR,IO8=TP[DH.RA$8#.TF-_=#!"]X1T3N/7#:0*
MDL=)YBZ)_&IZ"^L"V<;1_%MFBFOO"?ZUSM3J9/X=!FHT8T#'>3?@[/LYZ\-@ MWS'WB4U"/"JR? !(7CZ\;
*<';I^<^=X;]_K/-4# :.,I]<4*_0]H,\"H8$RO- M6(QA@)+'WYPZLUK]#N^T^[S6X+4V8W:GR=LM^-.\J#*
<;_P>].V7FX__^>4M MNYS+D5|>7>U"='VZ^G!]}^VK\?O=IYO;+[_=&[=?KH'M?;DQ[O_X<']*
*[FG\>7NX>.J\?!G_/'EZH^;VX>/-\;U'6S"EWOQT_W=I]N;*_SXU]LO M5U^N;Z\^&?RC^]USWLL1<(6UPXA&."V":\R064*
@OF/VP.4N28 M!^)K ^01]J:(<4SQ5I4GWJJ>6V?;R@Q[XI!TWLU)?,3OYAQ<=-IV&0IQ\1A6 M@K,
)+^!6&0[/9SP$;GG":8P$=<.CYS9W@T&:/4[D[D!? *E$",T('ILP!/ MFLIX:"X@IAM^%39 ![+CUL(J/."G]\O-G[./K MQZ*
*2B.>@VO((,@@+OH.,*A? %\\7'XJ+"4PH3"FYQ4GE""^FABLP!KQ "KJ% M6X!K.3M.L?89T1M%"!B;[+4!,-?*
*D>,1XH>91],C>KAQ M2*E]P^- +"%(K0+9@#60K% &!FD>I /Y2R%1SIWFF$T(GC8 /@WT)1 ;H;3 M*
*.0"DL/+GGD'CS2Q06=X4DPB1AE!)X3DM".Q.KX/7$=UCJ"9;*IX0&T MM0A (9!.UTL&FCMGX#4.@!\0@1I?@I[,@0'K*
*4<@VF=2ZP00X*MUK'KSXVON MZ?U?\/6)P2YO#X8SZ;SGD_2.#RBTX5V<738J%S7+K,^8\6C=UQKL_*B-W0RV M0X-*
M5@O"?D3_0N,?L<>->I6ZGC4$))7I"/O/4C&E+'!SD8F<4-JCO'ZC_N;-\BK[I\<$$U^1;G=L&D55N-YF(/PR??&SP B&^ :K
*>.XVLL*22A265JM6" MHJ(PY73-0HYFY?R:659^S035D(2PYFQ:R{(Z0+*F@^2+7+X^\$C3B>DT.J-XH.*
($42&:&1$MBNW%/J,WS Y(R/[E C$*4(]M9Q++SJHGPVCGEG8O$EG6D%B6 M&D(&(647X9P@**T&L UO.>0:2*
MF1T^CC0-TDY3^2GS7):A(-@P+Y3&#FE3D2.7[LK<'.Y!'CQ=6[F']5(M9R45W.OE5O*
6G!%SQ1L49EKHP!%>\';,@GQ7NU#BC91ESO&3/_&KY_N_FW]1W MQD;Q<1SR=^J']RJ&V?
%HB^FF]WD9&QV)4V$6!$+Q=>HB,ZO"328CH.6;Y=?S'@6"?:=YL=:CYG_>K!>_9)-!M18_:L4F\H5A M3IVR-
*21?,9#IWOEA?(:KA]'QD0(-U*FW3B_D0XH9+XZ!*@IWVVE[ZY'3Z[E\ M3W-& >8@FX+O>]76Z@A^)&DOEFDU993?(:3*
*H E[S !D/:&1"N\"6C#?Z1;F M:_&[C<)[3WPI=U&$PVJ:[0.B.-6G9)O$RF-K$UHTQ>,)8*_-]1XEW3R! =]Z*
MR(L++2UMM+2TMJ_37YZ<< WV8P7[')OZZF"_$&;%K5M'EZA"ZL&=4&F\ E4+ M19MAP"D>?:X@I/.4YK!Y9503J_J
*BXH4,*R0UCV\VSRVW@]&6%*OZ$_BUR3 MF^G1RQ>I?*2PA;Z\2OV@$UBN0S>1Z0%J(V.!D9$\^B(C001X8**
&#'!2H13, M2 0T8B3M&'V,)R9DOMZ5,4%$JZ-N-78BYG[$)J>@X%'X:T(6NM]B*,O?O2_*
MG+2P0NFBAGF(IC4C7+S1HF?9@+.5Z(G9 /#3[@&$%0Q;V^OO+R.=EN0\F"WO MD]]7E[P =T#]46AT)>_=
(.W!5FJ\;X-);$^-3GQ_C,#V'>:]B/M:NPGWL^ MP%/K&|>:!##_5%,H"(VIUPLB?NKUV8B?#W_']OW"_\#>-^UHKU*0RU*
M$6\I>OGV^;#EB4RGW!;?=?TG"K 5"0982B2,1R-9G2 4.P82BD&HP@:Q7 ,:9L>!$W):AQ'[3HD:8\IH@Y_PZ A%-B?
F+%%>G?06TR]FYO& MKT(5ID3+=%TI,A(I(TW.ZV(-4Q$7[5!E%%H0*IR2,A!45!$PAPT 3,>9SYW-
*C511ZQ0C'L"6PV>*A&+ \8@X& MS8+(E8XD>2/-Z>;Z/DFY%;SB^NY?MS?GM4Y2N$C<$'N90D:9)3"-ZZ*1)Y.T*
MDV49^(]{.8#T2@:<64Z$J.+R)<-X)-)2!>@KTH(%M[I\P%R8G!-^S]QFBU6]^[#JC
M:6OW>NG6:/6(_J(I'D_D@-6X6!RVJECWVG7/Z@TX["I-JV%V2A(MH E!$\(" M0N@\%R$TD1#JC:IYH0E!$T+I":%9?
2Y";)U=-BO5:F/[9$=-")H0GI\0EB1] M;4X(;2P)V[:*JL&5,I#RP(P0Q7O_X=/]LYD?=/=KJ[FD-65*+04$<7%VV:ZV
MMT^,+$\2O(9&!AI+:FPNA$;G[++5:I$J:%Q#-!84LMTXS.V@8FTE4:MO;WY*
*M02.GE,A94M9[<^1@DE2EWJINGX1=HC(599?.J("(K2K*NPZ5Q$Z"TBF>5S>I M?![,0ZNYI**
[\HC.Z85&AW=DC6J<5'CHJEA2U6(B.DAN!8V6-2@.'10KNXP* M0(%>H:9F%4>*
*(BI7|)P6H:%+*YFR#I!='Q2D8PA[\B+FJ,=W\HE_/5/TO$Z]1 M6UCQ=&5K^5X+(:]=&G#U^2^%*
*[5XGO@YS>#95K75V6:]85G5G2O[*N[,ZHZ4>IZ+B=PXP+4XTJ]T]Y9-5Q-_M7:4"F::N[8NF;DY=Z#:L5-NUPZ*
NJ7:J023)Q:)%ULNVI-AA2XOY"Z4'=]R# M.RX[2G%6TUU2NTAU6=QK?
*I.^OV3WGX+;.]N9'4M0I+>4EVJW])"0=:;NC)*2$ MTXHB^I_\L-"-T*R>738:.Q#YRN-BTJ _7M O<9BM"OH:@+*
[:V=Y&IT&O0;_W MY)506^=75XT.P4>8PWZT@!#@W[%1*)505]'T-<*RO?KI*%G3!K:K8*CH[MW*
*MDDVT*LDTL.%@>_MS8D>1W!HE+YI8M"I*,/QL%VG)&B6E1,F2'*-54=+"ZEWM MTF2%:)2\:#[1JBC!?*
L[MB^V%M!VAY!2,T/B5R6N(0.GZ_),S2+1/W4S04Y7GMA%6"/EL)&RQ-"\ 5(NL,-M95RJ*%21J@LR6#= M*
*"H=$8VRC7*H(_Q6M\;Y?N_)<=UIF;HIW;*
M9'OR!O&^\X/WSQ_B@5]$7.WJV>7__.W"JEGO2Q@H>'TDC+>:G@JP$WM[-(J M:."CC3"'#9!@% ML1W%*
*48*IE*?/63!8$.?J]:5MA'VW.&[+SS*[!AOM M$CFLYX1CETUPC N*,^JKYEVEEW>?RWL49F-11/^Y4*7W2,#*
*<<5*O*L#I^GY M,>B<(AAWB[#JHZFFNMW2'$^AU=UD-[8OX(3L-+;O9+[#3=]DWJHF34V:I2'- M)2Z+54FS*
Z39:NTL/5V3IB;-DR?-W22<7E3/+ENUHEYXFC0U:6K2?([. :N2 M9NWLLMDY?-(DE?
MMQ.!5\'_/>;RD">&2.5Y,T6>7O\#':@)RV1M-V)>Q'SIX MP;N NW#E(W__Y/2BH=J3S%UR6M7T%M:%2<31_%LR4[
Y]OA]>6A9.":KEFRE M6)W,OSA-$RZ-8S9 M@)]W \Z^G[,^S/ =LLO\EB-GPS-SU=?*
*KG[[^/GCEP>*7VN_OS=N;N^O_[B_O[W[M8EQ]N8&_5Y_^]_[VWKC[U?CU]LO5E^O;JT_&]=V7F]L'=MQP/",:.J$1\+$?*
*1!6*MN@'_LB(X-5&Y(O_1VPB8C"">G:!_^TXW.E%H MC.'L=&RC[\#[!F'%& <|Q*>YG(4\%,_K.:$=AR'UBN].DC' A(O8\1-*
!>-# MGUC0.W=]_SL:;\.(1?15B$*%S:E[!XPTF8$DL5 9>.'9\'(>4 IW"'GXGCP MBT.I_%Z/#D3X(C2>.(83AS2#,,*
(,_P%,PN_^E]MXO(:FD"WN02[!Q#%X+TQ[MP1CI7;EZL=1'' #NR)%(LL,2P78D1@B?6##UG=A*
1$23M_A/5P4G%H$E(O];>5]3GXFTS'\,&3G^$85#3GX5#/W9[M,Y]R_GWFB6P\#OP?(-U%W)UYM@/LV.O-W#-V
,XS(P8ZP:>D7_A!\A)8(=L9 M9[[%+W&M/#X@24ALCP\K)Y8)OI;!0HB3 ,4M XX&.-N!R@83T[C'=5RPE>$8 MQ
3#]]P)KK;8?$D,0PZ?!5P0#NXD_A+&A!K<^T<6.'X,:'#"[Z$L&0'0C1@L MAR-S#C,0-
*FR7.:.0/H*UC+@0J5F_CT)H@HJ0]3G0:P"B*8Y[":G@R^!>(FMN M? V<1P3F/;?CP*%!?(+_!B(E$N1TH!;C"D8/\ZQU.DT3?*
XF]W 8N_1$P ,0 M<+\/2XJ[% QP=((%D'K#D\.X.VX7LENP2TQD0,SO'C4A7L1UR"W^T&(8T-9 MFH: #(:>
(GD$EM9P0_X$.PB3AG\<(%C'L]VX)WPX-"V)COMX!#QX@L_^+(=F M?,.U5UC!!9?7XN?
*&KV($ZNM0KKC6'T/G]9JYOV.H9JJ) MO?S;\VME-7 1["'S:IQ@.?!!??.H4J&@50?H#+A(-#'&; *['/!![*K3:L Y*
MZL9!#?.1YX#]\-.&F/0&VVDMH0=R7,A()(+%9;^,.]-@#ESHZ%-S&02 BT; MK^$V>05RT@# %"59S)+>LF-Y4P%^^*

37AG& AQ^^%@9,$Q&/#+-41!P#QS^ MF]%'"E=+11$^PO;ER0J'C/&:FP.S(D>:N8C_D*OW!MD6DA,\/EU%YLZL8|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
MI@).*E2=R^N!EZ!X!2+>IYL'%"25DMJ#@PZ.JDGQ:X50IM3$#*%7 ,Z1X?D1 M3'+D(*N*_S=)H3X*7W2[0B.RD=QWB74WFJO ;-PX,>,!6'3O,$'9%4_::E-TL&66G] DD)=;]OQF+9>:C)/ M?O!]
[#);6&76.?;NLH^Z%S?C?>I ZHT XF2*1*0&(!HZ 9>R;O*0+YSW7%2& M[._99WP-R-R(-]+!IF&\'HQ;)8.QE %7E/CRQQ@,)T9#&V525'*ZA'";S].= M?LYK38[WW]A3-Z!F'@"@$+O =5'HFQ4>,^0T0HLG_,T.FFA+V2X&OM_+#Q6>MB^.S>0ZH621G:0)GFEA;Q?5X)L"L/#*[:(#G -XN&<#A:7)?$OL8;FR/A)F4 M>:Y'!X50S\!X;11G#P5A"\98%N/?W.TGUJ0@>UQXDK]7A(6-T(1%HUW-A5< MZ47)0)JQ"TL#I#&
('12+I380<)*QO9[CX1;J^OWR&646%6G9/P*\#_7Z2G!%9UQCX@\V^4L$ [0 M&0V &#E@OE@C$'K
L:*K4UYT93A(!C]93H&JI_(HY!&1;CQ[!,ZEC"9^/U7D M0NZZJHX"[.%W3C?#UO<2+4AL?
9;UHC((@D(0#_*@D]Y7R93H*5/7B/=(R,/G M>*0+YU?RMC"*>XD_%+UVN5=/G_^1+R5CZ/\5!0C\]@9?GY>>,P+S#4?[K+*D M7@T"QP9]%?B[N(8\ [!9&4F<' 6PIH+G?DMEBRNDYTGBN/%(M_TG#+CGC\33 MOBCQ_K.<_5?
UF"GI'IYQ/81C2-SV==%[@^6) MO1 ["))U@$%HPG0"TK\R\"F!>QPX%.^3^7(,9.E%#@4"(K5+J17W4S*)<(P!
M#!0!0;>#;.O!? -YFL%S9.B0\$5Y80QDZX2C2OHBU'(=&J[R6BLVI#B+X(48 M5
48*>#32W#:\\D+E<4D_^$(/3[KBBMPP"FC% 4[]YQ0 M..2REJY/UA$0L7.!C,%@^
MDC0)=&,!'()!)I)'HGU^M!LBT%!TA9?:,(R&&]Z;.CY''.| V$LO3AJR1G8: M&,C0CT-$O("1C B>.OK5Z/-/)%_Z/0CP7@%?9WW J"J9.04;DWSIQ]PHA-! M;4;*%%P\HNPLA@ M. %L#!\H1@".K-" T8(^%0M!V+(O0!)>J(M8.L")@U0;2<0@!@]?GZ#B-/X9!18@E25@K3Y$DCO\>GK$P8#]XE"H!7>SQ" MUZXPIS$X:%"\C6&6?AR@?)NQDJI+
<\"Z!W'_V.NS1U_DEX@=5:('40IKX$!"B,> M91;S'B&!Y>4J$8&37$#\#/"#23_=D1-%\]D42A'PRTB1R21:G(#1-7+91/%MK8775,A)1Z]#E<>?+V458%:^,D$D(_I=/YHX5$> M;_@,YW$ %F%DB/.0"T\/B&<394>1A#UV_0GQI"2Y0R:.P-E!@<2)'L.](8JN M*DN1U._>M ;''WWW48)W4.5Y"R2FI9$)^AXF-1'GWF<]XX7(>5Q14L&HO@# M$*COA]
((*.FUV0PN&:(0DZBHPB'JC^XV@@$:(E,&@@9.&B([T&68&B66$^*0K& M^LXGZ4F3Y+N,D)EP--3DQ>@T=74"0PVHE$J2>27'I4*G,\,Y5DQ99?,A.!Y+ MLY! 9<%L<-H-^16>CAQ .!0^K!@!=W!T\ M8,B4ANFKJ-JGZ<5X20\&(029Q$ZA(@^4K:(X;]9FX=!0GN:*L$.$HDUKCW=A M J0-T=@CW_XN[(Q'"Z^RV?U%SKP4'#&4NB(4BDI>S($!E^:A=0%99C>68&.B$03Q.# ^B],2CHS)>
MA1L',_+4X9[=3JF+AN*>I$:%$_2$]9R'JCZ'$Q@9#B+J5J0B2=]W7?^I\%3(MPBOUL@A3S/$[#ZVR&6IEJD>.':R2OO,EI[BH]V>LADM5\^"5]E0J6J?L&>, MR1!LGTYD2CFG2'>J:!A2,#UPB$C&H2K/,-
TFM8@YQXAZ3A(10D\Z:H24S?:H MG'>JH \P?3>M #1B473$EF"K,*:^O-(F_%T5Z62H9 .F2(L+'-2K1)SSGR\MB6)A\'GH>QYW53"V(NUL&8'THBFUWG%=3[G"9\-"Z*".F$NQWD_(6@:!_Q0- M,]Q"V
B38DY=/O'S9:U2!0_%/M\]6G"5S4J8$; 4BM#5)+1\E08;TA:CP4BD MN6,.-:: RR \1V04BE)S8]^!4?C]
<_*])E5X1CY@F*L@@_RM(EYOX&#IGS&+ MAA385\D?'++,'8XA>S/*DC/F*1790%% 4C:4\J7_Y!UWRHI5-C-F&'=1)(]$M/444"&9RJG,,+IN Q(712<&PE_@\\QC WU,'+'KCQX&#!M#%=:,(L4O <))I M$76=%E&.L1Q$6D2)F%^];/;VF?B02N)9$<>>S#\FYXCK#@MI.B8*0TE%8%DQE,XV40I/HF/(W5F3FO#J8@5FZ4\I0DSF MU)6R7U(-F:0O*;7GZSTD,/.GK+941CSPVJE\TBG\0!4@DI:7)#'='F MSB.&FX6$]&JOI*)\B)_&HS;E;Q%H(4\>7A%R/!6/X{(JDJ"?"[IH)[7OA<*? M@R5E,.#11V&'AS:GI'*E-M(KD^ CE 93%3'MN2AKUR7?B#$EX<[)7*6OT6-1 MC,778"PLC"CF*?4<*4O&$V?X+"P;&4BNR(%2A] A?T<#](#[&'@LLI5L$%#S M;LV(?!M..!(%?5CP7M7NE0J-N$45[*4(;SYV>GR$U:
(H\0[^H=^6E+U2F=+8 MWP-]IDGD]O7=OVYOSFN=]QEN(N&GZXZ72^;TX3*).@ 8I$$ M] ;Z(_&S2KH"O3XAU'S)1^;4^BZ9 MKVC!1:ZTB*"3IE,T1Z1-:!\0@YD6V3+G(E6A5P1J34VZ8@M")!6=Z4KLK7,7E MD[4'9VS^_,?
8#V.QHWE[S8CS* T237MGB-X@)$EPUG-%529I?,X&FN'M29WS MI' &6O%4!&DQ2>*L(I9"7D9(>URXBR8GX?JME\VW.$<0G4%KIH+1%(G.(8^T M8XN2^XB,L>)!IC!1$IA8$5]ALHSS'7^E]!L U'@LRH2M*!BP,NA-$Y
MF+;#*YI(LBDTMPDFQVB(#!2LSO-%X3;Y->+,((B28IC=(M)=P1E18H^%V6<7^#F1%^W\E6H7X[8V;.F;IGLW_DL3?=,$*E0%:2Q-2$N4.D_OPMA7*M@:\P(4I]&S4P6]0"_E/4>X
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
M07)+A=UT5L8#!+12B!\=Z/.YA:"]YYQZ)B7ADBWQB M0>_<]?
WQCFIP+IQG/0VY,!7DF8WHEYX8P"HJ<$'&X67/0=/XC:JJPN\AS[-? M.'],!"')'L@(QT#0X5YQ#AK:?.@DF^+QEC Y9S>W\^6@ZM=/YL/%#3JU8IA5:UZ!3N;8LGTC#PL:C, R/TX1'G6_R8TD'#PF6;+NYUK$MW MY;K&T
FQ]:V=VB')]"PRG#-K(GKY -52X6'@ #=)3"?\?I)TT>A]G=1OA%_N$[JE]+/D&:;QD-4&G# 5R(!_=5$-X$P.(U$-IMQKPJN/M,7I#&/H0" '#!%?1&8YVMV=%Q$+XYT\2C-,-([ARH$(@"!E8ZO 'RKY"W\N@ M*(,=>L[-]7VF##%&'P+J,"';
[X4IHL26!WPD&W-D IOD@S+T*X+HN.Q8=9,) MCE3#'#*LB,\Y>D0\-I(LX(/CBZX9V>;']RI;0]Z[=/O+Q/N7R'F_??SR\=O5 M)^-USW==%HA$ W19$:%R(5V,L= 0$@F%#KYY/O3O4Y+Z)KU@"9L(G1_&"&X; M
G/QL/Q.]A:I@*S#84%>M2KU3MMLYHO4 R";9N,G<4S)=4VJ-=&3_1>7?KL MNH!Z\K0GEL3N"7W-5BX[?
%'=K/Y4R54%3!AL#^W@D6K9"1]89NTGH2ZF$54S M+F2RH*21O573^DD,"-
^4*\0_/1H:J"B*C]*GT3#K^1N4#4JHLNKV#_CMAZ14
M"F5B4=E=8.TAC\2S:O@LP'#R+)7787R]_I;$D+].,/GT0G[PQC2+30I?9WP<4 M:WXN\=6G/^]?"FW$/(/4")!; Y#6@:%..LJ4U^HE1X$,(S]V4RPB_/%3Z5< MV.+]?JFWYW=+V'[@Z5+>_#D7CBN9*[*;;=2:2TWK&_/8SCX8+"D@#QF9H<>I MW7#" D3A$Y+6LIR/XA4$XH4LH?@GTL8Y.BC.\;=LGXX<'\PS0%%>67 YT[A*
MKY3I9\FUZGD.Y8&%#E6*%Y*)$3UQ%R0'8MY22)$5UM381'59#*IF6"'>^/N5^/N*\@G#[=W7^X+99198:1T M:T!/?(>A?HZ]=%603%!7621XV.KLD$Z"A=?75_+2'8BTFLAH*[)'*S^MQ* < MD>23&*FQ%00>5RX;A_R=^N%]SPG'+IN\I_XM6EIY.QVS76VCH3<*X&]/O5C:@$&J0GOQ].?-NMEH- N_JH(85_3YO$>A7-VR MUGK4_,^;]?J1#VKQHK^E310;"5!!'/[]K'Z6>@3(F_2N:M3@I'V;OZPSR_>T:\C[5UCLN=/-SOATEJR^>WP>!LE>4Y!.;O9+Z&E6 M=;-MSD%U6S!Q\)F7:MHW/Z8W?-GL5@-[U5AQ]GL%_*MGFGQVTE0]IU2SMBI- MJV%V_N=OM5;U_?.I
&R\L=9*S.>MRZ@LRX4T=H\?N_5&U;PX0NPF]UO+[]\" MQ^7;TG;)6-%^5N&G[40/:34^)-'CPZ?[N<+F(AHHF.KJ2-_KC-O5MEE=$^O% M&{LBHN5LUV!04Z];FT$=[N:T.AV].67=G)I9V\/6'.1)<(!*Z"U: Z2?V^ 8 M[NVQ-+&&0ATW.BD*EN)\/ZZ5C.K;]85B%Z*#^U(BCW$?6F9-;TMI=N6BZI9 MWTR'.+WSX0 UA0<_8NZZ)[_4#J7CL0Y[V_-C=&.J\6;4Q]IL:SJVD:&G:_2GC0#32>:3E:EDVJ];K9/E$Z.7(-NF=8S:="E MH_"U!"05M.3YW@)+_J%<19-

*]2Y%7*T7QE2>=@&2\I+16DE2P)%HO22N09_Q,_M6@'_B<#*

*U_Q$F)O1EK#W!>M"P.L&8{1_NNG$ERLD4K0_*DX5C];KG5YYH+FSY(*JV9Z37) $9&<#]G<5K+_W8/F6V=E9%/\U$&*

(W<.8-J'9" MT?N;1]R6AW_=_-B<>8E_=X{9%X-I&&TKZ[&O^K-2':?)O^CU-M1?Q+IC9D!L^,IMF:Y5TK@?VF_(J<-_7\,;E

*M^2@'-FFU*8^^&X]2:%&U!-N7=@VH#[$O:T2++1_W>@0/BV7Q!2K${&'X)O^F-M)D$US")5/F(.7JD;D=.-,:/5@H/2-.*

*[R$\&-BLK%EB%035F$.6;.&HU+WFU"MG-Kj%>82+Z2-YT+-3-ME2ML":FCX*Y5GWD,E/3AT_WFIP-%#2+-*

P73LM>VB1$;>^R/)--I?8?\GI.=K$[#;.XX.V9S?WLYXVUXX1TTMX&H;B'()V(XM4_+1)8CCRVJEU[MN"J\DWVIU6T.!UX

MEX+#TN#8-3BVXZ/E6ZEY%JZ-@_?V6@E[YDQ('<@4Z)$IY;O<[7C3NW!?HLAT'SH@%L'O>=OCL',]K,\?>_;P*TN:*

*XKBG50I-M7'1[9Q:Y@8>P\=@]G@,_O)0&Q]E4]("MZ!V?Y7-TU3*0>W,_74$;@[MK-/.-MNL.W!.*

MQ;U7:VU:,46#0[OW5NQ35U\AOW&O_K_U#Y0YOCETGP)=6[-4J=(#-N-M$0SQRQAV3&^QJY,/D_TIR.F]AO[R!-M-P-6,

*[ZCWO57(2R+S@\[.%]4*0>E'63:0:8=9(<^NU-P]6@'F7:0[=]!UB:I*

*MOTA5+J/=:5J@=*8$2BKU#_I:3J#4[K*3\C6TUH^7/A!7@T;P:2"XJ=/=MD9S-M^7;5VGW;P:UWM0Q6X&,V:^;-*

*AI[!UI!?,A;&@/==;L-'N-=X+QI(LX_"DG#R-M+BKPAYD%8=P-^9\QY@%$?L[*65]J8RQ>[@.Q.O[F^[TGQW6G38S&*

[6C,G&-$_M[*JM;%M%@O%V@19#FM?*0>E2U3MW:B77+;-2A^K"44;GK3A:?^&I{)KGSDI*

M(B.7&4Z!%%-3">EH/_/WRZLFO6^;-J<6/-3O&Z\LT54@]*1;MHHIB/=_M#GUVIV-ZTP9';7-LG<&QC.%MLX*C,#S:4X*C-*

*C>>E*4&1;WC--5H!)\(@G7Y-MAV,T-EHMLZYMC2=C:[Q9)X\V*C1,\@C3:A<).611Q!-/V"#5I]3*%*OF!@[6*

*MTL6+.J9E4+]/448WY(_*YMD\\\Q\,BY]\(8K0SKZ4-M]7-G1,M=G!2F&@D6[%-P)2M3(_M\5358[Q%9;([H&_-A)'88)A.[D0.?*

*S:@M3)-2R>GKG)DG&F4C4M=_?&6P/&&-M-#X@"_XM*L6P#JI(LTY./S3K>"D'I2-#M1%<&\&U$5P;P;417!O!Y\P\D;WX*

ME.REK=XG93-\W6B;K1)9E[3%6Z-W'?1VS(NC0^])6[L;9J-$&WIPQNXYJ;1Y-M4R6H[7L-IOIS)]GO/]LD%QE$?

V&E&8L!U-?_^]G?G#JS6OT.[{3[-MO-;@M39C=J?)VRWXT[RH-QO_UP!EXLO-Q__\\I;-@GD^TH_?OWQSQAM]H]Y-M-_0>

*<^L!,YJU86M+=2F,PJ48N90)-M1T(F=$@F-%Y+W?9-!<-LM*G]1(V5U5+%<6I+NP;OZA.OFAT=6GYTQO9:O:[K*

M6&QB;E\UDGR?EG9!KXL%$C1\!SS$,EO9L."?0\-_\G@0#IVQ$0Y90;Z__J.*

M%QF/<'$,'V#+)7E):##7]P;"",_%"QWOD8<1%?#">V4@,3T>XV/A(WS?D#,7-M[K'%&WJPA('L

*I7W$="HG]4S@"VMTBY2&==-R%RNO-+I\B1N"YP;O#N_-BKZ-ME\K$"B.\>D3-1\SQ<-391S!/+%#^,;*R!U7N,%;Q-*

*S0/PW!*A3KRLK.^3T0-MFV4I!Z4-J=J0J@VI&S7E/(1IGX*M4%M8M8556UA7F'F!\+@W0^I>%V*?MJC]-M-*

*O/NE*ASCUR)0{6F:@3OQ_#6,CMEL+OM%+U[-J7N=4>M6M.LEHTI:7/JSLVI-MLIX-R%YHMDMED0V-*

D]+&N+QF0U'@\BO+,CMD5PQ@7L+")-[=&R8=9_#/Z+R-M;WF5S^(*

LZR91E8;^1X3A@%%$],1LO;!R.'JB'W!:A2P,;D!=D0M"IS(P_,]C:'3_:Y-=-:<:A'546"-/;-?LRM(Z%-*

*MQZ6PTI9R4+1:A#;&ZJC6_=A<]RNQ'ZK-==^KIFVN)V=SE3)6!#*6KA>Q;\O5-M7B?*

>LLQ::O;VW]13.FLB8P$%!+K!Q@#5^Z%<0#[A-MOC$\6P(6<:/GP&=!:/0#?

T1^EC_,>]/H\QY5(0\C%L61'TS$Q>AN0OZ3U12')Y@-QJ8X\'1QNV8!H/N'SCEF/",/0T=>RC\26G^-M@M_O8Q?

*U+CK+0I@*7('/[_%'[OIC'1^4XNDM\E%*-@-6ZYP-$U[E-!=&^HM]+WE0IE1^P-$1S7O&31-/C)L,AM4PAPS(HLLY*

M8)9[;,0%)7UP_/&0!2-F?&)=!-2YKUR6SEG;+/S=OHB>^<"-YF-MK[-VM?;:Y_56GKB23?

';Y.0VSI3>GG(J,M:F:KI6V@STBM-8F^%+S-M98-K2S9]+73O-$#K%I#1-(

2E>PJAG026EL]\^@K64LZ[6<9;VD)+)P@9J-

*MBQUTK5BP#@>@1!S7AM;63U+1&UKB#6WMP*V[R^W4FN3+S/@W[E&^C.T'8Y_2-M3#-#)?8P*

*<6F\G0RD7,/*9I[{LASL5:7L%U(<)N'-AZ7N+UD8]KM=4JVZHUY-M*7OPRZ:M'O)!<8-ZSM7(A\'Q50')*

<>+F#=PNJY,F!050UD8\FBSH^)P'2&O-M6Y9IK5U#^L"DW4/KL2?71-%I8@%-M%J:,J,.F";6,0<\&WV4#PRUZMJQ+?*

*O$0FD$S54*R[;*-M7ECVYL=L!\0G%AJOJ!C+.LW^/+P]X"RD6K"OZC7SPO!A"V>?3[T*L5-&=E)<*

MW@$0ZV\FCW:PU2(N(XR@<."]P'GD'E9(]8,!\QS;Z'%8I5[%,)C]9^R(]I-A-MA6P]GUCLV<.O##.'K'V>J6P,NT0%@PF*

*J\+?<_CKF@RN4D]SO(!-%-EBA%-MR85;(,!:"-#*CML+3'HC2QVF#@34_1<-<;NK1FL.1TN*F'M,>K![%1HU.L*

MVAPX(>]E]D'#9DPU84TZJH8QUFP.,V6?8R@^GWF!)(T'0^0-Q+A%!&WAQZLU6!B&LOG,G<3Y9HT+-J+-M]V-?

()WU&@6QBUKU0J&G[U1;GLUO85UX3B+H_FWS-2GSJQ6O\,[{3ZO-7BMS9C=:?)V"_XT+^K-QO\USBYOO]Q_,\O

M;]EE08=8\4$W>'M9M+7;,.T]H31A/U0<_A6%EFYU\C3$R9,RB>0-=/9@A.0J-M9T]EMAZ^Z"^=Z4T]IV"YJ-"_IL1PH.?

*+0ZXT.U9*AW7VL*FT_1V7J,==!['># MC<>!_P,6-.*PH*_(?4GMP6M6$WZ"Q1/G]S@]OW&7^DZ(]=MQKP]X!>=FB15U*

*M SB[O'=^%-=OEIA/,FL_.2#[A'#U_*;LQ]0+X1L'\3Z&-ZV(!*NH-.P^ZM]O-MTF>[;C8:.RLU7*6UJ4=U.)%/\4^VW/YT>*

*[KR2>7;;/.*_0T/K!"T65H-WUX-M2Z9{0)]6X-3-CYW5:#UJ9]=ZDR^W<;Y9J6Y>:VME7G=0=<,U=@\$NXU*VZH?*

M)7;7B;';-L?EV]+F#FIY['([2^,Q/?)HM0^?[K>)Q5^92^]UDFN'TZS'B_-6-M[36V]%EQUQDYGNSJF^1:G5J.%?

K@="Y/^?:E9ID-O2^EXYFU:NUER[L?\@EQ-M@-HC2B0NGGHD^-QMJ6=QEW=QOX&HVM2A0P84J]GAA7"5&

*M'H=3@9AS(XKAZ12*B?DK0!8_+4]KD8/!L-BZ6?VI,I6_Y/$(OX*5YK"J41Q@-M<@7&+9NUGT0*19\]^@&%.<)T8-*

*J>8<8&BN%[I)L1!R+B6F02'IMGY220XO)+A\[J%#4TF>O-MD$Z7XSM-D,A*5F4];6-CDH_4B_F(3-*

*;+O!=Y2&>6AZS(,=K+.(:H(9*G/#D(-M>R'=RG&,@7T'1+\TZ#;0RO)$P0/!941K\^B[\8@;KT>PB#$N1Q?3.-(-?[,R*

M;-4>TB,-N3_A-9G!CGS5'-39\.3-Z<:86&.933C%GH8.G%X.G*,K7.25GWD,U(5YU1NR?1F&-M,,/V&*

*[BP@NU+W_$NV7X*QSK0U)H"9-W)\(BRC*[]D&A/91NMF&Q4){@=1&I1-MTZPWUTNQ.,PLGM(-JF:VFAV=6K2_U*)#*

<#P56,Q61,6!SFZ+/:5;.[?9W-=;V:NO\K@TB-@]!.B'[MO'3(H'ER$,\-M-@_>.?@H6!W_LQ0M(9P-J[F-MH]DDG,@TBD\DN*

*JM&FS-<]^M,13E221G'3+YGW*CPP_1][JPBF(RR(>A$^9\-MD_:B4>>^0$_53!'&Z3*_E:3(,*

*[JMKF^N[V6=1A5U%0T9QH8:GA\9?\:-I/X$-M7]ES0G0Z,_"FI)PTN5Y=[+*U0LE@>I_K/\$W,Y[A(W*'W7/7I656U7=QVE?*

*Y-M>L-?987-@HJEVB%6-M]3*0>U,X?8$;@^M/M.N^\.<7:GX(C2[COMOBN=^ZYT-MS"1P<9,7&J;02?*

*%A.U7^^D7"*U2K75.E:7B;Q:8"XTZJ;U>.$\,EZ]39H-M@Z?=>D?BUEM'<-*

$NOUIKTX:1VJMS_.!8O_JM!H=V^:W7SZF^0O+77GV"ZQ\H-MY+-&R]T\\9RC&5OS1L/R$E\-?

**!VO]*6I+.2CM/M;N8^T^/NS9G8(C5+N/M?MX-M_^[C-HG]16:D,MID!\5)9TJXWWHOL@^RBL)B?*

OHH!F(\3QMV0_QEC]DSD3Y5^6]'8-K7T^.ZTZ;&(W;T9@YP0A69%5K8]LL%HNU";*

*(>EULVIVUFX*JTU+AVQ:NI;=J@.T@Z!.E4HGACW$@B74'N(5G%@&146*,BW4-M%,(?C9PP='P//@M\6*

*3'EB+.RK&D(F9TU4$_UZ$Z+VSL1+"H?Z&)RN]'3RS@-MF4A2(6NE=C%EUEK2R^"(*JM\XV$4Q'8D=B&U85V+M5S15*

M-6W\/3GC;R)Y\2G)2UM[3\I6]KK3,)LE"@+3EEZ-WC70"_\=(7Q/.BJU959+-MM$'%Y0Z)_\T;Z@$K7VO8:C9-G[.E"1"J-*

6VC/#D;-MI90(1T(BE.I!!0,5M+7R1.T]5=,JD7%-&RLU>-$_:5-GNZ-3Z36R5-MJP;A[M-,*9230A$$S7T!#[&BSY2)T'_R>!

.G;$1#C%+W?&,__J.%QF/<'$,-M'Z#!3UX2&LSUO8$P77+Q'L=[Y&%$M8+P7AE\28_'D$+X"-\WY,R%>VSQAAZL

M7#!9T/4HL^C-PS-%4OIZ7M#3!L!2V=I.2AM-0&0&T-/.S9G8(I2QL-M0%0-M&P!7F'F!'*@-?*

*B=E,ZEW=.E,C>!#1O!KJVY>E,A(I,U^6\LBK:;9+AM3*K_M-MK_S&/IDI#,(66MI2X6.CB,3(7RD5NR@B\56C:=8IDC"*

.5'[%@,F]NC8,.,^-MAW]$/C.]Y%<_B-+.:.:GHJ1G48<=PE6=/-MQ*XPT;H^]T1+Y)?C--8>E2O=$#B9I]8NS.J-\V65F5NZ*?*

KR0!29L<8,-P+-M84,.F"_#YS9<-$GUD7+K!],X!./]YW(N,>.]R+Q_M:S3=C[-M$"@I#&5\;6-^-.I4T_BQ+U#]CD

*+&)UI(Y^JL&2JK::WL&Z(PYA_RXPRMR>>-M8G6*NK.+?X=!JHH.^'D7"/C[.>O#8-\Q]XE-0CQFLR9\QSN?6L/IZ<^=Y'Z:*

MW5_^PDHS%F,8\/[?S_[FU)G5ZG=XI]WGM0:OM1FS.TW>;L&?YD6]V?B_QMGE-M[9>;C__YY2V[+'_]B

^ZP=O+HJT]Z.AK$6]M/+-?%V2?)N&]3KQ6KYE6:0R(;12P$@$5+-"!T(A57_OP+D;#X9'!ANA?F[L>-M-#@N-

*#BV!L=VK+5*S7/\K6K1)F]]Y44SM'(F,!!(2K;!%CJAGX%\8#;Y(G&-MLT74KG'@LR-T^H$_(A?D'^;]:?*

1YCRIYAQ&+8O(\BLHW?<-"P_.LHQPOS)]%-M2=7MGA,RU_6?J"PW/,$&-*#[D__@=DR#08C(B@-M14-W/4!A1$

<<8;5[!&[_?%1P@'_,@'R/TE:M>C&SYI9AI.MY,/\N*]%>,-MP0JMZ$7]*445L+%CGX"J*N5CR($CXT40]F$N[('"1G*

D([@;1Q%[2&UV6J5>-MQ19/Z[E^W-^>U3KZD?24STG#,;0?+^>/+:@A5%$YF#&'%$49*

M.,]W\2,3EZ=AN[9X^3=_>1;-3/B^0=D]K"\#X:.-L#AE]W35-M[)1M4\O@>3D%#:I03A'VK^/S/],3WSD1O,U>)6JC?*

5P>Z36GKWW46P/HPJQJ M &D ;;R"KZOKU#@X7NR<@L7@PZ?[E4T&ZPBKY22$)1:VMEG?3"(],$WB #>G MUK[85 ?4F_/LF]/:"^%H;6V?9X16UP3V&V9+2]M:VMX<0'6SI@&D ;0Y@-8N MJGB\^#D%E>W^&=2UC$F]EC.IEY1$%A-$I=IJ{2"A<<%*'(><6Q;:NW"CZVW MM#1;6E];;G[>[=3:Y,O,^#?N45Y0FJ6 T?S9E .9L'IJJ:BOZ}7..CW%=B'%M;1X'>%PB]{*-J9HUO3&EVYCZ<3DZM9Z3F_'5&GET)^:J>EVS++.^=AWZ Q-W M#W)CJHT-NDCJC7D!%]6&ZL;IG16'J%2LD"1];NJ$93:US%J^;6F:5;TM)=R6 MZCKGMM8C#N=L^+:XPL;)J0X@"6D!M7S{8M6U1E?*?;EX:7HY@(-!%;#Q?&]! M${I#N>H4-*0'/V+NYEGA"!+MR*KY].N-_ERDWD+SO\-X\WV[T=?H)]H MY!X{V1)W;6J$9>!%%(U8#/\=WG^)-H M6*]N1JG)LK[8S+87BTJC\$!5,]1XX&&D##)#6"E.=3M#W_.XJPJ)%A7O9=0)M%=X[43/[@&_\(*N2;E+.LWQPP92;8KQ0EN+&>+$Z9FT!8"C+;A7 B.U.'IW9 M;C\8,, ^Q#6#I3Y&HL/R)Q9X]_J Y;-'>-:MC813D6_45M2M9,/Q^GWF!+*,KT-UMQU<#_8>!SX/V!%(PXK^@JD';-*S^$()G-:R?M]/Y^MKR+;[MS]AS+_C(-ZM>MO_[!]O_]<7MS M^_"_QM67&^/ZZNOMP]4GX]O'^[L_OEU_O#=>]["$=" "H,(AL E:9QBCBZV\ MWZP*4[-V0,C\.31L%@[//!\0OA= @:G>+(OW$PAQBI)[H1&]$DS'J!(!5J@$. MX'UTD/T ???@+MO&1N?(%-@8,XU0VOG.HS#7=AU>"TP$GCS&+@;$-Q'HKO-G M[/3PY2 +I:.P2WX4WPL$&;[C?#4X^B.RK_1 MZ *Y\4=8Q&C((NK?WF4N\F=B?_0**O2./W 8QB-S,;*!/@1!'8Y<,90QLV& MP,E<'WZG"NMTCUQ!+(..0Y&CIQ[P%#W1!8X8]_N.[5 W!-_A@IA?T)#H2<$ M^-J RZKS]!&@#-;6Z\D3@U)UXUAP8:,.#=R$.2V'J#+B)ZXBX>3.!5HY'P" M&S>]]B'WL)9[#,S?C@/:NT???:0)4HL&HP^S=.5&]+&>/[RF!QPG#O'0!++XMXL,!TC9>W\"2OU$L/P,J'X$>4MUZCVP"8FD2/%%'"IKJ?/Z_#I\IZC:N'[7O M1TFVT["(W;T?^R'QD'Z-DIM7T%M8%&,71_%MFJN;NB;O6 MJT4]H\6_PR#5QP?\O L_LYZ\-@WS'WB4U"U,RS1PN<*U-K.#W]N9/L]Y]MMDHN.V5]8:<9B# />__O9WY8+0HVSR]LO-Q__\\M;-@OF^4C?BG1>&I>W\,9X M!*?QI#+-K-7Y*H]18-EP[L9X'*3'F-!!\<<6F*^O)/:DWH$HA&AS!Y%84 MIZ:L3PEEOW@SD';UO6XSD-:%>=%8KRG&@KX;S9:UL[X;.^M0TFPU=-^-\?'WMW3B=?2PTS^^@P\'(Z?5<7O).$KMH&'%4JU9?APHV">E48D*9*.0+CX1,D.CV MH&FGZCBV-GL$H9PO$A?VWQ-AK]#99T'YO4Z\6:]M6K#N&6J/RZ4XU)X(&L)[MB:IHK%\F_"4@_RAE*4^?>)0]I1TO$?ET-]DZ'G^(*"]PO5ULWWQ8B44UF>H M>XW.VN_&U->+;]_1QIR:D)JP">E<>%8VL56RQ7[1:%DUL_U"V18[E;N.?6-J M5F,/&W,BTL3'?I_;Z!3&/N+4N=!0[;NI43;VZ)[G^STU0:+^8B6RM!BQ1E;) MRP9YGZ0@D037.@O8P>ZM7=(%-17\?:+Y-+M38AD)52:=*Q%1R(>RCY7A0^>W9YK0X_^N%C M@2R\B^C7?8;!7,^/](SFAZY$F.+->\8KJ]4T:_3%JUJE4Z^:K7Q.:[A(7YE5B(%(SW0<4A5B_<@H.D58F%+]X]4L49WXCR@*M$B0V$SU<M$(!&AKY7Y&!,0[9#RN5A@<@[$0YKO.\5>7&,7F8(#.A)IK* F)^F6KV]730H M]65*!TB\WU,!W?+N1N[E%@^FSJ#;TE>&LYFSLC$+,$J6.!1W/IQ4M]MXL4I M!_6M1W=E/M*V]IBM',M):9+D;YJFO%?D[%CM09+NI#E.D=OBP>.;9Z@GFX() MC^G*/%6X#XY5$3<>9I-@54H*);[U'#@&>9AC$0NGCT=[P?TB-\]J6695R@47M-;.Y97CL@L3,,B/QSC,^LP D#NNB@+/#7#T0WFUCC",2CHBS)*Q':R 4@C M(YDA0]L88!ZF"^L"5XF"U,C\/SC^-]Z'6^%IQN^R*CW'6=",EU:CD*4%I+/M"(8/!2Z/) MF%<0SVY,1P<;CX'14IASP>QRR(?'DG9@B!04G83J$*#H;P[\\1/K(M)GB+OM2"VBR[H8(8_/B"1Y*7I!WN#;1']H#H=M137'@*4;>#Y<:@LB"CB\FM+-'T5C MB28Y -2]!]'L!.4XH5 ^U_^$X/P%_^MP8.03YXQ"73/]' %7,LU$"*KT,,0V%R7;KER?$\VC.G!XHLP4A,O,2 7UJ6PVY.] S8IQ9A'M8'9^ MO6-69^AU+KG"5U?Q!A-"OEH]$\#I[\V.TE2R67J!0S'GTW M]J+_W]Z5MK>-(^F_PL?;/6W/2K(.G\E.GD>^$D\[CL=R]\Q^I$C(XH02-3QBM>W_]U@& ($7]BFW)EC[,="R)!% H%.I\"R??3;<(AHP%SY:*(M^M%7>AP_P; M/?(E]4@XQW-F5,RG1E(^PI@:2<'PGU$CC3JFEYI^;L[3)UHI5E\+RGE["@! MVI@+ W3,Q&Q'2V.U]IBOS92'?5M[VLS:[%^.C^J,B&#_L#V?Q*XNS8XL*ORC ME[3?4'=-+;96V/NT9@[.#M7- &=6*,)L*[-,!_3UP W?.!X-!_Z%GE6 M/'JLE3.(01=.;4XLC9?XOU.MV:2SE-2"("4$*%4)9N\@P2=T+:UHSG&QR+^)BV5$P)(GCDJ5N ML.?CX3%NF]"+OF>Y)=50QSA&H@31V+\T*W4E_6E)P$:T/+@O##<%,4*C^7-, M,(OW>)E,T*;;<,HE8?* G<3](%1-K>B:QY]W SLD["(7A)(#^CEQDK8Y$K)2 M?MEKU6M[K.9G'=$#(#(L/7"^D\GT]P2N[ZPQ=T(#V&XP(G,-=N=A[&:W1CXZ M-^0,<;9RW(;<\+&14P :#$XR\(J2Q,B7M.(!F%UQA@BI=%3V&0U= XO+LN_OM0[Q8/ZO#F*MKD$7LS*KUK! M2'0.&.W -S4HDQB8ZH!%=+2R'ZBNQJ&Z0B0RX,N3*#1TK,/>/1^X+NH]L*DM$/B2[PE4U;PH2G]P^P5(X5R?@UVI.2W=#WUTE!$ZH9J'IMZ)#"T;S-',RB> M_<2=YV$"0-->0G:)W@.],M=8EIQ!$IOZIO2N_&7_SIJ-@X_1@7WWD_=ZZ, M,^@S\GX\NW@F% ^9K.G,2*=77:_D+L]$>M M4R,'KG47(O/I7US38V/MJ4-@B_?QI?0#X78T3$9$/1@K<$?\+^^@;P&#VO# MBA_M&+_KF+^[5+_3$&'ZR8K%D&!\>*[!-N)#2J>D40=>!U-'#-,E&7/D4=.7 MHTO6H@PO'&;;VU&Q>RU>>HEL8 >"2AD Z!9G=H(W=I\R,@U1%V%@?9I,>RS5 ML?0,Z-7"=OJ(&2H3:\9UMBL+!$M:+4+?C,M3KG0OX"((N_&9S556.VVATL4MX<"+\S:+0I7+S!Z4/.SWBMZN*>N@N$)@$;;=C#R4ST3#6@+U0V*?Q(PN?Z4/KYDYM#?8;;W%XMN0^B#@R;*+$YE#R!:RHPD9'-14'3L KU-"FC#AV(%*P#6RLB2$J8020()KZ" M3QB-W6A5ZXUM>V=[;V?[![!>P30>!+]6/&)X28;9&+(+MLR<$)V7HIA';2W(M:S&,/,0H1HA.7>'8262&_RJ6[S'$J"=47#E*?*:MX8Q7E$9>D)Y:F!(Q@.OU M*/2/PL\N BQFUHN4MIB71M.W&:>50CRGV*&4FUF^)7+U[%+JDG$-.IH1+\?/M<3'J>J+L%7E7HF^+P@+LI46%;5:ITIK%O[VMOR5%>GEB\RK;670%7 MY9WK[,'CA%,9=OH:!&[Z'LXL<=E(CD1()/:H(@U#_9[OS%'HP^WNR0'S3T MNDG,+((*G%Z*PH&/0\"])N)9>K1!\U^OC(51B@ M6H-2S,<$'I!ME!%!O&F[/S!!1^M%2 _Y!O)FD^V*>1M&YCJJ1;!X"]1>3-!Z MRI;>1I6L"STR,]E#X0OTV9N#H"^4T/D),B;B1.GNYZ2.((DS!K>8V$I\3@* M(@X_8 5HF=TD)(B,K,ZC+66+X4#?^/K,(?EG) 0KBP5N8ADK&=G<*.Q)-M+RP3-'#=D+.S\L]D)ZY5+I^U(?/;L5#33&M+MS:_PC0)A002'!+JH1" Q!N0 M&P79RK@Y.=A!E,7'V2N/A0VH7\-_>9L2WCM0EKP??#K-BU771I0S&'SP@ *4 M)F4[I>ZPD_5<(J:?BYZL$=ISN%<&3.K*OPN)&U.U1JU,72+6_@^(X;MC*L0 MIG+X:YE?+$1?12+FPZ^U\^_F/;^&5-8*IP^#!3$2!\=4T_S-3D22"QJ/9?\M.F=T-UG;?W3.=C(B8X]l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

*%6Z>]9WZ/<#.W.?*I(%%L-!&PS-JI%[- M1IZJ(<&Q!98DXN]]^R'*\9$4"O=H55V8JAT(S;] M9X!&C+8FXT^>>*
(ADJ8LQ/85[JJN2Z'WFG$M&K%EGCZEO+0##O!KT]@X:^ HJ
M69$^%^+*'LR8"?].61KED95**5@O9JQRO;YX1'8NY$!21/U99ELF(E<7EVVS2/5"^V!>"!$:2F@E6_\]&NG0IYL M+.
*[+00G0T<-#XO@"J\D=H1%G?MA^S?H2/"!28<4"GI;@;(WCX[HL*U,G&RN: MJ9K"A&^6,%J<%B,G*BRB'GRK*
)D50\'AH?$(S9WP8,MCRW-TH!YH9?!8CV) M;18]P4HQE]/)W2DX$E4^-.N-O72^L@C?#>T>G/L$5&I1@5KK[W]>*T*
/5R!<6%R MO+)0&\G("G((K#0@+H]&:!3N*@RBR.+#OO!'0!6N1<27.K[M#11>]<"6J"OY MF4N]!!YB@*
5\)O@K8!C.4)JN&2L@6!6?EK29;&!J[&_:E7YY&MB-Y(LE# M,RN"[B *IW MWH$2KZ]Z:_O/]M7EV0ZYSQE_-*
:9;D;="P1YH7(_'-M8H"GCX($?'CP^UCE M"0'] WU3$%=(:=5LRE7@C(P)&>8\Y2IP! "KR5 3"JT>PO<0/%82:\GAJ2B7 M-
'C0AJD]D"D'H6V3D&BC94Q!)R*!,BG7A;'9F9U=G;H7= 8^V(7&H00@" MPZ0M ([-''.V!7Q6OVT6=%:*
(2"%4_18J$&%$"8,]Y8K_N6Z6E$M[PL4[E^R9 M"ADS%>F,B09T-MN.C@9+-
XJ$)QT1,"3>GSB^O+O+!"W=GHB!1.@?."M^);PN M2,(J69$R@FTB\4NQ94!R3Q+DI.%^Q3(R//-4?.-
*C@8<]0,@BUI/5#YG2)FF9 M@PUAB-M *]7W'(I\>1>;@\MC*:>&B"^JS)K4448,P0)!?.-_"&?@2=[160BC*
*M'F%"#0(7YB[DT>AY8:1*WLE@PVP:S.V+$,#&T0F"Z5(^/L^LQV;&S*3Z/,BK M@/I!F,T[/LHD@=>F6TX%):'$VCU/UC:*
*]G.#M=V^(#5NIEO+MH@52G64:I<^| M>5^W ,D*IO8 CB@F@YXJ&7V5TC0#&M<^O6KO2&,-Q0_YA1P%-,>M=NY*
__A^ M^UB!Y?HDZ- 634"\F"G0K-)Q?7.F \D9V8].+/N/'_4N8U*_C#]&NAQ)QYM MJ)*
(H::!T!WCU;Y%!ZYKUSS[,A+Y34\%"(AE$SLF+ &UN'[XF! H"NW)3&N M+V/0'C^.P&=![F]P1F^4'?*
\T9DT&!D&C[%)RKHA(!9.Z0T&?0D/O,9_&N#Z(M0>OLD9%3KBAD%X(98J-+FE45!%89"2 :.)8!)FU:?Y('XLQ8AK%
*$RQV^_R/ M'72B'NX>[AW@7];EGV>W.SL63,M6VCKW>S =@JEOA,,[8SX1;:%KK%,*Z!A= MQ #0,J_I8ZY"O&_0%*
*[PU\:P(/2*V7%>!U0T.IG[E)>*5\RP]SE MLGC6QN';S]IH8E>J$'F,@QL=V^>X[SE#TACYL 3^S7!J,JLH2L$,B2=T8Q&%*
*M:UB120<&2K]KQ_94N,.W*D.9-#WW,4ANO>@JV@F(H24RDY:]3 M+.!69TT@#N%_KAI9?*
EV#KW;'/V_MU1JM5N%7]5JC\/.R5S4:M>-&\2-EKRK[MO%EK'NT_RZ2.:@?'\[VI_//]5O$8"1)(1)C,7,!
*M_R*7_VVKM96JL210/]2M!ISTW6D_:XX>K1P2.NOJ>5YG-G]]T4&'Z0[13*SK MA!Q=<-*
*H[?.YO4\&@16;LKA5EVA([H9@6F^PJ\P-T(@(M*XTFM)OMV6S/9GLVVV-NSSXVT%W.YLQ]>46_I\D0# *],_*_1F'>>B[-*
@ MU6^$M^JU_3DY]WB'7^S8YX:,^]B_W:UIUINU@X/-[JSF[FP.SLINS=X"]^4S M;;,]F>S;;_:W9Y&K\W5,S>4[DE?
U5QO";0BW M4H1[,5M$)CUABE@3) S58%I**"XF;0>>Z_KBK=F0,Q-B=D$L"?$\!N;+;F21 M1;34??SEQ?
*9OYGU[>RZJ5>?A(L&T;O)GQ;=H(V;60\S\A$/O15F8]*!=2K%^ M;RGN[7$T]O&N@&;K8 DL(>O_N.,0]@ *L#T@U?*
R$0D()!I9*L[.2$?[Y"VUP MKL[RMVP:/->=I GTN0'[A-F!?9,]":Z'Z!Q4G\Y=$O?,19S0K&PW&,6Z_H:K
*M%HP!0.4=ZE%PB7*RC4J=&HZ,33O[&8 .Z3 M2-#L&6G-[*R1UK5VJK]7+)*B>_4C7?Q'C3@(##_%S>*J-8),'A7/|'^O*
M6_%V?%P[K!_.7?#6J!T=/T^56KW6.CIXGN(KT ".G]\B[)GJ^9JUYC.6J3W3
*MI/9J^T?'S_*J@UKK\.A9W@17W'%S%5E]\JMFK.=;M=*A,161;,YK6X(3W7FQ MOP8%:,54.$-$)GFKKBL-*
*3L'HLIV8*_"T:JOZ6/XL58YGH_N6#>Z_[^A7!H!.M53G-&2GE)?GQKE#]+ MP@)#UJQ95#-2C[$U-*
6=JA.%6:V3<:I,RV90YE]?$@M&2_(H3[8SFP9%I,:!= M?SET\6)
*(;8CC^M:GWT48>IYU4K(:Z,J)D/IY17NJD%@L"P6>#X.'A3)29F#T M%=V9_?%]4QV8*JRLB$VXV=F972*
*MC:3[F5K(W=8N(D^_"%;LR[)(LXA%BI7R5GT1I7SYVL*Q(A^]L*@E]AA!&P>+ M*N+DF#'D:@NL'^FW?TU-*
*;_/\&WM^R7B4G.((V:/W-A+15O MF]L7W">A1K^+^!5U C ?N16*9$H[V*Z+@S17#9#(&#_>&P3$44'B(D)WPVC*
MM!,5'/7[O@%K]^+RP@Y]3U#KDP ;&"&3;-L[LC$K@OK]D*R/2.>$@BH;GG(/ M&IS@9J4!<.'3Y1(A/'8[2Z_A?*
[V$4UTO_KCT";X^\/M\V_;R>7,'->N<=V-JZV^49S*^_M\-J['$?[K7E3.1K-VE']>7(!CO9JQU.R0A:/EI?
*$49;K;;/'O%>SQ..>G0C+ MQWC[$'[M$NSI?_V=S#?Q^T=N6*FHTJ'CWB%XLX]-. MK1\/,*
*HN_R8U]0;3R4'M_$J_K5CRYP(T*C9]JI;%\I-5?9 M7\WZ C81,%-4P=]BBTO]B74Y=&KTKEO0J*F=%X]K=9(N?*
[F=Z8I)#5.Q10:U M@Z4A+>_JU42>YH>J9I/W0K]W "3NL#^M4?5WV6/-MDE3BUL9_P*G 5%]RV=_M_M;F]*_GZ6\U]O:*
LK_AM(78UB66IY_Y4-(G\,?I[C!E"9,6<>7^@BJQMN% MYWBVIH]K;'-49CVISRKTF M3!';X@J!3922T!<">^EB6:/G,3T?
*X[="S"A"_M]C8B9$81LKG8UU.$M*KR1 K!L@-7((^M/H2?U4]*;>^?N>?W;JW-(9WAD#;J*
MFXM^/4]IH]ZHZHOSWP'&,OFP?E8?6G^G3\.TTN-%CBJRX.:LSG96F_^],.:SK M>5B;U5"ZCAT18(M@:2O#O^Z'VJL-?
*R8#QH$8.[3/JI>7>[C;KCVPOM2LCM,7 M3C\6X1QR8*_8SR@'6ALYL*9RH%6U]9'''N#1JLJ!GXQT(9-OI,%LTF!O(PW6*
*M5!KLY5WH+ V*3V6A7QU>?&!]&PR];D(_@].%&9<4'I_YI.YM3NIL)W5_HN=U//!R*
^>A)!P#0JA8<[SNK\YK[.DD#5KC;]NSNL:.J_B ML=EL_*>)_"F#5DDW\D /!57VDL)(I/MJU[-KI47$[Y^?6XT7X>>9BH1?
*C"T. M5YUO)TY0\VVKD>';-#$)+2^0Y"2L^Y[H@1@'EB4=[1LC(6+-E ;G8>2'EEUM M[&&931#*3_9=_F0MN+SY*
ERN$;=+"X>.)I68;>3V-/YOSLC_%]{0'CJ>[6_X MOYC_FW]]=T+^O3!YAL?
*_"7I'+!!X#=1U\MPA&%N)C$=+8!;^[PBNM#VN'RA0 MW(X==NVAB*K?'GWQ9+4=&JA9KS>M[<819J%U>=W[R*
*MI*SS8"5B<6 1,X\3V/6,3BT%7N&BV8E6W?D*
M+4/T=\94G=,O[YFI[NS'8!@,GD!$@>R"'S:Z8N!_9[W]+1]M69[>FK[C@(7 MQ_*&WQ&8X#WO\-*
GYQ9KM\!D"R7MKL\%7[9,UV^ KNRO\M=C;F]OS-=O;&\;E M61?YO/?.=O@OP#WNUP_WG MZ970Y.&? T?
BN%9_;1R)Y;'IB\6^EK&8XGZ%;WR'.#+;%Z% .?%>+X"Y_)F+ M]Q98N77WDG#H1?TUV.%YLF+>T09_M8>VA-5#C%74
*ZC%&0+C@:;'*9C8?)(^ M-5#XHO*K?0/S5@KS=K"!>5O=$,JJP;R-0:.5/3D/2./!5L%(9>=C=B3)9;6X MH6/5N?Q\W;*
[[X_:\,V_P64(;.1$8.,_B?Q0A:J.F"FHG+-SQ!L(KRB3S2IZK]LGIM]L;Z\NWJ]/+Z\\=Z_+Z MM!;\DJM9^O3K=*
[]N:>ZP(Z]"7/]J';4?!Y[?;]V>#1?7\72237!7I]L^B^N M1;_^W:U5G3R].%%S/4E G-.$H2[T:[5/FM_I=K)TR_GIU_NSF^?
R>!;K8U] M?ZSZ_E8T5L6[X<3-BI83+"G.B)N''Y5FA-WERSU'B_VJV/FRT=DV.MLZ'M8U MU-D^7YU?
*7UOMFG5^V3F_/CF__;RY*CV MR97\UF*AA=>,*Z^*V[]U6!Y"WNT&[A/IQ\/_$__#U!+ P04 " "G=)9 M.0ROJV\2 #:P@ #P*
&QH+3(P,C0P-C,P+GAS9.U=6W?B.!)^GU^AY65[MSED2("2=Y$QZC\.EF[,$6$RF=Y_V'"%N
*=XS%2'8N\^M7%QL,OLA*R.)=]SQ, M!U!])>DKE4IE2?[EKR]K%SPA0AWLW=6:9XT:0)Z%;<=;WM4>9_WZ=>VO7W[Z*
*MZ9<_U>O_N)\.01=;P1IY/N@0!'UD@V?'7P%_AO!)GN?)!J]%J1\6B7\EMX_K*6C0OKNJH;5W6VU?VHCZ?-QOU!;+@S;6U*
*MN+RX:O]E>=MHS^?6Y;Q9O[:N[7]fT6C78;/=]+>;\YN;1?/S]>?KA@!]H;?4 M6J$U!*QI'KU]H7>UE>]O;L_/GY^?*
SYXOSC!9GK<:C>;Y/QZ&IBA:"\NZCO?; M7NF7.7&C\A?G_.A9 M6VC;)W7_=8-H,UV(_7[.?
^>&O5&L]YJ)D35DJUZXZ)^T8Q7TO:W8O$:7I[+ M'VL_^CYQYH&/^HSD+EK P&4B@?=[%UGX2";69"+N(WL%8C]*
I$.R1/X(KA'= M0 NI^_#+3P!P7IWU!A,?> G)!:1S45-?"%6](&AMB"OC!M7I)&C4J4/T>N*
M3_FG.O]T]D+MVGEQK0&M+R'<:&F.RTCMX3@U2K4Z4 MK_,_Z\T6,P0-
*M5GF6UPW^U2/Y(Y1A]WHU*M#)/?..J2.R"Q;4$F*S_2]U=@. M;^UJA)):U4AW%P6YB 0X"9>3UR)C,$TD^J S^O; ;.3H*
MZ(Z\S_>K!-9MH[.J#C_(T4G]#SL"WG^3?C=9N-X"RR_8%_QL7(;#9@I6D03*
*M1V+B3/%*XI];2"R"784+.]\0O$'$=Q"-3[H"8$70XJ[FKNK1]/"O#4%GK!Y1 M@03_ICG/S-\1-D,)5H[W#4G@N!F?U>CC*
47R0XJ;^MMM-!M/1-Q/.?_H.TL M6M!M.Q-![O]XLRWHZC:;B5B!^Q9[Y^(S]CMP[+M:![.UP@0N6>7X]X_306;T
M)M3NRD>@$>S.!K\TQ']-4-^M+NI 2 (N^LOYH< !5$"1/?:^B+\/!W8H'!;)
M$3SHH,)R^V,I52S\,NK(O.X=C[]D=GKLC_,\7#0-6:]]KTQ-$:=GOFMUYN9 MCQX;,;?G870Q C00U<(=]A-:?')_8
*7TESZ[TT@T_[*BO/NSEC_W_HC6;FN#^>]*;&;,!^ M/SUC.AJ,OAZ?<846 M)?GMMY"_IQ1$6G\80@9%WXS1UYXY&)G?*
#-9KXV&W-S5[?W@-!449+O M#7/ .KP_&+%X:& ,M]W#O*3)_A$3Y111WK%VW_&@9SG0W?9ST8COW6J4]"\^*
MH%]HY!1O=>ZH!W&M(%(+MGIW0/2'>QS=$R^U:1>\W6U0RT7TX @'58KQ%L4*
*MQ+"P5LQ>!2E*B"G9N#ED8QL^,0PYW#.&7Q5+#7B^,IJ;DXI&:+#02X& P2/G6]52$6>2\,9F(Y(KI\ M-&/>N\<"FUY1?*
Y6'H&2J?/HZ906;F M1?G$%;2D\C4)9_H@$\2K$I(6;_EN(ZH%U[<0^I8*
M/4@\QUO2"2+F"A+DXZ[C!CZR#W_0(_YC="LM))'R2%M3[]<%X 40M0&15L#4 M J$7^!B$54KY]>UG(#&]GL7[S>!'Y(

MO"V[$X6]R9PP?;]U';<.2BLKE+G9U@G(2@%9*\"J!:)ZL3] K&;<%,.Z@:AR M@-5.BE;3W+
(WZNJ9C!I'27LB'92W{[>29.7DW#HKZ"T1=;P.).256;:QYA>G MX$7T$$&/SF-H4A*>R"ZI\G^A:CZL(^5 :N=#.])?S8&R@
M,+^)1)B*WPH2QL\F"M,?!^1]1P3@I}Y ,,6UU9 ^*T._&8J$7^YV%OR0C:: M^V*9K4?H$10I"4]DW;A2\$FHK7-
(L%,L\@>A:A#]Y].::Y=EN?Z?PY1"-42QN$A,Q5EQ$2>@XG8J/:&(9@45O%QDTS)R6$EH(#< M,5=9-
CJ$K53]/N2I"7ZAESXE60A*7A*9-2N^YXL$_0"GG4>4)1'O&#;.5C*JFTO/<>.]0N M7P>Q!H2;#_>:L$O85M&H
2"E<>B==*PD7ZF[H/28RH50!53"0;Q0T05-("TPY*:3\)S$)3T M%3MU66EFE ?OWCPRWZ-
!R:S>NH0="2HX22:3M#KP*][A# MX7))T)*'W^&YDC>DP]R#WIZ $>"5Y.]P%Z1FE)(AK>1'?62S MDFP4W/&HF0G4
U5R]YZCG/_OK/YROO^R$_EY{X4H_'4HX8NM!.?NZE\=^;"H M][):!%G-+,LTZQ)0BRKJ39RWNH4]ZN]UQ-0#G5)SA
MNZLMH,M?_,#?^\(6_T>"]_C)T3E_1X1/ OY:"?XNLEO&MX/MF7CS@QU([J/? MYA+WKF8)G35 V3#W'3_@A81%W-
5D2<='ZQJ0[X^0WZRQQVI 7@?L%XZ^>\', M0>^-D#\AV$+(IGV"UP-* ZYTO#!];/TVP[WUQL6O"&5WD ;"._K 1O./Z@*C
M_;D1?_X2H%:C?9G9WJSBZL;)]VSY_U5^.Z[#/CV@]1R1>)-D'4,3WRNC0U*A M&N_>HG=KXS4;%LI*]S'Q"8(S1-
9##+W[!^@'A VC5J-UG=^4(I(?U\"B[6-# MAM_52P)+ULX(3Y2;S,R_LVP?G!SJ> M#J2K"1M?7>$T)Z(RK/9&V 69]JP2.
[H5R&]X?WI+]5R"/4X*BZ1=7MSSF:%2 M?Q+X5-6P(I*G;1OK; OQW<9AJD%>VMGFFZNS$=ZGXU4K'8_\%5G-6*
[9:"N]%F2(+.4^\EIF\Z8&4 M=#5EN"Y^YFH6F.Q6BM\)@QPO%MDQCD*LG(%<%VT(#S@Y)@M!C37?K?F'^#A>
M##F'MKS<*'N:*8Y0SBX01}>4CO:PU&F=;A\ZY%?H!FCHP'FX%>V!]75 >(*& M#;* $)'5H [-
GB(R.3T6?"E#B.^L>AMH#5G;F;\ZR_?:&85/[Z_UH[O8 BQB M:*3MB)U6<[G_?L\B58_/")I2-(6++US&L7KN$242[2
M%0!9C5++G=ZN#Y(_QIO31JF2IV^?::V0';@L)A#IGL/["">]?'^"_60#A0DKS MR7P#4 E,]UU.Y6-
<55G34!UQ2EK&'3PAC^PIFV-9=/D,B:U<\!83/G$4(IE(M;-+/M7N%T.E'^+V#-ZS?U]!"@7AK+_3LM5STV>C)L1 _X
X]$5(I4E:.."48 MW^G1X /ZXP]64P_U?@\<_S4[*5Y,NISC5;CAOGQKG[?D&:<^6Q%F.ZW,\B5=
M%P_XXV#HAE%#ONVFESW]V R=QQ0]8?<)$1G:%8LK,F1.WR9A1Q8_4T^4/B6] M; G\AM&\O$S$W%?9R9:,XN7T#-
&M/?+F]74G57ZM'-U/* 8L\4]ZT0>8[TQ M)%$AG+:M/6_%C<(NY.HR"I_>+PR\)\>']((/)!DM-*I^=5?[T;9%CW>-CW19C
M_7.1Y7M:^1+XNKW0E2W37IQUL#;YR?DA"W+NM\?HL[U-Q^03PB4U=\Z38;'%"Q4;*HO$:&G%3^^&!Y[8)4CI
MU##D7A>HFE,R!4K@B&,1Y/:)1Z8%IA({X9V*-'>?RA5%'2%7UX.]O 2V8+ M&?'?D&L/O!D1S_U>Q0&1&7KQ[UTVU6;
[Z7=_?J1=^9&: ADL'^UV*:0_U<]) M8!41+J?3R'XZE!>,J*3*$GWH/R(XS# ?\>E#$KJ<)F&TDMOD+YK969F,XN5L M7-
Q#[3NF-R8U"H"<=@7R-T2(XS_S(-F138@O>SI0U#9X50L^.2\$M_3*8F(M3JN(0A-F2CE+Z3?";?12144E)P[;H=!9>A+=
[<[L,^$A%H:5N)>]^^]+Y9PT,?Y\3Y(WG%P>&+ \;[:PX?,ZNGV'5LWC#EKL9W89ZV
M/Z*MQ28B_&DXU0S5BXJ7,WC1V:'9Y0=?"-^#O>;KT? LL!3+?A9_1 WE[,+]
ME.)8W.OCXV@+>\!%,9%*LG(TU6HU6RWR&&V-)D/A%D87,$2A!_B?J]H'7@1O' MAZY(M;#>"WCXY(F[A^W[P&?
KD\BGY_\49Y9T($JZ<1XT4H^%&]GK]8RBI?3 M@#-6SGFIB5R1LN0EAG#.G[AV';CT,--B*
<9E=OD2#,O#TSYTEPO+;U4!P1(T M3X2)D#^982ZQR%.<1-D2-&)"\!_O8(5G43K8Q;[%]@?4$"P!.D!>=-'%\W]
MWDN8B9-[|) XBZ2.>S00RNDIMV\"X%>Y.^%:SV*^(CL6SA,IY1D>X^{J>:' MYYRI+KUX20ED49:46:60 E?
S5(L1D@1Z*4$\#A]3FZU^V4_'Z=[3%:MMSD"U.ZREF_)HN6-'%= M>)%3SM5-E.6*/3R(;FUB'V)ILIRS\H41RNE5-
7.L_ULYU2BF4IR[/"A5!L/4 MN=JIO'D7@BGFMF.AE_.F3 1<;8T#^ZW2F3A MLY5#[TD*J-.EOOO5EY)\JY
M+W6ZJ@^V<97GN(R/377WFTXND4930J(EX:5__40*A#$61J"\TL7U8+"DBVXL MWXTM(R/_]O>/)Z.]]SB=#2?
CGQ_Q']FC/1RG21Z.W_W\Z(^CY^ >_?V7'W[X MVW\!_.O)FY=[SR;I[3'\[VG4PQSS'L?AO/CO?DQ[OUS,OUS^#
[LO1Z%>9E, M3P!^6?S9T\GH^GPW?%\3S"AEI\3>>+9X M^?.CX_G\]*?'CS]\^/#CQS@=_3B9OGLL&)./EU<_NKC\XU??7
Y"+J[GW_O'B MT\M+9\-5%]+7\L?_^OWEVW2,)P&&X]D\C%.]P6SXTVSQYLM)"O.%U&^E:^_& M*^HK6%X&]2W@
B3_\>,L/_KEA[V]OGAV\>GOPC/[S]O#EBV?[1P?/GNR_W'_U].#M;P<'1V__&(>S M/"'3M$S^+
[Y]_.L6?'\V&)ZF_[_+ECS\SD,(H MG8T6\GI)KR]N4'=P-H-W M(9P.7@Y#'(Z&\R'.!E)ZYVQ.X# 3;H-)$#V]%
(B>&XV,2_ZE\'IG,V)MH?,2 M9G&A^(OO?ESE^AA\']GRG86D%U)>G9V<++X3"",GR[\OT\E) M&T7/)QV+^5R_Q,Y]
;#D<$'(%2I>3<;IC.@=SP]YMKQU!C9-U.S#BK$_T%%8]DWP\(54IY>T)&(OY"1 T-,H(13X+D68)V) MTE@;8FB-@:^I6$?
W\H'I?D-9MWO^3W%*?(_?O42*-994?;H"Q<)T#-QG*,';_M&I@A1#04SE%\YHN2BCO5V@S<1M0ZB%/#!%M-=$,
(,^'XQKCWDA4RK%D'0BF M7A!16DAPD4 LMY"T#CCT P-'2RVT\Q>3\;LCG)X\PSB_0HLN
MWB=>)&C!*TRMI>PN2X@Y(].9,8?8VF>LI&0=()@'!H0&,F^F__W9#.>S@34% M-6,>C
BFFB5BC).!TC$;)\E*E1(;Z_O\SIO2_V),Z?N[81SA^?>]POG!QS0Z MJV627R>3_&$X&@T,+
[H@A5XF&$Y1N2&O'&,$E@(W12>3LFQ,W3IT]2E+N@<. MKL.ZN2J.@?SU=$*.>?[I]2B,YY2Y'?
S[;'A::V5$XB"I)#$$#EI'#\K(#'$ M##F+'+,52O/6T/\6/7U*DAJ HIGHFX'A$HHQ,:')M%*L3F&Z8E& *Y*!4,QG
M6XS!)!LK_BY/_K:RH09*OI=(VY8_+DS.9V\J1/#,A 2<6\)6$04""[4(:XUV
MZ'PQN;%V5Q+2IS2G@:HW%W;CT&69>7.C.#KR)%IJ(B%*#LZG##%E)35!SXO2 M201SAP+'MC*6!GJ^OW";Z??
%^#W.YM57S%Z,]TNAT#O,1BF%(83 ME9.T>)=)O#"03@C;DQ,MZ@]F(MX#XE.DV"P6TIKXO2*1'T=CY)?
QY/1B3X60U:YI\&R5O.LU6@,6I0.7CP(D3P MF6N9%2H36YN8VVC:8.VHFN_)>$[H_?4?".)/GY[_B?_X3Q<(P7/+,@BO9%
M $J)H$06$(PKQ'C4**+0'*\5CU>L&ZUUJSYE0TVA<&4AJ;W,NT#_H$A>1"P6 MK OT^"7GP>PA*@+-UM>-
;Q'BI#2Y(Q"D-?A4X@C7/(6,V4G(7G@3D4*;!P%&CDIH+B& MBTRO3;"->5M-
24]]WGTP\%4"L;GHVV6**4W/,*_@,*H4@B26F$@<%#H'/NH, MUAKG?99!VM:5X1N)Z;G?:P2&!@IHAH=E/\;?
(_CLTMLDL4509'])H-;B!:& MX).BK$,J[U'F+$SK9=#5E/34_[5 0@/1=]TW<5GT""P[)8@2I@6H:!!BLHXR
M4>DQQZR=B=MIFK@#+';0,=$"%@U5L3$*$^[N&]=H+U@,-#)B,A()+?FQVO?
KD]%QD8(Z$S:W7;/+%D6CDP4CPRXKI5O MYP1$35= M_<=U 5\P*U&*"48TYNT;Y/0I:[H_!J[CNY7\F\'[:9@=
[X]S_55K$^_#J%;S M]^=/PW3ZB4ST/\+H# =.!G+*6@*:VM 1,P.OO09=6Y:284YQW1@::Q'6IVRJ
M'4C:ZZ1ADPV>AF$^^'B*X]EE8$\I?7 V$XL9%Q8_5.1RT-E'04YXC21(:)T1(&)OC!C96I=/+QZ M_SXE2NV4?
6\)MZRC+6IZGST3D7+)6@ZHT"%(P2@$TR6!8X6!CHA24$(W;R% M]!OT]"E5:H>!9AKH<@U)Y4)I.>?
@(J_[A@7E;T82,>1ZLE>8=&J=$[5;&;_T MM).3D\EX\;T73E4GYQVK16M#7&F5(*12P')ODA-%9-|:W]=IZ%/@NZ'>OPIL
M-A%W.P.7\[#R'D:OR:V^&#\-I\-Y&%TA;D#QD\G<"V#:&J)+4A2>*2B7PK B MR;T:,)T*W4Y5GX+=QL!HK))F4'F#\S
<8SX(TS$%WC.RS&J8GV$9IN%\ MH&01O*9IG!G"L6(:0K0!A I9"IV#3KXQ5&ZGJD^!<&.H-%9)R[!I2<>B?9:P
M>SK%8PK9A^_Q?$_YR\FL[IE06=<0];?'U\7WDEZWG WR]HA^_G[PZNCMX?/#UP=O]H]> MT*>MAX3<=I>NIH7?
E5]!6,MTP_$9V9F+M:O)>/8$RV2*5Z9$ MA'%>W?(W0,$"SS6>49X,49(*O/<*,EDBPV64PHMOJZ(Q1_A-1+N&$?
#=X^53534$"=+:3PG:9S[M^-]Q?CS)5W89# 1Y>*V=A"@S.>*L$9RR&G((F@N1_#[B[A] M=_25-)%K09:O@DP4(@0)
<[&.^N4H"'7K9"-]^J,)M"?UF]M7(Z%,R%E+*I@XO M3A BHZR&@DVF.,4%V'H#R(WV=;>V:5-]?S44Y)Y2;K MSR?#\7
VKVR^OXP*=;?%QT5;GO6;T< D.T2L%FC..PGHN66O7M!YEO3)LK='1 M@7+:]O6^.#D-PVF-!I\>A^D[\K6.@DMI'(-
YUQV3_86B]&TFWLP0GD^E\^)^% M1 [+]0%W ZUX\C)27.8X98>,*XB1 CXO;##%6T&?MK8(WZ3HCBG]P\!(!\IH M!A "
[Q7N6,G%:0P04-;&6UDW*AG"J'*8*!E3L;3N#?J"@ 9S$BE:6[BO6*Z M% /:>
1E*6R+SM=JBDVJI$SR;3TT_//=^Q06WU_#*T8AWD>ZW6!U?SZ?#N/9
MO+:0'DUNJ*9)SA+GGH&E;P,EZ&EUJ,D$6;I75 M\VPH7HZ M6J->M8!!5YQO;7Y=PQC2QCH/-1/&DJ7(8(RN.
[F00:!G&:Q6Q0G%.;K6!;=N M..E3AW(GH-R)ROL.7Y4S6A,,$<])O!@*!,,U.425G6#<^M@Z0=H&?.\K7[).
M%X6M)SC&6ABUE MEIB4X4\L:N6[CH]LX]@=P M7/VT;Z;!%H6IILOE,C-
!YD2"B8%B1B^)^$S64)CLH\;HRO6$=:M=J+MU$ST" MX2[UOM.F]:>'O[]^<_;7?/B'P<'^V]>O7CU:Z?]Z[?
<<$MNBDK/"^.1;;Z)HS$*?G'I7X-REUMOV/]^PX>T\NEB(*;* PE+P MH&M94ZE4M]O6N9U9.9984*+U.OA:A'7)_7.ZQ?
#=^'S20OIT-_WC64@+;8[S MXM4%HO/_G9WWD'Z65\Q\T:X./&@*MESFX&U*%/]9CUDF;]OO@NJ&E3Y5%MMC
M=64W^8[QL)5'^W5]8T'YX]K7D]E\BO/A%,_I7N2Y]?RNV2IN!,LHG4F@122C MZ1*C_)>\K3;"]\1$MK'YT;

*(=|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

M6NLIF8LZD3+D.M#'%0,>ZXSL@IKKJ)5WK5M-K4;U[%^8QH+O(:?QH;*]'=-;
M^GDX&I=RJWAMX*)%5KMNBJ(T>35*@K.F*MC'!B3G#4_"5P7V[-7DUY(Z"%Q
M\5M4\R),/PV$8^1Q>%JG)*55@GEP@10Y>6V5I26+YJTN[P!X]K1O+LX^YB;- ME?]?
KZ8I$]U^W[@D0X\EIB4]K3Y)4':YQ&"4PAH@\J,X":?3RX'O8Z">O1*T M%?
ORF4N[S6@],OWEU9N3_^RW?]O#A^PB6W7%TOK+38W6<^V,!X8UXN,EU=:" MD;X3"8M*-
OKVKFC/N:DE!!Y9*"#0U.HN\K%]"1F$SDJI4#+ZUK<+>Y.;VH7/ M%;FI7<2X=[FI)]=#MX_(R?E"TL?
IZ>4CYAE7R++1*.L$=D,.LB#')PH3P?!@ M$0BD"2?B17/*#T)IU4U^?4FFZD-&? MLBPN+K[*Q5&R
C%D9[F=EQ9+H,T@YZRJ43?7"UO.M%%T+WUOUVSYTF6J)A6 IRLV869OO-,9RB1ZT#[MH6C?
J6B_&]#L6&UZ(ZN/(H#;E_GU)GZ4AF=X)UOUP[BK\$I4J&E5X%B=X8@Y M@@^1]GHZ&GWK;?F?69M-%K'P2OJDY/?
0XG"2_P\P32-5V]/4AP MH$+.QD0&*DCR%WR1X&IC,<^Y(MWU/GD_(&*]*KD:;629WJY3\S08!**""X*(%9ARQ81Q'QO?
OU!8G8:S_N.]:5 MWECI85?[>3S.OP_/ZF#D>S-P;V:C#KASP4M&&*U20&9001#6 IO K.8M&N=
MBK,.KN]8Q7JCKX>*@9=8<#*I4E@\!\1'(3*W%E*N Q6LEK3:"@68C+<8%<^J M>270XY#^5*RFI/756'G!VJN(7IV-?
_]VE#?@"AT%OQ*,JZW_ZAX=:T-HD7UR M1NK"L9=JPW7_:EG/1'93Z?F2=VW7^+E?V^)Y*HTX9L\G/*F-I8$EQG)0]0^
M+"[PVHS%*OI_KD-K@[8^NC]UKB\J>^CR_!#I44KC"Y(DR1&'7^8).L$[Y+IH MR-[7]- Z?#&9 ,''Z+G,,N36MSGKX-
J]HO7%ZTKUV9*4AB<)M8[T'KSAZ+=1 M)!>Q1JRC^>IOP3\BZ#@S'DG/P$+FH[>C@3> CNW00IFLS70<%5+']R.GJ)
(/[(+E5&832O,YS]!"4"D!!IXU% M&I&:#_K>#.EWI%7-B>OA?&#Y?OHN?)W;S$B.7I#.4W1I(ZB<$CBL *5C-O"8
M4FQ]_K02U'>D1-O0T4/L_Q#@M7J_1[*A%W6/C=QFLII!6EOG@)']S#D#%UQR MR4HNJ7^/^!ZH[TA?MJ%C)Y$[*?3D
O.;82 W[3*NO+*(WR1TZ^\&40='IA A M&^M %0HXO7<&1.VK&K7/CO?O%77#_!U16X]D]A#1KY^(L2CC=,
;F(L0'JX@[)+*'O@QK0E^<8C9@B66AG067?*88 MEI;A)2/7T:"Q(HG"7/,6WML_O/,$]S,9;4W\ WIQ92G9 ,O(0+G$(!I)
MOH9W01=GDK6M*R+61W?P>7\]$=5#T+D$:3V%F2X1#%?),'K5P'CA07E6JN=0
MH'!I238E%=O:#>R.\E"K)EH1TT/6'H7%USW+TG]?#"=(V$GA9U_K+/,9.:.U MY\
JG^1UF0DO_QRP$57.R4XV$)'D=0DM)@F$ ^IM8M3M9'MS?6J1G7]ZLN^B&J M#Y6:C!-BGJ?YGX8S/"G+H2I-
EM1)!3884U,/(T2,$JS2SK$DE&S>MZ,#O,-7 MJIZHZN'NYS[4Z4GYZ6)*5GLZ/2J% F0RY(27?BU?5'"AU?
DPLSY:9A1D)@OY M?$*"DXY#\DQ9E9U(KHZTK0*>[A1>F!Y+]O0_8JS3^-*:OYWP]$
MS%))BQ06^WH[JA3X3,&.TR&JXA5CO'7]Q+K8#E^W^B"I!]?] <[K-P OB]^J MS*[^)@]T=-YR,K121C*YG&>
(V6DP,1).GU"4WA7J$7S?GU*U(JN'BZ7U1;/P M2 ^-+)A,!N9E+;BDC3U*BGIBUM):482//4QCWP+QP2O?
#@GMX=YJ3>A+CNQB M5A@L([FYVO,B) 4A^N@.7LMZ(FIWA_JOAJ,P2HL%DSW'R"AL,:[V M,([%$F*6P7)#88Q0/
J^&]5Z!.6AGL"V(J;G@XTWX]''#S@YK[*@Z/@%^96U M#7Y,.K,E,VMY#.YO'0>V-+6K&[".'%=O3TLN(VL]7 MX".7@]:4-
#'W;E"M9[MG,_4^##^$/[XS^'L4YVE0&)X-9XL:0<0HG!9< $!61W#2+MJ1.E!!]I@O>&<
M@MF>3AVZ8CUX[=H)B6U'ZY&$;MO.Z\EP)V7>S?_#^/AJ(-QTP"U/I9 /AZ$F M9C@IH)
[SOO$^N:"Y#&O4[ZS]N(/5E=YDWN/QYTFYF0+I0O1U?#-@K).A43@(M#I%P<<\,"8.%YG>
#V$*.:,HINSK'"PYJN]&5QH1T_!\D8S=/#WZV\JO:^VG@VQB MY+%D*%IK4-9%
<"ID8"4YY:40CIF5V\F2#S]8QAO)G=@L$L/#\6[KL428% MT84 2LL"+CH%-@=R?8SU+.XHEW)-Q >K8D] Z),>^
TR2C2QD$%,G%X<(24$ M$2P8Y96(NE@>6P=0ZZ/[4\TV(ZJ'D8"I6":G93C/VA_'7W$]Q3BG8PJ^/K_M-
8'A2SB[C/ZNYQW/;YQ'^>X?W/K-UZ-T=E$CPY?#Z>?Q-)SJ/!E??*9_L>1F MQC!1/\U+=X44)E'DD5.4-!8YK-'5I?^S[!JI_]
(??3B["3XO20D[756B\' M"#XLM;J2P&VI7DJ:]AX96)TZJ5.FO:=:)C(;$;BR&#$'F5QKB[[;%3[!5V*/ M%:*'8Y2=ONK*)!:C"(
FBSH^QD+DY()EYIF/N?BB^DC&^',WV(7J]ZD,/9P8 M;;76.TN\O?!%"TVIR.*8KEV.B)& 'J(O"4<@VS*U[OE
MTNAV]FY;E[10+H!'FVOJC@)OB@2A:S#F.'EYK3-4GL[0MTEI7!!5+A&NSI[\ MA:R@9@V *ID\!FX+A*1E2LFJW+S1X5:
#\)&[(:NI:=-+>>*OWM__.KX_?LZ MGOYRJ/[XEY,W+X_?GQ[_QV^O/_SC+J!UIHFO_]'; MSQ#?M/6LX[6>]
IE/&5,,D>;$&2H@T:2H[?300MZ.TP MV89<6E?3=<&W]XGEO>K1@WE$?1&T=]/.+VNVZOK&H[K!SP?J&NN8*ZC
:6%K MFAU"5+7QJ"0')48OLNYMQODB0$\UV;P_-5@V]WQK.GK(>KR'Z6I&ZCJ@>AIQ
MOA#0$\\UWYZX^P?.S:2^,Y6PW*2@).&J_5^49A&BMI; 95T45UR+UO>_.U2%
M=8>5[T@3N@A[J0:T])9_^NWT]=OCT]/3XY]_/7[!X?7;5R?O?SWZ\/KD[74) MY]5HY.&HC"?
G\^:/VMZ;;K3,1M[UU;/>X^;E).Z6#\A3.DBY13%N'I_O$.:"WS'A=M&C>FG,#F+ORJ9MKSP._IF>*]LZ=
MOF<#KHQ_9)KEE(/H'BT4*,)$O/&-,<0\FI]8W_HX">RIWN71N6>=5;L]+' M[,Y++-
=^W1I@>O*F[P!Y8B]Z>Z+NJ\#64NZ=^F2<4+*F0&5E2,-10G"20W+* M&F5**JY=>B?\G6]Y9X9[R+<_IC^9N?
JR3=M2Q<3_$"[T$]G-:N;"19LL :* M,#7GM_83YDF 3HQ):X-CN6_O; &L)[B+Z-T9:4S&0WUA[:.J]\=_/W![V_%\
M,]P@4KK[S[>/?AZ!TRBB(5;"QX\3_'@U_/9J*,"-"B26DS!$$?>U@*;4!BO) M<2@JR8"*E9!.EV:OPK3UQ-/%GW_I ?
F@HW2T7LVY L6B)@]{:;#)"H$\YN!:MEQ8_AF=7L4E3/7@PK;25P)]' .*ES,,5\079UM[)+$*018' XD62UA71>AI.
M7@8@[6CO%&ET$7_O[N8Z8+[72*,348_ZG9M(N7?JI<^"Z>2 W&="YF4"E^G- M0?*H%<,ZIJFY&=CS2*,=XUV$VW:
YXOQEUIY_G)R\?$E&;2S\;QY*]S=WL@ ME8S.! .Q3GY0&1,$- *0HT"9B@KWKW(75&@^]H0G"Q0VD?
NXO="61@$;.R3W^F M'#815L-W<3J9W9B;GW"\<1(^?QJF<#8W-59DIHSTD(0WH)1+$#4IE3:L:)^R
M1+W6E&]ZRBW+2S_=6-U' 1R,T]5.S U; ,U!72KU;4C7E[5K@.KB=*W2@65 M=NMT-
21JW)>46[_^2I\$%7UQDI4!)=6@J_3/PEGF0C%&P&C3C8JVN&OM%_1+G M:]?,=Q%N6^=KGAC+ MVF+<^^3=;=0-
Y3UN)ZR&SE9=X/%%';UQ[?1%ZSTJ 8Y5IT%D)*?N9SIG,K^?40ZM8&%K6106W5]N)B.AN?XV0^\>+%IS :X:7E
MR3E:H5(@=T-3N(>>@<=J@T+4A$_FZ%LGMJZ#ZV!?07&JW=C'90]
MG9>MA_!I#M+:.]Q1A;:@YPFLS[6'*@V/1JB:KXFTU]6!8;7YFR$G*%NNT,KF M==U/J$0KCN;V18>ZL-++
(>U9>1>^7FVC(3 9#*>EJNP)C'$0A"(KG-&H&)V0 MS0>2W@&P^[.@/EAZ<%2[J8C;'N^].!O>G#(J>ISG3D*I!XRJ"
\Q4"SD&"+W M!!#O#SY8=#1{ZQ,/BKIMI-4VQ/L5,_G*$PRC?/GM,%]A2LH')NK@!97JX(5D MP#O2JY*L4\DF$S:-
J#TH@0>(-59 MPTI)#8X+BD:]TD;G%.7]'H8+*+W_J8?&Y%92:]OZ^J?A^/.G,#D/"2]F-:0E
M[3J?:]=9QB_#A&E_CF,:ATW!*&ML86L?8UU=53@3!*0L,Z7EI;1$E82W/6I MAZ8 O4J]A^9-1V=GX]_K?
=^K\>1R5$"MV\3IR4U[@O>81F(;O+O7M5Y3M79&74-/[[&7<#Y@]6B4 MWPQ#')X-
9U_O0=:%F2PQ@P^N=MW($B*&!,*P7$K2EC6?6;0!S -3LKZ)ZB%J
M?.SL[@8D,FDL#_XRBUG5J3DA.@\FL!!M0"MDZVAR+6 'IC_MR5CJYK9,+C^] MB%A\
IXM:M/REID1MFF6^Y',V3S=?!V"K2MJ[C[K1"REMB(P90$Y?%,9 +E+-M& M11"\#J4SK_.ME6+8^:;K[N9?
G_#;I$)R7(.9Z[X,"'S62'IZ9=.^O&2W"K$JQWRG^M!%W/WKP;<[M%8?2) ,44=>VD8E!C%&!
(#/($\9BL/FUU2(@3Y#*W(:HQ^G?0,H[*4_]Z>CT M]>G)JU>OWQZ]??'ZZ,WIAZ,/Q[4OSKOWQZ?
TGWECG)QF$TO3G=NO%5M7(N&(HD;:F&13,/CML$UKMJ6SR3 MSUVQVDO<:-9M=A-
4X*>^Q4F"ON6(IDV\D=6TXQ!!\D!D,A?9" M%5=D*BLYW.?ZZ0UY;":T'JSN_.;V]?GG,)Q44"\^A0@W%U%3L="*>-TRX
"M)Q%;RJ M7<,<1)4]\YXT4[:>HW#]{ ,E?"/1[JCXXEO61ATKXW-1!900D386*R%H)' F M"&A M4]?
IH8>G"WU*O8<F(BT%W\-Z'"F"WSIG&@I,)YBOGY=M_TOCC:/@_MF/D G6(J60U<(CFKS).?
2OL3:;1"2*X$F:76^=*K0!VH>K0EXZ&VN!;#9VGQ M]R;@'LU>A,GDZW#T\>_A[()9(I&Q L%0[*FP"1V0S;G_P9>WX#
(%:SP%T<&76+MAU6H1,GQ&V<0D.4\EK-4F;HL5
M[C1)I0W7]ZW$]K)}ZIR3C,/!&_P8SHY',UK(U5@4KYD4&7+TM8A6*HC""@A, M<4Z&@>OT6*0ZQ?37C^,O/I}'7ZH%?
7.C#0L>^%09) W8&[>18L/#Z@KE$L6W M842K<:R1"+*:U=M/W6W6Q];B'S>479]N#8P+B")U5IX<
MF_S8S/)}X'!)&D=O%'81V5+J6KIH/Y^'+U]28[.$;D[/[TY/CH] M/?
YP6GLF?,3I<'3M91Z=5T]W7'X>C_/OP[.SC9VX%@_=WLUKOO1&CN#U,VZ< M@JQTBM6Q=UB3!*5/X)5
2%KE+!./+#WVHFWB'CT T2[#^?JC+S7ZU&[?]5I>58E3R/P% M,WE!] H.:27S!(OI3U]_#?\UGKPX"].K:7F"C"

*{7M#Z%-8,G,'!2DJ>%P=D0 M?8K8.F3H ._ITY"WT(;Q;ECI(2?B$:@W0-^&\V^U2FO {2DMN2/4ITE<[HWZ M]56L&6] [H&Z916^DT]"-)=@I4)AOA(Z%F*Y*E]U7+NM#5 M-*

*KGZQHS/F\>OEHH7.>ND(CS%EM4WE1MIS!8\/)E!N39^,=0^EF3\'%-0AT9#D$*1 M6F1?*

F$VFR!51_O[HS)+]9Y]5IHOX^T@NOLIE?8]G\^9>-:GM6\T*\CXR:%M49Z=;G[70YG=S>^_?-X_];W$0EM"X?>A5F]?'XS

*M3#6MK5YY?\#T:30^&W^\;HS+TJ/BD6A%#QZ"!X&R$)QDQ,Y$C%U>,75S_G M *EO+]\>C,/;*

<4UN^XPS//HX0;S,@+U$IHLU-G(!Y"*3$Z9X !^2 T,>6)16 MY%):EX,O1W.

^M&8@H8.ZC6R2[VM1^8/@2D5/!J0%#C1WBDRA$!:RZ60EC'E MM&U]TKL4S &K1AL">A@]]'A-=-%61^Q?4[J

M7C>2:'>"VT]R?:C%G<+<=Z,(;@19(MJSC$K5]Y$9 M8L@)+(N)V8C<^^8M9_>\440[QKL(=T>-(A!Y4%P(8%]7[<@:

<(HC".N3B%D' MBVYEE+"OC2(ZR7N-1A%=A+7#1A'&!NV"E"!+2:2@!L%Y)2@,M=&SP(TL;"6'

*M^]PH8D,>FPFM!ZM[V:P \YOQZ.^\,N32#?T%SS(%F[]-,?_T]5LS3U9KE8MF M@-Y)I)%WR'Y*7UQDL?9:4KL<[_X-9EVCJ*

*>W+L M.H-]&N>O/_X[*UH+\I{$7[8FV MK? [}UC9NG"VXZL/X0B33A*8#:EZ81*B*P'0Z42FW40N6G?3V8NKCQV1V>'^*

MHPL3.[__(9IK] ">7,15/(:'"8.1F..TF>NI'Q6]Q^[Y;^]D/MHMW8^GLR& M_W,U^NC^F>Z YTP+])RB!:RG\%I"X-*

J0(Y@39SS$;)N/SWL4T>Z5I6V>GR?CZ?3XCW1VD8>CC]>2&"2G/!3]#84%T"55""J4""%)(M(J&)L M/3-B/63/73MZD'\/-*

*N,;#A5=2JG.<_?U7(\TE'8O1Z91<*DPHW:LM1X<"M,;*

MR;"'>\YOO68#$\ROSB_("K(/[RUC0\4BT*'^6D9>6_DRR&$8CP(FR2W M.3&K6K<&[X[RN;\./?/20X^R^S#?

XNSA5FZM+D4X>D^+H0 P$3PGI0'F<_8V M:Z]=Z]O"=7]=VU!+OL>.II=XSA*_WU1H]&7%Q-"]PXGPW$>L$RN7)

)A,SD MXBG2XAA)BZW3I+YD/B6V#KP>P_/<]:&9K)YPO=2U-[QV?W6MF\CB$8E[H_L23=JZ] S%PL#.Q\<39X8.$VF

MAF?)!5,A-TZ2%H'5[M""^$>>=C5HM781IY@4)*N7SU)R\$8$"#[PVMY+&ME? M;?*

PJ=+LJEV^N\LKZ)L2\AR+ZGWQ*IA(J[*JQM2UNC(;!R9&8S07 IO/LWQ6 M1?*

*5M%62+.OLN1.U!X?,Z2]&Z0FTOU*QAG?TNM:P+74];9Q\5A3PB9V#S8T+%+/@4//C(R-9; M1'F_A.40ZNQ[V?*

5ZEOY3E]ZO@_4[+KWO1.4V==2;\/#TI?>"930!9%89E'&U MQPE'^K'X0H:Q)-6TF\?S+W?FZV]-Y%(P4+$APOY+%*

*[9L@^"CVO%:OE04G(UE?'S{CT?G/3T(B" MG9;>VXRVI, A.4LF*TH$%Q)YZ8A&*YL];YYW]GQ+[S=7C38$M)T2^'KT;C).*

*M.)V^/R)[]BOF8;C>QRS/*6A7XVQ'VFHY.,P<@@LR1!VS1KMRJUCZ\0=(NCJ,-*$ FJ9(Y=1%!-:WX[O:P)J[_=*/5#20^;R*

M!NE!6)QU,1HPK$XRXHI#Y)GV.BM3]-XJ$5M[&L\A;:MWA>J9JCX*]M;))DJJ M-B42 LCN1J#-,$-

T%%0YVB4Y"JV2YM]%)M?.+=+6="QU8G>4U--'LLY.DG"> M/+FF.+95YO@:R/+D@/X7*

I@MDHSYBF:W6$KZC=/D%P3G?/<&D&.N*B]56(F M#Y!)0.?H-1(IH6K><.IY)M=TT94MDFNZ$/(,X,&.

*[KR;GSX$W0M')& M$7!QO-POE=[S"\U=LM]>Q#N^TU3%F'K1JG.LA6:>090E@DZ%Q,&%*OP0[S2? MPD*

T8F&GUYH:3Z$=;3C8>5-Q M+5V)/'G0VF=0@3-PK$A@@EE6"R%=:%U@ON=-Q7L-LMN1T8,9N=O7=1TPWVN?

M\4Y$/=IU>A,I]]YG7'!/N%BNS)"[6VRDZ(LV-N=2=K'$8EGKL&/?^XRW8[R+ M<'?49]R&8&WMM"RMJ$V?

T((3H@#$(MRS 3!5T80^]IGO).\U^@SWD58.^PS M'DQ@D9-O40(A(O]"0ZC8O/#>>O1*N-*

43I?:YS_B&/#836B^7_U=B7/-4+&7Z M7XD.E$N:PM 0P<7@(;/ K//1YN8)K!TA'KC[UB=A/;C^*^ NC('6@=Q7%_+N

M<)^H#WF?:M!-Y9IQN'OSMA!ZX$;$FFLJ(YEZ)>KD4%<3;)(KUD96A&M]8+$W M:K>J(?F>:UT7ZGK0MO?

XN:;UC3[^1K#G I",&X],@PU:@C% 7UCPP@4."I:==+0,Y,24#XQA=Z^SZ R9_([$^P?0)KXN4!>O@?&"8??A\/!*

(7L'(.!D(L"5?TJSSV](T+S M$HPI0W0 TJ0T.7/7-HQ5@O+=DT&Q("Y)(5A,I,Y M?G)5JTC_U+1-*.MA?,$&J.EW!R:K;(-

*BH)BIS?9%J%FZ!2**4EBA!=B,J'PI*)*,\PO)IB'LS=C@CT](:.4P_P4SFK&RNDG MQ%D=)YIFX]'{6@T_PGP<)O57I@/I#*

(9_UZ!AE%.ERN>G^R/.M1^-R-AY]K+^4,<[F-X0;]Y'H\,SM>TRT7GBC'A1S2!_H:2_I:3=:.X.Q)41+

*MNNH$J.QK1EH,P$H*A6=)\63K764QDG9])NY_N65LS#2^!PYH.'JD7<9U]/1^G-;VDH5Y;BL!X\9F#*

*M]K4B1[,ZQU08B%X9C*D8WOSH=0F4IT_IV);J<7N1]W"#LPC6Y8RUZXRC=0#V ME-BQ$MS3I'DTH7(-*

]=B>AZ=1&.:-2$(LI#JG#_RSYAD0$Z9) E:@LQ^$#; M;I+.M-Y5'J(XN UE2T'W<-E[%]'U5)TU,/6T?2S"\S0[QK9TBI%/')6)

MI?DTX5TJPJH^)WI01=!]\#_2YP,OX39\ N^'DUGDXMYOMC/!*R>__T]1?, M'X>CC[<;@5UFSB-*AK66BL(8VALS;666?*

*G0I,:=-%*JTCAXW0WIPV\H.".LA M-VL!K,M:F36];3S+ 7U-'O/+I@=]TE+#^9I.4"1,C?"""7 "#:BH/7VG,V@O M-+U;B1G?*

*^G9HQ_JR8HO:*W7IPD8_E4\XP>GL?9CAZ>_A\U5/"Q.BXBD(" YK M6GU_<$P4,-+5/%6K?6K=?*

78QDMWG!32BZF$YT[9R[J%]J6ZL-^_ 7,M-48BQ M("2O2=4EN6L1=8V\G@>\G#O(KI5@;\.KI[W>+VC#V[@OH3?

*N$G<)J:[Y6\WUJ^&HIBR^P3#%:ZQ?!RZF M$J4SD+*L&=@I$$;O 0-J;XWDSM_K,;H\AW3UXYZ@?UR[=*O>Y-*

*J#9_AV/,/I MN_"U>CY7H MCT] MCZ1AIS@:CB=S7"\OD(@@GR.0!1/1@:W#UY7A#ERAR,<)E7Q4:%7,*U_MQ9_]*

MK$EL([&&"0H5D&(/ 5C?T7/S9SY[" M[276=H3TM_SRFCH^G$XOZJZ0QM/9=%"R)+/O(A@A$ID&C>!J5[0264B,&UG

*M:AJ7?_YSI[*1Y!J>WL]-A- /]$L-M#8J,_(62PD>E*ZCK"5M[MD4-[\EBTRO M8507??*

*9SI[&!Q'HX**G+FIZ4R[R4Z[W:N\@YIP#0*T/>6<@) D8/-;DE!8[1 MEM9GZ(MP/&O&FPEX:?%PZ]*G-[=J>*

*[:J9UKT06V*E%9";%1Y=#<:OE&4(= M;^2 80V&G2$/B&=.>Z@Q-DB>0_/RZ250VIZ'71X!V\AD,,Y1%%8;^%MK('"%*

MD R%YY(> 74][J67A'#:#%Q)LK2QCJQHG3GX M-&JRXL+E:;2DB_0;:L=T,KN9&G2:5"3{BE"O33C1HL??

ASWSK:2+7A$=T"4M\FBL& SKYG,(8 SV@&WPJH41#)F MK1OV_:)]B97?)>M=!-O#CO]W0E5-

*6$WZFJ\P&,$U\PKJK#=0\?+ 1(/3ELR8 M=X(YVWB'OX_AN5OV)K+MH3[H-I[KJK4U$/7D_C]$\S0._W8L/4+Y%B+N^46_*

MGLFIZ^ 3,F:U0S4H@9SA!J2M4BF]P0(4=7N8++(XE+0N-8QSXHM^]L#G[O9WEQZ#6_EOH&X

MGKB^!HR&;O>M1^_>T=Y0^/?IVT)R?;R+5W!BLKPF7@+Z.JI,&0Y>93(.,FJ3 M3?

9BO7%IR;P$9>Y+7]=!+:,)BJB8$P!/;@L/&T2&,GYMP$TMQQEDJAEZP;/ MAWMBOJ5\>*

[A%7]C681U,WV/OE$YQFE]V5\]F4X^G@7W-4^I&V(/@@-*A@RS!>KY7 >T@K7]8RKL0B@X\;A"?55Q3$ M@>=!

*$6.A4!F:6WK@[$];\S9V@5H(>D>IC*L[N^W#L _^W%VIK)SG\5->'B2 M?IS(C-21<1!22%!,)3*6QD#AI5BKF%'-*

*FZ\]KWZ<_>I)%_'WD55QE?!XI]T0 M"NYC9@&*JNV&:FFFBYY#+-YPJ3'&U+I:<1&.0]E+MI9Q#U-7[F.ZUL8U4/65*

M5X\9\@BC51>K+ M/OU94]I*:HT+DA?79MKHC4Z60PZN#GNG+T'%#"B%TKHPQ@-;2>.^5+.VK*YH*

*M([*V+^.2:CY#CU=.2\@V6P+$Z] T'6%N&C*B- 81U MF3.*)='5]C=9:O!22>#281)6:6%7SXW;E\8 S3G<6F2-.P-*

P_5"IS,!KI1A7 M#$JA12D>?"VP+,"CR5PBZN)7%#(N_>SGS^'V(FO;&F"A4MF!\-67-V3<4R"E MJDY69)P\>J=XE&0B-

*F[089_A]N+K'$__/%7KZ?W?2T_8(R5&,FF>X>*M,H: M\(9BLV)9<=PI(5U:3>+B#W_^+#806L-LACDB^T"O)!|*

('D4N+M9C3P$JH"/ M&,!83<;>!,^S6H/%19]] "1N+;*&-U%S7_DA(*4'CN(DX8N&5!APS%*

*M)++O1:CHUW@3%W[V\^=P>Y$U/ 0F0+<;'=QM^1)E,CX&]&0ET6X#;B<'42> MG,TII7*_P_X"&I=^_+-*

*GLHW@'I*Y\3SKVZ<;M;/([=YH \UUY"Y2[(,JD=]< M$CBD+UQZ+5QPI>C60W86X7C>K#>3\$/6?2O6ZWK?*

CD=7XY0'6@12M\C!Y[I, MLB,0+0J0ODB1HR1<++">)HS?VF>VFAK^\',:30)? ;#G M'CLZ)

I0F0:)}]3Q(L9HB"FDT4E+:TLHJG6]] Y[{(0H:OZ)Q!(]L@J :$. MCW-"F1RS9AE;O_E[V&.G"\?K]-*

CI(M5]Z;&S+)\E^YRT"068\DB&D-&.);(M@;%(CZE.&?S^D@4[,;QFLF 723])[M!%T=YBXL6 M,;4C*

*/F^X%UBD&7!C,E:*W>1:+R_R8+]ZDD7\?<^X^(R.3(9P:P*4#07=5@Y M4O@;.)0<6=$IUJON7MV-*

0]I'MI1OPXNOQ8AN36U8!]?W.N:F$V?KCC?91."[M"'.#26A/Q@^2)+=;%4OX.

7$@;YF+FWVJ3QK1>@^YJ87/>@BY]WEBR>O&<^0 MBZG'V)YL7A02N.!&V^ACRJU"'.U[OO@VV\#6,NZA/_2G+G5J+

[??/$.C*V; M*]Q=W+O+%]=8HK(^@(BU]E9)!['8 EGH8E3VR)H/N-G_?/'F.M!%RFW3V99F MNM(FE%B1$H2L+36+A:]*

*(=O'D\Q<&:W9O2#@.>8'=Q+\&OG!7:360RWQIF-\ ME;=AGB M72'4G*1@ZX_%6V91><_:GR_IP'L[8/"WGEJF*EUC?J1*

=]K /MS M[GHK9M>?N[X!+3VX%H^,CU:2#&TJ4%C.H%)DX&P6$!T%0IRA2KRUX3F,N>N] MJ$L7-

GI0DR7SP(N,G'E/T;"GC5DQM!"9C.!Y- 6-H2V\]?'T,YB[WH6J]>:N M=Y%S#Z[+DG2,4H+37BNP1==TC. AIA(

F2S!)%R;\E. ^YKTLLT]> ,I]\'] M@D$$OX8_AN<7YS^-)Y/Q[[6N,GRFOZE38(/0SGL'@=?;F%R_*^2\)W*\"R?1*

M,+Z+D1#+\!V(GO3%2-OH]2[D\]5T+/QZU&:U,G! T'7-W[1P.E".XG9F,Z10R'B1 M8S0OW0>96.8\9J;O=Y!?R?

*+RIQT8WXW$VK:T:R'$-UC'F4['5T9IP!1G2OM8 MRW9KN];.\M46!I$K(6+*VKDUAJRO\:3#9'P;<;8M*

*EN>?"]54E:Q!,*7VM77-M!/"A%HBBBL%)=-*N/H)\!E4+&_+:1G]-+9=-,F=)Y="]@0)&4476(>7TIH! MT=!.8DM.NG6"*
I@(8SYOS5O+MH8?AJ_$$AQ]'EVC2UQ?D0TQ"FAU-ITB69SCY M>SB{P)?#:(AZ$] M??
*+2MGAM65FK9C9)9C)81VM6*3CPEA3;&UEJ/V#R4M9HK+#OM< ;;@$MA-:P M;&UY82NM(>64)841W-*
".%.L[%GAC$K<6V=(BM-9U-M2'=\R>&6Q4C+/JQ-1=):4!N5)2TZ+KG1"\10G-
*80T!IP*ID97;P.KN\UW;P39^NF&6\B\%TJA"G6A5!='.=4G;O$P05K@$GG);T-MY/>L-4!N;Q6A>*
[IY+WK01ZHX5C7=;!]#W.N^K$U3HSCS81=.\O_Q4VEU-&%@LP-M7ZV<,(+T7-AZYRA]!@+GL77!X3[/NVK.?1?
Y{KP=N4(OE;$"4-1VO)XG\#)Y-MD-HZ*Z)$?[_%V&U(]^>LT[-R+L(O(=DG]-/X\GLP_VB"B-5B#%XT#I64+71*
*M5I"EYN6'@BH*GF-C+5@(Y+"<@.UEW4/9V0-0UV[I&K!Z<@660'H:;Z !::O4-M8-N)}[_+*
(.GM6%!U[E)1I7:7%A"\)C!!\T\C\X6T;KV;>*L,(SV)T>=!'T-MSOV#$)S64BJ9-KX;*-OR@K"Q(J&*
*(D.)7&:A4^O3H7TJ2._'0=A:TCV4F2TIU5P'U?=:-MEMZ)L?5*DC<1]^[*THM+P6@M0")R"I$9!U_3G:PWGO2>Z<#[-@;*
[5I;>@PYT-MD?.RM*95,I$%<$GVI14-//\" 231?2!8&J^NB'YWI>E=Q+\&F7I7:36<#]?*
*M/G,B)T_+8+3S25DGI)8(@1L/03)F"LLVJK*2QGT9T]&6Q-82:_LN+AG]HBD.-M$;9D<++6!YC@R$?,%IS./EO/K.9N-*
*85[,BVG,87;2ZQM++7DWAGF3E-:9P>XFU+8I9,LPN,905$B2.=7@/>G!<-M27+^HPK))]*J-696[D4LZ(-/9H'J1%*
*MP[TV>9T9*WLR_J_U7KBUQ!K6MRP?91>BS4:: ,ZQ6G!3!T8HY8#^SM:T^6SN-M=TS=X^E_.W!GNDFL8;W**
(SGSTMGHM-Q-<92M]8ZU]8$W(!(K/EEEC%U=4+@W-MA0:M=\/M9=:X7&3Q\"5=,BNA'ERB)5>OM
*M<&N)-2P5F4YF@]-9F,USC$\3CL)D.)Z?8T2&&)@TD)4DG3*BCF(1M%T[9ID6-MO!93K'.T0T^X=:Q#/]TY[;B*1Q7Q)N>*
(;P.#B1-...MGZOHJD-K31$SA5($:P+VEOA
MUTK^VB_:EYS@[I+U+H+MX^1^@4V;KU1+RQCMMY!JQRJ5#8=8^PUHJT4]J[8.
MUS+P6Q8)'8Z];RKQ'HK#%^%Z4\ON)M<7V6O@Z^MJ;P6V)[KD:\+D&NJQ-0T[
*M,AQW<")91*55+4VG+PH9Q1_*TH_)9RZ31.%W4D_9NYJLN@9\$BWI(OV=)PM9-MJ3ERK2@@C;1R:1!""*
1.,T;ADE.6MTX9V[-DH;;\=,:[4X,I%9-M[V1>?4ZZY£CU'<+XHH"5KXTT25G7M!K00,\^E4,I'V;K,I
*N^0U";WGG9D;_Q8GQ^/IS5(.T5XDN[K-\M-'N'%*3GXU$>*/+" C(/P=4[9.4MA%(L9*DTYR8STOT=J-2>(>N02U8Z:$H*
M9E%/MU-'0R9C0-I:M5!/*M"BBV<8%R0MZ5SZ\[G>]$SKS^%V%;*;?,!5K3>*
*M%9@=YB"AI+D[S00XJ>B+5EJ(%"4SJWMF[5OWXAUXJEL)LFVZP-K-=C5WP63E-M(!4G:NLP36XT;62R:!EL25*M,6UI?*
*WL8[RX^V5:X?1Q_7H9,U^L_N9A-9V&4-M"=K1^?B"+)#'J%1)&?+<-A6M*60F_?0:G>=,L,*;QR4K,!V"BO0B_Z59#"T[*
M[;U[?_SJ^/W[XY>G'TY>_/O1VY3MZ2]'[X]_.7GS\OC]Z?%__/;Z-MPS\V;K_7^0G;]^3;;E&-&O6]. M3TH33V3C]\T:
[A/2V<.9H@S-)E$OD^]'>-M-Y%RP+:F)JW(%@(9.M"VO0)\\497GWN3U_G3[FZ6-I">($>N"Z&C&!FX(04
M("PJ1SYO=JQUQ2\JU8\ZV#Z'OLQ=>)JG9X\FPAZ=TJ-MD2670'.A@?QE6P]D-0@3T)L8A)'FV9+?
*O1]3#]RO+]\^^FU<)R#=WATODY-D-M2QQ3O2DVA9QK)L'7+3)JZXW102C3^G1[*9A#VP#:2+V/OGRW\%PG#*Z!J*]=*
MX-&:)^K"TX:N^^:@C:S[V-@>(BO%>]V,@61K?Y'L/$21R4VVK&#)7@?6O"OG-MCMA?U7IG5^1W7?I(_/S\>C.:"K'
XA0N(V&W"F3K5.7D%TB@/WB5EG?5#-M.[@_/$$'?BV9.8^T5N)M8^>>Q=QBO]]00I]_*4.,+_N&2&\YNA$@,A]{0M@
M$8)4"3B&HGD4-IK6F71+H!S<;M]-XGWTWGL(ZSI;?-U@?77?6P;JB7;^%M2M-M5HELHQ
*,%%*8JA36Z7(F@S2%!8.69];S/O%DO??:$/4X_1M(>8=._M-BKN2K01,-9^P=)%B+5@E)//8DC3-\H=&("'3D)+*
([?.&I]V]VNYVB"0!

*MDDH1E)&:+!?9L)A(WPI#$6+S8Y[>5EG=MO?X^6*2/H4IOIN,/T["^7NLGST<-M?*
*7Q[45\M\NX^A0E.__VOJO)K219[UV_XH;><[>\44B*H)O9#M&)Y-P-/764-MR6IBU00H,T9[J]7%DQ;V#YU@";(W0@.*
[3E?97XG[,JS;.KZ>?1>/!OS)]&-MS_'F7^5S*T*./DI(PI*#'CD1H-YP*U;Z1)Q-U?P*L-WRXP9+C>[4#J_#QO4'*
M\X!OAN]L,KG"_&%T>5E&XS_#.#^+D]G0S7-!X23C,D$-5?>F%+SD#S8.FI;*
MD>P"VV%D]2ZO^I%)T8LX^ST[N8WTW%&LST]B,+%@[6SB+'CE&)1LC1)HO+D_MCK[E"

7KY>@[-MXNPOO;\,P\EYBK7IAE5@9:I?!7T0T>E,%LM+S;8$.6.=F#?=Y\()0XC^S[N-M6M9P6&LA!*
*6.8".OK;P34C#!#4B+PFI>O+3-;UQW,1H-S:(+WF;&*3[*DCQL-M4G@H04%AGCFCDM;-DQP;KY!(=RMW\])*
*[/LO1*PNQK6G*;HTPV&%*K"+4G+UFE-MX)(B2\5HY[.&IZBV?NE[OO0'W_O[%'';II]WS=LMU*MLG,TA8$D<#*_=SH]R*
M\^I;%(8B>\ZTT=O;W>[^OA^<-CT)MH?C]-<6YA;<\U10&FDU2&$,&TI'+%&-M0T;/K;!12]V[3;^%YVA;?*
*TL5;G,)'RO_)^$76DEX'?? G'7D!) D7.0">%#._M>A4U9GX0O[#QAQ!0E^2C!Z,3*0(C60#A%:24G:8ZXG]*
*(P)JM^CB#M5J^[SRA';YMN)M6,.V]GNZ.84C.QN1Y5DB-M(S(*X%B!@$9--*
+YX"K5<"J'OS_L&SH_,BM;2[J&8[1:T]V'\;CS+E,K_&2ZO-MD-S1#"U!5#IZ;X-"^D!<+1I8UY-
7QY#=IHQ2$%C383B$!AY>XF9&/2R:76#9HV(SH%6C24><,6OZO1-MK>4M.>LA4-_.P=:3.?+\R4OD-4>^:)Z%=.[^,*
(K&S#AEP]&##AXRQ?=A.VX'-M$FB5#UP($+7)N#+>TN(E0G(\L"2"]@$/8#R.$E0?UGH\5NHKXNC.>2GOI]Q-M3#O?
US%^KBE;W_!LF$9?\/5H,OEM-,;!Q7#>RR-]_S2FD.=R?D"8_W4UF74-M^A3^.G=2>HH^232^-J]/=62+)TFA-*
*LF()EQK8U+_]BGP*Y#:V\%-SM?];X<-M?!MD'.9EZYB79#G?E0^8Z*
TOP_>OSXCW@G2IS6FAC!7,Z7RWILD8^9PX9%M'M6>90O,K+U66-ZMA_,KH^=8R/^N_K5D6<1<%-#6YD!A(7^)0C[R
*MEZQF(N5;S-*864T7<-KD.YY&5_"S\RGPOE%?2#-]#?/*&/!F7<644G,"P<1J*
MK@,6$B[Y\TJE6)POFC5G:D]+.07./@4MKV!OYQ/K>XEGF1!_P.E@O.K*_=R0-MY\>1.[!%$41>NP<:8\"4D%)
P6WSQ,9]\)T"SWK3QPKR=#_$#M\KF^L'<-/Y-M7;EU=7=>&-65G@B-N5IG6T\ED)Q.(4/
*VHVXW$_TZ7Z.O175*1"EL>Q7Y(MV-M/LU>)GG,6XJD_W=5:?SL&X[#!;X836ZBS20Q!)$M9.T+J%]7Z*5A$-6+7C,;*
MM&_=?657;=-E5[TL((PW:8FKBR,N[G:G1]0\/,B@[%%*Y"N!''+W,@.O(P$-MF1>;&9%^IXR+K3-*
3=X+S(].C+ZFO8(8X8N/@G?_BQA#D51C7^LQ)_VV(^\%[-MP;&!Q!XHQ;).P2=U;^_^-BB88E2-*
O5/V#!19(0C9DGA2HM^7.NOF>?_[X#M4Z^5>>71_-^]-
*M04^E3?/SJPD):C*9>2J3N<)FO4DC>AZM!9VINLA7<<5I\-5'E#O3HKH>C$(:L-ML'6V(*149O-*
*C";B*L>;;.*X*]\RWWL&.1)0MK;^.PY-]Q-]G>^A7A&HV1LVT0^4@1X*G?)T8[HVI<9]AG.(^-M55J7#NX,[O"GF-V4N7]8_*
A-]-![MZXKW-77R7L@S9730R>.;1B7(=@.'OR3'9#>!Q7I;V&]Z10!_7T-ML('MB)9'CQ9US1BUOM:F<(A669#HLS-*
<,NE;=T4^)HFV.#E/A4/[:&4M=U1>-MRM6;GK-/;UZ]_?1Q=N_S]M/9V]]?O7UQ]NKCHR_.=GAF]\NM?8$WNH"JF];+
MT7-Z&%[@,-WPUA5!]KZP)-J('"6HVN4QH-A0HDTL1J.L;9W^MQY-Y[G-]Y\|
*MWZEE1(,Y!W#)"U!)1@@J9&#.:T;-16ML[1.O1G*HBZ)&^GXP]K>[>(]]^3-+-M1K@>4#(/#]](@]/,HGPV-X3QK\N'O(KX-*
7W-QN2Z:Y!V'I+BCQ3H!/C!3-PAE-M:=DL^IT.Z[;EA73->"SON04]1D=04T-WI^)>A^MZ4N%V9/OXRUN(M!G-87WC
*MPVIUU*M*#DL:Y442S&>(=3]*LDZ!8X&!EN3T"<.59COM8$^0+&M\X*?*E7TT*
M<;";QMF)IRR:6R0PZ&A;%W6AT7/PQFI3B@X[M\X8>F))"PUWGY;"[N&&:/MU-MYRX-?
*Z4G[*W*O:^='Z.'HZ0G2(L8HY:09,Z@4"CP/@OZI31&!*>5/83Y>+KI-M"?WR9!_Q-W8\/@2REXL-,^MO@8UR\|*
*M@8WB\0)L>%Y_#6)Q[!0+C(8!QJU7'SZ:>*3P[ZNO@^3Z^!P7<)@0@C;W^G1\]51S^YT=J*%YZ-M,>T]QH<:?71[F*
*IECF(YS'-'"#O8U.UJO?W6PYK3SN(?-91=XZ_S#AY6APC47M387[B*SMW(>[]N7[R_-E7)"1*
*M60Y2#2Z362&+7[*NO0R]@R!T)F,CN).!%YFVS_W:_(X3L*QMY=BP%_Y&8,O)-M]CM*
*6VUZ]U+U,4QN8[WLHNT.0CW4AWV=>^M$ELE!=G46.'<)8HX9'%>NL*R5-M5.F)ZGN->3Z>NO>195LUOQI^#L-*
4>T',,"T<=6/(RR^!@8QU/Y&YGG?$-IFS-M.D-1!1S*UE?NHH=#:SN(]JS(,EW?A]&PYDTI!E-'765#D$RAE-MH$2M2Y9".+
*[]^USUY)-086>1]7,,O'JM'T=7%Y^GLZ;UYXQ+5-(;L&@8.1?H-MR,'R9[I*OX>,L97-WQ6AR8MIA]<"U>\BX;#*
M\X6B"6L"Q!H7!=02&%+#*UGNF]'=>(,>;0"#I**^=NSLP__^>SU'Z_>O'KV-M\8\/KV;YC8].PMSXM.*
[IE[N#;91X^5L8C&>>S:9X'3R;)A?#T(<7!+TNBQ4-M=DF8WPT-8+H:U[9K]!?>CH;CY2^?*
A\G@%K<,]G&$FG_J%6LS@8(C"=(C*%1-M1BD;6S\G(G-!T<64UB(LR-,EFC'-X2W-M,%>"]*@M:*

[TI[8;LY]ZB>M!>#YFMU]_6^SH1FDQZ3??/X$2P4(3.R"AH4:4W@-8\$37_(L@Y'U3D.LITU$(/)^NKH(GEI5#40NM
SIP1M35=B1_X9L@&!O@_&P$>8P6_M>O",7X^&%U,PC)%63_M40]WY_V1R90AZNBYBL&WS_4X'_FV'>$=B
*/[2+EMYMU'' Y&X^%HBI-\A;0+_MNW1UO&6FU)2$5#LM\^+_*ZU!UV%>*@7QH-WPBL2M=4_1BY&=\&/VD]M;?;=_M'-*
*+;"NGE#-+29^7:NZ*D_F2!=]V:..31,M!)TMI3*MQMS\!;]_334&1'J?7Q_M1=Z"I)9UATR::(.CF+3.UU.%((6@P$0AK?*
*6Z\/N'3+LH4IVH(A\CM88>>87T_M9_AZO6DHDR//+@#M'1082(W@/='+&*4YP8LQE.W*N_7$G].=[B+6AI5_MV_L_M&*
*[/L_&3G^I.[SSYXM2@XL_M^N#L]I*P0^AI?95(#VK:1RIMU?-,,.X]FF<78YP?WBP,>!*>6XD%0M9U9>1I*
MT\H2T#YAM#-H@K=;_;7V\0Q^#\V-T.TBI@F"YV-B>"Y4:"L1W_8/)18R$/#_MP*)I?:^V$["?D4C]::[AO=N>^_-
++$@KR77R_D6#85['MK"4YRKEHC1](CQ)_M,H;>90BQ2#_LDE&,,:/9?J#4#,[/R+FCJ;/A0=;U=
*I.L)YW2SR8#>N@,WXO+_M,)D,R@#SL\F\X_'*STFGI$2A+ZD>K*JL:[-C0\(3)KIHE;3H6AO"#GA_1]X>_M7,|-*
V_]L\1YG,ET%E[GB_N<"&+&G]K32$(12(#!$F4IB\7YKF+X"@G40?V8F_M]JG-A^0SS5+O_H&Y5MO?8'R+TW-
*N%7D4O@;(QM2C(_N1)0\F*5NR#C;]WK(S_M5P'Z]8G53%,/:63[&W_VF=S[(CZ-PW!R.9_@E?]U-9]E\"G\=8Z:EV@H+F*"*
MT"L,"!&C@F!3X"EERXIL3+8&L']F2AY:ZP^)ZUJDAWU:W-;7@\,9W.FYCXZA_MB_EFPRZ45P&B-06<\]8++3B9Z!
[2PQXB^9GIU4_W#QGCNS+F)8X'WXC(W_#M_M]&HB7#[[,KHB7"IZFW3BX&THH$H)X&/DX!1#%P)&=_]"KS-
*GUF'YF5G31#\K_M#EP[G_ZO"I3?7X;A7&+GMGB1$^W@PAL-M)M71F=-:[8QV9)DL*VCS/KX/U::'=6]#M3/41EVH*
M5@P@N2&)X<$DC!%"K29.)4ABFC!>1F_3+Q2LAD_^OT^)_M/#@O:S591D/!JN2^];'"*
*]O".E8':+TWNGR;TI*X^JD/70[T!>FM&X2YP^VJ,_ML1_4([7&Z$OUNU.LF=Z>_-VLL$XBNMH8N9;&6_1'_B$X0\N127-*
LWTSQ=!L_M6Y>,)\]R?=35_[M>7$VFHR\X_H#SP[#)Y\'799ZDPV(\LXGL>7&@I">0WD*

OS!LI(<>L@1G^8L4=D[Q029M9C$&GC+0,BGN_MC&@A9*<@\N*LBCHRUQJ(?#V:TR9((RWT:$)>#R;7D+0(62E-?
*B9W]0H[T)JE_M"35G6Y<0HV1&]&0Z;L$X;49TE7L/"7WKYK4*H!%IL&J1!NJJL,RE"A_LP.*
MO7+1M6Z5_<3F81\TF&JAA@.QX^[DW5T_IJ4O;

*9$(7/6M(6^'-/RNZ7)_N(OVW-P.RJ/RS0+'<_89D.11HP_M3-9I?#Q_-)RLIPY!8V"^[%!LNNK)AW,'DJM85>8UXV"<(XY9**
<&[0"N4_M6J#BR!ENWU[7/?V$5-I$@_VK-:KI&(P^U+R@NM7_\/E]/.R/T6.04@K0.AD_MR&XD!R$4#]S;HG,JPC]_W?
RN>?H)Z;2)_!L604S&T_,/87@Q;S5CZ3T]\UP/_MHFIKWSPI,_^&GN\:!MNK-<@%C3;_M!
*<8^QUV[:+K]1[S],*N#\.^KKX/D&D8R]^$H"I*5<@BNZ&HO*))VFA/U_8.'IZG_-8=,[?6WC_:Z^U-*
^&OPY>K+5L?/R-.7]>_O3RH1L?1Q&QI.77:_MMB?3X](S8'T45EOM,+0>
[,.RTD[0DT5T4.'A%6XEHW@=D#6U^W@6E1'NA9L_MHKT=-%!] >R'@N$.0GI8T$*OE,!(GX$9]"!9R%8X6-*
@S7.X#TV;5>_!^;$_M/A+O@0O/4]IE=),/F'#PK=K#Q0YGC'?"!*
T22ST2)__4)19K4SUGII%0M\B.=3KK!UHYQPHP1@$%CTQ4)*?_MC(IDL%,$MV^;AM5P3H8_K43>0Q[9V7*
AUQW3^6W,FNR6_Q8EA3R1,_U/1(#_M#]GF$*-M[1KL"?&GB#CZ5%L/;;"VP%V=SKL#Y)XBE$?_/4[HTBL-]]-<,QWV
ML.4]!GK.R&5D_JRP9._^]%$!N&_?!?8XA:BM4ZTZI3X9V6X*CI\ZZ?537_]ON_MN7NT2$-
!HX3BZ\"UXB7X3+%CS,9G0;&C$*U#]&/[T;TK;;.#O8_$^^@$?S-#_M_+I7ZLW'@"X[ZZ2!+'B=P,_*N9#.@',Q6)VT$+)U-
*<]&0#^%N]1.)7VV:=RA_M(>\?PU&=9\SMDJ5(I(4.]6"!*8$++H_I6L:4=5"\=8N);9B.V!SN:=!@_%=_M-QVV+?*
EY]W76#7UX\9]D=2V][\NS16L$5P1)!!/(IXX"G.(!N,HZ.5>$+MOG_MOFQ\Q2^_]]"*?B[XQE>8'U+7>Z^<975R@ZP9U]I*
*-*G6O)?HG29#KK&Q^5F'_MY1>7>M!9#U<&M[R!63Q_ZZ!'&<6R]4"X6$UF"[7?+:;#]KHH6?*
\O6ZOC_ZH;E:U/%'>85U]A[-UW3T"+8+==81\BGHO<^@M?7Z_MHOX(=-Y'W3W0^/T8OX9!_M?O57;8"-M1GW?-*
S#BOR$9&-,#!$D<@E<]]9=*D-L;QDG)7_[_'[4S,W=$=*
*MO8WYD1@Q.H@Z^[@;F=T*7:ZZ%5J4(69^KG2T3]8,M.Q(7RS]VH^Y7@IE]FNT*
*MQ'GKOMV[X'H2Q9]OFW2M;]Z&'JBR!+*A#=P_<7#Q>8KYV3<*O2_PCPF6]\O7*
M@X+G#CT]$RB^CIY")$:K"#PYX!:U+_3?\=;-%+O@/2%]'4QM/=[<+]?P\]H:_M]/S'Z_M$@?#V>9=M_*+X>#?
1.Q,V^N@#,(#ZWEWO_G]V=47S"O30,^=#-PQ7K?@FOC_M:L?1I"0(DX(2N12I^F]]UMNB3HB<3XL
*#0OH^UC@8D7%D7L0,-(ZBJDC=#A$_M0TXFEN*QMM<-OK6I;+^*7QQNI>(^*AL;KF@Y#^I3^.O6'YY'Y")8Y*!,O;%)*
M,4#,]%FFDIR5REMTK2]F^U_5+U+W18$>LN9;KO#NLIQ+R67@"FG#45Z!YRR"_M-
*;*ZW$)QWU<'Z<9+^47GILKN(;FQY;+]+&1,CM?+3R@2Z9.4B<(!(9"6HZQ*_M1:,0?")+XR7\XFP3Y?*
9P:;G]PO;]>/3;:/PE?,!O.+S"!)%H?#,G^UQ^M=UQ@Q:G-T],7!%_MDEQ*0*A0@.>8:F=4A("%1.DLB5&&G/U3/E%:N[*
39.S3(4(?4[%;KO)L2+:?_M7O?]/)EHLK_2;!W7'^>A.DEQ6A.U2I9)0,$)1D$Q[SAT4ING[+5WKK_7W0_#%6_M?*
9/Z@KL19A\7FQ1W\)EG;MW]EB(DBD!EK$Z('36BC%G8-%:BOBBD.$IGT8]_M7-$OHO>A^A7,[GSU]3Y\G\U^_#1:
(%^N%R<4-KPK,\B+-9$']8IKNB7![X#LAUO6FEA4<>E(W43=[P>1<,V6MU@J,-&3U_MO=_DNVB
*62>+MBY8W3H)KJ>EG!_SGX*R5Y#X2=TTK2R4G'DUYY:D+4OU7VK[_M-&6#!L^R*
*))XR!P=,^DI;_7K5_:+XGU2807CCW4O=9V]MNX*HV01912]ID34_MQN*,D4NC+>0B'8K_[,>GI?SB=%-*
EKR!QLPNK6^N:#2RL%3/A\FQ8Z@%X_M_=VS]KIPN>@\.QA>S([$OU[6">CY7U>3:?6W;@Y>C%?962'._HD:7$!?.8.
*M=$Y.Q6_X_:I_$K=8RFF3^.#*7D'B9K=I,=:UZ3!<C_&;X/1U621/(\Q_MY.@HFBC9R-H)3T.,48+,QL3_HS7^_-Y(#RO[1?*
D^J;"BC]+S7>"K"8G[SY?X_M=43".R])^U@880BFSKUR]70[([A(_D-+X;!]G<9U!_)\>?Q@EVAYC[NS#IY
M;?.2&PRRNHZ':'>!CK#(:3@H41!;G:6NC1OR-O;8DZ(?D]#X2NHW,>]5X>5*
M_4:/&;ZU^8%%#%@,E8C<%2<5B<]B=MD*+]PQ_RW-AP@BZ'=@GY1N@?%KZ#U_MDZKW>A&^#J;ACFHU#Z*
M7]5IL_R8%%C!\C[N[3HL\<5H.!GD61?+T?#3._PG\Z]X%1^$X2P>(#6MAY7]8GN?5%C!^,
*[W=K=S/\Z&K_Y*M.1W96W&R+E-_MW_0N"AC4GCY3RR"FE,!HABZ+H&/S6L<]{9X0!_M4S@HR=>]2N;Y'S;,OH_%T*
M\.\9_Q=]M=[B7]-/?^+E-WPS&DX_3\Y9-(7[F,$FY6O]4810@]F-Y]1SDLO2_MO$\&^(3HMH!5;>">9TOO7XGX=6"I'?*
#C^%VK]ASCR%RR3T$:$,Z4\Q*UKX+"Y7_OO?[\F-EO)_9W\P^_T]EP]8_M_]/^]X\/9]_D2?*
W]YG\GO_Q\>SM]X\?/{[Z_^RZOZ4@"XO^_O-_M_N\N?/'&.W3I=ZFT2>_P$XV[?=.+MWW_KW4?
*JO[U]6MON%D"L8]I7H>]1E!,_M*ZB__YQ[I6QRINC6_7YWP=75GMUT/]_PMN??%W\X;X#.>7*1%5E'JE,0;7VB*
MSU0PT(I^/Q87F"VM1;$_S(:V+5Q>KK=HS=ESW[+UK:)5?1G_H\HB3_];NAQ-_M,/^/_SH=7^'-
;Y)+1I_>]TNL+R2+,W]S9RI.PW3VQ'M68-X5.@1N-/V"G,?1F);ZZ(@NE.=<6@N2U_S78B@$#$(#BSRKD%RF,+U"'>%=*
M"(%24+9%$SWS(Y2XZ+_M>C-I@G5&F%SDYOAFP]-_1-VU$E;#CY,@O1A]"\.$+\=7%R_Q&UZ.9IFZ"UB&
*MH60\!I#&U4IA1Z%\41XR.1^FPFM8>ML@O605\QDGK5V_M8#AFXA6%+5X)_\89ERQ"'^\G?*Y0X*E\?=W$T[*
*'=,6RDC]*U\&$#@%YX75N_M'8>H(_GY6:=B-+<^B.WJ.J$/K;N8&G9!GHRGY_6&=G0YR/,[W7HJ,'/33"I6*
M":D!+4^@R&Q#="6!L_*9#I&CVBFNI5?<\F3H5S=>S/]WGWH0VTCN#6WM:D0+_MJN^":9_=F].'"-
^;:6CC2KO(."&3M-&;_R)SIXK\,9CG2=%.PH9-W!16<%%_MHOUFIQS,)Z7T-
1'L(76^CUS[F">^G#\#,Z7#D0D7%H(X(E<=]6L!E>'>\G@_M+7.L.-U\UOT:*(?;X-OIZ?[_[P9"[F$BUMEPBN/%Z?*
BKR\&7Q;WD,G(3/&13_M;QYSH0U-2T7>OM:03,%,;J1-S?MH;01T_CQH)_"VH?)
*[HL@3O"60H*5H7K7)V>Z2\X05'\]_;WX@UE&0/7_L"_MT>1<8'')(((-I4ZA*!H\1@5&"&M9B<*GU@>4RW>?D+([B;7/C?*
Q6=^J4R4N1_M_8%V$H(44P(O%0>'Z+!P1&-;UX2M@'&"2N\][!X&R]W.4GQ7[NE??D:B1+OS39R%R8"
*[,U;KX9T0FRHJ$*VI])O45:]60ZODK3V2C$%Y_#_M^(),EO&RD,=1V]6CK?G2&:*O=RU1A)*3MEGIK7O[FH>?*
D'X;2;"'L66W.DK=_MH]O9EZ]A,)[U)D':F$P]L,5[8+KA_C2FSK6
M#@%KF=KYX=5_OGK[QZN7@TFXN!CC16WWL?!J9D>;CT[CW/7!W5,V'[6$1NF9
MMUXZL_N+]]XPRG//2N$97%$,%\V0I@(*"BRLY[T+5KG(V[#U-7NK'G^_"3<*
*MF.3(_DFPHHZZ4[4+LZ0P.>2@F,^%/J/6\<4F/(=*M&S*@_N6I9G_GTHVY?-P_M62^:/WY&G+ZN?[MJ!:ZP0^RZ"M?*
BN&T79#TE3:Y'=9P,RC;:VX$2'41_6'(DPA0XUX"Q_MGIBBDO09F_#D=\=27!:Q>5![;%)LR;$\-"?VD7@/7'@[FN+D

R8\|,KN+DL>_C&-M%XTD'N)B++(DD);I4TT%+G7!SA-XC10X9QUY\R/,-5A^>"(T%78/I]F;:P<,-M(Q3)6W-Z!%
FSCGFO[(N[+5R7N]A3=[R7N'PIM]A-76-M6]]80\)38J0/"[HDK".$%03Z'S##G39""^)C<5AT^Y<*;1^]QF=#:?HL/>84Y
M%K(P''PT-6?1"_"F3]MAPFN.R,7],7(_0N'-([7633R-:Z16UVS%]'+B&;*/-MNC8DTA-E*HBZF*2*)D!;;O&>:N'-8U7664P-
F[\4<8%HF5>|"ZB&Q35K@1R^NJ:[CAX]O)&-&Q?7K-=G1"ZZ\%G+.#)F*EGP27*P-MW-)&4IB5<:<<@:>E]0WE-
0=2^CYR[:4WQ/R0]9^#Z><75Y/IZ-N.GX?)H'8Q-M'0-28'@Q6W>F\$P(KB%;5S,#8H9(;AW8XI/@T@?
N6X\2VPW9R>P%/2]DA[2^-M[2@7]-X%9T^'7[MB/,ZY6!]ZWIM*'91T%%NTQ%MRQ%(0"BJ*-E5V$)R6Y%@C
MBX&KF)OGBQZ73%M.W)X4E_;0S8$X]/)J?)-V4"^>G/(1;*SGCZQ8"(IV7B-8-M3#9FYUWKCK+;,/T4>]BCE;-VP[@?
DBR;M.V\(#[UEUT3V?'>KQ6]Z!,!Y4<-MV,(L?7IN"Y=&08I9@M)D"&/6$:25+C-;BF>MF^D=BS2/V)D.R9E]--$#5S[5
M"N]+=V4Y3^1=J048=T-*[FLA-2H065>(QD'T]#.1R>8Z:9..K9/1=X!U67A$-FW9J)X&?
_91R8%62@4^8LRA*,O'0%IBRLT>3V-E-U;':4""$0-M,,63=E;[4LSV-MEK'W]22FTFQ[9I?<\'HZ^?P_A+2'@U)4B7!.[+#-
QEQAK<-MU&&[83C-909BM$4PE15@B?.\0W"Y.LGU?\;EVK]T]\KW?>NI,:%7J;=M[O3I-M\V"G?-Y_Z]DIN)/4&K=>-M?
Q/^-1HOESBOXY#2\!28!542.1"ZIA"1*&M2\DSE+57:(-\L(=O/IE-OX%@-M'ZKYT7-Z*Y]WX0N^*W*N9-69G%UR200Q%
M0E$FIA2B*DTL_8%5O\'2'U+S^PBWL<9?78U"7Z^;Y,RZ*^4ZR*&H>CQ@(-3Q-M-($KBD=TXO23!DJ^_<[##D9HI()1
_DU/#2=>1.C\?3S,_(A:$W+Z9/<1(%(-MSD.DR%-)FR-:*:SSZ;OJ9G)7:YV9\-M?!ZS8;;F+R:.M)H2R4(PBZ-]*RB+
(V=_T^8YP?2WB]&WOR^>./\8%[^X-M^19OWOKR7#SM.G7L?@I2:0RF"-M0H!-P5KM-:&A>)C45+(UBU?=T-
V^$//7IL(]Z".?OK\+8LXKP$7"O#'F-?3-MV:2-VKLRVIJXI;@A:^0Y1,8\H11&ZN*R2KLW^]O\KA-A0#^R;;M+UZ:3-RQ<-M
T])K;A4,RM(&U$@3*)+-&M5$)($X+??K>QRYM.1_'-Y=KV?G,-("Z*QB(M-M2!9IL>3X0R-O$7C.,8])U[+]G^/!%-
^5UC%J5@ZQKUK:!.A!W]**&'@]Y5"2*S84N_C^LNB.B-,9Y<-M&ET[R@0"Y@5C0/:+9:5\\KN=W77,9+Y!=&+\;"C^
]5.O!XBH&T^_G4>OL-M&.'2F2M0T4J(S@GP):'FSH186I\X;-3T$U#C<<)OF(*S!+>A-?
YY&>_96)SMK16*1,47KNM)!8@-MH-K->93.6F6]W3X?\TG-ON[+GVPEQ15'2NT&7_/,T#_*760HD>)BER-X)8#I
M*&U.@6+CUB6YQQM\W>NG_"B1KM!M#\-"YMZ'R\5)KS5D97FMR6+@4"IP.:2D
MD5D58^LKA=503DSS+02^@@C=QU_P/46IXLCCW-R*7A(S$,IM69#Y-0Q8R;]-MNLRK[^%EZXXQF_"*?
H5O.CE"G)VQ7V#=K+$RED=I*,LF)1K^]'H(=HD-M@$R;")Y;DUCKYF5[P#LUUO2DF!4DZJ4?
YRS4O45T6!*!IC=#F7C3E,#=9WT('83?3\H.2ZJV"?R@#L-M^PNA?
S;O)A&SP,"KO5(D'%\KC94HD))!AU:G[%O?;*R!X]WL*9QXBZ-MCV%F#V$M6\;L-*ROF7;K0!U1OET+U6VG0P>Y'Y08-
G,AM?/U[*S4%A,)O"%'-M./E@BZ'P.['F@R\/2XAMT^\.RH=]Q-T_#Y:YV$XEQH0%4=@,%'G2+"M@W&7E-MA6
:6]]=K01RA/E/;12U6?V/D'(/S7M>#KX-,CG;$XI]-Z=(AH&/M;%$*!I"-M8AP$=X&Q;"+%OZTS'98O/[]*V_B,CQ/F6]VV#
TI6J[^Y8-BY/R.?*19T#P)-MPTQ_\'4T"9>_CT=77Q\?,>[Y_.Z!9)<%-8HOSX.$!F_FI-[*:GLVS,]RG]TJ-M7%:HY/!?
C7'R_/M=>/2(RZMU0-ML?I3_6;NF_*GR*ACGRACC',,SE_"ZDFV@QPWEPC*Y8U)Z_8,:7K
MR!@DW\B:VE=9!2:2]VI[$L.&%QSKF.!)4F'47"5MBVS6H%I.%]H!U^ISA]TI-MV;WK#X<+"MBIXH-?N\FM;_[J
]0G'7UZ/PO#9FS"]&M/V=_M[Y"G-F(V)\CBX$:"D
M]>"MC>"3241"GDUT^RIZQ7M.3M%=9=FVNO6.O[G9W5PC'/(_DXY,JG]V22R-_MCL![^@%)(]PP=)%M-^?=
<1S^+/"IQZ2'5V_;W68/\)-99M;;T7-T_YWAQ5PY-MM9AT.,%S[D*TV0O@,=X>[L7F-M8&K\ZF^DB-4K>
(O3=^53^.O9=%Z'4$/Y3Z,/^)4^0UK/*_H'T^\4?UDEDF6U-MRS-]?,[0QT?!-/CB54"!O[C6ERO-
P/\B^>9#PD/S8ZWC\,C[HCM]]S#E^?W*-MV3#7VZRK<#EY-[S\OOU&:&4;K/]X.5=3O]'H_6?O=1OT"'+@=
[WOH)36+^-8K-MWMPA\-[K7_O-Q^^Q_PO'X\&-O@X<3T;#98-IZV-[Q4$$S,0J(E3@<5855<=[-M)RU3V+I;KGKRX4S"-
MG?VG&ULY+U[<^2X-ML2_X__T46&_KH5+=F^)R8V*O"B1+M$RB1+W?*G-M7X"/*DI5)-$42,W==9QCJR4"F?DC,Y%
()#+_Q__\|:-%3[RLLB+_CS^X/SM_-M-#RG!$_^O=M_@0T%W#SROP?N2XYHS-M\#VK[T%]S\'?B_*?
V1,&UUM%X-/979W7P/\5#_6/_7\D]. M'-+4]4/($0T@"ED*"'7$=F'**DYBF@1^BB[L_.8@0&A-7QC1F$#D.@MA%#D0N
M29+4C>(H=1I)MUG^SS_)-R*XXD"(EU?-/__C#_=U_?BG7W[Y_OW[SS](N?VY-M*.]^\1S'_Z5_^@_=XS^.GO_N-
T^[29+\TOQU_VB5G7I03.O^\K]^_7Q#[_D#-MAEE>U3BGDD"5_:E]?OFYH+AN4)_E"XP^(?\%^|>@_!5T/>B[/_^HV!_^|
[\!-MT,)1%EO^C:=__N\?OUV-DDQ^D4_\DO,[^6ZO>9D5[*;&9?T9$[X5W#>5U<^/
M_#_^4&4/CUO>_^Z^Y.GI:;=E^6)6R64BN71#R>7_.4;LES/8M\1O?8:-M<;_8XG$*TR_6V+T5%H(OS_"_S-
DLMQ_4QYRM]>WN29W-^O(;SX7-M5?6^R&NQ+(KE\?D#?L!WO+H5,US^R*I-'(11X!(?LIA0L21Q#V(4$8B=A'N)
M$[N)$VW]_<>]X3G\ZTW/1T-,D=(?-&2M1W2VY%6Q*VF[V@GJ,+K(/&"Y*64!F%HZ-O
M"&REUU.4KT4LJ+J(K3G9WD/I3S]A[S2F8G[X+T>OZ;+LF<,EG4&N>^(76@@_M[K&&+SZIM"P>-
6H"\TWV^(GV/@#$K&2^&MGQ!I^.5]*LI:>.EB47WX7.#\M\E=<[TI!1._6_\H?""'\W$4O]-/(PC%F*((HI%S8KPI!X<LK+
(*P,T:+[MPZ!FP623;RT+ZE9,_1)E2V87-M&C-K9OZQZ!@T=4E'C9K"%&L9-G5I!L9-8Y">@=M5\-[CQ\UU65#.6?5)L/]Y
MR.\;2EG.JZ_I^Y*SK-Y@EX=^0@GT61)-Y-D_#8=^!#DE1#AL08#<5,7(*5-<-MV-#U]
(%\.Z#D3\7V27ZVM"$.4DRS;59GO%+3;G4@IXW>(O#H&;Z7R$CBL%5P-M21X4*6@9.%^WM64]I($J(6PC:
(HKTDC;3?:+5/U?^+:N^M\TQI-Q!.KT5C$&-MVN+W!D%_H+;7/6&RY9LD]H6/-M([P>Q_6%:0@2#R;
<\6'$*$UP$D4DI)NCX,34XJ9#7DD1U-(Q$TK1K[-@3%EMT-+[%F?R3IV1D;D=X.7LD.U%&YFKI5-_'2<+1,41MTN
MKWO^^))'G5*'=W'_@3WQ:/\A/J]@@HXHBRT(,4W06=L-ZTD#2!@/B^MNJ2,!F[:4M"/3LXTK2-M*UL_6RB863MS-
'1LFXJ,H[9L<7"(9!RS'X2?+\1_EGR3:X'KRJGR3KPJ7[(]AS#P[L@]]Z-2R8OC7P-MM;0U7X3%57?
S2X+\.@"P*"VS=>'/1<&^"W?XDOYKEY6OYEU896_DI[2],X]WX%>Q==^5O-UC-M?"@><)8K[KA>8S&MG6=(J*>
(QL(J*^*(*%,Z)X8,]$W\ZZ!KKV=;1:U&1.@U-M:.S/9BMA'P[Z>U;?OQ?
+M%B0R\NJXK58G]_ORE*\G8T7.R2@R(,)XQ%$),.0-M!$$$]5@FW2#$B']>SH*H0'/QJ$X7EVQ2FGL>Q/(@N;@
.!5S@LOMMOC>;/C3-MHNR.DX#T5BY-QZ7>\]D"M=HJ:AE-W9C0LMAIK[D::%A:>E4HKKH":T#P>B'6
M&:IG8AC/9&Q'3-=OL&F:QG&*8QAXKEB1G3"%B1L>.5__]1.,!/>"NWQ]^XF#FC-6?R#Y_F+P9.MH_SZ-ME$?\>
[N3]WD^_J#WTD7XAFO^,4VYC%KB*&3$B2&E'I?I?P&,4[&"LXLV>#E@\(<>-?M(_(]OOKERQ&M4.#$N?8%V(L&>MF
M%_ZTTEGT9]|DK=ARC=9E?ETOZTU>S)'#]C989]'L)KE9YZ5#LI1ZCXS3TN^>5#LW8.#33^F=%
M8#WM,Y%5)\5D6I[1Y)*186NEE4QS/4@HF7G0(,WMX:'(]YNZH/^\]]K=R].*-MAE3U\>%Q6SQSWCQT+=YFM0G"T.,
<19#PR(=(5C!($N1!'CDQ#AS]^IZKG-!G-MPL'B49&&*=_0!"U;+_5VH^X-CUKW:,-_Z]$^F"1M.NETAXCM0O4@S/
MFD@_[GU;8KF?NGE^(,5VXZ"$Q1Y',&72]PIQ#-F.J/"]XH"X*-D=0E7CWB]F-M7MC"=[1
2TP]ZOU2^OFHM[%,>A9641RMF/=)UHUBWB]G6BWF?5*-8L]E^6C&D/^.0-#)L!OD@W0*&XE]'"4RV\8!LE/=6T-M
)!V#$)'8DM!"262]T8I=$!X';;0&FN:GO+P6/)[GE?9$V_S1;_P^FMZBW_L
M@Y;7DG]17]9UF9%=+8,HM\47(;X\V2ZVVX8SH;2\]C?,Q\2E;@P#1F04)$UA-M0@(&B?"+_$#\,W:IUBF87?
X6/N9ZP>T^3U\WB\7N&U$\]7H[G+5W<0.(7R38-M7S0Y]V(K(9@>GB9U?(,AXS(9_R7KH.?=9N+,
(]!:2[*QR]W*"3F+0'N]]-]9>L,D:-M/ZQ(]Y=H6O-0%^^+O"]V&9,E)O9'(#''3A-2!#'R?8@X#V&,"(-.$!#D)B@B
M6.E.XYE\K+8-&_(FE^3#[;9NR9:7X08,FIPVG?5"9L/7:\%LNH_[W2.L'-%>_M"VFSN/:RB.O$]&W@-!]I/FORM>+5-A
81*VM3*?ORDFG\I+6.[S=/E_CC/VM-MVM_5O.4_ZG="V'^]NG0]@&0&/%4_#^Y!]_MZ2@C-^WRV-MP=']2KA
GZ3W("&'4L.H8[D1HZA$H'5'$0=<8>.HM8X?447F_OO-#70Z_?/R]L0M[*=*\"AI+HZ=KO2"6]U4GN3?2EY:V(D>T-.
(D*C.'5@D]88HB!T-M(,8AAH!_:U@#5E=@2_#8.A,SY&+=8[+S
MH#HZ.3MS.OVU_IN@YCHD<"_+\I(5CV+N3UM\I[K]CPQ?VB9)59%DH3L,3X*._M-W6W8$SZ>0?!@N!Z)F)&9O";)&_)?
Y@1SLB3&)MS-9]B1]BA=S'WJ)F?\2&K-M'HL*;_]<%KO'_3&,^"UM&C_L..MV\$7^:BLOCPDW2>BSA-4)C%UY/<8-$<0Q
M]V7YH31*:4IT:]VB@X9!'L.+XZC6NWA]I[;<>8K4O,^_MU@->S\(LC[FV)V('*DL.R9G,K.J7V
'NM7MB:5:#4^3ON&35^VU1\=OBU_PQ-MDS0;'TCY#'ETA]5/D!O"H*$L[XW?9FW$_=-8HD_[$K51@TS8,S[+79P
MT#,LJA!TFQI;A\NSDIH=+8]/N][!\JQH+XZ5YY\VSGFIVXC;$FAA_DXQF;P$?2E\72HGR"P*H+[;B-KQ?/B2?/

M+%::LZN\%F\U$RK=E&BJ^C]=%]N,/F\H0S3B80H#CQ*AE4PFML8^#"+7%_L& MUW5C9%2Y=
({RPLK:$VLB8P=.VI)C0GT/]3U;=@S+FL[BJZ;7BZ"FI^ZZ@('? MNO]=),ZH#8CM"JFS=-^F7*HJ'*.U4Y4G,
UDR'+,8D&4140V&",G3G LEGR$ M(<()@Q@'5/PS3HE'0\Y1]M$_Z201)8TXNTO2GF1;,T@W=# $1342H"NCX<9>
M32Z#[?D)_]WMMH=SK{QY/B'6\5[XU$,&K.C E#D) M1)'/84+\&!)7:%/B^314]X M C8WZ&0WG'VXY+/B14[%69;3&4$?
I.GI_:=K3/;9"2,!YQ'G#(L)M"Y&$.28(3&+ PB9D7N#'1 MZI,T2FGA=:[YC:*]0F7FBMI!00]O3:57]O-G)7-DLLY3F=5]W-6
MW->NZ/P @W6'\[(YYKF5UXF;%)3[8BO&?]OSRX=:]=AE9I]%-512;T\S04,? M#!@ WWB]* .NDIKZZ*K
M.,3X5.95$===+2N5+K09]A>/$HR'%$72HK+A/,8/$1U0LR22)$Q>G<1@8!&U4 M:*\3RQGI0-
RSH]VX60M=Y7,>.V#9;'&M Y#):9"RQ/;.A^9)KGUBI S"B3,D M];%&%S_.S <=GV'AI5[>I+"6%C]!P_SR;@<"/656D-
Y]@NB\C*:W3=X\371> MM%?W4.PFBS81I+;]ACPEOL];XP0/A6% HPCB((TAXH$/$\^/H<-=QN(@<
MM]6F98W4IF>SE'M0&)6VI M0V,B@'PT9+WP\1BW+X+'HP^=DZ(ELR_"6;>MVF:XKWM\S0KH^)<'@K2((E< M&
(<)@\@ELFB\%\& > FE:>#&E.N42UN&32W#IE\U[667;/FRP8'S0YITM71]
MKS5?/$X2G@2(0==E/D0I"R%)'02]Q,=N',DJ>EH].GX'+]XX1_#_5R]>>4O[MQ]]3>Q/\NWB3AGF52P%M-3?3.I-OD-
^Y%-"G^;5FX MSQ[;MLP,:Z6^%X\W0W. M^*M!$0L/ARY-"$P\)%0X32*(P]2!PL-WB4\3"B.C@I/4EM8C25MT! ?-I'7
MO+8Q#9>:$EL#04^1!_*_O%6U1/*VDHR65']J:UJ]JK23V:]56&V0OSZ9?^&6[
MQLNZ;6;R,6>;,$FHFZ1BS^8C"I&',,1Q%,(X#G"4K]Y>:+8N-S!O.-I4 M%+F15HMQ);H+!_\:'F3+L!.-
$\!/VR:>0!I>Y%U2/5.CA]J:D;&.E9YY:6&: M;'[0H70[@9*V7=&2VI)%4:.Y]BW1@N&U%=$;;%C3X?:A*1_Q62.7_>2XY;[@
MAIPL6=_70MF[U9]M)ZY/2F9>K.!HQG7K%(P)=%2B8/1!O6^K*NN-[&Q>/__*
MZWO9U/Q)K'N++4DI$'JP[GG"+G3#@A+L13U3\X'E2 MBY]$2()REWL!)%'-H)4"5-/Z.:!< W=B]KNS*RJ@NUM3:
(689K!OB7P?=5""P MBI*J"]IK]\8(,Y?R#B#H\2/W03;%6H8-SF%DZV-4S,,C4O ![AILLC&Y3
M)WG6*1A]_[VH^:IKH:T955L..&V_U@9"EMS=LUA9U0NV =IKY]C*G/H^<^.3
MRVM[77Q;XR;.B:$+6ZAV[S>\]MF1OM"^=-*[OF=PIDBF^QT3:35VB-,R&2T
M0S@UWVK[@PEAAKN#]<<,S\2R/*OY9[&G/:J4(EY666?_;L[@/OZ0G3#X?W%< MW@IT^2:*4XHI=Z&/$(,(\0B2(
P@YXQ[#HHH";'6:9D9'PLK[L>]SAZ:3D!X MP_3@+1<7P'-MF5:7BB,*"QNC?48
MXZQX8Q72SHTQ]O.]+QX>BORF%EY]$M=$\@E$>AMUE MN3Q$! 1OFUW$,LBF*6,D3%+(?!1!)-8 2%@20Y+&">>>
[SK(ZY#]F+.WP+4G M;P-5WGZDRT*]MJ;8 DEO>>FPN6GUMR5\ 0:DK3:/GQ707B?X<5)KMW6?%?I$
MC_;Y,89I&7WQ_<_RDOCG#),F!T1FA[=7]38AYAPCZD,:.QRB2/]'U F@XU'B M1S&-_4BK3O1>]
MHMK*N9BEMVZ^A:KX1[D6R@.U;Y/?WFQ0^RG-7;#*-7$[]!$$6):Z\2TX@ M=H(
!@3C*$DBBM4N;9R8>V$E;\B!AIY^XTKSC+ M$798ZB,8N9Z\N85BF' 4PL"-(AI2Z@?<5S0"8S06-@8=63"@JZ\
[H_C,&@<; M4NL9B64%5C8:-@0W,QY& .@8D3G11HW)Z,"UC,HY"%F,$49"&,':$'?(B3(@;DIA1 M)
<.C27=A8]1Q<;A!+FF"[X(1T',"?NMYT8Q>]R*KMAE9_"\|,V8)*NVMB:;@ MEC8HJE17W:9H0O%ZLZ([W#2T?CSU#=
[RZOT]SG.!SX^LVLC>ISZ*9/ B#(0; M$R-("$.01TS\7QB$2.]"FPK1Q4/MIU3B C1L@(X/H2&"$TU#HH2H:A33+DZZ
MT4P+$!D$-M5EMA;@5""Y?(ZX^C#>MK(>+;YF-=-FX4? M5TQ,E*49;:
(97W9-.,7U0L]/O1"Z$4H@(L)%C4DJU=)#2#BEF%*E&V:SE!;6 MRI:VO)P+7E('+7DU)9W":UI1K:*@IZS&
"@KK;)P$^N@F*/56?'#057G9UY% M794%[%56?8#9(GI#[SG;;?G7="))LVV^XX24.[Y0W(@X6*ZL6"RJ,DX>)Y0D
M+]>.2S9/O"2%ZM]J3ESGHQZRH/QM]ZS(^A^3*=-IBZOY1NWG MPAXQ$E#AKT.9O J1\.)A$G(74D)2)V%.X.F5&5T&=
-[J@'YTABK^4;+(*=G M@X\SZ%] 9[W?E+[,EGP]#<*K.EKZ@+SVO@QFT#[LO'2#X(;G65%^*6I>?=AQ M
7"XB5'">>@YT ME)BEELC]Q&L&4.QZ-&$5![")D>=9ZFL+#)<'\.@O\.JH8L MR"5=P'8<2,K*QWXCT$R;
"L"ZVGZ@K(]'W">+[/9\::)[#]GF]-RC9YMC@Q; MZV1SFNO!N>;,@_K6I+_AFPYO^&YPS*DGC.;T'"*,0^7X$<8I#Z
LT,/.VY&QQI6S)8I*]6Y*S)3:S)/]2:]F12:G&[>5Q[I3].AHM]QPD\C*8^CY$GA]"0E($7>1[01Q@%S.E,D*G)E]8 M%P?TE-
S\IW/"/1\0TR'!?+;-1/:7R[7$:5)$;;V8M?>"V;;5V7 MQ5/&.'OW_-=*AB?VIN:2UME35F=<; H87&$'9B&S($H]#U(4!K
E./8BT/] MQ"G3*6:K3EK+]N]!M9] M#L R".H9*0/P[/D*^@!8@#\MK),)A!_W)&D=^)%?Z!<5)G5;63
MFPXJC%]U<2F)O2!RVBP.% 0)Q)3ZD' 7<<+2$#NJ(QIS MO\O:LP^N[2OL[]:X$8T(I0D,)6[(!2Y&&+DQ=
E,8F=R/4HURI[IL "PM;J M_>7-7\"GSU_?@,_^??
OZ*_AZ_?';Y>W5ES^#R_>W5W^[NKWZ>/.GI=PYLJ'.4#FGI&EBR"'H^-+*E:DW596)IQJ3O"J]C"A M*""$RIR=E,D";
E,7#>&S'-=SB(>N[%6A[,S^5G8DGWC5&;H'-+4BEW3N'3 M*YAHRG%NE>AS7U80$F\:='S(P8 E*(@Q08ZCY9A/4EMX
MY1K2!@/BFH>)TX"IV2QK,.A9I%$$%CA?5!+16A_P*5HKM_-6$/NX*[?*(.WX MWZ>BK$N.;\4>_W.!\W>_XGI7"@!.X!?
W!Y$Q"VB* HAB6:O)(RF,0S^!C'HA M1Q'B$4H5 X'SU!;6[XX!(#D D@7P#CQT3,@LMU@Y0J8 W&QXT"X<>GH^BX3^
M.:<"),K10[O0F(41S3\6G5"BN]2C,46%*=8*+JI+,X@R:@PR[$\L/")Y\UO, MR7/Z_$_X#M>-0W?.&N:(F\"QB*$
@<&+O<@2KGP8AC'4#@Q,25)&]6ITF4Y M=9*+'WY4%1AP<_$Z'D#'Q$7;IENS_$\DFKNC5U\=,]
(SH1&O\>PLK2V6@O/ M$URWH[_R_$>-A-5'FAF'ZY(_XHQU31#>=[>VDSA_V$LGRVWGFKW(G_L^\2\ MMWVO?
5(@2]I[FL;]"CLIYFL=G7[8,.0NO#7>['::3H\RSE'D,M6R*1$4!I3$_M3H*A$P8)1-3U((X"L5P'_2+$<3'RB59_?
8K:PFJZIWT'6NK@0-ZHR-(,=_ZC M42";H",L+%L8,1CC@_MW)XTQBDCD!YYF>-L6>$;!ZS4P4PPSV\)!S^9I Z ?
M$%81S%:X=Y+6NL%<%;&/0K5*@\Q;E;&+VS:7C0N;TFK-UP<
MDWA:&2T)JZ>")^0$OUD]FU$0ZZSN[*_G7+T_^XA0IS]TCSVJKU2W)9:M+B[+
M\MWS5<[:H@2*&G5][,+JU)$$@I;X=6-E](@N9]B+H9T\9VZGF08_*/JJ;YXJM MIU@*$MNKO3 GGI&"G9QP-
>V:$F>H6I//F3GP[W95EO.JN]1B(;RRYA#INBP^
MR=:T7WA].*O<)$'DHB2)H4M3X9;RV(%QDG@P#!A'U$MY1+0JK2A37EA=>S[M@)$+F:8&&E:_S%O[<;JOY[*I
ZSFOBX"FYZZVT-,V\?5EMZ2OZM.=U7?5QN. MUWZP_@1F9N;7+"]*X6@W!Z2\JC_O&VS&#@L"C$(8T2B%R'$H)$$4P-
3GF$>. MZSJ.5HQ@E-+"9D26"I1E:XOM5BZ%/?DSFI&.8Z9F*:P@H6<9S@)!VQC,"FA) M^UZ\)IB&X7T M5.9?+
<*G(>PPX*-_N:?^.R\KV@^@Y76?6! MI[P4OY<'93RO&LW9-Y_=)"[!3A!RZ"1Q*GO$(X@I"6%*(]\)"/%YK-0CVB93
M"R_VDL\V_PP,. 4]J^!K#O;,@H9;T+,+AOP>^BRK9_!;>V_3MNFMWH:> ?O_
MQ(M0S[A^BQ=BF)B]WHO1RN2VC>!XPKS8\EYQ^* M!YSEFR")?!PF'G1Y%$*Q324P]ED,"?:1ZQ,#]60" M4QH M!J?
G830^SC('Q\8QECHN-@ZO3LNZW*'5*WIO?5AU6GR%0ZJ1@?9"7)^R'.=4 M);Z"4,ABTN1GX@0B)@L1N*X+@R!*
<.0D*$FB)Z'(1B7D2YTIY3 M]U$N];=A'N5:.!&-K4:X]=V\?Y=(&:L$HESHO;Q[ETH9-)?DTTNA/R&,6=[\
M<*+UDN5/L/\B0_[4W\W6Y4O&FOT0WE[C3/@#[_%C5N/M(!]@0U(F_A.DT/$B M!R+'C2!N6LT&Q$'81S_D<;%7
!WYBQ%//;85W/V_<#'R*'0=;$+481]&+N(_M0"1+F2(2\,A7NN]FBZ&%M?U_4!;4S(L<-B'%0>0P/YTMIUE7^^SWHAY+7
MM M@W"B9.T"=,P-DN4DR*>"BF#P>I8HP&T++HM!Q;/863VN:_.\4Z%%*_,;;.GO M[NKW]_G==5[E?
\/;]_QF]_#0FN:]SF_)]E-17CYNR?:_R]X\G>]^7W?BI;56^/>R?*SP#]I%
MM)7P'!Z+LFY.!X"4#+]V(IK;H1KQ!NWWH!"46/(5:.Z3W@)]B]58SX+3+':B M36V]_(LI$"^B,,:3F-Z;NGG
VVU_F+WQ0NZ$.&8P2!&#B(<4R@]&T$]PY$81_M\6.U;@.C\R]LS;I;0_U)T-/4O07U$I!I>V)!3#V+H2>AP;VFDW*
<<8WIY7PK MWULZ*^+&[[E5%C@+H=,(\QQ;NP*_0Z7\VL"*RG74-9%^G]HR2766FK MT5G7]V\U)]B+(E>S#YN%Z?
^,LUQ6LOF;WV#9H^>P$6,X2GR>0(P3L=*ER!$_M.3%$S'6]%..4$]VB\F.$EE[L!-
F^[U21RS#N8]$F2\O0AMX6;18SM="X#20T M5\'S0-".9L]):"E*/4IFU>CSG+"OH\JSSYLI\OXFT57^N*NKS_R);_V^S564
M))AR!MV I! E)(38Y2D,DR1"'DI\S7H3$[065N>&%/_U&[RH8*2FNY8DUU/? MPYW!"]#2O0#*0&@KKX*
(EO1WBM*J*JP@\FLM5AEBJ,A9GM5*]-%K_):? >9 M6.[;Q-'N?@]S-UX<"9UV"
(P0"2#B/H:)BUSHQ8SZF#",0Z7&5CI$%U;ME@78 M_.3/2IT#T;FA]O_]:BZEN&2-,&M.A\-D5'WPQHB&O+'JB07-
NJ:EUG1-33B88)])V]NFC"($'%@S_F&V$_2
M*"0\3EFZR9LC0':KTW)BAK"2(B2M(AR15U:*ZXZ^]&)IF]993:9U&J*H9B#L

M@&+6BU>2!@/:H"4.6NK6>T(IBV]ML<(U@*&:!\,,0HLEPPRU,4?+L+F^;:=%GV0)/YL,USL]^
MXW3(E]M$*68>"ET842>1E;(B&!..:0-=Q TR2* BPI[6;T:,_],:FY0;T[("> MGXO6>[\8:MN!*|V-
CB;DBGN>Y8#4W/Y8QE! .V2&A*V=D2;U=3=)9M <[9<, MISFOX)&P@:3K1R[O/]SEV;_%?HWQO,[2#! MV"YS-
JC4)/ZV> ^#L]VQ+*9.$ MV^::[8A-&,>N,+L<$L='$'DQA9BY,:3<25Q.P@3%6@83U8MMW5V1. D44\F[D _]#;'>/LDV!
<[KUW M;>W8K^E'7.99?E==\|)I5-&&6#9>E$2AGQ+H8^I"Y+H>C,,(PR#T&&%.G+! M]]><%:X6-
@IM)+MX;,IS@9^R'%1-ZP[-_G)V7H"B]5@;5DU+,V /'/@#/8- MZA$8L-A$_#HFY0%"V\9FME:/OG&RB9LM0V:%IW6-
GDT8CPRDU[9+YYMSS'|(Z/F14V2F0^3Q(M@S /!6N*E-%+:7T^36=C< MM21!1_-9*QU_!I]IXV5/:NU
GB0*7@HN[9%%T=4+Q]N!P+ 4_!@4=B]ZSXLV M7]-]8NQ]5=?G^1_645=X6MOZ7(G='19\%FF;7-
#D%NQR,98_/&Z+9\X?Y;7G M34@)#SPW@AYR X@8Q3#ALF,G3N(X30."HU CR4*=|CI9%CTSK[,L0,,0Z#G] M?
MDP]FS%JA#/&C.;B)E5\51$:1E\E"W> CB96;_#L3/=EQYX:HYO9&V!%KI, M,-L>,#|\V*1(=EA]OK]\EQB3+Q5^_9_4]J.]Y-
UK_V(PK@ &@H_=MI9_:W<6 M@/_@)%7G6)D+ MTT;O\V);W#UW"1C((0EB 8+<"7R($M^#.&$(,D^899\%#E>
JK*E$;6%'L6/@ M O0L ,$#.#"AF1&O!N"LU;4+BY[!?1-$E.VL763,3&S' Q ;L<9 YDUD];75H^="=KP.5],5OYF^)
[+HRNL)WR'X -G/)/ (?0 M8^&WXKPI2Y:WH8-26-M'V2"OJAI#CGO3+<=G#\)+>.0T2[.6X!9 GP B2?
M#4 BI=YQ011OM\]RX#9[R"2+;%=VYTKM0H#%7YJQ8F@I%Y&&[9\D7?X#"SO# M+R2G%=]N)6>%#-_%U8?B/WL-
OOWD!G!,]M1 99XKN-?<"16'CQX2.BMV 7 MY?,??QY\:,+/:_L1[).R<7NZ)>7)\KQX:HO-RZDKFK4G"Q1@]B0-9"5@Q36X
MQ^*UY$4-".=YAS)G=E8G]6]Q=&%2F&*M-4E=FL%RI#%(>R5ZL>EX_MHX&'5Q ME5.Q(:GX)F1.S!*Q)^
L=B!RDQC&81K R$-1%))(_%DIBCM+:>5014M>ZE?/ M@+*AG4%L=MFQAX/>DK,>!,KKC#THS-
:8,R#1,6%]8HZ:KYGA:YDN-2D&9DMQ M@&&%UA>3=_W)?!+Y"44AY%Z"A+7"$22IZ\#$I4X41$'* Z7Z6U-$UHZI&K5R
M.XF.VH'0N3*?9Y3L=VB;DL=6P=%3)-8M(CHAY%%AT*EGM?V'&YYG1?FE]'FU MSW/M!
M6*;A0S]Y]LW/QL"9=1#.%5E/ UM]H"WR,_^3T9E#^!<6E0L L-<50]}T.4Q?AYI7L@+
(>F:S9V,4Q6H61OV+]^>!8.LZ]R$7 MZUYR/0^]HZNO9TYGF(C71.*ZI+Y]"X/(=RGU4@(]EF"(B(]AG*8I9!@%']:A
M%WMZS9],45EZE]/EP[>Q1LTF$*=A"1-?@,(\R'F:0.1[P]R3.(6(I1[V'>Y0 M%F^>>$F*U8 94M.&YM(>-&HF]FQO-
0UH0VZ?-KQ(8XI)D6PEW9VDL6X2W928 M1TEQDP]K[__>9<4WGG)YZXW_A>-M?=|=-OE.F)
(PB*$3.S*O!$5B^R>L5N2Z MB1N% ?)"I1[.$S06-E)#LJ"E]]PK&H5E=O=G0U@}33PAI_[QXZC REM!&X*;
M;0=U7K3.;FY.HM$=W>C M79UH:C)W(!Q%#-ZIR]V!%/2!1[M(>1NX(A=]N,* "(&"1/&D_@\9-
0TYDB:.)M1G,G21)B%$(?)APF(7,]$D0<(3'ZME!YV#A$E!VXZ, MH=1]CJR)+'HK\JP8^D5G7_%LJ\AL/^VZ165?"'7-
41/;UW[6]3KG[/NRU+[?; MXKO4KK0HV],-6:)V0PE+ DI#&#N(0D1#!F.&$NAA(C0D87ZH5@1:D=["]B-9 M&
(27+L">BR95]3M(DXPH^VQ**,XZK+:QT5/%MX)%V:VU#8^9BVL!)AW/5T?H M42]8:9*U/&
(=B0;>L=8P_5XO[XN*K89:SZ&]YH_M%>(_-@-O90+=T!XR5" M&L,D=6)(')1&-
,81PTI'',DEHX/#HF"AJIVLY<1;*;MF1V)]4R8@;!:W5ZF MY3FCU9D6;-CD9>9)P_!\K\V?BO)#L2-
UNMOVQP,'G=_$'@\)BU-(M$YP*9?0Y)#C ,$PH]A#R9'5[K7B]$MF%%71__&5QZ=7$53&J;1TMS3"W':#T M0]]:U;?
WQ=;EN5WPI(VY37>R8M'PYK+FS3T49AX M5XU_@,>. MW[:H33:XD]U>"I;WUKK[IYHNE?$K4;-
R:P"M9^HZCF0/PQ]@P,I%6P\(-JR M[BEP>;B 9_,G0N*)5MGS,;J!N]-;("D&:'7RV1S^KWJT9IQ>Z_6J*_[6L-U3
MMFV;=O7QQV/3[_L0_^;55V&#A&7JSHEOY+V"]X='3&M9VK7&LEI(7Z!L@Q!) M(Y0BF*0AD2$E K&;.F
V(O#\P$V<,%"]E6N%HZ7#P5V.8,_E,&3"*] Q"OHS M]H95T/(J6X;VW.X+ ZI?=+7SOF;/T-
9_"YHAZO_-7X#ZC>357X3AS>6U7HC6 M/6>KX(W?A[9#9K5[TU91&=ZOMCNQ:>R2%@]
<4FWK;>9UEN_$O(*#MMQ)M8E" M@N*$Q#!T&8:1!II>8/*^%(.+O=U>Y4%=>U=>[NMI?;Z&I; 0:^=_E M,E76=R)
(HIC!R*%>%*1!&"6J-6KF]2V>Y35D /0<_F"RA49_AFG5.[H.C9 MBC? 0R.SRR8NIGE=Y^&CE]2E*N]$2M?
L%.LE=*E*\R*=2WF0MJ7[P!]+3K/F M_5_F,M90UMF_N]KDGV7)'-:U8_+<),*I[T&>!A%$-$F%P4M"&!&/Q"F)N9,P
M18.G3'1AN](3WDJB;24]6*1P5W45Z63)/EG^3%G5U?&R\^GB9F)]U(-H2P//3VRO*FI$?? MHZLK^=@4-A1V;,ME847Y-
XVYK%K,M$,*:IFYM>U$V45RG9(\^__"XBO.-UM M@W9Q0N^?P:7VZ]X_X6?#=3",E M/'P)]!Z7=[)R\!V614P
[WMAR$RCI@9F(UY&>P1Z>2A^S&J\;1!I=-!2=6'M
MSV%T\5"?:;TU1%NVP5*B/U;_]_8G(5.1RP1D^44^?]CQV^)#5OUK)]YSFM&. MF-A>O>,Y3S.QBCW4]NVU3>9>>>!'I6
(]3X#MF]WB:[:Z/27H.=,[FS(&=G]9 M60-3O25G,3BUFF:?@XE1]VPC@]NUT3X'CF$_[;/FT3\\(:V8B M3F,T?\1M17(]\V
DM-8A]]Q09QQ;C\^]VD'UK'C#H^GYA\WB]Q^[A++FZ+NM MT=H5;M"
(R(].LK#>]71!VWBOI:P741^77RV0;D5T/<6;R6"[Z,L8S];PT(Z1 MSPIK*30^3F?
5B/BLN*\#X?,#SBN&\:W8;L7"_1V7;.,E8>#[K@==`C-Y <"' M!"/Q3QK&//22A&*E(-_$C86UMZ<(?
I,T04=4,W7_%#1]FGNFP'HZ]RNK<0&! M$])8KB4PI/_F905.B#A68>#4HV8]N*]:*IQDNBV]G7C9AR.#""$24_Z;I!
MA%,&2110Z#NQ$#3U2$BUKOA-$5MZ#[VO P&Q+6/6I1@4]-36V!H;GZ-<=!6 M714!+>GP)*E5E5E%Z-=:K33&L)U
\?!8\GN>RPY#[7GV%UXW&^"-XWBR9#"# M49S(_!6.8>S[\E]*Y["4)MA+Q ZU]/%63;LG:&DI]YZB>M;8D/(A-(Q?I5:(
M28M2?K3/X'U1/A;E/LQS^<#+C&+PES:-7O,6RA3(;K; $G1ZIN E:B^R5]9- M45&0WE9'@PE*ZS8VF!?
Y]+^!PA##BVVE+'177,[^FG[-<M3)VV^;8;DOAN&M(8DI=B&+A)V 6,ACX*/#2-_SB">3YXEJ/2!G]TVN;_
M!YISZ*=B^R1S,VB;9)[._O6!%%-]<_#Q$CI#R3E*M\0E3^T9.VI^ZQDEA1] MG,ZJ*CXK[FOEGA^@I]:,9YL;3G=E5C]__-
'V<);WWS>4\="A*(#4\<1,/G!2 MF% /P2@-O8!PXL8T5EG"QP@LO&;W)$%/LZGAH*;EHYA,*Z<-237CWWI"*BOC
MG"03I\EB;*M^XH>#UHU.N(JRS8G3Z]CLN$]BW>A_,NK#,M*?T. 2]$
MGU:9,P32#.W8D$7]4*"\7N;PX=7NVUY@L/AG,$6)O/,H?HH=6:F=LPB% M;NPX6G<>IX@M'@=]25^_1TF\R??
A/7F#%@>3N*G&@.R@H1L ZH&XW@/Q\0#$ MEPD@#.(_\Q):"_Y,D%HY\C,O[''81V&,F8)_SC#IXAP;CX11B!&!LIN8T&*"
M8)SX#B0N#7RQ860\(CIG0(,Y%S[S>75#+.ON+.GI[! *-14U%%!/(P=$[*G> M"L06AS1QD
^%U?.49N4;=YK%Q:WG0,WP/G.FY)PTSK8J29W=Y6]V$ M/LMR C+!H^HMU/.)-)"-SUR&0A3#D!!?
>MD4QCAT(8L=%#]Q%WBQ5E-G$R86 MMD$=2Z#G">R9N@![MB[
R<0ES:0MDS>@YA8LC:N>^5L$4OW\KS,PL9479L+"
MNQEB9X!TE$=VSEQF1NV&W\D%ZE1ME"Z*Y%+B1#%/H1^[*401]|\3FP@N@V'?$
M08)BPI%6#NDLQ:7#A*=*^FBVE)\%38J:*N9#,L8ZA]-Q>&SF7NZ4*ZZ"L7?2R[]7.:ZSE!C0_-0Y$WN
MF_@*OI8WMCZ'R.<.Q$GH03?" ?=0'"(':1]: M.9K+&QK!09^0*9@0F(&6CF?MKG
M+.6;F#HAC7T'=1,;#SGU:@Y1&L!KF?E7F,]VB#/"&O]5$L+(-G*S#R'E743.2V M=I3W:6-.TSM'W;V;]]K#I_;6S7.?
=8B9@R)*Q68.!1"%$84D=5+H^RCT"?4P M"
[0N&TY26]C0[6GW;2QZZI]9F6K(]9DI:WCHV:$SH#"X=:0@HK6;1U.T5KY] MI"#V\0TDE4'Z&[+;DEV6I7"
[LC;L_$'L]E3W6Z?&+]RI!V) 4E/?+)V4LIW6V)Y5W1830NH2]RUGYD2RVB[N*78O_RU*2U[4_B!.&L1\2&&*Y@\,P3A&
MCE@^79=A3_P'*U6<-&=AZ:CHY_>WJ]NKCS9_T5E0#F-66V67!TU-_>;32)('UW #R#'Z2#($L_R/8\P0.
M3"URUF*.B;7%VH"!55=P+^MGS'1>*;_+_&@?<4@VV>M0Z* 8<9)"S_<] MB)@70!RE,4Q3\7,J;**GC&Q0:U0+!)"R)
(>9AZ"=I0I-$ M*XE7B>K2NTFIE7LFVK01*]<,U"!5,VO6@=*S7C8PTL^ST9'95J:-
$LUUJTOV30M6_>X(BZD1<&T&>RO&R 74AH$D 78\8=YH0H MT4K_G2:WL+$XK-,-]1?7:#H.]
(S$#'AJUL$>)'IFX1PTM,V!FT"6[,_L54-_M@)K@KS5?<93!B8[<6S1Y>O?%5@SY5N<:;=5.CUY8:QNB8$ 5?./UKLRU^Z*-
MR*YPSG.VV)HG/882ZYWR3 IE=LYS>LKU3GHF17IQUC/]Y-E9[FV%UZNJVG&V M<2@G$>,4ADY,
(8H#!#'"##]1RW'@.@%#;--VOKRI<5DK>M^G]>E\E:]IJGN4 M;>9VU=88SAK"%X#PNRR71=L!P>)QRL%/6?
_0'XTSW%] &24Q3UC@P-25-ZEC M'T&2$!1DS@P
M1B&&*0L9#EB<,JIUPF@!O[,O5[2$+T!+V@Y.BGN[\Z77W,V9"'[.-8E38MF_M&O&"REM=AS@EZL05B)./:]>E^<+K;
JR]RQT5:[R,%.6LJ5UQ\R@[\&[?-SV3 MJPUS*?,3A\$TD=$;[_4P=H46.Y[+_^J$D=B**9:I4:.XL_++F&HYY*(Y+2J:

MLB=5RTC7+U]]W(LBE-.:O0A^O'F-\)&N3*.?8S,"N6T/O%X;_&N@7K7.%TV
M&L_RIILZ:XL%5G7VT%PYD_W2A27E/V3C\@9S>:XEWD.=E6VV54&VV5T;L+V0 M?RUDAVPQ\GM6WXMQLOB\L"
[R%AO+]JL>B$F^I2 '95;(H>#4X>I&/O'B_%7C< ME=5.%NZK"X#E,Y;*LJ_2AE*@?OV&;15DBO
ML^:#D=)7M'CDDN]#G*]L6]H7>=,A5?R(#SSN9*BIQO_D)YNYE_Q)*#K>5H/O M$;-
_[*]ZK4(O>:>TW,DN[8>272O3+J=2 M5@&9/#GNG"'Y>F!JI_6[WO<[6A!)<9]UZB/I234HEZ0YT##8*&<|<=U8WA[_
MQNE6? ?[_LZ7^^_]DQ#P|NO[JVLYI.E'W\QS+?3UH)Q=)VA9:;'Z5)1"G#\+ M0R G?L?
%)\9E&Z>+PT2+X@1Q4[@:04SWU2@$DH_M'7L, #CBTQE(B(;>.4BA9-T S /NV'Y1B M@/=_F\]$,X#\._M"]
(/2OXL78ROH_;;"K!M4_UV\N*.@_>^#*^T-Z%]SX:D)
MMW)?:DPPR[,G6;>ENY3DB/72]X((HCAQ(>+B)^*+K2@1.]#$HTX0)5AQ[SE+ M;.%EK:=_]*8'#ASHU]]?
QVYVLVD5$3T+OCH8RKM+]Z"8;2S/!$=G+Z(L[>@V M9'Z&M78@RK(,-A_]8_0[:7W,ZZQ^_E \"(.Y":CKD)@[T/-
\!R+&$<21Z\.0 MQ*> ^2%1K&;V>N*%C59+"OS6$E-4R"/AIRW1.2+I61U5:;1Z8YUBW:@GUHN)
M5NN%=8K]80^LDW_7/_[_^*_Z^?)[R2KA?WS*M6OHC Q?^NO_UTY^+TV3HV]P M/:@NP*>BJ/-"YZKG&
+3RF%)>$T]F9=[@6HV,V(:)0:,S;E:9L",4,/4@+E'M3=MUY+QO"[F_GHU_9_^[AW=%61;?FQKEC^(O]?,F<) ?^=B%H>
<1L4HQ+MSM M((4I]PB)8\=-]$YH=8@OK,N2E4./TGW]@_O0\0/V#(&>(]UF(!I 4\Y8F,8(M.M0-(')H). $XB=
(,0^10G%SN:)EZ1X:ZB'3"B#/5]N04;U6[C)'FZZ/-Q] MX,*E(-0SOC8_5(,N+_H06&L#HT%ZY3XQ^] <-
Y(QF,.TCIC8=.ZV\H!P*C#4 M14C[_]4$*B)_O2563>81ZX3(UE8!T<0>2F&./$PI&F:1HD3AV$0ZV>5+YVEIEN#;-
G7ZG@1Y@@GD" 9;TMB%Q(LOD@'%PZCSHIY;Y/P+)_MAY M$$Z%)VGW:&1MR:Z+;48S7EV7
M!;UDQ:/@]=,6WZF&7V8G6GCSUM$'?26JGHLFP4>RPME.9C)W'*D'9>81F@_/ M6 5'SPAJX@)^D^Q8"MLJ%QN&
MK,;;CS\>9>I^+5_U59=B^&Y7?RG]_^+U-<[8)HT<+Z ,P9"&!*+ BR'A"8$I M0B&-:$S<*-
WD_$[:L%NETU1])I2T(&FUX(@598WXP%N^9/9EQQD8L@9ZW@#9 MU2 O:O L/#S)G)AHP'^LT>Q"\%I:%1^CQ]'^
N"Z79B>X"D.J<\II#,GKL M:S#E6N? YM(.#H;/F,2P%=Z.5/Q?._%I?7P2_R7C151#SU8/A7S!#YQ]_'IKLZ>^-NVH,#]3/+#
P@4UM^+0&AI]RF&)Q?<>!8NJ6]#@PHO6WE@6.19ZL/ MG!BBI])566\^[LKBL<_1)V$6GA2/AI33Q')#VU4Y5&62
4ZA&WLA1&$2PD2H"/3]D$1)(CM=:06&5(@N MK$HOZK=WM_R;&_K9G@/-ZM%*2-(T=+#LFTAH&D 4N!%,
B>!G#"/4TYE^HO& M\8AU0,\^%9FLBP\,W"R K9]'8?O;T[-Y9\-CL57 L;R+=P@8D/R=-_8X!D&]
M'\")L=I'K)VS,ZBR]*W8;M.BE#.1'24!BF.(8090@_I,0-]GR 25! MDK!0J;]#*L&%C>^_8ENFY;A&G/(!GQ] T[9A"5C,MB
M!"T#8 B3S2XBNN*. M'LVIS;+6:9R63(,#.+UQ9F[6-7YN7(K;HNMG^]ZK1L3;["M9!KOO=+IQ(B>F
M;LI@(K8BLGIA(GYR74B0PQAA842=P,!)T.%A'6>AH59E?1]SLN?G N2*=O4 M-/S '5-Z/H,6Y)20A,H^3Q%#L@9XXD"
<^@&D$<9!E$3$TRN;8QUKG DHKSTZ MHSFT/;N/^;U,U6&]"Q UI^Y'K; M[9(&O%R CDL]QT47<37?
94$<]:R990BU'1A#("SY,+K45W5C#*%Y[%!,N-E,A"F(WY<),Q3J6:(S0PB:G M(PL&=#4=@%FDU"R(#?
GU3(61Z"8W%B?ELG?5\#29M>\(3@I[XG+?]/.F:2QM MO;&_9_7]^UU5%P^\?(>KK/J:7I<9E660?V35QG$)8CY+
(/42V77$C2!)7")4 M.&68IZX38:T B!K9Q9-;6B;:ZN4]&Q>@840N@QTKX#?)C*:.*P*KIO'VX=*-_M/]M!RB
E1D=P:]DQ2D173I31 >(X9T9KM'Y2ZZ_Y8R8;,MYF#YQ]*I]KQW_# M6YVKO1-3+&P'?OUR?
35LR=YPT%3EESSPO&JK,C==)[536J<@F=9ZBVCHJ;D. M$%:O\"I(:Y3$.C7O:NFK"L(-
$U=5'C>LP%;D=T(]'F1.^ZV8HEF &/(3%R,/ M(B\4*[M'/9CXK@N#.(BBA#N($U>KTMH)(@OKKR0))4T@B5X
2=9HS3X)D-H* M?:[8>HK:2'RK)[%^":X)D6R5VCI%8MV26A-"'I7.FGK6\+*E3&-M&S!6;;'+_MC9,XG!%?UCN*/)D\SB!.
@:3*"$,IWX;^&*W++LWJBGD,0DM==P34OXXAP3_M+]"7*SK,B.[NJD<71?
@&NOW&CX!%DVQBUSF0LX=60*,8(A1)&NS!VX2>8P2 M#^N7 #L/,N.J7>\N/U]^>?_Q;%!B(3U-6 B)PRA$D1_
V!>@4,\+2! BL973 M;A%I Q+MFE>V /$8 PQ=S!,J)L&KNO'B&GM7L]4*8,[RRNJ ME-
IZ=QX$>JM=._^%KL#ZUY9';)U8?F8P+I7E4<%/+JD//ZDX4)'[SG;;7E[M?/YI6WR_V3T^;ILJ4WA[V'-4M_+M'J[I)8BY-
(H=Z";:! U$J,V_BP(4T1$F< M>C1% =-273, ^EM;O 0]MOHCD#%SE8N_UT&RZ--7:$&U%W5\>0ST#T3.TS[:1 M/%V
%Z@.V *_-8P![S9T^LG9;9?)[_PX1?0R M9W_A6W:5W\KB+;OR^96B,9)@% <<^GXJM]Z^S.8D$0Q8BKS
=83'0E4SMHVY M6#J\WC7AS/*3*=S-'8=[P5[3G[1C4#VOVQS[:2.W&]*:$?@.S*L!Z_D CN?NFT^]6D+_V=
(/L_S/G\RP;D_7)_G/9;%[O,J[SLMRM2K$ MEY(+^E_%[KGY>+_Q)RY^L6$Q"S'%/L0$!1"%H?C)]3W(&*8Q01Y)(Z4^Z.8L
M++QR] R!A],+L.<)#)D">ZYD"\V&+\U20/K0]SG(RP*]MW#8QU*_NI Q'+8* M#^DSL&Y-(F_CLH5F<]D9K[ZW'AA-
DF6MYWA]]?J')<&H4LP]'SNB\T[0A#S MR($\=KTP=3P]UAP=0S5%;&&3U),&0]HJU^[T45.S,;:PT+,FQC!H&PT5^2R9
MATE2JQH"%:%?][S2&$/E;MM)W-QS7G\NNK;]\DPTCDCLIVD"8XPI1_X/((YI M#..8$Y]&Q/$"I6LJH;?T
M/]*C+O;ADCRH\0_5.VF]@"EN".S!H.G]]PBTE&6'&=#1!C]UU/]HLXZHDIS6 MZHE.4UNYK]B2Z,?
U1=6&G7OJUI5#L6O7MIX;TQ.T8^1T3\G.PL/\)&Q?3&B=_MXZY1*;T?:1U3>]-CJU&1QX^FQH>8:?A5_L3;+G"M!?
G"ZPTF*6>1RV#,8@81_M"C@D2&S_F9L0UX_2A"5:FGV"QL(.?:#8+=UZRGL*%#6E/5-4/64=2-E2:TI& MV-/-
"6$LZ>0I"]OJXH2(KW5PZE'#?&I>RV^[[Z8ZN$G9KCZ;1+C,D6R6(;QJ
M7R@BY3#!7@+3Q'4&A\K95QQDZV7PK_GKW9^&QEUC6 ;QD#UF> MR0B<+#W>.?2;-
'9DU:X0,BJKI%+9:9WZ!#J4(2_DPDZD@9;_K41VZ<2UEHD+ M<->RT1Q]XQ>,_-YRHKGQ5D15T1>WCI6F6]['#].>EJ
M1-=UV+6 ./+=]49K9Y%]$4+(ZYE%0^8]%UHH_)1?^;__C?,LYUU6-O*%R\#$ M1AV[#$.4,&$]D-BRN\1+B.AS
M:8J#F0:X!K*3.^![UX_SW']YND/G#97X/O?>A= #'SD5+Z7K7HNF=H;F+8T M2^"]9V-
>D@<]?;!GH+LW8!D6Y6POZ_"8)79]XX_BKTW9/MK=BMX)@_S4W&D5 M7AP&^4L@LQ[(QUT-?
LJ:,W7Q>>YRH=W;)M8T,N"/\MDO$^C:9TK^E!6[:I3S-I%?SBNDX]_!>YQCEN&\G_UG<"GFE2[Y%3:-
LFV%*'(NU.D.?)9#K:#PB&-BS_8*?[\L/[&>?,9_QN)0=9 MS1\$M?T+DTR\?
O0PD9V<.JW/=#1]3FV6M3+EM&0:),7IC3.N&B1]\.J;..;9 MDPQ4BHWY>]G54NS^/.*1E,41)$PL>"C%#!
(>A)!@ATLW.HU=K-,N+S0.J9K#; LHQ25L&8Q_MZA#-"F^O%M$XJ;7K$^$3WO%J0SR&?0US94E\AQ;GB>
M%>67HA;3[;B R]_$"#EI&#F0$%D*(G$=B%T4"8.5N+&'_=B+52]>GJ:PL&E" M/SO.?P=50Q;
(QK(58#L.)&5EE1R!9M88G2^PGA5;4%9ENW.^S&8&QT1V'4LS
M+=>HB1D9MI9MF>9Z8%1F'M0O<'B=5_DE^T=U798W3_2]C((T%7L5BQN.#%_8 M6%SSO)
(!14%YUZ8^5+)2I_BB;GCYE%$9T]L4@PM3($Q;#DORZ]D.-=$M%C%6 MD-*HA.'8G*N5+YP1:EBZ<.[1L]K?
#8[MOYUHX29;8[%0K.2,^2YU60B/5< M@!EXGN\ZR,7*%164]:YS2G9O54>UC?0[[<;C_^X'0GDR_>XYK?
M%>6AL86BFSPUQ})!^>T6[&F# W%U[W@2@'D7V9;LFH'Y$;$M>\8]PAFYQY,3
MK^8C]X@W=)25GC>]$$++KN39ULZ\+9K?O<,59UVSP\NRE'>HFGW2)HS" MR"$NA\0-Q?(1+W:3&
>0>RSFS'5(%&G57#R?I:776MD0]4E535-.FUP6_O"X M+9XY;U/40/'85CIHD_U)=R%R@+E=M_;E4J]HVIR\#?!ZAF?
VZN*9J_+ MO.[?SL?]VVF>A W3H,,:#-FV>8?&%H36KMR[$A*>*(LABZ(2<0L8C#V*,$4D)83#E# M<:#5?
=6(BX5MP\>]SAYPD[\\8*&_[],FZNL9"#.LU6S'X@CJF966'=CP PX,
M@8:CB^8V$&V:LPYXNP"2+2#XLF=:SH+%DM4QXV%5@W063*]MU7F3Z8=FV@(9
M[)KSLBD,^"'D_%+-0C,Q,3+'T(4A+&4C2?1'+3T51RT-Q]>#,%_3SL1E+TFL>
M:DP(#GZS6LU#44:C",W4O*L%:!2$&\9G5!X_(Z_Y4.O1BY(@I&$"$8\"B(*$_MPI@%&!+7]WV..
(Y2_7SFM6IB7M[@'V(B_F'N>!3ALU%:):^J;?6*UAH;GOMN0+4Q(>8>1'TP]BG+HJBE*4Z MYLHZJ/I&;_K4A=%4,WZV,=
(SB2T\+\CWM01_^MQ^<5]:C&XG,-(VESI"6S*B M2B17-:TZ(+PVN%ICM?.R#G-)KM^WM<6%QNR+BU?O>%J4?
%_5D%ODVZX M$Y"(N3&,'!\)HQ+',(GB_+(H\3V*2.ACI<(HEOE:.GC2&V[2<&10HM3V>T@2 ME/K4=R_*(R[?_X,D=
(1K&H0.CWG*212]K)AO^1[T%]7?WWN87A;>$%WM_[[#_M*M$6*SBP>N@W48&6V4&%V]Y&P$A:B[=Y*DD6"X!Y6@*
MIE5B:R5I+H'0((USD>G-$5UES^V-EP0X]]@+Y55PB/PT@$F(8QB3.*)1P@)/ M[0;XZXF73C'I,QLE+?
W\S4;TZ87A'('T++N:+$9IF4/&S\K$;"9:/?ERR/ZI M?,L7?S>[A/0N3^O]DOW#((8_,GSA+[^_B=-5-*^&5W),

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}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

MUX<6KVOU1:R_RA_DY_5Z75=TLS:C%Y;?Q(/^""YN&^YFB;+J-,OU1(14ST;@_M*2I)2! I>
<%207'$2LC6QAMG([N#9^T[S?#1+K/!GELS]$F?02J.5=C8X3E8_M+X,;_@?&\/?T[,+R%WDF,/\TT>,_Q_#>5>CY
MW4P3WV$HLJ=WY){>%0+S8)/K@B^9P<%]#F@FTLDSHI/IQMIM_M_Z1M'/"\SOC6,$M"XU]M%IC$8P(DV?I
R"WP4X_.D)!W2['ZLEQ_$Z9,5E?2
M/HKZ"3S"VG[%D=U8=U(.5YP$B^4Z[!M>@BTS]H)5T,9GR)#DRX#Z\R9R%,L;3%MCIE"A"#4G%-'O*(;+
M!W,3MI*!4&3."S_&^;$HI,AOIP7J(OCTG.5:WR^9/_S33RH9W='5N*F7M[6_MY/Z;T_>3ZCQ_9:/-
J*LT;4&KZ\WZ;EGK_OP?RS=B?Q>?)9*F69Q1E&-I&@)2_M5$@A4$)(40B64\I#6/CN@ZV13;;I?]G3"UHV-
?)&RVC0<&JZ90ROP9Y9G1]E_MHG._)3"\YT=GNV68^H'_G(PA?.%9[-FZ.GHN/K<=/C7E;5?BA;F)-RT^%7F_MI_&ZNN/
K6I%;F]K79JNPL^O\IMX%(N-^*&SW[-"",823E7\8F9K91FBE$2(_MQ#$I65:&A=UYK0VQD3WE<]+:ZEKBP1^&/'2$5I_:
[/R9+V7_O)2['N!#L2P$_M]#7ZJH_4M_.N+(0^&F-E<_0PT_9#,:IR/QFN3+S^Z[I;JU+$&>IBITD)]&*_ME>(4X3R6RL*+
K&2QNI?289#V+0-"Z*C:T;;S*1ZPW=,!%LNU$:@YST){2+[00>AE)9P_!;6X%WP$^K86O%I_(,R,_MS/I,?E;WF_OO?
ZI0Y%.U$&^6=;W4_UC-DKQ,.%%RE$N1(1QG9N)NAK)(EEF6_MA*DLK$XY_#3'/OHP;_1;/JZ"EI/
L!)H7H(],]9'B]8:O7BN.H:>@&/=*T7FNJ4%RI9Y^_7?*M;K/5IN;C52%1?EFNQ
MNB%/9B\@>8P93E*4,%W5&^8IHJ$L49&&)>4BC3_!04:=(C*R)#(Q_MYF*?
H,>8B[U7NYGK3;V4U5I7JL]RK\C#@B15H@',E0?2YSCM*TE(R2F)88_M=.RX7WKL+Z58[U_580;9D9X7,HNXH"A.&-
,.BJ#""%*.%!2\CCD.:Y+/U-AMH5+1=K16ZN+S-=_MOF+E,7(XEMR3&^HL/*GK.1;HT-V/DA9G]^
MVD*]+D^S)$YB%JM]!A<1T5LM@HA,(Q1*D?%(4LGM4CFC;_M1K9_SG9N\L6?'LRAOMB#>]$A8T>*?85SQ?
8_L>.$CM2\YC3PXZ)#0$_^T%^_MMD>A;\1"]+WS+,QB4B11J;++.)$.X#'4+-BL0+46,BR(.<0$:+W2&SO@1YF.U
MTLGXFBR.DU5FQ_MO_)4'5-Y_;BILZ*>!H\Z?[ECX:VH]T>B\?^^+++7O(//K^^5&[6A$E@A!A$1A
M62A;E42@@LL4%1%)8RSS7_H"*KH]0VAD8]V3U0F:AG#04_:6VIY3E)VY^A_?_M9]\NDL.+:R^(Y:NP]AR9:8MJ+PA[5%!
[Z7K'C/+FX6%N"YQ$,2<".[M@YYPX7@68C_MT'P$'4;TK?6U)==I\-DP51PENX.W>3G1V
M$2Z9=^A]7*B]@O)AC&DG5BUN342B.%R+;_[/S6]M.=T5!'?GC]>I#..BQ(C@_M4L425_A$:(I1'&4D3PGE.
4U18[/\HN<]71DZ%JI/@HP8@1[.8*](%?!7I2K_M3@V]ST'TOE\(YW.@%WS,/@Z%IG_"/LZ(1E+Z>_=&OAE^Z=.CD1Z
Q5'26)3A_M72%F,&S3A/IW,><_4EJOHO0<)0E.4L+%&5"A;Y%E*&"_M2(G41RBF0LJ,4*NQ?%#"
(W\V.A1US]X[+'<5W"GF@FH1K%OV['L?0*KM=]UC_M*@SF@!LVMF_#FA'E48,M*T%7E3ZC8%<%G.^
TV61N$BXS=7@BG^]T"W"]B_MO0=>OWXDU;S!5&]YT#7,=\NY6F^U&["MMLOR%&I/JK>+#$=5,S/C*%+<-#FK_]/
M,1B<_J0AE;-Z#B,D]X7_<_WP_*P?_L)%Q=Y6&I(H321")>11)3@%,4TE%F9_MI5FF"[.M8IMS-
,8^PCM1.IC#$?/.:NABB.)#;N!9W,@B6U>-^A#=K6S44060_MR.N2<&>#K+,W3A5/7>*\$SI=O'0_MG'U6HC^+M-K?
9T-Z*NEOQW,M\(C=A>_M5TSYLV;&N@[./BQK*:KU1CWQ&>8:E3@I49J5.<)*MXCFF")&6%1D"8NS4#C,_MP1W
DM7K/'@@[G?3D,D;^*QZQU&P,GUQNK+G0=1FUZR>?[-/"XCF%'@B-^39
M6"8K1E:U(SB(5F/#5="P%31\706&,UUEM5-Z<[7A[BKH\.<9T&R8DGRBF#ER_M,CUTV3"5G<0K&
[BD\T92IV',F1@7_,W3;RM=,Z6KIE;/L.:G0O(RSE5\5N0_M1IC%,.(I*5%
<%*GD.$NP1G&W[YZS)PV*W=RZZTR7ZT;WP38%4"T/_=DQ_=XE_MVNK5>GLX@K;@^T*3=-UR$="GX!?-B-
+87X(=+QW@=Z_[0:_"_&T$;0E/O0,$_M*N3$U@^Z@IN7V4'+[W>:,XK3M$ACC#*99\J=%,JQ)_E'C_J9=JAJ_MX"YU-
-78.Y7,TZR#!-.4=*T\5*"RD*98,83M<]0VB.P85%]Q*8]B>K0#O[0_MU_-#'EC+V:LV.T/U10R8U;KKP;G4IT]_ST4Z)TF]2'E-
G]#G"F-Z[W$S[!])_M;;JSOI'U=G1R6A0BT\VP89)BA#-:H*),*(HI3U1_F[&X3"!&?4QB9%/>$@PT
M1>![LZ1Z]V%GM,&EAM@H4%&R@YV7Q9)8G"$QJC.<%/#3!GBOAJ=4_R8.>.FU&_M!&4T(5RH#6,L981PHEN<$I8C4?
(R(VE)<69E;0?KCIU"5:2NVOGD@#%)A\+W_MF]0_D8_'_7ZDL4^".DKEF/C<2>[%DR4S3W#836">^K,CUFVG
MA7G!N_47&N]B_30K"8]{G!>(YD0%R(011**P0'D4,A%G..&BA)P.72(X\E%1_M%RA@"]"R!B([7-29W7?
6IR9@W@*H!#@JK]5DOA!R+Y&;%BW74O@CY%S;^\!?_MZ_;$77'_6?"*D?
F'Y6;!C0MNBU]8Q,J4%R$]HS!'&&LL79P52.*\P$2F4@@K_M6_$;8B-_U_?T@Y:!8,^:]5?QLLHN?OB]*@)FW[TZ@-
=,75;&==S@52ENP83;_M"P*)+ZR%/!MT7%YA]DC$6I9.>&)_CV-^;WTGZA/SH[<=GKOI*K.("!8548ZB
M3+:H6!2'(>)1*%3DD@N:6E5Z@BF/G0O4?_#36]9*LXM>1E$%S,T9%CI'\GLF_MKCK=VCM&/*;(H++
[2IQ9TYTVG095QU&2#;R_ZXQ$XY?X;I;SHI0\)4C&D42X
M2$*D,3L128M(Q"DMBPA4#K!;>63#W]&!3CG<"FYGW$]BP(SWLB0.'@!S"P$X[/K^?R;_]/T7SRTP9S%:W_ZSI'??
46PT\:]_M:GN#@(,SSLC<;Q;#Q879Q@5)/9;\]TMVPGY6@OUZNWS\O]2-K>FHO>+.8LXL_M-XG9](NRM9T+5\$-Z-
MF+J*0IM%U7?^H[Q=K_F%.;FV-Z/3=(QN2)AIH]BC]_MSE\)]-P>W;5NVZ/8(_YE>QHN.(Y&=:9)2%1RZQ1&FI0BD;Q
4:$1,G$9(2HS_M@=(LIB*_4Q*'=/8H:K]TC>WL"$/>W"YYZQ=8T]XV;70/<#^;KF_U^]H/PS>A_M)YSIO=_;LJI,G^R*S9?
Z[TWM_R@[!-2\76CI7YLP/[!78[_CVQ1S7?]^23O@_MB!0FK*=PU9+HI++$L3!&'@2[P;O
!N;*2A^6*S/]6+SS.,_P*3D]&0]HG0ZK-(RKB]$_IYEC@]"_TCRT/SP'@#<3\K&0A44].(L&3%&%"*2*%^_J[$K(S+,I1Y
MED:P(-:_D=&#VBU;P2],QOZB$;A:WG8PZ3H^;T[[KQW&$#D^!+MX=GS%PKX@_MOC7J@C_0"'^X.E=F)@:O7Z_HDZ
VP]9S1'RXDXY3'V"\D[0M:Y(:PN-91]R_M,"($%1]S%B'!]HNMOZ2]=J[':.
MLG,R'N2'>9%&]!]0T1T&,_<*YFTR\VDJ$X]F[A7U>#9S_^5N!ONY6BSK:OVT_M[;#ZH2O"9VE19C(OS&!FM8.-
HP01D60HBF-"6%&&F(":H$Y2&=E8SPSL#?XP_MQ('6>EI-=K8Z6'B8I;K*#3;57KD\&>II&I.:::^8AT;.?[&;B5XSM8?
=S'5&_MPGRH=9;]%G?]VUT]BGT7\]==+UX1AP4C#*,P+=3'5H0:,Z5(4$PCEF5A*$4)_MLEXH_V.G???
LM!'K,X8.H"/=^QW!>K=S!V_]$^8I1E_DV(FX;L.3?P&3G]3U_MN"KGT"LYK^/FL#1T9]54*]C-
Q5MS]'(K%JP2]WWZ:8=^G4D2]UU!B'BBI[7+_M7(-O1AA)FI0X2Z,XBT%SDT'41W95'5[,!OL9-]U2>?_MN@.[)2<=>/)),-
J3.B0GM1QZ([=%G(];6^>FYSB?/.)=?1'KK_('^3G#29Q(
MM<]!G'"B(:%R5,8L0Y)'*8[+/,R%U8@#%^(C.Z+GGW(SIOQT*F-U%6B8M:74_M4RF[F8\;M?
O4I6;7ZW5=T<(D4<\E+75ZE1?[@X$%_M107)4EZ4493)R_$:U?O3&HR%^I[4"Z73=]P\
[SZO9>=Y+9KGM28_1U2Z]=GW_M*&\\^,3[E;SLCK-:80KT.L#5DO0+3'6%*>7T[%?@&K!O#A?5(),R]OE[M?+Z_MR91
E7DDHY"7B!1Z:DZ41ZBD48PX+G&9A#Q/F=6Y]XFU1_YB&&I!0PY4)'9*_M#?W>8Z!P,.<_D(;;6U'>)6X!V0YY,
M)/A5[EM2U,<=2YIQQ,I3,K)L9%(A-&HS0$]>*O5=ZE@\72V]M?A4_M/6K$W;5ZL)4*<9H4\&?RSV7]=DY6]R_D?IN6)
(+'91]I'5$D.<))6B(:D@AE_M,:>_HT4XXY7ZC2[PH.D,"\P_MCI#6I<5#A76K&_8+#:D![A/I;&GOR9NF]MCMX[A3B-
M[&=AA].W[3;UD0G"S_MQ]?S3/20H*_20"?]6+Z_?Y@OGX18S9(X#]-2I*C$28FPC%-$4D(0RY(D*T+&_M+9O]
(43'KG81Z^"A9:0Y\]I:5G2_WDQ/6B\#L67'VAKMM7K1#XVB*YAS>@5]_MLO9DHZC+S;W]N!/-B)I](36BOK+UEE"@?
^K-9W@;+C@-QK0PY]P80)_(UV_M6\"R0/Q4AEZM]*&INK;J6U4O'\S!F\GO[72NEFA]$M2#:_']+(Q
ML\$TO>WU[5+;2X('Q?FO7OPN^_&<==<;V*TWEH<&R==PV_%Y'6*?ZEBR]?YM7_M]:UZ39;S]@&-,KVL7^6-
>C6VK_(63_]=6+&Z,]_5]8+OQZG?]DMUAO&'^+E^_MHW3P/S-!XR1BJ3Y@$AKH/26HS"E&0I_\XQ*7M
1E^T;E=N2OAV%1>_ND\8]_MOU>WBTI6C"C3WO,7;!D,_M_L!H9'X&9XW*=KMW5^-<\,&&)WV+X*GC%^%9Q\
MENK76Q#\#O_F"3L_53A*UA3;]H6L-2[OTZ)Q3:'V(P2O28C"T5E^6_!Z_G3[
M7>,B5.NGS_^C/F45$V_O%!FVMD5IZ5]E9&?]FPZ!YD_:8+<,!)])_3\]M#5<_M!&_O-)B)/63+!9WTNU*_ZH#Y04M-
7.D1I\P+X)^]M$Z(+A>6G@S9Q4[$+L*+_MY1TP@UW5Z]EW]>!(72U_6ZP>!%.AB.#MZ7@D,
<%)&*)",!7%A5&*"@/G$R51_M0429"FE5._1+961;WM(%)A3Z%=-OL-[$A=F]O:36QF@E25\\H!;HQ_+J7WMK_M[%]
[$D.T$F]K@W87P[^7'Q=<9QPWI('TL?P^/K]K9!O:$_NK_3?OO*[+WSAW_MD6!VLJ?CK3KE//M.'ZF#I2;[*)T6H?
L1.G/%:&U7;6XBDD5)0ARB$,M0UZMP_M5!9QBC)<)IC0*"O5LG[[K:;!U[3K#X(E>.#]M=O*CZ(TF.E>?WW[\:AD](;4
M&E707T+(6>#I6J:FS#8Y]\.A2';[U0C_;IBUC/4IQ%48DSE.>9BF$3_ME])2)@)E/.9A&"=Q2_6LY6"_^-
BAZ^;A8:X/BZJ6)GA(_3--V%FY]WS0;W!+

MQ=2'^ZSN/N;>6_5V9^F)J[./A3]NOCYQC2MD^XG2;8O]{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

M;KT^+E0 0>;7C"TWBUTYY\-:=@>V7F<0Q?:R?&|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

[YIQ_B8:GO6K/5I\>S:]5HOO9%[O]==]'7,XM!9? MRS.[9FO9R8?5U.,-GS=*5*_H,^K*1TSWU=WLWO\LU*Z)Y+*
*M'S\U\UI3T]_;7Z#:/IHV1P,S$C?E:36^3?G*OM6#^,X06?(_9",#HS?3+78 MZ7 _A.Y1\,(L"O8J-*
*A#**;44%XBFB<9=*=2P)$,*$H2;T@]7@0$5=KQW M-*
*W>]"O5]1GP:^CY']>M1A*GP$8EI*#4"$Q9C+XT\6%/FH^EGSRC8]>OY1TT. MFK1]+(IQ93@?*
($PC]+$9U'SH@V"ML,/1Y M7;^@#=EJBH7<4>#&ISZD/%5Z# M LHS;!#%]],>GGLK.8# R]TCI!N=?V\+T7\1&?*
8%%UOSUGD5A MY@:ICT2H=$(UC$H#-U+]$[%TOKQ0"%V=T*$WLZ8<'SV]7NS[XE%OT&)9?&8188LB G4:0,
>KB]ALXDB_74 "#J-M M/ ;OX:S*]12KG-%VR3DT7>,5Y5$+C=LT6;J Q,X$,ZO0\A>F,9L^#4R_6[WD*7+?E*
*M\^18^#'_E=3P2Y4YH ZBB9\D KLIHED:(^Q[,2*8!8A$:1J32+KCGE9EDK<3 MSZUTZGCZLDYU 9W-'V$?5ZUS$*
*'520\,Z$"]CW.CD .CB18[(N]COWL6WOMW MBVUA[LB?G[),L,U-UOOW^PPS3OPT0]Q7UU9$D**4^A0EA(9$1-*
3E+NC2OQ$7 M\Q]]]V:92;:FB[^)%R'GW ZHOA/R7X-X]C3V6!2Q&+(PQPHPD,E2 M@H(D53U9/4I]4*
'E28IS&ZU=K:V6\L7N!^?] X3D=TG1":0:J1D0!30@+70]YH5SX M<>C);4P2BY >XA//U3AN;-L'B-
\7]HTT;HZ&A;9NB]@EP.RE; M[^^,+="\;\7.IFB6%V)GLV0NOCFW3P9)CS".8D1=AI%/ T("7$H0-7>1]G-;$@5*
*MJ;9^<4/]PI%$8:9P7%IZ!LZ:#&!F"P@?;'BT8%DR)^.T%C426K#?]K[>0_#\ M);'.BU*UIZD^;H626MOEC 0NQB)T44QII-*
)B790&D4!N$M+8Y2+%GE;=HA$: M<^4U#@AG76$MP87K:BQ38[6X,LG:2A0WH9HD5L)<- M2OF:P#2<_#7TX&)I8!.
<=Q/"IH:;=@GNAGC4"[TM5CE[/50"3%/!>$ABE'!. M$?82@E)/&IQ$X!1' .$O36"M!0IOBS$:GI0]MOCLE)CTWP2IXF
*G:Q5O_T5!T M9BD3K8W/6N_:*7H+]Z/5A'_:8U;W0?B%LNNF4=E=R>LY/V\WU1=IDU9>ZV"Z;DCDBI^A M(*
FD%X!#Z04$)$(NIC'!2>#1+#6&9S2FOM\1I%R/,-6TV,R D8*SD-N&B=0 M(4U%]\+1%H1YU&*
*8HNV800^E]XD8#$,>C!>,/&*S>?7^Y%!(]UW$PE,=+1.$ M!4E1*OP0I9AYPA,1"ST+':N7NA?5(;[K1:U6,?*
*B]6TWIZ6FY/9D PWGB,-2 M6^]9#F$GB/T"#:BG#F,UGS*LDUY58K,[Y+UG/F,ISP+D9>I:0RA"1##&R O2 MR&5N&%/.*
[C?%A]ST=/QH=I![VEH?\-WZA&'M8D#I*8,K$%^) L]C35&"%/0*
MALP^+\)BH>X^_FU5U3Z:>]D2V'VP3NI5]PXRU"/&5#FS2N[%1?ZB[A[_4195
MI1(5W"SR$T1=/T*8N;$]0,$1SD3H>5XLUTY0@M(G9F7RQU5YT!V?W(]V <8 M]'P# M14P_/%
E1(JQ!]^TX7EL*/$!E654>AW]BU!/#SRRL<9.I9D2?Y0L^*
*MW(U/F._23!VIA7X@/6.J[B+%,?)$C&F44A(EH&ZG8\1F]XMWA2G4A575E*NF M?H97/"*
(W79_8CC2@'K&Q(,Q+=HP@M%W HX_4^Y3S& $]6-QC[!GX+=_OHMI-_MW%Y>3>-
$",H$"H,TE7YPPA#%D4"!%P61%P<\XUIQ]][99S^IJ@[59<#W>4]E M,:ZE9R,$'T?EE;J*[7RME0GPTVK$,O7>
<1G7%_]W3.Q2[N#L+IWM@='F2V M9+;MAZK/1?E=/,OW^4@J(16W>'I2!8#5&4@<)#P,B<2R5SE'/N(T-!#(G*S*
ME&:9&T;A_5H\D#I>)ETIAX8NT@Q!/K\X.#S6\+"O?I7J5:N9ODM_V-".EW(^)ZZ&,_M":6SE"":48X8C7P6"?"%N7XRJ:
[''>>'0U_T(L^K1!B]_YP]KUC-G0![$H4'P,UE8BLN;L#!LN%R M"_M7ZYYIQ"!_)MTDOCU>B,_X'P_N.ZH6T[#J[(#5,>
=:$Z+_M3:6[M YN[R5I@W21B)T=A!A!GG93TC/E/]Z7X31(O!K?@7@1>1=WH:EY6=9 MWA==N-[EM;Q=\MZ'">-*
*,LNW3=J5,>CVUZMI>BD>QKO(7<:@)T?B6+F(Y*Z+N(A3Q,2N$F:@*Y90HC/GW.V8Z4U'$?,O*FQ8N3E@T2MMR;,*
M)4"82;.H\-+)2>Y#;X'(8AB"VMQ+^VTC1^>E'; #G+_MY9]Y=8\C2EFAGFR^)X:;>M-^4"D M+U,]-*
D>5]Z4''VS1!.W0R1@!/U$\'R;R%E6KU_W@O S.:E M"^?",6X[T5R=/D!2L;<].>_RCG_JI_I ',.R Y7LK7N7?\:7X^>;?*
*R5OPF8 MT?UE/P>P87^O=V)IQ5B<_467HO=Z.6_7N'?CPVSQ_$3*M9RVNA5EW3_O<.-9 MT%0^D2!&/+6T48I2U?*
0QPXQZ4413+P"=F0\1FGDQVI%5J=),3=CX.L>@J/0L MN@T!P"RO&7:P69P"9LE\#9)9U,Q,@7UK#B;'&ZIM?
17ZT.Y;;DI#5V6T<"]" M.(XBE/C81PE.(^Y1D4&5]6CZN56TN7%OK);'HM!41F. 0!74Q@97NUX(MI3M
*M>/)E5:P7V(EB]8\R+>FW(?E:\)VV=D)-'X5<@G.Y'H:Q%]#$1V[J4X3]D*M-_M7X1()O_"6'"378'JWI*_*
DW4X"#4/,QNH&K3NWZ0LTS1(_"Q4 MV^;_0SB0 J49YBCR>1HQ+-T,KM6_SK(DS[EVUC#@[)?YC[K M.U!R-
H7S8)0B8B):/>LQL\!@YF3'S(738:<."7T51.V;ZQR]JEILAR-[]N4, M<5@R."8<+&J!SA#16Y-TSE1G%
((]7/U3:1#2+JJ$B(_;4@5@ZF^KWLM5]Y1D M,<%"H(BH#EPNEONNR,?(Q[&'LS#E+O$-
LNT@/"R3+%=SU+F[V]0^M4PY#5>M MVETTH0;@'020V#6/%VU+T;RZG"7)F16; XK 9NDY7=++%Z(#"]6W+!UT#C.#
M=+4B5763U13;]A1NB/(8S[RLH0@'&.L&O^YR(V2V(L#U^48=_?QE,3,+D]-*
*ML,Z[K[4#5]EC1#!ZAN$\N##UAR(%J_@P&$N*W$-@474=!OA6*4=&FJG>]9]5 MT]T4'T7S[^OU\5HE+A1E+E>AC)*
(@C+G40C?!]B8L182Y]=1"Z150%N(@Y :+ M_RC195;['0O.;SLF?G?RM=/A Z:IXW+44]KSQ6)8!-Y8%&!5UH)H2:O':2V]
MX%]PW^]ZWD.FV7_/SZMZ)TE6NU);GYI?',]W!7$64)IAU3L]03@C&*5QE]'$ M3?W035F<^]
C%QVBL^<%'E@XE'US=ER8U\'3D:>F3V]92D!?_GP!&603ZB.V MEE]H07+A/$-](9PF'0*>-'"Z; M)E!;N6-3Y);-]=($?Y;I?*
L'G1Q[. MY9,-=OIZ:0!VJB+T]B\B_5MT@#7[=2D,QRNCI_^M7F]_%GRZI+_<[>":*IA*
*MSZ/+)$!=_B22]M:IE1;>:>4[$RI,Z0916EP=)T 9*57??(LITPB8KA*-#3-S M:;^)C7*6;\OB)>>"?*
WC]6Z5N_[8YR^N'2[;)7V]%O8]9'&9)P%"@3L(P9A% M!4X1]IGKX300/O,A?*
5/T28/T$MY413+B,+7+^VVKSFVRHOS=>6ZY4B5ALAU' M#MFS!/-Z
5+6\W_GD1U,T978ZLWQ;4=6ORE&G'S]NI/GQ;F-3 M.]K,JCZ[6>VHZ^GEI)C&5=,F>&
*,:@@W,"@W*0#>UERN$[(6$<01Q1D_!&TK MI0NN,52KQ]H2N5'@UM9H\NE%#)(NAIU-TAY_1AA]H*K'K?I%G?*
Q7C[HM]DU9 M)]RHC^*#6(LLW]S=U\=-I8?ZH9DWP53;0'U1A@D-*
M(A1ZC"),.$=$OBKDRU_Z-.9N(,#!^<5A+!+R/RZD\UN#Z_>ZO=M%GBMV[7O#+(ZS+,X0CM,(X211EV9X
M)M>U.")>EK T)K F%7UD9EYR=D2=ENIT V"(B/0,^?G 8886CMF@!\48)&MM M'J)+-R)8@SH:3,*T=&&N=MU^]O/A-*
*5.^.HE'=N!ZYZ.GC>6AAN@@$"L_<'L1B*W/[E,"R MF=N# $\RMX='PKNL70GT6J/W'@HC00,2)9RC,A MU\=*
+Z1U,O/<.1D[6HXBIM\Y[1C]N%:=A0D8.-;# VJ$ULNZ4>>SXYD6:W76 M"Z#;VZQ-
%PE/]TW4J^^BX=;CB]KRB],IG6EW.1PM0&"!*D/F-(C+2H=\+% ME&D,3E>G1L?-6K7\L]P0Y@_KQK5DK]T[S?*
MMX3>QN8LS< KY^-_RJZT'+4/.CJ.CZ_^= M3?
*6%\T&^V+4]7^%0(J=@P.HU<[Q*ZD4AH]+'#_R0($Q\'Z6N1Y#+/,PC2A,? MT_95?EIK%@_Z)5[DCML97J.*
<^I=ZAWK;DW=^*T"7#%(G_\+1?'<7CLK_*3[M,=T9!;ML[7T0A[]BB7X3$1M6\C\;-5?,N*
T[#@?.;Y$"EB&;%HV>;;0I%9BEFQ+(#/=SM-':++B^"8*970^KP]UV77S#,*T=HV]07/A055\(IT>L@&?-*
+,1=_I2O'^2.0.T5,E'> M9["X$WY0Y0O.6N:4\5Q%C.>)DBX22P-A.\B$@8^]KTL(Y1)H^_IKT'^E! W1]$;Q&GJA5GB45"9*
MX1CS"G%%&7)"@3?A3@-_A])B"7.$WQ_MPV]IVL&O9\0,4<&,E18@>-WB4]9MU2/NS+QLG>%32"?
*U@WN&&%Y,_$,=%GXD M&_&9Y.7?R6]K=2E@Y/&9[8*BX]2$'%)7H*PY0SD$*
*%N\D#B,ROY'8,^>R]Q&'09W<1AP9;J75[]$@7.CZ(<%^A%+.Y+*4 MQ*]=D=S,>P''(DNCD/KG]-I=K]C>*
<<_9<\KH#4A,_YN 3\P[&X"_=QVN_,5 MQ1L@\YX-=S6*WTV,-\QK;NOH=6OK'7H7=I]="NP+0B*.DH_F"$=RPTVINE!,*
M!_^SB+((IL2ZA&=7ZMY"D-?KK"B?#)RVO+44_4YI 13_;U,+IPC676XF*E) M*Q2[K5QK7;++9F*
#A7&2EPU]WLR<['V)Z_7S=E-]$2]BY;>'RXQ&T)]BE@F M%W\/.) ^2NN[^920,(DHOG\1)2W "J]#'_+1=[DP^O:*
[%6);YKBC MZ+\P'4N7J;O6A^_GU1CQ5A@TS8&\":$:L2]?4I#A[FO51X+?+O_0 M=,,(M6TKHT7[?
*>P.1"R#E@@T"7F_H=X4%/_(8]'DCP_YDRZ-LV73_T@_MR'B2H50$;M."U5F *@WB<>%YKA=[6,OE&*4R]ZF*
AR#07(P+9]PL6(,,#)F# MT&]KNQ:.,;66$W146O[709W'YUY$,;7@[=13;S'X'MD'\EIMR$8J.U?
37)NRJ3K+WQ$1!0BWV>9%],HD5L"S6ID(V1F5L0=9; VR,>C;%<@LB<"L_ACTY4.JCVD &ZP]-O;L4I7'-M-
/COU!W3&0T_V).>=B'=^->;[%-9WT(X>-I?\K6HG6V-LRZ=:>;3MQUU=<8G MZ1=K46RK55MI6^XHCG)A.UN)?
RC>F@V%I6Q8B!R,CLNT""QV=@:!VSU(_SUG MF"F;5Z1M8B#?
*^DW65C6Y4ZT,#M'D!!.6NGZ$./9#N<#R&*6)YR,O\@('O.@=*+EPOE'S8>C$W4^0Z9ZVV;KDH*9#"M"@B?00D#;RJ#5*
MHKEL"BU$#"B-*6)']$$8C)&:,UL':4G3UIYT ;9AG&!*9G#RR) 68%S"0 M5GL-;):4?8S2HBJN ?FM8NL\ MY=?*
RRW#Q]5+]X5IN7=N^4")]B/W:1P)F0 MRW]B(Y]&7&ZN2>9'2K!@>.'[)I'P0WNE_N?6F]G/,IS9X\\/LZT:M0E*

*MY_*M5:KF*5G]G_SY]N#BWN.!FR8Q0U$H]PLX"5)$0A$BP=TX343H)B*#U8[] M(S.S(6F+*
]64+YR&MB.).XHZM)14KZ#&K8L]^# ;8XKI,AC MOI^&-!)>H*69(S1F5LN6K-.A][WT#8IE5&
3.6H323B[{OIC@*6)81!KHSVT]F=L/2$'4454>1-^?ZUY"ZWG MT9GUK4-1;NCD!$_YNCV%DK_^-_U;:'VHQY7-
F"8EHUCM7:U? *7X:':Z7P+ MGJ$-@CD^,AL>9GI"IKI9KGEU2UY5D$U-J\+I3${RD;Q^+=:;Q\LU_P]!I$\M M7-
\7@B&2\!3AF >(^HE<#!,",#(S7VDF9/N6%S\O (CD]-8-/ 8^7M2TZ7SV? MWN6;E;A/B,
XQ@1Y42SM1AH3E&#.D1>$+@FP"#*]1-*^R6]'+AU(TERMVQ*^GQ%5,S%-!$:8A REE,1RW2)2Z:33
MFX:19N1XD,C,"J?(-B&. V'M4.JP9":#QU;PPG2O#RH\?#R,63M^; 6[60 9
M]+HA$>1)3(,AY.$GEXHA3_+>"2)/CS6O#R']:?6O3__:YB]D51>?V%R1LGR5 M"V&SG
G/"P.:RC5=A.JH*E$_Q1E*0NR[21 0-_6AQ2$F]K"!^KB(5,_MB ,;\((0TP+4] =LBP7H).PD4O 0X>#"
(1MGQX2M0DU&H"W6@)BFN7@!"&TQ M]%5_T'\8GIR65\]%159_E,7V^7K-5EO5\D7EPLOM>+Z63F3;;+Y8J_!?N66;
MK;H5O>O">_5(R@=1W7MA(J3=D!MLN1] F/G2;TECAH+(EQ8FDFX+T;TF9HFE MV8-V#9=.S:;JH=
RZG0Y=?:L7CA'S-;*6-0-7UC#KWYFF:57-NE0O<.+@(8$ M_[N__U\P.7?A9D[N-P[64W 8S,Z]F&JW':,V*
M<\+B_B]CO<;LOQP]MWLID MUP_7Z\^]9---=K/=5+SVKOZV?]DV_-._-J^7/TM>_5&N-_QZ?5N6_U'N/EW-_M9#9C
C/KN,H@0.IR/U(_.=*37#\()U]WBI'791K^M:WO7Z@*#553LUQN3.2P
MVS(O2D<]6SEWCV3C$+G>*GP;TC3$57L4B5*ZK2-G;!;?Q[@I6>Q5P(S,HF_! MHNFR(DZC'$!S]HME"IXMF&X^X?
F3&1;#S-?Y1GR1SI6<5WY-#SE=B<;H?MD7 MG(F"C"9))A#!F:H_%S-$A-P+QIA[
7.]T(]A)6\UB,YL%QL64,V#&W#5$D.@-&,J'2I@T0PKLKG M 0.> &AC F4/]K-OE#OX9]K%,@?
](73S!@=&F*VI'[.55+6]NB]>:'OIXK8L M7O)*_D!6G9X,UU)7<[*Z9*S8]D#P0QW@4'THQ:&3L-1HLF9]6*W%]YGOQQX)
M4Q0SYB(:\P*_8+O%*PU[*(]"VY._/RN]B? MM(C8WSI8RQ U6W@^99E@FYOLTY^LCC"H6YXW:Y4N\R9EICYES-
E&\#:EYO@7 MG9'=T\K#&:9\HO?TLKI/@R@BE"1(8"Y7)T^$*/52@I+4CO]&9UO>3N\[AVZYA]\?,V* MY8N>L,0#]';
(^A3>_/+XB:,\DTX&2OUD?^])Q=7PUWE]EI;,7P#0HNO]+X!W M8/']A3@])P>G.=K]=-O977%@+A-
A1)'+L8]PZLK%DT9";O(\GK@"4Y$$\"2; M 6K+9-&TAZH=ZB9Y,4,"@R2^6!"#46;+]03F.EN>@F@U*V6(UCNDG4S-[L\K
MF7KHS-YB1Q,WG;1NUOL^6G4;K;^M"U]LJZH6C_Y69@E=>FYL/K;H[7 M*Y7ETL8;?9\G5/ (I:['$79%A$@0A2AA
661YW11!"K],#O'M> MRUZ=FH-S^Y+-]A8U#X!^I7<#/#TZ[{68-T";6U2VFZ;-QN_[-%J;6_R#S=EF
M)VRV('P3&^5PUB$B+OB'U[]5ZF2NC?NL'R[9)G^IN=YW3X\2E4(N%$294)X/-6%4.
LS&RRKRY__-7Y_.7FWW\XG[_??'4^7W^[_'9U M_>T/Y_+J[OKOUW?7GWYH%N,Z0\QZ)GA>X<%LJN2EV>SON%&F]3?
%D).O?W?V M/#D'IF9I<&\N$TO&TX"!1:VAN8#>FK)1L]G.A,PS)! L8*]G1$T MEMR9/@J+^BLC$-\Z)&-
##0^MVU)DMZ+\\2B-NM]JL?O,CWS?#5/D)J&+L$NE M_B4A1XF+LP23*,H8]!-@+Y6YLY,4C7VI->=9W>-N"I15B@7G-
[FN\6*U4EG]MZH_U;W\'"NKV2D_SG/5"D/2/0XALC6:6 OC64/Z,9@ MGIR9C0XVT]D?
[%'P[4K<9#\>I3FX^731TW==._^Q@3006)4803@7#L>8AF
MW$=QBKU8,"_.@A2BNF/$9M;@'6GEFM;$D2JD[2CR;6-*X*(Z*C@]K;4E#ICR M-NCOM-7<'EB4-
'B6U]"+K@'ZKSUK/S%G[Z+.D6@KR0ZSSHOQ6;$35[2IP M3X7'@Y +1'@<(YRP"!'LNBA*I%]-
X\S#J6N_^M$X4S.;"7B=EY9=I^'7J1EV MCAICS%%^9^+-C=N?]WH?,#OU_Y-7,4\FID*(NG)T$9)I E*
MOV!1)#W9F)5%TIS;M,44DW-7X]-H_GV];I.V=]7Y[R/"/8[# D1!PA[G"/J M1QRY)&)BVD8)%H-
;K4ISKQ@[>@[O^TX^%T%67=,[+I*0)M038E1S\&U*AS8 MZG&N7 S:5&EBM=:Q:HK>PLVK-.&?]K'2?
1!^#%8?/MP]/7Q=/^?*&.V[V.N> MUPOK[E#)$/K'4,/PI\^9K"""]>P8:+E+E0PX M-0>6CH(F$1]=]0S/NMAASB2P[FG-]&
#M>/_O"MN1:$J?GU>PY6N__&Y56Y_MD\NY*YS;3S=U)3NQKO8>;+%9%[I;B#$Q:"C?^1(_JIXF^#G4^6C7G
S1+F>M',2(>5668/\E@H7(37&<9 D5P@,EA@[0 M6?!,94?WW,.48SE!SU&,T<,T51OL&6J,.')?W##2I)
MRA7WDFVV9+5ZO24Y_WM5WR=J<\[!;JOF=#/K9-=O$@3ZJI@A\].PL"-4'[T-S M;:19@US?=PDA#&5^ZB,LTA2E L?
R__P@$0D-PL0T">(MK25S(!1M=>N@O<9U M9@K$B=2@*_=9LH!9@+:G9-\+XHYTR"&L-
G/@CBA]%Y)$$.01W(@!A\QT^G. M-;+VBO"]+U3*0B10%+@$81JI=D[8192+,_HS&@OAWV^*#5GIJ?(I"9 &[PEI M?[I?
BO5#D[C$!=U<."M57FM7[KQ,YRS6,!WND9*>ZIZ'':;Q'5H7NVOX]A1U M&(DE_>PAL*A:#@-\]XTC(^'^]=^KS?
KAXZ;W*L#E6J[DAQL!L 5>.*9U]6_MBZI.6U>MW[5NP;@++G]OKK>|N1"C[Y+#I3OMG,\J6)C*6Y2IY6B9L9",?'DX
MM<6\>F-!=/U[\TG,O(*V\"9,,U736-7G2:4GD&8^2@EE"!,>"H(S+PX$Q!,P MJ)$*7_WOU",,,:AB"BHW.G==4-
LU.V53#'RU5:[2LY4E3\\DGYC_]5 M!T8^_:EB).*;W%[?_12K%_&U6&\>]WL2)H0&F"(>IQ["42;WPFD4(C_@@>!>
M%@<1J'?<>>S,O*Q_DBO0$ZG7E@XOCFB8N7!\U_.M=130D;Z>^BXG4YC:CW8A MN' 4/W41Q"Z3%\T"?
K.VF*AE1S[SMRS08>97:68 $!R@S0%D5O UB?]'E&6> M2Q=#&H9BK>4B#SPUG\HTU)P=.6 [MR&0VAGIYX(U2RY_
]I*7O@8DL$4[]Z' MELK6'N.XDW@].LS,1;@EKW7&P5UQR>1.JQ2W9?$LRLWKK7Q-&TE*[;^>U9![
MZOJHAUD:XOMUG=/_[_2]_GT.M+[&M/D:3_C0 M/S(BS[GRO.N5G^>;;0FM?
0F0]=XB;UE$1M9IQX.S*9R6"V?'QH53,]}4.-[S M8F\1A^.WM& #"""^Z,,,%\G8A-ICAC,JYG4CCH47DO9N&'HG2!"5!)
U*YH5(_M;M)3%&8DS0*6,2*TNA!-DYK_&/XI;S.WZGKO]3V8!Q6F7YU50+=?;GI&PXXT M8$:B.4_"N ?
R%JNFCL*S6;)W'Y"R]?+'07<6RQW_EXC/^SY+]8J_;-*N#Z
M^G$K[HJ_Y\6J=OENLK\63^)*7>8H7[^0GY=/&]T0/W3>F=6Y9/PK5#+_MWIXE%9=63#DM5XYDZT)M9;])4W5NZ&Y-
Z(+&J2QH\",U+)_QL5T;Q105\'&!X+#79WZBG6B MS7?Q+%_N(ZG$Y7;S6)1MF&U?4Q=SC$,>9,@3D8GKM#*
M4(>3GEDYOQ>K55:4]5W#NA:0JM]U8$GM8!]*\J0=8H,*=C+$.*.X@*Y[IR1G MDR/7$=,1+U9K$YN+8#"2!YUOJ2"?
(>'U&L"OKQ1/6)4T:"N1&B'B5I& D_3K3:6(P1F=DF*+*.HNL<"&L;@&') M3*JZ%;PPI>Z#"C]7&/D:=_\7K& W.V$
O6Z(W9K$-&BAAI](M$7)TR1)*/8B1!+A(QR$_M3.XW18R\@.(X"_T@PUH%)W4)SFR$]W2/VK@8E7"?
%)V>6;0I$.!FTD@6\$M7 MF@!MW;R:(K?L]2M-\"=WL'2?,^W,\"+66U'=)Y2&. H]Q'W549R'":)QB6
M)0DC/,9N![J]MYMX[HA12P;:=*%%K:>9)EA@&C@)PZ"?PC'/UIHHM-,NW#GA M&,QINX0W?X^*G^M[QF(WSCR*
(EZWB0LS M1+,P1,+W. E"$62NUGG'"(V95:2AZK1D+QQ%6(K%4:3UU&9,/N,:9 DU3)F, M &LKF :DD;,/^72C9O*'@W:-
S;F(HFF VNF5YNR#AM=_IG+ M58Q83'VNG4>6IC2 8&"U[-A+)96MAX"BZYQPP#?KG8C(\%'!]_$YKM04['-5NTI
MKQY)^2 =HSB+L!\2[6Z]L0AV_0 EZB>?!['+ L'#V 5D#P]3TOHBS\X25CT]
MCZ@[+7GM]/J0H";/$<[!;=R_=!ZLVN<'%C";G1XT"4D.J^EQASS('5*U.32' MRM?.YE&H-
E!YP9U,.@5YDVC7W%$6^UMEK*@VTG40?^Z*Y]ZJE->]Z5+[1-:D2?EHDKNE
M'-92[H](ZTS/BA7/XH@+^0Q9.Z)>SB\4(T]JZO(P0)*3)/A6W?[ZB_.5O"J!
M29$(=>].B5K.5DKONY3XFOAH49,BG>J(O/D*.X)7L)Z:6M_R^6%B!,$R*]6T$099P&!&>^KQ?4L<70W)O0HY9
U71/(#D$VM/_VKO1 MW-HN*''@1O@L85NN:FE;7+;VVN>RL^S.W)+P3O;QMN8ULZ+2"Y0TBR?QI:BJ
M^S2*B)TB^Z]^BT7%(*>BDS%Q29G&0AICSFR+WNW/Y1ERW9/3RGX9\6!)33N7B&D;9E HA M(2(4]_^+B?!YP#T_O)
<[1EK,+J$NE5_T:]);[HPE\=G?5Y@!>F7F"65IGC MN1==,GIAO;7__8-,[F#5-WXNR[(^&]"'^?-5]:F;[TW,IZ=\@-Z^.
(ZKS'G8 M8/K2=]?*UL'', [#JU5'4RUXIZH/PO%E]MX1<#VX?7FN:Q.#NP.E0LQ# =Z0';E/-VK-?O'T1EI#&G MLRVF-(-
NGHS/,BP)K=):%'&4T3A'V56)8&$2(NP&-_M/2&24(".X/O)S*QQB]AS1-6LJOZ
C/2Q3H2:WN\=%F"OJA/92K2P!5>7UW4/E#+N=!2A(A-UR!0)AAN35E]8]XE/_T M2[E'?
5!F]@"=F55T1]7ID#5*EQD2DYZ26@ /TU(3W&_UG4!E24^_]"RJJ!-0 MWVKJU'"X&
[]ODZWZU7WZDZT>_DY6WY]+52S[Q_;IJ7Q5?7.JS?J.KF"U]>$S MSZRSQ]7>.QT15FI;3$H.Y",=2T',,C+$!U5\/
M%M@#Z&7?TKI_//>B]WTOK+=K?/\@^,K^\87SZJ:\V3R6G\KU0W7+;]9[#?ZV M4;__67W/5DRI]UF5;>-+DJ3-
CH62,V>5/"2<['F=?YBDZ7S:7=]4G=LE&O0 M\5]V+C;-
P)]YI1:O;-44E9>K5],]XVC]4FE_9MUW;+RF:9]AX3<$LR)+OQS+_M?
H9%V1HY'C;H+^:)6!16US6Q.:WI=;S/^4I\V]8*R;CK16G"4$A=Z;J0V$4T M]AF*@R#)&/:(3[1]GO5-/K>GTMQ'4_2L;*

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|%IG&=1=N^KZ]2S+?$XB:0KB@"([X6-]F55/Q\|YFP.A3X1:SE!.VIMN X3MPX06[] MAW+ISC B*8]01+TX\$3 L0L]{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}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l;$P^Y\;_(&YU=N-/KE9H;Z_M!-= ((%!QDL.O6KBP0NM"OE"4$O-OA?&BD7[,RMKPF!W/C8!@\.K-+T<_MCB]_G4[^G'_Y,+FZ=N/O_TFESLX[TPZ!Y[)2\M 9LE%=Q*+RRO_(>5B_=G_M5M:$Q?Y\;0(>YU_2:'1'/4(XN"30;TZA/!N@MC.Z@#M1YES@T1I10TD\6K,_ MV[*JCMB5BTU@8'TXUGF5DDF0O?8E2<6_H]1_H%EJA9C6;K\'^4HQ<-TZ1]IQ MN1$_=!EY^YRFPTE(E*!+$D/!&=,D(OY]#^F2Y_MC0!@VP7_[KQK1!LL@RDNQ2",@^2S1;H%_R,4!T.4<\P3ZY-

_VZ@4)>W?&?6 M-2+R?[]Q4_S$T?>S=#V9S@?<>9LT4T!9456X!W#$><@Z12$)8C?M]W3QPL*; M >$=I.*
[MP]!&,+&\N@{'\:.;IT$6&4G!#;@8<0-42/ N$4@\,ID DUS5,198X2N M6*F\&@^9#DCBQL0OS/GN6EMT$@+|91{()H*
*QZ.[DD#*SC$;4<$H?>%;/H=!M:6$* 626S"BD%4B-M8O7]FZ55-1SA*
MK,;:EB#R>3;N]'_&EXOC"=TNHFTZ'D;20P(H3.ZWXR#)-%+$RT3L4;>W;]U M-X-'PW'/2FSM&1Q%ZQU,DUO0K7@D-*
*AI$<2[-'?#R Z^B VLM)<+]G/:,@3}> M;3, -!SHW)EU/8O\>%)>:;],QG=1F,R\$GBS@14F%UV6P?I,0#&&%Z'3*NR9*
*M3O5\Q+.Q9_!=35W)VSK]?^XT M1^@2#T8'#9Q2'BA1.K Z!__Q]IMAH.&@Y-ZL;,(=N*T/63[#%4BC#&YF@Y I*
*MI]8;T)0BI*DDX+D5H(P4(KMBU%:I_EZY^F;0:#X&68&UC;R /R]/]LX:2[D# M[HTK1BX'$S-N(7 33=3""'7PZ.#TX^')*
*[_=GAXI1_FKIO9LV/FS0PNG;L>+$+1Y38YS9^&8S<.0S?Z/%FF5=U#D%B>!1]> M(*G()1#]#FO@;"82= F";NN<#:*
[F5\@Y';1Y3%,H_GL[CL/YW$;NG95-7=K M',QF:3Z[WZ5Q)M*H4#TJA@>-4 O&>P%).$>C3R3K=7IFEUT^I:"?!E>=(>%.
*M&55@=X_WTE/J;V_9^TWD%$+V+("/M-2D9 ?6> Z!&6:YMI*R=2&/W3'SC)!^*
MH;./9%>"9!|\VMX"5$$I2T>PLA33\6EH,GJ3Y71.%R"TZ;Y[A#>PS"(9_&!T) MN,RDRU%R3;JKF37TM("-|
COX8^^%HE.'R7C!F$>;&E M,F/) M O4<>>0#!2^E!"JLYS9FG]>W;:24A_31,Z0XI M^W.[_<@\8J0*= MZD)H0+*
<4,WTV+XIQ=C0^R'DX&KIYFIW?^-DP#MUTF&:XV4E8?!?UZ'^?#,?S MO^&OWZ (%TI"H)&)2I4$&J63RGG"V+J-*
*Q5Y]I9X);L(LJ0?&M MQ-8 1D_G7]+T]LA-QN$N8!6BT[XD %&-#@(1"O K"S%&:J@,939)9>RM)*2? MWG0=8&I_-C>*
E27] R,Y$0Y-.ADH!9%9!,O+'XQ$0R,-)]PK&-_= >NG"UUG MKPU;,,(!7^MXZ#S]POEPH?46;?2^3$;()%EQ .;?[UD3
^%&%<,_2G0!HM90 M> 4\&NN3E@*US65V 4@F]+6KP_6^5MG)R)J0/,|VM?ST >Z%3XI$4 ;*O#2 M3:6(+7*P0?#*
*J%6>K2LHW8WF&D)67,>DO<7W@GW8/I;4!G>H.K_L"C M@="<,HYG*60TY(17&8]6D,"TMMY(9:VL;AR]1$R_EUUW*
K_^@8P]/%VV;/T M-8UO[D\"8;;,,RBA_(C7?S2X"XLNJN:&-@C"/&6U2ABD00)I37H)" 9TI-T"4S>UTV^T[>
M^U]^HU2=@2EBD)H %)+?R2MWHOU/K]_^C10SLM[,0-3 EN&,N:$#=)\]LLUV\DL3)F.N-S*
*XIHE6'G\$)F]$"SU@P$\@6,I12D53R$ M@.S*ZVT\Z[CXS1C3;_^G:;\7Z%D*4D_'E19I>E6/Q.,YN#&.*46]!Q DXA&P*
*MR@#*74C%#C<;-U0;02DJ:L:D[!-'^(FA "RW>:Q[QZ]%.O'!"X+T+#)E1ZETM M^)0C)$4T5R5#RE2WKE^DIAG+NCM*
51)%"Z!:[3$\VI#%.UIQEB H0E#=YA+[MSZ9T8Q$!53!WVY80>PMKNT.(515,
TA;:0D^UL:/!BFZ$NTE92*E@"9$<&)#X$VB&"/9-,JO=T>5,451)%O]=8N7M+H>5D MA#^\7 R?3[/Y[^F__LN-A^.TW->*
HZ$G[@.DY#?U&+3N"SEZ,;@ H9VGN4(G&0S=% M97HY.PCAYNIFY.8IHJ,P#,/Y('F1:4+SKK1N1NA+C]"W!#
(ZFHS'*6I_6S[M.E7]1BP[E-E8>Q1$G=9U]R5XW:WAX6/B0<&B?F2QK/AU[3T08\GLU*H=9K1*
M_QR(Z'AT!KU,4S)GN$9GPI" /BC7P6;-K:L=N]R2Q)[F%;^I8=ZEU!K0>C]R M;1#QD$:="03F,&E4B'Q3(@/-B@6:O';Y!
*M.6MH &3D1YG=2_-:C)P+4*BD3VLWN^#7>>PV9'-#5Q>']SL M"R*]_*<@_*L;E1KC@_D'-YU^1[-*
QZ8<$R55,OI0-.P?"DW+[!P74RJBH#4&Q MV@G@&Q'6[PM=Y["J+YSWW\?X\T(T7])\&-QH]G1?
E;L:/UQ]C7L+3H;HPE"E5 99MBHB M.MG6I 1<$'1O\,:7U=/QGE+0=Z"],A)^M-
*9W9G>/M^1L.A^1F\U.\\)/7+#$BR!DEAY29!)5)#?@">K)XA,0X4.@J7:A M]HO$]/VZMK?*J,ON!G#SF/Y;Y O<PD@R46?*
*81Y[[0?KQM RSU?T,-(1_C7V8)DRQ- 9A#%2DD^GN.H<:EPDC/ M0Z*2K1LCMY=ZN:>BD;AR1;VR&X,;@,C!:#3YLR3P?*
IL/TYN_#S?C'[L^C](.MT4H?!(5H#)XC30BXH"WR+"OC0K9956\ L1%EC2B>'>7__)FKOC!:@-C3%F,Y
M2J=9DJ!088)@D8%7I95@2=LDINRA=J71#I.!^NV6M8^?O >[FP'+\W)B'TC@ MRA;U7,I32G:#+0-FW?&RM2JS?OZ?
63?1QUU(J(&%-6:G7@K M/)Y+]!,1!,@,@8N!P',Z&@T21&=A;;2]OMOWK>5]#=/V]]&%UHM<)G.=? MD,6STYOY;.*
[&I1/&0 LOG X$C/6HI"U!VS+G -023[/(G]<.LV9_H=OV[N. MU%_.H-U/ . IH?3\ O__?*
*#DXOSTT^GGP[.#BR^:>W)KZ^MTMGSZ%;;J_0R MNLQ*O+]>'Q1=HLHY[X#*,J7(6@8FEUPSEZFT(<<-*
*@_Y;G.$72*G]_NDB8289 M<$H5DY$&L"QJL$30++UVU/^?_/Y90]ZO/7ENP>&>'[ON*3\/:>RFP\DB&FM,*
M1B\"]7)098H.2;B![#(H%Y(A7GA%-@H^OO+@M7+QOB^KW24YJ9PULO$1 ?X^B%80Z M]+7@!1NI@M.$9+P"E\!19*
M 5I9R](@/N;7.W5LME8C%\R.PIQTR=D&M,E],Z2';J$:!I2XYG2AXIB@(CINQ M HTTPQ5%VRRE3&M;K"O(:$2?
[(>;6FQN "EW%?VWTV4'WCLN(T_76D[8VAI M>5Q>]:1$%9MTDJ1VYOHS$A])$-=!R#[L;0(==
[C^A)Q:QIU^3_,OD_AHP-I MJ:1C0)6HK4O%UZ=78]0TNQ#!1T=%RP.QGBTSR*Q2@AKDA.UC9NU%#52:57)S]G'_'[]*
*M]_/]'D@#KH@,DA'@//MR@C08 M*15DQ;C)D2AC7V]^7Y.B?ELGUO/)>I-2 WKN?D^WA^N7-$YY.!^@3E8B4 G!*
M!8D7N^" OH0 RB3U047C;>W'T!=(Z;>_8B=6U7[L;@8U=\;A]A.#O[$<,/%Y M,EW(:CZ?#OW-O,35+B8OG1UKHE=)
F1@]AOBG6QDWZ[M.7;]"?0B[+8Z-?"$!]LR KA(I60\9# L.9#4-3WCE->.V:Q9:>&[AH25<;6 MCEQM_HTSP140/W\),-*
#M"^-"HPBU9G""'7+SY2Q4 DT]4H;IY6MWD/T"0&;@>>>]!-MW MYVT#VNGU, MSFO[B9L.P2,,:$..3$4]"-3]"\)R
9:QX+8X&FYAUHGX8?BL2 M-P/7^XG3=R>?!O32Q^$L+/>4XOV6GNYYY; 9Q]KU+RL)V0QH[^4587]>-
PB8C\/1S3S%@5129I\)]%0& MCRL3P1O\PUI/L_*XFU3[>$%4C8#S7MY.JC![P9@T>@(^6WPP4[R75I$LWY-8[2Y1P?CM
M>!"OAN-A]969#[_>OY\KP5RR$B^_F,2B_!RL+YD[D1B!S%)&UWYFV8RRS9(U MWTMLNP-I-("Q@ZORQO-
?"ZFARLQF M!HDE:HW$[87:FF@]19MAZKU$M"MROP4L%:J/K]{=<+KH+W:;_)ZL2YQ0#3(P MA2C;#%_O,Z9=43+-
H>Z%>/UMK&$9V#0QAQ!L M!&9C4<7>HS>!C V)"",U])ZP?;61&Z&O_<2F.Y61@V*
*L$+D_#9+)Y(Q0S/<:\^S,X.NBR\5.7&T #4]C<\Y'8SCQ8,O3CZ!6XK'B M&6(IK[?*J;QKUZ9O' ?LS%#K A>[|*
*[MHPXN:CI39X!3%(7LP^4CQ>9)$5*6N'_M_UM]/'+%^&=GUDPG/9;J2Z0!]?-*%(XX+1Q/!F0HI8ZZ%#U&/#\Y(K]4HIGG*
*MZCV8]X^!=O;"WP6N*D[@!3RMCLQ)3C--40&7'AF4;0:?F0=*E&/H8TCZO+U* MGW'0SA(!.L'/_AQ_%QUZG(V2,=2I?*
*C%!O.A4GZ@N6N,Z]8/\&[EZ]U5U'6AVFHP MO8';\%'M*7.+)IT2U;%DI;PF@74V *5;X1'0QH?:I9G;5O2^]Z#SC]QM0*%LM7S)JI."92PM2>-P@CQD,-QX"=<(Y)D/@M3/Y.RKK?5?QZVX%M3T2[1*)XW2) MNXP=5/=ZSD24D0/3OH3H97G-*
0_*9"URCXVI#K)W+LD-U[[L=>_,X 8TU>KR M*!VE,EXI()R6(5,J@HGHD=H<@U E;=G4OLE:+$7K BW[,*
[P!H^>E^B@N+#.) M9J QZ^*0.KRP<1M94D9=L,)7?V!MLQ[M+9"S"]/?Z\";#Z>_?SX[_U_Y^AO MAX<'9R=')
[]V.OOFE07?9 S.-INN-!'GP^0]_,%_;'AUW3?=G.1%W2/X>29 M- R-;\]MJ6GA 5!U!9!&<1\I):&+"5>OD55[4HZ2*MM,*
*%U.5UJG:W $#;X< M%8G6$:)9]>J6AB;EU,;!:U-SMN!VW]-15DX"X8$(&U@_J[TH_=,%E&9[8*WB*
MVDA)_/\M4W.VD>2K4W.V86O?N'AQIDM,CK!RY^?_%0C)=.G&($DQ:W71*"(_M:V#CO4S-V4JH&TW-*
*V8;##5C/*Q)^'5>*6$: !I-P!\2"C3Z#,2$Q+:AVN;9; MWOK4G!T4224&-*
P"1EX+C2=)G%)0OCP5RU+PR9,$ZGTDNB34R=]5^WN]2+QA MSOQ6$M[P+6(;=C>#FNH]5@/)Z$,.!=&[C*
J;)>2"2D""\-[$&3UR>X]-M1] MRT+,_3';J[;@/PBGV:%M[+@RV2;AI?C#S=(USA\OYBZ\0P=E*)<5Q\-5H**
*M/_[OF^6@B>43=ZDLY"XSF7.INTFI9%IXP-..DM%)6(VLB*ZVHNUH*\U-)MH' M]"V(NW'4?R[?*
*6.QY\5N?)^BNI_EPFI8[7EQLGT?(C55\D"(G+]")MY*4UPLC MP3GDB,HIE,Y&D=#:,&0]=[.6Y.4I=X?[-!+*
[O<^;%F^#_86\V$]H7_RU*U>9 M4N!IY!"((ZRY*4U=(7,W433P*KIN4V4[-_9M\6Y 1R"6*LB< M\?Q8#V6&(OIQ>*
MDPQ)4N:$\-Q5SP/:A[FAC1U!:_^=!-& QM]J;8HG+@1C V3'&%[Z&K4Q:F!(MQ@CF,U51U4[OJ-*
*[0YBV[0]9STRL*I@$WY%&"IJ,DD>0D&&8)"!$$H"+F" 22 M64R&YU_[\V/+W->W[!RY#V!V9&H#<-*
@^F=)9PKR7N$$92ZXW2V#P^@9IF7;< MQ&A=I]FG[;)>W[=Y#[HZE9&K8%PD(F(I*2,>U^&? 9-P,5R]4M" IX@AMOI*
M/]WUO3R3[,[;!H#Q2 2:+D,R ,5,U).%/]EEA"(E#,>K4PDU$[NV?*RZNP1 MHNO$GAVYW(%O88S.SVD>.V,RDI*
*8(Z5$1,$K&41N+0I!L%1FAW^Y\UP_OT>VY1*3Z-+(%W2((S7B'+.2[]4 M51($=72U'ZHW(JQR&8(V1ML@*1#O?*
M33&E6T1P?,F1",D$QQ M6GLA.9Y-(=6#,P5#N0PBBG@F9!5Y_UM(Z@?N.S[>%3C_L-0.DL MS9$?=*
[5PM_N(DC'C0\:2)!E^A"GX+@E>+='HHF5W.7:K\^K>DW9%H?/!7X MW0!J#D*XN;H9E2#52[D_=\?!2^*84(*
*WN"N]%24J5247LZR,)KA)5[WI\J;$_M]1O;[$_Q=2*5!N"VXM4U2\:32QQ*KWO<@2=@98XE;3&P*(RUV7?EBATW6=]9*
MQ?_:C<%-0.1Y-&.@61(DX26!XG]R4E'"C2/U0SW,J&G&W=I3K M#S#9B\D[P^0Z38>3B)N9SCM(.:%1BA
9&O^F]%85RH_-40+A2+MP--ENG^$:_MT2)U(+([:W=&Q]^%1\P2U\"7129PG_+/CF*5W>VLG86 MW?*
*WBS97Q[0.3W5C:[XR(H]GLQHU#FN2P"$3-RJUZ,T:^IZOKT>1{2M>EN'!@_MK)-9B#$.9,EE^Z^!/-XV?)M. 9**)S 14*
*M&< CHHC@1)E&'K4*CEB>0VU'?]RFZN^V]ML?@.QM0/4A\+HV<7DA7CIHN6F M=[,4RS6/=_Q"O&<)_8K9<)*

*[.T_3K,*0E]\Y2F%R.%Y^RX-] N>!R*>10A].. MSWC]^ZA)Z2&M7 XY^NIH{GI/S54$[@/YI@#0@.FWPG-*
&'RAE&S+$8!5ZS]QD M8O\Z5$($(Q:,PU,3K-1"(XN8K3W([@D![14,5HEW;,W; M=IR#!>[/TO7--'PIUM\//M'
INR#D!:OZ< 0\#:!,R)!TDY$@IL.JI.7FW5$ M]3P.J@O=4TT&M;'UUJ4)!^>_?3H^_7NW\P]^7.1MR@Y>V5S](H.BFCZ-
)G_.M[O/)N54Y]8P7V+UL)(,L>0E4&4,452782W=U1;\0$_EDH+L'/7$9=R=*HUM MT-*
*&PV45@,@HA7(]UGX_;+2D8#_)OU))L V;&[""'MAR-W'V *VYK\/Y,,W. MT^5BB$W)>4XD*IDX 1,4NA$,+3S/E*
=%G4X)]4NVW9V-M:0U JL=I/\2D"] MH@6$+4E?L:G;7#)]F1*)$LC(-!"1X14>2\A,X&9PGPG-QMK0>H6F1C!5$PC/*
*MP593*NV@;'6?K=MT0L$+X0J/)-6++ELKV]]:?;DB[:+4(#]{M8]]-06\W1@.9:B&,)S2HZ@'SUXCJ.7?K M#3!622*
M(.Q'%QH/!)5&62"IO[2',#0DCU+64A9!.UM_3>8IK.(]]A9NS&X M 8BQ'AE&B5.4*
M$^*M.N)&G@21@H'A)24[XM\LD1&RI]*A M6#:>>QYD@A4LGC&83A*3ZH$+B;;\CQ[D20R PSA MA>?1@W6>
*EXIW](M6I([NLS^JK2/?A/VWQCKO0.A 47],>'*8;@0,?Y]E&YG M*1U_MD#_Z'G^ M$%]:E W +E^[^5F<-*
*:9A:I0=;].)O'/X6B$FSI"V8XOAWZ4%ELYNKIV MPVEA X :XRPGN" M+OO2&&7K&8M4:PBQS)35DJ--P02DH*Q.7M*
HJM>/KB>IWP+"YD!94X -X'%1 MC;V"5W<)/_<1W@$5R8@H."A3IF$4.\27P7(LVF 4EYFF3FKC-R&NWZ+"YC#: MC5
;0"LR=%ILDX]I^=]'++PM/;OGGQ%6E3DM8")!_K'2^,\X6KK_:8'_3Z6K MK4@WIZ[?BL#F\-
J16)L$[$$(DQOD//([#;\N7F:=-8G+"%:6]*]E087E -G MO;>41^YB[8?&3>CJ-R[4%29>A=Z>*
*NH_0%^:)3S;U7#\Q]BC)5T""'N,%TQ[M M+F;GB2\MXUQAGS,$'"4&@O$TN"2,?%YQO:H;Q18K]AOMZ1A877*_?VR]S,2C*
M\5=D_F2=\) T91C=!8\9:7;,TW@-D-BIH7;O6:W/J^G7QWS@5N".A-:!X7]A9";'-7F D%4$1 M/-:@++,@+,G%.LJ0*=?*
*(RQRRKFWV;D]E(R6*QUW6C]424@-:\;/[?M=Z-?SG MS7";<*]XN.;?/X_<>([&>FDW=*
[UXV@])X_\1#4Z4J]I)0O$R.EA63G",CB?6A M=]NMS:EKLOZL&DZ>UY]U([1VPO2XGY!27-0ZG;M1.LTO[U!
(5/R&"]!.J9+$ M[,GST+:0P)3/#]A=E;D-=DD5IGN.Q(;"WHR6=;FYWF7VYF>,G,9@%.8FFX?'8BV7A,E(!>T31F' PW%*
((E0HMH6#"U&^OL2&J3)69O MA=0NQ-D":I]?%,OFL;^G^9=)7/)V\?,!\Y$+KA-(8TO2@!!@(_J31CHOLA6$ MT-
J59)O2UJ2_\V8W>PV!-72O/]_>W:%+R^+EPNK;G\2:!],9JBO<"YQYO"$HC
M^&@D.]Q>S8DECO'Y!KZ^GWG[!N7M037#C8WY^C*N&]2/*>@(A#+2\T]FC*>_MHYOIH^1:L\RLKQT*W8_B?*
*M].WQB_;RCT;>!Y1HJFYL&VT'(OI:0&M"*CV,7QY/Q)9K 5X5W,S3#*
*MD9HR;\@'&4ETH#47((*08!)5$#)1PF1)\"X'VVY8(.?I8U=^-E#[-BZ%)%Y/#VTG2 MLP'5-.2,IFYR)5G*<*
;E(0&RM<$X2;G;H"9RX^6:C)G7QEEG_&_@OOU\K]H? MQM8;YRUQI?.'C[B%Q
*PXDQ+N@UJBD'G$57_H_I&,)L/>7:NP7<70$}))0W3X,_M<4-383'S?G%,!E$P]KA#+1LR+3V,B[=O U"]!3%*H,O?*
U4/+RU0U&9[N&F>5 MA-2_48>Z>5'E<<^P^WE?@ZB\ISY'R%)$-IX,,)%(#D883ECAJA7;\(7/KS) M4' ']UX-*
WC:@FS9GV,I7&6ZB33P(\,8Y$))G,-X(T-&AA:BT)?Z-TK0WI+C) M.'!7.NT-A?NN8L.#F'A2/J/^#A0/>,*
<'',:E+""'>9DU];7]U[,0 MW4IH#<#Q,.<4YJ?Y\!N:$N/+=(;7^NFX;+;\?TDJ^NI&2^<<^3@,>.DO4CC&
M\>DW'OWFT3B,;HKC_G$XNY[,W.C7Z>3F&O_%"V^-BK!LJ2N502J#B-0C[V* MG)0F-K(D7>V$B/YWW;_C7?
*DII7]V;@6B!@R:O7BS'*G]8Y7K+<<>2V$I&;PC MN2-EE+L,$>_(H@5117F@0B>?*
*HN/!U+Y)WG:'_08;*A^GAL'1P(WUIFI%J$"_M9PZ2BJR,N=3@*9J9D5AB?3K6S]PMEF<_W&CEHZ-)U! MXKU;:-*
*MJ$VV"9,(XL$G'DD8GP*K,@?C^@-D^GU7\/D:OGI MOQR<'YV??OIT='}P\N'HX/C\XN#B\/?#DXO/9X?G^)^#BZ/3DZ=[F*
VOKD?/_M^OD_?X?:[&-_?B#Z^79N/_T'[-380/HV3V,4^%_V',]Y;&N)0/D\&0W#X\BK MX@J11S5(48"H] (3N
E+&51RYA#[78D+U.S]]B2Z:4;W\ZK^H"PQX^/=[,L M/C\2VVF^/3EN='}%R=G-)G=3$O-\/GP'0*/VR.'!V+&LPOA&*
MM<:OIZSXVNNYOM^RY%>C3RV(G#O\=SILMB;9^FZ M3.%%)_]NXYI9%Q6Q()AE^(?':
*[VTC)4V>Z:"D,+63LIXB99^U4]W>/EA]G8-_M632JDCX>_G*QO>Y9_*L:2N;'Y2MIDX_)SU? @%*G@K8<[R*!]Y-*
&B3E)'#"F M9$![6092^]EX-25=R/+SV>&GP[.SPX_G%ZK*P!'\[/?Z(M1N'AO_]Q=/$?VPM\\X^N@8H=-
*U().HML_5+BA@=OV;SK9#)_@% DI0^QE^"R M%.70YY*A78J1'.5)F*:E1JL%%&M_I9& MJ%HO2I[*S?*
3[11F\\@+\M)%240I(YVF+VD\&WY-C[K] M/]VNYEP()C,H[DB9*[_EB\Y#/AT2,"=Q[T%X\$FA?8A\U2K]%W,M5O';D-?*
WUUC.L-D9T)] (#W3Q%+GI6M M3<;E9>+@VW V4-H0DY,_(YDN34D2>%'FQW)+A/>61:F]&R=K".K] :DC'#Q7
M@M6$TL38RF>[^#BY-CQRQ_=I,9K0Z/_/L&7$M7#9@%-)_^=)2YNU1TW?SQUY
*M3V/O3WQOH\0Z%5T#T%QM<#R$9AYL4NZ3,2[Y,NH5O:F0 S@:+2C<;-:\O*76 MMMLV)J[O^K3N'(E.Q--*
HV+4$M(XN2O[7^2\=7)Q=/+KXUY9=I'&XS')^%=*5#T/G 0=-%QP2\(%V@";_* MJ!@E(7-*
*;^[!N1>#>;;N;+/8H$I29SDY0($Q39$?FX#35D%FRAF>G3?W"J*TH M[-=\ZPY;/^3L=B>W1I7:IX.CL[\='/]Q^/OAP?D?*
9XOTUAW4V>J/J:'(-B"P MD@K]Y(;3O[G1S:/[ZR$S2X3@:40I1U$F?ZB@P(=2L2:5T#:[;&7MAIOKZ-E7
M0:WZ[$?)CU9)0\N4.+XLO[;2VM!BD0)6J-,TMH%9VL)ZE?]5,/%.&]WUE3IBG4*4IY[J(,=A/:>@YOU4;/JE*FZB)]*
M5&?]\L?YTRAE9]2I2;I5?(JJ:2[%'$TB?UPO*Q* MNP>3HU21:"SH;-"R+G\X6\"4)$'+EQ&>:I?1K-G7Q6TXK-7F?*
LD>9,,-8#6 M?9FP91P8(? /)FTV>'XX]9V_N!EE_;]?:DAYKG8Z$$OC2N?\\-=B>#PR-^YX M<)O/.!SGR?
1JL5R)M,UVUTS;+U53?>VYT5IFUTM)HLEK&PDC9?Z.!820![J] M!KS%K,REUL77?N#8+&%WG[2=YRL Z+&_HQJ33@
*MHWC-%'(,EH[:*0'B]@9V7$W.Z$583+SJW;['/#OSM6ZPGG@]!ET0H MIBKUR#RO'5A"B*3)Y1BJ9\JO(ZAGC'4-*
AY=2(O:630M 6]^^R0?T#$1O+0. MC0*-!)TX,,,I!",T$LJZ+#H]P6@J 6)_P:ZNL]B!R^U 9-6I.KY_,9'?[M\,2/PQW]R"?
_NH9K M^#(YE;R]L_0UC6]2&5E47G:+L5X&8WVXFE.3(K\4BV.%1YODG5'F%64M6M6>7 MIXL\E!QZHZ-
*4&933";6'X24ECT 2.COE!=Y4M6?SO$1+)P6D*WN.N47CO(=& M>CM*
8=,/KE&NLLF:E6]KES[X/G:]W@B$56*T6@($UE:+!"+MX424 88Q*0< M-=4+P+E MN5\SJ$L,/K>*
*(WE2ZC9I+SQL6W/4R0(VS2+V^ZYFTO=;<^)-K],W=MM%+OQ M MA(I:H(U-,EICGEHP+G$(SEHM*5>)UTYX>--*
*^(6L6N_O10AK?!Y%D;0WEP$T4 M(#+CR(DRALX3*C5)*A/]=IQX2MQ[ZBBR#:*>Z\!NI-6HLKMU2/(CA^3/1P[)*
M[KINTP^NXE'NLHDW=C9I3EH1%Q$CP>CP%';38:N!84C0+K2PF>P=-(61V'7W1QZ-==[P\EY3.F(I!U;8*
*MC+!*Q%D]8[*UXQQ==7]\>)%XOD+I?QH6?M'HIHS9?=K+0KH0J94!7)EX+S@I MS_6EA@-*
YPXF2+%!TBP"C3YHW5V M3]U=]/N&V3&B>Q%UH]?QFKZDN]I,KW]DQPU5.[ROMW-[X].L.3 >U^,0:[*
*MRVA1&5K\D=3+^[9^W/1&2)20.698?W SI))N-FHZ*2 MA<"9<-V!;F,R^[U<^P!C-Q)L]$I=61>]ZV6Z[L,Z*^+N*
)=6[+++!2'>10;._M:W0>LM6E.U."
[%,6T]ML:.U^:V]2RGT\='XX6EB9OR\:C]9X.CXKEN<4#@PF!@M7,,I,H]SV:+B="&VX]'L;'+U8^MV9T!I5*
M6Z]45^^]P#;[V#U>4//WG%5.T M.[SC-GX I3FBUB'_TW2F]HOY.GK>R6/Y%EA9D?A81QHM
MA+K6%@%:SI,RQ9&)FH PI6T>SP)8RI8%KDUFM4]4PY6W]>2^58GM-D)H 5%/ MBC^+!4AD,!!#&1%J>0 3?
*8*47!8D>4%D=02]EQ+;K02[ML1V&R[W")$R&F?R MU8U#^CB]N?R(QV?ZZ!KRK*X'F4_F\X?U.*O:7(Y===?AL&-*
M%BI1LTB$XA9]-*O*$ $_7B* I2)9VH >VV9#Q7&51U<%?O5P3:PEH%^_5#*

*(V>S\21GR$&6O%0\0>CT6^"$)$&<))1ME*WX&F)>(J"? M*Z6B8">UN=SOQ;*H5UJ,K)\NGD^6NC&B?F59 >-E*
*$OFI7J;:)#&).(#:F(? M7KU45GURC]*O(ZM)/<;UK"(,;Z:3ZW1G"'EM;1*LI)G@9\@O\[B&]5%\@Y@=C?UBROJ%1-*
EX%=I=8JZ MTYF40.&M'#452?/Z4SPVH:SOZ1VU$;$EY'803P.@.T^C_-E]OU7,SA'N%"W# M5DMCFJP.,";PA,:DA/>&
<5W]6?\Q 6U#:!<)_Q!DVY7=/0?91L.'F)!\BPU MO.0'A5)X;,$[] @,28E:W%!B_E7;]_$G]NLC=RCV?
3C7K\!_3Q&MOFERX[C\ MZS#>]B$(ZP@S'C<>$+0V+ &,9R#-B+HP/SSM.05TG_QX_NU5[J%0AV>]HN+*
MBR_#:41FSN]T6.(EN9DZ"+FT,1-<@J$,_3DKI)(Q>.[CJW!X_JG]3C+L%@5[M<;!?X?\RG%Q_<=,K%]+-
*O#B%B.2K!9)',7T=AA0F5]=N_,C9=TQJI3/>:,5; M+",[C H,0A(\9ZX);OE5<&R[ZD;@D>\3/)U*H %S] 6'\?*
B^X68@,3"%3B.U M,2+?O-[JB@:@-;!:#3YLSQT?IL,/^#R MPWD969QFI^-/PS%^?
SB^/$LA#;\NTLZ>Y8<:PKWR/H+$(P2BW,TV:@?)LN3C0AK,B1>!WOU!=-
HL.$\\Y8[]!9JU^.]1$O/^>X=WUB[L;Q1'VG#R26[ND[;??P;CF+IT-': M=A@&(U[FF"D$5;J4.<2GS4)*

2M$$]+5CJC[@9Z>!+)4[$1R<'YV??OIT=')P M\N'HX/C\XN!BT>EH4JK[/Z:Y&XYVZ4JPS:=7Z5"P\W8JH>X@+)*H
MA^/+NU[R#W//L]$((PM2!0280H!Y2TO]'^,FB(#:] VPEZFIV+]VN<9L,:7M M>.(6
%X1W[^=^&BC9D+P$L#"K4N%IXP("B0+0@)SG.KJ_MQNI/9K>E7"T9I> MM)V)K07K;&WE;=).T#*-
UF=6HK:,@>.60*21I6+&&E.[.VK#=>UO HFM2MZW MD4\+8'M2V!FE-
"&'!)XQCFS)'(S($7@TSN9H:,X=C6=M(M103[!K2]ZWX7*C MIA\ES<[9]=;5OJ7.;U3JOI6L-BAUWH9Q#;<[ML)(*$O
:UUR6<<0D@74\@DH<]6HVF8?7^U/MW>[@CEK94)\V]GJ70B MM1;06+)("6I_1B5=-
ZS4+]%M%T"E,*G*V;]]KAH["_,LD'HV_IME\$87XW7T; M7MU-)$O ME&!3]D)'22.M7<#TA("-<*/?-6YV9W@#:#F?3|
(_ODQ&*(?9X7_>+.PV;Y,T M5@.AI,3"! 4K';H&UHHLK7,\U^YH]",5&^'&O&O<[,GZ!L#S\7;9^YG?CT=_M_U>*=)";
(")H"90G= 2(11\ [V"0B3'&J6"H/FLGPKQ&U$;0LN\:6G4%TP#2 MRE079%;Y3SDJ7]UH\1 X_^"FT^_#|>5BV!5N*GC%O
,2,@5AE0-/= 2J2+#9 M<$5#]5YLFQ"V60"2O&O(U9=0H^F5AP=G)TP,&54JP>W%$=XIHK45)P)5FVD): D8D!B2A
M^4:S(CGQRHKD)5KV'"%LLK=+[34DMDEOTG[)%Y:MT9E'%B0C#*II+-R/>9^ M^,Q^7U;JB.]1D&$/?
O4;GUKL_B&I#Y5U<,D0%%X9I.:< T-JFPK OM1(7N"8/)6$FD
M;J@5IW>C&R=75Y/Q+>/FRT#^(C5BLO@>;B_%S^Y[^>6#Z=2-+Y<3'@=:H;(4 M 7E++5I]27.P,61P)AK",
[7Z'Y57%YAO++LVT'H;B;L;W#8RB)P4ODUM1<;'P@G6:R,#0I57IS2@K&V 16*FTBDY2+VDFV6Q/9SUMR=2QV
M*)G>'Y"7ALE5<;0?S!/J;7;&0D[(*6&= 5?>.B6-Z/4ZEHE[O6'NZL_N-[N@ MMD%6@7\-Z)XG#P$'7]%M72K86]7[*-
Q["_.!RC($;31D01@((36R2TC(6K@0 M7,0MUDZ1VYK(?A,4JB+M;035 !)?,$@?:]?'=BFZNCH0*00X:E"O2T[*VJ
M4Q:R5A:961N'6Y+8;WI#)RCL4D@-8'"C^W[A$2UO>\%+AH:U8"0OY?R!@4VH M^Y-"!B=%DW3=Y#IL3&*_,1"=8+!+
(;T+# Y\>8D@V@"AJ33%DP),<.5HJ5CZ M@G+':A=PODY5OUD3/2%M*U&\D\>ASY,Y?
NK0C<+"M)@ME/IX@GL/HYN84*^7 MQMTW\]NGD;C4_>E6 -X'LIG.8? MR%BX<8.@T%-'/PV4+#.$#
<'S[)P$[W,2U$=-6.VP7Q7"&WW5V@9?/]0'O;E M&U70)Z'9Y??/[CXGQG)?OZ1]90E%L2OJ>R&WT9
MG$S&I:$0+HX_O#P:HUS2;/[YYE&C41>3C3D&(*8\D^I82H=TAN \8Y*7OL6O
MEYV_OLZ^VNSWX7B"@/]^]]G+2DX>'#I_J(QDWT92%KZ(EL.2J";Q8GCV=5N MH;.2D-
X>P"H+^+G*V9_K/3H0,0T'Q^G2C0Y1<K1\ ["VN207>-1 [M>'X CA_2))-
@RNL(GJM!F4"="L[$'#]^.8[;Z*)03TG4Y7JCQN>O MIZ+NDFC@&OTT'_GZ7CX-?W L%^^_^[^
M]V3Z8>1FRYYNBJ$Q025N3:32V#:EHNV MTI-M?Q77,SEF17>LM19!=G:]0@UGI"T25/ ME6_,->2\!ZCM@H'G5;:5!-
)SNK0KC_RSXV$H?59*2?)%"E_&D]'D\OOM9FA(MW"9!(++B.5%OP%GM(2 IRI>42Z]>55BOK]-?
D<>;P*8^KQM02HMWJZOK-$\' ME].T+%.YW8G,6FE/&:#UAY:"H ZL"P84F@F>:Q9SKIW,]3(U_15MO*E*JB2.
M!H"U/",E_/CC1H1P-BG@Z$^@?< B.(/_MSF#ZFJ9^TLF$$*H8PAZ5JRHEFH+R"-[%)KX0+1/U#[OZ?!_SX20K42[=D+(
M-ESN%23K1EVD1)V@C &QLJA-K< (FH!I&YB/TNED7K6H7_KTEF:$;"6M#6:$ M;,.XOOO4KAEQH;23QG$./.>
QT$E,%8P= ^UM\11Q3-Y5?[O94;(CABHQL & M[([E-_!
<=C*^7,33EV;:;VD4T0G\8Y;B+]_OQS>3TI0[2P+)&HX7K/%@G$2; M2GL?G&1HJ]?.7=^&OGYK4+NP2CJ3SKM
WN(;CUYQO&*.2*I!:FY!)%IRRJ." MZ"(3,H>0JV<7;$UDOU=<=WC9&IC["*\!=*X+H3+T';D,'(AVI^Y(VT@%
MYZ^:8:T&MM\6._49WH!ZNC,QCN\37Z.0P9>>J2:5D6/_/WMONAQ'CJ2+OLI] M
9_!OIC=/UJ[94=0F9I,4M6:IS^.Y"HRR5P"D0&J3Y49 MQ37"X?[!X0[?I$] 9B="TBIGF7ADJ;5M=H^(:=LOC&& #>-
S!T!Y]FVQ/)O] MSV7%WMW;V!.>,^T*C5>HU1\SA%?>1M'BCNN^64 M[7C? 9+NTO^WY6)U61LZFW^YXMQ)=6V1-
8(L.D#8-=TJNI22-Z2LZYTL[08RY1R=]8)+A1FU8ZTQM!=* M1HMLM$7)0?P\& ??<3E;Y$]G87G6% V?EV&^NC#WR7#
[<+Y,7\,*+[O5U\A? M_J_SRU%/)Y9Q9#H64J2U^JII:2V90T%)JG[C8.C7\ #*GO:<:!V-C2:DG MM:3I5,Y<1V "-1W8!
<$GY(!9%+(PZX3PL4SL:2WKD=32/OPS?/8!0.$ M]?-OY[0%R&V]9?B=*!:%#FOW@YQ*A$V2VYR8;=XY=G\JIVU:UA9?
M(\NH XUT=UGO\.R^\6>M+D4XTJVE\L5-M!PGI0'F<_8V:Z]=ZZ#_+G1-V[1L M7#-\L!PZP-9UZ6+Z[_-Z.??R?
$FK^;#6HBOIZL?PK+/,Z/P(=\U"2M[5)3(0
MA*SC#;QGICB36A^#&\CHXQ)@_+++@H1+H"$0;F'7UHP^+TUGZ>1*,]"QE#J6H M7#4LZ5K.R-$UHB2G1 [BB-
7VOQ+7QWW"\0#75EI/L$/'XMOWQ;RZN8LRR{5)
M99G5*,3LFBGA@OUC-.K8\]UC]^L8PHI)VG8XY47A1D'1=;)ATG6*232D, T9
M:3PK;_SQ%,F8;3L>\9$N@F;6>TE.3P3):FJ0J#VF'F[NT51>762H[],JP!>O@HFT)*OJ_75M%9"-Q.C,9H+@=BZZ?L3
M[/C1%B,#FH#L(ZX.#,U]FTFH9'FIPZU2,K7-G5\[].3J64V+]EY+T;JD^;=M M K(75 8V =E';D^F<\.:BU&QG$3.P-8!%
<4L^!0\^,AHEUM$>;?P\/=I C** MUAM9!D\&7=<5FH)E- %DKBZ;<;55#T?ZLOA"6Z@DU;3)S!/K"[*7Z(?U!=E=
M#AT1R#= MIT^365%2O;I2,9/.1Q6A9H=#5H7Y6&+0=R>S/Z'TZ:/!ICVO.U!*CS2B<-%(
MP4*]CRQDC'IF2(\+O2X%KO6;2_0%.1Q6;80Q[3GW9OYAN4BX6GU\1GKW#\RS M<'566YY3T*ZZKHYVAN7@,',
(+L@0=1VR9[<>;P\^?II:FTXVX'.><3Y MO@V['X MP&F=+ NVEA>3HG7H("844)LNC <-JY(TK#I%G,B*M3-%
[JT3S28LC)=Z.=HTZ.AA'%MO^P/07P)SC ME_KBS\=-R4VJ=C,4 L@VB34#*T-T&,"1%/G1\M+&B/?
Z$AY1/WD!TETB1N^;A) JDG) JY8!CQP\C<Y-8*<9U';YL5,GA>3@,[1=A0IH6K>D?*WS_:!U,#\H/VD5??YMZ]\!O+
M*NHB/%ARVNEL< &JQP8>Z9R(BHFL6T/Q=\P.V@LA [*#]A%7WTC1JKX]+VX+H=
+ED98G632^=7/QWS8[:"^H#,P.VD=N'<#RL5 NSZPDKT(= MG,I F93(M4*@K/<"Q$#K?1WCZT?!09[A-?WD4G_X?
4LA.>,7'3N:PS%>? F M:.(4(_^,C)9RMS_'$PJO'Q,Y[=G=@6IZ+*2KBC$U34#G6&MA/8,H2P2="K&/ M"U7X[QYAGT(Q-
9)(!]AZ.*[+T7LMD@4M5>V[S!U$I15PI3"$%!7JUC4"G079 MIT!6&WET *S'AP1HZ4KDR8/6/H,*G-7*2 E,,,MJG;
<+K8N7A_?Z"'Y>HA3 MV4XD710_=IZ7G!/*V"Y"I[LP6(CN3;D@9U+V<42BV6M;?0G,Y)C+]$^.I)C
M'RYW.Y+#AF!M'28@K;A=_-""$Z(RA"+1''M):X>1'/LP MKN.1',$$%CF=GR70"N@,U1#J6KSPWGKT2KCM0PZ?RDB.
S'0C($=F")OYAG+ M'K=D*=-_)3I0+FER#T,$%X.'S *SSD>;FZ=U":V]XH -:(CF(9#OI&AK)LV]S8PY^OC_TNX;
(.*PM/M]Q-,!Z*[IED(I M*5 "-YKHSJQ6S'D#.3$E ^,87>O4Y3X&=XP.G(-8W $TMDVW\;I(6;#.52Z7
MU;NQSKG!E'(Q1FILW>"AP62A:;/E GFJ M@15R7&,(/&LE>6M3_,GO_$L/S\U^)$
MY%PX!@,A%P6J.CN>>]J/0O,2C"E!M:X=.(C0:?V#T?$YOO">)D()%D7_X/)S6A)Y/7Q'/ZISX=+:8?
ZR%X'/,K*R_LKJ1/J<&.IZ M3U:[-5D=P1F3Z8,*)02%,MTQ!#9E1C6A9;?:,:?;D<#F-L#K0J%ONTP(SZ*+3
MX(H@7O+@@>QN1FZA\J0^=QZX,5C]$P;2&Z A(?;> QD?@?' MYE5!QWJ,Y6JVEDK-
&!*!D6[/'+2OI66:U>GSPD#TRF!,Q?#FP9D'2.FE(<=0 M62_:,[Y3_%Q,1+U*2!7,&Y&$
&0AU2&K9%$RR8#,2$DF;2PZM$YPV4K4M)AJ M(OH=X'2X'#H UH7;\CJDV>GL[.>:/XH)39:H@>PT@L+
B37:0@P^F!*2=*:U M3KI/12^EG(W5T4!V=P>8JVQX;50T];(ZU.0)+1 ""@[<.T,N=#+:-&^MLH&. M:?7-4-D^"I4#&-
T!6'[=/?1':ZXXK-$-1" MS,C/M06\<(IV493!6N=-;-T" M>2,AO=1?-=8QPYG>(W(N-
X"GHUO5H7C,1DV,X0Z"KJM2C([TJ$PLS0>P;B9E M8H-YN)"WP>8 CG< G)>XG/T@,?S -W-
R0L_7N51_HX74J]GG/_^.^_PO?+2G\3HN(I" @,.:Y9S0'!,%##2U?0]JWUJW7QS,R73(JN1 MF.]7N SE>0?
(J5K\9K^M=Y0I"C$6A.0U;2M)%D5$75T/IW)0$54>XQ;_5RIZ MJE(1\UDC'96MD\1,O4!]DP
M&3*F0,9W@%PUD/,+I,GWLY"K-<;,[SNCY=*[:"@@.7 007':#&)@0E6").X M-7>[^@Q&SZ,$]02A0V6^&$L ':#I%
[W\]CJGQ]()6T*TX#.=ZBK[VMLH!F E MA<*S-"6T-JS>HN!GG^Y,7Z>N)A* ME,Y RK+FO:9 &\)
]P(#:6R.Y\W>:7#Z<3;?]=1W=*ATHUGL9;+Y7H=+|^1A*A/KDY(E'6TN@A$BD0K3"*ZV
MCRN1A<2XD<5OA\##SY_XUJ0I#!IQN@ M;4DV4#;%K4-ZD>D=SH--SY[8_VA\'@SF7@?
&8V7#ZGVY2.^X,FF\BYSS@F3V M&C* 0TX0,'JH.2(I<(RVM/97-]$Q;67N",;C8&8W TS[4HBWMS+]:]4W;'I0
MJZ*%K42.6XF@%+*^60F%A: U_;Y0C*I6>MV2^-4(OQZ$WAQ@6,C MD\$X1VYR'0A@K8' %4(R*C%DS+'F?
80WD#']#>E N3]^T;X_JSLY8ZZTWB\) MB244C1AVSH&)8> 76-#Q"7:I%BIITE&=I8YQ.T3L#;1M.T2&HC^1W@=+
8)H35 M:GEV,]7F4\)Y6,X6:^[81&1&GB!J7F]QI(1::0TL>^-LD-;PG0)]](9;&**O

M;O#SX,NGO25MI7K:|'9J<%S2_>=|]1W3K,PP7X4XO4T6A06;>P3: /$3 -%JED5 7K3GN(@:G+:T8;P3S+5N-
G"7AFFOVUL:,8,XW!E"KJ8XZMH6G79-[?0*2B"G M\[?N&I=E9'2(9FQ=I'V?BFD-E&%2?00B!
[!XXM/F8YA_N:R4D)JT)VIR$"TY MB+8$"%'5SB^RR.)2T+B3([3E=+E^X;2!F98FQV$\[$'PEQE.,5E>L^T ?9T7 MI
P'KS(A5T9MLLE>]8-O8OHITPB&R"LN^(^@';=' <;?#)1,*: 'EP6GE0? M1C*B; #-+4>9)&K9ND?F@3X'.(O.|-R6K%_
Z0]%!_DA*+##YJ M$)ZVF2(#&CP/ LAJ+[2H+&WS'GI#>@*-ECS0^J!JP>].8?-K"QID1NK(. @I
M)"BF$NTP8Z#P4JQ5S*CFW3B>:"N@O42_=RN@?>30 ;"N0O6_=!1 P7W,+$!1 MM:-
+59RT9.'7[SA4F.,J74]SB8ZIDU,:1XL',KI#M%RA7FA<\J1 5\W_+,, MZW 0#1+.]<)5LBRW-H V4S)Q4'"PA+=
Y@!V=P":Q^TW],()EP/@>C%9*G H M(HBD. ^J.-F\[J]CX[F%Q/LDT'E- LWK)%![N021N>.RUK"A MC72>TU'N9!
(00N;&EU"$WEZK]=#3IXT:-X1#*PYVH%!^/9G:7N>,AA(,]\4! MPUH?ZXP#QS.'P(RQ0?(8"4:>>(M+9<6O"[RYH<&
[W1R7+(P=4!M/0A MJ)@!I5!:%\9X8%LUQX":G",ENATHL:U%.?NP;^J2O(U%!(;(54Y+R#;;FC!: MAX3H".N3+R,:=_?
BKFT)QI&RC8;+?SC[II;_OJ)"85WF##V@JYTYLM3@I9+ MI<,DK-+";I^9TF-)9G/Y#V;?Q/+G^CZ
S8G72C&N&)1"3%@/R @8"_!H,I>(MNO@ME10//KNGT/]P^0]G7X?[WYX(7UUS0P=8"@3@ZO=$QLE!=XI'2:KLX))L
MVU.X=YS]OQ_[)I:_^#>O5W?='W_"&"LQTKGE'2I",%G%WF0"M&7%<:>$=&D[M #8_O*3B8KV?IP6@*G46? !C-
1UH)GB>U0X(MV/3LG]ZO&P!@,/NF=@'O+T#I$Z>*%;YH2)4):QWF=[H$:. "#F;?
M/*_79/Z:T.!*)/Q,1B(ABQ86JU.0R>:Z\A=)'\652)_IB1P2!^X]%JXX$K1 MK4<4;*)CXO&9+2'3C-T=0:;RY]UB?CF"[T2+0-
B."RN;"&%!]&B .F+%#E* M6L=8H/F5DMU@\R2N'!NRO.-6#K>/TT&3*N_I]GTR2TDCMO'(88ZELN0-V&L M!>63J-.
<"^AD8M0^FZQ;AX:/U\ M>"I]'/:1^RY]'/9A=0<'S4-Y:]GGI WQ@2F/I$D9G9^=(KJ/'#H
UH:6]B49P:P*4#07=9HFDM\7.)0<6=$IUK2140^O/ALZ M#-%" [G<'4YN];W')+2G'05),L)
[L,0.3D9[H(^92YM]:CU;],D,A]A+QKL. MA]B'X1T YX&\V>0UXQDR&8.@T-->BD("%]QH&WU,N?5$D8-ST(_:ZV&(DAG,
MZ0[16@[R'AW7+0]V%WIWG# MI!83*U*"D+4XON@"T1?:5SS)S)71]]I$MLX;/G8:^5Y"VR%O>!\.=J Y#ATR MJ+P-
ZT1KZ0JMDA/7;/VR>,LL*N]9^YN:IS+DN_#\1YPLZ'Y\1_AG[-OY]^>+Y;+
MQ5^U@C5\IY_4T7%!:.>[@\#K_7RNGQ5R:1*Y(X43*QD_1C_JA^CKZ6:Z$<;& MDL[$ R%_6=#[[U5$9XLW\
[2LHPI/'!WYR@@#P1&SE);K.MM8;4E>G#*2OK_U
MAN#Q=_1TOS@,*FW9V1,N+H'^J8*\\N@:|:L3Y922S&9(H9"2)7]CW=@!9&*9 M\YB9OMN-
>"M""GY;3_Y]8ZPT8G&'J'F+=8[9:G&I/$^8XDQI'VN5;&VG65MR MVL(@U)-U/ Y:AK"VUV1TJ1*Y#2R!*5V;#4!?
*@UE:AB MF[Z9QMSRY%+*G)2 KH+".*R,> :*AT]*6 MG'1K+_O0R<)'+V$:8L@.Y74'<'F]6.+LR_R"^O3S!=E8-
6WRV6J%I"%GRW^$ MTW.\2:L\471({J>S4XOJ"&J7(:)!*-$:P6*2YFZ5\V H[4EBGY520V VIHRF MKJ/<7
FJF4V2F0S6$8]4"@Z\I4WDC2RU:S!9<3OT4AA02GOT&JH#CZT6#)P: M AMK06G-*:""-
<"D\Y+X0X=IZVFW3R;;?"\9[YIMO@_#.P#. MAO$F5@NGO'& O$ZG")ZL;C*YP3+N4$NNBFK=O_K 4'C=9H=1:ENA
ME\I8 2AJNU3/$WB9/$AMG151HK_;:NAW[G0^7-Y[]3G?A_D=(.G3U\7R[//= M.@XC58@Q>-
ZUD74)CM!EIK.'PJJ*'B.C1&TD9!IDQ;&.:J&<[Q'V%Q/:S4L MZ#J%QJA2.W5*"!XS^*"9Y]'9(EH71SU RK1*IX&0M\'F (YW
)S'E6<(3FNI M$QA5HQ.&5PN?!4A&<\9%4M*W'HO8\J)))&=M M'Y05M 96-!092N0R"YU:N^4'U_..ED,USM$UF-
\=8N9R3]49Q49K 1*1DT?! M./@:FK?>>&(-TX&/C9H>S]WA$MZMJG6WK?B'HV64=]8 M_,.Y-
79OW$FE9-.,2L*$*ED%$=,$.LTYB M&NZUR;OT\S]\I-=HR?.MS[! MW)M:_!M'4H5HLY$F@'.L9O[7GN)*.:"?
Y9I'F\W=QH1M)WJ-E@M_!--O/^Y- M??9O3J*5SD:G90#RC6TM%JOM%;P!D5CQR2IC[/;JJB%9R*-EJ,<^_8?S;^KC M?^-
$ETR*Z%>E:(E#59'4'@9$**7+C%N,V/;"S('S',9+0N!]?$_F'L3BG^U M/#OY1*S'FHGT*>$\+&>+]9U89(B!20-
92<*O$75(@"!SQC'+M. U,7N7^T)Z MPZV[0OKJYI[PP9=/;!XVO5INP^&I(7))Y_SU7=,LS+#?-7=)VG&'9UL7D53 M^T-
IB)PKD")8%[2WPN^4P+,-)@\1,,T]8B.A+EISN(?PPX;=L^:,EI8Q.AL@ MU>Y/*AL.L186:ZM%O6>W#G=2*-3UW?
6+^/Y'^.$KEKPO5/\O*U%(\NKELRT MD916M:R//BAD9&(I2U\FG[E,$H5OW0-[&TW]Y;7O+_D=X'2P&#J U>-I 59J
MCEPK,M8C<4H:A! "+483*8A.6=XZJZ?CM(RVLM\K/V,?072 JHV/7B"]QE9:S=?
^Z$W1%)RX#F%B+6A*K+1ET!'"5]TG'"*WC0?U+SL RYGB_QJGD\4N3T!F8?@:D!>>0NA% M9*LVYR8QV
MVA'@]P!Y_:73CH>^%A+J 'R,.F"%.I N&0-2$)>4"N3*%-I$P@G&!;DW.K=N M!W]HM[&C7J"W
=-0CO=DX]KZBHP.\Q!0DEKWY<)<%+1!ZVT$"E*9K9W_6G0 M(_>H%Y^_[?I!3.T)'8^T<=7GY^MSL(\TU*>?5N:\JB-41-
M>\%K=)XSP0IO[@%NH6GB3)#QK)Z6LNBT1=F'CZ]>O_KX\=7+3Y_?O_A?S]Z]
M?/'^CS_>O_OT]VO6__WSS^3\/[ENV]QM:-#,;MJQ&'!RZ_05_DI[<;U>Y[_?'$:5JO+Z^$@A!?H@>MB2 UG!DY(
<*B:+_9AY7Y(EC]DF6)A"9B*3X)-) M9-A9;XP.0IG6]]L/$C-M.&4L5=.&]QV Z#;]5_G'Q7JMC(%D:].+[#Q$D35X
MRPJ6['5@S5OGW:-B:NNFB7CO*IUAO.X!+8MOWQ;S]0(N\V2$"(G;;,"9.AXQ M>071*0[<)V:=]4$U[P-
\CXB)3Z:!4KT+DD$L[@ CG\[C"O_[G#CWZ@=]N.YM M(;SFZ$2 R'WM06 1@E0).(:B>10VFM9)2 ^0,FU\=;0CJ0'?
^X3/Y:XBHJ5@ M5I"N+62>B4(^I27++^=B:5?(%)H/.'Z0F(F/IQ:BW@Z?_C>'X"N^FWI;*,0 M#!221:\4UH%
)H,TA06#EF0L5=B38"QMIE M5+H(L9;3<3IU#>VJ@/((6N?^L=52LP:!+&#VD%2*H(S4I#=(@\1$$BL,16@^
MKV)'S3K,H;D)H0CI;>',0:G&NG+)$A@5660N6EJZC:EYH]Z-A$R;#S';Q=M@ MGO>@
"KU'_'[^3)]#2O\L%Q\689O'[&"K9^=G7Q7+V M/Y@_+Y[CS5_E$RM"CCY*2&
(]JX.3OJA3A(J5/I$*0=4<:6TH[\>+.A!"]ZYH MCB[/B?,V+CS']7K>K%;GF#\N3D_+8OE76.:;R SYI8S+!"G4S')C2LU#\6#K
M4%Y%O YLAV&UN[QJVIN_=H :A;4=*+Q;-PVW5W;BA BL)%+]!6O+$&?!*\>@ M9&N40./-
W0'8+:]T;I,RC4H:1]X/7_.CZZ2PLS]HHG=5Z(1=+ M>'F^)/5ZD4M[L;17W[Z?+GXBKG_IPVF8KTY2K'TIK (K4]V'M
6CTYGTJY>8 M3;$ARAVUT+[OGD8MC0JJX\BA8Y6EM1""8P ;>>W3G9"\5VY 6A16\^*E;1XB
M':"RFM\M3JJR]F'^0)7U:I['/?I<\#8S#CEG2OFB8E#
M<-2\"F/:HV\/YD]K:=_*HKSC95SY$1>2NN(61YEL,+1#1*AMO>D\#RXI.N,9 MV9O6\!35UM-
N5Y=.&^1H:GV/R>Y^7+9;J]RTXVP. 4OB8'AMY%>4O6AZ@,*P M0-_31F_O@+W[^Z:M AO->6O(Y![-
H5O+.TD%I9%6@Q3&@-(VTK%L-&3TW H; MM=2CVT2WZ.G"EVLI_FVGV]&R>,)>G96T2L<],&<=68+$/Q>Y
!Z4LUY%C9GO MJ*.>I%=5E 79*/'HQ.M'\PDM(77D%*V=FLC;'-6T8,UF5C.WE3 MZ;)]9#&QNW?
XYM$BA6@$*>PDR(1T(H'G28(,TB0M;.."XZRWY*)ILM!#A");7 MJ,SOQW[_.Y[F-_//M=KW?/ESTY;$VKPWE@R1VTP:&7--
)1" ,0EMF4 7=ZBK MWN>5TY99CV;%MV5UCX??33R2;,>(+*\+$I"!,JQ 0",@&E\\L\3 $,8^^V[(
MF;8,NWV4N!7G^P+1A[!\OUPGL>=_A--S)(6[7ATM2>GHO8&0=*!]432X)"5@ M'J_=NWBH\ANPT8Y""QI]CSB$PLC83
M,U'&I)-+K?N6/D[1M)W]VT.J(?^[0].#>P2E";&P!,'6Z"1Y+>1J\%J?5S3/ M0CIW=^Y78U0-4EB$O,D@C)\<"2"-H'
M/(+6VON6] EEX;4400>(>G_V%9=TO-/[O^)\-?N!;^9I\0W?+E:KUXLESK[, M+]J!I9^?E^3+GE[(+O_7^6K=Y/!S^.>)D]
(,7?>/KP-Y8AW%YXFQJ$TR(D=F M7&NMUH#LW9#Y!-+YIA+E_NCU%^B=XY>]B3\W_'+V8]9QGF^:F#WDA[_OGS$
M1%)\&7[^L9B?27TVS_^)87GB=):<,P/.!?*!/!)S2ZTK2L%D+H)@LG5]YQ[D M[0,*)Q#E'ELT':C.34M[B>F4.'UO:4$8X5P.
(&VLE]?TP<>@ 3-+FOM8D+>. M7>Y!WFZH>P+!\;%%TR'J+KJ>71NT+AKKLZN-U0UYX3I:B*D44N *?3*Q^!Q'
M!MJO%.V&K2=P_3^" 'J"TXD.Q 81 CBEZUR]D("<'S)A@[",(_TTM)XB=?WR MW4#R!.[UA[&U(SS<4IRU@.A#F-U3G-
HPG9W1M8T#'=>:=*;/B4.V6NJ490K- M_V1!-,!Y#[6@WFUFI596@OH-7'S64KGW\Y/JYOPD%MSV:7Z M(O3Z'
MY.-6#D2R+F(L".KT=*"QD3I)#3N:DU4RD7+L&-$9ETP7L!MPG%#N8 M3KP=8'M?GSRDM:3G>:.'?
L.&8DJI6>E@8CU5 A:2!;E*2J58G"_$B]8H'VDI MN^']"04V>A!Y!\B_D]B>:8$?\6RVW)0R%D) MK?
=-2*:YD"%@'7U1[F;W#H^6;*5J-ZP]I8!)6T'T@["K=*V+7HKIO_K_GGV M Y?A"[Y8K&ZN!)+$$$2VD+4OH&K;'2\-
@RA8])K9H'WK_I.[TK8;VIY0$&04 MH4P](WYCXX^;9(F+&RA^4F0PMF@%TI5 MG%FX'6D=87,B\V,MME.N5#;)L;O
M1LYNT'H"H8RQ1-"!D;;//;DJQ<5H-#$LJ.IO"0A".&"*+%/I @;9.LK;.H0Q M7E?
F\88'C"6BCM"WPY66*H(3\1I(6=. ^]DW20Q81R!@-/!1N1.K\KG&\]JOC M8Z^Q@#J"WBYAZ6Q8S7O@0%RL;?FC@^B9
O26/"'RNQF.%AAIE#$P6NCVR(JO MA8@Z1-^=$*+PF0GNB6'2^IJK'R"6C*!#I-4DE,2[_F*XXS5Y/![&!@BB)UB=

M>!0,D6P-07X,J!H&P)J:/BP7-PQ:@:BDS9,U!">C)YR>6R*='WI3^2?>B;MOWM-&3T%TBJ>+2_"KUOB,U1ZLY"6E5-2H
M7!>D8JP9_HZKPCWSK;765J*FQ5@3T>|-I\/ET-&PK@>(72CVN@\7|QK66[/*-M9"X#*PY2C
&4UPC.9PV2%:.SD\:9UEG'CQ(T[6WPT916.Z%T@+-[:[C<)HX3-M;XRM-1610-4I(&:6ZT3+'&A-2ED?-]P02]:
<[T#Z.RPX2YG^$3-_MM$/E($=:CO(&:WV;@:BX83S9HDKKWB,[$]>#P3X("/O;[0=(I0.X/:S4+S)<-M+ZP'0?9!D
&8J2.CLD_@):.%(0M!.!Z\;MV89!>ZIHU5'>UD;"ZB)P"[RRW+
MHT>+NI:9U$MKKSA$2TZW1)^=X9))WWHPW&Z43:O?VB-B3\@=()X.0+?CCGU[-MG6%C'0;R;6B;!EJ:LK*.%^(>-
*GQC)D\)],ZV6U?&J<-F1Y-!XXJN@Z@>3/\-M;1^6?L9_GCT_K5FG+&:'A3:[KUUDE:LMAGPN8%76*7"!]F9
7"NG=1C)T[JU-M#:]TCRFZ@Y'Z-Y=Q<80ZH_U&^L*D/5O?5@0@]?)^!?U'W,LL[-U']&[52%W-M*ZMN?KZJY23AGR=<&
[+4I0%OM:3SK'!P@FM(0IA"=E.A3=M">:>@?&WQ^_JBQ>^)%#Y8$0,@-W7O!5HD;3>@;QEMC'*IW.E(
MM*&+\KYOG3:EJP&JQN9T!UIN1]MHE]Y>[_#L?:G[*!G'A5(9C)"E3O]F$)-&-MX(;Y0%PHY>[DIF.Y9_LL8[+9*^-"[C
';C3Y3SZX9=O)L6LY]=_";/[P*7-I-M-E4QU?(=(-\XDQ)*#KPB.P@%2[SFL@=]K)+ZENN:;([,4;=*=PCIX/AHT0^2
ME(0UPI)[G3"!XCY!C((!M\Y)70*IC=9W),=J[3G&.)LN,#^6?/NIO![C8-2)-M3%-4-IBN0U^-)AN4"82B(\I2$D/5NAG
5(;1&%-6G[QAM(_\.QGZNR,;7F*9-MS3%?71-]=HFTOCVZ9DD,B-I$LA#7(A(I0)!:@K0Z2>0E%='Z]G#D)4WC]7:Z
M/8Z"B^Y]B+TN5M=]F)SB&(L%H^I<-^8*T^DR?%_;9@#I$<(.N*(M$@>4%<I=C.DYW].1(#F0._M:KS*+6.-]$*35:
*J3=T!8+A"3-5(U@H,<36+0NF7?%$_EZVI*=P:KS3;C.M&J@%R3+3J>]$;6N92IWR6^=
(UX0!S8U+K5N@;2%IHNE]/<%X7\$\N2NJFPMG-M4YRG#042!0>54JK)?
P6T3%Z*K)Q,K97T&'YW^[E]O3O>^PBNZ9U0VV99M?_2-MF\]_O'KW^=.Z&].[SV_>_>W5NQ=O7GTZN*'5#L]LT71J7]
(;-88B8'R;76>8-MOUC,SPB&9/_.4&[0T8(*F0@;FA&WU+6MG8.-U,R;67F-M>%BY]JX:R&'J5O#7A5,7*=1_X-
G717XS_X$7!NS]JR*^"]_PHKH5HTG><4B*-M.UJG$^_#,[6B7UE:,8M^IRXMV_K##Z!Q6B2VP,=B-F%-
#,J'UG%9\:R\2(+Y-M#'%MHUJGP+'-R-@@5T@8KC3;2JLERSM%SJ]]V*1%C%%+2#)G-M\J'%
N^SH"^E,2(XK>PQ,/0$^N'M)?J]^^^M(X>)S[N/@?;9I7K.N4@,P!1/-MH'3U;PLCHKT0$E&(C#NUZ=QRM%V_<-
HRY\;FT6%L[$'VEVVKF!"!]H0-+B,M-M7-D!$64"9KQ+4C.6^$XIX[M(?\H680.$=5?OD8O34Y26#,U%I5S2
D3FK+B.B89QKU8];L"M._?5G\^'=Z](7,Z9,;<6]X-MX;3EWPVW_%!F3HR#"ZJOFK>67'@DT!M=?"V;8>-=?2A)$-
'*"NT>NY#>#H+;-M;YMFTP\6UZ(![Z:MY/\5_#]?AF_A"^T-^L,U-X++A'E28B5K4H3>.PA"9]H)-M@CL9>)%W@V(;ZO8??
\>T5?H--W];,O8*BTNF^QELE!KHV)R'%/Y*_'#(XK-M5UC62JHT-!A3:H7&X=G6^ONRQF3^Y2$@5$-MCI)\'T=&%(I-*
[&)Q6CH^&S=9^)A;J8=UC7"O64CQG<'H:OM]6EQ_N7KV3_"-MZ3F>,"Y126O-HF'$)_3$,3IJ1<[(3$J,8^NTF*U$=1;
.U#ZCX)JJ"BZQ=:S-MFA^$^6)%PA7OHN'@?'"%?SYH-L7IMP2D44M@20^LN>=NIZBS,,B:Z#A9&IP,'-M7S]{_$?S]
[^^>J/5\\^_?GQU3HEZ>#LJ4>?UB)O:G=R&V5,O0ZSY5K8-SDO-MJYND%S)R"L\%F,CD5)5-MJ_6#-S3S
6;;$+7>#,^1L]0]7/]{&>K%:ZS?M[.-M0IR=DMU7#;Y07Y;?UY*(\^62M@7]PKO%?'GUY?.PFEV:"ABSQ42&92F1&$/[-MA
Q$;8%Y9LE60,%#ZV+\9L1/>U0VP]M==3:-<'LX5.DT>%]>T(MG9Z]#JBN^-MN#9U.J=H#;DM)?
%Z):+!A5)H1=$7G0(ML?5TK(=HZ01SQX7&W?.VA9PZQ=O;-M>A0MKX?W:
(=21&!8FWNY;,!79\HB^L2]T9:W'O6WC::)W8,FDM\!3@>+H0-8-M76_2YS^O/_W[#)=$U%=:V-\\7;/,!T=
[35B(ZWM>EB)$0^LKS)4@/6K+6BNU-MW2B;UD?H0\6-(,,N:KNO%W/)R772^/T57FX\;8KWGA4(M*UKEF,&)X*%(C1Y
MY3J$7*FS7B=%ER'2*0#<+U=S+_0T[Z]Q'AVG1:"F'U0F;P>-M50<,":?/G7,NCT(!G*P-M,Q"HRR5D)DVTP9%7J+#V;:
(EA*#_1"&M];KPN[=%NX!-]6#&C@R"0S@X,0C^-M"M^O#T9EN*T)3O3&IE#F-L'-M)BXW!_*B48L(G-69A%)Z\%
(ZD"EQ9|$'9[=7=_-SZS,D2M0^7R'VI'L">B>=Q-M"L9=I?[9ER5>>/"7^BH)SZW$4KOZ5TZ0,4R<2$!JT6AGT
1OMXKXP<=/+NU#-M)+5HS+;)12_$QC5(PTJ..4$*S('*CD-4&$$$'J525CN5=Q']YL=/EI+?3/0-MV-
;!+4&++H_#M=8YG82;;6"(=@J4.G;GVTX+28G]'+Z4%?WLR)-%R=?3@_J[7_C'%32_I<[2T=-MI(;8G04>8T0=R.
(7V]5F&UHZ"6D>'T>+*87:@U+_M:%ZS9RO..NK*R;<9#/<
M9+;>R!BM3<379%3MDVL8."YHM24B<\%@4*U;+1Y"9R>AU,E-?309=W,'=;V0-M$UW0F:P8E.-C&6N)@2_\HM6;
(B-.1[&]0'C3DY]^S&NPIAS,\-[TWHNP^OII-MO2%(8.L5;-
H$)@N=C8G@N5&@K$=P&#R46,BAP\"B:1UGW8FPIW\GUD:SM9?B
MTS$L7UY25[N&XWQU691UJ=%/5,I%:=J,/$E2VMYE"+%(,"R2\HXQH]E^#=N,-MG*?
O+!W5O&PGVAXT[54QYAE]MIJ1J-?K>7$Y-3SL]5%?]6-6U>GI$2=@%A#-M'RKKVEK5$+.%B2Y:)6WS4KTA]$[;
&!ZG!]=YAW@^P'K>BV#3#;'XK'E&P/P+W.O,1<2^1OUO0.-MSTZX560U^7IQ84R]|;806?)@DK(EZV"C'BTK>A-
!T\QB[1"4S:36-03W'?5W-M>F?"6)V*@YJ7:,CG9()6JS-@1(P*@DV!IY0M*\>?+-*)ZG[Q>Y=F)CXZAB-G6$P645P&B-
06<\]8++3B=*",DW=ZG9*)I-MH_U!M(&@.E"U+W$Y^T'B^X'O%E6(X?39M\4YK4-%;Y-.'+P-!50I-7R,')QB-MZ$+-Z.
[F;0P&W$.T3#1-LS_(-1%6%Z"[?Y%1)WU>,/C$%B]R(FM%>*-!U0F?-MSF5-++(QV9)DL*V]^\WZT94S]Z^>/;I[Z_?
MOO^/-^]>O__XQ[//;]Z_>XFKM)Q]KR]Y,R^+Y;?U^P[NL#7H;2TZ<+5;;J,.
M79_.OQ/7J@D73NLU_NO3Q5^W7GW=/,E899+A#*)W!#6?)/@@--18,JD^I:-N
M'8+9D;0!]_SUJ1_"++\\K_OVPWKD)EF[UXOV/ADKDP"7!:EYFQ/$H#/HDID4-M4A=]MQ?EAMO[+2^9-N5C#/'?
NFUOR>"IVQ]?)I?0:MI,ZJI.5/*%M*PDG8N5-M)T)ZC#^U1,EI$[!E(:,;L#N%SIT>JDTJ<7
MDPHOS,37LWF8I_IY(J]B;4\NF;K>-GD6"-XF9-L1I<@!-*]!97,D2EI4NO0
MQ%":I\WQ&O,4FT2J4Y]U:4E>#E9M_7U&/'WU3_(^\NRLMM-\;3F^HU'=YQ^;&'M7#W=B:VD3=W-9'RQ>);-M)
16>F_ZWS*'Z+)WH+VM,ZJTI_-9.B@Z6.X";H>MCY7'Z!D<-YW-9V=X.ON!-M9%:>A?F763R]NK&YF,*9^4E6!K,0M-
)8DW0<;2X7;-#O;30N<(/8VFW=A:X^-M9J$.1LF]H&AKD71@S7T(/]?%8I\7ETNXXAZNR#9]7^HA<+4XLE29#B;D:N[J
M:OB2J6%X-BL**6#N(Y>M@Z#[T#>ME38:[$8340?PNQFTOF':\.KYSUM?7122-M)>68%C4@H6HA:[867#+D8-
/F$D44I63KHI!]:9PV=W\T&(XJJ@Z@>*'=WV[2-M[L]__A'^:[%<)Q9>C-6VP2=>+/
0;/6T$D1+1B>W*:,A9DKN1SEW=R)OXCO7-M47&R\4AN+[2^\7BSL'?AVU7AN!762=K>=5Y;
[>EDR>^RA3:XH67+I#FV'ZNQ-M'XD3EW^.!97=(3E8;AW\L7YZFSQ#9&AM5I\A)QNX38OWW',[S7R"*S&-/
M&8@M9-I&M!"R4Q!Y<59%'8F21-JNQ5=0HR2&3&2RKI%QL3EOA.HJD-ET&,-IBU:Z-!,(4L
M,@U6)3(:5!UVK$2=QZ6R0Z]<=*U[S3Q-RL3AJF,Z-"V$T2FF+JYTKC9=R8ZI
M8!"B=@(4UG3,&!$2HO!92]*YK8=3;"6JCWO>0:+?-4Z'RV':..>ZZ"%<4G^E-M:X5E.A1IP#!9YS3S4.\':=?
I$#0&YLL.+1(W/;D_+-R0VZ(=$Z?%P(?EXLRXE0AU4D"1(SYB546+*V].\MKZF-MCZOYYNAHR]YIH?(?
N#K[!A(]I@:9_^V2?D\>HE-$M78F$]2)12$E!LBR2#$)-MH_1V?;'QT7U'Q'-V3@N#Y^'GBL1P!>@76/,;+U?!7#;2"
79"T\G:R1_-MCSDZ60NQA/$D2S9;P?#("Z9M.#,:)%JQM-5XK8E?S5+@&PK%D*&Q&N%FK'D-M"))
["!J3*C$[.A2W]Q=\X.'3=G09UZ@8R,JI<^A^S,X"OE@LOR^6M\\]GCSS-MFG$PSA&>K93@72".2"U0<>0,=\D:W_ST:1N?
C:')LR<^-28+3[6EU93Z.\8-M3L^^7C6>SC$(:04(G0SIM^0@A.*!>UMT3D58Y[-M5LNSDX]A_N6B=[TENE3FN5X-
:U#.%W+'"F)(RE;KG:[%Z*FW+BWH]YL+-MBU]>.*U=>93+K\,9W-JK@X[\I25<@BNZ-IF44Q0%AWQ7T-YR86^!_AG[-
OY]^NSC-/MJY$#KY3-M6=$6D?_RTHF%?HC(%BWX-[7@9_/;A"-+GA0UM^^NI!'Q]'$;&GYIDY%)17H-MHC-@?
1166^TPM)[N_A-MT]XU'#=&UD(ESBARZSFT#]'2'X-.D?5B!,9W-*"_+1;YK]GIZ=5X-M)8LQ116A1)E-A5IPX9@#-&@-
,\'ZTCKKXU<*)@ZMC0.6-4SN-"+K^]V;)FZ7-MJ527^9A.9QVE-^V<-T6OA\"B)[1+LA!1$<]:MU9XA)R)@W#C@*<5^SM
TIMY-MQK)'XKJ-69-^=<"B)$V@/4F<-J1S5+M[3.'UC\V-MJ:,Y(Y>1";#"TK;V4@"=\AP$]SD&3T9Y6;CH/RX=9_-M!-
,3RG88VO/G?!%7N%S[SV_FW_/Z,=DZ=)?K05]EQV7.S@J[JTL"FRJ'=|^'R7/BG,COZYE3\R]O:\.R-M:TY=W358([BB)8A@
ME-48!3/-!762?GBM!E^W301U_1R>S9KF#65"P=J+]G-M*2W/,=_?)MY[Y2RK<_EDS0[4!J))M8JRU
:0=.:H;*SV'J*EDW&U7>&PJ?PZ-MP.$MBV?M*]ZZ@%!&L6P]Q-J"4=6]%#$FT)GS+%TL1HPVQ.LN,=.FA$[E-PT0
M2$_(NKJI/W#KWG#A^N+"6U\8@\SJ'!/+-K@H$GAA7%#T/[>C.>B-U]*)03D,
M:@\!>$JY=X#_#TO\'F9YW>9VA74@R\6\L@WAJV1C3-P1)'()2G-2%;K4CAM>-M,LY*X*)U%?

CNU'6"T4G1=+=WXSBB[0"T&PZXM]=#@0P/9,G$""61&Z>3@*#FF!O(}(.H#9%>&/M$'Z#YQ]^7J&^=D/7(8O^.<
MR_GIVUG!$X<>E0D!>/3DQ#%:=>#) ;>H9:'E.MZZ*=D0>KOKP] &ED<380=P
MO8JH7JWY]I2:$\V2B998YVU)H"+SX)@P@+*6#_B *K1NC_P8/=WU>&@#MV8B MZ
!.&_1%5XOXRWSV/[2),K%Y5F;AGI;_=6HD_>S\&^:-B75B*Q]L,_C6*KK]*KIKS-$?_@\0=S]CXULRXFK*[^?PSUL_/(G(1;#(
M09D:ADLQ0,RD"5))SDKE+;K64?OQ5]5=AY+^]D4#./R>^^17;CB7DLO %=(Q MJ;P"SUD$:V1U4(3B?
JQ>LHV7TEV/EOYVQ*&"_SVW01V)BLGQ&AN'(I&4@4SD M0PF!Q 5E52HRA>:S+!HO8=HKYRQ::'9B MR'=V&]R?
7KRO/U3\9ENE3M6>T^M^GB033196@JWCF51)!<@V8I"$=$E*8P2. M93=10R]'R!>']%N^V5?^V0ZT
<=''^[#7KW""ME(H9)%<& M5.T6Y I]R5!5!S\GO%M?-SP9NO4X>O[T@J2CR:@#_(US:6!T-,.MDT=8%J\=*B&Z\E-
U0_:\=XCQ4\K_9!MA8X[VVWTXL"4>6:JG5 MSF[*!@V>90$DH) Y.F92S^;)PRO;;7O\:\<[&^'BZ>Z6Z_S1A\)B)8LHHU U
M7ZAV#6>,K#9M(1?I4 2>0_,F52,M9;?]\"\3"&T]^3XWP'HFXHH^':=OYJ7& M1>IW\QII>'TL@GP;/YE'2GY?EK'BN?
_.E^=59/RYEK,>)6=%0*\H]U/O C@ M,W>@0VFEJ54CL@8R &*6]!
MU%%219)RD&/%>D=>VFXE24\W4MP3,GZ[#;/ZB*?K>]G%AR7^F"W.5Y=5.!A# MCHZ&A<=[)97*Q+.7R_Q M^X)X?
5*2]K$P(CF8.CS,U9A'1G"1^(N6*:M:IT7^0L!NV'MZH=W#N=P!1%H; M8K>NKFPRRNHZF*/&IIWA$%+P4*
(@+R1+79HWZQYM,;M:]][<(M4X@_=]N&[RF M1\O3_;6+*JX8,!FK$3@J3LR0GJ1C,A1=6&*&6QN.D)S3;D&[;8??
(IHZ$0KZ MW!(#0LO?9V?A=-U0\WT\G7U9/^Z$T])50@Y.H*AGI8=H.(=D40D7O ZZDXO*
M/5:UV^9X>H';SO#0YPYIH2YN%W05SRP6@:!"J!PA9C@52'M(57(1H>CF$WG& M7]5N.^2W"
)/B8??;H>\6,Q7L[QNSKR8?UZ&^>IB42<^6V4TG:Q8ZE@NE!8B MYKTGB;OA]^G%;\>45 = ?*01VK-OB^79
M['_6,KSL2_H._WGV^2_8%_+.9G7U"<2RBD+8JU-@\>HF6WEG9/+US9A/<=8&BC83)+M*);+*O[)9V1?>&<*J;.
M%'8F,E+KD=:%5D#BULIB,8;FTWCW(G WM/TFT;XF4FH&P?__W^_QG-;^?]8_M6O^D_M5'+/]?
_??/CV]^>3X!,RV6W_^-3-V+IS__\].;=Z\^??KTZF]_O'KW M^7?OG.>P@;;[%TGN$\TS88IA,NW_81O]>
M$5@QZQB'JUT[,V3#H\'(R#%OW8OO(5J&ZKV;+N-W\W"'+R<]_7O[PHM$XY\E% M5B3(: 0HZQ/M8,%
_I^+"XP6UHO?W\RIVVEW00[=]7?V,+JX!S^1"+"2OV= M+7\Q-B0$;G) !89I#JIZ^%&28X6,\<1*+$RV+MUZE"),38V',
["KYEL>@#: M!>V7PSI+I89U)?+L,PE(S' -*X M6C'OR*TMRD.F(Y8S&V-
D8:O\'WO#M$,1FF"@&0.GQ<%]##.3>=;;@>&8"<,Q M@E?"@"'S/EF./M[-L-T@_,-V_6C)5DTD/HQ5$XMY(TP5KP-
_'0+RPNM,5PY1 M1[*BLT[%:&Y]$-M%?? &'RU]J(VX![-L0I&OEF%_)">S$?>[MP_EAF)('/!
<@3<>ZS1(4GNTB\!%9047B93B3AF/>R-H2O^RE4P?A<@!#.[MM[R>-7_E:E\=CY'6H84
GL@05LIJ<'6FIPS>,L>*TSLEO#J=?;N,@EWY4H*';&J<*Q=2O%HJLJ&UAF0*9C*P;&K>
MONU1@J8YND;#4#OF=X"D1X[SFV!M"0+7UWZ!D:&N&&V1^AW@W--62P+'_O>O;6DIO6K/N
RT7(6Y;+3/FW5L^4LGM>0O2VT"!O(VXC9T1[* M$KRG+15*BM9%JYS=?HORR NZN$!M*,A%%(QK3NLAR
QE=7,^.!YBAC.\,[P M_$(;UGA9R"VH$US0UA* #-'74&<4H>2D;59ZJTGSP,.[N#(>Q9QIPO?OSU<$YPG?^OD7:[V,D-
!Y.:U+:IZ^(9V_K;UIF19&;:2] X0.8'T'('JW.,,5 M&7XX^U$WUF50V5HT/E6JN=4U$0\A:&4@^ABYEB*IV-HJWTA(?]
Y1,J+UBR? M-I+ZYSS.3D\Q7YWS]]=B1$&I3 1'>IH.^5CS.+D"XP.M@DMD)C]N8N_RFFF#
M98W!T9RO'>B6RS9*]]?!6&1)(+'%IUIX4RJ#R!ST7*-T,NO(FP<]'J!EV@#: M2!JF">,[-#C%8*&$=7)6W
ZD#}ATCIJHT$KS9(IWAC9.@([O"QW-'TTFKG< M3@@](.J7>@//3- 1(QA>/.VQ5.N_7(3BA,VN"&7&RC/KP3)N*-
A'ZV_WX7*G M999&A:1-E.0AH"%F9 ?.IP*2T>>:?N1=V6K0#"JS/%)Y[5ZRVJ',3I[O_R$RQ^SA&L[
M1UCEO%29W&E61_BQ *[87WC-!R'?U.-N"6$KE-[YY6!31W&)JPN ^(K)[- M\^4*KBIXC,A%%
[YN*DF;1B4+/DD.EEM2=H59&7=J/[8;3NX3,%UAW""9W@?(M0 9WX$ENBG(^#ZM9; 5M\$ESZP'WK
M49B[43;M@33:;<4(8GD28+O<1+GD_]O>E36WK2OI]_DOF %(<'N9*L=+;FJ2 MV!7[9.H\N;#*O%2!Y<8,T*YM)
[..50WM\O<8_#B8.J-_,E3\ITMJ^>35+,O MG=*,HX2;K2*L$\0H^/ XP%PD7*99:KLN<9].;E/4W]6[C8;"S M#8C_'-
L,G##4F0JB#"48P\2?*1B7$7P;!%&TLEH4VWZ <)!B;MV9=3H<1K<1 MV'A N#8W;=["J$_O6%&H^7H>4%F8*;YAD
J(9A6FB&$=(AC29#!\CU4M@M7 M#]%K$-V.]LK8NP9GDR#Y #3;#!X5)6&410QA&<'@P6"V+",2 H0@A,5.$H?:
M=BK&,,W\"]2F,>) RHV Q_$I[#Q_/EJ(XB *,1.P#@?/3P-"49HIC"(A">;A M9G&XLYG1=NKZ0J+?;!@#5CG=
<.5%;G:IBGP1 >82HJ4YNOD!)1*$_29?W$J39'07KH< MVJK; Y?
CLNBH"+@EU\U=7DFP<;/UERQ5,E%1BK#&$*]A%J(LX@DXS00S2;5, MDOXKCTN.219TG_PC?VSK+8F62?
&AF%,!,,)HEI @!69'"I7?=AF6"4QCE60(IDF M#&(JPA'7L4182:ZH9DD6#SH1Z^'(7@7<)8M,1;2T;5['"'E*LO^LREG%[N_,
MG+@R2Z83DJ6)1L1DSU%L:B!&"7Q*4H)5K 7>32L=Q9&]"@SBR-$>H3Z*,[%C M;-
>,6>=JONS"AO:4QED2X1CA9+4)'F+$F0Z1IC$7@G&JK7B5O0JX\RJ6@"UM M6]DQ5ME\V=JE9W@*OG-3\U!T^&
M$X6B#&L5ZA2"YZY(H5;BWV?EPW]L)*Z=P.:;9Q_PW)Z;K2W[!!AI00].4/:$ MTU^?BI5F!!37$'"*EFIK$5E/!-H@Y4H&
(=9(Q' >V7T_OTVE8](!MT^;H>0!6 ML?" 6R?S>?FWN=IY4<("?,D;O9R_K3!QFV6,A6%$D-8!F(S!HMQ4)4$Q9CKC
MFH9!:+MPV3#-O"QC-I(-NX4^[$/C1VVA[=V@IP[JLCH%3?)F]0: J[I#PXB2 MD*XB
0CD&$3Q:2!#I)*0!D$8,Y;U']T,:>K!^-Y/TDFT.*]|]Q-IH4%.SI..EM6QG[GO^Z5:)1\ M[H.J+^]5D1>SEW6Z3(%^T93%#U-
YN5#RG%7F5^K;,)!$1)DRTVH&S$\Q+!.9 M>5PTPJEF$$,&HIBP3)C$"<%V$:LK&>:MN&ES=0CN2Q1MG5@_59?
S'_4(4Q(21!2H0:T11B MN8S"NC85.LJX#+16MF%VWEDX;TO =A9E=D%Q .&M59T-X_5?*[,3*]4%L=Q M!B%?9
I",.A(!FH@\+-84IJ);-AYP\3L_V>-O,R4L<,MBU!X2JRO.8.U:=X\ MWO(HDBF&?D224$1Y$B*>I@'*M%
126/&M>T=I4Z%O,R8.!ZMQ@'A ;LZ"BG? MBC04F <)&$F"D0(>H4PJCF"XB)!+!L[7=CV6#G7\W *W0RE;*/C[;+1,P#9A
M*) FIHZ'P PQ11DBA(=IDM D2_K?6)S\;/3'VKFV:%(//,W3@\9$8A5C6%.& M3'-$HU0@EM(
X8B'B12,9\3VS>Z#WHPF'VN'>I)]/>#%VS.8=7B62IV&610A M21-
B[GIBE*J0HE0R(2*%$\]Y[3.R=E6&L>9C;5';M+Z7)/]NFLT>V"W$7(0) MG"&MS9VL0
K$I9(P*E))3'"6A;;+XG3I,XQ.'VMKVSH./G"JY,<1]KC_O8*/GS-/7> M;8P70PO6!UI!)Q"/X L-D@1QG40HS'A,=,Q@[K?]2LP
M8;Q[F-MB1\+%4\? MAKU>\EK]M31'26"\IA[]$.P^038>?AVDI*6'7G?;>GJM,S37JG!,4:BQ>92, MP^PF4@
[,K61A)919GL*V*?+Y!H3K^6NT_PH-JF<28@45K"L8)*@-*49 E9S MSE,I=6>>K(7^>?!TJQ7TW]28F&IN#X*EW3[
GZTK]G 9*$:,SZ,AHIFIC$ # MC82(5;J22,C,]G':'E6\(LX(C'M(,\;@?O)FDY2>2!*$49J9_2QM:JT(E,40 MK(F,)3J&I:G
U]\LVZ>,7]P9!74_?4;8W3\";:^AI%1@'"0HT'C5"8CQL*0(MDU32+ API&P?A[4]XAUQQH#<39T1%O>/-L]K
ADJHLW%-1UQ&%188932E(&+ MCG24D"S2S/9FT3Y='#]T=>09:YS)/:#.6?Z02UA*U+<$,P)+.XPR;BKS,!TA M)C!!
4D9QC+F&;$]13TU[I5G&8GEF\M 8PSKZ<+Y+*]%631YL53R\EZMBX+7
MK)#P@_NR9O//5;F\'[^>/E"^C67VE"Y96GVWJW"RJ\+3LBR*64PS$9IKR# K M2:51!E,<(C*,A<98!<+V(=*!*EJXS?
@L]4LAYDMI7L]H4V*S_W4K->,AB12* M8RP1#01%*2$P4,,P$((J+;#MO([#M71^$^UH/&NY WE,!+V8,0?W\+2LFWI=
M=;R^+N?R5@B!0YJF*%D55)0P'S"F B1C'<'/*,FX[6VG">HZOP'G(VLG8?JQ MZ+LZ/+^J2KVYV*.S@!*E&*(B-
46]2&K*8!!8IV=@70G&QK;7H>.U=7X3ST?R
M3D'T@W%7%?!I#A8_D8N\R(V=F_Q!F3M$1:UNN2**)UI"*)Z8%7Y*418395[^
M(B34<9B&MO.V[&GO_#JAE]RVB/C'XOJ9 B5%OB8 =']15DW^/ZMQ;R,1AH3& M"A:?YEY '"2(J1"^%2:MCL>4[A;M?
4^>=VCN_":CCQRWA;3KE]8/6". @9>B M65;FH<9"KI)A3N]8-
5/U+4L%F%Q(%'#&US?.&9<HD7>XHL[OH;JEKU41E98J#U;<\S *N0H%X&IE0B!(P;6">^<&KZPBQEOTUAB>IX/[2
MK&=+L(DH?6 V?BE !UB _F"-NDVD3!(<9D@3+-95GS@+&$J($(&*812J_C>_ MK*GC_M*N]RP=C=Y'8^R9V:,V]]]-
[,+C*-%1EB(I364@'<-$$042.JHP25,F MDB | DU?ZN#^:K"?W!R-TT+(">WOAY6<1Q=8P'G8/.LKFQP;RL MEP#\I\?
71N^V4[U.]%4A5CJ%()P$! ")0_.2!]4H5IE(29)A(@>]W'?PVNGH M77-_&?J=EUU^D<6M@]_C!5;7:23%,B(T1"FFX G
U"@S12T#22G#@<@RVE^B MJ*,!MQF-7G*AM Z,E_3:7+J)L)9QQC7BVCR4@3%!J800/8RX-N]DI$G:__)V M9Q-
N*&83OEY&C+"E%YSXH1[*^8.JSI8*($TWMZ9HQ$06) HE*385 DB".&$2*

MD5B:I_H2G;'^/;"N%GQCQ!CXWG!BNBV]H,2-JA9?2U:23+7K_XLUX=?GDCDZ3 .A
M,!)IFB(:Q3%*>9R@F,I0L\#4N+&=R/".W7-[?;Z5*:" 2C#B&$)*F,0ST0, 7G5&F M I5I:KL^A#7EW5X&]'V
N.6*^Y(7KYZ^5D*NQ7\IZAQX<5,Q8_>3JF+%;(7? M@/H6KYC_4O*:],.;FPY,K' M=>MXO*]K;^U2.3"*<$O%;TTU-Z<9-
:PR*@GPW4!@^@E^^J])M.P0ZXRBATW! M_89Q/A$;K8!7W]EB:J3T4I*3I?N8$*FE^[Y UD< [,.L4Z*B1P. M6[]AO'" *
[U,]1QS_VJZ$WPESDFIC+&.L,T0'CG#FVI1-'9]X0N13DH_3':% M;PWBER>T!-A^J4[J'4SV@]['METP5(N\8!8]X:Y$-S4
QGK#/?;P JOS7_=Y M91.J'8%N[LJ/1:K=&EX =;;"LVL!+V"Y5F)9K6]MS&8G M#RR?GRP:"QBURW5S;WHL8)VV\?
4T_KRJ3LO%_7.*A-5#^+?2K9R]]RAMX+_6;MMXP85PP/:2!"<-U(W7;S/1CUE:!SO;B#\'GY4CM,HOK%9NJ MMYE,9C:>?
&+4)L\97IUV+P<9X?=9GBM0WNDLS_NDJ-^'C<.W,[ZKT@8HKR5Y MG1ZVM^,>S2NJL;A7T2G8F5,;&QD,,9-
KES>;-9M.35UU[8AR=A8\%JUV4SC& M9ZM0P>:/=5[;R;#8*]394?'$V'NO>1RC=]W\ZZH2E]5-79W73;Y8V?*;:NY*
M:0?)00TX.U@>B^HA9G.,\.6R 1]?K'9T[+G2_5*=G3:/Q;+70/Y,@-_+YD_U M-%,K2T-T4 /.CJ8M3):]9G.,\ 4(+0NU[:F-K+
<](IT=6X]%L=LT?N%VME0W MY>9F)_2ST&4E5J'U5&=[2#O.#KDM(3S$B:['"_C,OY^N77?0_RH4Z+9=%4SU^ M97\?
_O.QMP=F]MDP!![>D@#Z/%?2S;/=2XVVM^P7Y]4H73>U,>@0F^#[L[F M;=)AJ%W]H@2XL3DK-@I_6=R;JJ70
6ZJ73S:B=W&M>@N)\ 2*0ZSK#\K,)LA M7H=8=RD$%A9A?L9Z+0I:7D?
OBG53IMPRB'XMI5]N=Y>JAG7A#_77,J^>_(H= MIWQ ,VXJ;MLZ,AAF0U^S@*X>CI4!]%JRE>R?
#F4M9/Y?]96J8+6U,.5D M;"?^#)$_85R#<:;G^CP)<7;@>@ *+T?
D;N]='PC]4F)IWDH_!3+A;K?:NZ*6[X_**L3N[G?/YG90.S@UMS&:GM0ZRT8#X/8#6T&T5ZC*R&PABES%
<+WYLXS0:H^,,M#[KE\-,X0E*5U5E':A=F>[& MTPBL]AC$]2[=7\WCR=^5K(V*%J!JD^!TQM M:'Z8&.15Q\Y_B?D,
(J@?]U4CWW;!]@@=UIR[2YH'8GZP!1U#_V=U7LB+"K2] MU$^=^%P51O'3ATK^69FS=%G,3@KY1_%0-](" 48WZL?
0/PS?TIZQ'7/%+*^^ M%!O]=S7=[0\$&W]6-N;S\:WZX31&LV6RN1W3Y2=T<';6M/(=^@$_:J*]!9H< MW]JSH-
./4:;UQ\O,,K;K-.:MXFM] M"_EVWEP[OHNY7/7MM"QD?5;!!UQ,L:2"LXNE=GAD%PC'K#I[D+*^K"Z;N^H< M-
*ROY&7QU)OOC?G_O^L?>BY,MVZ:N3$0K-RL4OG@NMZ:1'1+KG.8M^Q?K3?
1]X]ZIUY<4T^*6H+Q2ZYSB+.L=ZUWT;.QV)Y M4S9L;N/ZW]XL9U521H^Y5ENX1^A$-$LVGS]>L5Q: JI-I+-
Z*./QZK",ZYPJ M<^0.&]Y6C99)7^PSE/,]GF3>//]E\ MN38E+&\6ZY?3<@W**.BM+70/;,I=G9"1<(\SI>MEXXZ;^5FO)I'K.
[#273D' M*_]H;*TD#VO*78F1T7MW8TSI'?[?5?.E$.7"TA[ZH ;<51]QAO5^LWF'\)M-
MYF,AW='0(,2]VCL:84;7#X2]=3^FYYO-+SN@#VUC$-X^[3X=:#SO!OEE] M(X_O]C8&0>W3QM6!QG,]]AE?SEGU-
:\;BT?=^Z4.@M.G[:Q> [D&*UGF?QD M8[O(0=D*/FUF=9O&^<[_UOG;![!/]B D?=K*&F@LAY N:S1C[/[V*7#_6M9=
M^5J:U7REQ.8/-TC.FWK[/\^0MLL>!*(O&UB=YG$>[>Q$WE.'7ZO 07#YM '5 M91;7%6I-0&5Z9 FP-
GF#\/)IPZC#*#YL\5MYU>REH$$_^;3+TV8&YT%(.3E5 MDKG1B\TI#AZ>>V?K^+E/^B!D?=H+&6PPU]-:41>?"MV8
M*T36\H_WR!QT)\"G79$>XSC/('B^_64O5:!=YB#H?-H&Z3&.KZ\/G/S-*GF3 M+_)B=J17"-
I;L/(:P0#E+;Q*L&YEL6KB#07&33^M$J?,EAN!WXK[W BU-$ON
ME>JN2ET7%J^FPSZ+N(YOMOI9?.1XGTQW=>H.1LO+MXNWVEU!LTVU*.3%G,VL M(/5:HKM"=8?BU&H)3U
R(_ZTJ&5E#Z8=DNVC>OML.VYDE0^0[NYIXV! <9B5O\3P2C.XN*EI SQ/0W+X/<[Q%6;?-?[\8 M_O%F"FI.^OQ#
[_<,VC&I.Z\ENUVL3QH%'4;Q0.P5CE@GUBM5C?#55%O[%>9 MF@SFQ=;ZT^/S[URQ1_-_]\X\]ZB05W-
6F,/&LW+!\L(RYD=1T$"\\\7]O'Q4ZKJ!(.UR=:[9Z\K'L&=_.TXI<%1TRP--[0$=5KJ=W$/S(E^9 MXD<^NVOJZY,?UT>A17]
[3B87%_08;'K7<5_;I N!T.14GT[!SLJ&3%M&[=C% M!^C^*&0U?YQ=*[&L\B97]>0TQKU2W=4+.0RU+I/X-
GYKTI<5;FP,+Z>1;DK M'(8.&\Z[P,BGV$&:,Y8HRY8;DH]+RU TR+3756/PS#:;P['8+T>V8_?_M6L MJ+1Z^%!,C
M&2L).4.[82$K9W]3;V@R"->/E2](DL[QLU_>"Z7[K#K M-1YH+^?;^VUZ?B^;C:IV3MJ&M^)L.I,JSAWV.[Y'W_S
?.&P,O[/?_M?4$L! M A0#% @ IW0"69G+6<2C P %Q, \ (! &5X M,C(Q<3(R,#(T+FAT;5!+ 0(4 Q0 (*=T EG%9U#J>P< $
H / M " = # !E>#,Q,7$R,C R-"YH=&U02P$"% ,4 " "G=)9(-03!_^W ;<@@ M$P @ 'U2 , ;&@M,C R-# V,S!?<')E+GAM;%!+!08 ."@ *'$" E 00
! end XML 67 lh-20240630_htm.xml IDEA: XBRL DOCUMENT 0000920148 2024-01-012024-06-30 0000920148 2024-
08-01 0000920148 2024-06-30 0000920148 2023-12-31 0000920148 2024-04-012024-06-30 0000920148 2023-04-
012023-06-30 0000920148 2023-01-012023-06-30 0000920148 us-gaap:CommonStockMember 2022-12-31
0000920148 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000920148 us-gaap:RetainedEarningsMember
2022-12-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000920148 2022-
12-31 0000920148 us-gaap:CommonStockMember 2023-01-012023-03-31 0000920148 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000920148 us-gaap:RetainedEarningsMember 2023-
01-012023-03-31 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31
0000920148 2023-01-012023-03-31 0000920148 us-gaap:CommonStockMember 2023-06-30 0000920148 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0000920148 us-gaap:RetainedEarningsMember 2023-06-30
0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000920148 2023-06-30
0000920148 us-gaap:CommonStockMember 2023-04-012023-06-30 0000920148 us-
gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000920148 us-gaap:RetainedEarningsMember 2023-
04-012023-06-30 0000920148 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30
0000920148 us-gaap:CommonStockMember 2023-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-
03-31 0000920148 us-gaap:RetainedEarningsMember 2023-03-31 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000920148 2023-03-31 0000920148 us-
gaap:CommonStockMember 2023-12-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2023-12-31
0000920148 us-gaap:RetainedEarningsMember 2023-12-31 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000920148 us-gaap:CommonStockMember
2024-01-012024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000920148
us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0000920148 2024-01-012024-03-31
0000920148 us-gaap:CommonStockMember 2024-03-31 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-
03-31 0000920148 us-gaap:RetainedEarningsMember 2024-03-31 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000920148 2024-03-31 0000920148 us-
gaap:CommonStockMember 2024-04-012024-06-30 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-04-
012024-06-30 0000920148 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000920148 us-
gaap:CommonStockMember 2024-06-30 0000920148 us-gaap:AdditionalPaidInCapitalMember 2024-06-30
0000920148 us-gaap:RetainedEarningsMember 2024-06-30 0000920148 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000920148 us-
gaap:SegmentContinuingOperationsMember 2024-01-012024-06-30 0000920148 us-
gaap:SegmentContinuingOperationsMember 2023-01-012023-06-30 0000920148 us-
gaap:SegmentDiscontinuedOperationsMember 2024-01-012024-06-30 0000920148 us-
gaap:SegmentDiscontinuedOperationsMember 2023-01-012023-06-30 0000920148 us-

gaap:SegmentContinuingOperationsMember 2024-06-30 0000920148 us-gaap:SegmentContinuingOperationsMember 2023-06-30 0000920148 lh:DiagnosticsMember 2024-04-012024-06-30 0000920148 lh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 lh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-01-012024-06-30 0000920148 2023-09-30 0000920148 lh:FortreaRevolverDue2028Member 2023-09-30 0000920148 lh:FortreaTermLoanAMaturing2028Member 2023-09-30 0000920148 lh:FortreaTermLoanBMaturing2028Member 2023-09-30 0000920148 srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:ClientMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:EuropeMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:ClientMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 us-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:EuropeMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 us-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:MedicareandMedicaidMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:EuropeMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:MedicareandMedicaidMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:EuropeMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberlh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 lh:LabCorpDiagnosticsMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:EuropeMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberlh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 lh:LabCorpDiagnosticsMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 srt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMem 2023-04-012023-06-30 0000920148 srt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMem 2023-04-012023-06-30 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:CovanceDrugDevelopmentMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMember 2024-04-012024-06-30 0000920148 srt:EuropeMember 2024-04-012024-06-30 0000920148 lh:OthercountriesMember 2024-04-012024-06-30 0000920148 srt:NorthAmericaMember 2023-04-012023-06-30 0000920148 srt:EuropeMember 2023-04-012023-06-30 0000920148 lh:OthercountriesMember 2023-04-012023-06-30 0000920148 srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:ClientMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:EuropeMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberlh:ClientMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:ClientMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 us-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30

0000920148 srt:EuropeMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberus-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 us-gaap:SelfPayMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:MedicareandMedicaidMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:EuropeMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberlh:MedicareandMedicaidMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:MedicareandMedicaidMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:EuropeMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberlh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:ThirdpartyMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberlh:LabCorpDiagnosticsMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:EuropeMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberlh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 lh:LabCorpDiagnosticsMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-01-012024-06-30 0000920148 srt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2023-01-012023-06-30 0000920148 srt:EuropeMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMemberlh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2023-01-012023-06-30 0000920148 lh:BiopharmaceuticalandmedicaldevicecompaniesMemberlh:DrugDevelopmentMember 2023-01-012023-06-30 0000920148 srt:NorthAmericaMember 2024-01-012024-06-30 0000920148 srt:EuropeMember 2024-01-012024-06-30 0000920148 lh:OthercountriesMember 2024-01-012024-06-30 0000920148 srt:NorthAmericaMember 2023-01-012023-06-30 0000920148 srt:EuropeMember 2023-01-012023-06-30 0000920148 lh:OthercountriesMember 2023-01-012023-06-30 0000920148 country:US 2024-04-012024-06-30 0000920148 country:US 2023-04-012023-06-30 0000920148 country:US 2024-01-012024-06-30 0000920148 country:US 2023-01-012023-06-30 0000920148 lh:DiagnosticsMember 2024-06-30 0000920148 lh:DiagnosticsMember 2023-12-31 0000920148 lh:DrugDevelopmentMember 2024-06-30 0000920148 lh:DrugDevelopmentMember 2023-12-31 0000920148 us-gaap:AccountsReceivableMember 2024-01-012024-06-30 0000920148 lh:UnbilledContractsReceivableMember 2024-01-012024-06-30 0000920148 us-gaap:NotesReceivableMember 2024-01-012024-06-30 0000920148 lh:BaystateMedicalCenterMember 2024-06-30 0000920148 lh:ProvidenceMedicalFoundationMember 2024-06-30 0000920148 lh:WestpacLabsInc.Member 2024-06-30 0000920148 lh:InvitaeCorporationMember 2024-06-30 0000920148 lh:OtheracquireesMember 2024-01-012024-06-30 0000920148 srt:MaximumMemberus-gaap:CustomerListsMember 2024-01-012024-06-30 0000920148 lh:BaystateMedicalCenterMember 2024-04-012024-06-30 0000920148 lh:WestpacLabsInc.Member 2024-04-012024-06-30 0000920148 lh:InvitaeCorporationMember 2024-04-012024-06-30 0000920148 lh:BaystateMedicalCenterMember 2024-01-012024-06-30 0000920148 lh:ProvidenceMedicalFoundationMember 2024-01-012024-06-30 0000920148 lh:WestpacLabsInc.Member 2024-01-012024-06-30 0000920148 lh:InvitaeCorporationMember 2024-01-012024-06-30 0000920148 us-gaap:GoodwillMember 2024-01-012024-06-30 0000920148 us-gaap:OtherNoncurrentAssetsMember 2024-01-012024-06-30 0000920148 lh:OperatingLeaseLiabilityMember 2024-04-012024-06-30 0000920148 us-gaap:OtherNoncurrentLiabilitiesMember 2024-04-012024-06-30 0000920148 lh:OtherAcquisitionsMember 2024-06-30 0000920148 lh:BioReferenceHealthMember 2024-01-012024-06-30 0000920148 lh:OtheracquireesMember 2023-01-012023-06-30 0000920148 srt:MinimumMemberus-gaap:CustomerListsMember 2024-01-012024-06-30 0000920148 srt:MaximumMemberus-gaap:CustomerListsMember 2023-01-012023-06-30 0000920148 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-01-012023-06-30 0000920148 us-gaap:GoodwillMember 2023-01-012023-06-30 0000920148 us-gaap:AccruedLiabilitiesMember 2023-01-012023-06-30 0000920148 us-gaap:OtherNoncurrentLiabilitiesMember 2023-01-012023-06-30 0000920148 lh:LabCorpDiagnosticsMember 2023-12-31 0000920148 lh:CovanceDrugDevelopmentMember 2023-12-31 0000920148 lh:CovanceDrugDevelopmentMember 2024-01-012024-06-30 0000920148 lh:LabCorpDiagnosticsMember 2024-06-30 0000920148 lh:CovanceDrugDevelopmentMember 2024-06-30 0000920148 us-gaap:CustomerRelationshipsMember 2024-06-30 0000920148 us-gaap:CustomerRelationshipsMember 2023-12-31 0000920148 lh:PatentsLicensesAndTechnologyMember 2024-06-30 0000920148 lh:PatentsLicensesAndTechnologyMember 2023-12-31 0000920148 us-gaap:NoncompeteAgreementsMember 2024-06-30 0000920148 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000920148 us-gaap:LicensingAgreementsMember 2024-06-30 0000920148 us-gaap:LicensingAgreementsMember 2023-12-31 0000920148 lh:InProcessRAAndMediaMember 2024-06-30 0000920148 lh:InProcessRAAndMediaMember 2023-12-31 0000920148 us-gaap:OtherCurrentLiabilitiesMember 2024-06-30 0000920148 us-gaap:OtherCurrentLiabilitiesMember 2023-12-31 0000920148 us-gaap:InterestRateSwapMember 2024-06-30 0000920148 us-gaap:InterestRateSwapMember 2023-12-31 0000920148 us-gaap:RevolvingCreditFacilityMember 2024-06-30 0000920148 us-gaap:CommonStockMember 2023-12-31 0000920148 us-gaap:CommonStockMember

2024-01-012024-06-30 0000920148 us-gaap:CommonStockMember 2024-06-30 0000920148 us-gaap:SubsequentEventMember 2024-07-24 0000920148 us-gaap:SubsequentEventMember 2024-07-252024-07-25 0000920148 us-gaap:SubsequentEventMember 2024-07-25 0000920148 lh:InitialDamagesMember 2024-04-012024-06-30 0000920148 lh:EnhancedDamagesMember 2024-04-012024-06-30 0000920148 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000920148 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000920148 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000920148 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000920148 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000920148 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000920148 lh:Seniornotesdue2027Member 2024-06-30 0000920148 lh:SeniorNotesDue2022Memberlh:A2018SwapAgreementsMember 2024-06-30 0000920148 lh:SeniorNotesDue2024Memberlh:A2022SwapAgreementsMember 2024-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DiagnosticsMember 2024-04-012024-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DiagnosticsMember 2023-04-012023-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DiagnosticsMember 2024-01-012024-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DiagnosticsMember 2023-01-012023-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DrugDevelopmentMember 2024-04-012024-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DrugDevelopmentMember 2023-04-012023-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DrugDevelopmentMember 2024-01-012024-06-30 0000920148 us-gaap:OperatingSegmentsMemberlh:DrugDevelopmentMember 2023-01-012023-06-30 0000920148 us-gaap:IntersegmentEliminationMember 2024-04-012024-06-30 0000920148 us-gaap:IntersegmentEliminationMember 2023-04-012023-06-30 0000920148 us-gaap:IntersegmentEliminationMember 2024-01-012024-06-30 0000920148 us-gaap:IntersegmentEliminationMember 2023-01-012023-06-30 0000920148 us-gaap:OperatingSegmentsMember 2024-04-012024-06-30 0000920148 us-gaap:OperatingSegmentsMember 2023-04-012023-06-30 0000920148 us-gaap:OperatingSegmentsMember 2024-01-012024-06-30 0000920148 us-gaap:OperatingSegmentsMember 2023-01-012023-06-30 0000920148 us-gaap:CorporateMember 2024-04-012024-06-30 0000920148 us-gaap:CorporateMember 2023-04-012023-06-30 0000920148 us-gaap:CorporateMember 2024-01-012024-06-30 0000920148 us-gaap:CorporateMember 2023-01-012023-06-30 0000920148 lh:KerriiAndersonMember 2024-04-012024-06-30 0000920148 lh:KerriiAndersonMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure utr:Rate3410000032700000000000920148--12-312024Q2false10-Qtrue2024-06-30false1-11353LABCORP HOLDINGS INC.DE99-2588107358 South Main StreetBurlington,NC27215336229-1127Common Stock, $0.10 par valueLHNYSEYesYesLarge Accelerated Filerfalsefalsefalse8396327726510000053680000020889000001913300000157500000185400000441800000474600000192000000.0-593000008005800000787500000016712300000167251000003220900000303370000063975000006071500000229453000000900000-200000-1200000195000000-1690000039500000-2380000026770000020500000.056510000047730000062100004980000013120000011370000020560000015520000720000051700000-131500000998000000-700000-1100000170000000-2300000-650000052800000-133200000102100000100000300000-500000600000060000060000060000060000060000-660000052500000-132700000101500000199000000.024160000030120000050390000030000020000060000060000019870000024140000493200000100966000000021290000002129000000049000000.049000000.000647000000647000000276000000027444200000103415000000018890000001889000000005250000052500000000-20181000002380000000.0-178010000000645000000645000000268000000026800000018200000001820000000381000000038100000810000009415370000087850000007700000384000007888200000-593000007875000000002280000000.00228000000.0000-126100000-126100000006090000006090000002670000000267000000147000000014700000031600000003160000077000008201854000007959600000002053000000205300000000-6600000-660000000602000000602000000231000000023100000030800000003080000000-77200000-228000000100000000.07700000125000008177600000-192000000.08005800000433900000402400000038800000311400000285000000.062400000673000008860000085103910000016200000366000003100000192200000107600000-26800000-74100000-27700000161000000-21600000302000000-51700000-160300000-308000003480000-166400000-272800000531300000347200000012540000053130000047260000026200000.018150000020000020000013500000057810000-3286000000-24700000-578100000-353300000951900000142090000093210000014209000003780000038700000267000005440000012250000012900000221700000-124700000001609100000-221700000014844000000-320000063000000-271700000161000000053680000043000000.001094000002651000001930600000BASIS OF FINANCIAL STATEMENT PRESENTATION Labcorp® Holdings Inc. (Labcorp® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. On April 25, 2024, the Company announced plans to implement a new public holding company structure, with Labcorp Holdings Inc. as the new holding company. On May 17, 2024, the Company completed the holding company reorganization (Reorganization) and Labcorp Holdings Inc. became the successor issuer to Laboratory Corporation of America Holdings (LCAH). The new holding company has no independent assets or operations and its sole ownership interest is in LCAH. The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the six months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:120%">The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Company's fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Annual Report. The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in "Accumulated other comprehensive income (loss)." BASIS OF FINANCIAL STATEMENT PRESENTATION Labcorp® Holdings Inc. (Labcorp® or the Company) is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. On April 25, 2024, the Company announced plans to implement a new public holding company structure, with Labcorp Holdings Inc. as the new holding company. On May 17, 2024, the Company completed the holding company reorganization (Reorganization) and Labcorp Holdings Inc. became the successor issuer to Laboratory Corporation of America Holdings (LCAH). The new holding company has no independent assets or operations and its sole ownership interest is in LCAH. The Company reports its business in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), formerly Drug Development. For further financial information about these segments, see Note 12 (Business Segment Information) to the Condensed Consolidated Financial Statements. During the three months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. During the six months ended June 30, 2024, Dx and BLS contributed approximately 78% and 22%, respectively, of revenues to the Company. The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and do not contain certain information included in the Company's fiscal year 2023 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Annual Report. The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value, or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance

sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in "Accumulated other comprehensive income (loss)." 0.780.220.780.220.200 2. DISCONTINUED OPERATIONS On June 30, 2023 (the Distribution Date), Labcorp completed the previously announced separation (the Separation) from the Company of Fortrea Holdings Inc. (Fortrea), formerly the Company's Clinical Development and Commercialization Services (CDCS) business, into a separate, publicly-traded company. All historical operating results of Fortrea are presented as Discontinued Operations, net of tax, in the Condensed Consolidated Statements of Operations. The spin-off is expected to be treated as tax-free for the Company and its shareholders for U.S. federal income tax purposes. The spin-off of Fortrea from Labcorp was achieved through the Company's pro-rata distribution of 100% of the outstanding shares of Fortrea common stock to holders of record of Labcorp common stock. Each holder of record of Labcorp common stock received one share of Fortrea common stock for every share of Labcorp common stock held at 5:00 p.m., Burlington, North Carolina, time on June 20, 2023, the record date for the distribution. In June 2023, Fortrea, prior to the Separation and while a subsidiary of the Company, issued $570.0 of 7.500% senior secured notes due 2030 (the Fortrea Notes). The proceeds from the Fortrea Notes were used to fund cash payments of approximately $1,600.0 to the Company in connection with the Separation. The Company does not guarantee the Fortrea Notes following the Separation. Also in June 2023, Fortrea entered into three floating secured overnight financing rate (SOFR) credit facilities totaling $1,520.0. These are comprised of a $450.0 Revolver maturing June 30, 2028; a $500.0 Term Loan A maturing June 30, 2028; and a $570.0 Term Loan B maturing June 30, 2030. </div><div style="margin-bottom:7pt;margin-top:3pt;text-align:justify;text-indent:13.5pt">In connection with the spin-off, the Company entered into several agreements with Fortrea on or prior to the Distribution Date that, among other things, provide a framework for the Company's relationship with Fortrea after the spin-off, including a separation and distribution agreement, a tax matters agreement, an employee matters agreement, and a transition services agreement. These agreements contain the key provisions relating to the spin-off, including provisions relating to the principal intercompany transactions required to effect the spin-off, the conditions to the spin-off and provisions governing the relationship between Fortrea and the Company after the spin-off. The costs to provide these services are included in operating income but the service fees are included in other income.</div><div style="margin-bottom:7pt;margin-top:3pt">Financial Information of Discontinued Operations</div><div style="margin-bottom:7pt;margin-top:3pt;text-align:justify;text-indent:13.5pt">Earnings from discontinued operations, net of tax in the Consolidated Statements of Operations reflect the after-tax results of Fortrea's business and Separation-related fees, and do not include any allocation of general corporate overhead expense or interest expense of the Company.</div><div style="margin-bottom:7pt;margin-top:3pt;text-align:justify;text-indent:13.5pt">The following table summarizes the significant line items included in Earnings from Discontinued Operations, Net of Tax in the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023:</div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenues</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">766.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,506.6 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>

<tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenues</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">629.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,244.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Gross profit</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">262.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general and administrative expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of intangibles and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and other charges</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Operating income</td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.1 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income (expense):</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other, net</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Earnings before income taxes</td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40.2 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45.6 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision for income taxes</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.3 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Net earnings attributable to Labcorp Holdings Inc.</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 570000000.00.07500160000000015200000004500000000.0500000000.0570000000.07665000001506600000625

style="margin-bottom:7pt;margin-top:3pt;text-align:justify;text-indent:13.5pt">The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Three Months Ended June 30, 2024</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Three Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payer/Customer</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Clients</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Patients</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-

height:100%">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medicare and Medicaid</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Third party</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:8pt;font-weight:400;line-height:100%">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Dx revenues by payer</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS</td><td colspan="3" style="background-

color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:right;vertical-align:bottom">23 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Six Months Ended June 30, 2024</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-

*right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Six Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payer/Customer</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff

weight:400;line-height:100%">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Patients</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medicare and Medicaid</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Third party</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Dx revenues by payer</td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Pharmaceutical, biotechnology, and medical device companies</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-

height:100%">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively.</div><div style="margin-bottom:7pt;margin-top:3pt">Accounts Receivable, Unbilled Services and Unearned Revenue</div><div style="margin-top:3pt;text-align:justify;text-indent:13.5pt">The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers as of June 30, 2024 and December 31, 2023:</div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx accounts receivable</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,331.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS accounts receivable</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">791.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">810.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less BLS allowance for doubtful accounts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">2,088.9 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">1,913.3 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross unbilled services</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">159.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">192.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less reserve for unbilled services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unbilled services</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">157.5 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">185.4 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Unearned revenue</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">388.3 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">421.7 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $26.8 and $20.2 for the

three months ended June 30, 2024 and 2023, respectively, and $77.8 and $72.8 for the six months ended June 30, 2024 and 2023, respectively.</div><div style="margin-bottom:3pt;margin-top:3pt">Credit Loss Rollforward</div><div style="margin-top:3pt;text-align:justify;text-indent:13.5pt">The Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">Accounts Receivable</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unbilled Services</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">Note and Other Receivables</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">32.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">40.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Plus, credit loss expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Less, write-offs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">36.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The credit loss expense in the first six months primarily related to the collection risk from several biotech receivable balances. The Company's revenues by segment and by payers/customer groups for the three and six months ended June 30, 2024, and 2023, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Three Months Ended June 30, 2024</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Three Months Ended June 30, 2023</td></tr><tr><td colspan="3"

*style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payer/Customer</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff

New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Patients</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medicare and Medicaid</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">

%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ccceff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Third party</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Dx revenues by payer</td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

*serif;font-size:8pt;font-weight:400;line-height:100%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Pharmaceutical, biotechnology, and medical device companies</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Six Months Ended June 30, 2024</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">For the Six Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">North America</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Europe</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payer/Customer</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td

colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Clients</td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ccceff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Patients</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-

color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medicare and Medicaid</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Third party</td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total Dx revenues by payer</td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid

*#000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> Revenues in the U.S. were $2,698.8 (83.8%) and $2,537.0 (83.6%) for the three months ended June 30, 2024 and 2023, respectively, and were $5,353.4 (83.7%) and $5,094.4 (83.9%) for the six months ended June 30, 2024 and 2023, respectively. 0.24000.240.24000.240.10000.100.10000.100.08000.080.08000.080.36000.360.35000.350.78000.780.77000.77 style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td

style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx accounts receivable</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,331.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,135.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS accounts receivable</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">791.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">810.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less BLS allowance for doubtful accounts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(34.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">2,088.9 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">1,913.3 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross unbilled services</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">159.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">192.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less reserve for unbilled services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unbilled services</td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">157.5 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">185.4 </td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Unearned revenue</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">388.3 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">421.7 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 133140000011352000007916000008108000003410000032700000208890000019133000001593000001929000

rollforward for the allowance for credit losses for the six months ended June 30, 2024, was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">Accounts Receivable</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unbilled Services</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">Note and Other Receivables</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">32.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">40.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Plus, credit loss expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Less, write offs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">36.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
327000007500000700000409000003400000003400000020000000.057000000770000034100000180000007000003
ACQUISITIONS AND DISPOSITIONS <span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">During the six months ended June 30, 2024, the Company acquired several businesses and related
assets for cash of approximately $293.1. These acquisitions consisted of the clinical and outreach businesses of
Baystate Medical Center ($116.6), Providence Medical Foundation ($54.9), and Westpac Labs, Inc. ($97.7) and an
escrow payment of $23.9 for selected assets of the Invitae Corporation that is anticipated to close on August 5,
2024. The preliminary purchase considerations for these acquisitions were allocated under the acquisition method
of accounting to the estimated fair market value of the net assets acquired, including approximately $159.4 in
identifiable intangible assets. A residual amount of tax deductible goodwill of approximately $141.7 was recorded as
of June 30, 2024. The amortization period for non-compete agreements and customer list assets acquired from these
businesses are 5 and 15 years, respectively. The valuation of acquired assets and assumed liabilities, include the
following:
2931000001166000005490000097700000239000001594000001417000000P15Y000000001800000018000000072
39000007070000025900000451000000141700000-
74000007960000029000000.05080000001594000000740000000023900000239000000157500000558000009770000021
39000007200000090000000810000-39000003700000000370000001090000090000000118000000-
39000001466000005490000097700000239000003231000000300000000.000030000000.00116600000549000009770001
1500000-2940000019500000-10600000-8300000-2300000-
10600000032209000003100500000641200000062065000002053000001934000004328000004095000001350000-
4900000EARNINGS PER SHARE<div style="margin-bottom:7pt;margin-top:3pt;text-align:justify;text-
indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings attributable to the
Company by the weighted average number of shares of the Company's common stock outstanding. Diluted earnings
per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average
number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of
the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily
from the Company's outstanding stock options, restricted stock awards, restricted stock units, and performance
share awards.
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The following represents a reconciliation of basic earnings per share to diluted earnings per share for
the three and six months ended June 30: <div style="margin-bottom:3pt;margin-top:5pt;text-
align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-
bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.981%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%">
</td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td
style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%">
</td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%">
</td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td
style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td
style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%">
</td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%">
</td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td
style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%">
</td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%">
</td><td style="width:1.0%"></td><td style="width:5.199%"></td><td style="width:0.1%"></td></tr><tr><td
colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </td><td
colspan="33" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-
height:100%">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="33" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-
height:100%">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:9pt;font-weight:400;line-height:100%"> </td><td colspan="15" style="border-top:2pt solid
#000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</td><td colspan="3"
style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid
#000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:100%">2024</td><td colspan="3" style="border-top:2pt solid
#000000;padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:100%">2023</td></tr><tr><td colspan="3" style="padding:0 1pt">
</td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-
align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-

weight:400;line-height:100%">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic earnings per share:</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net earnings</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">205.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.44 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">155.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.75 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">433.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5.15 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">363.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4.10 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Dilutive effect of employee stock options and awards</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

*colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">- </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">- </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5.13 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">363.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4.08 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Employee stock options and awards</td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following represents a reconciliation of basic earnings per share to diluted earnings per share for the three and six months ended June 30: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="33" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:

height:100%">Per Share Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Earnings</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Shares </td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Per Share Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic earnings per share:</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net earnings</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">205.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.44 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">155.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.75 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

*style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">433.3 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.1 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5.15 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">363.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4.10 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Dilutive effect of employee stock options and awards</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net earnings including impact of dilutive adjustments</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">205.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.3 </td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.43 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">155.0 </td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89.0 </td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.74 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">433.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5.13 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">363.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

* 20530000084100000 2.44115000000.0887000001.754333000008410000005.15363000000.0886000004.10200006 following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Employee stock options and awards</td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 400000500000300000400000 6. GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Dx</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">BLS</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td*

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,813.9 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">1,328.6 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">6,142.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 25pt 2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom">Foreign currency impact and other adjustments to goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"

style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">4,944.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,275.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,220.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations. The components of identifiable intangible assets were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Customer relationships</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3,947.8 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(1,444.1)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,503.7 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3,868.6 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(1,367.2)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,501.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patents, licenses, and technology</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">520.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(283.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">237.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">526.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

*colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(273.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">253.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Non-compete agreements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">152.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(72.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">130.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(60.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">69.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

2px 1pt;text-align:right;vertical-align:middle">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(18.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(15.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">18.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,149.7 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,817.7)</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,332.0 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,058.4 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,716.4)</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,342.0 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Amortization of intangible assets for the three and six months ended June 30, 2024, and 2023, was $62.2 and $51.5 and $122.3 and $104.9, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $125.0 for the remainder of fiscal 2024, $237.2 in fiscal 2025, $228.2 in fiscal 2026, $216.9 in fiscal 2027, $209.1 in fiscal 2028, and $1,735.8 thereafter. The changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Dx</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">BLS</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Total</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,813.9 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">1,328.6 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">6,142.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 25pt 2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom">Foreign currency impact and other adjustments to goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64.0)</td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">4,944.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,275.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,220.2 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>4813900000132860000061425000001417000000141700000-10700000-53300000-64000000.04944900000127530000062202000000he components of identifiable intangible assets were as follows:<div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Customer relationships</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px

0;text-align:right;vertical-align:middle">3,947.8 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(1,444.1)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,503.7 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3,868.6 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(1,367.2)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">2,501.4 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Patents, licenses, and technology</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">520.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(283.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">237.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">526.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(273.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">253.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Non-compete agreements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">152.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(72.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">130.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(60.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">69.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Canadian licenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">495.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">495.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">498.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">498.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(18.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">16.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">34.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(15.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">18.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,149.7 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,817.7)</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,332.0 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,058.4 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,716.4)</td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,342.0 </td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
3947800000144410000025037000003868600000136720000025014000005203000002831000002372000005260.225%20000000.0907000000.0644PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY The Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were no preferred shares outstanding as of June 30, 2024, and December 31, 2023. The changes in common shares issued during the six months ended June 30, 2024 are summarized below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Issued and Outstanding</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Common shares at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83.9 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:bottom">Shares issued under employee stock plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Shares repurchased</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Common shares at June 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Share Repurchase Program When the Company repurchases shares of Common Stock, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a reduction in retained earnings. During the six months ended June 30, 2024, the Company purchased 0.5 shares of its common stock at an average price of $202.66 for a total cost of $100.0. As of June 30, 2024, the Company had outstanding authorization from the board of directors to purchase up to $430.4 of the Company's common stock. On July 24, 2024, the Board adopted a new share repurchase plan authorizing up to $1,000.0 of the Company's shares in addition to the remaining amount outstanding under the previous plan. In aggregate, the share repurchase authorization is $1,430.4. Dividends For the six months ended June 30, 2024, the Company paid $122.5 in common stock dividends. On July 25, 2024, the Company announced a cash dividend of $0.72 per share of common stock for the third quarter, or approximately $61.2 in the aggregate. The dividend will be payable on September 13, 2024, to stockholders of record of all issued and outstanding shares of common stock as of the close of business on August 29, 2024. The declaration and payment of any future dividends will be at the discretion of the Company's board of directors.</div><div>Accumulated Other Comprehensive Earnings (Loss)</div><div style="margin-bottom:7pt;margin-top:3pt;text-indent:13.5pt">The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows:</div><div style="margin-bottom:3pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.334%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Benefit Plan Adjustments</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Earnings (Loss)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(47.6)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11.7)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-

align:bottom">(59.3)</td><td style="background-color:#ccceff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Current year adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(131.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Amounts reclassified from accumulated other comprehensive income</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Tax effect of adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(179.1)</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(12.9)</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(192.0)</td><td

style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 265000000.00.1030000000.00.100 The changes in common shares issued during the six months ended June 30, 2024 are summarized below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Issued and Outstanding</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Common shares at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83.9 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:justify;vertical-align:bottom">Shares issued under employee stock plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Shares repurchased</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Common shares at June 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 8390000040000050000083800000500000202.66100000000.0430400000100000000014304000001225000002607-250.72612000002024-09-132024-08-29 The components of accumulated other comprehensive earnings (loss) during the six months ended June 30, 2024 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.334%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Benefit Plan Adjustments</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Earnings (Loss)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-

color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(47.6)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11.7)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(59.3)</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Current year adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(131.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Amounts reclassified from accumulated other comprehensive income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Tax effect of adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance as of June 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px

0;text-align:right;vertical-align:middle">(179.1)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(12.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(192.0)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> -47600000-11700000-59300000-131500000-1500000-133000000.00-200000-2000000-500000-500000-179100000-12900000-192000000.0COMMITMENTS AND CONTINGENCIES272000000.0817000000.0100000000.0FAIR VALUE MEASUREMENTS The Company's population of financial assets and liabilities subject to fair value measurements as of June 30, 2024, and December 31, 2023, was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:36.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements as of</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value as of</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Using Fair Value Hierarchy</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Noncontrolling interest put</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Noncontrolling interest</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15.0 </td><td

style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15.0 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross currency swaps</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash surrender value of life insurance policies</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">96.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation asset</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liability</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements as of</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value as of</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Using Fair Value Hierarchy</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncontrolling interest put</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncontrolling interest</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross currency swaps</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash surrender value of life insurance policies</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation asset</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liability</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Company's condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value. The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of multiple measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments, which are typically invested in a similar manner to the participant's allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Contingent accrued earn-out business acquisition consideration liabilities are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair

value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3. The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the senior notes, based on market pricing, was approximately $4,812.3 and $4,850.4 as of June 30, 2024, and December 31, 2023, respectively. The Company's note and debt instruments are classified as Level 2 instruments, as the fair market values of these instruments are determined using other observable inputs.</div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:13.5pt">The Company's population of financial assets and liabilities subject to fair value measurements as of June 30, 2024, and December 31, 2023, was as follows:</div><div style="margin-bottom:3pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:36.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.438%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements as of</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value as of</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Using Fair Value Hierarchy</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Noncontrolling interest put</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Noncontrolling interest</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15.0 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-

top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">15.0 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:top">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross currency swaps</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash surrender value of life insurance policies</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px

0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation asset</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation liability</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td

style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements as of</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value as of</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Using Fair Value Hierarchy</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncontrolling interest put</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncontrolling interest</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15.5 </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross currency swaps</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swaps</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash surrender value of life insurance policies</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred compensation asset</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Contingent consideration</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses and other; Other liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 15000000.0015000000.0010360000001036000000797000000797000000964000000964000000031000000.0031

CASH FLOW INFORMATION <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom">Cash paid during period for:</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom">Interest</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">106.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">109.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom">Income taxes, net of refunds</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">153.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Disclosure of non-cash financing and investing activities: </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom">Change in accrued property, plant, and equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom">Cash paid during period for:</td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom">Interest</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">106.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

***style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">109.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom">Income taxes, net of refunds</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">153.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Disclosure of non-cash financing and investing activities: </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:justify;vertical-align:bottom">Change in accrued property, plant, and equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
106600000109500000153000000.013330000019200000-16500000BUSINESS SEGMENT INFORMATION The following table is a summary of segment information for the three and six months ended June 30, 2024, and 2023. The “management approach” has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM. Segment asset information is not presented because it is not used by the CODM at the segment level. The Corporate costs not allocated to segments include the costs of centralized functions, other charges such as acquisition expenses, spin-off costs, remaining unallocated costs of the CDCS business, and COVID-19 related costs unrelated to the segment. Centralized functions include corporate governance, executive management and related human resources, finance, legal, risk management, and information technology functions. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:42.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">***

2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenues:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,524.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,340.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,004.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,723.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">707.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">699.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,417.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,360.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Intercompany eliminations and other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25.0)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12.4)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3,220.9 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">3,033.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,397.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,071.5 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating Earnings:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Dx segment operating income</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">441.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">409.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">859.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">851.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLS segment operating income</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">104.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Segment operating income</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">548.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">514.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,066.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,029.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General corporate and unallocated expenses</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(180.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(177.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(309.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(300.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of intangibles and other assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(62.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(122.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(104.9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill and other asset impairments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restructuring and other charges</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total operating income</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">294.8 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">266.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">616.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">596.1 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>

* 2524900000234080000050046000004723600000707000000.0699000000.0141790000013603000001100000.0180300000-177900000-309200000-300100000622000005150000012230000010490000002800000250000050000000.0116000001580000001660000023306720000051700000300000000.0 Insider Adoption or Termination of Trading Arrangements: During the fiscal quarter ended June 30, 2024, none of the Company's directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
 <table style="border-*

collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Name and Title</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Date Adopted</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Character of Trading Agreement</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Duration </td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top">Kerrii B. Anderson</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">May 3, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Rule 10b5-1 Trading Arrangement</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Up to </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,000)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> (1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5/3/2025(2) </td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Director</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> (1) The figure presented represents the shares to be sold on the vesting of equity awards before reduction for shares to be withheld for tax purposes (2) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table. falsetruefalsefalseKerrii B. AndersonMay 3, 20243000Director"